drug,event,count,anomaly_score,prr,ror,chi2,serious_rate,death_rate,hosp_rate,rarity_score,reasons
Pembrolizumab,Pneumonitis,15,145,3.688,3.688,26.22,0.800,0.267,0.733,8.218,PRR=3.69 (显著关联); χ²=26.2 (统计显著); 死亡率=26.7%; 严重事件率=80.0%; 罕见+严重; 住院率=73.3%
Nivolumab,Confusional state,10,145,3.169,3.169,13.43,1.000,0.400,1.000,8.623,PRR=3.17 (显著关联); χ²=13.4 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Pancreatitis,6,145,5.695,5.695,20.08,1.000,0.333,1.000,9.134,PRR=5.70 (显著关联); χ²=20.1 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Hypercalcaemia,5,145,6.697,6.697,20.57,1.000,0.600,1.000,9.317,PRR=6.70 (显著关联); χ²=20.6 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Aspartate aminotransferase increased,18,145,5.369,5.369,55.07,1.000,0.500,0.722,8.036,PRR=5.37 (显著关联); χ²=55.1 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=72.2%
Nivolumab,Blood bilirubin increased,6,145,4.270,4.270,13.36,1.000,0.500,1.000,9.134,PRR=4.27 (显著关联); χ²=13.4 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Hypothyroidism,10,145,13.857,13.857,88.78,0.800,0.300,0.600,8.623,PRR=13.86 (显著关联); χ²=88.8 (统计显著); 死亡率=30.0%; 严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Nivolumab,Acute kidney injury,12,145,5.130,5.130,34.68,1.000,0.333,0.917,8.441,PRR=5.13 (显著关联); χ²=34.7 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=91.7%
Nivolumab,Hypopituitarism,7,145,26.618,26.618,106.01,1.000,0.286,1.000,8.980,PRR=26.62 (显著关联); χ²=106.0 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Blood alkaline phosphatase increased,8,145,6.519,6.519,31.76,1.000,0.750,0.750,8.847,PRR=6.52 (显著关联); χ²=31.8 (统计显著); 死亡率=75.0%; 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Nivolumab,Hepatic function abnormal,10,145,8.162,8.162,51.69,1.000,0.800,0.500,8.623,PRR=8.16 (显著关联); χ²=51.7 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Nivolumab,Gamma-glutamyltransferase increased,7,145,11.405,11.405,51.68,1.000,1.000,0.714,8.980,PRR=11.40 (显著关联); χ²=51.7 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Atezolizumab,Hyperglycaemia,9,145,6.915,6.915,39.53,1.000,0.222,1.000,8.729,PRR=6.92 (显著关联); χ²=39.5 (统计显著); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Mental status changes,5,145,7.178,7.178,23.09,1.000,0.800,1.000,9.317,PRR=7.18 (显著关联); χ²=23.1 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Autoimmune hepatitis,7,145,13.429,13.429,63.66,1.000,0.429,1.000,8.980,PRR=13.43 (显著关联); χ²=63.7 (统计显著); 死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Transaminases increased,5,145,4.415,4.415,11.98,1.000,0.400,0.800,9.317,PRR=4.42 (显著关联); χ²=12.0 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Atezolizumab,Pneumonitis,14,145,4.260,4.260,31.39,1.000,0.429,0.857,8.287,PRR=4.26 (显著关联); χ²=31.4 (统计显著); 死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Atezolizumab,Acute respiratory failure,5,145,10.636,10.636,35.99,1.000,0.600,1.000,9.317,PRR=10.64 (显著关联); χ²=36.0 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Myocarditis,9,145,47.043,47.043,196.97,1.000,0.333,0.889,8.729,PRR=47.04 (显著关联); χ²=197.0 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Durvalumab,Enterocolitis,5,145,9.373,9.373,30.37,1.000,0.800,0.800,9.317,PRR=9.37 (显著关联); χ²=30.4 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ipilimumab,Intestinal perforation,13,145,14.088,14.088,113.76,1.000,0.385,0.692,8.361,PRR=14.09 (显著关联); χ²=113.8 (统计显著); 死亡率=38.5%; 严重事件率=100.0%; 罕见+严重; 住院率=69.2%
Ipilimumab,Confusional state,10,145,2.848,2.848,10.83,0.900,0.400,0.700,8.623,PRR=2.85 (显著关联); χ²=10.8 (统计显著); 死亡率=40.0%; 严重事件率=90.0%; 罕见+严重; 住院率=70.0%
Ipilimumab,Hyponatraemia,11,145,3.556,3.556,17.96,1.000,0.273,0.818,8.528,PRR=3.56 (显著关联); χ²=18.0 (统计显著); 死亡率=27.3%; 严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Ipilimumab,Muscular weakness,10,145,3.363,3.363,14.83,1.000,0.300,1.000,8.623,PRR=3.36 (显著关联); χ²=14.8 (统计显著); 死亡率=30.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Peritonitis,5,145,8.901,8.901,28.00,1.000,0.600,0.800,9.317,PRR=8.90 (显著关联); χ²=28.0 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Trastuzumab,Balance disorder,6,145,3.731,3.731,10.17,1.000,0.333,0.500,9.134,PRR=3.73 (显著关联); χ²=10.2 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Ascites,12,145,4.407,4.407,26.55,1.000,0.500,0.417,8.441,PRR=4.41 (显著关联); χ²=26.6 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=41.7%
Bevacizumab,Epistaxis,12,145,3.426,3.426,17.81,1.000,0.250,0.417,8.441,PRR=3.43 (显著关联); χ²=17.8 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=41.7%
Rituximab,Bronchopneumonia,5,145,14.956,14.956,40.25,1.000,0.400,1.000,9.317,PRR=14.96 (显著关联); χ²=40.2 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rituximab,Cytomegalovirus infection,9,145,8.989,8.989,45.97,1.000,0.222,0.556,8.729,PRR=8.99 (显著关联); χ²=46.0 (统计显著); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Rituximab,Sinusitis,7,145,3.847,3.847,12.39,0.857,0.286,0.714,8.980,PRR=3.85 (显著关联); χ²=12.4 (统计显著); 死亡率=28.6%; 严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Epcoritamab,Hospitalisation,14,145,14.504,14.504,121.11,1.000,0.286,1.000,8.287,PRR=14.50 (显著关联); χ²=121.1 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Epcoritamab,Bacteraemia,5,145,10.604,10.604,32.58,1.000,0.400,0.600,9.317,PRR=10.60 (显著关联); χ²=32.6 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Epcoritamab,Neurotoxicity,6,145,10.823,10.823,39.86,1.000,0.667,0.667,9.134,PRR=10.82 (显著关联); χ²=39.9 (统计显著); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Epcoritamab,Cytomegalovirus infection,14,145,23.080,23.080,174.13,1.000,0.357,0.571,8.287,PRR=23.08 (显著关联); χ²=174.1 (统计显著); 死亡率=35.7%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Epcoritamab,Hypogammaglobulinaemia,8,145,36.133,36.133,132.22,1.000,0.375,0.500,8.847,PRR=36.13 (显著关联); χ²=132.2 (统计显著); 死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Imatinib,Myocardial infarction,9,145,3.025,3.025,10.47,0.889,0.444,0.444,8.729,PRR=3.02 (显著关联); χ²=10.5 (统计显著); 死亡率=44.4%; 严重事件率=88.9%; 罕见+严重; 住院率=44.4%
Erlotinib,Neoplasm,5,145,4.432,4.432,11.36,1.000,0.400,0.600,9.317,PRR=4.43 (显著关联); χ²=11.4 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Erlotinib,Haemoptysis,6,145,5.466,5.466,18.21,1.000,0.333,0.667,9.134,PRR=5.47 (显著关联); χ²=18.2 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Erlotinib,Eye irritation,9,145,43.439,43.439,157.63,1.000,0.222,0.444,8.729,PRR=43.44 (显著关联); χ²=157.6 (统计显著); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Erlotinib,Pulmonary embolism,14,145,2.489,2.489,11.14,1.000,0.357,0.571,8.287,PRR=2.49 (显著关联); χ²=11.1 (统计显著); 死亡率=35.7%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Gefitinib,Gastrointestinal haemorrhage,9,145,5.794,5.794,29.54,1.000,0.333,0.667,8.729,PRR=5.79 (显著关联); χ²=29.5 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Gefitinib,Malignant pleural effusion,5,145,13.346,13.346,39.95,1.000,0.400,0.600,9.317,PRR=13.35 (显著关联); χ²=39.9 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Gefitinib,Metastases to meninges,6,145,18.941,18.941,63.86,1.000,0.333,0.500,9.134,PRR=18.94 (显著关联); χ²=63.9 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Lung disorder,8,145,4.792,4.792,20.37,1.000,0.500,0.625,8.847,PRR=4.79 (显著关联); χ²=20.4 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Osimertinib,Weight decreased,17,145,2.299,2.299,11.21,0.882,0.353,0.412,8.093,PRR=2.30 (显著关联); χ²=11.2 (统计显著); 死亡率=35.3%; 严重事件率=88.2%; 罕见+严重; 住院率=41.2%
Osimertinib,Pulmonary embolism,14,145,2.589,2.589,12.21,1.000,0.500,0.857,8.287,PRR=2.59 (显著关联); χ²=12.2 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Osimertinib,Cardiac failure,8,145,3.152,3.152,10.41,0.875,0.250,0.500,8.847,PRR=3.15 (显著关联); χ²=10.4 (统计显著); 死亡率=25.0%; 严重事件率=87.5%; 罕见+严重; 住院率=50.0%
Osimertinib,Pneumonitis,15,145,2.791,2.791,15.32,1.000,0.533,0.733,8.218,PRR=2.79 (显著关联); χ²=15.3 (统计显著); 死亡率=53.3%; 严重事件率=100.0%; 罕见+严重; 住院率=73.3%
Crizotinib,Hypoxia,9,145,4.713,4.713,23.04,1.000,0.333,1.000,8.729,PRR=4.71 (显著关联); χ²=23.0 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Crizotinib,Posterior reversible encephalopathy syndrome,6,145,10.982,10.982,42.35,1.000,0.333,0.833,9.134,PRR=10.98 (显著关联); χ²=42.4 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Paclitaxel,General physical health deterioration,14,145,2.971,2.971,15.89,1.000,0.357,0.857,8.287,PRR=2.97 (显著关联); χ²=15.9 (统计显著); 死亡率=35.7%; 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Paclitaxel,Mucosal inflammation,12,145,3.228,3.228,15.92,1.000,0.833,0.667,8.441,PRR=3.23 (显著关联); χ²=15.9 (统计显著); 死亡率=83.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Paclitaxel,Hypophagia,7,145,3.905,3.905,12.83,1.000,1.000,0.571,8.980,PRR=3.90 (显著关联); χ²=12.8 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Paclitaxel,Oropharyngeal pain,8,145,3.627,3.627,13.01,1.000,1.000,0.625,8.847,PRR=3.63 (显著关联); χ²=13.0 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Paclitaxel,Oral candidiasis,11,145,15.999,15.999,95.85,1.000,0.818,0.545,8.528,PRR=16.00 (显著关联); χ²=95.8 (统计显著); 死亡率=81.8%; 严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Docetaxel,Leukopenia,13,145,3.611,3.611,20.76,1.000,0.231,0.538,8.361,PRR=3.61 (显著关联); χ²=20.8 (统计显著); 死亡率=23.1%; 严重事件率=100.0%; 罕见+严重; 住院率=53.8%
Docetaxel,Prostate cancer,6,145,8.233,8.233,28.20,1.000,0.833,0.500,9.134,PRR=8.23 (显著关联); χ²=28.2 (统计显著); 死亡率=83.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Haemolytic anaemia,6,145,5.870,5.870,18.72,1.000,0.500,0.833,9.134,PRR=5.87 (显著关联); χ²=18.7 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Cisplatin,Condition aggravated,6,145,4.556,4.556,13.72,1.000,0.333,0.500,9.134,PRR=4.56 (显著关联); χ²=13.7 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Rhabdomyolysis,5,145,7.591,7.591,21.54,1.000,1.000,0.600,9.317,PRR=7.59 (显著关联); χ²=21.5 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Cisplatin,Drug interaction,8,145,4.377,4.377,17.24,1.000,0.500,0.625,8.847,PRR=4.38 (显著关联); χ²=17.2 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Lenalidomide,Myelodysplastic syndrome,7,145,5.323,5.323,21.43,1.000,0.286,0.571,8.980,PRR=5.32 (显著关联); χ²=21.4 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Lenalidomide,Pulmonary embolism,12,145,2.905,2.905,13.62,1.000,0.250,0.750,8.441,PRR=2.90 (显著关联); χ²=13.6 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Lenalidomide,Deep vein thrombosis,16,145,7.627,7.627,76.32,1.000,0.312,0.500,8.153,PRR=7.63 (显著关联); χ²=76.3 (统计显著); 死亡率=31.2%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Lenalidomide,Syncope,7,145,3.489,3.489,11.23,1.000,0.429,0.571,8.980,PRR=3.49 (显著关联); χ²=11.2 (统计显著); 死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Pomalidomide,Cardiac failure congestive,6,145,4.142,4.142,12.90,1.000,0.333,0.500,9.134,PRR=4.14 (显著关联); χ²=12.9 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Bortezomib,Renal failure acute,12,145,3.249,3.249,16.35,1.000,0.333,0.833,8.441,PRR=3.25 (显著关联); χ²=16.3 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Carfilzomib,Tumour lysis syndrome,5,145,4.099,4.099,10.51,1.000,0.800,0.800,9.317,PRR=4.10 (显著关联); χ²=10.5 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Renal failure,13,145,3.152,3.152,17.28,1.000,0.385,0.692,8.361,PRR=3.15 (显著关联); χ²=17.3 (统计显著); 死亡率=38.5%; 严重事件率=100.0%; 罕见+严重; 住院率=69.2%
Carfilzomib,Cardiac failure,9,145,4.877,4.877,24.42,1.000,0.778,0.889,8.729,PRR=4.88 (显著关联); χ²=24.4 (统计显著); 死亡率=77.8%; 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Carfilzomib,Cardiac arrest,9,145,7.669,7.669,43.65,1.000,0.667,0.556,8.729,PRR=7.67 (显著关联); χ²=43.6 (统计显著); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Carfilzomib,Pulmonary hypertension,5,145,13.996,13.996,45.45,1.000,0.800,0.800,9.317,PRR=14.00 (显著关联); χ²=45.4 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Upper gastrointestinal haemorrhage,5,145,15.862,15.862,50.91,1.000,0.600,0.800,9.317,PRR=15.86 (显著关联); χ²=50.9 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Septic shock,7,145,3.622,3.622,12.00,1.000,0.714,0.571,8.980,PRR=3.62 (显著关联); χ²=12.0 (统计显著); 死亡率=71.4%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Carfilzomib,Hypertension,10,145,2.787,2.787,10.48,1.000,0.400,0.600,8.623,PRR=2.79 (显著关联); χ²=10.5 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Carfilzomib,Acute kidney injury,11,145,4.864,4.864,29.67,1.000,0.455,0.818,8.528,PRR=4.86 (显著关联); χ²=29.7 (统计显著); 死亡率=45.5%; 严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Venetoclax,Cytomegalovirus infection,5,145,6.405,6.405,19.07,1.000,0.600,0.600,9.317,PRR=6.40 (显著关联); χ²=19.1 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Venetoclax,Acute myeloid leukaemia,7,145,7.953,7.953,34.39,1.000,1.000,0.429,8.980,PRR=7.95 (显著关联); χ²=34.4 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Venetoclax,Tumour lysis syndrome,17,145,14.801,14.801,153.74,1.000,0.294,0.882,8.093,PRR=14.80 (显著关联); χ²=153.7 (统计显著); 死亡率=29.4%; 严重事件率=100.0%; 罕见+严重; 住院率=88.2%
Venetoclax,Splenomegaly,9,145,44.823,44.823,175.80,0.889,0.556,0.778,8.729,PRR=44.82 (显著关联); χ²=175.8 (统计显著); 死亡率=55.6%; 严重事件率=88.9%; 罕见+严重; 住院率=77.8%
Venetoclax,Chronic lymphocytic leukaemia,14,145,111.977,111.977,391.15,1.000,0.643,0.500,8.287,PRR=111.98 (显著关联); χ²=391.2 (统计显著); 死亡率=64.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Ibrutinib,Subdural haematoma,9,145,21.495,21.495,103.33,1.000,0.333,1.000,8.729,PRR=21.50 (显著关联); χ²=103.3 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Ecchymosis,6,145,50.071,50.071,111.63,0.833,0.333,0.667,9.134,PRR=50.07 (显著关联); χ²=111.6 (统计显著); 死亡率=33.3%; 严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Ibrutinib,Pleural effusion,16,145,2.586,2.586,13.84,1.000,0.375,0.875,8.153,PRR=2.59 (显著关联); χ²=13.8 (统计显著); 死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Ibrutinib,Lung infiltration,7,145,15.584,15.584,62.95,1.000,0.714,1.000,8.980,PRR=15.58 (显著关联); χ²=62.9 (统计显著); 死亡率=71.4%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Gingival bleeding,5,145,10.423,10.423,31.40,0.800,0.400,0.600,9.317,PRR=10.42 (显著关联); χ²=31.4 (统计显著); 死亡率=40.0%; 严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Ibrutinib,Haemorrhage intracranial,5,145,6.669,6.669,19.43,1.000,0.800,0.800,9.317,PRR=6.67 (显著关联); χ²=19.4 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Acute respiratory failure,6,145,7.700,7.700,27.48,1.000,0.833,0.833,9.134,PRR=7.70 (显著关联); χ²=27.5 (统计显著); 死亡率=83.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Ibrutinib,Cerebral haemorrhage,12,145,10.860,10.860,78.11,0.917,0.750,0.667,8.441,PRR=10.86 (显著关联); χ²=78.1 (统计显著); 死亡率=75.0%; 严重事件率=91.7%; 罕见+严重; 住院率=66.7%
Ibrutinib,Petechiae,5,145,9.809,9.809,29.57,1.000,0.400,0.600,9.317,PRR=9.81 (显著关联); χ²=29.6 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Olaparib,Intestinal obstruction,7,145,3.846,3.846,12.53,1.000,0.286,0.429,8.980,PRR=3.85 (显著关联); χ²=12.5 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Talazoparib,Septic shock,7,145,3.537,3.537,11.50,1.000,0.857,1.000,8.980,PRR=3.54 (显著关联); χ²=11.5 (统计显著); 死亡率=85.7%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Talazoparib,Second primary malignancy,5,145,4.221,4.221,10.97,1.000,0.400,0.600,9.317,PRR=4.22 (显著关联); χ²=11.0 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Palbociclib,Breast cancer,7,145,6.628,6.628,27.20,0.857,0.286,0.429,8.980,PRR=6.63 (显著关联); χ²=27.2 (统计显著); 死亡率=28.6%; 严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Ribociclib,Syncope,7,145,3.536,3.536,11.50,0.857,0.286,0.571,8.980,PRR=3.54 (显著关联); χ²=11.5 (统计显著); 死亡率=28.6%; 严重事件率=85.7%; 罕见+严重; 住院率=57.1%
Ribociclib,Pulmonary oedema,5,145,5.101,5.101,14.48,1.000,0.600,0.800,9.317,PRR=5.10 (显著关联); χ²=14.5 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Vemurafenib,Skin papilloma,9,145,107.594,107.594,229.74,0.889,0.222,0.556,8.729,PRR=107.59 (显著关联); χ²=229.7 (统计显著); 死亡率=22.2%; 严重事件率=88.9%; 罕见+严重; 住院率=55.6%
Vemurafenib,Gamma-glutamyltransferase increased,7,145,8.950,8.950,38.27,1.000,0.286,0.571,8.980,PRR=8.95 (显著关联); χ²=38.3 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Vemurafenib,Acne,7,145,4.639,4.639,17.11,1.000,0.286,0.429,8.980,PRR=4.64 (显著关联); χ²=17.1 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Vemurafenib,Rash erythematous,5,145,7.151,7.151,21.36,0.800,0.400,0.600,9.317,PRR=7.15 (显著关联); χ²=21.4 (统计显著); 死亡率=40.0%; 严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Vemurafenib,Metastasis,7,145,13.192,13.192,55.79,1.000,0.429,0.429,8.980,PRR=13.19 (显著关联); χ²=55.8 (统计显著); 死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Vemurafenib,Toxic epidermal necrolysis,6,145,13.419,13.419,48.58,1.000,0.833,1.000,9.134,PRR=13.42 (显著关联); χ²=48.6 (统计显著); 死亡率=83.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Dabrafenib,Investigation,9,145,21.040,21.040,103.74,1.000,0.444,1.000,8.729,PRR=21.04 (显著关联); χ²=103.7 (统计显著); 死亡率=44.4%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Myasthenia gravis,6,130,35.192,35.192,110.92,0.833,0.333,0.167,9.134,PRR=35.19 (显著关联); χ²=110.9 (统计显著); 死亡率=33.3%; 严重事件率=83.3%; 罕见+严重
Durvalumab,Immune thrombocytopenic purpura,8,130,62.674,62.674,202.30,1.000,1.000,0.000,8.847,PRR=62.67 (显著关联); χ²=202.3 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Durvalumab,Pulmonary alveolar haemorrhage,9,130,52.925,52.925,209.57,1.000,1.000,0.000,8.729,PRR=52.92 (显著关联); χ²=209.6 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Trastuzumab,Metastases to liver,9,130,3.361,3.361,12.79,1.000,0.222,0.222,8.729,PRR=3.36 (显著关联); χ²=12.8 (统计显著); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重
Trastuzumab,Breast cancer metastatic,9,130,4.945,4.945,23.11,1.000,0.333,0.333,8.729,PRR=4.94 (显著关联); χ²=23.1 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Haemorrhage,9,130,4.621,4.621,21.37,1.000,0.222,0.222,8.729,PRR=4.62 (显著关联); χ²=21.4 (统计显著); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Impaired healing,5,130,10.987,10.987,32.29,1.000,0.600,0.200,9.317,PRR=10.99 (显著关联); χ²=32.3 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Neuropathy peripheral,16,130,2.328,2.328,10.77,1.000,0.250,0.312,8.153,PRR=2.33 (显著关联); χ²=10.8 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Gastrointestinal perforation,8,130,12.325,12.325,57.30,1.000,0.500,0.250,8.847,PRR=12.32 (显著关联); χ²=57.3 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Skin discolouration,6,130,6.367,6.367,21.69,1.000,0.333,0.333,9.134,PRR=6.37 (显著关联); χ²=21.7 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Colitis ischaemic,6,130,16.790,16.790,55.63,1.000,1.000,0.000,9.134,PRR=16.79 (显著关联); χ²=55.6 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Migraine,6,130,7.694,7.694,26.97,1.000,1.000,0.000,9.134,PRR=7.69 (显著关联); χ²=27.0 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Rituximab,Rheumatoid arthritis,8,130,43.141,43.141,121.61,1.000,0.250,0.375,8.847,PRR=43.14 (显著关联); χ²=121.6 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Rituximab,Blood pressure systolic increased,5,130,67.310,67.310,89.74,1.000,0.400,0.200,9.317,PRR=67.31 (显著关联); χ²=89.7 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Rituximab,Hypogammaglobulinaemia,5,130,12.236,12.236,34.10,1.000,0.400,0.400,9.317,PRR=12.24 (显著关联); χ²=34.1 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Rituximab,Progressive multifocal leukoencephalopathy,5,130,14.956,14.956,40.25,1.000,0.400,0.200,9.317,PRR=14.96 (显著关联); χ²=40.2 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Blood lactate dehydrogenase increased,9,130,10.165,10.165,56.10,0.778,0.333,0.111,8.729,PRR=10.16 (显著关联); χ²=56.1 (统计显著); 死亡率=33.3%; 严重事件率=77.8%; 罕见+严重
Epcoritamab,C-reactive protein increased,10,130,11.666,11.666,71.22,1.000,0.500,0.200,8.623,PRR=11.67 (显著关联); χ²=71.2 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Intentional underdose,6,130,9.411,9.411,34.65,1.000,0.833,0.000,9.134,PRR=9.41 (显著关联); χ²=34.6 (统计显著); 死亡率=83.3%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Delirium,9,130,11.618,11.618,63.88,1.000,0.222,0.111,8.729,PRR=11.62 (显著关联); χ²=63.9 (统计显著); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Tumour pseudoprogression,6,130,216.536,216.536,178.20,1.000,0.333,0.333,9.134,PRR=216.54 (显著关联); χ²=178.2 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Imatinib,Leukaemia recurrent,12,130,63.093,63.093,206.49,1.000,0.583,0.083,8.441,PRR=63.09 (显著关联); χ²=206.5 (统计显著); 死亡率=58.3%; 严重事件率=100.0%; 罕见+严重
Imatinib,Chronic myeloid leukaemia,18,130,118.651,118.651,364.47,1.000,0.389,0.000,8.036,PRR=118.65 (显著关联); χ²=364.5 (统计显著); 死亡率=38.9%; 严重事件率=100.0%; 罕见+严重
Imatinib,No therapeutic response,5,130,5.456,5.456,14.46,1.000,0.600,0.400,9.317,PRR=5.46 (显著关联); χ²=14.5 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Incorrect dose administered,8,130,12.859,12.859,61.20,1.000,0.750,0.000,8.847,PRR=12.86 (显著关联); χ²=61.2 (统计显著); 死亡率=75.0%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Non-small cell lung cancer,5,130,4.812,4.812,12.78,1.000,0.600,0.400,9.317,PRR=4.81 (显著关联); χ²=12.8 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Lung cancer metastatic,6,130,50.587,50.587,112.85,1.000,0.833,0.333,9.134,PRR=50.59 (显著关联); χ²=112.9 (统计显著); 死亡率=83.3%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Dermatitis acneiform,7,130,8.745,8.745,36.85,1.000,0.571,0.286,8.980,PRR=8.75 (显著关联); χ²=36.8 (统计显著); 死亡率=57.1%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Lung neoplasm malignant,11,130,4.907,4.907,28.90,1.000,0.364,0.364,8.528,PRR=4.91 (显著关联); χ²=28.9 (统计显著); 死亡率=36.4%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Dry skin,14,130,3.965,3.965,26.78,0.786,0.429,0.357,8.287,PRR=3.96 (显著关联); χ²=26.8 (统计显著); 死亡率=42.9%; 严重事件率=78.6%; 罕见+严重
Gefitinib,Metastases to central nervous system,14,130,4.928,4.928,36.92,1.000,0.286,0.357,8.287,PRR=4.93 (显著关联); χ²=36.9 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Rash generalised,7,130,5.653,5.653,22.29,0.857,0.286,0.143,8.980,PRR=5.65 (显著关联); χ²=22.3 (统计显著); 死亡率=28.6%; 严重事件率=85.7%; 罕见+严重
Gefitinib,Disease recurrence,8,130,13.905,13.905,66.15,1.000,0.250,0.000,8.847,PRR=13.91 (显著关联); χ²=66.2 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Emphysematous cystitis,5,130,173.542,173.542,138.49,1.000,0.600,0.400,9.317,PRR=173.54 (显著关联); χ²=138.5 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Osimertinib,Dry skin,13,130,3.686,3.686,22.15,0.615,0.308,0.231,8.361,PRR=3.69 (显著关联); χ²=22.2 (统计显著); 死亡率=30.8%; 严重事件率=61.5%; 罕见+严重
Osimertinib,Intentional product misuse,5,130,7.618,7.618,22.87,0.600,0.400,0.400,9.317,PRR=7.62 (显著关联); χ²=22.9 (统计显著); 死亡率=40.0%; 严重事件率=60.0%; 罕见+严重
Crizotinib,Non-small cell lung cancer metastatic,5,130,27.440,27.440,76.32,0.800,0.400,0.200,9.317,PRR=27.44 (显著关联); χ²=76.3 (统计显著); 死亡率=40.0%; 严重事件率=80.0%; 罕见+严重
Crizotinib,Non-small cell lung cancer,18,130,36.293,36.293,327.24,0.833,0.778,0.333,8.036,PRR=36.29 (显著关联); χ²=327.2 (统计显著); 死亡率=77.8%; 严重事件率=83.3%; 罕见+严重
Crizotinib,Lung adenocarcinoma,6,130,16.475,16.475,61.69,0.667,0.333,0.167,9.134,PRR=16.47 (显著关联); χ²=61.7 (统计显著); 死亡率=33.3%; 严重事件率=66.7%; 罕见+严重
Paclitaxel,Metastases to bone,8,130,3.806,3.806,14.06,1.000,0.250,0.125,8.847,PRR=3.81 (显著关联); χ²=14.1 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Metastases to liver,11,130,4.379,4.379,23.92,1.000,0.364,0.182,8.528,PRR=4.38 (显著关联); χ²=23.9 (统计显著); 死亡率=36.4%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Breast cancer,6,130,4.579,4.579,13.96,1.000,0.333,0.000,9.134,PRR=4.58 (显著关联); χ²=14.0 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Haematotoxicity,7,130,4.513,4.513,15.94,1.000,0.286,0.143,8.980,PRR=4.51 (显著关联); χ²=15.9 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Leukopenia,11,130,3.163,3.163,14.07,0.909,0.364,0.182,8.528,PRR=3.16 (显著关联); χ²=14.1 (统计显著); 死亡率=36.4%; 严重事件率=90.9%; 罕见+严重
Paclitaxel,Alopecia,14,130,2.481,2.481,10.90,1.000,0.357,0.071,8.287,PRR=2.48 (显著关联); χ²=10.9 (统计显著); 死亡率=35.7%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Breast cancer metastatic,10,130,5.811,5.811,31.88,1.000,0.800,0.400,8.623,PRR=5.81 (显著关联); χ²=31.9 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Metastases to lung,6,130,4.834,4.834,15.05,1.000,0.333,0.333,9.134,PRR=4.83 (显著关联); χ²=15.1 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Hypoaesthesia,10,130,2.962,2.962,11.32,0.900,0.400,0.400,8.623,PRR=2.96 (显著关联); χ²=11.3 (统计显著); 死亡率=40.0%; 严重事件率=90.0%; 罕见+严重
Paclitaxel,Pancreatic carcinoma,5,130,18.125,18.125,47.99,1.000,1.000,0.000,9.317,PRR=18.13 (显著关联); χ²=48.0 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Palmar-plantar erythrodysaesthesia syndrome,11,130,4.800,4.800,27.00,1.000,0.273,0.182,8.528,PRR=4.80 (显著关联); χ²=27.0 (统计显著); 死亡率=27.3%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Metastases to liver,9,130,3.295,3.295,12.32,1.000,0.444,0.111,8.729,PRR=3.29 (显著关联); χ²=12.3 (统计显著); 死亡率=44.4%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Metastases to lung,8,130,6.462,6.462,28.71,1.000,0.625,0.250,8.847,PRR=6.46 (显著关联); χ²=28.7 (统计显著); 死亡率=62.5%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Gastrointestinal perforation,6,130,7.484,7.484,25.46,1.000,0.667,0.000,9.134,PRR=7.48 (显著关联); χ²=25.5 (统计显著); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Peritonitis,5,130,5.963,5.963,16.32,1.000,0.600,0.400,9.317,PRR=5.96 (显著关联); χ²=16.3 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Functional gastrointestinal disorder,5,130,27.437,27.437,61.28,1.000,1.000,0.000,9.317,PRR=27.44 (显著关联); χ²=61.3 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Hepatitis B,6,130,12.256,12.256,41.80,1.000,0.500,0.333,9.134,PRR=12.26 (显著关联); χ²=41.8 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Toxicity to various agents,15,130,3.283,3.283,20.43,1.000,0.667,0.133,8.218,PRR=3.28 (显著关联); χ²=20.4 (统计显著); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Myelodysplastic syndrome,10,130,4.937,4.937,25.71,1.000,0.500,0.300,8.623,PRR=4.94 (显著关联); χ²=25.7 (统计显著); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Cardiotoxicity,7,130,14.306,14.306,55.58,1.000,0.429,0.000,8.980,PRR=14.31 (显著关联); χ²=55.6 (统计显著); 死亡率=42.9%; 严重事件率=100.0%; 罕见+严重
Carboplatin,Osteosarcoma,5,130,17.467,17.467,43.39,1.000,0.400,0.000,9.317,PRR=17.47 (显著关联); χ²=43.4 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Haematotoxicity,8,130,4.974,4.974,20.63,1.000,0.375,0.000,8.847,PRR=4.97 (显著关联); χ²=20.6 (统计显著); 死亡率=37.5%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Nephropathy toxic,5,130,15.185,15.185,40.97,1.000,0.400,0.400,9.317,PRR=15.19 (显著关联); χ²=41.0 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Disseminated intravascular coagulation,6,130,5.291,5.291,16.81,1.000,0.667,0.333,9.134,PRR=5.29 (显著关联); χ²=16.8 (统计显著); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Deafness,8,130,9.123,9.123,41.67,1.000,0.250,0.000,8.847,PRR=9.12 (显著关联); χ²=41.7 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Ovarian disorder,6,130,7.457,7.457,25.34,1.000,0.333,0.000,9.134,PRR=7.46 (显著关联); χ²=25.3 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Renal failure chronic,5,130,9.761,9.761,27.87,1.000,0.400,0.200,9.317,PRR=9.76 (显著关联); χ²=27.9 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Lenalidomide,Acute myeloid leukaemia,5,130,6.260,6.260,18.96,1.000,0.600,0.000,9.317,PRR=6.26 (显著关联); χ²=19.0 (统计显著); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Bortezomib,Myelodysplastic syndrome,8,130,4.398,4.398,17.88,1.000,0.250,0.250,8.847,PRR=4.40 (显著关联); χ²=17.9 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Carfilzomib,Myocardial infarction,8,130,4.826,4.826,21.40,1.000,0.375,0.375,8.847,PRR=4.83 (显著关联); χ²=21.4 (统计显著); 死亡率=37.5%; 严重事件率=100.0%; 罕见+严重
Carfilzomib,Intestinal perforation,5,130,5.170,5.170,14.78,1.000,0.400,0.400,9.317,PRR=5.17 (显著关联); χ²=14.8 (统计显著); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Carfilzomib,Thrombotic microangiopathy,6,130,25.981,25.981,90.83,1.000,0.333,0.333,9.134,PRR=25.98 (显著关联); χ²=90.8 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Ibrutinib,Lymphocyte count increased,13,130,108.960,108.960,315.08,0.846,0.231,0.385,8.361,PRR=108.96 (显著关联); χ²=315.1 (统计显著); 死亡率=23.1%; 严重事件率=84.6%; 罕见+严重
Olaparib,Depression,9,130,4.036,4.036,17.34,0.889,0.222,0.333,8.729,PRR=4.04 (显著关联); χ²=17.3 (统计显著); 死亡率=22.2%; 严重事件率=88.9%; 罕见+严重
Olaparib,Intentional product misuse,14,130,29.254,29.254,183.21,0.714,0.286,0.214,8.287,PRR=29.25 (显著关联); χ²=183.2 (统计显著); 死亡率=28.6%; 严重事件率=71.4%; 罕见+严重
Olaparib,Ovarian cancer,5,130,16.174,16.174,44.11,0.800,0.800,0.400,9.317,PRR=16.17 (显著关联); χ²=44.1 (统计显著); 死亡率=80.0%; 严重事件率=80.0%; 罕见+严重
Vemurafenib,Skin reaction,7,130,22.789,22.789,86.27,1.000,0.286,0.143,8.980,PRR=22.79 (显著关联); χ²=86.3 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Vemurafenib,Metastatic malignant melanoma,8,130,15.925,15.925,74.93,1.000,0.250,0.125,8.847,PRR=15.92 (显著关联); χ²=74.9 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Dabrafenib,Ejection fraction decreased,7,130,5.976,5.976,23.96,1.000,0.286,0.286,8.980,PRR=5.98 (显著关联); χ²=24.0 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Dabrafenib,Tremor,9,130,4.851,4.851,23.33,0.556,0.333,0.333,8.729,PRR=4.85 (显著关联); χ²=23.3 (统计显著); 死亡率=33.3%; 严重事件率=55.6%; 罕见+严重
Dabrafenib,Metastatic malignant melanoma,8,130,15.575,15.575,73.03,1.000,0.750,0.375,8.847,PRR=15.57 (显著关联); χ²=73.0 (统计显著); 死亡率=75.0%; 严重事件率=100.0%; 罕见+严重
Dabrafenib,Malignant melanoma,10,130,29.244,29.244,143.67,1.000,0.300,0.300,8.623,PRR=29.24 (显著关联); χ²=143.7 (统计显著); 死亡率=30.0%; 严重事件率=100.0%; 罕见+严重
Pembrolizumab,Urinary retention,4,125,11.546,11.546,30.06,0.750,0.250,0.750,9.540,PRR=11.55 (显著关联); χ²=30.1 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Pembrolizumab,General physical health deterioration,8,125,2.587,2.587,7.15,0.875,0.375,0.750,8.847,PRR=2.59 (显著关联); 死亡率=37.5%; 严重事件率=87.5%; 罕见+严重; 住院率=75.0%
Pembrolizumab,Agitation,4,125,12.316,12.316,32.02,0.750,0.250,0.500,9.540,PRR=12.32 (显著关联); χ²=32.0 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Pembrolizumab,Metastatic malignant melanoma,4,125,8.396,8.396,21.50,1.000,0.750,0.500,9.540,PRR=8.40 (显著关联); χ²=21.5 (统计显著); 死亡率=75.0%; 罕见+严重; 住院率=50.0%
Nivolumab,Pulmonary embolism,9,125,2.103,2.103,4.81,1.000,0.222,1.000,8.729,PRR=2.10 (显著关联); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Encephalopathy,3,125,5.684,5.684,10.04,1.000,0.667,1.000,9.827,PRR=5.68 (显著关联); χ²=10.0 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Nivolumab,Dehydration,18,125,2.073,2.073,9.15,1.000,0.222,1.000,8.036,PRR=2.07 (显著关联); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Respiratory failure,8,125,2.496,2.496,6.59,1.000,0.875,0.875,8.847,PRR=2.50 (显著关联); 死亡率=87.5%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Nivolumab,Multiple organ dysfunction syndrome,4,125,13.004,13.004,33.61,1.000,0.750,0.750,9.540,PRR=13.00 (显著关联); χ²=33.6 (统计显著); 死亡率=75.0%; 罕见+严重; 住院率=75.0%
Nivolumab,C-reactive protein increased,4,125,4.919,4.919,10.98,1.000,0.750,0.750,9.540,PRR=4.92 (显著关联); χ²=11.0 (统计显著); 死亡率=75.0%; 罕见+严重; 住院率=75.0%
Nivolumab,Thyroiditis,4,125,36.418,36.418,74.64,1.000,0.250,1.000,9.540,PRR=36.42 (显著关联); χ²=74.6 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Transfusion,3,125,9.745,9.745,18.92,1.000,0.667,1.000,9.827,PRR=9.75 (显著关联); χ²=18.9 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Atezolizumab,Sepsis,11,125,2.302,2.302,7.52,1.000,0.273,0.909,8.528,PRR=2.30 (显著关联); 死亡率=27.3%; 严重事件率=100.0%; 罕见+严重; 住院率=90.9%
Atezolizumab,Haemoptysis,4,125,5.883,5.883,14.38,1.000,1.000,1.000,9.540,PRR=5.88 (显著关联); χ²=14.4 (统计显著); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Respiratory failure,6,125,2.326,2.326,4.24,1.000,0.333,0.833,9.134,PRR=2.33 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Atezolizumab,Urinary retention,3,125,10.116,10.116,20.52,1.000,0.333,0.667,9.827,PRR=10.12 (显著关联); χ²=20.5 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Atezolizumab,Toxic epidermal necrolysis,3,125,9.051,9.051,18.17,1.000,0.333,1.000,9.827,PRR=9.05 (显著关联); χ²=18.2 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Atezolizumab,Meningitis,3,125,14.333,14.333,29.16,1.000,0.333,1.000,9.827,PRR=14.33 (显著关联); χ²=29.2 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Durvalumab,Myositis,4,125,15.613,15.613,40.02,1.000,0.750,0.750,9.540,PRR=15.61 (显著关联); χ²=40.0 (统计显著); 死亡率=75.0%; 罕见+严重; 住院率=75.0%
Durvalumab,Atrial fibrillation,8,125,2.259,2.259,5.19,1.000,0.250,0.875,8.847,PRR=2.26 (显著关联); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Durvalumab,Cerebrovascular accident,5,125,2.464,2.464,4.02,1.000,0.400,1.000,9.317,PRR=2.46 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Product dose omission,4,125,17.032,17.032,43.18,1.000,0.250,0.500,9.540,PRR=17.03 (显著关联); χ²=43.2 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Ipilimumab,Chills,9,125,2.692,2.692,8.69,0.556,0.333,0.444,8.729,PRR=2.69 (显著关联); 死亡率=33.3%; 严重事件率=55.6%; 罕见+严重; 住院率=44.4%
Ipilimumab,Septic shock,5,125,2.175,2.175,2.93,1.000,0.400,1.000,9.317,PRR=2.18 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Haemorrhoids,3,125,6.456,6.456,11.63,1.000,0.333,1.000,9.827,PRR=6.46 (显著关联); χ²=11.6 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ipilimumab,Cholecystitis,3,125,9.436,9.436,17.90,1.000,0.333,1.000,9.827,PRR=9.44 (显著关联); χ²=17.9 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ipilimumab,Large intestine perforation,4,125,5.844,5.844,13.67,1.000,0.500,0.750,9.540,PRR=5.84 (显著关联); χ²=13.7 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Trastuzumab,Muscular weakness,11,125,2.547,2.547,9.07,1.000,0.273,0.455,8.528,PRR=2.55 (显著关联); 死亡率=27.3%; 严重事件率=100.0%; 罕见+严重; 住院率=45.5%
Trastuzumab,Hydrocephalus,4,125,11.187,11.187,25.53,1.000,0.750,1.000,9.540,PRR=11.19 (显著关联); χ²=25.5 (统计显著); 死亡率=75.0%; 罕见+严重; 住院率=100.0%
Trastuzumab,Vertigo,5,125,3.411,3.411,7.31,1.000,0.400,1.000,9.317,PRR=3.41 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Trastuzumab,Sleep disorder,4,125,5.084,5.084,10.69,0.750,0.250,0.500,9.540,PRR=5.08 (显著关联); χ²=10.7 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Trastuzumab,Mitral valve incompetence,4,125,15.983,15.983,34.44,1.000,0.250,0.500,9.540,PRR=15.98 (显著关联); χ²=34.4 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Trastuzumab,Cardiac failure congestive,8,125,3.068,3.068,9.65,1.000,0.250,0.625,8.847,PRR=3.07 (显著关联); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Bevacizumab,Convulsion,6,125,3.418,3.418,8.90,1.000,0.333,0.833,9.134,PRR=3.42 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Bevacizumab,Renal failure acute,9,125,2.215,2.215,5.38,1.000,0.222,0.667,8.729,PRR=2.22 (显著关联); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Bevacizumab,Coma,4,125,5.589,5.589,12.32,1.000,0.500,0.750,9.540,PRR=5.59 (显著关联); χ²=12.3 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Bevacizumab,Fistula,4,125,24.600,24.600,48.61,1.000,0.500,0.500,9.540,PRR=24.60 (显著关联); χ²=48.6 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Gastric perforation,3,125,7.091,7.091,12.33,1.000,0.333,1.000,9.827,PRR=7.09 (显著关联); χ²=12.3 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Rituximab,Lung disorder,7,125,3.194,3.194,9.05,1.000,0.286,0.571,8.980,PRR=3.19 (显著关联); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Rituximab,Fall,13,125,2.111,2.111,6.73,1.000,0.308,0.846,8.361,PRR=2.11 (显著关联); 死亡率=30.8%; 严重事件率=100.0%; 罕见+严重; 住院率=84.6%
Rituximab,Foot deformity,3,125,26.897,26.897,36.00,1.000,0.333,1.000,9.827,PRR=26.90 (显著关联); χ²=36.0 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Rituximab,Septic shock,7,125,2.047,2.047,3.34,1.000,0.714,0.429,8.980,PRR=2.05 (显著关联); 死亡率=71.4%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Rituximab,Laryngitis,3,125,16.137,16.137,25.63,1.000,0.333,0.667,9.827,PRR=16.14 (显著关联); χ²=25.6 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Rituximab,Arthropathy,4,125,8.969,8.969,20.43,1.000,0.250,0.500,9.540,PRR=8.97 (显著关联); χ²=20.4 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Rituximab,Clostridium difficile colitis,4,125,5.124,5.124,10.73,1.000,0.250,0.750,9.540,PRR=5.12 (显著关联); χ²=10.7 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Rituximab,Graft versus host disease,4,125,13.454,13.454,29.57,1.000,0.250,0.500,9.540,PRR=13.45 (显著关联); χ²=29.6 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Rituximab,Thrombotic thrombocytopenic purpura,4,125,15.376,15.376,32.92,1.000,0.500,0.500,9.540,PRR=15.38 (显著关联); χ²=32.9 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Rituximab,Nasopharyngitis,8,125,2.762,2.762,7.82,1.000,0.250,0.625,8.847,PRR=2.76 (显著关联); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Rituximab,Aspergillus infection,3,125,20.172,20.172,30.07,1.000,0.333,0.667,9.827,PRR=20.17 (显著关联); χ²=30.1 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Rituximab,Purpura,4,125,5.664,5.664,12.20,1.000,0.250,1.000,9.540,PRR=5.66 (显著关联); χ²=12.2 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Rituximab,Bronchiectasis,3,125,80.693,80.693,56.82,1.000,1.000,0.667,9.827,PRR=80.69 (显著关联); χ²=56.8 (统计显著); 死亡率=100.0%; 罕见+严重; 住院率=66.7%
Epcoritamab,Hypoalbuminaemia,4,125,6.266,6.266,14.62,1.000,0.500,0.500,9.540,PRR=6.27 (显著关联); χ²=14.6 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Imatinib,Renal failure chronic,4,125,6.982,6.982,15.55,1.000,0.250,0.500,9.540,PRR=6.98 (显著关联); χ²=15.6 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Erlotinib,Drug hypersensitivity,4,125,5.387,5.387,11.93,1.000,0.500,0.500,9.540,PRR=5.39 (显著关联); χ²=11.9 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Erlotinib,General physical health deterioration,9,125,2.136,2.136,4.92,1.000,0.667,0.889,8.729,PRR=2.14 (显著关联); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Erlotinib,Brain neoplasm,4,125,7.923,7.923,18.97,1.000,0.500,0.500,9.540,PRR=7.92 (显著关联); χ²=19.0 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Pleural effusion,13,125,2.151,2.151,7.24,0.846,0.308,0.692,8.361,PRR=2.15 (显著关联); 死亡率=30.8%; 严重事件率=84.6%; 罕见+严重; 住院率=69.2%
Gefitinib,Gait disturbance,7,125,2.404,2.404,5.18,0.857,0.286,0.714,8.980,PRR=2.40 (显著关联); 死亡率=28.6%; 严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Gefitinib,Duodenal ulcer,3,125,9.452,9.452,17.28,1.000,0.333,1.000,9.827,PRR=9.45 (显著关联); χ²=17.3 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Gefitinib,Cerebral infarction,4,125,6.935,6.935,16.41,1.000,0.250,1.000,9.540,PRR=6.93 (显著关联); χ²=16.4 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Osimertinib,Skin burning sensation,3,125,13.127,13.127,23.71,1.000,0.333,0.667,9.827,PRR=13.13 (显著关联); χ²=23.7 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Osimertinib,Pneumothorax,4,125,5.002,5.002,10.86,1.000,0.250,0.750,9.540,PRR=5.00 (显著关联); χ²=10.9 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Osimertinib,Metastases to bone,5,125,2.736,2.736,4.94,1.000,0.600,0.600,9.317,PRR=2.74 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Osimertinib,Lung disorder,6,125,3.504,3.504,9.44,1.000,0.667,0.667,9.134,PRR=3.50 (显著关联); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Osimertinib,Metastases to central nervous system,8,125,2.671,2.671,7.50,1.000,0.625,0.500,8.847,PRR=2.67 (显著关联); 死亡率=62.5%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Osimertinib,Cardiac tamponade,3,125,11.668,11.668,21.29,1.000,0.667,0.667,9.827,PRR=11.67 (显著关联); χ²=21.3 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Osimertinib,Hepatic function abnormal,6,125,3.504,3.504,9.44,1.000,0.667,0.667,9.134,PRR=3.50 (显著关联); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Osimertinib,Lymphangiosis carcinomatosa,3,125,11.668,11.668,21.29,1.000,0.333,0.667,9.827,PRR=11.67 (显著关联); χ²=21.3 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Crizotinib,Thrombosis,6,125,2.925,2.925,6.92,0.833,0.500,0.500,9.134,PRR=2.92 (显著关联); 死亡率=50.0%; 严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Crizotinib,Pulmonary embolism,9,125,2.026,2.026,4.32,1.000,0.444,0.667,8.729,PRR=2.03 (显著关联); 死亡率=44.4%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Crizotinib,Oedema,5,125,2.775,2.775,5.19,0.600,0.400,0.600,9.317,PRR=2.78 (显著关联); 死亡率=40.0%; 严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Paclitaxel,Septic shock,7,125,2.205,2.205,4.12,1.000,0.857,0.571,8.980,PRR=2.21 (显著关联); 死亡率=85.7%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Paclitaxel,Drug effect incomplete,4,125,16.563,16.563,35.90,1.000,0.250,0.500,9.540,PRR=16.56 (显著关联); χ²=35.9 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Docetaxel,Hypokalaemia,9,125,2.715,2.715,8.50,1.000,0.222,1.000,8.729,PRR=2.71 (显著关联); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Docetaxel,Rales,3,125,27.410,27.410,36.77,1.000,0.667,1.000,9.827,PRR=27.41 (显著关联); χ²=36.8 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Docetaxel,Angioedema,4,125,13.711,13.711,30.25,0.750,0.250,0.500,9.540,PRR=13.71 (显著关联); χ²=30.2 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Docetaxel,Cachexia,3,125,7.474,7.474,12.73,1.000,1.000,0.667,9.827,PRR=7.47 (显著关联); χ²=12.7 (统计显著); 死亡率=100.0%; 罕见+严重; 住院率=66.7%
Docetaxel,Computerised tomogram thorax abnormal,3,125,82.232,82.232,57.97,1.000,0.333,1.000,9.827,PRR=82.23 (显著关联); χ²=58.0 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Doxorubicin,Klebsiella infection,3,125,17.134,17.134,27.47,1.000,0.333,0.667,9.827,PRR=17.13 (显著关联); χ²=27.5 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Doxorubicin,Hepatic cirrhosis,4,125,16.326,16.326,35.30,1.000,0.250,0.500,9.540,PRR=16.33 (显著关联); χ²=35.3 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Radiation pneumonitis,3,125,7.329,7.329,12.10,1.000,0.333,1.000,9.827,PRR=7.33 (显著关联); χ²=12.1 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Carboplatin,Bone marrow toxicity,4,125,24.444,24.444,43.12,1.000,1.000,0.500,9.540,PRR=24.44 (显著关联); χ²=43.1 (统计显著); 死亡率=100.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Pulmonary haemorrhage,4,125,5.750,5.750,12.18,1.000,1.000,1.000,9.540,PRR=5.75 (显著关联); χ²=12.2 (统计显著); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Carboplatin,Nephropathy toxic,3,125,6.663,6.663,10.88,1.000,0.667,0.667,9.827,PRR=6.66 (显著关联); χ²=10.9 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Carboplatin,Faecaloma,3,125,24.434,24.434,32.34,1.000,0.333,1.000,9.827,PRR=24.43 (显著关联); χ²=32.3 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Cisplatin,Chest pain,13,125,2.080,2.080,6.47,1.000,0.231,0.615,8.361,PRR=2.08 (显著关联); 死亡率=23.1%; 严重事件率=100.0%; 罕见+严重; 住院率=61.5%
Cisplatin,Toxicity to various agents,10,125,2.010,2.010,4.53,1.000,0.600,0.500,8.623,PRR=2.01 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Ischaemic stroke,3,125,6.301,6.301,10.47,1.000,0.333,0.667,9.827,PRR=6.30 (显著关联); χ²=10.5 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Cisplatin,Incorrect route of drug administration,4,125,15.612,15.612,33.51,1.000,0.250,0.500,9.540,PRR=15.61 (显著关联); χ²=33.5 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Body temperature increased,4,125,5.463,5.463,11.69,1.000,0.250,1.000,9.540,PRR=5.46 (显著关联); χ²=11.7 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Clostridium test positive,3,125,20.481,20.481,30.59,1.000,0.333,1.000,9.827,PRR=20.48 (显著关联); χ²=30.6 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Cisplatin,Odynophagia,3,125,13.654,13.654,22.59,1.000,0.667,1.000,9.827,PRR=13.65 (显著关联); χ²=22.6 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Lenalidomide,Abasia,4,125,10.895,10.895,28.38,1.000,0.500,0.500,9.540,PRR=10.90 (显著关联); χ²=28.4 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Lenalidomide,Sepsis,12,125,2.032,2.032,5.81,1.000,0.667,0.667,8.441,PRR=2.03 (显著关联); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Lenalidomide,Cerebrovascular accident,6,125,2.956,2.956,7.10,1.000,0.333,0.500,9.134,PRR=2.96 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Bortezomib,Syncope,6,125,2.102,2.102,3.14,1.000,0.333,1.000,9.134,PRR=2.10 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Pathological fracture,3,125,9.875,9.875,17.83,1.000,0.333,1.000,9.827,PRR=9.88 (显著关联); χ²=17.8 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Bortezomib,Cardiac failure congestive,6,125,2.635,2.635,5.44,1.000,0.333,0.667,9.134,PRR=2.64 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Bortezomib,Spinal compression fracture,3,125,7.596,7.596,13.52,1.000,0.333,0.667,9.827,PRR=7.60 (显著关联); χ²=13.5 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bortezomib,Plasma cell myeloma recurrent,3,125,14.108,14.108,24.77,1.000,0.333,0.667,9.827,PRR=14.11 (显著关联); χ²=24.8 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bortezomib,Respiratory failure,9,125,2.046,2.046,4.36,1.000,0.778,0.444,8.729,PRR=2.05 (显著关联); 死亡率=77.8%; 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Bortezomib,Pulmonary oedema,5,125,3.580,3.580,8.11,1.000,0.400,0.600,9.317,PRR=3.58 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Carfilzomib,Renal failure acute,8,125,3.023,3.023,9.88,1.000,0.375,0.875,8.847,PRR=3.02 (显著关联); 死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Carfilzomib,Sepsis,12,125,2.087,2.087,6.28,1.000,0.417,0.750,8.441,PRR=2.09 (显著关联); 死亡率=41.7%; 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Carfilzomib,Acute respiratory distress syndrome,4,125,5.432,5.432,12.66,1.000,0.750,1.000,9.540,PRR=5.43 (显著关联); χ²=12.7 (统计显著); 死亡率=75.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Respiratory failure,7,125,2.265,2.265,4.58,1.000,0.286,0.857,8.980,PRR=2.26 (显著关联); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Carfilzomib,Oedema peripheral,8,125,2.663,2.663,7.63,1.000,0.375,0.625,8.847,PRR=2.66 (显著关联); 死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Carfilzomib,Hepatitis B,3,125,8.383,8.383,16.19,1.000,0.667,0.667,9.827,PRR=8.38 (显著关联); χ²=16.2 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Carfilzomib,Staphylococcal bacteraemia,3,125,17.816,17.816,33.82,1.000,0.667,0.667,9.827,PRR=17.82 (显著关联); χ²=33.8 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Carfilzomib,Plasma cell myeloma recurrent,3,125,20.362,20.362,37.76,1.000,0.667,0.667,9.827,PRR=20.36 (显著关联); χ²=37.8 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Carfilzomib,Acute myocardial infarction,3,125,7.500,7.500,14.25,1.000,0.333,0.667,9.827,PRR=7.50 (显著关联); χ²=14.3 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Venetoclax,Hyperkalaemia,4,125,5.669,5.669,13.08,1.000,0.250,0.750,9.540,PRR=5.67 (显著关联); χ²=13.1 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Venetoclax,Hypoxia,7,125,3.234,3.234,9.68,1.000,0.286,1.000,8.980,PRR=3.23 (显著关联); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Presyncope,4,125,7.938,7.938,19.65,1.000,0.750,1.000,9.540,PRR=7.94 (显著关联); χ²=19.6 (统计显著); 死亡率=75.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Septic shock,5,125,2.110,2.110,2.69,1.000,0.800,1.000,9.317,PRR=2.11 (显著关联); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Ileus,4,125,5.669,5.669,13.08,1.000,0.250,1.000,9.540,PRR=5.67 (显著关联); χ²=13.1 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Abdominal distension,6,125,2.870,2.870,6.61,1.000,0.333,0.667,9.134,PRR=2.87 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Venetoclax,Blood potassium increased,4,125,11.341,11.341,28.52,1.000,0.500,0.750,9.540,PRR=11.34 (显著关联); χ²=28.5 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Venetoclax,Blood phosphorus increased,3,125,39.672,39.672,55.03,1.000,0.667,0.667,9.827,PRR=39.67 (显著关联); χ²=55.0 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Venetoclax,Neuralgia,4,125,13.231,13.231,32.98,1.000,0.750,0.750,9.540,PRR=13.23 (显著关联); χ²=33.0 (统计显著); 死亡率=75.0%; 罕见+严重; 住院率=75.0%
Venetoclax,Pseudomonal sepsis,3,125,119.019,119.019,85.42,1.000,0.667,1.000,9.827,PRR=119.02 (显著关联); χ²=85.4 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Ibrutinib,Pulmonary mass,4,125,8.333,8.333,19.99,1.000,0.250,1.000,9.540,PRR=8.33 (显著关联); χ²=20.0 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Myocardial infarction,6,125,2.469,2.469,4.72,1.000,0.667,0.667,9.134,PRR=2.47 (显著关联); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Ibrutinib,Cardiac failure,8,125,3.000,3.000,9.44,1.000,0.375,0.750,8.847,PRR=3.00 (显著关联); 死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Ibrutinib,Post procedural haemorrhage,4,125,33.340,33.340,60.75,1.000,0.250,1.000,9.540,PRR=33.34 (显著关联); χ²=60.8 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Hemiparesis,3,125,5.878,5.878,10.00,1.000,0.667,0.667,9.827,PRR=5.88 (显著关联); χ²=10.0 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Ibrutinib,Bronchopulmonary aspergillosis,3,125,9.086,9.086,16.43,1.000,1.000,1.000,9.827,PRR=9.09 (显著关联); χ²=16.4 (统计显著); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Lymphadenopathy,5,125,2.346,2.346,3.49,1.000,0.400,0.800,9.317,PRR=2.35 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Progressive multifocal leukoencephalopathy,3,125,9.086,9.086,16.43,1.000,0.667,1.000,9.827,PRR=9.09 (显著关联); χ²=16.4 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Ibrutinib,Fungal sepsis,3,125,49.981,49.981,55.81,1.000,0.333,1.000,9.827,PRR=49.98 (显著关联); χ²=55.8 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Malignant pleural effusion,3,125,6.662,6.662,11.66,1.000,0.333,1.000,9.827,PRR=6.66 (显著关联); χ²=11.7 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Subdural haemorrhage,3,125,49.981,49.981,55.81,1.000,0.333,1.000,9.827,PRR=49.98 (显著关联); χ²=55.8 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Gastric ulcer,4,125,6.666,6.666,15.54,1.000,0.250,1.000,9.540,PRR=6.67 (显著关联); χ²=15.5 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Upper gastrointestinal haemorrhage,3,125,5.878,5.878,10.00,1.000,0.333,0.667,9.827,PRR=5.88 (显著关联); χ²=10.0 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Ibrutinib,Haematoma,3,125,9.086,9.086,16.43,1.000,0.667,0.667,9.827,PRR=9.09 (显著关联); χ²=16.4 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Ibrutinib,Systemic inflammatory response syndrome,4,125,9.524,9.524,22.98,1.000,0.500,1.000,9.540,PRR=9.52 (显著关联); χ²=23.0 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Autoimmune haemolytic anaemia,4,125,8.889,8.889,21.41,1.000,0.250,0.750,9.540,PRR=8.89 (显著关联); χ²=21.4 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Olaparib,Anxiety,9,125,2.789,2.789,9.05,0.889,0.222,0.556,8.729,PRR=2.79 (显著关联); 死亡率=22.2%; 严重事件率=88.9%; 罕见+严重; 住院率=55.6%
Rucaparib,Ascites,10,125,2.286,2.286,6.13,1.000,0.300,0.500,8.623,PRR=2.29 (显著关联); 死亡率=30.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Niraparib,Limb discomfort,4,125,6.229,6.229,12.15,0.750,0.250,0.500,9.540,PRR=6.23 (显著关联); χ²=12.1 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Talazoparib,Condition aggravated,4,125,4.885,4.885,10.90,0.750,0.250,0.750,9.540,PRR=4.89 (显著关联); χ²=10.9 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Talazoparib,Alanine aminotransferase increased,9,125,2.405,2.405,6.80,1.000,0.222,0.556,8.729,PRR=2.40 (显著关联); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Talazoparib,Blood bilirubin increased,5,125,3.571,3.571,8.37,1.000,0.400,0.600,9.317,PRR=3.57 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Talazoparib,Deep vein thrombosis,5,125,2.128,2.128,2.78,1.000,0.400,1.000,9.317,PRR=2.13 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Vemurafenib,Brain oedema,3,125,6.696,6.696,11.88,1.000,1.000,0.667,9.827,PRR=6.70 (显著关联); χ²=11.9 (统计显著); 死亡率=100.0%; 罕见+严重; 住院率=66.7%
Vemurafenib,Convulsion,5,125,3.249,3.249,6.91,1.000,0.400,0.800,9.317,PRR=3.25 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Dabrafenib,Hyponatraemia,8,125,2.152,2.152,4.48,1.000,0.250,1.000,8.847,PRR=2.15 (显著关联); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Dabrafenib,Acrochordon,4,125,46.616,46.616,74.19,1.000,0.250,0.500,9.540,PRR=46.62 (显著关联); χ²=74.2 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Dabrafenib,Rhabdomyolysis,4,125,7.358,7.358,17.60,1.000,0.250,0.750,9.540,PRR=7.36 (显著关联); χ²=17.6 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Dabrafenib,Metastases to meninges,3,125,7.485,7.485,13.47,1.000,0.667,0.667,9.827,PRR=7.49 (显著关联); χ²=13.5 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Pembrolizumab,Anaemia,33,120,2.675,2.675,30.83,0.606,0.303,0.606,7.430,PRR=2.68 (显著关联); χ²=30.8 (统计显著); 死亡率=30.3%; 严重事件率=60.6%; 住院率=60.6%
Nivolumab,Pneumonitis,28,120,7.367,7.367,126.63,1.000,0.250,0.893,7.594,PRR=7.37 (显著关联); χ²=126.6 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 住院率=89.3%
Nivolumab,Alanine aminotransferase increased,22,120,6.298,6.298,82.60,1.000,0.545,0.773,7.835,PRR=6.30 (显著关联); χ²=82.6 (统计显著); 死亡率=54.5%; 严重事件率=100.0%; 住院率=77.3%
Nivolumab,Malignant neoplasm progression,68,120,5.207,5.207,190.09,1.000,0.926,0.735,6.707,PRR=5.21 (显著关联); χ²=190.1 (统计显著); 死亡率=92.6%; 严重事件率=100.0%; 住院率=73.5%
Atezolizumab,Pneumonia,29,120,3.308,3.308,41.72,1.000,0.379,0.966,7.559,PRR=3.31 (显著关联); χ²=41.7 (统计显著); 死亡率=37.9%; 严重事件率=100.0%; 住院率=96.6%
Durvalumab,Pneumonitis,38,120,11.014,11.014,265.83,1.000,0.237,0.605,7.288,PRR=11.01 (显著关联); χ²=265.8 (统计显著); 死亡率=23.7%; 严重事件率=100.0%; 住院率=60.5%
Ipilimumab,Malignant neoplasm progression,60,120,4.029,4.029,114.92,1.000,0.567,0.517,6.832,PRR=4.03 (显著关联); χ²=114.9 (统计显著); 死亡率=56.7%; 严重事件率=100.0%; 住院率=51.7%
Ipilimumab,Pyrexia,41,120,2.201,2.201,23.81,0.927,0.220,0.878,7.212,PRR=2.20 (显著关联); χ²=23.8 (统计显著); 死亡率=22.0%; 严重事件率=92.7%; 住院率=87.8%
Rituximab,Infection,21,120,2.868,2.868,21.96,1.000,0.286,0.667,7.881,PRR=2.87 (显著关联); χ²=22.0 (统计显著); 死亡率=28.6%; 严重事件率=100.0%; 住院率=66.7%
Rituximab,Febrile neutropenia,34,120,2.052,2.052,16.01,1.000,0.265,0.588,7.400,PRR=2.05 (显著关联); χ²=16.0 (统计显著); 死亡率=26.5%; 严重事件率=100.0%; 住院率=58.8%
Epcoritamab,Neutrophil count decreased,20,120,4.977,4.977,53.52,0.950,0.400,0.450,7.930,PRR=4.98 (显著关联); χ²=53.5 (统计显著); 死亡率=40.0%; 严重事件率=95.0%; 住院率=45.0%
Gefitinib,Interstitial lung disease,22,120,5.274,5.274,63.28,1.000,0.545,0.591,7.835,PRR=5.27 (显著关联); χ²=63.3 (统计显著); 死亡率=54.5%; 严重事件率=100.0%; 住院率=59.1%
Osimertinib,Dyspnoea,35,120,2.042,2.042,16.52,0.771,0.343,0.600,7.371,PRR=2.04 (显著关联); χ²=16.5 (统计显著); 死亡率=34.3%; 严重事件率=77.1%; 住院率=60.0%
Osimertinib,Interstitial lung disease,29,120,7.410,7.410,126.60,1.000,0.517,0.586,7.559,PRR=7.41 (显著关联); χ²=126.6 (统计显著); 死亡率=51.7%; 严重事件率=100.0%; 住院率=58.6%
Docetaxel,Pleural effusion,20,120,2.714,2.714,18.75,1.000,0.350,0.500,7.930,PRR=2.71 (显著关联); χ²=18.7 (统计显著); 死亡率=35.0%; 严重事件率=100.0%; 住院率=50.0%
Docetaxel,Neutropenia,51,120,2.588,2.588,42.30,1.000,0.255,0.412,6.994,PRR=2.59 (显著关联); χ²=42.3 (统计显著); 死亡率=25.5%; 严重事件率=100.0%; 住院率=41.2%
Doxorubicin,Febrile neutropenia,59,120,4.064,4.064,111.07,1.000,0.203,0.542,6.848,PRR=4.06 (显著关联); χ²=111.1 (统计显著); 死亡率=20.3%; 严重事件率=100.0%; 住院率=54.2%
Cisplatin,Renal failure acute,19,120,4.539,4.539,42.90,1.000,0.368,0.789,7.982,PRR=4.54 (显著关联); χ²=42.9 (统计显著); 死亡率=36.8%; 严重事件率=100.0%; 住院率=78.9%
Lenalidomide,Pneumonia,41,120,3.886,3.886,76.01,1.000,0.366,0.805,7.212,PRR=3.89 (显著关联); χ²=76.0 (统计显著); 死亡率=36.6%; 严重事件率=100.0%; 住院率=80.5%
Bortezomib,Infection,21,120,3.518,3.518,32.66,1.000,0.238,0.524,7.881,PRR=3.52 (显著关联); χ²=32.7 (统计显著); 死亡率=23.8%; 严重事件率=100.0%; 住院率=52.4%
Carfilzomib,Pneumonia,29,120,2.728,2.728,28.41,1.000,0.345,0.828,7.559,PRR=2.73 (显著关联); χ²=28.4 (统计显著); 死亡率=34.5%; 严重事件率=100.0%; 住院率=82.8%
Venetoclax,Febrile neutropenia,44,120,4.066,4.066,86.58,1.000,0.205,1.000,7.142,PRR=4.07 (显著关联); χ²=86.6 (统计显著); 死亡率=20.5%; 严重事件率=100.0%; 住院率=100.0%
Venetoclax,Sepsis,24,120,3.673,3.673,40.79,1.000,0.625,0.917,7.748,PRR=3.67 (显著关联); χ²=40.8 (统计显著); 死亡率=62.5%; 严重事件率=100.0%; 住院率=91.7%
Venetoclax,Pneumonia,26,120,2.018,2.018,12.04,1.000,0.269,1.000,7.668,PRR=2.02 (显著关联); χ²=12.0 (统计显著); 死亡率=26.9%; 严重事件率=100.0%; 住院率=100.0%
Ibrutinib,Platelet count decreased,27,120,2.260,2.260,16.85,0.889,0.296,0.556,7.630,PRR=2.26 (显著关联); χ²=16.8 (统计显著); 死亡率=29.6%; 严重事件率=88.9%; 住院率=55.6%
Ibrutinib,Atrial fibrillation,29,120,6.755,6.755,112.67,0.862,0.207,0.690,7.559,PRR=6.75 (显著关联); χ²=112.7 (统计显著); 死亡率=20.7%; 严重事件率=86.2%; 住院率=69.0%
Ibrutinib,White blood cell count increased,26,120,25.832,25.832,335.75,0.885,0.231,0.500,7.668,PRR=25.83 (显著关联); χ²=335.7 (统计显著); 死亡率=23.1%; 严重事件率=88.5%; 住院率=50.0%
Talazoparib,Thrombocytopenia,46,120,5.210,5.210,131.68,1.000,0.283,0.500,7.097,PRR=5.21 (显著关联); χ²=131.7 (统计显著); 死亡率=28.3%; 严重事件率=100.0%; 住院率=50.0%
Talazoparib,Febrile neutropenia,29,120,3.006,3.006,34.54,1.000,0.241,0.966,7.559,PRR=3.01 (显著关联); χ²=34.5 (统计显著); 死亡率=24.1%; 严重事件率=100.0%; 住院率=96.6%
Talazoparib,Pancytopenia,29,120,6.996,6.996,123.49,1.000,0.207,0.517,7.559,PRR=7.00 (显著关联); χ²=123.5 (统计显著); 死亡率=20.7%; 严重事件率=100.0%; 住院率=51.7%
Bevacizumab,Fatigue,18,115,0.416,0.416,13.62,1.000,0.222,0.500,8.036,χ²=13.6 (统计显著); 死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Rituximab,Decreased appetite,5,115,0.240,0.240,11.38,1.000,0.800,0.800,9.317,χ²=11.4 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Rituximab,Vomiting,9,115,0.280,0.280,15.53,1.000,0.333,0.556,8.729,χ²=15.5 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Epcoritamab,Nausea,8,115,0.202,0.202,23.61,0.875,0.625,0.500,8.847,χ²=23.6 (统计显著); 死亡率=62.5%; 严重事件率=87.5%; 罕见+严重; 住院率=50.0%
Epcoritamab,Fatigue,7,115,0.187,0.187,23.28,0.857,0.286,0.429,8.980,χ²=23.3 (统计显著); 死亡率=28.6%; 严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Epcoritamab,Haemophagocytic lymphohistiocytosis,9,115,0.000,0.000,314.76,1.000,0.667,0.444,8.729,χ²=314.8 (统计显著); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Epcoritamab,COVID-19 pneumonia,7,115,0.000,0.000,244.81,1.000,0.429,0.571,8.980,χ²=244.8 (统计显著); 死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Gefitinib,Fatigue,13,115,0.337,0.337,15.81,1.000,0.385,0.462,8.361,χ²=15.8 (统计显著); 死亡率=38.5%; 严重事件率=100.0%; 罕见+严重; 住院率=46.2%
Ibrutinib,Nausea,17,115,0.402,0.402,13.96,1.000,0.235,0.706,8.093,χ²=14.0 (统计显著); 死亡率=23.5%; 严重事件率=100.0%; 罕见+严重; 住院率=70.6%
Talazoparib,Diarrhoea,5,115,0.169,0.169,19.33,0.600,0.400,0.600,9.317,χ²=19.3 (统计显著); 死亡率=40.0%; 严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Pembrolizumab,Adrenal insufficiency,10,110,9.278,9.278,59.68,0.700,0.000,0.700,8.623,PRR=9.28 (显著关联); χ²=59.7 (统计显著); 严重事件率=70.0%; 罕见+严重; 住院率=70.0%
Pembrolizumab,Colitis,13,110,3.045,3.045,16.16,0.692,0.077,0.692,8.361,PRR=3.05 (显著关联); χ²=16.2 (统计显著); 严重事件率=69.2%; 罕见+严重; 住院率=69.2%
Pembrolizumab,Hypopituitarism,5,110,16.509,16.509,52.30,1.000,0.000,1.000,9.317,PRR=16.51 (显著关联); χ²=52.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Autoimmune hepatitis,9,110,14.905,14.905,85.77,1.000,0.000,0.889,8.729,PRR=14.91 (显著关联); χ²=85.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Pembrolizumab,Hyponatraemia,12,110,4.420,4.420,28.02,0.583,0.083,0.500,8.441,PRR=4.42 (显著关联); χ²=28.0 (统计显著); 严重事件率=58.3%; 罕见+严重; 住院率=50.0%
Pembrolizumab,Aspartate aminotransferase increased,17,110,5.109,5.109,48.70,0.588,0.059,0.471,8.093,PRR=5.11 (显著关联); χ²=48.7 (统计显著); 严重事件率=58.8%; 罕见+严重; 住院率=47.1%
Pembrolizumab,Acute kidney injury,8,110,3.334,3.334,11.83,1.000,0.125,1.000,8.847,PRR=3.33 (显著关联); χ²=11.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Hepatitis,9,110,10.699,10.699,62.40,1.000,0.000,1.000,8.729,PRR=10.70 (显著关联); χ²=62.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Pancreatitis,5,110,4.714,4.714,12.93,1.000,0.000,1.000,9.317,PRR=4.71 (显著关联); χ²=12.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Blood bilirubin increased,6,110,4.333,4.333,13.68,0.833,0.000,0.667,9.134,PRR=4.33 (显著关联); χ²=13.7 (统计显著); 严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Nivolumab,Adrenal insufficiency,15,110,15.304,15.304,145.20,1.000,0.133,1.000,8.218,PRR=15.30 (显著关联); χ²=145.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Lipase increased,6,110,13.676,13.676,52.77,1.000,0.000,0.500,9.134,PRR=13.68 (显著关联); χ²=52.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Nivolumab,Hyperthyroidism,11,110,23.979,23.979,154.05,1.000,0.091,0.818,8.528,PRR=23.98 (显著关联); χ²=154.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Nivolumab,Transaminases increased,12,110,9.473,9.473,72.91,1.000,0.167,0.833,8.441,PRR=9.47 (显著关联); χ²=72.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Nivolumab,Hyperglycaemia,10,110,6.175,6.175,37.02,1.000,0.000,1.000,8.623,PRR=6.17 (显著关联); χ²=37.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Hyponatraemia,11,110,3.957,3.957,21.64,1.000,0.091,1.000,8.528,PRR=3.96 (显著关联); χ²=21.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Autoimmune hepatitis,12,110,21.990,21.990,157.29,1.000,0.000,0.917,8.441,PRR=21.99 (显著关联); χ²=157.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=91.7%
Nivolumab,Hypophysitis,14,110,26.770,26.770,212.02,1.000,0.071,1.000,8.287,PRR=26.77 (显著关联); χ²=212.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Enteritis,5,110,28.474,28.474,79.46,1.000,0.000,1.000,9.317,PRR=28.47 (显著关联); χ²=79.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Uveitis,5,110,12.653,12.653,40.90,1.000,0.000,0.600,9.317,PRR=12.65 (显著关联); χ²=40.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Atezolizumab,Alanine aminotransferase increased,10,110,3.329,3.329,14.93,1.000,0.000,0.800,8.623,PRR=3.33 (显著关联); χ²=14.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Atezolizumab,Haematuria,9,110,8.793,8.793,52.45,0.778,0.000,0.667,8.729,PRR=8.79 (显著关联); χ²=52.5 (统计显著); 严重事件率=77.8%; 罕见+严重; 住院率=66.7%
Atezolizumab,Systemic inflammatory response syndrome,5,110,22.096,22.096,71.09,1.000,0.000,1.000,9.317,PRR=22.10 (显著关联); χ²=71.1 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Hyperthyroidism,6,110,13.269,13.269,53.98,1.000,0.000,0.833,9.134,PRR=13.27 (显著关联); χ²=54.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Atezolizumab,Pleural effusion,11,110,2.989,2.989,13.39,1.000,0.091,1.000,8.528,PRR=2.99 (显著关联); χ²=13.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Acute kidney injury,17,110,9.682,9.682,109.30,1.000,0.176,0.882,8.093,PRR=9.68 (显著关联); χ²=109.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=88.2%
Atezolizumab,Influenza like illness,9,110,12.974,12.974,78.99,0.889,0.000,0.778,8.729,PRR=12.97 (显著关联); χ²=79.0 (统计显著); 严重事件率=88.9%; 罕见+严重; 住院率=77.8%
Atezolizumab,Pericardial effusion,7,110,6.825,6.825,30.32,1.000,0.000,1.000,8.980,PRR=6.82 (显著关联); χ²=30.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Hyponatraemia,9,110,4.017,4.017,18.51,1.000,0.111,0.889,8.729,PRR=4.02 (显著关联); χ²=18.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Atezolizumab,Hypoxia,6,110,3.961,3.961,12.11,1.000,0.167,1.000,9.134,PRR=3.96 (显著关联); χ²=12.1 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Aspartate aminotransferase increased,11,110,3.939,3.939,21.87,1.000,0.000,0.818,8.528,PRR=3.94 (显著关联); χ²=21.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Atezolizumab,Colitis,11,110,3.169,3.169,14.98,1.000,0.000,0.909,8.528,PRR=3.17 (显著关联); χ²=15.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=90.9%
Atezolizumab,Pancreatitis,5,110,5.858,5.858,17.86,1.000,0.000,0.800,9.317,PRR=5.86 (显著关联); χ²=17.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Durvalumab,Hyperthyroidism,7,110,13.146,13.146,59.69,1.000,0.000,0.714,8.980,PRR=13.15 (显著关联); χ²=59.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Durvalumab,Hepatitis,10,110,12.384,12.384,80.36,1.000,0.200,0.600,8.623,PRR=12.38 (显著关联); χ²=80.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Durvalumab,Immune-mediated hepatitis,8,110,125.354,125.354,261.69,1.000,0.000,0.625,8.847,PRR=125.35 (显著关联); χ²=261.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Durvalumab,Respiratory tract infection,5,110,6.332,6.332,19.27,1.000,0.200,1.000,9.317,PRR=6.33 (显著关联); χ²=19.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Biliary tract infection,5,110,78.144,78.144,139.19,1.000,0.000,1.000,9.317,PRR=78.14 (显著关联); χ²=139.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Hypothyroidism,5,110,6.165,6.165,18.63,1.000,0.000,0.800,9.317,PRR=6.17 (显著关联); χ²=18.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Durvalumab,Pericardial effusion,7,110,5.567,5.567,22.79,1.000,0.000,1.000,8.980,PRR=5.57 (显著关联); χ²=22.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Adrenal insufficiency,7,110,6.198,6.198,26.20,0.714,0.000,0.714,8.980,PRR=6.20 (显著关联); χ²=26.2 (统计显著); 严重事件率=71.4%; 罕见+严重; 住院率=71.4%
Durvalumab,Hypophysitis,5,110,7.100,7.100,22.17,1.000,0.000,1.000,9.317,PRR=7.10 (显著关联); χ²=22.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Diabetic ketoacidosis,5,110,21.309,21.309,64.85,1.000,0.000,1.000,9.317,PRR=21.31 (显著关联); χ²=64.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Neck pain,3,110,6.380,6.380,11.69,0.667,0.333,0.000,9.827,PRR=6.38 (显著关联); χ²=11.7 (统计显著); 死亡率=33.3%; 罕见+严重
Ipilimumab,Adrenal insufficiency,12,110,10.286,10.286,77.77,1.000,0.083,1.000,8.441,PRR=10.29 (显著关联); χ²=77.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,VIIth nerve paralysis,6,110,12.940,12.940,48.80,1.000,0.000,0.833,9.134,PRR=12.94 (显著关联); χ²=48.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Ipilimumab,Renal failure acute,10,110,3.308,3.308,14.40,1.000,0.200,1.000,8.623,PRR=3.31 (显著关联); χ²=14.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Enterocolitis,9,110,17.601,17.601,95.60,1.000,0.111,0.556,8.729,PRR=17.60 (显著关联); χ²=95.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Ipilimumab,Hypophysitis,13,110,21.419,21.419,160.84,1.000,0.000,0.692,8.361,PRR=21.42 (显著关联); χ²=160.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=69.2%
Ipilimumab,Haematochezia,6,110,7.023,7.023,25.69,1.000,0.000,0.833,9.134,PRR=7.02 (显著关联); χ²=25.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Ipilimumab,Hypopituitarism,5,110,14.625,14.625,45.46,1.000,0.200,0.800,9.317,PRR=14.63 (显著关联); χ²=45.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ipilimumab,Colitis ulcerative,3,110,24.538,24.538,41.22,1.000,0.333,0.333,9.827,PRR=24.54 (显著关联); χ²=41.2 (统计显著); 死亡率=33.3%; 罕见+严重
Trastuzumab,Paraesthesia,10,110,4.004,4.004,18.91,1.000,0.200,0.500,8.623,PRR=4.00 (显著关联); χ²=18.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Trastuzumab,Ventricular hypokinesia,4,110,37.296,37.296,58.33,0.750,0.250,0.250,9.540,PRR=37.30 (显著关联); χ²=58.3 (统计显著); 死亡率=25.0%; 罕见+严重
Trastuzumab,Cardiac arrest,5,110,2.330,2.330,3.37,1.000,1.000,0.400,9.317,PRR=2.33 (显著关联); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Trastuzumab,Ascites,7,110,2.200,2.200,4.08,0.857,0.429,0.286,8.980,PRR=2.20 (显著关联); 死亡率=42.9%; 严重事件率=85.7%; 罕见+严重
Trastuzumab,Mucosal inflammation,12,110,3.115,3.115,14.85,1.000,0.000,0.750,8.441,PRR=3.11 (显著关联); χ²=14.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Bevacizumab,Posterior reversible encephalopathy syndrome,6,110,7.694,7.694,26.97,1.000,0.000,1.000,9.134,PRR=7.69 (显著关联); χ²=27.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bevacizumab,Colon cancer metastatic,3,110,46.102,46.102,51.19,1.000,0.333,0.000,9.827,PRR=46.10 (显著关联); χ²=51.2 (统计显著); 死亡率=33.3%; 罕见+严重
Bevacizumab,Protein urine present,5,110,38.461,38.461,78.29,1.000,0.200,0.600,9.317,PRR=38.46 (显著关联); χ²=78.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bevacizumab,Intestinal perforation,5,110,3.342,3.342,7.14,1.000,0.400,0.400,9.317,PRR=3.34 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Metastases to liver,7,110,2.797,2.797,7.13,1.000,0.286,0.286,8.980,PRR=2.80 (显著关联); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Cetuximab,Anaphylactic reaction,11,110,30.247,30.247,204.43,1.000,0.000,0.455,8.528,PRR=30.25 (显著关联); χ²=204.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=45.5%
Rituximab,Neurological decompensation,3,110,20.172,20.172,30.07,0.667,0.667,0.000,9.827,PRR=20.17 (显著关联); χ²=30.1 (统计显著); 死亡率=66.7%; 罕见+严重
Rituximab,Bronchitis,13,110,8.166,8.166,60.08,1.000,0.077,0.923,8.361,PRR=8.17 (显著关联); χ²=60.1 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=92.3%
Rituximab,Gastroenteritis,6,110,8.504,8.504,29.01,1.000,0.000,0.667,9.134,PRR=8.50 (显著关联); χ²=29.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Rituximab,Drug effect decreased,4,110,26.910,26.910,48.00,0.750,0.250,0.250,9.540,PRR=26.91 (显著关联); χ²=48.0 (统计显著); 死亡率=25.0%; 罕见+严重
Rituximab,Hypophosphataemia,7,110,5.714,5.714,21.56,1.000,0.000,1.000,8.980,PRR=5.71 (显著关联); χ²=21.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rituximab,Pulmonary alveolar haemorrhage,4,110,8.278,8.278,18.83,1.000,0.750,0.000,9.540,PRR=8.28 (显著关联); χ²=18.8 (统计显著); 死亡率=75.0%; 罕见+严重
Rituximab,Upper respiratory tract infection,6,110,4.751,4.751,14.51,1.000,0.167,0.667,9.134,PRR=4.75 (显著关联); χ²=14.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Rituximab,Sciatica,5,110,33.654,33.654,67.71,1.000,0.200,0.800,9.317,PRR=33.65 (显著关联); χ²=67.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Rituximab,Cataract,6,110,7.024,7.024,23.62,1.000,0.167,0.500,9.134,PRR=7.02 (显著关联); χ²=23.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Rituximab,B-cell lymphoma recurrent,4,110,26.910,26.910,48.00,1.000,0.750,0.000,9.540,PRR=26.91 (显著关联); χ²=48.0 (统计显著); 死亡率=75.0%; 罕见+严重
Rituximab,Pneumonia adenoviral,3,110,40.346,40.346,44.32,1.000,1.000,0.333,9.827,PRR=40.35 (显著关联); χ²=44.3 (统计显著); 死亡率=100.0%; 罕见+严重
Rituximab,Cystitis haemorrhagic,3,110,6.206,6.206,10.24,1.000,0.667,0.333,9.827,PRR=6.21 (显著关联); χ²=10.2 (统计显著); 死亡率=66.7%; 罕见+严重
Epcoritamab,Product dose omission issue,11,110,79.656,79.656,257.84,0.545,0.091,0.455,8.528,PRR=79.66 (显著关联); χ²=257.8 (统计显著); 严重事件率=54.5%; 罕见+严重; 住院率=45.5%
Epcoritamab,Therapy non-responder,3,110,54.025,54.025,60.64,0.333,0.333,0.333,9.827,PRR=54.02 (显著关联); χ²=60.6 (统计显著); 死亡率=33.3%; 罕见+严重
Epcoritamab,Therapy interrupted,6,110,108.266,108.266,154.47,0.667,0.000,0.500,9.134,PRR=108.27 (显著关联); χ²=154.5 (统计显著); 严重事件率=66.7%; 罕见+严重; 住院率=50.0%
Epcoritamab,Inappropriate schedule of product administration,10,110,72.367,72.367,226.71,0.900,0.200,0.500,8.623,PRR=72.37 (显著关联); χ²=226.7 (统计显著); 严重事件率=90.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,B-cell lymphoma,4,110,18.018,18.018,41.59,1.000,0.250,0.000,9.540,PRR=18.02 (显著关联); χ²=41.6 (统计显著); 死亡率=25.0%; 罕见+严重
Epcoritamab,Injection site erythema,3,110,15.434,15.434,27.52,0.667,0.333,0.000,9.827,PRR=15.43 (显著关联); χ²=27.5 (统计显著); 死亡率=33.3%; 罕见+严重
Epcoritamab,Serum ferritin increased,3,110,27.011,27.011,41.69,1.000,0.667,0.333,9.827,PRR=27.01 (显著关联); χ²=41.7 (统计显著); 死亡率=66.7%; 罕见+严重
Epcoritamab,Renal impairment,8,110,2.623,2.623,7.23,1.000,0.625,0.250,8.847,PRR=2.62 (显著关联); 死亡率=62.5%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Altered state of consciousness,4,110,16.016,16.016,37.82,1.000,0.750,0.250,9.540,PRR=16.02 (显著关联); χ²=37.8 (统计显著); 死亡率=75.0%; 罕见+严重
Epcoritamab,Pneumonia cytomegaloviral,3,110,54.025,54.025,60.64,1.000,0.667,0.333,9.827,PRR=54.02 (显著关联); χ²=60.6 (统计显著); 死亡率=66.7%; 罕见+严重
Epcoritamab,Lymphadenopathy,5,110,2.537,2.537,4.21,0.800,0.400,0.400,9.317,PRR=2.54 (显著关联); 死亡率=40.0%; 严重事件率=80.0%; 罕见+严重
Epcoritamab,Myelosuppression,3,110,36.016,36.016,49.58,1.000,0.333,0.333,9.827,PRR=36.02 (显著关联); χ²=49.6 (统计显著); 死亡率=33.3%; 罕见+严重
Epcoritamab,Tumour lysis syndrome,5,110,3.106,3.106,6.37,1.000,1.000,0.400,9.317,PRR=3.11 (显著关联); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Cytomegalovirus test positive,8,110,72.271,72.271,181.37,1.000,0.125,0.500,8.847,PRR=72.27 (显著关联); χ²=181.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,Lymphoma,3,110,21.609,21.609,35.78,1.000,0.333,0.333,9.827,PRR=21.61 (显著关联); χ²=35.8 (统计显著); 死亡率=33.3%; 罕见+严重
Imatinib,Blood potassium decreased,8,110,5.520,5.520,23.45,1.000,0.125,0.625,8.847,PRR=5.52 (显著关联); χ²=23.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Imatinib,Fluid retention,11,110,8.496,8.496,52.63,1.000,0.182,0.455,8.528,PRR=8.50 (显著关联); χ²=52.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=45.5%
Imatinib,Acute graft versus host disease,4,110,52.375,52.375,64.59,1.000,0.250,0.000,9.540,PRR=52.37 (显著关联); χ²=64.6 (统计显著); 死亡率=25.0%; 罕见+严重
Imatinib,Diabetes mellitus,7,110,5.096,5.096,18.51,1.000,0.143,0.429,8.980,PRR=5.10 (显著关联); χ²=18.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Imatinib,Weight increased,8,110,3.615,3.615,12.75,1.000,0.000,0.625,8.847,PRR=3.62 (显著关联); χ²=12.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Imatinib,Colon cancer,4,110,20.949,20.949,40.58,1.000,0.250,0.000,9.540,PRR=20.95 (显著关联); χ²=40.6 (统计显著); 死亡率=25.0%; 罕见+严重
Erlotinib,Bone pain,6,110,2.526,2.526,4.97,1.000,0.333,0.167,9.134,PRR=2.53 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Memory impairment,5,110,3.061,3.061,6.15,1.000,0.400,0.000,9.317,PRR=3.06 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Liver injury,3,110,8.414,8.414,15.19,1.000,0.333,0.000,9.827,PRR=8.41 (显著关联); χ²=15.2 (统计显著); 死亡率=33.3%; 罕见+严重
Erlotinib,Haemorrhage,5,110,2.630,2.630,4.53,1.000,0.400,0.200,9.317,PRR=2.63 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Metabolic acidosis,3,110,11.219,11.219,20.30,1.000,0.667,0.000,9.827,PRR=11.22 (显著关联); χ²=20.3 (统计显著); 死亡率=66.7%; 罕见+严重
Erlotinib,Lung neoplasm malignant,6,110,2.434,2.434,4.57,1.000,0.833,0.000,9.134,PRR=2.43 (显著关联); 死亡率=83.3%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Liver disorder,7,110,4.766,4.766,17.70,1.000,0.143,0.571,8.980,PRR=4.77 (显著关联); χ²=17.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Gefitinib,Metastases to liver,6,110,2.668,2.668,5.62,1.000,0.333,0.167,9.134,PRR=2.67 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Renal impairment,7,110,2.187,2.187,4.10,0.857,0.286,0.143,8.980,PRR=2.19 (显著关联); 死亡率=28.6%; 严重事件率=85.7%; 罕见+严重
Gefitinib,Lung infection,5,110,2.889,2.889,5.52,1.000,0.800,0.400,9.317,PRR=2.89 (显著关联); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重
Gefitinib,International normalised ratio increased,5,110,8.674,8.674,26.30,1.000,0.000,0.600,9.317,PRR=8.67 (显著关联); χ²=26.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Osimertinib,Chest pain,10,110,2.015,2.015,4.65,0.900,0.400,0.300,8.623,PRR=2.01 (显著关联); 死亡率=40.0%; 严重事件率=90.0%; 罕见+严重
Osimertinib,Cardiopulmonary failure,3,110,13.127,13.127,23.71,1.000,1.000,0.333,9.827,PRR=13.13 (显著关联); χ²=23.7 (统计显著); 死亡率=100.0%; 罕见+严重
Osimertinib,Product use issue,7,110,2.853,2.853,7.53,0.571,0.286,0.286,8.980,PRR=2.85 (显著关联); 死亡率=28.6%; 严重事件率=57.1%; 罕见+严重
Osimertinib,Drug dose omission,8,110,2.140,2.140,4.42,0.875,0.375,0.375,8.847,PRR=2.14 (显著关联); 死亡率=37.5%; 严重事件率=87.5%; 罕见+严重
Osimertinib,Nail disorder,8,110,13.376,13.376,64.13,0.750,0.125,0.500,8.847,PRR=13.38 (显著关联); χ²=64.1 (统计显著); 严重事件率=75.0%; 罕见+严重; 住院率=50.0%
Osimertinib,Musculoskeletal chest pain,3,110,6.176,6.176,10.73,1.000,0.667,0.000,9.827,PRR=6.18 (显著关联); χ²=10.7 (统计显著); 死亡率=66.7%; 罕见+严重
Crizotinib,Fluid retention,5,110,5.485,5.485,15.86,0.600,0.000,0.600,9.317,PRR=5.48 (显著关联); χ²=15.9 (统计显著); 严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Paclitaxel,Palmar-plantar erythrodysaesthesia syndrome,7,110,3.030,3.030,8.29,1.000,0.286,0.286,8.980,PRR=3.03 (显著关联); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Tachycardia,9,110,3.629,3.629,14.63,1.000,0.000,0.444,8.729,PRR=3.63 (显著关联); χ²=14.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Paclitaxel,Hypertension,13,110,2.247,2.247,7.99,1.000,0.308,0.231,8.361,PRR=2.25 (显著关联); 死亡率=30.8%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,VIIth nerve paralysis,5,110,7.249,7.249,20.76,1.000,0.000,0.600,9.317,PRR=7.25 (显著关联); χ²=20.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Paclitaxel,Pancreatic carcinoma metastatic,3,110,28.972,28.972,39.09,1.000,1.000,0.333,9.827,PRR=28.97 (显著关联); χ²=39.1 (统计显著); 死亡率=100.0%; 罕见+严重
Paclitaxel,Invasive ductal breast carcinoma,3,110,8.690,8.690,15.15,1.000,0.667,0.000,9.827,PRR=8.69 (显著关联); χ²=15.2 (统计显著); 死亡率=66.7%; 罕见+严重
Paclitaxel,Respiratory failure,10,110,2.014,2.014,4.58,1.000,0.600,0.200,8.623,PRR=2.01 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Liver disorder,6,110,3.345,3.345,8.51,1.000,0.500,0.167,9.134,PRR=3.35 (显著关联); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Breast cancer recurrent,4,110,14.492,14.492,32.30,1.000,0.250,0.000,9.540,PRR=14.49 (显著关联); χ²=32.3 (统计显著); 死亡率=25.0%; 罕见+严重
Paclitaxel,Renal impairment,8,110,2.109,2.109,4.17,1.000,0.250,0.250,8.847,PRR=2.11 (显著关联); 死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Paraesthesia,7,110,2.781,2.781,7.00,0.857,0.286,0.143,8.980,PRR=2.78 (显著关联); 死亡率=28.6%; 严重事件率=85.7%; 罕见+严重
Paclitaxel,Acute hepatitis C,5,110,72.509,72.509,97.12,1.000,0.000,1.000,9.317,PRR=72.51 (显著关联); χ²=97.1 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Paclitaxel,Kaposi^s sarcoma,3,110,21.729,21.729,32.71,1.000,0.333,0.000,9.827,PRR=21.73 (显著关联); χ²=32.7 (统计显著); 死亡率=33.3%; 罕见+严重
Docetaxel,Mucosal inflammation,13,110,3.341,3.341,18.18,1.000,0.077,0.615,8.361,PRR=3.34 (显著关联); χ²=18.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=61.5%
Docetaxel,Hypocalcaemia,9,110,6.341,6.341,31.57,1.000,0.000,0.556,8.729,PRR=6.34 (显著关联); χ²=31.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Docetaxel,Neutropenic sepsis,17,110,10.195,10.195,98.36,1.000,0.118,0.765,8.093,PRR=10.19 (显著关联); χ²=98.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=76.5%
Docetaxel,Acute respiratory distress syndrome,5,110,4.033,4.033,9.56,1.000,0.600,0.400,9.317,PRR=4.03 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Intracranial pressure increased,5,110,68.596,68.596,91.57,1.000,0.000,1.000,9.317,PRR=68.60 (显著关联); χ²=91.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Docetaxel,Tinnitus,6,110,12.668,12.668,42.42,1.000,0.000,0.500,9.134,PRR=12.67 (显著关联); χ²=42.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Docetaxel,Infusion related reaction,11,110,2.517,2.517,8.82,0.909,0.364,0.273,8.528,PRR=2.52 (显著关联); 死亡率=36.4%; 严重事件率=90.9%; 罕见+严重
Docetaxel,Osteonecrosis of jaw,8,110,7.088,7.088,31.93,1.000,0.000,0.625,8.847,PRR=7.09 (显著关联); χ²=31.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Docetaxel,Neutropenic colitis,3,110,10.278,10.278,17.60,1.000,0.667,0.333,9.827,PRR=10.28 (显著关联); χ²=17.6 (统计显著); 死亡率=66.7%; 罕见+严重
Docetaxel,Infusion site extravasation,4,110,21.938,21.938,42.75,1.000,0.250,0.000,9.540,PRR=21.94 (显著关联); χ²=42.8 (统计显著); 死亡率=25.0%; 罕见+严重
Docetaxel,Eccrine squamous syringometaplasia,3,110,41.115,41.115,45.24,1.000,0.333,0.000,9.827,PRR=41.12 (显著关联); χ²=45.2 (统计显著); 死亡率=33.3%; 罕见+严重
Docetaxel,Skin plaque,3,110,41.115,41.115,45.24,1.000,0.333,0.000,9.827,PRR=41.12 (显著关联); χ²=45.2 (统计显著); 死亡率=33.3%; 罕见+严重
Doxorubicin,Septic shock,7,110,2.174,2.174,3.96,1.000,1.000,0.143,8.980,PRR=2.17 (显著关联); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Left ventricular dysfunction,9,110,14.321,14.321,71.46,1.000,0.111,0.667,8.729,PRR=14.32 (显著关联); χ²=71.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Doxorubicin,Neutropenic sepsis,8,110,4.161,4.161,16.12,1.000,0.000,0.875,8.847,PRR=4.16 (显著关联); χ²=16.1 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Doxorubicin,Hypophosphataemia,6,110,5.045,5.045,15.92,1.000,0.000,0.667,9.134,PRR=5.04 (显著关联); χ²=15.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Doxorubicin,Ejection fraction decreased,6,110,4.083,4.083,11.76,1.000,0.167,0.500,9.134,PRR=4.08 (显著关联); χ²=11.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Hyperglycaemia,6,110,2.197,2.197,3.49,1.000,0.333,0.333,9.134,PRR=2.20 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Invasive ductal breast carcinoma,3,110,8.566,8.566,14.87,1.000,0.667,0.000,9.827,PRR=8.57 (显著关联); χ²=14.9 (统计显著); 死亡率=66.7%; 罕见+严重
Doxorubicin,Thrombosis,7,110,2.247,2.247,4.32,1.000,0.286,0.286,8.980,PRR=2.25 (显著关联); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Visual impairment,7,110,2.174,2.174,3.96,1.000,0.286,0.000,8.980,PRR=2.17 (显著关联); 死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Osteosarcoma,4,110,14.285,14.285,31.76,1.000,0.750,0.000,9.540,PRR=14.29 (显著关联); χ²=31.8 (统计显著); 死亡率=75.0%; 罕见+严重
Doxorubicin,Cardio-respiratory arrest,4,110,6.014,6.014,13.31,1.000,1.000,0.250,9.540,PRR=6.01 (显著关联); χ²=13.3 (统计显著); 死亡率=100.0%; 罕见+严重
Doxorubicin,B-cell lymphoma recurrent,4,110,28.572,28.572,51.30,1.000,0.750,0.000,9.540,PRR=28.57 (显著关联); χ²=51.3 (统计显著); 死亡率=75.0%; 罕见+严重
Doxorubicin,Ischaemic stroke,4,110,9.523,9.523,22.06,1.000,0.750,0.000,9.540,PRR=9.52 (显著关联); χ²=22.1 (统计显著); 死亡率=75.0%; 罕见+严重
Doxorubicin,Ileus paralytic,5,110,17.866,17.866,47.20,1.000,0.000,0.800,9.317,PRR=17.87 (显著关联); χ²=47.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Doxorubicin,Haematotoxicity,5,110,3.039,3.039,5.95,1.000,0.600,0.000,9.317,PRR=3.04 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Carboplatin,Hypokalaemia,11,110,3.026,3.026,12.67,1.000,0.000,0.818,8.528,PRR=3.03 (显著关联); χ²=12.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Carboplatin,Purpura,5,110,6.791,6.791,18.52,1.000,0.000,1.000,9.317,PRR=6.79 (显著关联); χ²=18.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carboplatin,Pulmonary arterial hypertension,3,110,24.434,24.434,32.34,1.000,0.667,0.000,9.827,PRR=24.43 (显著关联); χ²=32.3 (统计显著); 死亡率=66.7%; 罕见+严重
Carboplatin,Intestinal perforation,5,110,2.656,2.656,4.46,1.000,0.400,0.400,9.317,PRR=2.66 (显著关联); 死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Carboplatin,Lymphopenia,7,110,7.447,7.447,28.67,0.857,0.143,0.857,8.980,PRR=7.45 (显著关联); χ²=28.7 (统计显著); 严重事件率=85.7%; 罕见+严重; 住院率=85.7%
Carboplatin,Convulsion,6,110,2.716,2.716,5.60,1.000,0.333,0.167,9.134,PRR=2.72 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Carboplatin,Hydronephrosis,5,110,6.112,6.112,16.39,1.000,0.000,0.800,9.317,PRR=6.11 (显著关联); χ²=16.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carboplatin,Tachycardia,10,110,3.448,3.448,14.55,1.000,0.100,0.500,8.623,PRR=3.45 (显著关联); χ²=14.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Hypovolaemia,6,110,10.484,10.484,34.51,1.000,0.167,1.000,9.134,PRR=10.48 (显著关联); χ²=34.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Septic shock,7,110,2.079,2.079,3.49,1.000,1.000,0.143,8.980,PRR=2.08 (显著关联); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Capillary leak syndrome,5,110,19.525,19.525,49.32,1.000,0.000,1.000,9.317,PRR=19.52 (显著关联); χ²=49.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Local swelling,5,110,4.711,4.711,11.99,1.000,0.000,1.000,9.317,PRR=4.71 (显著关联); χ²=12.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Chronic obstructive pulmonary disease,10,110,7.402,7.402,41.81,1.000,0.200,0.900,8.623,PRR=7.40 (显著关联); χ²=41.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=90.0%
Cisplatin,Hypocalcaemia,9,110,6.317,6.317,31.40,1.000,0.111,0.667,8.729,PRR=6.32 (显著关联); χ²=31.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Cisplatin,Hypomagnesaemia,17,110,8.814,8.814,85.18,0.941,0.118,0.706,8.093,PRR=8.81 (显著关联); χ²=85.2 (统计显著); 严重事件率=94.1%; 罕见+严重; 住院率=70.6%
Cisplatin,Pyelonephritis,3,110,11.703,11.703,19.80,1.000,0.333,0.333,9.827,PRR=11.70 (显著关联); χ²=19.8 (统计显著); 死亡率=33.3%; 罕见+严重
Cisplatin,Hyponatraemia,14,110,3.094,3.094,17.03,0.857,0.071,0.714,8.287,PRR=3.09 (显著关联); χ²=17.0 (统计显著); 严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Cisplatin,Deep vein thrombosis,14,110,3.838,3.838,24.63,1.000,0.143,0.857,8.287,PRR=3.84 (显著关联); χ²=24.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Cisplatin,Infected dermal cyst,7,110,95.777,95.777,140.22,1.000,0.000,1.000,8.980,PRR=95.78 (显著关联); χ²=140.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Atelectasis,5,110,7.192,7.192,20.30,1.000,0.200,1.000,9.317,PRR=7.19 (显著关联); χ²=20.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Lethargy,8,110,5.760,5.760,24.96,1.000,0.000,0.875,8.847,PRR=5.76 (显著关联); χ²=25.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Cisplatin,Oesophageal rupture,4,110,109.294,109.294,82.64,1.000,0.250,0.000,9.540,PRR=109.29 (显著关联); χ²=82.6 (统计显著); 死亡率=25.0%; 罕见+严重
Cisplatin,Metastases to bone,6,110,2.602,2.602,5.19,1.000,0.500,0.167,9.134,PRR=2.60 (显著关联); 死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Cardiotoxicity,4,110,6.427,6.427,14.28,1.000,0.750,0.250,9.540,PRR=6.43 (显著关联); χ²=14.3 (统计显著); 死亡率=75.0%; 罕见+严重
Cisplatin,Osteosarcoma,3,110,9.102,9.102,15.63,1.000,0.667,0.000,9.827,PRR=9.10 (显著关联); χ²=15.6 (统计显著); 死亡率=66.7%; 罕见+严重
Cisplatin,Ocular hyperaemia,5,110,5.693,5.693,15.40,1.000,0.000,0.800,9.317,PRR=5.69 (显著关联); χ²=15.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Cisplatin,Non-small cell lung cancer metastatic,3,110,8.191,8.191,14.03,1.000,1.000,0.000,9.827,PRR=8.19 (显著关联); χ²=14.0 (统计显著); 死亡率=100.0%; 罕见+严重
Cisplatin,Secondary adrenocortical insufficiency,4,110,21.857,21.857,42.57,1.000,0.250,0.000,9.540,PRR=21.86 (显著关联); χ²=42.6 (统计显著); 死亡率=25.0%; 罕见+严重
Cisplatin,Aortic thrombosis,4,110,54.646,54.646,67.59,1.000,0.250,0.000,9.540,PRR=54.65 (显著关联); χ²=67.6 (统计显著); 死亡率=25.0%; 罕见+严重
Lenalidomide,Haemoglobin decreased,13,110,2.456,2.456,10.27,0.923,0.154,0.462,8.361,PRR=2.46 (显著关联); χ²=10.3 (统计显著); 严重事件率=92.3%; 罕见+严重; 住院率=46.2%
Lenalidomide,Influenza,10,110,9.493,9.493,61.19,1.000,0.000,1.000,8.623,PRR=9.49 (显著关联); χ²=61.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Lenalidomide,Renal failure,16,110,3.846,3.846,29.95,1.000,0.062,0.625,8.153,PRR=3.85 (显著关联); χ²=29.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Lenalidomide,Diabetes mellitus,5,110,6.096,6.096,18.33,1.000,0.200,0.600,9.317,PRR=6.10 (显著关联); χ²=18.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Lenalidomide,Infection,10,110,2.219,2.219,6.18,1.000,0.600,0.400,8.623,PRR=2.22 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Lenalidomide,Neuropathy peripheral,15,110,3.280,3.280,21.38,1.000,0.200,0.467,8.218,PRR=3.28 (显著关联); χ²=21.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=46.7%
Lenalidomide,Plasma cell myeloma recurrent,3,110,19.832,19.832,36.66,1.000,0.667,0.333,9.827,PRR=19.83 (显著关联); χ²=36.7 (统计显著); 死亡率=66.7%; 罕见+严重
Lenalidomide,Thrombosis,18,110,10.802,10.802,125.21,1.000,0.000,0.444,8.036,PRR=10.80 (显著关联); χ²=125.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Pomalidomide,Cardiac disorder,5,110,5.626,5.626,16.73,1.000,0.200,1.000,9.317,PRR=5.63 (显著关联); χ²=16.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Lung adenocarcinoma,4,110,7.318,7.318,17.28,1.000,0.500,0.250,9.540,PRR=7.32 (显著关联); χ²=17.3 (统计显著); 死亡率=50.0%; 罕见+严重
Bortezomib,Neutropenic sepsis,8,110,4.799,4.799,20.26,1.000,0.000,1.000,8.847,PRR=4.80 (显著关联); χ²=20.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Hypophosphataemia,6,110,5.817,5.817,19.66,1.000,0.000,1.000,9.134,PRR=5.82 (显著关联); χ²=19.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Upper respiratory tract infection,5,110,4.706,4.706,12.35,1.000,0.000,0.600,9.317,PRR=4.71 (显著关联); χ²=12.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bortezomib,Diabetes mellitus,5,110,4.334,4.334,10.96,1.000,0.000,0.800,9.317,PRR=4.33 (显著关联); χ²=11.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Bortezomib,Plasma cell leukaemia,4,110,65.885,65.885,82.48,1.000,1.000,0.250,9.540,PRR=65.89 (显著关联); χ²=82.5 (统计显著); 死亡率=100.0%; 罕见+严重
Bortezomib,Necrotising fasciitis,4,110,11.977,11.977,28.56,1.000,1.000,0.000,9.540,PRR=11.98 (显著关联); χ²=28.6 (统计显著); 死亡率=100.0%; 罕见+严重
Bortezomib,Prostate cancer,4,110,5.987,5.987,13.61,1.000,0.250,0.250,9.540,PRR=5.99 (显著关联); χ²=13.6 (统计显著); 死亡率=25.0%; 罕见+严重
Bortezomib,Amyloidosis,3,110,98.769,98.769,70.31,1.000,0.667,0.000,9.827,PRR=98.77 (显著关联); χ²=70.3 (统计显著); 死亡率=66.7%; 罕见+严重
Bortezomib,Orthostatic hypotension,5,110,14.981,14.981,43.38,1.000,0.000,0.800,9.317,PRR=14.98 (显著关联); χ²=43.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Bortezomib,Therapeutic response changed,3,110,49.384,49.384,55.10,1.000,0.667,0.333,9.827,PRR=49.38 (显著关联); χ²=55.1 (统计显著); 死亡率=66.7%; 罕见+严重
Bortezomib,Leukaemia recurrent,3,110,7.053,7.053,12.43,1.000,0.333,0.000,9.827,PRR=7.05 (显著关联); χ²=12.4 (统计显著); 死亡率=33.3%; 罕见+严重
Bortezomib,Periorbital oedema,7,110,33.000,33.000,104.94,1.000,0.000,1.000,8.980,PRR=33.00 (显著关联); χ²=104.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Rash maculo-papular,7,110,4.121,4.121,14.20,1.000,0.000,1.000,8.980,PRR=4.12 (显著关联); χ²=14.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Intestinal dilatation,6,110,39.577,39.577,99.15,1.000,0.000,1.000,9.134,PRR=39.58 (显著关联); χ²=99.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Duodenal stenosis,7,110,77.006,77.006,152.23,1.000,0.000,1.000,8.980,PRR=77.01 (显著关联); χ²=152.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Influenza,7,110,6.413,6.413,27.41,1.000,0.000,1.000,8.980,PRR=6.41 (显著关联); χ²=27.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Cardiac failure congestive,11,110,7.510,7.510,51.97,1.000,0.182,0.818,8.528,PRR=7.51 (显著关联); χ²=52.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Carfilzomib,Diverticulitis,5,110,6.259,6.259,19.02,1.000,0.000,0.800,9.317,PRR=6.26 (显著关联); χ²=19.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Thrombotic thrombocytopenic purpura,5,110,39.663,39.663,100.21,1.000,0.000,0.800,9.317,PRR=39.66 (显著关联); χ²=100.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Chronic obstructive pulmonary disease,8,110,9.783,9.783,50.87,1.000,0.125,1.000,8.847,PRR=9.78 (显著关联); χ²=50.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Urinary tract infection,11,110,2.775,2.775,11.41,1.000,0.000,1.000,8.528,PRR=2.78 (显著关联); χ²=11.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Arrhythmia,5,110,9.150,9.150,29.67,1.000,0.200,0.800,9.317,PRR=9.15 (显著关联); χ²=29.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Fluid retention,4,110,4.636,4.636,10.14,0.750,0.250,0.250,9.540,PRR=4.64 (显著关联); χ²=10.1 (统计显著); 死亡率=25.0%; 罕见+严重
Carfilzomib,Chronic kidney disease,5,110,47.596,47.596,111.19,1.000,0.200,1.000,9.317,PRR=47.60 (显著关联); χ²=111.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Plasmacytoma,4,110,31.702,31.702,69.64,1.000,0.750,0.250,9.540,PRR=31.70 (显著关联); χ²=69.6 (统计显著); 死亡率=75.0%; 罕见+严重
Carfilzomib,Cardiomyopathy,5,110,7.673,7.673,24.35,1.000,0.000,0.800,9.317,PRR=7.67 (显著关联); χ²=24.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Venetoclax,Pneumocystis jirovecii pneumonia,6,110,7.225,7.225,26.43,1.000,0.167,1.000,9.134,PRR=7.22 (显著关联); χ²=26.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Pancreatitis,6,110,4.966,4.966,16.39,1.000,0.000,0.833,9.134,PRR=4.97 (显著关联); χ²=16.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Venetoclax,Ventricular tachycardia,3,110,7.933,7.933,14.74,1.000,0.667,0.333,9.827,PRR=7.93 (显著关联); χ²=14.7 (统计显著); 死亡率=66.7%; 罕见+严重
Venetoclax,Laboratory test abnormal,6,110,5.544,5.544,19.03,1.000,0.000,0.667,9.134,PRR=5.54 (显著关联); χ²=19.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Venetoclax,Platelet transfusion,3,110,17.001,17.001,30.77,1.000,0.333,0.333,9.827,PRR=17.00 (显著关联); χ²=30.8 (统计显著); 死亡率=33.3%; 罕见+严重
Ibrutinib,Leukocytosis,7,110,8.656,8.656,36.37,1.000,0.143,0.857,8.980,PRR=8.66 (显著关联); χ²=36.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Ibrutinib,Tumour lysis syndrome,7,110,4.171,4.171,14.49,1.000,0.143,1.000,8.980,PRR=4.17 (显著关联); χ²=14.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Contusion,10,110,4.844,4.844,25.67,0.900,0.100,0.600,8.623,PRR=4.84 (显著关联); χ²=25.7 (统计显著); 严重事件率=90.0%; 罕见+严重; 住院率=60.0%
Ibrutinib,Epistaxis,12,110,3.716,3.716,20.61,0.833,0.083,0.667,8.441,PRR=3.72 (显著关联); χ²=20.6 (统计显著); 严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Ibrutinib,Investigation,9,110,20.062,20.062,98.33,1.000,0.000,1.000,8.729,PRR=20.06 (显著关联); χ²=98.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Haemorrhage,7,110,3.767,3.767,12.34,0.857,0.143,0.714,8.980,PRR=3.77 (显著关联); χ²=12.3 (统计显著); 严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Ibrutinib,Melaena,5,110,7.250,7.250,21.41,0.800,0.000,0.600,9.317,PRR=7.25 (显著关联); χ²=21.4 (统计显著); 严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Ibrutinib,Gastrointestinal haemorrhage,9,110,5.569,5.569,27.89,1.000,0.111,1.000,8.729,PRR=5.57 (显著关联); χ²=27.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Musculoskeletal pain,6,110,4.084,4.084,12.03,0.667,0.167,0.500,9.134,PRR=4.08 (显著关联); χ²=12.0 (统计显著); 严重事件率=66.7%; 罕见+严重; 住院率=50.0%
Ibrutinib,Lymphocytosis,6,110,100.147,100.147,142.40,1.000,0.167,0.833,9.134,PRR=100.15 (显著关联); χ²=142.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Ibrutinib,Haemoptysis,5,110,4.387,4.387,11.17,1.000,0.200,1.000,9.317,PRR=4.39 (显著关联); χ²=11.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Olaparib,Suicidal ideation,4,110,19.400,19.400,40.40,1.000,0.250,0.250,9.540,PRR=19.40 (显著关联); χ²=40.4 (统计显著); 死亡率=25.0%; 罕见+严重
Olaparib,Peripheral swelling,14,110,3.586,3.586,22.26,0.643,0.143,0.500,8.287,PRR=3.59 (显著关联); χ²=22.3 (统计显著); 严重事件率=64.3%; 罕见+严重; 住院率=50.0%
Olaparib,Acute myeloid leukaemia,5,110,3.932,3.932,9.28,1.000,0.600,0.200,9.317,PRR=3.93 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Olaparib,Myelodysplastic syndrome,6,110,2.816,2.816,6.17,1.000,0.833,0.167,9.134,PRR=2.82 (显著关联); 死亡率=83.3%; 严重事件率=100.0%; 罕见+严重
Olaparib,Blood magnesium decreased,5,110,5.597,5.597,15.26,1.000,0.000,0.600,9.317,PRR=5.60 (显著关联); χ²=15.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Olaparib,Cognitive disorder,6,110,7.942,7.942,27.55,1.000,0.000,0.500,9.134,PRR=7.94 (显著关联); χ²=27.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Olaparib,Balance disorder,5,110,3.162,3.162,6.42,1.000,0.600,0.400,9.317,PRR=3.16 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Olaparib,Haemolytic anaemia,6,110,6.989,6.989,23.92,0.833,0.000,0.500,9.134,PRR=6.99 (显著关联); χ²=23.9 (统计显著); 严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Olaparib,Eructation,4,110,19.400,19.400,40.40,0.500,0.250,0.250,9.540,PRR=19.40 (显著关联); χ²=40.4 (统计显著); 死亡率=25.0%; 罕见+严重
Rucaparib,Blood count abnormal,13,110,3.764,3.764,20.94,0.615,0.077,0.462,8.361,PRR=3.76 (显著关联); χ²=20.9 (统计显著); 严重事件率=61.5%; 罕见+严重; 住院率=46.2%
Rucaparib,Drug prescribing error,5,110,32.754,32.754,54.82,1.000,0.200,0.600,9.317,PRR=32.75 (显著关联); χ²=54.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Rucaparib,Terminal state,4,110,15.715,15.715,29.09,1.000,0.250,0.250,9.540,PRR=15.72 (显著关联); χ²=29.1 (统计显著); 死亡率=25.0%; 罕见+严重
Rucaparib,Blood magnesium decreased,9,110,8.049,8.049,37.37,0.778,0.000,0.667,8.729,PRR=8.05 (显著关联); χ²=37.4 (统计显著); 严重事件率=77.8%; 罕见+严重; 住院率=66.7%
Rucaparib,Intestinal obstruction,12,110,4.922,4.922,28.39,1.000,0.083,1.000,8.441,PRR=4.92 (显著关联); χ²=28.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rucaparib,Small intestinal obstruction,8,110,3.574,3.574,11.90,1.000,0.125,1.000,8.847,PRR=3.57 (显著关联); χ²=11.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Niraparib,Intestinal obstruction,10,110,3.430,3.430,13.50,1.000,0.100,0.600,8.623,PRR=3.43 (显著关联); χ²=13.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Niraparib,Small intestinal obstruction,10,110,4.084,4.084,17.70,1.000,0.200,1.000,8.623,PRR=4.08 (显著关联); χ²=17.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Niraparib,Laboratory test abnormal,15,110,7.582,7.582,55.87,0.733,0.067,0.533,8.218,PRR=7.58 (显著关联); χ²=55.9 (统计显著); 严重事件率=73.3%; 罕见+严重; 住院率=53.3%
Niraparib,Retching,14,110,10.459,10.459,69.99,0.714,0.000,0.500,8.287,PRR=10.46 (显著关联); χ²=70.0 (统计显著); 严重事件率=71.4%; 罕见+严重; 住院率=50.0%
Niraparib,Hospitalisation,14,110,6.872,6.872,47.15,1.000,0.143,1.000,8.287,PRR=6.87 (显著关联); χ²=47.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Niraparib,Dyspepsia,14,110,2.529,2.529,10.59,0.643,0.143,0.429,8.287,PRR=2.53 (显著关联); χ²=10.6 (统计显著); 严重事件率=64.3%; 罕见+严重; 住院率=42.9%
Niraparib,Petechiae,6,110,6.428,6.428,18.85,0.833,0.000,0.500,9.134,PRR=6.43 (显著关联); χ²=18.9 (统计显著); 严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Niraparib,Feeding disorder,7,110,13.338,13.338,42.35,0.857,0.000,0.429,8.980,PRR=13.34 (显著关联); χ²=42.4 (统计显著); 严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Niraparib,Hospice care,10,110,28.610,28.610,94.08,0.800,0.000,0.800,8.623,PRR=28.61 (显著关联); χ²=94.1 (统计显著); 严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Niraparib,Adverse drug reaction,11,110,4.016,4.016,18.99,0.909,0.182,0.545,8.528,PRR=4.02 (显著关联); χ²=19.0 (统计显著); 严重事件率=90.9%; 罕见+严重; 住院率=54.5%
Niraparib,Emotional distress,15,110,32.238,32.238,148.45,0.733,0.133,0.467,8.218,PRR=32.24 (显著关联); χ²=148.5 (统计显著); 严重事件率=73.3%; 罕见+严重; 住院率=46.7%
Niraparib,Gingival bleeding,5,110,5.355,5.355,12.72,1.000,0.000,0.600,9.317,PRR=5.35 (显著关联); χ²=12.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Talazoparib,Leukopenia,6,110,2.628,2.628,5.57,1.000,0.333,0.333,9.134,PRR=2.63 (显著关联); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Talazoparib,Neutrophil count decreased,10,110,2.984,2.984,11.99,1.000,0.100,0.700,8.623,PRR=2.98 (显著关联); χ²=12.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Talazoparib,Ventricular arrhythmia,5,110,77.462,77.462,137.93,1.000,0.000,1.000,9.317,PRR=77.46 (显著关联); χ²=137.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Palbociclib,Tumour marker increased,6,110,5.386,5.386,17.97,0.667,0.000,0.500,9.134,PRR=5.39 (显著关联); χ²=18.0 (统计显著); 严重事件率=66.7%; 罕见+严重; 住院率=50.0%
Ribociclib,Acute kidney injury,8,110,3.387,3.387,12.18,1.000,0.000,1.000,8.847,PRR=3.39 (显著关联); χ²=12.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ribociclib,Musculoskeletal chest pain,3,110,8.272,8.272,15.92,0.667,0.333,0.000,9.827,PRR=8.27 (显著关联); χ²=15.9 (统计显著); 死亡率=33.3%; 罕见+严重
Ribociclib,Blood test abnormal,3,110,7.401,7.401,14.00,1.000,0.667,0.000,9.827,PRR=7.40 (显著关联); χ²=14.0 (统计显著); 死亡率=66.7%; 罕见+严重
Vemurafenib,Blood bilirubin increased,8,110,4.620,4.620,19.42,0.875,0.125,0.500,8.847,PRR=4.62 (显著关联); χ²=19.4 (统计显著); 严重事件率=87.5%; 罕见+严重; 住院率=50.0%
Vemurafenib,Liver disorder,5,110,3.371,3.371,7.38,0.800,0.400,0.400,9.317,PRR=3.37 (显著关联); 死亡率=40.0%; 严重事件率=80.0%; 罕见+严重
Vemurafenib,Malignant melanoma,4,110,7.941,7.941,19.26,1.000,1.000,0.250,9.540,PRR=7.94 (显著关联); χ²=19.3 (统计显著); 死亡率=100.0%; 罕见+严重
Vemurafenib,VIIth nerve paralysis,4,110,6.807,6.807,16.14,1.000,0.500,0.250,9.540,PRR=6.81 (显著关联); χ²=16.1 (统计显著); 死亡率=50.0%; 罕见+严重
Vemurafenib,Drug interaction,6,110,4.126,4.126,12.33,1.000,0.167,0.667,9.134,PRR=4.13 (显著关联); χ²=12.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Vemurafenib,Blood alkaline phosphatase increased,7,110,4.394,4.394,15.81,1.000,0.143,0.571,8.980,PRR=4.39 (显著关联); χ²=15.8 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Vemurafenib,Electrocardiogram QT prolonged,8,110,6.988,6.988,33.21,1.000,0.000,0.500,8.847,PRR=6.99 (显著关联); χ²=33.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Vemurafenib,Hepatocellular injury,6,110,9.758,9.758,35.89,1.000,0.167,0.500,9.134,PRR=9.76 (显著关联); χ²=35.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Vemurafenib,Metastases to central nervous system,8,110,2.726,2.726,7.84,0.875,0.375,0.125,8.847,PRR=2.73 (显著关联); 死亡率=37.5%; 严重事件率=87.5%; 罕见+严重
Vemurafenib,Hepatic function abnormal,7,110,4.245,4.245,15.01,1.000,0.143,0.429,8.980,PRR=4.25 (显著关联); χ²=15.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Vemurafenib,Erythema,15,110,3.544,3.544,23.94,0.933,0.133,0.667,8.218,PRR=3.54 (显著关联); χ²=23.9 (统计显著); 严重事件率=93.3%; 罕见+严重; 住院率=66.7%
Vemurafenib,Skin exfoliation,5,110,2.929,2.929,5.68,1.000,0.600,0.400,9.317,PRR=2.93 (显著关联); 死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Vemurafenib,Rash maculo-papular,7,110,4.473,4.473,16.23,1.000,0.000,0.429,8.980,PRR=4.47 (显著关联); χ²=16.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Vemurafenib,Cholestasis,6,110,10.223,10.223,37.61,1.000,0.167,0.500,9.134,PRR=10.22 (显著关联); χ²=37.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Vemurafenib,Drug reaction with eosinophilia and systemic symptoms,3,110,21.433,21.433,35.45,1.000,0.333,0.000,9.827,PRR=21.43 (显著关联); χ²=35.5 (统计显著); 死亡率=33.3%; 罕见+严重
Dabrafenib,Convulsion,6,110,3.886,3.886,11.20,1.000,0.167,1.000,9.134,PRR=3.89 (显著关联); χ²=11.2 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Dabrafenib,Drug interaction,7,110,4.804,4.804,17.92,0.857,0.000,0.571,8.980,PRR=4.80 (显著关联); χ²=17.9 (统计显著); 严重事件率=85.7%; 罕见+严重; 住院率=57.1%
Dabrafenib,Ill-defined disorder,4,110,9.321,9.321,22.74,0.750,0.500,0.250,9.540,PRR=9.32 (显著关联); χ²=22.7 (统计显著); 死亡率=50.0%; 罕见+严重
Dabrafenib,Pain,17,110,2.085,2.085,8.66,0.941,0.294,0.353,8.093,PRR=2.08 (显著关联); 死亡率=29.4%; 严重事件率=94.1%; 罕见+严重
Dabrafenib,Haemorrhage intracranial,6,110,8.748,8.748,31.88,1.000,0.167,0.667,9.134,PRR=8.75 (显著关联); χ²=31.9 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Dabrafenib,C-reactive protein increased,7,110,7.208,7.208,30.02,1.000,0.000,0.857,8.980,PRR=7.21 (显著关联); χ²=30.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Dabrafenib,Liver function test abnormal,8,110,7.785,7.785,37.41,0.875,0.000,0.625,8.847,PRR=7.78 (显著关联); χ²=37.4 (统计显著); 严重事件率=87.5%; 罕见+严重; 住院率=62.5%
Dabrafenib,Feeling cold,3,110,8.061,8.061,14.62,0.333,0.333,0.000,9.827,PRR=8.06 (显著关联); χ²=14.6 (统计显著); 死亡率=33.3%; 罕见+严重
Pembrolizumab,Tumour lysis syndrome,3,105,2.305,2.305,2.06,1.000,0.333,1.000,9.827,PRR=2.31 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Lower respiratory tract infection,3,105,4.773,4.773,7.91,1.000,0.667,1.000,9.827,PRR=4.77 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Haemoptysis,3,105,3.459,3.459,4.76,1.000,0.333,1.000,9.827,PRR=3.46 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Seizure,3,105,3.008,3.008,3.68,1.000,0.333,1.000,9.827,PRR=3.01 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Cellulitis,4,105,3.483,3.483,6.42,1.000,0.250,1.000,9.540,PRR=3.48 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Lung infection,3,105,2.231,2.231,1.90,1.000,0.333,1.000,9.827,PRR=2.23 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Adverse event,4,105,2.675,2.675,3.86,0.500,0.250,0.500,9.540,PRR=2.67 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Pembrolizumab,Cardiac arrest,3,105,2.231,2.231,1.90,1.000,1.000,1.000,9.827,PRR=2.23 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Hypoxia,4,105,2.073,2.073,2.07,1.000,0.500,1.000,9.540,PRR=2.07 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Pneumonia aspiration,3,105,4.546,4.546,7.36,1.000,0.667,0.667,9.827,PRR=4.55 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Nivolumab,Tumour lysis syndrome,3,105,2.272,2.272,1.98,1.000,1.000,0.667,9.827,PRR=2.27 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=66.7%
Nivolumab,Small intestinal obstruction,3,105,2.783,2.783,3.15,1.000,0.667,1.000,9.827,PRR=2.78 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Nivolumab,Lung disorder,3,105,2.164,2.164,1.75,1.000,0.667,0.667,9.827,PRR=2.16 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Nivolumab,Hepatotoxicity,3,105,3.326,3.326,4.43,1.000,0.333,1.000,9.827,PRR=3.33 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Atezolizumab,Hepatic enzyme increased,4,105,3.017,3.017,5.01,1.000,0.250,0.750,9.540,PRR=3.02 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Atezolizumab,Lung infection,3,105,2.772,2.772,3.17,1.000,0.333,1.000,9.827,PRR=2.77 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Atezolizumab,Intestinal obstruction,3,105,3.015,3.015,3.76,1.000,0.333,1.000,9.827,PRR=3.01 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Atezolizumab,Upper respiratory tract infection,3,105,4.646,4.646,7.77,1.000,0.333,1.000,9.827,PRR=4.65 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Durvalumab,Small intestinal obstruction,3,105,2.863,2.863,3.34,1.000,0.333,1.000,9.827,PRR=2.86 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Durvalumab,Ascites,4,105,2.033,2.033,1.96,1.000,0.250,1.000,9.540,PRR=2.03 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Lung infection,4,105,3.069,3.069,5.10,1.000,0.500,0.750,9.540,PRR=3.07 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Ipilimumab,Blood bilirubin increased,4,105,2.478,2.478,3.23,1.000,0.250,0.750,9.540,PRR=2.48 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Ipilimumab,Tremor,4,105,2.336,2.336,2.81,0.750,0.500,0.750,9.540,PRR=2.34 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Ipilimumab,Drug-induced liver injury,3,105,4.088,4.088,6.19,1.000,0.333,1.000,9.827,PRR=4.09 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ipilimumab,Hypothyroidism,3,105,3.065,3.065,3.78,1.000,0.333,1.000,9.827,PRR=3.07 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ipilimumab,Small intestinal obstruction,3,105,2.502,2.502,2.48,1.000,0.333,1.000,9.827,PRR=2.50 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ipilimumab,Adverse event,4,105,2.370,2.370,2.91,0.750,0.250,0.750,9.540,PRR=2.37 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Ipilimumab,Hyperthyroidism,3,105,4.229,4.229,6.52,1.000,0.333,1.000,9.827,PRR=4.23 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ipilimumab,Diabetes mellitus,3,105,3.065,3.065,3.78,1.000,0.667,1.000,9.827,PRR=3.07 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Ipilimumab,Hepatitis,4,105,3.718,3.718,7.08,1.000,0.250,0.500,9.540,PRR=3.72 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Ipilimumab,Clostridium difficile colitis,3,105,5.575,5.575,9.65,1.000,0.333,1.000,9.827,PRR=5.57 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Trastuzumab,Cystitis,3,105,2.465,2.465,2.31,1.000,0.333,0.667,9.827,PRR=2.47 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Trastuzumab,Blister,3,105,2.044,2.044,1.44,1.000,0.333,1.000,9.827,PRR=2.04 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Trastuzumab,Lacrimation increased,4,105,3.607,3.607,6.43,1.000,0.250,0.500,9.540,PRR=3.61 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Disease progression,52,105,2.035,2.035,23.79,1.000,0.327,0.115,6.975,PRR=2.04 (显著关联); χ²=23.8 (统计显著); 死亡率=32.7%; 严重事件率=100.0%
Bevacizumab,Drug ineffective,21,105,2.607,2.607,18.27,0.952,0.333,0.286,7.881,PRR=2.61 (显著关联); χ²=18.3 (统计显著); 死亡率=33.3%; 严重事件率=95.2%
Bevacizumab,Herpes zoster,3,105,2.047,2.047,1.46,1.000,0.333,0.667,9.827,PRR=2.05 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bevacizumab,Haematemesis,4,105,3.966,3.966,7.59,1.000,0.250,1.000,9.540,PRR=3.97 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Bevacizumab,Body temperature increased,3,105,4.389,4.389,6.64,1.000,0.333,0.667,9.827,PRR=4.39 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bevacizumab,Peritonitis,3,105,3.687,3.687,5.07,1.000,0.667,0.667,9.827,PRR=3.69 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Bevacizumab,Condition aggravated,4,105,3.235,3.235,5.40,1.000,0.500,0.500,9.540,PRR=3.23 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Pulmonary haemorrhage,3,105,5.121,5.121,8.24,1.000,1.000,1.000,9.827,PRR=5.12 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Rituximab,Disease progression,88,105,3.207,3.207,108.84,1.000,0.636,0.045,6.449,PRR=3.21 (显著关联); χ²=108.8 (统计显著); 死亡率=63.6%; 严重事件率=100.0%
Rituximab,Burning sensation,4,105,2.390,2.390,2.86,0.750,0.250,0.500,9.540,PRR=2.39 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Rituximab,Blood glucose increased,4,105,2.390,2.390,2.86,1.000,0.250,0.500,9.540,PRR=2.39 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Rituximab,Disseminated intravascular coagulation,3,105,2.372,2.372,2.10,1.000,0.667,0.667,9.827,PRR=2.37 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Rituximab,Pneumocystis jirovecii pneumonia,4,105,3.074,3.074,4.83,1.000,0.500,0.750,9.540,PRR=3.07 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Rituximab,Cholestasis,4,105,4.678,4.678,9.48,1.000,0.500,1.000,9.540,PRR=4.68 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=100.0%
Epcoritamab,Cytokine release syndrome,202,105,2096.545,2096.545,6919.79,0.990,0.386,0.327,5.618,PRR=2096.54 (显著关联); χ²=6919.8 (统计显著); 死亡率=38.6%; 严重事件率=99.0%
Epcoritamab,Pyrexia,47,105,2.241,2.241,28.30,1.000,0.447,0.340,7.076,PRR=2.24 (显著关联); χ²=28.3 (统计显著); 死亡率=44.7%; 严重事件率=100.0%
Epcoritamab,Diffuse large B-cell lymphoma,109,105,703.932,703.932,3602.13,1.000,0.523,0.183,6.235,PRR=703.93 (显著关联); χ²=3602.1 (统计显著); 死亡率=52.3%; 严重事件率=100.0%
Imatinib,Drug ineffective,26,105,2.808,2.808,25.89,1.000,0.346,0.115,7.668,PRR=2.81 (显著关联); χ²=25.9 (统计显著); 死亡率=34.6%; 严重事件率=100.0%
Imatinib,Pulmonary oedema,4,105,2.227,2.227,2.39,1.000,0.500,0.500,9.540,PRR=2.23 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Erlotinib,Rash,95,105,5.592,5.592,279.40,0.989,0.274,0.337,6.372,PRR=5.59 (显著关联); χ²=279.4 (统计显著); 死亡率=27.4%; 严重事件率=98.9%
Erlotinib,Death,194,105,5.592,5.592,530.17,1.000,1.000,0.052,5.658,PRR=5.59 (显著关联); χ²=530.2 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Erlotinib,VIIth nerve paralysis,3,105,4.589,4.589,7.18,1.000,0.333,1.000,9.827,PRR=4.59 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Gefitinib,Hepatic function abnormal,4,105,2.235,2.235,2.48,1.000,0.500,1.000,9.540,PRR=2.24 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=100.0%
Gefitinib,Dermatitis acneiform,3,105,3.353,3.353,4.38,1.000,0.333,0.667,9.827,PRR=3.35 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Osimertinib,Skin discolouration,3,105,3.280,3.280,4.22,1.000,0.667,0.667,9.827,PRR=3.28 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Osimertinib,Drug hypersensitivity,3,105,4.038,4.038,5.96,1.000,0.333,0.667,9.827,PRR=4.04 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Osimertinib,Malignant neoplasm progression,42,105,2.304,2.304,27.19,1.000,0.500,0.310,7.188,PRR=2.30 (显著关联); χ²=27.2 (统计显著); 死亡率=50.0%; 严重事件率=100.0%
Osimertinib,Death,118,105,3.176,3.176,141.74,1.000,1.000,0.161,6.155,PRR=3.18 (显著关联); χ²=141.7 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Osimertinib,Seizure,3,105,2.281,2.281,1.97,1.000,0.667,0.667,9.827,PRR=2.28 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Osimertinib,Productive cough,4,105,4.377,4.377,8.98,1.000,0.750,0.750,9.540,PRR=4.38 (显著关联); 死亡率=75.0%; 罕见+严重; 住院率=75.0%
Osimertinib,Gastrooesophageal reflux disease,4,105,2.258,2.258,2.55,1.000,0.250,0.750,9.540,PRR=2.26 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Crizotinib,Death,78,105,2.514,2.514,60.17,1.000,1.000,0.077,6.569,PRR=2.51 (显著关联); χ²=60.2 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Crizotinib,Disease progression,105,105,6.658,6.658,390.55,0.533,0.457,0.133,6.272,PRR=6.66 (显著关联); χ²=390.5 (统计显著); 死亡率=45.7%; 严重事件率=53.3%
Crizotinib,Hepatic function abnormal,4,105,2.827,2.827,4.32,1.000,0.250,0.750,9.540,PRR=2.83 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Crizotinib,Transaminases increased,4,105,2.656,2.656,3.79,0.750,0.250,0.500,9.540,PRR=2.66 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Paclitaxel,Neuropathy peripheral,21,105,2.957,2.957,23.50,1.000,0.476,0.286,7.881,PRR=2.96 (显著关联); χ²=23.5 (统计显著); 死亡率=47.6%; 严重事件率=100.0%
Paclitaxel,Pneumothorax,4,105,4.139,4.139,8.03,1.000,0.250,0.500,9.540,PRR=4.14 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Paclitaxel,Vertigo,3,105,2.020,2.020,1.39,1.000,0.667,1.000,9.827,PRR=2.02 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Paclitaxel,Balance disorder,4,105,2.465,2.465,3.09,1.000,0.500,0.750,9.540,PRR=2.47 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Paclitaxel,Hypocalcaemia,4,105,2.633,2.633,3.58,1.000,0.500,0.750,9.540,PRR=2.63 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Paclitaxel,Respiratory distress,4,105,3.621,3.621,6.50,1.000,0.500,0.500,9.540,PRR=3.62 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Paclitaxel,Hydronephrosis,3,105,3.949,3.949,5.61,1.000,0.333,1.000,9.827,PRR=3.95 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Paclitaxel,Ileus,3,105,2.996,2.996,3.49,1.000,0.667,0.667,9.827,PRR=3.00 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Docetaxel,Pneumocystis jirovecii pneumonia,3,105,2.283,2.283,1.92,1.000,0.333,0.667,9.827,PRR=2.28 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Docetaxel,Oral pain,3,105,2.004,2.004,1.35,1.000,0.333,1.000,9.827,PRR=2.00 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Docetaxel,Large intestine perforation,3,105,2.834,2.834,3.11,1.000,0.333,0.667,9.827,PRR=2.83 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Docetaxel,Blood lactate dehydrogenase increased,4,105,2.963,2.963,4.52,1.000,0.750,0.750,9.540,PRR=2.96 (显著关联); 死亡率=75.0%; 罕见+严重; 住院率=75.0%
Docetaxel,Gastritis,3,105,2.163,2.163,1.67,1.000,0.333,1.000,9.827,PRR=2.16 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Docetaxel,Metastasis,3,105,3.574,3.574,4.74,1.000,0.333,0.667,9.827,PRR=3.57 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Doxorubicin,Disease progression,82,105,3.146,3.146,98.75,1.000,0.512,0.037,6.519,PRR=3.15 (显著关联); χ²=98.8 (统计显著); 死亡率=51.2%; 严重事件率=100.0%
Doxorubicin,Hepatic failure,3,105,2.253,2.253,1.87,1.000,0.667,0.667,9.827,PRR=2.25 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Doxorubicin,Clostridium difficile infection,3,105,2.518,2.518,2.43,1.000,0.333,1.000,9.827,PRR=2.52 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Doxorubicin,Infection,29,105,4.405,4.405,62.76,1.000,0.276,0.345,7.559,PRR=4.40 (显著关联); χ²=62.8 (统计显著); 死亡率=27.6%; 严重事件率=100.0%
Doxorubicin,Acute myeloid leukaemia,3,105,2.195,2.195,1.75,1.000,0.333,0.667,9.827,PRR=2.20 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Doxorubicin,Sepsis,22,105,2.392,2.392,15.64,1.000,0.591,0.318,7.835,PRR=2.39 (显著关联); χ²=15.6 (统计显著); 死亡率=59.1%; 严重事件率=100.0%
Doxorubicin,Lower respiratory tract infection,4,105,4.080,4.080,7.84,1.000,0.250,0.750,9.540,PRR=4.08 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Doxorubicin,Ileus,3,105,2.953,2.953,3.38,1.000,0.333,0.667,9.827,PRR=2.95 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Carboplatin,Hypocalcaemia,4,105,2.221,2.221,2.36,1.000,0.250,0.750,9.540,PRR=2.22 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Carboplatin,Blister,4,105,2.443,2.443,2.97,1.000,0.250,0.500,9.540,PRR=2.44 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Gastric perforation,3,105,5.637,5.637,8.92,1.000,0.333,1.000,9.827,PRR=5.64 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Carboplatin,Disseminated intravascular coagulation,3,105,2.155,2.155,1.64,1.000,1.000,0.667,9.827,PRR=2.15 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=66.7%
Carboplatin,Hepatic failure,4,105,2.641,2.641,3.53,1.000,1.000,0.500,9.540,PRR=2.64 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Gastritis,4,105,2.641,2.641,3.53,1.000,0.250,0.750,9.540,PRR=2.64 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Cisplatin,Haematemesis,3,105,2.559,2.559,2.51,1.000,0.333,1.000,9.827,PRR=2.56 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Cisplatin,Hepatic failure,4,105,2.952,2.952,4.48,1.000,0.750,0.500,9.540,PRR=2.95 (显著关联); 死亡率=75.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Bacteraemia,3,105,4.311,4.311,6.34,1.000,0.667,1.000,9.827,PRR=4.31 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Cisplatin,Skin discolouration,4,105,3.524,3.524,6.16,1.000,0.500,0.500,9.540,PRR=3.52 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Lenalidomide,Plasma cell myeloma,40,105,11.013,11.013,278.78,1.000,0.550,0.250,7.237,PRR=11.01 (显著关联); χ²=278.8 (统计显著); 死亡率=55.0%; 严重事件率=100.0%
Lenalidomide,Chronic obstructive pulmonary disease,4,105,4.305,4.305,9.05,1.000,0.500,0.500,9.540,PRR=4.31 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Lenalidomide,Gastrointestinal disorder,3,105,2.133,2.133,1.68,1.000,0.333,1.000,9.827,PRR=2.13 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Lenalidomide,Cardiac disorder,3,105,2.890,2.890,3.40,1.000,0.333,0.667,9.827,PRR=2.89 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Lenalidomide,Rash pruritic,3,105,2.569,2.569,2.66,1.000,0.333,0.667,9.827,PRR=2.57 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Pomalidomide,Death,78,105,2.999,2.999,87.20,1.000,1.000,0.103,6.569,PRR=3.00 (显著关联); χ²=87.2 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Pomalidomide,Plasma cell myeloma,67,105,25.191,25.191,977.67,0.955,0.672,0.179,6.721,PRR=25.19 (显著关联); χ²=977.7 (统计显著); 死亡率=67.2%; 严重事件率=95.5%
Pomalidomide,Influenza,3,105,2.767,2.767,3.14,0.667,0.333,0.667,9.827,PRR=2.77 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bortezomib,Plasma cell myeloma,40,105,7.763,7.763,180.66,1.000,0.350,0.275,7.237,PRR=7.76 (显著关联); χ²=180.7 (统计显著); 死亡率=35.0%; 严重事件率=100.0%
Bortezomib,Thrombocytopenia,29,105,2.192,2.192,16.67,1.000,0.241,0.241,7.559,PRR=2.19 (显著关联); χ²=16.7 (统计显著); 死亡率=24.1%; 严重事件率=100.0%
Bortezomib,Hyperkalaemia,3,105,3.404,3.404,4.47,1.000,0.333,0.667,9.827,PRR=3.40 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bortezomib,Musculoskeletal pain,4,105,2.581,2.581,3.48,1.000,0.500,1.000,9.540,PRR=2.58 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Sinus tachycardia,3,105,4.702,4.702,7.41,1.000,0.333,1.000,9.827,PRR=4.70 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Bortezomib,Hypercalcaemia,4,105,3.763,3.763,7.04,1.000,0.250,1.000,9.540,PRR=3.76 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Chronic obstructive pulmonary disease,4,105,3.062,3.062,4.92,1.000,0.500,0.500,9.540,PRR=3.06 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Bortezomib,Respiratory distress,3,105,2.991,2.991,3.53,1.000,0.333,0.667,9.827,PRR=2.99 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bortezomib,Haematemesis,3,105,3.085,3.085,3.74,1.000,0.667,0.667,9.827,PRR=3.08 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Bortezomib,Multi-organ failure,3,105,3.656,3.656,5.04,1.000,1.000,0.667,9.827,PRR=3.66 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=66.7%
Carfilzomib,Plasma cell myeloma,56,105,17.720,17.720,604.90,0.982,0.643,0.393,6.901,PRR=17.72 (显著关联); χ²=604.9 (统计显著); 死亡率=64.3%; 严重事件率=98.2%
Carfilzomib,Pneumonia aspiration,3,105,4.749,4.749,7.88,1.000,0.333,0.667,9.827,PRR=4.75 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Carfilzomib,Gastrointestinal haemorrhage,4,105,3.221,3.221,5.59,1.000,0.250,0.750,9.540,PRR=3.22 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Carfilzomib,Sinusitis,3,105,2.687,2.687,2.93,1.000,0.333,0.667,9.827,PRR=2.69 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Carfilzomib,Mental status changes,3,105,3.391,3.391,4.61,1.000,0.667,1.000,9.827,PRR=3.39 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Venetoclax,Mental status changes,3,105,2.832,2.832,3.23,1.000,0.333,1.000,9.827,PRR=2.83 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Venetoclax,Hyperbilirubinaemia,3,105,5.408,5.408,9.23,1.000,0.333,0.667,9.827,PRR=5.41 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Venetoclax,Peripheral sensory neuropathy,3,105,3.837,3.837,5.58,1.000,1.000,1.000,9.827,PRR=3.84 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Dysuria,3,105,3.398,3.398,4.55,1.000,0.667,1.000,9.827,PRR=3.40 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Venetoclax,Fluid retention,3,105,2.832,2.832,3.23,1.000,0.667,0.667,9.827,PRR=2.83 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Ibrutinib,Neutropenic sepsis,4,105,2.258,2.258,2.54,1.000,0.500,1.000,9.540,PRR=2.26 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Pneumonia aspiration,3,105,3.330,3.330,4.31,1.000,0.333,0.667,9.827,PRR=3.33 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Ibrutinib,VIIth nerve paralysis,3,105,4.542,4.542,7.06,1.000,0.333,0.667,9.827,PRR=4.54 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Ibrutinib,Dyspnoea exertional,3,105,2.561,2.561,2.57,1.000,0.333,1.000,9.827,PRR=2.56 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Clostridium difficile infection,3,105,2.938,2.938,3.41,1.000,0.333,1.000,9.827,PRR=2.94 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Candida infection,3,105,3.701,3.701,5.15,1.000,0.333,1.000,9.827,PRR=3.70 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Hypomagnesaemia,4,105,2.018,2.018,1.87,1.000,0.500,1.000,9.540,PRR=2.02 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Neck pain,3,105,4.542,4.542,7.06,1.000,0.333,0.667,9.827,PRR=4.54 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Ibrutinib,Pulmonary oedema,4,105,2.835,2.835,4.24,0.750,0.250,0.750,9.540,PRR=2.84 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Ibrutinib,Cardiac arrest,4,105,2.184,2.184,2.33,1.000,0.500,0.750,9.540,PRR=2.18 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Ibrutinib,Inappropriate schedule of drug administration,3,105,3.223,3.223,4.06,1.000,0.667,0.667,9.827,PRR=3.22 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Ibrutinib,Gastric haemorrhage,3,105,5.259,5.259,8.66,1.000,0.333,1.000,9.827,PRR=5.26 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Mental status changes,4,105,3.250,3.250,5.49,1.000,0.500,1.000,9.540,PRR=3.25 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=100.0%
Olaparib,Off label use,49,105,3.789,3.789,83.34,0.735,0.286,0.224,7.034,PRR=3.79 (显著关联); χ²=83.3 (统计显著); 死亡率=28.6%; 严重事件率=73.5%
Olaparib,Product use issue,36,105,18.685,18.685,349.72,0.750,0.306,0.167,7.342,PRR=18.68 (显著关联); χ²=349.7 (统计显著); 死亡率=30.6%; 严重事件率=75.0%
Olaparib,Hypophagia,4,105,2.114,2.114,2.11,1.000,0.250,0.500,9.540,PRR=2.11 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Rucaparib,Dyspnoea exertional,4,105,2.067,2.067,1.89,0.750,0.500,0.750,9.540,PRR=2.07 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Rucaparib,Malnutrition,3,105,3.681,3.681,4.69,1.000,0.333,1.000,9.827,PRR=3.68 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Niraparib,Hydronephrosis,3,105,2.335,2.335,1.90,1.000,0.333,1.000,9.827,PRR=2.33 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Niraparib,Neoplasm recurrence,4,105,3.114,3.114,4.58,1.000,0.250,1.000,9.540,PRR=3.11 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=100.0%
Niraparib,Vaginal haemorrhage,4,105,4.894,4.894,9.09,1.000,0.250,0.750,9.540,PRR=4.89 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Talazoparib,Neoplasm progression,76,105,93.943,93.943,2204.79,0.632,0.434,0.237,6.595,PRR=93.94 (显著关联); χ²=2204.8 (统计显著); 死亡率=43.4%; 严重事件率=63.2%
Talazoparib,Hypoxia,4,105,2.084,2.084,2.10,1.000,0.750,1.000,9.540,PRR=2.08 (显著关联); 死亡率=75.0%; 罕见+严重; 住院率=100.0%
Talazoparib,Oropharyngeal pain,3,105,2.015,2.015,1.43,0.667,0.333,0.667,9.827,PRR=2.01 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Talazoparib,Haemorrhage intracranial,3,105,5.153,5.153,8.82,1.000,1.000,0.667,9.827,PRR=5.15 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=66.7%
Talazoparib,Lower respiratory tract infection,3,105,4.798,4.798,7.97,1.000,0.333,1.000,9.827,PRR=4.80 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Talazoparib,Myelodysplastic syndrome,3,105,2.139,2.139,1.70,1.000,0.667,1.000,9.827,PRR=2.14 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Palbociclib,Breast cancer metastatic,22,105,20.480,20.480,247.24,0.773,0.318,0.227,7.835,PRR=20.48 (显著关联); χ²=247.2 (统计显著); 死亡率=31.8%; 严重事件率=77.3%
Palbociclib,Haemoptysis,3,105,2.620,2.620,2.71,1.000,0.333,0.667,9.827,PRR=2.62 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Ribociclib,Acute respiratory distress syndrome,3,105,3.905,3.905,5.84,1.000,1.000,1.000,9.827,PRR=3.90 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Ribociclib,Cardiac arrest,3,105,2.266,2.266,1.97,1.000,1.000,1.000,9.827,PRR=2.27 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Vemurafenib,Rash,60,105,3.466,3.466,88.82,0.850,0.233,0.217,6.832,PRR=3.47 (显著关联); χ²=88.8 (统计显著); 死亡率=23.3%; 严重事件率=85.0%
Vemurafenib,Disease progression,57,105,2.631,2.631,49.57,0.912,0.614,0.088,6.883,PRR=2.63 (显著关联); χ²=49.6 (统计显著); 死亡率=61.4%; 严重事件率=91.2%
Vemurafenib,Hepatitis,4,105,3.247,3.247,5.53,1.000,0.250,0.750,9.540,PRR=3.25 (显著关联); 死亡率=25.0%; 罕见+严重; 住院率=75.0%
Vemurafenib,Blister,4,105,3.572,3.572,6.53,1.000,0.500,0.750,9.540,PRR=3.57 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Vemurafenib,Multi-organ failure,3,105,3.967,3.967,5.81,1.000,1.000,1.000,9.827,PRR=3.97 (显著关联); 死亡率=100.0%; 罕见+严重; 住院率=100.0%
Dabrafenib,Cerebral haemorrhage,3,105,2.277,2.277,1.95,1.000,0.667,1.000,9.827,PRR=2.28 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Dabrafenib,Disorientation,3,105,4.191,4.191,6.31,1.000,0.667,1.000,9.827,PRR=4.19 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Dabrafenib,Hepatic failure,3,105,2.757,2.757,3.02,1.000,0.667,0.667,9.827,PRR=2.76 (显著关联); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Dabrafenib,Body temperature increased,3,105,4.990,4.990,8.12,0.667,0.333,0.667,9.827,PRR=4.99 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Dabrafenib,Pancreatitis,3,105,2.053,2.053,1.48,1.000,0.333,1.000,9.827,PRR=2.05 (显著关联); 死亡率=33.3%; 罕见+严重; 住院率=100.0%
Dabrafenib,Seizure,4,105,3.105,3.105,5.08,1.000,0.500,0.750,9.540,PRR=3.11 (显著关联); 死亡率=50.0%; 罕见+严重; 住院率=75.0%
Epcoritamab,Death,16,100,0.384,0.384,14.63,1.000,1.000,0.250,8.153,χ²=14.6 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Cytomegalovirus infection reactivation,8,100,0.000,0.000,279.79,1.000,0.375,0.375,8.847,χ²=279.8 (统计显著); 死亡率=37.5%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Tumour associated fever,6,100,0.000,0.000,209.84,1.000,0.333,0.333,9.134,χ²=209.8 (统计显著); 死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Imatinib,Blast crisis in myelogenous leukaemia,8,100,0.000,0.000,201.39,1.000,0.625,0.250,8.847,χ²=201.4 (统计显著); 死亡率=62.5%; 严重事件率=100.0%; 罕见+严重
Imatinib,Acute lymphocytic leukaemia recurrent,5,100,0.000,0.000,125.87,1.000,0.800,0.000,9.317,χ²=125.9 (统计显著); 死亡率=80.0%; 严重事件率=100.0%; 罕见+严重
Imatinib,Neutropenia,5,100,0.218,0.218,13.21,0.800,0.600,0.200,9.317,χ²=13.2 (统计显著); 死亡率=60.0%; 严重事件率=80.0%; 罕见+严重
Carboplatin,Death,18,100,0.293,0.293,28.11,1.000,1.000,0.167,8.036,χ²=28.1 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Death,14,100,0.254,0.254,28.36,1.000,0.929,0.143,8.287,χ²=28.4 (统计显著); 死亡率=92.9%; 严重事件率=100.0%; 罕见+严重
Lenalidomide,Nausea,9,100,0.293,0.293,14.43,0.889,0.222,0.222,8.729,χ²=14.4 (统计显著); 死亡率=22.2%; 严重事件率=88.9%; 罕见+严重
Bortezomib,Disease progression,9,100,0.349,0.349,10.28,1.000,0.667,0.222,8.729,χ²=10.3 (统计显著); 死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Rucaparib,Death,16,100,0.209,0.209,43.72,1.000,1.000,0.188,8.153,χ²=43.7 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Niraparib,Death,18,100,0.205,0.205,50.10,1.000,1.000,0.389,8.036,χ²=50.1 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Palbociclib,Death,18,100,0.421,0.421,13.27,1.000,1.000,0.167,8.036,χ²=13.3 (统计显著); 死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Pembrolizumab,Renal failure,8,95,1.829,1.829,2.80,1.000,0.250,0.875,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Pembrolizumab,Dehydration,7,95,0.789,0.789,0.38,1.000,0.429,1.000,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Sepsis,9,95,1.500,1.500,1.40,1.000,0.333,1.000,8.729,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Interstitial lung disease,6,95,1.709,1.709,1.65,1.000,0.500,1.000,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Asthenia,6,95,0.528,0.528,2.42,0.833,0.500,0.833,9.134,死亡率=50.0%; 严重事件率=83.3%; 罕见+严重; 住院率=83.3%
Pembrolizumab,Disease progression,15,95,0.827,0.827,0.51,0.733,0.733,0.467,8.218,死亡率=73.3%; 严重事件率=73.3%; 罕见+严重; 住院率=46.7%
Pembrolizumab,Pulmonary embolism,6,95,1.397,1.397,0.64,1.000,0.500,0.833,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Pembrolizumab,Pneumonia,17,95,1.501,1.501,2.63,1.000,0.235,0.941,8.093,死亡率=23.5%; 严重事件率=100.0%; 罕见+严重; 住院率=94.1%
Pembrolizumab,Vomiting,16,95,0.870,0.870,0.29,0.812,0.312,0.750,8.153,死亡率=31.2%; 严重事件率=81.2%; 罕见+严重; 住院率=75.0%
Pembrolizumab,Constipation,8,95,0.883,0.883,0.12,0.625,0.250,0.625,8.847,死亡率=25.0%; 严重事件率=62.5%; 罕见+严重; 住院率=62.5%
Nivolumab,Fatigue,15,95,0.513,0.513,6.48,1.000,0.267,0.933,8.218,死亡率=26.7%; 严重事件率=100.0%; 罕见+严重; 住院率=93.3%
Nivolumab,Dysphagia,5,95,1.589,1.589,1.03,1.000,0.400,1.000,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Dyspnoea,15,95,1.088,1.088,0.10,1.000,0.267,1.000,8.218,死亡率=26.7%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Pneumonia,11,95,0.941,0.941,0.04,1.000,0.455,0.909,8.528,死亡率=45.5%; 严重事件率=100.0%; 罕见+严重; 住院率=90.9%
Nivolumab,Blood creatinine increased,7,95,1.779,1.779,2.23,1.000,0.286,1.000,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Anaemia,7,95,0.523,0.523,2.89,1.000,0.429,0.714,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Nivolumab,Sepsis,6,95,0.972,0.972,0.00,1.000,0.667,1.000,9.134,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Decreased appetite,5,95,0.406,0.406,4.16,1.000,0.400,1.000,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Pleural effusion,9,95,1.915,1.915,3.65,1.000,0.667,1.000,8.729,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Death,4,95,0.119,0.119,24.58,1.000,1.000,0.500,9.540,χ²=24.6 (统计显著); 死亡率=100.0%; 罕见+严重; 住院率=50.0%
Nivolumab,Off label use,9,95,0.965,0.965,0.01,1.000,0.444,0.889,8.729,死亡率=44.4%; 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Nivolumab,Pain,5,95,0.760,0.760,0.36,1.000,0.400,0.800,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Nivolumab,Interstitial lung disease,6,95,1.684,1.684,1.56,1.000,0.500,1.000,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Asthenia,13,95,1.452,1.452,1.71,1.000,0.385,0.846,8.361,死亡率=38.5%; 严重事件率=100.0%; 罕见+严重; 住院率=84.6%
Atezolizumab,Dyspnoea,17,95,1.567,1.567,3.24,1.000,0.294,0.824,8.093,死亡率=29.4%; 严重事件率=100.0%; 罕见+严重; 住院率=82.4%
Atezolizumab,Hypotension,5,95,1.369,1.369,0.47,1.000,0.400,0.800,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Atezolizumab,Abdominal pain,6,95,1.012,1.012,0.00,1.000,0.333,0.833,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Atezolizumab,Renal failure,6,95,1.686,1.686,1.58,1.000,0.333,1.000,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Febrile neutropenia,18,95,1.820,1.820,6.12,1.000,0.222,0.889,8.036,死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Durvalumab,Respiratory failure,6,95,1.897,1.897,2.38,1.000,0.500,0.667,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Durvalumab,Aspartate aminotransferase increased,7,95,1.987,1.987,3.19,1.000,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Durvalumab,Alanine aminotransferase increased,7,95,1.862,1.862,2.61,1.000,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Durvalumab,Sepsis,10,95,1.698,1.698,2.67,1.000,0.700,0.700,8.623,死亡率=70.0%; 严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Durvalumab,Abdominal pain,8,95,1.109,1.109,0.08,1.000,0.375,0.875,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Durvalumab,Radiation pneumonitis,5,95,29.301,29.301,81.98,0.800,0.000,0.200,9.317,PRR=29.30 (显著关联); χ²=82.0 (统计显著); 严重事件率=80.0%; 罕见+严重
Durvalumab,Toxicity to various agents,5,95,1.658,1.658,1.23,1.000,0.400,1.000,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Pulmonary embolism,8,95,1.670,1.670,2.00,1.000,0.250,1.000,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Lipase increased,7,95,15.109,15.109,65.41,1.000,0.000,0.286,8.980,PRR=15.11 (显著关联); χ²=65.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Ipilimumab,Hypotension,8,95,1.588,1.588,1.62,1.000,0.250,0.875,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Ipilimumab,Pain,6,95,0.824,0.824,0.21,1.000,0.333,0.833,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Ipilimumab,Sepsis,10,95,1.482,1.482,1.46,1.000,0.400,0.900,8.623,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=90.0%
Ipilimumab,Dyspnoea,14,95,0.910,0.910,0.12,1.000,0.429,1.000,8.287,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Pancytopenia,5,95,0.927,0.927,0.03,1.000,0.400,1.000,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Weight decreased,8,95,1.215,1.215,0.29,1.000,0.250,0.625,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Ipilimumab,Atrial fibrillation,7,95,1.714,1.714,1.94,1.000,0.429,0.857,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Ipilimumab,Anaemia,12,95,0.816,0.816,0.47,1.000,0.333,0.917,8.441,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=91.7%
Ipilimumab,Pneumonia,9,95,0.688,0.688,1.20,1.000,0.333,1.000,8.729,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Malaise,5,95,0.530,0.530,1.99,1.000,0.600,0.800,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ipilimumab,Asthenia,9,95,0.707,0.707,1.03,0.778,0.333,0.667,8.729,死亡率=33.3%; 严重事件率=77.8%; 罕见+严重; 住院率=66.7%
Ipilimumab,Pleural effusion,7,95,1.324,1.324,0.52,1.000,0.571,0.857,8.980,死亡率=57.1%; 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Ipilimumab,Back pain,6,95,1.025,1.025,0.00,0.833,0.333,0.500,9.134,死亡率=33.3%; 严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Trastuzumab,Hypoaesthesia,17,95,5.253,5.253,47.11,1.000,0.118,0.353,8.093,PRR=5.25 (显著关联); χ²=47.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Trastuzumab,Metastases to bone,8,95,3.672,3.672,13.21,0.750,0.000,0.125,8.847,PRR=3.67 (显著关联); χ²=13.2 (统计显著); 严重事件率=75.0%; 罕见+严重
Trastuzumab,Ejection fraction decreased,12,95,9.357,9.357,64.41,0.833,0.000,0.083,8.441,PRR=9.36 (显著关联); χ²=64.4 (统计显著); 严重事件率=83.3%; 罕见+严重
Trastuzumab,General physical health deterioration,8,95,1.564,1.564,1.48,1.000,0.500,0.875,8.847,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Trastuzumab,Nasopharyngitis,9,95,3.273,3.273,12.21,0.778,0.111,0.222,8.729,PRR=3.27 (显著关联); χ²=12.2 (统计显著); 严重事件率=77.8%; 罕见+严重
Trastuzumab,Pneumonia,8,95,0.417,0.417,6.13,1.000,0.375,0.625,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Trastuzumab,Metastases to central nervous system,14,95,3.969,3.969,26.06,1.000,0.143,0.143,8.287,PRR=3.97 (显著关联); χ²=26.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Trastuzumab,Palmar-plantar erythrodysaesthesia syndrome,11,95,4.896,4.896,27.84,0.818,0.000,0.091,8.528,PRR=4.90 (显著关联); χ²=27.8 (统计显著); 严重事件率=81.8%; 罕见+严重
Trastuzumab,Pain in extremity,16,95,2.313,2.313,10.51,0.938,0.062,0.188,8.153,PRR=2.31 (显著关联); χ²=10.5 (统计显著); 严重事件率=93.8%; 罕见+严重
Trastuzumab,Erythema,9,95,1.593,1.593,1.80,1.000,0.222,0.556,8.729,死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Trastuzumab,Chest discomfort,12,95,4.741,4.741,29.04,1.000,0.000,0.250,8.441,PRR=4.74 (显著关联); χ²=29.0 (统计显著); 严重事件率=100.0%; 罕见+严重
Trastuzumab,Burning sensation,8,95,5.465,5.465,23.46,0.875,0.000,0.125,8.847,PRR=5.47 (显著关联); χ²=23.5 (统计显著); 严重事件率=87.5%; 罕见+严重
Trastuzumab,Hepatic enzyme increased,5,95,1.863,1.863,1.80,1.000,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Trastuzumab,Injection site pain,5,95,27.985,27.985,62.63,0.800,0.000,0.000,9.317,PRR=27.99 (显著关联); χ²=62.6 (统计显著); 严重事件率=80.0%; 罕见+严重
Trastuzumab,Myalgia,12,95,2.803,2.803,12.11,0.833,0.083,0.167,8.441,PRR=2.80 (显著关联); χ²=12.1 (统计显著); 严重事件率=83.3%; 罕见+严重
Trastuzumab,Rhinorrhoea,6,95,4.418,4.418,13.18,0.833,0.000,0.000,9.134,PRR=4.42 (显著关联); χ²=13.2 (统计显著); 严重事件率=83.3%; 罕见+严重
Trastuzumab,Epistaxis,13,95,3.408,3.408,18.87,0.615,0.077,0.154,8.361,PRR=3.41 (显著关联); χ²=18.9 (统计显著); 严重事件率=61.5%; 罕见+严重
Trastuzumab,Cerebrovascular accident,6,95,1.784,1.784,1.87,1.000,0.500,0.833,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Bevacizumab,Constipation,5,95,0.363,0.363,5.28,1.000,0.600,0.600,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bevacizumab,Metastases to lymph nodes,5,95,4.522,4.522,11.54,1.000,0.000,0.400,9.317,PRR=4.52 (显著关联); χ²=11.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Necrotising fasciitis,5,95,15.383,15.383,43.28,1.000,0.200,0.000,9.317,PRR=15.38 (显著关联); χ²=43.3 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Glioblastoma,4,95,0.000,0.000,118.86,1.000,0.500,0.500,9.540,χ²=118.9 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Colitis,6,95,0.898,0.898,0.07,1.000,0.500,0.500,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Pulmonary embolism,7,95,1.091,1.091,0.05,1.000,0.571,0.571,8.980,死亡率=57.1%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Bevacizumab,Pneumonia,10,95,0.575,0.575,2.93,1.000,0.700,0.700,8.623,死亡率=70.0%; 严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Bevacizumab,Palmar-plantar erythrodysaesthesia syndrome,11,95,5.385,5.385,32.14,0.909,0.091,0.091,8.528,PRR=5.38 (显著关联); χ²=32.1 (统计显著); 严重事件率=90.9%; 罕见+严重
Bevacizumab,Pleural effusion,5,95,0.703,0.703,0.59,1.000,0.600,0.600,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bevacizumab,Nuclear magnetic resonance imaging abnormal,6,95,46.179,46.179,102.38,1.000,0.000,0.000,9.134,PRR=46.18 (显著关联); χ²=102.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Cardiac disorder,7,95,4.897,4.897,18.05,1.000,0.000,0.000,8.980,PRR=4.90 (显著关联); χ²=18.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Weight decreased,13,95,1.515,1.515,2.07,1.000,0.231,0.692,8.361,死亡率=23.1%; 严重事件率=100.0%; 罕见+严重; 住院率=69.2%
Bevacizumab,Treatment failure,5,95,6.991,6.991,20.19,1.000,0.000,0.000,9.317,PRR=6.99 (显著关联); χ²=20.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Visual acuity reduced,6,95,7.694,7.694,26.97,1.000,0.000,0.167,9.134,PRR=7.69 (显著关联); χ²=27.0 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Cerebrovascular accident,10,95,3.423,3.423,14.84,1.000,0.100,0.100,8.623,PRR=3.42 (显著关联); χ²=14.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Venoocclusive liver disease,5,95,7.690,7.690,22.47,1.000,0.200,0.000,9.317,PRR=7.69 (显著关联); χ²=22.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Interstitial lung disease,8,95,1.537,1.537,1.37,1.000,0.250,0.625,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Bevacizumab,Endophthalmitis,8,95,246.585,246.585,209.59,1.000,0.000,0.000,8.847,PRR=246.59 (显著关联); χ²=209.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Product quality issue,10,95,44.079,44.079,166.91,1.000,0.000,0.100,8.623,PRR=44.08 (显著关联); χ²=166.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Cetuximab,Blood pressure decreased,11,95,22.438,22.438,161.53,0.636,0.091,0.182,8.528,PRR=22.44 (显著关联); χ²=161.5 (统计显著); 严重事件率=63.6%; 罕见+严重
Cetuximab,Anxiety,6,95,3.884,3.884,11.81,0.667,0.000,0.333,9.134,PRR=3.88 (显著关联); χ²=11.8 (统计显著); 严重事件率=66.7%; 罕见+严重
Cetuximab,Hypersensitivity,15,95,7.261,7.261,70.12,0.800,0.067,0.267,8.218,PRR=7.26 (显著关联); χ²=70.1 (统计显著); 严重事件率=80.0%; 罕见+严重
Cetuximab,Loss of consciousness,6,95,6.390,6.390,24.18,1.000,0.167,0.000,9.134,PRR=6.39 (显著关联); χ²=24.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Cetuximab,Flushing,8,95,9.691,9.691,52.65,1.000,0.000,0.250,8.847,PRR=9.69 (显著关联); χ²=52.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Cetuximab,Hyperhidrosis,6,95,5.800,5.800,21.30,0.833,0.000,0.333,9.134,PRR=5.80 (显著关联); χ²=21.3 (统计显著); 严重事件率=83.3%; 罕见+严重
Rituximab,Thrombocytopenia,14,95,0.827,0.827,0.47,1.000,0.286,0.500,8.287,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Rituximab,Pulmonary embolism,10,95,1.386,1.386,0.98,1.000,0.400,0.900,8.623,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=90.0%
Rituximab,Abdominal pain,10,95,0.801,0.801,0.46,1.000,0.600,0.900,8.623,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=90.0%
Rituximab,Urinary tract infection,10,95,1.416,1.416,1.11,1.000,0.400,0.800,8.623,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Rituximab,Off label use,18,95,1.169,1.169,0.40,0.944,0.333,0.444,8.036,死亡率=33.3%; 严重事件率=94.4%; 罕见+严重; 住院率=44.4%
Rituximab,Pleural effusion,7,95,0.870,0.870,0.13,1.000,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Rituximab,Pneumonia,17,95,0.870,0.870,0.30,1.000,0.471,0.706,8.093,死亡率=47.1%; 严重事件率=100.0%; 罕见+严重; 住院率=70.6%
Rituximab,Blood pressure increased,10,95,3.247,3.247,13.29,0.900,0.200,0.400,8.623,PRR=3.25 (显著关联); χ²=13.3 (统计显著); 严重事件率=90.0%; 罕见+严重
Rituximab,Haemoglobin decreased,6,95,0.636,0.636,1.17,1.000,0.333,1.000,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rituximab,Pain,10,95,0.916,0.916,0.07,1.000,0.300,0.500,8.623,死亡率=30.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Rituximab,Dehydration,5,95,0.326,0.326,6.58,1.000,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Rituximab,General physical health deterioration,5,95,0.920,0.920,0.03,1.000,0.400,0.800,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Rituximab,Arthralgia,14,95,1.526,1.526,2.29,1.000,0.214,0.571,8.287,死亡率=21.4%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Rituximab,Pain in extremity,6,95,0.789,0.789,0.31,1.000,0.333,0.833,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Rituximab,Oxygen saturation decreased,5,95,5.175,5.175,13.58,1.000,0.200,0.400,9.317,PRR=5.18 (显著关联); χ²=13.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Rituximab,Platelet count decreased,13,95,0.840,0.840,0.36,1.000,0.231,0.769,8.361,死亡率=23.1%; 严重事件率=100.0%; 罕见+严重; 住院率=76.9%
Rituximab,Sepsis,15,95,1.490,1.490,2.18,1.000,0.267,0.467,8.218,死亡率=26.7%; 严重事件率=100.0%; 罕见+严重; 住院率=46.7%
Rituximab,Respiratory failure,9,95,1.670,1.670,2.18,1.000,0.667,0.556,8.729,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Rituximab,Renal failure,8,95,1.064,1.064,0.03,1.000,0.375,0.500,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,Fall,7,95,1.465,1.465,0.96,1.000,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Epcoritamab,Vomiting,3,95,0.124,0.124,17.69,1.000,0.333,0.667,9.827,χ²=17.7 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Epcoritamab,Neutropenia,9,95,0.546,0.546,3.21,1.000,0.444,0.778,8.729,死亡率=44.4%; 严重事件率=100.0%; 罕见+严重; 住院率=77.8%
Epcoritamab,Injection site reaction,6,95,54.131,54.131,121.28,0.833,0.167,0.000,9.134,PRR=54.13 (显著关联); χ²=121.3 (统计显著); 严重事件率=83.3%; 罕见+严重
Epcoritamab,Abdominal pain,9,95,0.963,0.963,0.01,0.889,0.444,0.556,8.729,死亡率=44.4%; 严重事件率=88.9%; 罕见+严重; 住院率=55.6%
Epcoritamab,Pneumonia,14,95,0.955,0.955,0.03,1.000,0.500,0.500,8.287,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,Cytomegalovirus viraemia,5,95,90.162,90.162,122.14,1.000,0.000,0.200,9.317,PRR=90.16 (显著关联); χ²=122.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Epcoritamab,Dyspnoea,3,95,0.167,0.167,11.87,1.000,0.667,1.000,9.827,χ²=11.9 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=100.0%
Epcoritamab,Sepsis,10,95,1.304,1.304,0.66,1.000,0.700,0.500,8.623,死亡率=70.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,Pancytopenia,8,95,1.327,1.327,0.60,1.000,0.625,0.500,8.847,死亡率=62.5%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,Anaemia,5,95,0.294,0.294,8.05,1.000,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Epcoritamab,Thrombocytopenia,5,95,0.386,0.386,4.64,1.000,0.800,0.600,9.317,死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Epcoritamab,Pneumocystis jirovecii pneumonia,5,95,5.300,5.300,14.74,1.000,0.200,0.200,9.317,PRR=5.30 (显著关联); χ²=14.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Epcoritamab,Aspartate aminotransferase increased,6,95,1.300,1.300,0.39,1.000,0.500,0.500,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Imatinib,Swelling,8,95,5.244,5.244,21.95,1.000,0.125,0.250,8.847,PRR=5.24 (显著关联); χ²=22.0 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Chronic graft versus host disease,7,95,91.790,91.790,134.08,1.000,0.143,0.000,8.980,PRR=91.79 (显著关联); χ²=134.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Nephrolithiasis,5,95,13.098,13.098,35.78,1.000,0.200,0.400,9.317,PRR=13.10 (显著关联); χ²=35.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Chronic myeloid leukaemia transformation,4,95,0.000,0.000,100.70,1.000,0.500,0.500,9.540,χ²=100.7 (统计显著); 死亡率=50.0%; 罕见+严重; 住院率=50.0%
Imatinib,Thrombocytosis,10,95,87.546,87.546,189.23,1.000,0.000,0.000,8.623,PRR=87.55 (显著关联); χ²=189.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Sepsis,8,95,0.751,0.751,0.61,1.000,0.500,0.625,8.847,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Imatinib,Pancytopenia,7,95,0.839,0.839,0.20,1.000,0.429,0.429,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Imatinib,Cerebrovascular accident,16,95,5.010,5.010,41.16,1.000,0.125,0.375,8.153,PRR=5.01 (显著关联); χ²=41.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Neoplasm recurrence,15,95,35.897,35.897,205.80,1.000,0.067,0.067,8.218,PRR=35.90 (显著关联); χ²=205.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Oedema,9,95,3.146,3.146,11.26,0.667,0.000,0.333,8.729,PRR=3.15 (显著关联); χ²=11.3 (统计显著); 严重事件率=66.7%; 罕见+严重
Imatinib,Haemoglobin decreased,11,95,1.160,1.160,0.22,1.000,0.273,0.455,8.528,死亡率=27.3%; 严重事件率=100.0%; 罕见+严重; 住院率=45.5%
Imatinib,Feeling abnormal,11,95,3.608,3.608,17.44,1.000,0.000,0.364,8.528,PRR=3.61 (显著关联); χ²=17.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Blindness,5,95,5.456,5.456,14.46,1.000,0.000,0.400,9.317,PRR=5.46 (显著关联); χ²=14.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Hypotension,6,95,0.753,0.753,0.45,1.000,0.667,0.500,9.134,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Imatinib,Bladder cancer,10,95,18.756,18.756,93.96,1.000,0.000,0.100,8.623,PRR=18.76 (显著关联); χ²=94.0 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,General physical health deterioration,7,95,1.271,1.271,0.37,1.000,0.571,0.571,8.980,死亡率=57.1%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Imatinib,Eye swelling,8,95,20.988,20.988,81.15,1.000,0.000,0.000,8.847,PRR=20.99 (显著关联); χ²=81.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Imatinib,Drug intolerance,9,95,3.146,3.146,11.26,1.000,0.111,0.222,8.729,PRR=3.15 (显著关联); χ²=11.3 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Dizziness,8,95,0.776,0.776,0.49,1.000,0.250,0.875,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Erlotinib,Dyspnoea,12,95,0.638,0.638,2.30,1.000,0.333,0.417,8.441,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=41.7%
Erlotinib,Dry skin,15,95,4.161,4.161,30.79,1.000,0.067,0.133,8.218,PRR=4.16 (显著关联); χ²=30.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Convulsion,6,95,3.744,3.744,10.49,1.000,0.167,0.333,9.134,PRR=3.74 (显著关联); χ²=10.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Metastases to central nervous system,5,95,1.557,1.557,0.92,1.000,0.600,1.000,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Erlotinib,Dry eye,5,95,7.019,7.019,20.67,1.000,0.000,0.000,9.317,PRR=7.02 (显著关联); χ²=20.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Eye pruritus,5,95,15.318,15.318,44.53,1.000,0.200,0.200,9.317,PRR=15.32 (显著关联); χ²=44.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Growth of eyelashes,5,95,33.703,33.703,76.79,1.000,0.000,0.400,9.317,PRR=33.70 (显著关联); χ²=76.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Hair texture abnormal,5,95,12.035,12.035,36.08,1.000,0.000,0.000,9.317,PRR=12.03 (显著关联); χ²=36.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Cough,11,95,1.570,1.570,2.09,1.000,0.455,0.545,8.528,死亡率=45.5%; 严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Erlotinib,Skin fissures,6,95,11.239,11.239,40.60,1.000,0.000,0.167,9.134,PRR=11.24 (显著关联); χ²=40.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Headache,9,95,0.889,0.889,0.12,1.000,0.333,0.444,8.729,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Erlotinib,Pneumonia,16,95,1.024,1.024,0.01,1.000,0.625,0.812,8.153,死亡率=62.5%; 严重事件率=100.0%; 罕见+严重; 住院率=81.2%
Erlotinib,Acne,11,95,7.436,7.436,48.40,1.000,0.000,0.273,8.528,PRR=7.44 (显著关联); χ²=48.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Constipation,6,95,0.479,0.479,3.21,0.833,0.333,0.500,9.134,死亡率=33.3%; 严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Erlotinib,Oedema peripheral,5,95,1.151,1.151,0.09,1.000,0.400,0.800,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Erlotinib,Dehydration,17,95,1.440,1.440,2.09,1.000,0.294,0.765,8.093,死亡率=29.4%; 严重事件率=100.0%; 罕见+严重; 住院率=76.5%
Erlotinib,Hypotension,7,95,1.137,1.137,0.11,1.000,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Erlotinib,Muscular weakness,5,95,1.324,1.324,0.37,1.000,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Erlotinib,Respiratory failure,7,95,1.603,1.603,1.46,1.000,0.714,0.714,8.980,死亡率=71.4%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Erlotinib,Malaise,5,95,0.436,0.436,3.47,1.000,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Erlotinib,Prostate cancer,5,95,8.022,8.022,24.02,1.000,0.000,0.000,9.317,PRR=8.02 (显著关联); χ²=24.0 (统计显著); 严重事件率=100.0%; 罕见+严重
Erlotinib,Infection,8,95,1.275,1.275,0.44,1.000,0.250,0.625,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Erlotinib,Sepsis,6,95,0.719,0.719,0.62,1.000,0.500,0.833,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Erlotinib,Urinary tract infection,5,95,0.861,0.861,0.11,1.000,0.600,0.600,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Gefitinib,Pyrexia,9,95,0.383,0.383,8.41,1.000,0.222,0.889,8.729,死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Gefitinib,Transaminases increased,9,95,5.128,5.128,25.16,1.000,0.000,0.333,8.729,PRR=5.13 (显著关联); χ²=25.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Gefitinib,Acne,10,95,6.821,6.821,40.07,0.600,0.100,0.100,8.623,PRR=6.82 (显著关联); χ²=40.1 (统计显著); 严重事件率=60.0%; 罕见+严重
Gefitinib,Pneumonia,13,95,0.851,0.851,0.32,1.000,0.692,0.538,8.361,死亡率=69.2%; 严重事件率=100.0%; 罕见+严重; 住院率=53.8%
Gefitinib,Skin disorder,7,95,4.960,4.960,18.72,0.714,0.000,0.286,8.980,PRR=4.96 (显著关联); χ²=18.7 (统计显著); 严重事件率=71.4%; 罕见+严重
Gefitinib,Paronychia,7,95,40.541,40.541,120.54,1.000,0.143,0.286,8.980,PRR=40.54 (显著关联); χ²=120.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Gefitinib,Constipation,5,95,0.410,0.410,4.03,1.000,1.000,0.600,9.317,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Gefitinib,Dehydration,6,95,0.506,0.506,2.75,1.000,0.667,0.667,9.134,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Gefitinib,Urinary tract infection,5,95,0.887,0.887,0.07,0.800,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Gefitinib,Drug resistance,9,95,18.417,18.417,93.63,0.889,0.000,0.111,8.729,PRR=18.42 (显著关联); χ²=93.6 (统计显著); 严重事件率=88.9%; 罕见+严重
Gefitinib,Hepatotoxicity,5,95,4.447,4.447,11.46,1.000,0.200,0.000,9.317,PRR=4.45 (显著关联); χ²=11.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Gefitinib,Anaemia,14,95,0.810,0.810,0.58,1.000,0.214,0.500,8.287,死亡率=21.4%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Respiratory failure,8,95,1.900,1.900,3.12,1.000,1.000,0.500,8.847,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Flatulence,8,95,5.244,5.244,23.06,0.875,0.000,0.000,8.847,PRR=5.24 (显著关联); χ²=23.1 (统计显著); 严重事件率=87.5%; 罕见+严重
Gefitinib,Drug intolerance,8,95,3.655,3.655,13.48,1.000,0.000,0.000,8.847,PRR=3.66 (显著关联); χ²=13.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Gefitinib,Onychoclasis,9,95,13.044,13.044,70.30,0.889,0.000,0.000,8.729,PRR=13.04 (显著关联); χ²=70.3 (统计显著); 严重事件率=88.9%; 罕见+严重
Gefitinib,Hyperplasia,7,95,121.633,121.633,180.06,1.000,0.000,0.000,8.980,PRR=121.63 (显著关联); χ²=180.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Gefitinib,Mouth ulceration,7,95,11.580,11.580,49.08,1.000,0.000,0.000,8.980,PRR=11.58 (显著关联); χ²=49.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Gefitinib,Gene mutation,7,95,40.541,40.541,120.54,1.000,0.000,0.000,8.980,PRR=40.54 (显著关联); χ²=120.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Osimertinib,Malaise,13,95,1.210,1.210,0.44,0.923,0.462,0.692,8.361,死亡率=46.2%; 严重事件率=92.3%; 罕见+严重; 住院率=69.2%
Osimertinib,Hypotension,6,95,1.008,1.008,0.00,1.000,0.500,0.833,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Osimertinib,Pneumonia,17,95,1.135,1.135,0.25,0.941,0.765,0.647,8.093,死亡率=76.5%; 严重事件率=94.1%; 罕见+严重; 住院率=64.7%
Osimertinib,Vomiting,18,95,0.743,0.743,1.48,0.889,0.500,0.444,8.036,死亡率=50.0%; 严重事件率=88.9%; 罕见+严重; 住院率=44.4%
Osimertinib,Pleural effusion,11,95,1.819,1.819,3.71,0.909,0.364,0.545,8.528,死亡率=36.4%; 严重事件率=90.9%; 罕见+严重; 住院率=54.5%
Osimertinib,Pyrexia,17,95,0.743,0.743,1.41,0.941,0.294,0.706,8.093,死亡率=29.4%; 严重事件率=94.1%; 罕见+严重; 住院率=70.6%
Osimertinib,Atrial fibrillation,9,95,1.911,1.911,3.57,1.000,0.667,0.667,8.729,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Osimertinib,Muscle spasms,11,95,2.926,2.926,12.39,0.545,0.091,0.182,8.528,PRR=2.93 (显著关联); χ²=12.4 (统计显著); 严重事件率=54.5%; 罕见+严重
Osimertinib,Muscular weakness,6,95,1.667,1.667,1.48,0.833,0.333,0.500,9.134,死亡率=33.3%; 严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Osimertinib,Urinary tract infection,10,95,1.845,1.845,3.54,0.900,0.500,0.700,8.623,死亡率=50.0%; 严重事件率=90.0%; 罕见+严重; 住院率=70.0%
Osimertinib,Cardiac failure chronic,3,95,0.000,0.000,101.91,1.000,0.667,0.667,9.827,χ²=101.9 (统计显著); 死亡率=66.7%; 罕见+严重; 住院率=66.7%
Osimertinib,Oedema peripheral,5,95,1.197,1.197,0.15,0.800,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Osimertinib,Liver disorder,11,95,8.230,8.230,54.60,0.818,0.182,0.364,8.528,PRR=8.23 (显著关联); χ²=54.6 (统计显著); 严重事件率=81.8%; 罕见+严重
Osimertinib,Dehydration,7,95,0.598,0.598,1.79,1.000,0.286,1.000,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Crizotinib,Pyrexia,9,95,0.485,0.485,4.65,0.667,0.222,0.667,8.729,死亡率=22.2%; 严重事件率=66.7%; 罕见+严重; 住院率=66.7%
Crizotinib,Confusional state,6,95,1.777,1.777,1.90,0.833,0.333,0.833,9.134,死亡率=33.3%; 严重事件率=83.3%; 罕见+严重; 住院率=83.3%
Crizotinib,Hepatic enzyme increased,7,95,4.212,4.212,15.19,0.571,0.000,0.286,8.980,PRR=4.21 (显著关联); χ²=15.2 (统计显著); 严重事件率=57.1%; 罕见+严重
Crizotinib,Pneumonia,12,95,0.992,0.992,0.00,1.000,0.417,0.500,8.441,死亡率=41.7%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Crizotinib,Dyspepsia,9,95,3.957,3.957,17.68,0.556,0.000,0.222,8.729,PRR=3.96 (显著关联); χ²=17.7 (统计显著); 严重事件率=55.6%; 罕见+严重
Crizotinib,Pleural effusion,6,95,1.210,1.210,0.21,1.000,0.333,0.500,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Crizotinib,Diplopia,5,95,12.193,12.193,39.14,0.600,0.200,0.200,9.317,PRR=12.19 (显著关联); χ²=39.1 (统计显著); 严重事件率=60.0%; 罕见+严重
Crizotinib,Liver function test abnormal,7,95,8.315,8.315,36.80,0.714,0.143,0.000,8.980,PRR=8.32 (显著关联); χ²=36.8 (统计显著); 严重事件率=71.4%; 罕见+严重
Crizotinib,General physical health deterioration,5,95,1.500,1.500,0.78,1.000,0.600,0.600,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Paclitaxel,Dizziness,12,95,1.015,1.015,0.00,1.000,0.333,0.750,8.441,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Paclitaxel,Bronchospasm,5,95,9.061,9.061,26.33,1.000,0.000,0.000,9.317,PRR=9.06 (显著关联); χ²=26.3 (统计显著); 严重事件率=100.0%; 罕见+严重
Paclitaxel,Renal failure,13,95,1.915,1.915,5.10,1.000,0.769,0.615,8.361,死亡率=76.9%; 严重事件率=100.0%; 罕见+严重; 住院率=61.5%
Paclitaxel,Sepsis,12,95,1.269,1.269,0.62,1.000,0.917,0.417,8.441,死亡率=91.7%; 严重事件率=100.0%; 罕见+严重; 住院率=41.7%
Paclitaxel,Pancytopenia,11,95,1.490,1.490,1.61,1.000,0.545,0.727,8.528,死亡率=54.5%; 严重事件率=100.0%; 罕见+严重; 住院率=72.7%
Paclitaxel,Proteinuria,7,95,3.692,3.692,11.72,1.000,0.143,0.286,8.980,PRR=3.69 (显著关联); χ²=11.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Paclitaxel,Flushing,14,95,8.863,8.863,71.77,1.000,0.000,0.214,8.287,PRR=8.86 (显著关联); χ²=71.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Paclitaxel,Muscular weakness,6,95,1.379,1.379,0.57,1.000,0.333,0.500,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Paclitaxel,Abdominal pain,18,95,1.598,1.598,3.63,1.000,0.278,0.667,8.036,死亡率=27.8%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Paclitaxel,Pain in extremity,13,95,1.915,1.915,5.10,0.923,0.615,0.462,8.361,死亡率=61.5%; 严重事件率=92.3%; 罕见+严重; 住院率=46.2%
Paclitaxel,Pulmonary embolism,10,95,1.494,1.494,1.49,1.000,0.500,0.600,8.623,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Paclitaxel,Feeling hot,6,95,6.962,6.962,23.79,1.000,0.000,0.000,9.134,PRR=6.96 (显著关联); χ²=23.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Paclitaxel,Pneumonia,11,95,0.598,0.598,2.77,1.000,0.636,0.636,8.528,死亡率=63.6%; 严重事件率=100.0%; 罕见+严重; 住院率=63.6%
Paclitaxel,Metastases to lymph nodes,5,95,4.263,4.263,10.49,1.000,0.200,0.000,9.317,PRR=4.26 (显著关联); χ²=10.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Paclitaxel,Osteonecrosis of jaw,6,95,5.273,5.273,16.93,1.000,0.000,0.000,9.134,PRR=5.27 (显著关联); χ²=16.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Paclitaxel,Cardiac failure,5,95,1.574,1.574,0.95,1.000,0.600,0.600,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Paclitaxel,Anaphylactic reaction,5,95,4.998,4.998,13.14,1.000,0.200,0.200,9.317,PRR=5.00 (显著关联); χ²=13.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Paclitaxel,Weight decreased,6,95,0.639,0.639,1.15,1.000,0.333,0.500,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Docetaxel,Pneumonitis,13,95,1.869,1.869,4.69,1.000,0.385,0.538,8.361,死亡率=38.5%; 严重事件率=100.0%; 罕见+严重; 住院率=53.8%
Docetaxel,Sepsis,11,95,1.095,1.095,0.08,1.000,0.364,0.727,8.528,死亡率=36.4%; 严重事件率=100.0%; 罕见+严重; 住院率=72.7%
Docetaxel,Erythema,18,95,3.328,3.328,24.93,1.000,0.056,0.111,8.036,PRR=3.33 (显著关联); χ²=24.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Docetaxel,Respiratory failure,8,95,1.502,1.502,1.22,1.000,0.875,0.625,8.847,死亡率=87.5%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Docetaxel,Malaise,5,95,0.355,0.355,5.54,1.000,0.400,0.800,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Docetaxel,Metastases to central nervous system,7,95,1.810,1.810,2.28,1.000,0.286,0.429,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Docetaxel,Cerebrovascular accident,5,95,1.442,1.442,0.62,1.000,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Docetaxel,Haemoglobin decreased,8,95,0.872,0.872,0.14,1.000,0.250,0.875,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Doxorubicin,Abdominal pain,11,95,0.939,0.939,0.04,1.000,0.273,0.545,8.528,死亡率=27.3%; 严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Doxorubicin,Pneumonia,18,95,0.981,0.981,0.01,1.000,0.389,0.500,8.036,死亡率=38.9%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Malaise,13,95,0.986,0.986,0.00,1.000,0.231,0.846,8.361,死亡率=23.1%; 严重事件率=100.0%; 罕见+严重; 住院率=84.6%
Doxorubicin,General physical health deterioration,8,95,1.598,1.598,1.63,1.000,0.375,0.875,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Doxorubicin,Peripheral sensory neuropathy,5,95,4.927,4.927,12.85,1.000,0.200,0.000,9.317,PRR=4.93 (显著关联); χ²=12.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Doxorubicin,Bone marrow failure,12,95,3.581,3.581,19.01,1.000,0.083,0.083,8.441,PRR=3.58 (显著关联); χ²=19.0 (统计显著); 严重事件率=100.0%; 罕见+严重
Doxorubicin,Venoocclusive liver disease,7,95,11.126,11.126,44.69,1.000,0.000,0.000,8.980,PRR=11.13 (显著关联); χ²=44.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Doxorubicin,Abdominal compartment syndrome,5,95,10.208,10.208,29.48,1.000,0.000,0.000,9.317,PRR=10.21 (显著关联); χ²=29.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Hypersensitivity,18,95,3.452,3.452,26.12,1.000,0.111,0.056,8.036,PRR=3.45 (显著关联); χ²=26.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Chest pain,7,95,0.965,0.965,0.01,1.000,0.286,0.571,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Carboplatin,Erythema,18,95,2.964,2.964,19.86,1.000,0.056,0.333,8.036,PRR=2.96 (显著关联); χ²=19.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Flushing,10,95,4.898,4.898,24.70,0.800,0.000,0.200,8.623,PRR=4.90 (显著关联); χ²=24.7 (统计显著); 严重事件率=80.0%; 罕见+严重
Carboplatin,Pneumonia,16,95,0.742,0.742,1.32,0.938,0.438,0.688,8.153,死亡率=43.8%; 严重事件率=93.8%; 罕见+严重; 住院率=68.8%
Carboplatin,Pulmonary embolism,12,95,1.528,1.528,1.96,1.000,0.417,0.750,8.441,死亡率=41.7%; 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Carboplatin,White blood cell count decreased,14,95,1.029,1.029,0.01,1.000,0.286,0.500,8.287,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Pancytopenia,16,95,1.874,1.874,5.76,1.000,0.438,0.688,8.153,死亡率=43.8%; 严重事件率=100.0%; 罕见+严重; 住院率=68.8%
Carboplatin,Sepsis,9,95,0.792,0.792,0.45,1.000,0.667,0.444,8.729,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Carboplatin,Treatment failure,5,95,5.556,5.556,14.58,1.000,0.000,0.000,9.317,PRR=5.56 (显著关联); χ²=14.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Feeling hot,6,95,5.870,5.870,18.72,1.000,0.000,0.000,9.134,PRR=5.87 (显著关联); χ²=18.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Visual impairment,15,95,4.381,4.381,31.63,1.000,0.067,0.000,8.218,PRR=4.38 (显著关联); χ²=31.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Deafness,10,95,11.138,11.138,60.64,1.000,0.200,0.000,8.623,PRR=11.14 (显著关联); χ²=60.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Bone marrow failure,14,95,3.651,3.651,22.35,1.000,0.071,0.286,8.287,PRR=3.65 (显著关联); χ²=22.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Venoocclusive liver disease,5,95,6.112,6.112,16.39,1.000,0.000,0.000,9.317,PRR=6.11 (显著关联); χ²=16.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Abdominal compartment syndrome,5,95,8.733,8.733,24.17,1.000,0.000,0.000,9.317,PRR=8.73 (显著关联); χ²=24.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Carboplatin,Platelet count decreased,12,95,0.702,0.702,1.40,0.917,0.250,0.500,8.441,死亡率=25.0%; 严重事件率=91.7%; 罕见+严重; 住院率=50.0%
Carboplatin,Blood creatinine increased,6,95,0.813,0.813,0.24,1.000,0.500,0.667,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Carboplatin,Hypotension,5,95,0.583,0.583,1.39,1.000,0.600,0.600,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Carboplatin,General physical health deterioration,7,95,1.187,1.187,0.19,1.000,0.571,0.571,8.980,死亡率=57.1%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Carboplatin,Renal impairment,8,95,1.777,1.777,2.42,1.000,0.375,0.500,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Pleural effusion,7,95,0.883,0.883,0.10,1.000,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Cisplatin,Drug ineffective,9,95,0.940,0.940,0.03,0.778,0.333,0.444,8.729,死亡率=33.3%; 严重事件率=77.8%; 罕见+严重; 住院率=44.4%
Cisplatin,Pneumonia,16,95,0.830,0.830,0.51,1.000,0.500,0.438,8.153,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=43.8%
Cisplatin,Abdominal pain,13,95,1.068,1.068,0.05,0.923,0.385,0.692,8.361,死亡率=38.5%; 严重事件率=92.3%; 罕见+严重; 住院率=69.2%
Cisplatin,Hypertension,7,95,1.097,1.097,0.06,1.000,0.286,0.429,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Cisplatin,Sepsis,14,95,1.406,1.406,1.49,1.000,0.643,0.429,8.287,死亡率=64.3%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Cisplatin,Mucosal inflammation,8,95,1.952,1.952,3.32,1.000,0.250,0.500,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Constipation,17,95,1.137,1.137,0.26,1.000,0.235,0.765,8.093,死亡率=23.5%; 严重事件率=100.0%; 罕见+严重; 住院率=76.5%
Cisplatin,Bone marrow failure,15,95,4.424,4.424,32.71,1.000,0.067,0.000,8.218,PRR=4.42 (显著关联); χ²=32.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Cisplatin,Venoocclusive liver disease,7,95,10.639,10.639,42.29,1.000,0.000,0.143,8.980,PRR=10.64 (显著关联); χ²=42.3 (统计显著); 严重事件率=100.0%; 罕见+严重
Cisplatin,Abdominal compartment syndrome,5,95,9.761,9.761,27.87,1.000,0.000,0.000,9.317,PRR=9.76 (显著关联); χ²=27.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Cisplatin,Visual impairment,11,95,3.422,3.422,16.05,1.000,0.182,0.000,8.528,PRR=3.42 (显著关联); χ²=16.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Cisplatin,Hypotension,9,95,1.198,1.198,0.27,1.000,0.333,0.556,8.729,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Cisplatin,Inappropriate antidiuretic hormone secretion,9,95,30.813,30.813,117.29,1.000,0.000,0.333,8.729,PRR=30.81 (显著关联); χ²=117.3 (统计显著); 严重事件率=100.0%; 罕见+严重
Cisplatin,Dysphagia,6,95,1.153,1.153,0.11,0.833,0.333,0.667,9.134,死亡率=33.3%; 严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Cisplatin,Urinary tract infection,10,95,1.437,1.437,1.21,1.000,0.400,0.800,8.623,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Cisplatin,White blood cell count decreased,9,95,0.727,0.727,0.86,1.000,0.333,0.778,8.729,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=77.8%
Cisplatin,Erythema,7,95,1.194,1.194,0.20,1.000,0.429,0.429,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Lenalidomide,Pancytopenia,15,95,3.327,3.327,21.93,1.000,0.133,0.200,8.218,PRR=3.33 (显著关联); χ²=21.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Lenalidomide,Asthenia,13,95,1.169,1.169,0.30,1.000,0.231,0.462,8.361,死亡率=23.1%; 严重事件率=100.0%; 罕见+严重; 住院率=46.2%
Lenalidomide,Toxicity to various agents,15,95,5.341,5.341,45.78,1.000,0.067,0.067,8.218,PRR=5.34 (显著关联); χ²=45.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Lenalidomide,Atrial fibrillation,6,95,1.652,1.652,1.45,1.000,0.333,1.000,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Lenalidomide,Vomiting,4,95,0.213,0.213,11.13,1.000,0.250,0.500,9.540,χ²=11.1 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Lenalidomide,Disease progression,3,95,0.162,0.162,12.48,1.000,0.333,0.667,9.827,χ²=12.5 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Lenalidomide,Malaise,9,95,1.094,1.094,0.07,1.000,0.222,0.667,8.729,死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Lenalidomide,Full blood count decreased,15,95,10.455,10.455,101.15,1.000,0.133,0.333,8.218,PRR=10.46 (显著关联); χ²=101.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Lenalidomide,Unevaluable event,9,95,6.149,6.149,33.24,1.000,0.000,0.000,8.729,PRR=6.15 (显著关联); χ²=33.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Lenalidomide,Rash generalised,5,95,5.147,5.147,14.64,1.000,0.000,0.200,9.317,PRR=5.15 (显著关联); χ²=14.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Lenalidomide,Local swelling,6,95,9.937,9.937,38.66,1.000,0.000,0.167,9.134,PRR=9.94 (显著关联); χ²=38.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Pomalidomide,Muscle spasms,9,95,3.484,3.484,14.49,0.667,0.000,0.111,8.729,PRR=3.48 (显著关联); χ²=14.5 (统计显著); 严重事件率=66.7%; 罕见+严重
Pomalidomide,Pancytopenia,11,95,2.667,2.667,10.54,1.000,0.091,0.091,8.528,PRR=2.67 (显著关联); χ²=10.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Pomalidomide,Full blood count decreased,16,95,12.675,12.675,133.64,0.938,0.062,0.312,8.153,PRR=12.67 (显著关联); χ²=133.6 (统计显著); 严重事件率=93.8%; 罕见+严重
Pomalidomide,Sepsis,7,95,1.295,1.295,0.45,1.000,0.714,0.714,8.980,死亡率=71.4%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Pomalidomide,Neuropathy peripheral,14,95,3.405,3.405,21.52,0.714,0.000,0.286,8.287,PRR=3.40 (显著关联); χ²=21.5 (统计显著); 严重事件率=71.4%; 罕见+严重
Pomalidomide,Bronchitis,8,95,8.650,8.650,45.13,1.000,0.000,0.375,8.847,PRR=8.65 (显著关联); χ²=45.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Pomalidomide,Unevaluable event,11,95,8.672,8.672,62.05,0.909,0.000,0.091,8.528,PRR=8.67 (显著关联); χ²=62.1 (统计显著); 严重事件率=90.9%; 罕见+严重
Pomalidomide,Drug dose omission,10,95,4.025,4.025,20.45,0.600,0.000,0.300,8.623,PRR=4.03 (显著关联); χ²=20.5 (统计显著); 严重事件率=60.0%; 罕见+严重
Pomalidomide,Swelling face,6,95,6.613,6.613,24.71,1.000,0.000,0.167,9.134,PRR=6.61 (显著关联); χ²=24.7 (统计显著); 严重事件率=100.0%; 罕见+严重
Pomalidomide,Laboratory test abnormal,6,95,7.229,7.229,27.54,0.833,0.000,0.167,9.134,PRR=7.23 (显著关联); χ²=27.5 (统计显著); 严重事件率=83.3%; 罕见+严重
Pomalidomide,Nasopharyngitis,12,95,8.445,8.445,65.64,0.583,0.000,0.167,8.441,PRR=8.44 (显著关联); χ²=65.6 (统计显著); 严重事件率=58.3%; 罕见+严重
Bortezomib,Sepsis,11,95,1.317,1.317,0.77,1.000,0.727,0.727,8.528,死亡率=72.7%; 严重事件率=100.0%; 罕见+严重; 住院率=72.7%
Bortezomib,Gastrointestinal disorder,7,95,3.783,3.783,12.41,1.000,0.143,0.286,8.980,PRR=3.78 (显著关联); χ²=12.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Bortezomib,Deep vein thrombosis,6,95,1.829,1.829,2.06,1.000,0.333,0.833,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Bortezomib,Rectal adenocarcinoma,5,95,32.961,32.961,74.95,1.000,0.000,0.200,9.317,PRR=32.96 (显著关联); χ²=75.0 (统计显著); 严重事件率=100.0%; 罕见+严重
Bortezomib,Hypotension,8,95,1.278,1.278,0.45,1.000,0.250,0.625,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Bortezomib,Interstitial lung disease,5,95,1.008,1.008,0.00,1.000,0.600,0.800,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Bortezomib,Asthenia,11,95,0.699,0.699,1.34,1.000,0.455,0.455,8.528,死亡率=45.5%; 严重事件率=100.0%; 罕见+严重; 住院率=45.5%
Bortezomib,Dyspnoea,11,95,0.571,0.571,3.32,0.909,0.273,0.727,8.528,死亡率=27.3%; 严重事件率=90.9%; 罕见+严重; 住院率=72.7%
Bortezomib,Graft versus host disease,5,95,23.543,23.543,60.90,1.000,0.000,0.200,9.317,PRR=23.54 (显著关联); χ²=60.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Bortezomib,Electrolyte imbalance,5,95,8.238,8.238,24.60,1.000,0.200,0.200,9.317,PRR=8.24 (显著关联); χ²=24.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Bortezomib,Peripheral sensory neuropathy,7,95,8.552,8.552,35.81,1.000,0.143,0.143,8.980,PRR=8.55 (显著关联); χ²=35.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Bortezomib,Renal failure,5,95,0.801,0.801,0.23,1.000,0.600,0.800,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Chest pain,7,95,1.880,1.880,2.69,1.000,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Carfilzomib,Haemoglobin decreased,7,95,1.318,1.318,0.51,0.857,0.571,0.429,8.980,死亡率=57.1%; 严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Carfilzomib,Diarrhoea,12,95,0.421,0.421,8.97,1.000,0.417,0.917,8.441,死亡率=41.7%; 严重事件率=100.0%; 罕见+严重; 住院率=91.7%
Carfilzomib,Asthenia,12,95,1.105,1.105,0.11,0.917,0.417,0.750,8.441,死亡率=41.7%; 严重事件率=91.7%; 罕见+严重; 住院率=75.0%
Carfilzomib,Toxicity to various agents,9,95,3.130,3.130,11.87,1.000,0.000,0.111,8.729,PRR=3.13 (显著关联); χ²=11.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Carfilzomib,Pancytopenia,8,95,1.752,1.752,2.41,1.000,0.375,0.875,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Carfilzomib,Infection,8,95,1.802,1.802,2.67,1.000,0.250,0.750,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Carfilzomib,Unevaluable event,14,95,10.649,10.649,96.77,1.000,0.000,0.071,8.287,PRR=10.65 (显著关联); χ²=96.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Carfilzomib,Thrombocytopenia,7,95,0.718,0.718,0.74,1.000,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Carfilzomib,Back pain,8,95,1.604,1.604,1.70,0.750,0.375,0.750,8.847,死亡率=37.5%; 严重事件率=75.0%; 罕见+严重; 住院率=75.0%
Venetoclax,Infection,8,95,1.504,1.504,1.26,0.875,0.500,0.750,8.847,死亡率=50.0%; 严重事件率=87.5%; 罕见+严重; 住院率=75.0%
Venetoclax,Off label use,12,95,1.132,1.132,0.17,0.917,0.333,0.500,8.441,死亡率=33.3%; 严重事件率=91.7%; 罕见+严重; 住院率=50.0%
Venetoclax,Malignant neoplasm progression,7,95,0.403,0.403,5.86,1.000,0.714,0.571,8.980,死亡率=71.4%; 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Venetoclax,Pancytopenia,10,95,1.847,1.847,3.58,1.000,0.400,0.700,8.623,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Venetoclax,Respiratory failure,7,95,1.890,1.890,2.71,1.000,0.429,0.714,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Venetoclax,Drug dose omission,6,95,1.789,1.789,1.94,0.833,0.333,0.667,9.134,死亡率=33.3%; 严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Venetoclax,Dehydration,12,95,1.180,1.180,0.31,1.000,0.250,0.917,8.441,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=91.7%
Venetoclax,Renal failure,6,95,1.165,1.165,0.13,1.000,0.833,0.500,9.134,死亡率=83.3%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Venetoclax,Dizziness,9,95,1.033,1.033,0.01,0.778,0.222,0.444,8.729,死亡率=22.2%; 严重事件率=77.8%; 罕见+严重; 住院率=44.4%
Venetoclax,Pleural effusion,5,95,0.908,0.908,0.04,1.000,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Venetoclax,Decreased appetite,9,95,0.643,0.643,1.68,0.889,0.444,0.889,8.729,死亡率=44.4%; 严重事件率=88.9%; 罕见+严重; 住院率=88.9%
Venetoclax,Disease progression,10,95,0.469,0.469,5.68,0.900,0.600,0.500,8.623,死亡率=60.0%; 严重事件率=90.0%; 罕见+严重; 住院率=50.0%
Venetoclax,Blood creatinine increased,5,95,1.094,1.094,0.04,1.000,0.600,0.800,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Venetoclax,Pain,7,95,0.936,0.936,0.03,0.857,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Venetoclax,Transfusion,5,95,16.551,16.551,50.11,1.000,0.200,0.200,9.317,PRR=16.55 (显著关联); χ²=50.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Ibrutinib,Febrile neutropenia,8,95,0.558,0.558,2.64,1.000,0.500,1.000,8.847,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Back pain,13,95,1.871,1.871,4.78,0.923,0.231,0.769,8.361,死亡率=23.1%; 严重事件率=92.3%; 罕见+严重; 住院率=76.9%
Ibrutinib,Renal failure acute,7,95,1.837,1.837,2.44,1.000,0.286,0.857,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Ibrutinib,Deep vein thrombosis,5,95,1.527,1.527,0.84,1.000,0.400,0.800,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Neutropenia,9,95,0.505,0.505,4.12,0.889,0.333,0.778,8.729,死亡率=33.3%; 严重事件率=88.9%; 罕见+严重; 住院率=77.8%
Ibrutinib,Urinary tract infection,10,95,1.755,1.755,2.97,1.000,0.300,0.800,8.623,死亡率=30.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Renal failure,8,95,1.319,1.319,0.57,1.000,0.500,1.000,8.847,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Cough,6,95,0.827,0.827,0.20,0.833,0.500,0.667,9.134,死亡率=50.0%; 严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Ibrutinib,Rash,13,95,0.631,0.631,2.62,1.000,0.231,0.692,8.361,死亡率=23.1%; 严重事件率=100.0%; 罕见+严重; 住院率=69.2%
Ibrutinib,Hypotension,8,95,1.293,1.293,0.49,1.000,0.250,0.875,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Ibrutinib,Abdominal pain,7,95,0.687,0.687,0.94,1.000,0.429,0.714,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Ibrutinib,Dizziness,15,95,1.476,1.476,2.11,0.800,0.333,0.667,8.218,死亡率=33.3%; 严重事件率=80.0%; 罕见+严重; 住院率=66.7%
Ibrutinib,Haematochezia,5,95,4.631,4.631,12.09,1.000,0.000,0.400,9.317,PRR=4.63 (显著关联); χ²=12.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Ibrutinib,Weight decreased,7,95,0.862,0.862,0.15,1.000,0.429,0.714,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Ibrutinib,General physical health deterioration,5,95,1.139,1.139,0.08,1.000,0.800,0.800,9.317,死亡率=80.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Thrombocytopenia,15,95,1.102,1.102,0.13,1.000,0.467,0.867,8.218,死亡率=46.7%; 严重事件率=100.0%; 罕见+严重; 住院率=86.7%
Ibrutinib,Pancytopenia,7,95,1.068,1.068,0.03,1.000,0.714,0.857,8.980,死亡率=71.4%; 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Ibrutinib,Headache,9,95,0.880,0.880,0.14,1.000,0.333,0.778,8.729,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=77.8%
Ibrutinib,Sepsis,10,95,1.206,1.206,0.33,1.000,0.600,1.000,8.623,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Dehydration,11,95,0.905,0.905,0.10,1.000,0.364,1.000,8.528,死亡率=36.4%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Hyponatraemia,5,95,1.251,1.251,0.23,1.000,0.400,0.800,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Decreased appetite,7,95,0.418,0.418,5.37,0.857,0.286,0.714,8.980,死亡率=28.6%; 严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Ibrutinib,Respiratory failure,6,95,1.350,1.350,0.50,1.000,0.667,1.000,9.134,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Olaparib,Pneumonitis,7,95,1.032,1.032,0.01,1.000,0.429,0.429,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Olaparib,Pneumonia,8,95,0.433,0.433,5.56,0.875,0.625,0.625,8.847,死亡率=62.5%; 严重事件率=87.5%; 罕见+严重; 住院率=62.5%
Olaparib,Pyrexia,14,95,0.504,0.504,6.33,0.643,0.286,0.571,8.287,死亡率=28.6%; 严重事件率=64.3%; 罕见+严重; 住院率=57.1%
Olaparib,Chills,7,95,1.464,1.464,0.94,0.857,0.286,0.429,8.980,死亡率=28.6%; 严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Olaparib,Hot flush,5,95,5.197,5.197,13.86,0.800,0.200,0.200,9.317,PRR=5.20 (显著关联); χ²=13.9 (统计显著); 严重事件率=80.0%; 罕见+严重
Olaparib,Pain,14,95,1.410,1.410,1.52,0.714,0.214,0.429,8.287,死亡率=21.4%; 严重事件率=71.4%; 罕见+严重; 住院率=42.9%
Olaparib,Abdominal pain upper,17,95,3.048,3.048,20.22,0.765,0.176,0.353,8.093,PRR=3.05 (显著关联); χ²=20.2 (统计显著); 严重事件率=76.5%; 罕见+严重
Olaparib,Dehydration,8,95,0.569,0.569,2.45,0.875,0.375,0.750,8.847,死亡率=37.5%; 严重事件率=87.5%; 罕见+严重; 住院率=75.0%
Olaparib,Dry mouth,9,95,4.301,4.301,19.09,0.667,0.000,0.222,8.729,PRR=4.30 (显著关联); χ²=19.1 (统计显著); 严重事件率=66.7%; 罕见+严重
Olaparib,Dyspepsia,15,95,4.664,4.664,35.64,0.533,0.133,0.400,8.218,PRR=4.66 (显著关联); χ²=35.6 (统计显著); 严重事件率=53.3%; 罕见+严重
Olaparib,Muscle spasms,12,95,2.671,2.671,11.01,0.583,0.000,0.167,8.441,PRR=2.67 (显著关联); χ²=11.0 (统计显著); 严重事件率=58.3%; 罕见+严重
Olaparib,Ascites,5,95,1.597,1.597,1.02,1.000,0.400,0.600,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Olaparib,Febrile neutropenia,3,95,0.180,0.180,10.64,1.000,0.333,0.667,9.827,χ²=10.6 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Rucaparib,Feeding disorder,5,95,8.932,8.932,22.99,0.600,0.000,0.400,9.317,PRR=8.93 (显著关联); χ²=23.0 (统计显著); 严重事件率=60.0%; 罕见+严重
Rucaparib,Pneumonia,4,95,0.145,0.145,18.85,1.000,0.250,0.500,9.540,χ²=18.9 (统计显著); 死亡率=25.0%; 罕见+严重; 住院率=50.0%
Rucaparib,Abdominal distension,17,95,4.655,4.655,37.26,0.529,0.000,0.235,8.093,PRR=4.65 (显著关联); χ²=37.3 (统计显著); 严重事件率=52.9%; 罕见+严重
Rucaparib,Adverse drug reaction,13,95,5.690,5.690,36.89,0.615,0.000,0.308,8.361,PRR=5.69 (显著关联); χ²=36.9 (统计显著); 严重事件率=61.5%; 罕见+严重
Rucaparib,Wrong technique in product usage process,5,95,14.036,14.036,33.53,0.600,0.000,0.200,9.317,PRR=14.04 (显著关联); χ²=33.5 (统计显著); 严重事件率=60.0%; 罕见+严重
Niraparib,Ascites,9,95,1.772,1.772,2.58,1.000,0.222,0.556,8.729,死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Niraparib,Febrile neutropenia,3,95,0.106,0.106,21.00,1.000,0.333,0.667,9.827,χ²=21.0 (统计显著); 死亡率=33.3%; 罕见+严重; 住院率=66.7%
Niraparib,Inappropriate schedule of drug administration,9,95,6.176,6.176,27.03,0.667,0.000,0.222,8.729,PRR=6.18 (显著关联); χ²=27.0 (统计显著); 严重事件率=66.7%; 罕见+严重
Niraparib,Disturbance in attention,5,95,14.282,14.282,31.77,0.800,0.000,0.000,9.317,PRR=14.28 (显著关联); χ²=31.8 (统计显著); 严重事件率=80.0%; 罕见+严重
Niraparib,Stress,13,95,27.921,27.921,120.92,0.923,0.000,0.308,8.361,PRR=27.92 (显著关联); χ²=120.9 (统计显著); 严重事件率=92.3%; 罕见+严重
Niraparib,Fall,14,95,1.454,1.454,1.72,1.000,0.214,0.786,8.287,死亡率=21.4%; 严重事件率=100.0%; 罕见+严重; 住院率=78.6%
Niraparib,Heart rate irregular,6,95,8.571,8.571,25.22,0.833,0.000,0.167,9.134,PRR=8.57 (显著关联); χ²=25.2 (统计显著); 严重事件率=83.3%; 罕见+严重
Niraparib,Palpitations,13,95,5.315,5.315,32.69,0.692,0.077,0.231,8.361,PRR=5.31 (显著关联); χ²=32.7 (统计显著); 严重事件率=69.2%; 罕见+严重
Niraparib,Feeling abnormal,18,95,4.238,4.238,33.51,0.778,0.000,0.278,8.036,PRR=4.24 (显著关联); χ²=33.5 (统计显著); 严重事件率=77.8%; 罕见+严重
Niraparib,Haematuria,6,95,1.657,1.657,1.34,1.000,0.333,1.000,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Niraparib,Flatulence,12,95,4.203,4.203,22.12,0.583,0.083,0.250,8.441,PRR=4.20 (显著关联); χ²=22.1 (统计显著); 严重事件率=58.3%; 罕见+严重
Niraparib,Abdominal distension,15,95,3.481,3.481,20.70,0.800,0.067,0.200,8.218,PRR=3.48 (显著关联); χ²=20.7 (统计显著); 严重事件率=80.0%; 罕见+严重
Niraparib,Transfusion,6,95,9.350,9.350,27.29,1.000,0.167,0.167,9.134,PRR=9.35 (显著关联); χ²=27.3 (统计显著); 严重事件率=100.0%; 罕见+严重
Niraparib,Photosensitivity reaction,9,95,3.283,3.283,11.29,0.778,0.000,0.222,8.729,PRR=3.28 (显著关联); χ²=11.3 (统计显著); 严重事件率=77.8%; 罕见+严重
Talazoparib,White blood cell count decreased,8,95,1.096,1.096,0.06,0.875,0.250,0.500,8.847,死亡率=25.0%; 严重事件率=87.5%; 罕见+严重; 住院率=50.0%
Talazoparib,Pulmonary embolism,7,95,1.648,1.648,1.67,0.857,0.429,0.571,8.980,死亡率=42.9%; 严重事件率=85.7%; 罕见+严重; 住院率=57.1%
Talazoparib,Sepsis,6,95,0.992,0.992,0.00,1.000,0.333,0.667,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Talazoparib,Haematotoxicity,10,95,11.106,11.106,72.03,0.900,0.000,0.200,8.623,PRR=11.11 (显著关联); χ²=72.0 (统计显著); 严重事件率=90.0%; 罕见+严重
Talazoparib,Hepatocellular injury,5,95,10.100,10.100,32.81,1.000,0.200,0.200,9.317,PRR=10.10 (显著关联); χ²=32.8 (统计显著); 严重事件率=100.0%; 罕见+严重
Palbociclib,Sepsis,5,95,0.620,0.620,1.11,1.000,1.000,0.800,9.317,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Palbociclib,Abdominal pain upper,8,95,1.626,1.626,1.78,0.625,0.375,0.500,8.847,死亡率=37.5%; 严重事件率=62.5%; 罕见+严重; 住院率=50.0%
Palbociclib,Depression,11,95,6.130,6.130,38.76,0.636,0.182,0.182,8.528,PRR=6.13 (显著关联); χ²=38.8 (统计显著); 严重事件率=63.6%; 罕见+严重
Palbociclib,Full blood count decreased,10,95,4.872,4.872,26.06,0.600,0.000,0.200,8.623,PRR=4.87 (显著关联); χ²=26.1 (统计显著); 严重事件率=60.0%; 罕见+严重
Ribociclib,Sepsis,6,95,1.002,1.002,0.00,1.000,0.333,0.667,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Ribociclib,Pneumonia,8,95,0.700,0.700,0.98,1.000,0.250,0.750,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Ribociclib,Breast cancer,5,95,6.018,6.018,18.06,1.000,0.200,0.000,9.317,PRR=6.02 (显著关联); χ²=18.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Ribociclib,Cough,6,95,1.165,1.165,0.13,1.000,0.333,0.833,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Ribociclib,Dyspnoea,16,95,1.200,1.200,0.50,0.875,0.312,0.688,8.153,死亡率=31.2%; 严重事件率=87.5%; 罕见+严重; 住院率=68.8%
Ribociclib,Electrocardiogram QT prolonged,15,95,20.890,20.890,190.38,1.000,0.000,0.067,8.218,PRR=20.89 (显著关联); χ²=190.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Ribociclib,Rash pruritic,7,95,6.581,6.581,28.26,0.571,0.000,0.000,8.980,PRR=6.58 (显著关联); χ²=28.3 (统计显著); 严重事件率=57.1%; 罕见+严重
Abemaciclib,Drug ineffective,16,95,2.750,2.750,16.10,0.562,0.062,0.125,8.153,PRR=2.75 (显著关联); χ²=16.1 (统计显著); 严重事件率=56.2%; 罕见+严重
Abemaciclib,Weight decreased,15,95,2.497,2.497,12.24,0.533,0.000,0.267,8.218,PRR=2.50 (显著关联); χ²=12.2 (统计显著); 严重事件率=53.3%; 罕见+严重
Vemurafenib,Diarrhoea,18,95,0.477,0.477,9.52,1.000,0.278,0.444,8.036,死亡率=27.8%; 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Vemurafenib,Squamous cell carcinoma,10,95,18.883,18.883,107.18,1.000,0.000,0.300,8.623,PRR=18.88 (显著关联); χ²=107.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Vemurafenib,Photosensitivity reaction,18,95,17.079,17.079,177.60,0.778,0.111,0.333,8.036,PRR=17.08 (显著关联); χ²=177.6 (统计显著); 严重事件率=77.8%; 罕见+严重
Vemurafenib,Pneumonia,8,95,0.533,0.533,3.10,1.000,0.375,0.875,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Vemurafenib,Toxic skin eruption,5,95,10.518,10.518,32.25,1.000,0.000,0.400,9.317,PRR=10.52 (显著关联); χ²=32.3 (统计显著); 严重事件率=100.0%; 罕见+严重
Vemurafenib,Uveitis,5,95,9.933,9.933,30.47,0.800,0.000,0.000,9.317,PRR=9.93 (显著关联); χ²=30.5 (统计显著); 严重事件率=80.0%; 罕见+严重
Vemurafenib,Mass,5,95,12.772,12.772,38.75,0.800,0.000,0.200,9.317,PRR=12.77 (显著关联); χ²=38.7 (统计显著); 严重事件率=80.0%; 罕见+严重
Vemurafenib,Keratoacanthoma,5,95,44.711,44.711,92.06,1.000,0.200,0.200,9.317,PRR=44.71 (显著关联); χ²=92.1 (统计显著); 严重事件率=100.0%; 罕见+严重
Vemurafenib,Alopecia,14,95,3.063,3.063,17.22,0.929,0.143,0.143,8.287,PRR=3.06 (显著关联); χ²=17.2 (统计显著); 严重事件率=92.9%; 罕见+严重
Vemurafenib,Renal failure,8,95,1.414,1.414,0.90,1.000,0.375,0.500,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Vemurafenib,Ocular hyperaemia,5,95,7.449,7.449,22.39,1.000,0.000,0.200,9.317,PRR=7.45 (显著关联); χ²=22.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Vemurafenib,Myalgia,10,95,2.935,2.935,11.37,0.900,0.100,0.200,8.623,PRR=2.94 (显著关联); χ²=11.4 (统计显著); 严重事件率=90.0%; 罕见+严重
Vemurafenib,Skin toxicity,8,95,15.925,15.925,74.93,0.875,0.000,0.125,8.847,PRR=15.92 (显著关联); χ²=74.9 (统计显著); 严重事件率=87.5%; 罕见+严重
Vemurafenib,Sunburn,6,95,21.473,21.473,70.91,0.833,0.167,0.333,9.134,PRR=21.47 (显著关联); χ²=70.9 (统计显著); 严重事件率=83.3%; 罕见+严重
Vemurafenib,Hyperkeratosis,14,95,27.980,27.980,197.38,0.929,0.071,0.143,8.287,PRR=27.98 (显著关联); χ²=197.4 (统计显著); 严重事件率=92.9%; 罕见+严重
Vemurafenib,Squamous cell carcinoma of skin,6,95,15.337,15.337,54.52,1.000,0.167,0.167,9.134,PRR=15.34 (显著关联); χ²=54.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Vemurafenib,Skin disorder,7,95,5.112,5.112,19.60,0.857,0.143,0.286,8.980,PRR=5.11 (显著关联); χ²=19.6 (统计显著); 严重事件率=85.7%; 罕见+严重
Vemurafenib,Skin lesion,5,95,8.514,8.514,25.95,1.000,0.200,0.400,9.317,PRR=8.51 (显著关联); χ²=26.0 (统计显著); 严重事件率=100.0%; 罕见+严重
Vemurafenib,Inflammation,5,95,8.514,8.514,25.95,0.800,0.000,0.400,9.317,PRR=8.51 (显著关联); χ²=26.0 (统计显著); 严重事件率=80.0%; 罕见+严重
Vemurafenib,Sepsis,6,95,0.763,0.763,0.42,1.000,0.333,0.667,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Vemurafenib,Hypercholesterolaemia,6,95,214.769,214.769,176.70,0.833,0.000,0.000,9.134,PRR=214.77 (显著关联); χ²=176.7 (统计显著); 严重事件率=83.3%; 罕见+严重
Vemurafenib,Gastritis,5,95,4.965,4.965,13.47,1.000,0.000,0.000,9.317,PRR=4.97 (显著关联); χ²=13.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Basal cell carcinoma,16,95,33.154,33.154,247.21,1.000,0.000,0.062,8.153,PRR=33.15 (显著关联); χ²=247.2 (统计显著); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Headache,17,95,1.794,1.794,5.43,0.941,0.235,0.412,8.093,死亡率=23.5%; 严重事件率=94.1%; 罕见+严重; 住院率=41.2%
Dabrafenib,Panniculitis,17,95,199.797,199.797,484.93,1.000,0.059,0.000,8.093,PRR=199.80 (显著关联); χ²=484.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Uveitis,5,95,9.715,9.715,29.63,1.000,0.000,0.200,9.317,PRR=9.72 (显著关联); χ²=29.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Pancytopenia,5,95,0.792,0.792,0.26,1.000,0.400,1.000,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Dabrafenib,Sepsis,6,95,0.746,0.746,0.49,1.000,0.500,0.667,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Dabrafenib,Dyspnoea,9,95,0.494,0.494,4.40,0.889,0.333,0.556,8.729,死亡率=33.3%; 严重事件率=88.9%; 罕见+严重; 住院率=55.6%
Dabrafenib,Terminal state,5,95,43.730,43.730,89.90,1.000,0.000,0.400,9.317,PRR=43.73 (显著关联); χ²=89.9 (统计显著); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Palmar-plantar erythrodysaesthesia syndrome,9,95,4.851,4.851,23.33,0.889,0.000,0.222,8.729,PRR=4.85 (显著关联); χ²=23.3 (统计显著); 严重事件率=88.9%; 罕见+严重
Dabrafenib,Renal failure,9,95,1.565,1.565,1.69,1.000,0.222,0.889,8.729,死亡率=22.2%; 严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Dabrafenib,Malignant neoplasm progression,6,95,0.304,0.304,9.08,1.000,0.333,0.667,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Dabrafenib,Malaise,12,95,1.111,1.111,0.12,0.917,0.333,0.417,8.441,死亡率=33.3%; 严重事件率=91.7%; 罕见+严重; 住院率=41.7%
Dabrafenib,Hyperkeratosis,14,95,27.362,27.362,192.62,0.857,0.000,0.214,8.287,PRR=27.36 (显著关联); χ²=192.6 (统计显著); 严重事件率=85.7%; 罕见+严重
Dabrafenib,Dermatitis acneiform,8,95,10.781,10.781,52.47,0.875,0.000,0.250,8.847,PRR=10.78 (显著关联); χ²=52.5 (统计显著); 严重事件率=87.5%; 罕见+严重
Dabrafenib,Gamma-glutamyltransferase increased,5,95,5.828,5.828,16.60,1.000,0.000,0.400,9.317,PRR=5.83 (显著关联); χ²=16.6 (统计显著); 严重事件率=100.0%; 罕见+严重
Pembrolizumab,Alanine aminotransferase increased,16,90,4.458,4.458,37.70,0.500,0.000,0.438,8.153,PRR=4.46 (显著关联); χ²=37.7 (统计显著); 罕见+严重; 住院率=43.8%
Pembrolizumab,Confusional state,7,90,2.200,2.200,4.24,0.857,0.143,0.857,8.980,PRR=2.20 (显著关联); 严重事件率=85.7%; 罕见+严重; 住院率=85.7%
Pembrolizumab,Hypophysitis,4,90,5.432,5.432,12.62,0.750,0.000,0.750,9.540,PRR=5.43 (显著关联); χ²=12.6 (统计显著); 罕见+严重; 住院率=75.0%
Nivolumab,Hypotension,11,90,2.472,2.472,8.84,1.000,0.182,1.000,8.528,PRR=2.47 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Gastritis,4,90,4.919,4.919,10.98,1.000,0.000,1.000,9.540,PRR=4.92 (显著关联); χ²=11.0 (统计显著); 罕见+严重; 住院率=100.0%
Nivolumab,Diabetic ketoacidosis,4,90,15.172,15.172,38.72,1.000,0.000,1.000,9.540,PRR=15.17 (显著关联); χ²=38.7 (统计显著); 罕见+严重; 住院率=100.0%
Nivolumab,Hypoxia,5,90,2.585,2.585,4.47,1.000,0.000,1.000,9.317,PRR=2.58 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Autoimmune colitis,3,90,27.291,27.291,46.34,1.000,0.000,1.000,9.827,PRR=27.29 (显著关联); χ²=46.3 (统计显著); 罕见+严重; 住院率=100.0%
Nivolumab,Enterocolitis,4,90,7.001,7.001,17.38,1.000,0.000,1.000,9.540,PRR=7.00 (显著关联); χ²=17.4 (统计显著); 罕见+严重; 住院率=100.0%
Nivolumab,Hypokalaemia,5,90,2.394,2.394,3.75,1.000,0.200,1.000,9.317,PRR=2.39 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Systemic inflammatory response syndrome,3,90,9.095,9.095,17.58,1.000,0.000,1.000,9.827,PRR=9.10 (显著关联); χ²=17.6 (统计显著); 罕见+严重; 住院率=100.0%
Nivolumab,Tubulointerstitial nephritis,3,90,12.404,12.404,24.11,1.000,0.000,1.000,9.827,PRR=12.40 (显著关联); χ²=24.1 (统计显著); 罕见+严重; 住院率=100.0%
Atezolizumab,Syncope,5,90,3.019,3.019,6.26,1.000,0.200,1.000,9.317,PRR=3.02 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Seizure,4,90,5.098,5.098,11.83,1.000,0.000,1.000,9.540,PRR=5.10 (显著关联); χ²=11.8 (统计显著); 罕见+严重; 住院率=100.0%
Atezolizumab,Hypercalcaemia,4,90,6.556,6.556,16.53,1.000,0.000,0.500,9.540,PRR=6.56 (显著关联); χ²=16.5 (统计显著); 罕见+严重; 住院率=50.0%
Atezolizumab,Pulmonary embolism,8,90,2.344,2.344,5.75,1.000,0.125,0.750,8.847,PRR=2.34 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Atezolizumab,Pleuritic pain,3,90,28.668,28.668,52.32,1.000,0.000,1.000,9.827,PRR=28.67 (显著关联); χ²=52.3 (统计显著); 罕见+严重; 住院率=100.0%
Atezolizumab,Hypokalaemia,5,90,3.019,3.019,6.26,1.000,0.200,1.000,9.317,PRR=3.02 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Lower respiratory tract infection,3,90,5.929,5.929,10.91,1.000,0.000,1.000,9.827,PRR=5.93 (显著关联); χ²=10.9 (统计显著); 罕见+严重; 住院率=100.0%
Atezolizumab,Blood creatine phosphokinase increased,4,90,10.930,10.930,29.65,1.000,0.000,0.750,9.540,PRR=10.93 (显著关联); χ²=29.7 (统计显著); 罕见+严重; 住院率=75.0%
Atezolizumab,Diabetes mellitus,4,90,5.883,5.883,14.38,1.000,0.000,1.000,9.540,PRR=5.88 (显著关联); χ²=14.4 (统计显著); 罕见+严重; 住院率=100.0%
Atezolizumab,Myositis,4,90,19.130,19.130,50.44,1.000,0.000,0.750,9.540,PRR=19.13 (显著关联); χ²=50.4 (统计显著); 罕见+严重; 住院率=75.0%
Atezolizumab,Rhabdomyolysis,3,90,8.598,8.598,17.15,1.000,0.000,1.000,9.827,PRR=8.60 (显著关联); χ²=17.2 (统计显著); 罕见+严重; 住院率=100.0%
Atezolizumab,Muscular weakness,5,90,2.257,2.257,3.29,0.800,0.200,0.600,9.317,PRR=2.26 (显著关联); 严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Atezolizumab,Myocardial infarction,3,90,2.045,2.045,1.51,1.000,0.667,0.333,9.827,PRR=2.04 (显著关联); 死亡率=66.7%; 罕见+严重
Atezolizumab,Cholecystitis acute,3,90,34.403,34.403,59.57,1.000,0.000,0.667,9.827,PRR=34.40 (显著关联); χ²=59.6 (统计显著); 罕见+严重; 住院率=66.7%
Durvalumab,Acute kidney injury,5,90,2.052,2.052,2.51,1.000,0.200,0.800,9.317,PRR=2.05 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Durvalumab,Chest pain,9,90,2.412,2.412,6.85,0.889,0.111,0.667,8.729,PRR=2.41 (显著关联); 严重事件率=88.9%; 罕见+严重; 住院率=66.7%
Durvalumab,Gastrointestinal pain,3,90,46.806,46.806,65.66,1.000,0.000,1.000,9.827,PRR=46.81 (显著关联); χ²=65.7 (统计显著); 罕见+严重; 住院率=100.0%
Durvalumab,Delirium,4,90,5.675,5.675,13.40,1.000,0.000,1.000,9.540,PRR=5.68 (显著关联); χ²=13.4 (统计显著); 罕见+严重; 住院率=100.0%
Durvalumab,Diabetes mellitus,4,90,4.802,4.802,10.65,1.000,0.000,0.750,9.540,PRR=4.80 (显著关联); χ²=10.6 (统计显著); 罕见+严重; 住院率=75.0%
Durvalumab,Arthritis,4,90,5.853,5.853,13.95,1.000,0.000,0.500,9.540,PRR=5.85 (显著关联); χ²=13.9 (统计显著); 罕见+严重; 住院率=50.0%
Durvalumab,Muscular weakness,7,90,2.624,2.624,6.47,1.000,0.000,0.571,8.980,PRR=2.62 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Durvalumab,Appendicitis,3,90,28.082,28.082,47.82,1.000,0.000,1.000,9.827,PRR=28.08 (显著关联); χ²=47.8 (统计显著); 罕见+严重; 住院率=100.0%
Durvalumab,Hypersensitivity,6,90,2.006,2.006,2.82,1.000,0.167,0.833,9.134,PRR=2.01 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Durvalumab,Stress cardiomyopathy,3,90,15.600,15.600,30.02,1.000,0.000,1.000,9.827,PRR=15.60 (显著关联); χ²=30.0 (统计显著); 罕见+严重; 住院率=100.0%
Durvalumab,Pericarditis,4,90,11.020,11.020,28.77,1.000,0.000,1.000,9.540,PRR=11.02 (显著关联); χ²=28.8 (统计显著); 罕见+严重; 住院率=100.0%
Durvalumab,Neoplasm,3,90,3.508,3.508,4.88,0.667,0.333,0.333,9.827,PRR=3.51 (显著关联); 死亡率=33.3%; 罕见+严重
Durvalumab,Toxic skin eruption,3,90,7.388,7.388,13.97,1.000,0.000,0.667,9.827,PRR=7.39 (显著关联); χ²=14.0 (统计显著); 罕见+严重; 住院率=66.7%
Ipilimumab,Metastases to central nervous system,6,90,2.294,2.294,4.02,1.000,0.000,1.000,9.134,PRR=2.29 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Rectal haemorrhage,5,90,3.789,3.789,9.13,1.000,0.200,1.000,9.317,PRR=3.79 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Headache,17,90,2.104,2.104,8.97,0.824,0.118,0.765,8.093,PRR=2.10 (显著关联); 严重事件率=82.4%; 罕见+严重; 住院率=76.5%
Ipilimumab,Syncope,6,90,2.612,2.612,5.44,1.000,0.167,0.833,9.134,PRR=2.61 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Ipilimumab,Proctalgia,3,90,40.898,40.898,56.85,1.000,0.000,1.000,9.827,PRR=40.90 (显著关联); χ²=56.9 (统计显著); 罕见+严重; 住院率=100.0%
Ipilimumab,Acute myocardial infarction,3,90,6.456,6.456,11.63,1.000,0.000,1.000,9.827,PRR=6.46 (显著关联); χ²=11.6 (统计显著); 罕见+严重; 住院率=100.0%
Ipilimumab,Speech disorder,4,90,2.405,2.405,3.01,1.000,0.500,0.250,9.540,PRR=2.40 (显著关联); 死亡率=50.0%; 罕见+严重
Ipilimumab,Uveitis,3,90,6.133,6.133,10.91,1.000,0.000,0.667,9.827,PRR=6.13 (显著关联); χ²=10.9 (统计显著); 罕见+严重; 住院率=66.7%
Ipilimumab,Dysuria,3,90,3.503,3.503,4.81,1.000,0.333,0.000,9.827,PRR=3.50 (显著关联); 死亡率=33.3%; 罕见+严重
Ipilimumab,Sarcoidosis,3,90,13.631,13.631,25.64,1.000,0.000,0.667,9.827,PRR=13.63 (显著关联); χ²=25.6 (统计显著); 罕见+严重; 住院率=66.7%
Ipilimumab,Hypophosphataemia,4,90,4.545,4.545,9.68,1.000,0.250,0.250,9.540,PRR=4.54 (显著关联); 死亡率=25.0%; 罕见+严重
Trastuzumab,Neurotoxicity,4,90,5.084,5.084,10.69,1.000,0.000,0.500,9.540,PRR=5.08 (显著关联); χ²=10.7 (统计显著); 罕见+严重; 住院率=50.0%
Trastuzumab,Infusion related reaction,9,90,2.064,2.064,4.41,1.000,0.111,0.444,8.729,PRR=2.06 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Trastuzumab,Left ventricular dysfunction,3,90,3.493,3.493,4.57,1.000,0.333,0.333,9.827,PRR=3.49 (显著关联); 死亡率=33.3%; 罕见+严重
Trastuzumab,Oxygen saturation decreased,4,90,4.142,4.142,8.00,1.000,0.250,0.000,9.540,PRR=4.14 (显著关联); 死亡率=25.0%; 罕见+严重
Trastuzumab,Oropharyngeal pain,5,90,2.086,2.086,2.53,1.000,0.000,0.600,9.317,PRR=2.09 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Trastuzumab,Cardiac failure,7,90,2.175,2.175,3.96,1.000,0.143,0.429,8.980,PRR=2.18 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Trastuzumab,Hypokalaemia,7,90,2.105,2.105,3.63,1.000,0.000,0.857,8.980,PRR=2.11 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Trastuzumab,Cellulitis,5,90,2.689,2.689,4.65,1.000,0.000,1.000,9.317,PRR=2.69 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Trastuzumab,Breast cancer,4,90,2.795,2.795,4.04,0.750,0.500,0.250,9.540,PRR=2.80 (显著关联); 死亡率=50.0%; 罕见+严重
Trastuzumab,Ataxia,3,90,7.624,7.624,13.07,1.000,0.000,0.667,9.827,PRR=7.62 (显著关联); χ²=13.1 (统计显著); 罕见+严重; 住院率=66.7%
Bevacizumab,Large intestine perforation,4,90,4.391,4.391,8.85,1.000,0.500,0.250,9.540,PRR=4.39 (显著关联); 死亡率=50.0%; 罕见+严重
Bevacizumab,Dysphonia,4,90,3.616,3.616,6.54,1.000,0.500,0.250,9.540,PRR=3.62 (显著关联); 死亡率=50.0%; 罕见+严重
Bevacizumab,Mucosal inflammation,9,90,2.495,2.495,7.17,1.000,0.111,0.667,8.729,PRR=2.50 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Bevacizumab,Metastases to lung,4,90,3.235,3.235,5.40,1.000,0.500,0.250,9.540,PRR=3.23 (显著关联); 死亡率=50.0%; 罕见+严重
Bevacizumab,Dermatitis,3,90,2.710,2.710,2.87,1.000,0.333,0.000,9.827,PRR=2.71 (显著关联); 死亡率=33.3%; 罕见+严重
Bevacizumab,Cerebral infarction,4,90,6.148,6.148,13.88,1.000,0.000,0.500,9.540,PRR=6.15 (显著关联); χ²=13.9 (统计显著); 罕见+严重; 住院率=50.0%
Bevacizumab,Intestinal obstruction,5,90,2.794,2.794,5.10,1.000,0.000,1.000,9.317,PRR=2.79 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bevacizumab,Blood creatine phosphokinase increased,4,90,5.855,5.855,13.07,1.000,0.000,0.500,9.540,PRR=5.86 (显著关联); χ²=13.1 (统计显著); 罕见+严重; 住院率=50.0%
Bevacizumab,Osteonecrosis of jaw,3,90,2.560,2.560,2.54,1.000,0.333,0.333,9.827,PRR=2.56 (显著关联); 死亡率=33.3%; 罕见+严重
Bevacizumab,Device related infection,4,90,7.234,7.234,16.80,0.750,0.000,0.500,9.540,PRR=7.23 (显著关联); χ²=16.8 (统计显著); 罕见+严重; 住院率=50.0%
Bevacizumab,Cardiac arrest,4,90,2.014,2.014,1.85,1.000,1.000,0.000,9.540,PRR=2.01 (显著关联); 死亡率=100.0%; 罕见+严重
Bevacizumab,Loss of consciousness,6,90,3.128,3.128,7.60,1.000,0.000,0.667,9.134,PRR=3.13 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Bevacizumab,Thrombocytopenic purpura,3,90,92.205,92.205,65.41,1.000,0.000,1.000,9.827,PRR=92.21 (显著关联); χ²=65.4 (统计显著); 罕见+严重; 住院率=100.0%
Bevacizumab,Neoplasm,3,90,2.303,2.303,1.99,1.000,0.667,0.000,9.827,PRR=2.30 (显著关联); 死亡率=66.7%; 罕见+严重
Cetuximab,Cardiac arrest,4,90,4.111,4.111,8.65,1.000,0.250,0.000,9.540,PRR=4.11 (显著关联); 死亡率=25.0%; 罕见+严重
Rituximab,Mobility decreased,3,90,3.361,3.361,4.26,0.667,0.333,0.333,9.827,PRR=3.36 (显著关联); 死亡率=33.3%; 罕见+严重
Rituximab,Neutropenic sepsis,7,90,3.366,3.366,9.93,1.000,0.000,1.000,8.980,PRR=3.37 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rituximab,Musculoskeletal stiffness,3,90,3.666,3.666,4.93,0.667,0.333,0.333,9.827,PRR=3.67 (显著关联); 死亡率=33.3%; 罕见+严重
Rituximab,Lymphopenia,3,90,2.987,2.987,3.43,1.000,0.333,0.000,9.827,PRR=2.99 (显著关联); 死亡率=33.3%; 罕见+严重
Rituximab,Dyspepsia,8,90,2.132,2.132,4.27,1.000,0.125,0.875,8.847,PRR=2.13 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Rituximab,Influenza,6,90,3.047,3.047,7.12,0.833,0.000,0.667,9.134,PRR=3.05 (显著关联); 严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Rituximab,Encephalitis,3,90,13.448,13.448,22.18,1.000,0.000,1.000,9.827,PRR=13.45 (显著关联); χ²=22.2 (统计显著); 罕见+严重; 住院率=100.0%
Rituximab,Escherichia urinary tract infection,4,90,35.880,35.880,55.93,1.000,0.000,1.000,9.540,PRR=35.88 (显著关联); χ²=55.9 (统计显著); 罕见+严重; 住院率=100.0%
Rituximab,Hyperthermia,4,90,17.939,17.939,36.93,1.000,0.000,0.750,9.540,PRR=17.94 (显著关联); χ²=36.9 (统计显著); 罕见+严重; 住院率=75.0%
Rituximab,Vertigo,5,90,3.281,3.281,6.79,1.000,0.200,0.600,9.317,PRR=3.28 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Rituximab,Neutropenic colitis,3,90,10.085,10.085,17.19,1.000,0.000,0.667,9.827,PRR=10.09 (显著关联); χ²=17.2 (统计显著); 罕见+严重; 住院率=66.7%
Rituximab,No therapeutic response,4,90,4.304,4.304,8.41,1.000,0.250,0.250,9.540,PRR=4.30 (显著关联); 死亡率=25.0%; 罕见+严重
Rituximab,Diabetes mellitus,3,90,2.016,2.016,1.37,1.000,0.333,0.000,9.827,PRR=2.02 (显著关联); 死亡率=33.3%; 罕见+严重
Rituximab,Weight increased,7,90,3.194,3.194,9.05,1.000,0.000,0.857,8.980,PRR=3.19 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Epcoritamab,Disorientation,3,90,4.320,4.320,6.63,1.000,0.667,0.333,9.827,PRR=4.32 (显著关联); 死亡率=66.7%; 罕见+严重
Epcoritamab,Immune effector cell-associated neurotoxicity syndrome,38,90,0.000,0.000,1328.98,1.000,0.395,0.526,7.288,χ²=1329.0 (统计显著); 死亡率=39.5%; 严重事件率=100.0%; 住院率=52.6%
Epcoritamab,Disseminated intravascular coagulation,3,90,3.176,3.176,3.99,1.000,0.667,0.333,9.827,PRR=3.18 (显著关联); 死亡率=66.7%; 罕见+严重
Epcoritamab,COVID-19,21,90,0.000,0.000,734.44,1.000,0.524,0.571,7.881,χ²=734.4 (统计显著); 死亡率=52.4%; 严重事件率=100.0%; 住院率=57.1%
Epcoritamab,Blood pressure decreased,3,90,2.769,2.769,3.05,1.000,0.333,0.000,9.827,PRR=2.77 (显著关联); 死亡率=33.3%; 罕见+严重
Epcoritamab,Gastrointestinal haemorrhage,4,90,2.441,2.441,3.09,1.000,0.750,0.250,9.540,PRR=2.44 (显著关联); 死亡率=75.0%; 罕见+严重
Epcoritamab,Femoral neck fracture,3,90,21.609,21.609,35.78,1.000,0.000,1.000,9.827,PRR=21.61 (显著关联); χ²=35.8 (统计显著); 罕见+严重; 住院率=100.0%
Imatinib,Pollakiuria,4,90,2.908,2.908,4.33,1.000,0.250,0.250,9.540,PRR=2.91 (显著关联); 死亡率=25.0%; 罕见+严重
Imatinib,Depression,6,90,2.310,2.310,3.93,1.000,0.000,0.500,9.134,PRR=2.31 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Imatinib,Metastasis,3,90,3.413,3.413,4.35,1.000,0.333,0.000,9.827,PRR=3.41 (显著关联); 死亡率=33.3%; 罕见+严重
Imatinib,Fall,13,90,2.054,2.054,6.22,1.000,0.077,0.462,8.361,PRR=2.05 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=46.2%
Imatinib,Sudden death,3,90,4.906,4.906,7.55,1.000,1.000,0.000,9.827,PRR=4.91 (显著关联); 死亡率=100.0%; 罕见+严重
Imatinib,Pulmonary mass,3,90,4.618,4.618,6.95,1.000,0.333,0.333,9.827,PRR=4.62 (显著关联); 死亡率=33.3%; 罕见+严重
Imatinib,Acute myeloid leukaemia,3,90,2.012,2.012,1.36,1.000,0.667,0.333,9.827,PRR=2.01 (显著关联); 死亡率=66.7%; 罕见+严重
Imatinib,Drug resistance,4,90,4.760,4.760,9.66,1.000,0.750,0.000,9.540,PRR=4.76 (显著关联); 死亡率=75.0%; 罕见+严重
Imatinib,Renal disorder,5,90,2.727,2.727,4.75,1.000,0.200,0.600,9.317,PRR=2.73 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Imatinib,Angioedema,3,90,8.724,8.724,14.80,1.000,0.000,1.000,9.827,PRR=8.72 (显著关联); χ²=14.8 (统计显著); 罕见+严重; 住院率=100.0%
Erlotinib,Diarrhoea,64,90,1.707,1.707,16.24,1.000,0.250,0.438,6.767,χ²=16.2 (统计显著); 死亡率=25.0%; 严重事件率=100.0%; 住院率=43.8%
Erlotinib,Conjunctivitis,3,90,6.731,6.731,11.82,1.000,0.000,0.667,9.827,PRR=6.73 (显著关联); χ²=11.8 (统计显著); 罕见+严重; 住院率=66.7%
Erlotinib,Ocular hyperaemia,4,90,5.387,5.387,11.93,1.000,0.000,0.500,9.540,PRR=5.39 (显著关联); χ²=11.9 (统计显著); 罕见+严重; 住院率=50.0%
Erlotinib,Vision blurred,7,90,2.482,2.482,5.57,1.000,0.000,0.429,8.980,PRR=2.48 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Erlotinib,Wound,3,90,4.589,4.589,7.18,1.000,0.333,0.000,9.827,PRR=4.59 (显著关联); 死亡率=33.3%; 罕见+严重
Erlotinib,Pulmonary haemorrhage,3,90,5.609,5.609,9.44,1.000,0.667,0.000,9.827,PRR=5.61 (显著关联); 死亡率=66.7%; 罕见+严重
Erlotinib,Haematuria,6,90,3.260,3.260,8.28,1.000,0.000,0.667,9.134,PRR=3.26 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Erlotinib,Eating disorder,4,90,11.226,11.226,27.06,0.750,0.000,0.500,9.540,PRR=11.23 (显著关联); χ²=27.1 (统计显著); 罕见+严重; 住院率=50.0%
Erlotinib,Pulmonary fibrosis,3,90,5.313,5.313,8.79,1.000,0.333,0.333,9.827,PRR=5.31 (显著关联); 死亡率=33.3%; 罕见+严重
Erlotinib,Nail disorder,4,90,5.387,5.387,11.93,1.000,0.000,0.500,9.540,PRR=5.39 (显著关联); χ²=11.9 (统计显著); 罕见+严重; 住院率=50.0%
Erlotinib,Skin exfoliation,4,90,2.171,2.171,2.30,1.000,0.250,0.250,9.540,PRR=2.17 (显著关联); 死亡率=25.0%; 罕见+严重
Gefitinib,Epistaxis,8,90,2.479,2.479,6.36,0.500,0.250,0.250,8.847,PRR=2.48 (显著关联); 死亡率=25.0%; 罕见+严重
Gefitinib,Rash,34,90,1.797,1.797,10.73,0.912,0.412,0.412,7.400,χ²=10.7 (统计显著); 死亡率=41.2%; 严重事件率=91.2%; 住院率=41.2%
Gefitinib,Diarrhoea,71,90,1.972,1.972,29.20,0.915,0.352,0.408,6.663,χ²=29.2 (统计显著); 死亡率=35.2%; 严重事件率=91.5%; 住院率=40.8%
Gefitinib,Metastases to lung,3,90,2.665,2.665,2.81,1.000,0.333,0.000,9.827,PRR=2.66 (显著关联); 死亡率=33.3%; 罕见+严重
Gefitinib,Seizure,3,90,2.259,2.259,1.91,1.000,0.333,0.333,9.827,PRR=2.26 (显著关联); 死亡率=33.3%; 罕见+严重
Gefitinib,Skin toxicity,3,90,4.520,4.520,7.05,1.000,0.333,0.000,9.827,PRR=4.52 (显著关联); 死亡率=33.3%; 罕见+严重
Gefitinib,Proteinuria,4,90,2.390,2.390,2.93,1.000,0.250,0.000,9.540,PRR=2.39 (显著关联); 死亡率=25.0%; 罕见+严重
Gefitinib,Gamma-glutamyltransferase increased,3,90,3.248,3.248,4.14,1.000,0.333,0.333,9.827,PRR=3.25 (显著关联); 死亡率=33.3%; 罕见+严重
Gefitinib,Blood alkaline phosphatase increased,4,90,2.310,2.310,2.70,1.000,0.250,0.250,9.540,PRR=2.31 (显著关联); 死亡率=25.0%; 罕见+严重
Gefitinib,Melaena,4,90,5.779,5.779,13.13,1.000,0.000,1.000,9.540,PRR=5.78 (显著关联); χ²=13.1 (统计显著); 罕见+严重; 住院率=100.0%
Gefitinib,Coma,4,90,6.304,6.304,14.64,1.000,0.000,1.000,9.540,PRR=6.30 (显著关联); χ²=14.6 (统计显著); 罕见+严重; 住院率=100.0%
Gefitinib,Hepatitis,3,90,2.309,2.309,2.02,1.000,0.333,0.333,9.827,PRR=2.31 (显著关联); 死亡率=33.3%; 罕见+严重
Osimertinib,Pneumonia aspiration,3,90,3.499,3.499,4.72,1.000,0.667,0.333,9.827,PRR=3.50 (显著关联); 死亡率=66.7%; 罕见+严重
Osimertinib,Metastases to lymph nodes,4,90,4.001,4.001,7.83,1.000,0.500,0.250,9.540,PRR=4.00 (显著关联); 死亡率=50.0%; 罕见+严重
Osimertinib,Pericardial effusion,4,90,2.258,2.258,2.55,1.000,0.750,0.250,9.540,PRR=2.26 (显著关联); 死亡率=75.0%; 罕见+严重
Osimertinib,Myocardial infarction,6,90,2.595,2.595,5.29,1.000,0.167,0.500,9.134,PRR=2.59 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Osimertinib,Herpes zoster,3,90,2.332,2.332,2.07,0.667,0.333,0.333,9.827,PRR=2.33 (显著关联); 死亡率=33.3%; 罕见+严重
Osimertinib,Metastasis,3,90,4.565,4.565,7.17,1.000,0.333,0.000,9.827,PRR=4.56 (显著关联); 死亡率=33.3%; 罕见+严重
Crizotinib,Photopsia,4,90,35.097,35.097,71.73,0.750,0.000,0.750,9.540,PRR=35.10 (显著关联); χ²=71.7 (统计显著); 罕见+严重; 住院率=75.0%
Paclitaxel,Cough,16,90,2.012,2.012,7.27,1.000,0.125,0.438,8.153,PRR=2.01 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=43.8%
Paclitaxel,Cyanosis,3,90,43.459,43.459,48.04,1.000,0.000,1.000,9.827,PRR=43.46 (显著关联); χ²=48.0 (统计显著); 罕见+严重; 住院率=100.0%
Paclitaxel,Non-small cell lung cancer,3,90,2.348,2.348,2.07,1.000,0.667,0.000,9.827,PRR=2.35 (显著关联); 死亡率=66.7%; 罕见+严重
Paclitaxel,Second primary malignancy,4,90,2.069,2.069,1.99,1.000,0.500,0.000,9.540,PRR=2.07 (显著关联); 死亡率=50.0%; 罕见+严重
Paclitaxel,Dermatitis,3,90,2.555,2.555,2.52,1.000,0.333,0.000,9.827,PRR=2.55 (显著关联); 死亡率=33.3%; 罕见+严重
Paclitaxel,Metastases to skin,3,90,5.793,5.793,9.56,1.000,0.333,0.000,9.827,PRR=5.79 (显著关联); 死亡率=33.3%; 罕见+严重
Paclitaxel,Gastrointestinal perforation,3,90,3.475,3.475,4.55,1.000,0.667,0.333,9.827,PRR=3.48 (显著关联); 死亡率=66.7%; 罕见+严重
Paclitaxel,Hypertensive crisis,3,90,7.242,7.242,12.46,1.000,0.000,0.667,9.827,PRR=7.24 (显著关联); χ²=12.5 (统计显著); 罕见+严重; 住院率=66.7%
Paclitaxel,Lymphopenia,3,90,3.218,3.218,3.98,0.667,0.667,0.333,9.827,PRR=3.22 (显著关联); 死亡率=66.7%; 罕见+严重
Paclitaxel,Cardiovascular disorder,3,90,7.900,7.900,13.71,1.000,0.000,0.667,9.827,PRR=7.90 (显著关联); χ²=13.7 (统计显著); 罕见+严重; 住院率=66.7%
Paclitaxel,Alveolitis allergic,3,90,10.863,10.863,18.85,1.000,0.000,1.000,9.827,PRR=10.86 (显著关联); χ²=18.9 (统计显著); 罕见+严重; 住院率=100.0%
Paclitaxel,Respiratory tract infection,3,90,2.227,2.227,1.82,1.000,0.333,0.333,9.827,PRR=2.23 (显著关联); 死亡率=33.3%; 罕见+严重
Docetaxel,Type IV hypersensitivity reaction,3,90,20.557,20.557,30.72,1.000,0.000,0.667,9.827,PRR=20.56 (显著关联); χ²=30.7 (统计显著); 罕见+严重; 住院率=66.7%
Docetaxel,Oedema,7,90,2.493,2.493,5.51,0.857,0.000,0.571,8.980,PRR=2.49 (显著关联); 严重事件率=85.7%; 罕见+严重; 住院率=57.1%
Docetaxel,Acute myeloid leukaemia,3,90,2.107,2.107,1.56,1.000,1.000,0.333,9.827,PRR=2.11 (显著关联); 死亡率=100.0%; 罕见+严重
Docetaxel,Cellulitis,5,90,2.636,2.636,4.45,1.000,0.000,1.000,9.317,PRR=2.64 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Docetaxel,Photosensitivity reaction,5,90,2.688,2.688,4.64,1.000,0.000,0.600,9.317,PRR=2.69 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Docetaxel,Aphagia,3,90,4.836,4.836,7.47,1.000,0.333,0.000,9.827,PRR=4.84 (显著关联); 死亡率=33.3%; 罕见+严重
Docetaxel,Skin exfoliation,7,90,3.255,3.255,9.39,1.000,0.143,0.429,8.980,PRR=3.26 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Docetaxel,Eye pain,3,90,6.324,6.324,10.52,1.000,0.000,1.000,9.827,PRR=6.32 (显著关联); χ²=10.5 (统计显著); 罕见+严重; 住院率=100.0%
Docetaxel,Weight increased,5,90,2.247,2.247,3.07,1.000,0.000,0.800,9.317,PRR=2.25 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Docetaxel,Photophobia,3,90,13.704,13.704,22.69,1.000,0.000,1.000,9.827,PRR=13.70 (显著关联); χ²=22.7 (统计显著); 罕见+严重; 住院率=100.0%
Docetaxel,Papilloedema,3,90,10.278,10.278,17.60,1.000,0.000,0.667,9.827,PRR=10.28 (显著关联); χ²=17.6 (统计显著); 罕见+严重; 住院率=66.7%
Docetaxel,Trismus,4,90,18.282,18.282,37.74,1.000,0.000,1.000,9.540,PRR=18.28 (显著关联); χ²=37.7 (统计显著); 罕见+严重; 住院率=100.0%
Docetaxel,Speech disorder,6,90,2.493,2.493,4.72,1.000,0.167,1.000,9.134,PRR=2.49 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Docetaxel,Bradycardia,4,90,7.834,7.834,17.85,1.000,0.000,1.000,9.540,PRR=7.83 (显著关联); χ²=17.9 (统计显著); 罕见+严重; 住院率=100.0%
Docetaxel,Dermatitis,3,90,2.417,2.417,2.20,1.000,0.333,0.000,9.827,PRR=2.42 (显著关联); 死亡率=33.3%; 罕见+严重
Docetaxel,Atypical pneumonia,4,90,21.938,21.938,42.75,1.000,0.000,0.750,9.540,PRR=21.94 (显著关联); χ²=42.8 (统计显著); 罕见+严重; 住院率=75.0%
Docetaxel,Haematocrit decreased,5,90,2.797,2.797,5.04,1.000,0.000,1.000,9.317,PRR=2.80 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Docetaxel,Renal cell carcinoma,3,90,82.232,82.232,57.97,1.000,0.000,1.000,9.827,PRR=82.23 (显著关联); χ²=58.0 (统计显著); 罕见+严重; 住院率=100.0%
Docetaxel,Agranulocytosis,3,90,6.324,6.324,10.52,1.000,0.000,0.667,9.827,PRR=6.32 (显著关联); χ²=10.5 (统计显著); 罕见+严重; 住院率=66.7%
Docetaxel,Soft tissue infection,4,90,21.938,21.938,42.75,1.000,0.000,0.500,9.540,PRR=21.94 (显著关联); χ²=42.8 (统计显著); 罕见+严重; 住院率=50.0%
Docetaxel,Facial pain,3,90,8.222,8.222,14.10,1.000,0.000,1.000,9.827,PRR=8.22 (显著关联); χ²=14.1 (统计显著); 罕见+严重; 住院率=100.0%
Docetaxel,Lung infection,5,90,2.284,2.284,3.20,1.000,0.200,0.800,9.317,PRR=2.28 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Docetaxel,Breast cancer,4,90,2.740,2.740,3.87,1.000,0.500,0.000,9.540,PRR=2.74 (显著关联); 死亡率=50.0%; 罕见+严重
Docetaxel,Cardio-respiratory arrest,3,90,4.110,4.110,5.91,1.000,1.000,0.000,9.827,PRR=4.11 (显著关联); 死亡率=100.0%; 罕见+严重
Docetaxel,Hepatic failure,4,90,2.963,2.963,4.52,1.000,1.000,0.000,9.540,PRR=2.96 (显著关联); 死亡率=100.0%; 罕见+严重
Doxorubicin,Gastric haemorrhage,3,90,4.508,4.508,6.82,1.000,0.333,0.333,9.827,PRR=4.51 (显著关联); 死亡率=33.3%; 罕见+严重
Doxorubicin,Progressive multifocal leukoencephalopathy,3,90,7.787,7.787,13.45,1.000,0.000,0.667,9.827,PRR=7.79 (显著关联); χ²=13.4 (统计显著); 罕见+严重; 住院率=66.7%
Doxorubicin,Deafness,3,90,2.953,2.953,3.38,1.000,1.000,0.333,9.827,PRR=2.95 (显著关联); 死亡率=100.0%; 罕见+严重
Doxorubicin,Encephalopathy,3,90,3.568,3.568,4.75,1.000,0.333,0.000,9.827,PRR=3.57 (显著关联); 死亡率=33.3%; 罕见+严重
Doxorubicin,Bladder cancer,3,90,4.078,4.078,5.88,1.000,0.333,0.000,9.827,PRR=4.08 (显著关联); 死亡率=33.3%; 罕见+严重
Doxorubicin,Escherichia bacteraemia,3,90,10.708,10.708,18.52,1.000,0.000,0.667,9.827,PRR=10.71 (显著关联); χ²=18.5 (统计显著); 罕见+严重; 住院率=66.7%
Doxorubicin,Hepatosplenic candidiasis,4,90,57.147,57.147,70.91,1.000,0.000,1.000,9.540,PRR=57.15 (显著关联); χ²=70.9 (统计显著); 罕见+严重; 住院率=100.0%
Doxorubicin,Agranulocytosis,4,90,9.523,9.523,22.06,1.000,0.000,0.750,9.540,PRR=9.52 (显著关联); χ²=22.1 (统计显著); 罕见+严重; 住院率=75.0%
Doxorubicin,Blood lactate dehydrogenase increased,3,90,2.253,2.253,1.87,1.000,0.333,0.333,9.827,PRR=2.25 (显著关联); 死亡率=33.3%; 罕见+严重
Doxorubicin,Cytomegalovirus test positive,3,90,9.518,9.518,16.54,1.000,0.000,1.000,9.827,PRR=9.52 (显著关联); χ²=16.5 (统计显著); 罕见+严重; 住院率=100.0%
Doxorubicin,Eosinophil count increased,3,90,10.708,10.708,18.52,1.000,0.000,1.000,9.827,PRR=10.71 (显著关联); χ²=18.5 (统计显著); 罕见+严重; 住院率=100.0%
Carboplatin,Cellulitis,6,90,2.876,2.876,6.29,1.000,0.000,0.833,9.134,PRR=2.88 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Carboplatin,Renal failure acute,11,90,2.188,2.188,6.21,1.000,0.182,0.727,8.528,PRR=2.19 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=72.7%
Carboplatin,Mucosal inflammation,10,90,2.224,2.224,5.89,1.000,0.100,0.700,8.623,PRR=2.22 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Carboplatin,Eye pruritus,3,90,5.637,5.637,8.92,1.000,0.333,0.000,9.827,PRR=5.64 (显著关联); 死亡率=33.3%; 罕见+严重
Carboplatin,Gastrointestinal perforation,3,90,2.931,2.931,3.27,1.000,0.667,0.333,9.827,PRR=2.93 (显著关联); 死亡率=66.7%; 罕见+严重
Carboplatin,Tachypnoea,3,90,7.329,7.329,12.10,1.000,0.000,0.667,9.827,PRR=7.33 (显著关联); χ²=12.1 (统计显著); 罕见+严重; 住院率=66.7%
Carboplatin,Dermatomyositis,3,90,18.325,18.325,26.93,1.000,0.000,1.000,9.827,PRR=18.32 (显著关联); χ²=26.9 (统计显著); 罕见+严重; 住院率=100.0%
Carboplatin,Lung adenocarcinoma,3,90,3.857,3.857,5.26,1.000,1.000,0.333,9.827,PRR=3.86 (显著关联); 死亡率=100.0%; 罕见+严重
Carboplatin,Drug resistance,3,90,3.186,3.186,3.82,1.000,0.333,0.000,9.827,PRR=3.19 (显著关联); 死亡率=33.3%; 罕见+严重
Carboplatin,Haematotoxicity,4,90,2.035,2.035,1.86,1.000,0.250,0.000,9.540,PRR=2.04 (显著关联); 死亡率=25.0%; 罕见+严重
Carboplatin,Productive cough,3,90,2.220,2.220,1.77,1.000,0.333,0.333,9.827,PRR=2.22 (显著关联); 死亡率=33.3%; 罕见+严重
Carboplatin,Embolism,5,90,3.819,3.819,8.62,1.000,0.000,0.600,9.317,PRR=3.82 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Carboplatin,Staphylococcal sepsis,3,90,7.329,7.329,12.10,1.000,0.000,1.000,9.827,PRR=7.33 (显著关联); χ²=12.1 (统计显著); 罕见+严重; 住院率=100.0%
Cisplatin,Electrolyte imbalance,3,90,3.723,3.723,5.06,1.000,0.333,0.000,9.827,PRR=3.72 (显著关联); 死亡率=33.3%; 罕见+严重
Cisplatin,Hyperkalaemia,4,90,3.901,3.901,7.27,1.000,0.250,0.250,9.540,PRR=3.90 (显著关联); 死亡率=25.0%; 罕见+严重
Cisplatin,Rash generalised,5,90,3.035,3.035,5.90,1.000,0.000,0.800,9.317,PRR=3.03 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Cisplatin,Swelling face,6,90,3.489,3.489,9.08,1.000,0.000,0.833,9.134,PRR=3.49 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Cisplatin,Oropharyngeal pain,6,90,2.483,2.483,4.68,1.000,0.000,0.667,9.134,PRR=2.48 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Cisplatin,Pulmonary embolism,14,90,2.016,2.016,6.38,1.000,0.071,0.643,8.287,PRR=2.02 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=64.3%
Cisplatin,Peritonitis,3,90,3.276,3.276,4.08,1.000,0.333,0.333,9.827,PRR=3.28 (显著关联); 死亡率=33.3%; 罕见+严重
Cisplatin,Large intestine perforation,3,90,2.824,2.824,3.08,0.667,0.667,0.333,9.827,PRR=2.82 (显著关联); 死亡率=66.7%; 罕见+严重
Cisplatin,Aortic dissection,4,90,36.430,36.430,56.86,1.000,0.000,1.000,9.540,PRR=36.43 (显著关联); χ²=56.9 (统计显著); 罕见+严重; 住院率=100.0%
Cisplatin,Aphagia,4,90,6.829,6.829,15.32,1.000,0.000,1.000,9.540,PRR=6.83 (显著关联); χ²=15.3 (统计显著); 罕见+严重; 住院率=100.0%
Cisplatin,Eye haemorrhage,4,90,13.660,13.660,30.12,1.000,0.000,0.750,9.540,PRR=13.66 (显著关联); χ²=30.1 (统计显著); 罕见+严重; 住院率=75.0%
Cisplatin,Chest discomfort,7,90,2.517,2.517,5.62,1.000,0.143,0.857,8.980,PRR=2.52 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Cisplatin,Troponin increased,3,90,8.191,8.191,14.03,1.000,0.000,1.000,9.827,PRR=8.19 (显著关联); χ²=14.0 (统计显著); 罕见+严重; 住院率=100.0%
Cisplatin,Metastases to lung,3,90,2.099,2.099,1.54,1.000,0.333,0.333,9.827,PRR=2.10 (显著关联); 死亡率=33.3%; 罕见+严重
Cisplatin,Renal tubular necrosis,3,90,10.240,10.240,17.52,1.000,0.000,1.000,9.827,PRR=10.24 (显著关联); χ²=17.5 (统计显著); 罕见+严重; 住院率=100.0%
Cisplatin,Renal impairment,10,90,2.533,2.533,8.13,1.000,0.100,0.500,8.623,PRR=2.53 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Dermatitis,4,90,3.310,3.310,5.53,1.000,0.250,0.250,9.540,PRR=3.31 (显著关联); 死亡率=25.0%; 罕见+严重
Cisplatin,Non-small cell lung cancer,3,90,2.213,2.213,1.78,1.000,1.000,0.000,9.827,PRR=2.21 (显著关联); 死亡率=100.0%; 罕见+严重
Cisplatin,Gastric haemorrhage,3,90,4.311,4.311,6.34,1.000,0.333,0.333,9.827,PRR=4.31 (显著关联); 死亡率=33.3%; 罕见+严重
Cisplatin,Acute respiratory distress syndrome,3,90,2.274,2.274,1.90,1.000,1.000,0.000,9.827,PRR=2.27 (显著关联); 死亡率=100.0%; 罕见+严重
Cisplatin,Drug clearance decreased,4,90,36.430,36.430,56.86,1.000,0.000,1.000,9.540,PRR=36.43 (显著关联); χ²=56.9 (统计显著); 罕见+严重; 住院率=100.0%
Cisplatin,Blood creatine increased,3,90,8.191,8.191,14.03,1.000,0.000,1.000,9.827,PRR=8.19 (显著关联); χ²=14.0 (统计显著); 罕见+严重; 住院率=100.0%
Lenalidomide,Renal disorder,3,90,2.774,2.774,3.13,1.000,0.667,0.333,9.827,PRR=2.77 (显著关联); 死亡率=66.7%; 罕见+严重
Lenalidomide,No therapeutic response,3,90,5.337,5.337,9.25,1.000,0.667,0.333,9.827,PRR=5.34 (显著关联); 死亡率=66.7%; 罕见+严重
Lenalidomide,Somnolence,4,90,2.284,2.284,2.68,1.000,0.750,0.000,9.540,PRR=2.28 (显著关联); 死亡率=75.0%; 罕见+严重
Lenalidomide,Musculoskeletal disorder,3,90,19.832,19.832,36.66,1.000,0.000,0.667,9.827,PRR=19.83 (显著关联); χ²=36.7 (统计显著); 罕见+严重; 住院率=66.7%
Lenalidomide,Fall,9,90,2.455,2.455,7.14,1.000,0.111,0.667,8.729,PRR=2.45 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Lenalidomide,Drug intolerance,4,90,2.313,2.313,2.76,1.000,0.250,0.250,9.540,PRR=2.31 (显著关联); 死亡率=25.0%; 罕见+严重
Lenalidomide,Spinal fracture,3,90,8.675,8.675,16.74,1.000,0.000,1.000,9.827,PRR=8.67 (显著关联); χ²=16.7 (统计显著); 罕见+严重; 住院率=100.0%
Lenalidomide,Drug dose omission,6,90,2.088,2.088,3.16,1.000,0.167,0.667,9.134,PRR=2.09 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Lenalidomide,Increased upper airway secretion,3,90,69.417,69.417,79.00,1.000,0.000,1.000,9.827,PRR=69.42 (显著关联); χ²=79.0 (统计显著); 罕见+严重; 住院率=100.0%
Lenalidomide,Pulmonary thrombosis,3,90,9.915,9.915,19.33,1.000,0.000,0.667,9.827,PRR=9.91 (显著关联); χ²=19.3 (统计显著); 罕见+严重; 住院率=66.7%
Pomalidomide,White blood cell count decreased,13,90,2.025,2.025,6.25,0.846,0.154,0.462,8.361,PRR=2.03 (显著关联); 严重事件率=84.6%; 罕见+严重; 住院率=46.2%
Pomalidomide,Cerebrovascular accident,6,90,3.304,3.304,8.82,1.000,0.000,0.500,9.134,PRR=3.30 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Pomalidomide,Syncope,5,90,2.722,2.722,5.04,1.000,0.000,0.600,9.317,PRR=2.72 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Pomalidomide,Contusion,4,90,2.756,2.756,4.15,0.500,0.250,0.250,9.540,PRR=2.76 (显著关联); 死亡率=25.0%; 罕见+严重
Pomalidomide,Palpitations,3,90,2.980,2.980,3.65,0.667,0.333,0.333,9.827,PRR=2.98 (显著关联); 死亡率=33.3%; 罕见+严重
Pomalidomide,Fall,8,90,2.423,2.423,6.20,0.750,0.000,0.625,8.847,PRR=2.42 (显著关联); 严重事件率=75.0%; 罕见+严重; 住院率=62.5%
Pomalidomide,Deep vein thrombosis,5,90,2.371,2.371,3.69,1.000,0.000,0.800,9.317,PRR=2.37 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Pomalidomide,Thrombosis,6,90,3.451,3.451,9.54,1.000,0.000,0.667,9.134,PRR=3.45 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Pomalidomide,Staphylococcal sepsis,3,90,15.508,15.508,30.63,1.000,0.000,0.667,9.827,PRR=15.51 (显著关联); χ²=30.6 (统计显著); 罕见+严重; 住院率=66.7%
Pomalidomide,Upper limb fracture,3,90,38.774,38.774,61.70,1.000,0.000,0.667,9.827,PRR=38.77 (显著关联); χ²=61.7 (统计显著); 罕见+严重; 住院率=66.7%
Pomalidomide,Blood count abnormal,4,90,2.685,2.685,3.92,1.000,0.250,0.250,9.540,PRR=2.68 (显著关联); 死亡率=25.0%; 罕见+严重
Bortezomib,Fall,11,90,2.160,2.160,6.18,1.000,0.182,0.818,8.528,PRR=2.16 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Bortezomib,Squamous cell carcinoma of the hypopharynx,3,90,98.769,98.769,70.31,1.000,0.000,0.667,9.827,PRR=98.77 (显著关联); χ²=70.3 (统计显著); 罕见+严重; 住院率=66.7%
Bortezomib,Cardiomyopathy,4,90,4.116,4.116,8.11,1.000,0.500,0.250,9.540,PRR=4.12 (显著关联); 死亡率=50.0%; 罕见+严重
Bortezomib,Right ventricular dysfunction,3,90,98.769,98.769,70.31,1.000,0.000,1.000,9.827,PRR=98.77 (显著关联); χ²=70.3 (统计显著); 罕见+严重; 住院率=100.0%
Bortezomib,Fatigue,19,90,0.471,0.471,10.40,1.000,0.211,0.421,7.982,χ²=10.4 (统计显著); 死亡率=21.1%; 严重事件率=100.0%; 住院率=42.1%
Bortezomib,Lung disorder,4,90,2.123,2.123,2.16,1.000,0.250,0.000,9.540,PRR=2.12 (显著关联); 死亡率=25.0%; 罕见+严重
Bortezomib,Acute myeloid leukaemia,4,90,3.465,3.465,6.14,1.000,1.000,0.250,9.540,PRR=3.47 (显著关联); 死亡率=100.0%; 罕见+严重
Bortezomib,Aplasia,3,90,98.769,98.769,70.31,1.000,0.000,0.667,9.827,PRR=98.77 (显著关联); χ²=70.3 (统计显著); 罕见+严重; 住院率=66.7%
Bortezomib,Polyneuropathy,3,90,7.596,7.596,13.52,1.000,0.000,0.667,9.827,PRR=7.60 (显著关联); χ²=13.5 (统计显著); 罕见+严重; 住院率=66.7%
Bortezomib,Fungal infection,3,90,5.197,5.197,8.50,1.000,0.333,0.333,9.827,PRR=5.20 (显著关联); 死亡率=33.3%; 罕见+严重
Bortezomib,Febrile bone marrow aplasia,4,90,32.941,32.941,59.96,1.000,0.000,1.000,9.540,PRR=32.94 (显著关联); χ²=60.0 (统计显著); 罕见+严重; 住院率=100.0%
Carfilzomib,Neuropathy peripheral,11,90,2.416,2.416,8.39,0.909,0.091,0.636,8.528,PRR=2.42 (显著关联); 严重事件率=90.9%; 罕见+严重; 住院率=63.6%
Carfilzomib,Urinary retention,3,90,8.383,8.383,16.19,1.000,0.000,1.000,9.827,PRR=8.38 (显著关联); χ²=16.2 (统计显著); 罕见+严重; 住院率=100.0%
Carfilzomib,Supraventricular tachycardia,4,90,10.565,10.565,27.65,1.000,0.000,1.000,9.540,PRR=10.57 (显著关联); χ²=27.6 (统计显著); 罕见+严重; 住院率=100.0%
Carfilzomib,Hypertensive crisis,3,90,11.877,11.877,23.35,1.000,0.000,1.000,9.827,PRR=11.88 (显著关联); χ²=23.3 (统计显著); 罕见+严重; 住院率=100.0%
Carfilzomib,Haemolytic uraemic syndrome,3,90,23.756,23.756,42.58,1.000,0.000,0.667,9.827,PRR=23.76 (显著关联); χ²=42.6 (统计显著); 罕见+严重; 住院率=66.7%
Carfilzomib,Confusional state,8,90,2.608,2.608,7.29,1.000,0.125,0.625,8.847,PRR=2.61 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Carfilzomib,Hypoxia,5,90,2.700,2.700,4.93,1.000,0.000,0.800,9.317,PRR=2.70 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Disseminated intravascular coagulation,3,90,4.190,4.190,6.54,1.000,0.333,0.333,9.827,PRR=4.19 (显著关联); 死亡率=33.3%; 罕见+严重
Carfilzomib,Asthma,4,90,11.187,11.187,29.31,1.000,0.000,1.000,9.540,PRR=11.19 (显著关联); χ²=29.3 (统计显著); 罕见+严重; 住院率=100.0%
Carfilzomib,Posterior reversible encephalopathy syndrome,4,90,7.313,7.313,18.43,1.000,0.000,0.500,9.540,PRR=7.31 (显著关联); χ²=18.4 (统计显著); 罕见+严重; 住院率=50.0%
Carfilzomib,Transient ischaemic attack,3,90,7.500,7.500,14.25,1.000,0.000,1.000,9.827,PRR=7.50 (显著关联); χ²=14.3 (统计显著); 罕见+严重; 住院率=100.0%
Carfilzomib,Hypercalcaemia,4,90,5.432,5.432,12.66,1.000,0.000,1.000,9.540,PRR=5.43 (显著关联); χ²=12.7 (统计显著); 罕见+严重; 住院率=100.0%
Venetoclax,Syncope,5,90,2.087,2.087,2.61,1.000,0.000,1.000,9.317,PRR=2.09 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Drug-induced liver injury,4,90,5.473,5.473,12.49,1.000,0.000,1.000,9.540,PRR=5.47 (显著关联); χ²=12.5 (统计显著); 罕见+严重; 住院率=100.0%
Venetoclax,Bradycardia,3,90,7.933,7.933,14.74,1.000,0.000,0.667,9.827,PRR=7.93 (显著关联); χ²=14.7 (统计显著); 罕见+严重; 住院率=66.7%
Venetoclax,Autoimmune haemolytic anaemia,3,90,7.437,7.437,13.69,1.000,0.000,1.000,9.827,PRR=7.44 (显著关联); χ²=13.7 (统计显著); 罕见+严重; 住院率=100.0%
Venetoclax,Hypotension,11,90,2.154,2.154,6.22,1.000,0.091,0.909,8.528,PRR=2.15 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=90.9%
Venetoclax,Atrial fibrillation,10,90,2.424,2.424,7.61,1.000,0.100,0.800,8.623,PRR=2.42 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Venetoclax,Bronchopulmonary aspergillosis,3,90,10.818,10.818,20.44,1.000,0.000,1.000,9.827,PRR=10.82 (显著关联); χ²=20.4 (统计显著); 罕见+严重; 住院率=100.0%
Venetoclax,Supraventricular tachycardia,3,90,6.262,6.262,11.15,1.000,0.000,0.667,9.827,PRR=6.26 (显著关联); χ²=11.1 (统计显著); 罕见+严重; 住院率=66.7%
Venetoclax,Acute kidney injury,7,90,2.482,2.482,5.64,1.000,0.000,1.000,8.980,PRR=2.48 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Squamous cell carcinoma of skin,3,90,6.999,6.999,12.76,1.000,0.000,0.667,9.827,PRR=7.00 (显著关联); χ²=12.8 (统计显著); 罕见+严重; 住院率=66.7%
Venetoclax,Sinusitis bacterial,3,90,119.019,119.019,85.42,1.000,0.000,0.667,9.827,PRR=119.02 (显著关联); χ²=85.4 (统计显著); 罕见+严重; 住院率=66.7%
Venetoclax,Embolism,4,90,4.810,4.810,10.46,1.000,0.000,0.500,9.540,PRR=4.81 (显著关联); χ²=10.5 (统计显著); 罕见+严重; 住院率=50.0%
Venetoclax,Aplastic anaemia,3,90,23.802,23.802,39.86,1.000,0.000,0.667,9.827,PRR=23.80 (显著关联); χ²=39.9 (统计显著); 罕见+严重; 住院率=66.7%
Venetoclax,Blood sodium decreased,4,90,8.820,8.820,22.06,0.750,0.000,0.500,9.540,PRR=8.82 (显著关联); χ²=22.1 (统计显著); 罕见+严重; 住院率=50.0%
Ibrutinib,Disease progression,41,90,1.708,1.708,10.67,1.000,0.707,0.537,7.212,χ²=10.7 (统计显著); 死亡率=70.7%; 严重事件率=100.0%; 住院率=53.7%
Ibrutinib,Cardiac failure congestive,5,90,2.192,2.192,2.94,1.000,0.200,1.000,9.317,PRR=2.19 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Blood urine present,3,90,8.329,8.329,14.99,0.667,0.000,0.667,9.827,PRR=8.33 (显著关联); χ²=15.0 (统计显著); 罕见+严重; 住院率=66.7%
Ibrutinib,Haematuria,6,90,3.227,3.227,8.12,1.000,0.167,1.000,9.134,PRR=3.23 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Haemolytic anaemia,4,90,4.937,4.937,10.59,1.000,0.000,0.750,9.540,PRR=4.94 (显著关联); χ²=10.6 (统计显著); 罕见+严重; 住院率=75.0%
Ibrutinib,Bronchitis,5,90,3.268,3.268,6.93,0.800,0.200,0.800,9.317,PRR=3.27 (显著关联); 严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Atrial flutter,3,90,6.246,6.246,10.78,1.000,0.000,1.000,9.827,PRR=6.25 (显著关联); χ²=10.8 (统计显著); 罕见+严重; 住院率=100.0%
Ibrutinib,Gout,4,90,19.050,19.050,42.15,1.000,0.000,1.000,9.540,PRR=19.05 (显著关联); χ²=42.2 (统计显著); 罕见+严重; 住院率=100.0%
Ibrutinib,Blood lactate dehydrogenase increased,4,90,3.602,3.602,6.57,1.000,0.250,0.250,9.540,PRR=3.60 (显著关联); 死亡率=25.0%; 罕见+严重
Olaparib,Herpes zoster,4,90,2.644,2.644,3.61,1.000,0.750,0.250,9.540,PRR=2.64 (显著关联); 死亡率=75.0%; 罕见+严重
Olaparib,Laboratory test abnormal,4,90,2.585,2.585,3.44,1.000,0.500,0.250,9.540,PRR=2.58 (显著关联); 死亡率=50.0%; 罕见+严重
Olaparib,Fluid retention,3,90,2.076,2.076,1.51,1.000,0.333,0.333,9.827,PRR=2.08 (显著关联); 死亡率=33.3%; 罕见+严重
Olaparib,Ovarian cancer recurrent,4,90,29.101,29.101,52.35,1.000,0.000,0.500,9.540,PRR=29.10 (显著关联); χ²=52.3 (统计显著); 罕见+严重; 住院率=50.0%
Rucaparib,Product dose omission,4,90,7.143,7.143,14.72,1.000,0.000,0.750,9.540,PRR=7.14 (显著关联); χ²=14.7 (统计显著); 罕见+严重; 住院率=75.0%
Rucaparib,Stent placement,3,90,9.818,9.818,15.05,1.000,0.000,0.667,9.827,PRR=9.82 (显著关联); χ²=15.1 (统计显著); 罕见+严重; 住院率=66.7%
Rucaparib,Unevaluable event,9,90,2.602,2.602,7.42,0.556,0.000,0.444,8.729,PRR=2.60 (显著关联); 严重事件率=55.6%; 罕见+严重; 住院率=44.4%
Rucaparib,Liver function test increased,6,90,6.937,6.937,21.39,0.500,0.000,0.500,9.134,PRR=6.94 (显著关联); χ²=21.4 (统计显著); 罕见+严重; 住院率=50.0%
Rucaparib,Hospitalisation,5,90,2.231,2.231,2.90,1.000,0.000,1.000,9.317,PRR=2.23 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rucaparib,Faeces discoloured,3,90,7.363,7.363,11.40,1.000,0.000,1.000,9.827,PRR=7.36 (显著关联); χ²=11.4 (统计显著); 罕见+严重; 住院率=100.0%
Niraparib,Renal function test abnormal,3,90,7.340,7.340,10.85,1.000,0.000,1.000,9.827,PRR=7.34 (显著关联); χ²=10.9 (统计显著); 罕见+严重; 住院率=100.0%
Niraparib,Panic attack,3,90,8.563,8.563,12.61,0.667,0.000,0.667,9.827,PRR=8.56 (显著关联); χ²=12.6 (统计显著); 罕见+严重; 住院率=66.7%
Niraparib,Middle insomnia,3,90,25.692,25.692,26.88,1.000,0.000,0.667,9.827,PRR=25.69 (显著关联); χ²=26.9 (统计显著); 罕见+严重; 住院率=66.7%
Niraparib,Dysstasia,3,90,5.709,5.709,8.25,0.667,0.333,0.333,9.827,PRR=5.71 (显著关联); 死亡率=33.3%; 罕见+严重
Niraparib,Mean cell volume increased,3,90,17.128,17.128,21.50,1.000,0.000,0.667,9.827,PRR=17.13 (显著关联); χ²=21.5 (统计显著); 罕见+严重; 住院率=66.7%
Niraparib,Product use in unapproved indication,9,90,2.660,2.660,7.60,0.667,0.111,0.444,8.729,PRR=2.66 (显著关联); 严重事件率=66.7%; 罕见+严重; 住院率=44.4%
Niraparib,Mouth haemorrhage,3,90,12.846,12.846,17.67,0.667,0.000,0.667,9.827,PRR=12.85 (显著关联); χ²=17.7 (统计显著); 罕见+严重; 住院率=66.7%
Niraparib,Haematochezia,6,90,2.937,2.937,6.17,0.833,0.000,0.833,9.134,PRR=2.94 (显著关联); 严重事件率=83.3%; 罕见+严重; 住院率=83.3%
Niraparib,Stent placement,3,90,8.563,8.563,12.61,1.000,0.000,0.667,9.827,PRR=8.56 (显著关联); χ²=12.6 (统计显著); 罕见+严重; 住院率=66.7%
Niraparib,Eye pain,3,90,3.952,3.952,5.07,0.667,0.333,0.333,9.827,PRR=3.95 (显著关联); 死亡率=33.3%; 罕见+严重
Niraparib,Joint injury,4,90,17.133,17.133,28.67,1.000,0.000,0.500,9.540,PRR=17.13 (显著关联); χ²=28.7 (统计显著); 罕见+严重; 住院率=50.0%
Niraparib,Gastroenteritis viral,3,90,7.340,7.340,10.85,0.667,0.000,0.667,9.827,PRR=7.34 (显著关联); χ²=10.9 (统计显著); 罕见+严重; 住院率=66.7%
Talazoparib,Cytopenia,4,90,13.265,13.265,34.41,1.000,0.000,0.500,9.540,PRR=13.27 (显著关联); χ²=34.4 (统计显著); 罕见+严重; 住院率=50.0%
Talazoparib,Acute respiratory distress syndrome,3,90,3.864,3.864,5.74,1.000,0.667,0.000,9.827,PRR=3.86 (显著关联); 死亡率=66.7%; 罕见+严重
Talazoparib,Syncope,5,90,2.442,2.442,3.94,0.800,0.000,0.800,9.317,PRR=2.44 (显著关联); 严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Talazoparib,Loss of consciousness,4,90,3.042,3.042,5.01,1.000,0.250,0.250,9.540,PRR=3.04 (显著关联); 死亡率=25.0%; 罕见+严重
Talazoparib,Performance status decreased,3,90,13.918,13.918,27.01,1.000,0.000,1.000,9.827,PRR=13.92 (显著关联); χ²=27.0 (统计显著); 罕见+严重; 住院率=100.0%
Talazoparib,Ventricular extrasystoles,3,90,17.398,17.398,32.92,1.000,0.000,1.000,9.827,PRR=17.40 (显著关联); χ²=32.9 (统计显著); 罕见+严重; 住院率=100.0%
Talazoparib,Blood potassium increased,3,90,9.278,9.278,18.02,1.000,0.000,1.000,9.827,PRR=9.28 (显著关联); χ²=18.0 (统计显著); 罕见+严重; 住院率=100.0%
Talazoparib,Blood creatinine decreased,3,90,27.838,27.838,47.36,1.000,0.000,1.000,9.827,PRR=27.84 (显著关联); χ²=47.4 (统计显著); 罕见+严重; 住院率=100.0%
Palbociclib,Electrocardiogram QT prolonged,5,90,3.975,3.975,9.68,1.000,0.000,1.000,9.317,PRR=3.98 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Palbociclib,Clostridium difficile colitis,4,90,6.662,6.662,15.67,1.000,0.000,0.750,9.540,PRR=6.66 (显著关联); χ²=15.7 (统计显著); 罕见+严重; 住院率=75.0%
Palbociclib,Fluid retention,3,90,2.496,2.496,2.43,1.000,0.333,0.333,9.827,PRR=2.50 (显著关联); 死亡率=33.3%; 罕见+严重
Ribociclib,Drug-induced liver injury,4,90,6.470,6.470,15.85,1.000,0.000,0.500,9.540,PRR=6.47 (显著关联); χ²=15.9 (统计显著); 罕见+严重; 住院率=50.0%
Ribociclib,Rhinorrhoea,3,90,3.428,3.428,4.69,0.667,0.333,0.333,9.827,PRR=3.43 (显著关联); 死亡率=33.3%; 罕见+严重
Ribociclib,Transaminases increased,5,90,3.609,3.609,8.53,1.000,0.200,0.600,9.317,PRR=3.61 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Ribociclib,Breast cancer metastatic,4,90,3.349,3.349,5.99,1.000,0.500,0.250,9.540,PRR=3.35 (显著关联); 死亡率=50.0%; 罕见+严重
Ribociclib,Hyperbilirubinaemia,3,90,6.392,6.392,11.72,1.000,0.000,1.000,9.827,PRR=6.39 (显著关联); χ²=11.7 (统计显著); 罕见+严重; 住院率=100.0%
Ribociclib,Tumour marker increased,3,90,3.347,3.347,4.50,1.000,0.333,0.000,9.827,PRR=3.35 (显著关联); 死亡率=33.3%; 罕见+严重
Abemaciclib,Renal failure,11,90,2.406,2.406,8.27,1.000,0.000,0.636,8.528,PRR=2.41 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=63.6%
Abemaciclib,Syncope,5,90,2.284,2.284,3.33,1.000,0.000,0.800,9.317,PRR=2.28 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Abemaciclib,Blood count abnormal,6,90,3.476,3.476,9.52,0.667,0.000,0.500,9.134,PRR=3.48 (显著关联); 严重事件率=66.7%; 罕见+严重; 住院率=50.0%
Abemaciclib,Tachycardia,5,90,2.856,2.856,5.50,0.600,0.000,0.600,9.317,PRR=2.86 (显著关联); 严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Vemurafenib,Skin discolouration,3,90,3.347,3.347,4.38,1.000,0.667,0.333,9.827,PRR=3.35 (显著关联); 死亡率=66.7%; 罕见+严重
Vemurafenib,Cerebral haemorrhage,3,90,2.328,2.328,2.07,1.000,0.333,0.333,9.827,PRR=2.33 (显著关联); 死亡率=33.3%; 罕见+严重
Vemurafenib,Proteinuria,5,90,3.135,3.135,6.47,1.000,0.000,0.600,9.317,PRR=3.13 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Vemurafenib,Aspartate aminotransferase increased,10,90,2.209,2.209,6.00,1.000,0.100,0.500,8.623,PRR=2.21 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Vemurafenib,Alanine aminotransferase increased,11,90,2.290,2.290,7.23,1.000,0.091,0.545,8.528,PRR=2.29 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Vemurafenib,Pericardial effusion,5,90,2.929,2.929,5.68,1.000,0.000,1.000,9.317,PRR=2.93 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Vemurafenib,Pericarditis,3,90,5.952,5.952,10.28,1.000,0.000,1.000,9.827,PRR=5.95 (显著关联); χ²=10.3 (统计显著); 罕见+严重; 住院率=100.0%
Vemurafenib,Rash generalised,5,90,3.971,3.971,9.69,0.800,0.200,0.800,9.317,PRR=3.97 (显著关联); 严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Vemurafenib,Eosinophilia,4,90,14.297,14.297,34.27,1.000,0.000,0.500,9.540,PRR=14.30 (显著关联); χ²=34.3 (统计显著); 罕见+严重; 住院率=50.0%
Vemurafenib,Dermatitis,3,90,3.150,3.150,3.93,0.667,0.333,0.333,9.827,PRR=3.15 (显著关联); 死亡率=33.3%; 罕见+严重
Dabrafenib,Surgery,3,90,8.733,8.733,15.94,0.667,0.000,0.667,9.827,PRR=8.73 (显著关联); χ²=15.9 (统计显著); 罕见+严重; 住院率=66.7%
Dabrafenib,Toxic skin eruption,3,90,5.515,5.515,9.29,1.000,0.333,0.000,9.827,PRR=5.52 (显著关联); 死亡率=33.3%; 罕见+严重
Dabrafenib,Hospitalisation,5,90,3.972,3.972,9.67,1.000,0.200,1.000,9.317,PRR=3.97 (显著关联); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Dabrafenib,Hyperhidrosis,6,90,3.228,3.228,8.17,0.833,0.167,0.500,9.134,PRR=3.23 (显著关联); 严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Dabrafenib,Keratoacanthoma,3,90,17.469,17.469,30.12,1.000,0.000,0.667,9.827,PRR=17.47 (显著关联); χ²=30.1 (统计显著); 罕见+严重; 住院率=66.7%
Dabrafenib,Brain neoplasm,3,90,5.822,5.822,9.96,1.000,0.333,0.333,9.827,PRR=5.82 (显著关联); 死亡率=33.3%; 罕见+严重
Nivolumab,Colitis,55,85,16.719,16.719,559.41,1.000,0.000,1.000,6.919,PRR=16.72 (显著关联); χ²=559.4 (统计显著); 严重事件率=100.0%; 住院率=100.0%
Nivolumab,Pyrexia,60,85,3.748,3.748,102.65,0.967,0.100,0.933,6.832,PRR=3.75 (显著关联); χ²=102.7 (统计显著); 严重事件率=96.7%; 住院率=93.3%
Atezolizumab,Febrile neutropenia,20,85,2.501,2.501,16.47,1.000,0.200,0.950,7.930,PRR=2.50 (显著关联); χ²=16.5 (统计显著); 严重事件率=100.0%; 住院率=95.0%
Durvalumab,Colitis,22,85,5.520,5.520,69.81,0.909,0.182,0.727,7.835,PRR=5.52 (显著关联); χ²=69.8 (统计显著); 严重事件率=90.9%; 住院率=72.7%
Ipilimumab,Diarrhoea,74,85,2.457,2.457,54.39,0.919,0.122,0.743,6.622,PRR=2.46 (显著关联); χ²=54.4 (统计显著); 严重事件率=91.9%; 住院率=74.3%
Ipilimumab,Colitis,48,85,12.429,12.429,365.56,1.000,0.188,0.771,7.055,PRR=12.43 (显著关联); χ²=365.6 (统计显著); 严重事件率=100.0%; 住院率=77.1%
Ipilimumab,Dehydration,21,85,2.194,2.194,12.35,1.000,0.190,0.905,7.881,PRR=2.19 (显著关联); χ²=12.4 (统计显著); 严重事件率=100.0%; 住院率=90.5%
Rituximab,Infusion related reaction,27,85,7.055,7.055,105.73,0.926,0.185,0.593,7.630,PRR=7.05 (显著关联); χ²=105.7 (统计显著); 严重事件率=92.6%; 住院率=59.3%
Crizotinib,Lung neoplasm malignant,49,85,55.731,55.731,1110.79,0.469,0.429,0.082,7.034,PRR=55.73 (显著关联); χ²=1110.8 (统计显著); 死亡率=42.9%
Paclitaxel,Interstitial lung disease,21,85,4.168,4.168,42.17,1.000,0.048,0.714,7.881,PRR=4.17 (显著关联); χ²=42.2 (统计显著); 严重事件率=100.0%; 住院率=71.4%
Docetaxel,Febrile neutropenia,43,85,2.712,2.712,39.63,1.000,0.140,0.628,7.165,PRR=2.71 (显著关联); χ²=39.6 (统计显著); 严重事件率=100.0%; 住院率=62.8%
Carboplatin,Febrile neutropenia,47,85,2.666,2.666,41.19,1.000,0.191,0.638,7.076,PRR=2.67 (显著关联); χ²=41.2 (统计显著); 严重事件率=100.0%; 住院率=63.8%
Cisplatin,Febrile neutropenia,35,85,2.151,2.151,18.78,1.000,0.200,0.486,7.371,PRR=2.15 (显著关联); χ²=18.8 (统计显著); 严重事件率=100.0%; 住院率=48.6%
Pomalidomide,Pneumonia,39,85,4.120,4.120,80.05,1.000,0.179,0.795,7.262,PRR=4.12 (显著关联); χ²=80.1 (统计显著); 严重事件率=100.0%; 住院率=79.5%
Bortezomib,Neuropathy peripheral,26,85,4.282,4.282,55.14,0.962,0.115,0.462,7.668,PRR=4.28 (显著关联); χ²=55.1 (统计显著); 严重事件率=96.2%; 住院率=46.2%
Carfilzomib,Atrial fibrillation,20,85,6.246,6.246,74.84,1.000,0.100,0.800,7.930,PRR=6.25 (显著关联); χ²=74.8 (统计显著); 严重事件率=100.0%; 住院率=80.0%
Venetoclax,Neutropenia,46,85,3.373,3.373,66.13,0.826,0.152,0.543,7.097,PRR=3.37 (显著关联); χ²=66.1 (统计显著); 严重事件率=82.6%; 住院率=54.3%
Venetoclax,Platelet count decreased,22,85,2.164,2.164,12.44,0.955,0.182,0.636,7.835,PRR=2.16 (显著关联); χ²=12.4 (统计显著); 严重事件率=95.5%; 住院率=63.6%
Ibrutinib,Haemoglobin decreased,24,85,3.433,3.433,35.75,0.833,0.125,0.417,7.748,PRR=3.43 (显著关联); χ²=35.8 (统计显著); 严重事件率=83.3%; 住院率=41.7%
Olaparib,Anaemia,54,85,2.870,2.870,55.71,0.815,0.130,0.407,6.937,PRR=2.87 (显著关联); χ²=55.7 (统计显著); 严重事件率=81.5%; 住院率=40.7%
Rucaparib,Haemoglobin decreased,28,85,2.392,2.392,18.97,0.821,0.071,0.429,7.594,PRR=2.39 (显著关联); χ²=19.0 (统计显著); 严重事件率=82.1%; 住院率=42.9%
Niraparib,Thrombocytopenia,69,85,3.004,3.004,72.09,0.971,0.188,0.638,6.692,PRR=3.00 (显著关联); χ²=72.1 (统计显著); 严重事件率=97.1%; 住院率=63.8%
Niraparib,Platelet count decreased,120,85,6.898,6.898,393.01,0.908,0.033,0.475,6.139,PRR=6.90 (显著关联); χ²=393.0 (统计显著); 严重事件率=90.8%; 住院率=47.5%
Niraparib,Blood creatinine increased,25,85,2.671,2.671,21.13,0.960,0.080,0.680,7.707,PRR=2.67 (显著关联); χ²=21.1 (统计显著); 严重事件率=96.0%; 住院率=68.0%
Niraparib,Contusion,28,85,9.472,9.472,128.11,1.000,0.071,0.607,7.594,PRR=9.47 (显著关联); χ²=128.1 (统计显著); 严重事件率=100.0%; 住院率=60.7%
Niraparib,Haematocrit decreased,26,85,16.017,16.017,177.72,1.000,0.115,0.423,7.668,PRR=16.02 (显著关联); χ²=177.7 (统计显著); 严重事件率=100.0%; 住院率=42.3%
Niraparib,White blood cell count decreased,39,85,2.189,2.189,20.72,0.949,0.103,0.410,7.262,PRR=2.19 (显著关联); χ²=20.7 (统计显著); 严重事件率=94.9%; 住院率=41.0%
Niraparib,Dry mouth,23,85,8.430,8.430,94.74,0.870,0.043,0.478,7.791,PRR=8.43 (显著关联); χ²=94.7 (统计显著); 严重事件率=87.0%; 住院率=47.8%
Talazoparib,Anaemia,70,85,6.304,6.304,252.11,0.871,0.100,0.457,6.678,PRR=6.30 (显著关联); χ²=252.1 (统计显著); 严重事件率=87.1%; 住院率=45.7%
Talazoparib,Haemoglobin decreased,19,85,3.708,3.708,33.38,0.842,0.053,0.579,7.982,PRR=3.71 (显著关联); χ²=33.4 (统计显著); 严重事件率=84.2%; 住院率=57.9%
Talazoparib,Platelet count decreased,20,85,2.291,2.291,13.24,0.850,0.100,0.700,7.930,PRR=2.29 (显著关联); χ²=13.2 (统计显著); 严重事件率=85.0%; 住院率=70.0%
Talazoparib,Product use in unapproved indication,19,85,18.605,18.605,218.18,0.421,0.263,0.105,7.982,PRR=18.60 (显著关联); χ²=218.2 (统计显著); 死亡率=26.3%
Talazoparib,Off label use,28,85,3.262,3.262,38.95,0.464,0.250,0.107,7.594,PRR=3.26 (显著关联); χ²=38.9 (统计显著); 死亡率=25.0%
Abemaciclib,Dehydration,31,85,3.559,3.559,49.96,0.839,0.000,0.548,7.492,PRR=3.56 (显著关联); χ²=50.0 (统计显著); 严重事件率=83.9%; 住院率=54.8%
Dabrafenib,Pyrexia,103,85,5.340,5.340,284.24,0.796,0.058,0.505,6.291,PRR=5.34 (显著关联); χ²=284.2 (统计显著); 严重事件率=79.6%; 住院率=50.5%
Dabrafenib,Chills,34,85,10.802,10.802,220.11,0.912,0.147,0.412,7.400,PRR=10.80 (显著关联); χ²=220.1 (统计显著); 严重事件率=91.2%; 住院率=41.2%
Nivolumab,Platelet count decreased,5,80,0.534,0.534,1.94,1.000,0.800,0.400,9.317,死亡率=80.0%; 严重事件率=100.0%; 罕见+严重
Atezolizumab,Death,17,80,0.654,0.654,2.88,1.000,1.000,0.176,8.093,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Durvalumab,Thrombocytopenia,12,80,1.231,1.231,0.49,1.000,1.000,0.167,8.441,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Durvalumab,Disease progression,9,80,0.497,0.497,4.34,0.889,0.556,0.333,8.729,死亡率=55.6%; 严重事件率=88.9%; 罕见+严重
Trastuzumab,Malignant neoplasm progression,9,80,0.367,0.367,9.23,0.889,0.222,0.333,8.729,死亡率=22.2%; 严重事件率=88.9%; 罕见+严重
Trastuzumab,Drug ineffective,9,80,0.962,0.962,0.01,0.778,0.222,0.111,8.729,死亡率=22.2%; 严重事件率=77.8%; 罕见+严重
Trastuzumab,Dizziness,14,80,1.151,1.151,0.25,1.000,0.214,0.286,8.287,死亡率=21.4%; 严重事件率=100.0%; 罕见+严重
Trastuzumab,Toxicity to various agents,7,80,1.407,1.407,0.75,1.000,0.286,0.286,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Malignant neoplasm progression,13,80,0.587,0.587,3.52,1.000,0.308,0.385,8.361,死亡率=30.8%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Sepsis,6,80,0.656,0.656,1.01,1.000,0.500,0.333,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Dizziness,6,80,0.527,0.527,2.40,1.000,0.333,0.167,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Bevacizumab,Respiratory failure,5,80,1.030,1.030,0.00,1.000,0.800,0.200,9.317,死亡率=80.0%; 严重事件率=100.0%; 罕见+严重
Cetuximab,Malignant neoplasm progression,16,80,1.494,1.494,2.44,1.000,0.562,0.250,8.153,死亡率=56.2%; 严重事件率=100.0%; 罕见+严重
Cetuximab,Death,17,80,0.717,0.717,1.77,1.000,1.000,0.176,8.093,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Rituximab,Oedema,5,80,1.702,1.702,1.31,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Rituximab,Leukopenia,5,80,1.256,1.256,0.24,1.000,0.400,0.200,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Rituximab,Myocardial infarction,5,80,1.639,1.639,1.13,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Rituximab,Post transplant lymphoproliferative disorder,3,80,0.000,0.000,77.68,1.000,0.667,0.000,9.827,χ²=77.7 (统计显著); 死亡率=66.7%; 罕见+严重
Rituximab,Pruritus,6,80,0.623,0.623,1.28,1.000,0.333,0.333,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Rituximab,Neuropathy peripheral,5,80,0.601,0.601,1.24,1.000,0.600,0.000,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Atrial fibrillation,6,80,1.285,1.285,0.35,1.000,0.333,0.333,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Disease progression,3,80,0.126,0.126,17.34,1.000,0.333,0.333,9.827,χ²=17.3 (统计显著); 死亡率=33.3%; 罕见+严重
Epcoritamab,General physical health deterioration,5,80,1.232,1.232,0.20,1.000,0.400,0.200,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Infection,10,80,1.725,1.725,2.80,1.000,0.300,0.400,8.623,死亡率=30.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Febrile neutropenia,8,80,0.603,0.603,1.97,1.000,0.500,0.375,8.847,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,White blood cell count decreased,5,80,0.525,0.525,2.03,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Pleural effusion,6,80,0.994,0.994,0.00,1.000,0.833,0.333,9.134,死亡率=83.3%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Drug ineffective,11,80,1.531,1.531,1.87,0.818,0.273,0.273,8.528,死亡率=27.3%; 严重事件率=81.8%; 罕见+严重
Epcoritamab,Cardiac failure,5,80,1.957,1.957,2.15,1.000,0.800,0.400,9.317,死亡率=80.0%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Malignant neoplasm progression,11,80,0.580,0.580,3.14,1.000,0.273,0.091,8.528,死亡率=27.3%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,Interleukin-2 receptor increased,3,80,0.000,0.000,104.92,1.000,0.333,0.333,9.827,χ²=104.9 (统计显著); 死亡率=33.3%; 罕见+严重
Epcoritamab,Alanine aminotransferase increased,6,80,1.219,1.219,0.22,1.000,0.333,0.333,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Epcoritamab,High-grade B-cell lymphoma,3,80,0.000,0.000,104.92,1.000,0.333,0.000,9.827,χ²=104.9 (统计显著); 死亡率=33.3%; 罕见+严重
Imatinib,Pleural effusion,7,80,0.847,0.847,0.18,1.000,0.286,0.143,8.980,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Imatinib,Anaemia,12,80,0.521,0.521,4.91,0.917,0.333,0.333,8.441,死亡率=33.3%; 严重事件率=91.7%; 罕见+严重
Imatinib,Off label use,7,80,0.429,0.429,5.00,0.857,0.571,0.143,8.980,死亡率=57.1%; 严重事件率=85.7%; 罕见+严重
Imatinib,Abdominal pain,18,80,1.443,1.443,2.20,0.889,0.278,0.389,8.036,死亡率=27.8%; 严重事件率=88.9%; 罕见+严重
Imatinib,Thrombocytopenia,6,80,0.338,0.338,7.33,1.000,0.500,0.167,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Imatinib,Cardiac failure,5,80,1.422,1.422,0.57,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Imatinib,Gastric neoplasm,3,80,0.000,0.000,75.52,1.000,0.333,0.333,9.827,χ²=75.5 (统计显著); 死亡率=33.3%; 罕见+严重
Imatinib,Pyrexia,8,80,0.257,0.257,16.13,1.000,0.125,0.625,8.847,χ²=16.1 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Erlotinib,Epistaxis,6,80,1.771,1.771,1.85,1.000,0.333,0.167,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Off label use,9,80,0.713,0.713,0.97,1.000,0.667,0.222,8.729,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Weight decreased,14,80,1.796,1.796,4.49,0.929,0.286,0.357,8.287,死亡率=28.6%; 严重事件率=92.9%; 罕见+严重
Erlotinib,Pain in extremity,8,80,1.332,1.332,0.61,1.000,0.375,0.375,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Pain,8,80,0.911,0.911,0.07,1.000,0.250,0.375,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Abdominal pain,5,80,0.493,0.493,2.48,1.000,0.400,0.000,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Disease progression,10,80,0.397,0.397,8.59,1.000,0.400,0.300,8.623,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Anaemia,11,80,0.613,0.613,2.51,1.000,0.364,0.273,8.528,死亡率=36.4%; 严重事件率=100.0%; 罕见+严重
Erlotinib,Abdominal pain upper,6,80,1.159,1.159,0.12,1.000,0.333,0.167,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Abdominal pain,5,80,0.507,0.507,2.27,0.800,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=80.0%; 罕见+严重
Gefitinib,Off label use,17,80,1.422,1.422,1.95,0.824,0.412,0.176,8.093,死亡率=41.2%; 严重事件率=82.4%; 罕见+严重
Gefitinib,Renal failure,5,80,0.843,0.843,0.14,1.000,0.800,0.400,9.317,死亡率=80.0%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Malaise,9,80,0.818,0.818,0.34,0.889,0.667,0.333,8.729,死亡率=66.7%; 严重事件率=88.9%; 罕见+严重
Gefitinib,EGFR gene mutation,3,80,0.000,0.000,100.88,1.000,0.333,0.000,9.827,χ²=100.9 (统计显著); 死亡率=33.3%; 罕见+严重
Gefitinib,Weight decreased,13,80,1.710,1.710,3.50,0.923,0.538,0.231,8.361,死亡率=53.8%; 严重事件率=92.3%; 罕见+严重
Gefitinib,Drug ineffective,6,80,0.785,0.785,0.33,1.000,0.667,0.333,9.134,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Cough,5,80,0.714,0.714,0.54,0.600,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=60.0%; 罕见+严重
Gefitinib,Pruritus,8,80,1.082,1.082,0.05,0.875,0.375,0.375,8.847,死亡率=37.5%; 严重事件率=87.5%; 罕见+严重
Gefitinib,Pain,6,80,0.698,0.698,0.74,0.833,0.500,0.333,9.134,死亡率=50.0%; 严重事件率=83.3%; 罕见+严重
Gefitinib,Ascites,5,80,1.904,1.904,1.97,1.000,0.400,0.200,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Gefitinib,Bone marrow failure,5,80,1.682,1.682,1.27,1.000,0.400,0.000,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Osimertinib,Erythema,7,80,1.531,1.531,1.19,0.571,0.286,0.143,8.980,死亡率=28.6%; 严重事件率=57.1%; 罕见+严重
Osimertinib,Pain in extremity,9,80,1.568,1.568,1.71,0.778,0.222,0.333,8.729,死亡率=22.2%; 严重事件率=77.8%; 罕见+严重
Osimertinib,Back pain,11,80,1.647,1.647,2.57,0.727,0.364,0.364,8.528,死亡率=36.4%; 严重事件率=72.7%; 罕见+严重
Osimertinib,Respiratory failure,8,80,1.919,1.919,3.22,1.000,1.000,0.125,8.847,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Osimertinib,Disease progression,13,80,0.540,0.540,4.76,0.923,0.692,0.154,8.361,死亡率=69.2%; 严重事件率=92.3%; 罕见+严重
Osimertinib,Cough,13,80,1.949,1.949,5.46,0.923,0.462,0.231,8.361,死亡率=46.2%; 严重事件率=92.3%; 罕见+严重
Osimertinib,Pruritus,8,80,1.092,1.092,0.06,0.750,0.375,0.125,8.847,死亡率=37.5%; 严重事件率=75.0%; 罕见+严重
Osimertinib,Off label use,13,80,1.085,1.085,0.08,0.692,0.231,0.385,8.361,死亡率=23.1%; 严重事件率=69.2%; 罕见+严重
Osimertinib,Constipation,9,80,0.755,0.755,0.67,0.556,0.222,0.111,8.729,死亡率=22.2%; 严重事件率=55.6%; 罕见+严重
Osimertinib,Dizziness,6,80,0.601,0.601,1.50,0.667,0.500,0.167,9.134,死亡率=50.0%; 严重事件率=66.7%; 罕见+严重
Osimertinib,Insomnia,6,80,1.287,1.287,0.36,0.833,0.333,0.167,9.134,死亡率=33.3%; 严重事件率=83.3%; 罕见+严重
Osimertinib,Platelet count decreased,13,80,1.095,1.095,0.10,0.846,0.308,0.231,8.361,死亡率=30.8%; 严重事件率=84.6%; 罕见+严重
Osimertinib,Stomatitis,9,80,1.761,1.761,2.72,0.667,0.222,0.111,8.729,死亡率=22.2%; 严重事件率=66.7%; 罕见+严重
Crizotinib,Asthenia,10,80,0.845,0.845,0.27,0.900,0.300,0.400,8.623,死亡率=30.0%; 严重事件率=90.0%; 罕见+严重
Paclitaxel,Asthenia,15,80,0.846,0.846,0.39,1.000,0.333,0.333,8.218,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Pneumonitis,7,80,1.028,1.028,0.00,1.000,0.429,0.286,8.980,死亡率=42.9%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Metastases to central nervous system,5,80,1.340,1.340,0.40,1.000,0.600,0.400,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Malignant neoplasm progression,14,80,0.597,0.597,3.54,1.000,0.286,0.214,8.287,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Ascites,5,80,1.591,1.591,1.00,1.000,0.800,0.400,9.317,死亡率=80.0%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Oedema peripheral,9,80,1.837,1.837,3.10,1.000,0.333,0.333,8.729,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Dysphagia,5,80,1.011,1.011,0.00,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Decreased appetite,13,80,0.684,0.684,1.76,1.000,0.308,0.385,8.361,死亡率=30.8%; 严重事件率=100.0%; 罕见+严重
Paclitaxel,Malaise,10,80,0.762,0.762,0.69,1.000,0.500,0.400,8.623,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Neuropathy peripheral,10,80,1.257,1.257,0.48,1.000,0.300,0.300,8.623,死亡率=30.0%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Dysphagia,5,80,0.957,0.957,0.01,0.600,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=60.0%; 罕见+严重
Docetaxel,Constipation,8,80,0.523,0.523,3.25,0.875,0.500,0.250,8.847,死亡率=50.0%; 严重事件率=87.5%; 罕见+严重
Docetaxel,Chest pain,5,80,0.764,0.764,0.34,1.000,0.600,0.400,9.317,死亡率=60.0%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Cough,10,80,1.156,1.156,0.19,1.000,0.400,0.200,8.623,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Abdominal pain,15,80,1.246,1.246,0.66,1.000,0.533,0.333,8.218,死亡率=53.3%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Interstitial lung disease,10,80,1.736,1.736,2.81,1.000,0.500,0.400,8.623,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Docetaxel,Epistaxis,7,80,1.698,1.698,1.81,0.857,0.429,0.143,8.980,死亡率=42.9%; 严重事件率=85.7%; 罕见+严重
Doxorubicin,Neuropathy peripheral,6,80,0.770,0.770,0.39,1.000,0.500,0.000,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Malignant neoplasm progression,13,80,0.545,0.545,4.58,1.000,0.462,0.231,8.361,死亡率=46.2%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Headache,13,80,1.104,1.104,0.12,1.000,0.308,0.385,8.361,死亡率=30.8%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Constipation,9,80,0.615,0.615,2.03,1.000,0.333,0.333,8.729,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Rash,6,80,0.246,0.246,13.08,1.000,0.000,0.500,9.134,χ²=13.1 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Respiratory failure,5,80,0.957,0.957,0.01,1.000,0.400,0.200,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Pulmonary embolism,10,80,1.472,1.472,1.38,1.000,0.500,0.400,8.623,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Dizziness,8,80,0.658,0.658,1.33,1.000,0.375,0.375,8.847,死亡率=37.5%; 严重事件率=100.0%; 罕见+严重
Doxorubicin,Cerebral haemangioma,6,80,0.000,0.000,165.29,1.000,0.000,0.667,9.134,χ²=165.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Carboplatin,Respiratory failure,9,80,1.517,1.517,1.42,1.000,0.556,0.222,8.729,死亡率=55.6%; 严重事件率=100.0%; 罕见+严重
Carboplatin,Pulmonary vasculitis,3,80,0.000,0.000,70.32,1.000,0.667,0.000,9.827,χ²=70.3 (统计显著); 死亡率=66.7%; 罕见+严重
Carboplatin,Renal failure,11,80,1.351,1.351,0.90,1.000,0.455,0.273,8.528,死亡率=45.5%; 严重事件率=100.0%; 罕见+严重
Carboplatin,Drug ineffective,8,80,0.744,0.744,0.65,1.000,0.250,0.125,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Carboplatin,Confusional state,6,80,0.989,0.989,0.00,1.000,0.500,0.333,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Pneumonitis,9,80,1.260,1.260,0.44,1.000,0.667,0.333,8.729,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Malignant neoplasm progression,12,80,0.480,0.480,6.28,1.000,0.667,0.333,8.441,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Neuropathy peripheral,6,80,0.736,0.736,0.53,1.000,0.333,0.333,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Disease progression,15,80,0.487,0.487,7.50,1.000,0.467,0.267,8.218,死亡率=46.7%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Respiratory failure,6,80,1.106,1.106,0.06,1.000,0.667,0.167,9.134,死亡率=66.7%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Fatigue,12,80,0.244,0.244,26.01,1.000,0.167,0.667,8.441,χ²=26.0 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Cisplatin,Metastases to liver,5,80,1.728,1.728,1.38,1.000,0.400,0.000,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Renal failure,14,80,1.955,1.955,5.81,1.000,0.286,0.357,8.287,死亡率=28.6%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Interstitial lung disease,5,80,0.836,0.836,0.15,1.000,1.000,0.000,9.317,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Cisplatin,Potentiating drug interaction,5,80,0.000,0.000,131.52,1.000,0.000,1.000,9.317,χ²=131.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Chemotherapeutic drug level increased,5,80,0.000,0.000,131.52,1.000,0.000,1.000,9.317,χ²=131.5 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Lenalidomide,Neutropenia,15,80,1.188,1.188,0.42,1.000,0.467,0.267,8.218,死亡率=46.7%; 严重事件率=100.0%; 罕见+严重
Lenalidomide,Constipation,5,80,0.548,0.548,1.79,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Lenalidomide,Thrombocytopenia,14,80,1.429,1.429,1.67,1.000,0.357,0.214,8.287,死亡率=35.7%; 严重事件率=100.0%; 罕见+严重
Lenalidomide,Dizziness,9,80,1.206,1.206,0.30,1.000,0.222,0.222,8.729,死亡率=22.2%; 严重事件率=100.0%; 罕见+严重
Bortezomib,Atrial fibrillation,5,80,0.972,0.972,0.00,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Bortezomib,Drug ineffective,7,80,0.874,0.874,0.12,0.714,0.286,0.143,8.980,死亡率=28.6%; 严重事件率=71.4%; 罕见+严重
Bortezomib,Pain in extremity,7,80,1.134,1.134,0.10,0.857,0.286,0.286,8.980,死亡率=28.6%; 严重事件率=85.7%; 罕见+严重
Bortezomib,Pancytopenia,11,80,1.694,1.694,2.86,1.000,0.364,0.364,8.528,死亡率=36.4%; 严重事件率=100.0%; 罕见+严重
Bortezomib,Off label use,16,80,1.267,1.267,0.82,1.000,0.312,0.375,8.153,死亡率=31.2%; 严重事件率=100.0%; 罕见+严重
Bortezomib,Cardiac failure,5,80,1.788,1.788,1.59,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Carfilzomib,Disease progression,16,80,0.910,0.910,0.13,1.000,0.625,0.250,8.153,死亡率=62.5%; 严重事件率=100.0%; 罕见+严重
Carfilzomib,Platelet count decreased,9,80,1.018,1.018,0.00,1.000,0.444,0.111,8.729,死亡率=44.4%; 严重事件率=100.0%; 罕见+严重
Carfilzomib,Neutropenia,5,80,0.396,0.396,4.40,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Carfilzomib,Nausea,10,80,0.335,0.335,12.40,1.000,0.100,1.000,8.623,χ²=12.4 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Drug ineffective,8,80,1.450,1.450,1.05,0.875,0.375,0.250,8.847,死亡率=37.5%; 严重事件率=87.5%; 罕见+严重
Venetoclax,Drug ineffective,7,80,1.054,1.054,0.02,0.571,0.429,0.143,8.980,死亡率=42.9%; 严重事件率=57.1%; 罕见+严重
Venetoclax,Nausea,15,80,0.422,0.422,11.04,0.933,0.200,0.733,8.218,χ²=11.0 (统计显著); 严重事件率=93.3%; 罕见+严重; 住院率=73.3%
Olaparib,Asthenia,18,80,1.027,1.027,0.01,0.778,0.222,0.389,8.036,死亡率=22.2%; 严重事件率=77.8%; 罕见+严重
Olaparib,Renal failure,11,80,1.609,1.609,2.30,1.000,0.364,0.273,8.528,死亡率=36.4%; 严重事件率=100.0%; 罕见+严重
Rucaparib,Neutropenia,6,80,0.197,0.197,18.29,1.000,0.000,0.500,9.134,χ²=18.3 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Niraparib,Pneumonia,6,80,0.190,0.190,19.07,1.000,0.000,0.833,9.134,χ²=19.1 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Niraparib,Neutropenia,11,80,0.318,0.318,14.73,1.000,0.000,0.545,8.528,χ²=14.7 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Niraparib,Pyrexia,11,80,0.232,0.232,25.63,1.000,0.000,0.818,8.528,χ²=25.6 (统计显著); 严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Talazoparib,Pain,8,80,1.257,1.257,0.40,0.625,0.250,0.375,8.847,死亡率=25.0%; 严重事件率=62.5%; 罕见+严重
Palbociclib,Malaise,13,80,1.208,1.208,0.43,0.615,0.231,0.308,8.361,死亡率=23.1%; 严重事件率=61.5%; 罕见+严重
Palbociclib,Pyrexia,7,80,0.300,0.300,10.84,0.857,0.143,0.714,8.980,χ²=10.8 (统计显著); 严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Palbociclib,Pancytopenia,8,80,1.288,1.288,0.48,1.000,0.250,0.250,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Ribociclib,Death,15,80,0.469,0.469,8.37,1.000,1.000,0.000,8.218,死亡率=100.0%; 严重事件率=100.0%; 罕见+严重
Ribociclib,Urinary tract infection,6,80,1.449,1.449,0.79,1.000,0.333,0.333,9.134,死亡率=33.3%; 严重事件率=100.0%; 罕见+严重
Ribociclib,Malignant neoplasm progression,8,80,0.546,0.546,2.86,1.000,0.250,0.125,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Ribociclib,Disease progression,6,80,0.330,0.330,7.78,1.000,0.500,0.000,9.134,死亡率=50.0%; 严重事件率=100.0%; 罕见+严重
Vemurafenib,Fatigue,18,80,0.484,0.484,9.15,0.944,0.278,0.333,8.036,死亡率=27.8%; 严重事件率=94.4%; 罕见+严重
Vemurafenib,Pain,8,80,0.967,0.967,0.01,0.750,0.250,0.125,8.847,死亡率=25.0%; 严重事件率=75.0%; 罕见+严重
Vemurafenib,Drug ineffective,9,80,1.231,1.231,0.36,0.778,0.778,0.222,8.729,死亡率=77.8%; 严重事件率=77.8%; 罕见+严重
Vemurafenib,Constipation,5,80,0.423,0.423,3.75,1.000,0.400,0.400,9.317,死亡率=40.0%; 严重事件率=100.0%; 罕见+严重
Vemurafenib,Malignant neoplasm progression,8,80,0.416,0.416,6.20,1.000,0.625,0.125,8.847,死亡率=62.5%; 严重事件率=100.0%; 罕见+严重
Vemurafenib,Headache,8,80,0.836,0.836,0.24,1.000,0.250,0.375,8.847,死亡率=25.0%; 严重事件率=100.0%; 罕见+严重
Vemurafenib,Off label use,6,80,0.500,0.500,2.84,0.667,0.333,0.000,9.134,死亡率=33.3%; 严重事件率=66.7%; 罕见+严重
Vemurafenib,Dermal cyst,3,80,0.000,0.000,104.04,0.667,0.333,0.000,9.827,χ²=104.0 (统计显著); 死亡率=33.3%; 罕见+严重
Dabrafenib,Asthenia,11,80,0.742,0.742,0.93,0.909,0.273,0.364,8.528,死亡率=27.3%; 严重事件率=90.9%; 罕见+严重
Dabrafenib,Constipation,7,80,0.582,0.582,1.98,0.857,0.286,0.143,8.980,死亡率=28.6%; 严重事件率=85.7%; 罕见+严重
Pembrolizumab,Hypothyroidism,9,75,12.274,12.274,71.53,0.333,0.000,0.222,8.729,PRR=12.27 (显著关联); χ²=71.5 (统计显著); 罕见+严重
Pembrolizumab,Infection,3,75,0.639,0.639,0.59,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Fall,3,75,0.784,0.784,0.17,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Blood alkaline phosphatase increased,6,75,4.782,4.782,15.82,0.500,0.167,0.333,9.134,PRR=4.78 (显著关联); χ²=15.8 (统计显著); 罕见+严重
Pembrolizumab,Stomatitis,4,75,1.001,1.001,0.00,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Nivolumab,Septic shock,3,75,1.419,1.419,0.35,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Nivolumab,Rash,4,75,0.260,0.260,8.05,0.750,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Nivolumab,Dizziness,3,75,0.386,0.386,2.81,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Muscular weakness,4,75,1.419,1.419,0.47,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Hepatic enzyme increased,3,75,1.770,1.770,0.94,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Nivolumab,Pruritus,4,75,0.697,0.697,0.50,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Nivolumab,Arthralgia,4,75,0.705,0.705,0.47,0.500,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Nivolumab,Haemoglobin decreased,3,75,0.531,0.531,1.20,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Nivolumab,Pain in extremity,3,75,0.657,0.657,0.52,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Nivolumab,Oedema peripheral,3,75,0.920,0.920,0.02,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Nivolumab,Malaise,3,75,0.351,0.351,3.46,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Nivolumab,General physical health deterioration,3,75,0.920,0.920,0.02,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Atezolizumab,Neutrophil count decreased,4,75,1.413,1.413,0.46,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Atezolizumab,Cardiac failure,3,75,1.827,1.827,1.06,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Atezolizumab,Off label use,4,75,0.532,0.532,1.58,0.750,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Atezolizumab,Interstitial lung disease,4,75,1.396,1.396,0.43,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Atezolizumab,Malaise,4,75,0.592,0.592,1.08,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Atezolizumab,Erythema multiforme,4,75,28.697,28.697,69.76,1.000,0.000,0.250,9.540,PRR=28.70 (显著关联); χ²=69.8 (统计显著); 罕见+严重
Atezolizumab,Septic shock,3,75,1.789,1.789,0.99,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Atezolizumab,General physical health deterioration,3,75,1.159,1.159,0.06,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Durvalumab,Hypokalaemia,3,75,1.445,1.445,0.39,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Durvalumab,Metastases to central nervous system,5,75,2.166,2.166,2.92,1.000,0.200,0.200,9.317,PRR=2.17 (显著关联); 严重事件率=100.0%; 罕见+严重
Durvalumab,Pain,4,75,0.623,0.623,0.87,0.750,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Durvalumab,Interstitial lung disease,3,75,0.848,0.848,0.08,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Durvalumab,Urticaria,6,75,4.076,4.076,12.46,0.333,0.000,0.333,9.134,PRR=4.08 (显著关联); χ²=12.5 (统计显著); 罕见+严重
Durvalumab,Fall,3,75,0.795,0.795,0.15,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Ipilimumab,Death,67,75,1.973,1.973,27.72,1.000,1.000,0.209,6.721,χ²=27.7 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Ipilimumab,Renal failure,3,75,0.590,0.590,0.81,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Ipilimumab,Thyroid disorder,3,75,17.526,17.526,31.87,1.000,0.000,0.333,9.827,PRR=17.53 (显著关联); χ²=31.9 (统计显著); 罕见+严重
Ipilimumab,Oedema peripheral,3,75,0.827,0.827,0.10,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Peripheral swelling,3,75,0.979,0.979,0.00,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Ipilimumab,General physical health deterioration,4,75,1.111,1.111,0.04,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Ipilimumab,Hypokalaemia,4,75,1.702,1.702,1.08,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Hypoxia,3,75,1.361,1.361,0.27,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Ipilimumab,Myocardial infarction,3,75,1.458,1.458,0.41,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ipilimumab,Lung disorder,3,75,1.945,1.945,1.28,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Ipilimumab,Myalgia,3,75,0.949,0.949,0.01,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Trastuzumab,Cardiac disorder,5,75,3.040,3.040,5.94,0.800,0.000,0.400,9.317,PRR=3.04 (显著关联); 严重事件率=80.0%; 罕见+严重
Trastuzumab,Cardiotoxicity,4,75,6.580,6.580,14.76,1.000,0.000,0.250,9.540,PRR=6.58 (显著关联); χ²=14.8 (统计显著); 罕见+严重
Trastuzumab,Hyponatraemia,3,75,0.620,0.620,0.66,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Trastuzumab,Platelet count decreased,4,75,0.262,0.262,7.88,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Trastuzumab,Death,24,75,0.451,0.451,14.65,1.000,1.000,0.167,7.748,χ²=14.7 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Trastuzumab,Hypersensitivity,10,75,2.058,2.058,4.85,0.900,0.200,0.300,8.623,PRR=2.06 (显著关联); 严重事件率=90.0%; 罕见+严重
Trastuzumab,Loss of consciousness,3,75,1.351,1.351,0.25,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Trastuzumab,Palpitations,5,75,2.796,2.796,5.05,1.000,0.000,0.400,9.317,PRR=2.80 (显著关联); 严重事件率=100.0%; 罕见+严重
Trastuzumab,Septic shock,4,75,1.176,1.176,0.10,1.000,1.000,1.000,9.540,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Trastuzumab,Renal failure acute,3,75,0.639,0.639,0.58,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Trastuzumab,Metastases to breast,3,75,16.774,16.774,26.81,1.000,0.000,0.000,9.827,PRR=16.77 (显著关联); χ²=26.8 (统计显著); 罕见+严重
Trastuzumab,Skin exfoliation,6,75,2.797,2.797,6.05,0.833,0.167,0.000,9.134,PRR=2.80 (显著关联); 严重事件率=83.3%; 罕见+严重
Trastuzumab,Atrial fibrillation,4,75,0.656,0.656,0.68,1.000,0.500,1.000,9.540,死亡率=50.0%; 罕见+严重; 住院率=100.0%
Trastuzumab,Neutrophil count increased,3,75,9.318,9.318,16.10,1.000,0.000,0.333,9.827,PRR=9.32 (显著关联); χ²=16.1 (统计显著); 罕见+严重
Trastuzumab,Metastases to spine,3,75,9.318,9.318,16.10,1.000,0.000,0.000,9.827,PRR=9.32 (显著关联); χ²=16.1 (统计显著); 罕见+严重
Trastuzumab,Anxiety,7,75,2.039,2.039,3.32,0.857,0.000,0.286,8.980,PRR=2.04 (显著关联); 严重事件率=85.7%; 罕见+严重
Trastuzumab,Bone pain,7,75,2.479,2.479,5.45,0.714,0.000,0.143,8.980,PRR=2.48 (显著关联); 严重事件率=71.4%; 罕见+严重
Trastuzumab,Sepsis,4,75,0.395,0.395,3.51,1.000,0.750,0.750,9.540,死亡率=75.0%; 罕见+严重; 住院率=75.0%
Trastuzumab,Hip fracture,3,75,6.988,6.988,11.87,1.000,0.000,0.000,9.827,PRR=6.99 (显著关联); χ²=11.9 (统计显著); 罕见+严重
Trastuzumab,Tooth extraction,3,75,27.957,27.957,37.58,0.667,0.000,0.000,9.827,PRR=27.96 (显著关联); χ²=37.6 (统计显著); 罕见+严重
Trastuzumab,Musculoskeletal stiffness,4,75,5.326,5.326,11.37,0.500,0.000,0.000,9.540,PRR=5.33 (显著关联); χ²=11.4 (统计显著); 罕见+严重
Trastuzumab,Weight increased,5,75,2.291,2.291,3.24,0.800,0.000,0.200,9.317,PRR=2.29 (显著关联); 严重事件率=80.0%; 罕见+严重
Trastuzumab,Muscle tightness,3,75,16.774,16.774,26.81,1.000,0.000,0.000,9.827,PRR=16.77 (显著关联); χ²=26.8 (统计显著); 罕见+严重
Bevacizumab,Nasopharyngitis,3,75,1.109,1.109,0.03,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bevacizumab,Syncope,3,75,0.949,0.949,0.01,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Bevacizumab,Blood creatinine increased,3,75,0.502,0.502,1.40,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Bevacizumab,Rectal haemorrhage,5,75,2.846,2.846,5.29,1.000,0.000,0.400,9.317,PRR=2.85 (显著关联); 严重事件率=100.0%; 罕见+严重
Bevacizumab,Gait disturbance,3,75,0.876,0.876,0.05,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bevacizumab,Tachycardia,4,75,1.595,1.595,0.81,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Oedema peripheral,4,75,0.835,0.835,0.12,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Speech disorder,4,75,1.807,1.807,1.31,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Bevacizumab,Eye pain,3,75,7.091,7.091,12.33,1.000,0.000,0.000,9.827,PRR=7.09 (显著关联); χ²=12.3 (统计显著); 罕见+严重
Bevacizumab,Abdominal distension,3,75,1.070,1.070,0.01,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Bevacizumab,Abdominal discomfort,3,75,0.676,0.676,0.44,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Bevacizumab,Abdominal compartment syndrome,4,75,8.199,8.199,19.28,1.000,0.000,0.000,9.540,PRR=8.20 (显著关联); χ²=19.3 (统计显著); 罕见+严重
Bevacizumab,Ocular hyperaemia,4,75,4.918,4.918,10.40,1.000,0.000,0.000,9.540,PRR=4.92 (显著关联); χ²=10.4 (统计显著); 罕见+严重
Bevacizumab,Infected skin ulcer,3,75,92.205,92.205,65.41,1.000,0.000,0.000,9.827,PRR=92.21 (显著关联); χ²=65.4 (统计显著); 罕见+严重
Bevacizumab,Muscle spasms,4,75,0.883,0.883,0.06,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Lung infection,3,75,1.486,1.486,0.44,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Bevacizumab,Blindness,4,75,4.918,4.918,10.40,1.000,0.000,0.250,9.540,PRR=4.92 (显著关联); χ²=10.4 (统计显著); 罕见+严重
Bevacizumab,Eye discharge,3,75,11.524,11.524,20.27,1.000,0.000,0.000,9.827,PRR=11.52 (显著关联); χ²=20.3 (统计显著); 罕见+严重
Bevacizumab,Packed red blood cell transfusion,4,75,24.600,24.600,48.61,1.000,0.000,0.250,9.540,PRR=24.60 (显著关联); χ²=48.6 (统计显著); 罕见+严重
Cetuximab,Dermatitis acneiform,5,75,10.828,10.828,37.21,0.400,0.000,0.200,9.317,PRR=10.83 (显著关联); χ²=37.2 (统计显著); 罕见+严重
Cetuximab,Pruritus generalised,4,75,13.208,13.208,36.52,0.500,0.000,0.000,9.540,PRR=13.21 (显著关联); χ²=36.5 (统计显著); 罕见+严重
Cetuximab,Hypotension,8,75,2.439,2.439,6.35,0.875,0.125,0.250,8.847,PRR=2.44 (显著关联); 严重事件率=87.5%; 罕见+严重
Cetuximab,Oxygen saturation decreased,3,75,6.713,6.713,12.92,1.000,0.000,0.000,9.827,PRR=6.71 (显著关联); χ²=12.9 (统计显著); 罕见+严重
Rituximab,Cardiac failure,4,75,1.155,1.155,0.08,1.000,0.750,0.750,9.540,死亡率=75.0%; 罕见+严重; 住院率=75.0%
Rituximab,Oropharyngeal pain,5,75,2.007,2.007,2.26,0.800,0.200,0.400,9.317,PRR=2.01 (显著关联); 严重事件率=80.0%; 罕见+严重
Rituximab,Dizziness,4,75,0.306,0.306,5.97,0.750,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Rituximab,Interstitial lung disease,4,75,0.654,0.654,0.68,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Rituximab,Scleroderma,3,75,20.172,20.172,30.07,1.000,0.000,0.333,9.827,PRR=20.17 (显著关联); χ²=30.1 (统计显著); 罕见+严重
Rituximab,Somnolence,3,75,0.983,0.983,0.00,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Rituximab,Throat irritation,4,75,6.726,6.726,15.00,1.000,0.000,0.000,9.540,PRR=6.73 (显著关联); χ²=15.0 (统计显著); 罕见+严重
Rituximab,Chest discomfort,6,75,2.096,2.096,3.06,0.833,0.000,0.000,9.134,PRR=2.10 (显著关联); 严重事件率=83.3%; 罕见+严重
Rituximab,Tremor,6,75,2.374,2.374,4.21,0.833,0.167,0.333,9.134,PRR=2.37 (显著关联); 严重事件率=83.3%; 罕见+严重
Rituximab,Confusional state,3,75,0.533,0.533,1.16,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Rituximab,Cerebrovascular accident,3,75,0.830,0.830,0.10,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Rituximab,Haemorrhage,4,75,1.654,1.654,0.94,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Rituximab,Thrombosis,4,75,1.168,1.168,0.09,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Rituximab,Lung infection,3,75,1.300,1.300,0.19,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Rituximab,Herpes virus infection,3,75,26.897,26.897,36.00,1.000,0.000,0.333,9.827,PRR=26.90 (显著关联); χ²=36.0 (统计显著); 罕见+严重
Rituximab,Lung neoplasm malignant,4,75,1.264,1.264,0.20,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Rituximab,Injection site erythema,3,75,11.526,11.526,19.43,1.000,0.000,0.333,9.827,PRR=11.53 (显著关联); χ²=19.4 (统计显著); 罕见+严重
Rituximab,Gastrointestinal disorder,4,75,1.680,1.680,1.00,0.750,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Rituximab,White blood cell count abnormal,3,75,11.526,11.526,19.43,1.000,0.000,0.333,9.827,PRR=11.53 (显著关联); χ²=19.4 (统计显著); 罕见+严重
Rituximab,Blood pressure fluctuation,4,75,15.376,15.376,32.92,1.000,0.000,0.000,9.540,PRR=15.38 (显著关联); χ²=32.9 (统计显著); 罕见+严重
Rituximab,Pyoderma gangrenosum,3,75,40.346,40.346,44.32,1.000,0.000,0.000,9.827,PRR=40.35 (显著关联); χ²=44.3 (统计显著); 罕见+严重
Epcoritamab,Hypotension,3,75,0.510,0.510,1.35,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Epcoritamab,Hypoxia,4,75,1.617,1.617,0.87,1.000,1.000,0.500,9.540,死亡率=100.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,Blood bilirubin increased,3,75,1.611,1.611,0.64,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Epcoritamab,Pain,4,75,0.480,0.480,2.15,0.750,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,Asthenia,3,75,0.204,0.204,8.89,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Epcoritamab,Diffuse large B-cell lymphoma refractory,96,75,0.000,0.000,3357.43,1.000,0.500,0.167,6.362,χ²=3357.4 (统计显著); 死亡率=50.0%; 严重事件率=100.0%
Epcoritamab,Septic shock,3,75,1.124,1.124,0.04,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Epcoritamab,Oedema peripheral,3,75,0.728,0.728,0.29,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Epcoritamab,Decreased appetite,3,75,0.192,0.192,9.78,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Epcoritamab,Constipation,4,75,0.340,0.340,4.89,1.000,0.750,0.500,9.540,死亡率=75.0%; 罕见+严重; 住院率=50.0%
Imatinib,Death,79,75,1.484,1.484,10.65,1.000,1.000,0.013,6.557,χ²=10.7 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Imatinib,Blister,5,75,3.357,3.357,7.04,1.000,0.200,0.000,9.317,PRR=3.36 (显著关联); 严重事件率=100.0%; 罕见+严重
Imatinib,Joint swelling,6,75,2.965,2.965,6.73,0.833,0.167,0.333,9.134,PRR=2.96 (显著关联); 严重事件率=83.3%; 罕见+严重
Imatinib,Hepatic lesion,4,75,9.521,9.521,21.50,1.000,0.000,0.000,9.540,PRR=9.52 (显著关联); χ²=21.5 (统计显著); 罕见+严重
Imatinib,Gastric cancer,4,75,20.949,20.949,40.58,1.000,0.000,0.000,9.540,PRR=20.95 (显著关联); χ²=40.6 (统计显著); 罕见+严重
Imatinib,Myalgia,10,75,2.148,2.148,5.42,1.000,0.000,0.400,8.623,PRR=2.15 (显著关联); 严重事件率=100.0%; 罕见+严重
Imatinib,Blood iron decreased,4,75,14.963,14.963,31.88,0.750,0.000,0.250,9.540,PRR=14.96 (显著关联); χ²=31.9 (统计显著); 罕见+严重
Imatinib,Spinal fracture,4,75,6.982,6.982,15.55,1.000,0.000,0.250,9.540,PRR=6.98 (显著关联); χ²=15.6 (统计显著); 罕见+严重
Imatinib,Palpitations,5,75,2.618,2.618,4.36,1.000,0.000,0.200,9.317,PRR=2.62 (显著关联); 严重事件率=100.0%; 罕见+严重
Imatinib,Infection,3,75,0.362,0.362,3.19,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Imatinib,Hypophagia,4,75,1.903,1.903,1.53,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Imatinib,Intra-abdominal haemorrhage,3,75,15.704,15.704,24.82,1.000,0.000,0.333,9.827,PRR=15.70 (显著关联); χ²=24.8 (统计显著); 罕见+严重
Imatinib,Foetal exposure during pregnancy,4,75,26.186,26.186,46.57,1.000,0.000,0.000,9.540,PRR=26.19 (显著关联); χ²=46.6 (统计显著); 罕见+严重
Imatinib,Neoplasm malignant,6,75,3.022,3.022,6.98,1.000,0.000,0.167,9.134,PRR=3.02 (显著关联); 严重事件率=100.0%; 罕见+严重
Imatinib,Metastases to liver,7,75,2.381,2.381,4.93,1.000,0.143,0.143,8.980,PRR=2.38 (显著关联); 严重事件率=100.0%; 罕见+严重
Imatinib,Hepatic neoplasm,3,75,19.630,19.630,29.15,1.000,0.000,0.000,9.827,PRR=19.63 (显著关联); χ²=29.1 (统计显著); 罕见+严重
Imatinib,Haemorrhage,4,75,1.610,1.610,0.84,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Imatinib,Tachycardia,3,75,1.005,1.005,0.00,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Imatinib,Cardiac disorder,5,75,2.845,2.845,5.18,1.000,0.000,0.400,9.317,PRR=2.85 (显著关联); 严重事件率=100.0%; 罕见+严重
Imatinib,Swelling face,5,75,2.727,2.727,4.75,1.000,0.000,0.000,9.317,PRR=2.73 (显著关联); 严重事件率=100.0%; 罕见+严重
Imatinib,Maternal exposure during pregnancy,4,75,17.457,17.457,35.79,1.000,0.000,0.000,9.540,PRR=17.46 (显著关联); χ²=35.8 (统计显著); 罕见+严重
Imatinib,Periorbital oedema,3,75,7.137,7.137,11.96,1.000,0.000,0.000,9.827,PRR=7.14 (显著关联); χ²=12.0 (统计显著); 罕见+严重
Imatinib,Face oedema,3,75,7.137,7.137,11.96,1.000,0.000,0.000,9.827,PRR=7.14 (显著关联); χ²=12.0 (统计显著); 罕见+严重
Imatinib,Rectal cancer,3,75,26.174,26.174,34.93,1.000,0.000,0.000,9.827,PRR=26.17 (显著关联); χ²=34.9 (统计显著); 罕见+严重
Imatinib,Foetal death,3,75,39.262,39.262,43.03,1.000,0.000,0.000,9.827,PRR=39.26 (显著关联); χ²=43.0 (统计显著); 罕见+严重
Erlotinib,Interstitial lung disease,4,75,0.819,0.819,0.15,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Erlotinib,Pleural fibrosis,4,75,134.737,134.737,102.87,1.000,0.000,0.000,9.540,PRR=134.74 (显著关联); χ²=102.9 (统计显著); 罕见+严重
Erlotinib,Lip swelling,3,75,6.731,6.731,11.82,1.000,0.000,0.000,9.827,PRR=6.73 (显著关联); χ²=11.8 (统计显著); 罕见+严重
Erlotinib,Eye discharge,4,75,19.246,19.246,42.65,1.000,0.000,0.250,9.540,PRR=19.25 (显著关联); χ²=42.6 (统计显著); 罕见+严重
Erlotinib,Haemoglobin decreased,3,75,0.393,0.393,2.69,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Erlotinib,Neuropathy peripheral,3,75,0.447,0.447,1.96,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Erlotinib,Erythema,4,75,0.824,0.824,0.14,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Erlotinib,Therapeutic product ineffective,3,75,50.494,50.494,56.43,1.000,0.000,0.333,9.827,PRR=50.49 (显著关联); χ²=56.4 (统计显著); 罕见+严重
Erlotinib,Arthralgia,4,75,0.522,0.522,1.66,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Erlotinib,Skin ulcer,3,75,6.310,6.310,10.94,1.000,0.000,0.333,9.827,PRR=6.31 (显著关联); χ²=10.9 (统计显著); 罕见+严重
Erlotinib,Febrile neutropenia,4,75,0.279,0.279,7.11,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Erlotinib,Hypoxia,3,75,1.120,1.120,0.04,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Gefitinib,Platelet count decreased,3,75,0.243,0.243,6.77,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Gefitinib,Septic shock,4,75,1.458,1.458,0.53,1.000,1.000,0.500,9.540,死亡率=100.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Cardiac failure congestive,3,75,1.331,1.331,0.23,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Gefitinib,Blood pressure increased,4,75,1.556,1.556,0.74,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Gefitinib,Confusional state,3,75,0.687,0.687,0.41,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Gefitinib,Toxicity to various agents,3,75,0.725,0.725,0.30,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Gefitinib,Death,65,75,1.606,1.606,12.88,1.000,1.000,0.169,6.752,χ²=12.9 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Gefitinib,Metastases to bone,6,75,3.304,3.304,8.51,1.000,0.167,0.167,9.134,PRR=3.30 (显著关联); 严重事件率=100.0%; 罕见+严重
Gefitinib,Stomatitis,4,75,0.751,0.751,0.31,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Hair growth abnormal,3,75,14.854,14.854,26.32,0.667,0.000,0.000,9.827,PRR=14.85 (显著关联); χ²=26.3 (统计显著); 罕见+严重
Gefitinib,Dysphagia,4,75,0.961,0.961,0.01,1.000,0.750,0.500,9.540,死亡率=75.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Depression,4,75,1.980,1.980,1.78,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Skin exfoliation,5,75,2.842,2.842,5.34,0.800,0.200,0.400,9.317,PRR=2.84 (显著关联); 严重事件率=80.0%; 罕见+严重
Gefitinib,Sepsis,4,75,0.489,0.489,2.03,1.000,0.750,0.500,9.540,死亡率=75.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Neutrophil count decreased,3,75,0.636,0.636,0.59,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Gefitinib,Abdominal discomfort,3,75,0.763,0.763,0.21,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Gefitinib,Rash pustular,3,75,6.498,6.498,11.40,0.667,0.000,0.333,9.827,PRR=6.50 (显著关联); χ²=11.4 (统计显著); 罕见+严重
Gefitinib,Drug interaction,5,75,3.271,3.271,6.97,0.800,0.200,0.000,9.317,PRR=3.27 (显著关联); 严重事件率=80.0%; 罕见+严重
Gefitinib,General physical health deterioration,4,75,0.941,0.941,0.01,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Osimertinib,Dysgeusia,4,75,0.772,0.772,0.26,0.750,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Osimertinib,Abdominal discomfort,4,75,1.035,1.035,0.00,0.750,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Osimertinib,Dysphagia,3,75,0.722,0.722,0.30,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Osimertinib,Hypoxia,3,75,1.165,1.165,0.07,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Osimertinib,Neoplasm progression,3,75,0.928,0.928,0.02,0.667,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Osimertinib,Fall,4,75,0.798,0.798,0.19,0.750,0.750,0.500,9.540,死亡率=75.0%; 罕见+严重; 住院率=50.0%
Osimertinib,Deep vein thrombosis,4,75,1.271,1.271,0.22,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Osimertinib,Acute kidney injury,3,75,0.904,0.904,0.03,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Osimertinib,Thrombosis,3,75,1.127,1.127,0.04,0.667,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Osimertinib,Onychoclasis,10,75,15.285,15.285,89.84,0.500,0.100,0.100,8.623,PRR=15.28 (显著关联); χ²=89.8 (统计显著); 罕见+严重
Osimertinib,Acne,3,75,1.809,1.809,1.00,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Osimertinib,Memory impairment,3,75,1.841,1.841,1.06,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Osimertinib,Sepsis,3,75,0.369,0.369,3.09,1.000,1.000,0.667,9.827,死亡率=100.0%; 罕见+严重; 住院率=66.7%
Osimertinib,Cerebrovascular accident,3,75,1.081,1.081,0.02,1.000,1.000,0.667,9.827,死亡率=100.0%; 罕见+严重; 住院率=66.7%
Osimertinib,Neutrophil count decreased,4,75,0.862,0.862,0.08,0.750,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Osimertinib,Gait disturbance,4,75,1.345,1.345,0.33,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Osimertinib,Heart rate increased,4,75,1.866,1.866,1.48,0.750,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Osimertinib,Hypophagia,3,75,1.874,1.874,1.12,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Crizotinib,Dizziness,18,75,2.363,2.363,12.86,0.333,0.111,0.167,8.036,PRR=2.36 (显著关联); χ²=12.9 (统计显著); 罕见+严重
Crizotinib,Renal failure acute,3,75,1.002,1.002,0.00,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Crizotinib,Platelet count decreased,3,75,0.307,0.307,4.51,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Crizotinib,Oedema peripheral,15,75,4.870,4.870,40.03,0.400,0.067,0.200,8.218,PRR=4.87 (显著关联); χ²=40.0 (统计显著); 罕见+严重
Crizotinib,Pain,4,75,0.584,0.584,1.14,0.500,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Crizotinib,Cerebrovascular accident,3,75,1.353,1.353,0.26,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Crizotinib,Sepsis,4,75,0.619,0.619,0.90,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Crizotinib,Joint swelling,9,75,7.922,7.922,44.73,0.333,0.000,0.111,8.729,PRR=7.92 (显著关联); χ²=44.7 (统计显著); 罕见+严重
Crizotinib,Abdominal distension,5,75,2.610,2.610,4.56,0.600,0.200,0.400,9.317,PRR=2.61 (显著关联); 严重事件率=60.0%; 罕见+严重
Crizotinib,Oesophagitis,5,75,12.911,12.911,41.33,0.400,0.000,0.400,9.317,PRR=12.91 (显著关联); χ²=41.3 (统计显著); 罕见+严重
Crizotinib,Renal failure,4,75,0.849,0.849,0.10,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Crizotinib,Impaired gastric emptying,3,75,26.301,26.301,44.50,1.000,0.000,0.333,9.827,PRR=26.30 (显著关联); χ²=44.5 (统计显著); 罕见+严重
Crizotinib,Abdominal pain,4,75,0.511,0.511,1.79,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Crizotinib,Thrombocytopenia,4,75,0.375,0.375,3.99,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Crizotinib,Gastrooesophageal reflux disease,6,75,4.390,4.390,13.88,0.500,0.000,0.000,9.134,PRR=4.39 (显著关联); χ²=13.9 (统计显著); 罕见+严重
Paclitaxel,Throat tightness,3,75,6.207,6.207,10.41,1.000,0.000,0.000,9.827,PRR=6.21 (显著关联); χ²=10.4 (统计显著); 罕见+严重
Paclitaxel,Chills,4,75,0.814,0.814,0.16,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Paclitaxel,Cardiac failure congestive,3,75,1.113,1.113,0.03,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Paclitaxel,Sarcoidosis,4,75,14.492,14.492,32.30,1.000,0.000,0.250,9.540,PRR=14.49 (显著关联); χ²=32.3 (统计显著); 罕见+严重
Paclitaxel,Atrial fibrillation,3,75,0.507,0.507,1.36,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Paclitaxel,Erythema,13,75,2.452,2.452,9.87,1.000,0.077,0.308,8.361,PRR=2.45 (显著关联); 严重事件率=100.0%; 罕见+严重
Paclitaxel,Hepatic function abnormal,4,75,1.868,1.868,1.46,1.000,0.750,0.500,9.540,死亡率=75.0%; 罕见+严重; 住院率=50.0%
Paclitaxel,Epistaxis,4,75,0.997,0.997,0.00,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Paclitaxel,Platelet count decreased,3,75,0.203,0.203,8.93,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Paclitaxel,Hearing impaired,4,75,6.819,6.819,15.50,1.000,0.000,0.250,9.540,PRR=6.82 (显著关联); χ²=15.5 (统计显著); 罕见+严重
Docetaxel,Skin toxicity,4,75,4.984,4.984,10.37,1.000,0.000,0.000,9.540,PRR=4.98 (显著关联); χ²=10.4 (统计显著); 罕见+严重
Docetaxel,Metastases to bone,7,75,3.098,3.098,8.58,1.000,0.143,0.286,8.980,PRR=3.10 (显著关联); 严重事件率=100.0%; 罕见+严重
Docetaxel,Renal failure acute,4,75,0.842,0.842,0.11,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Docetaxel,Gastrointestinal haemorrhage,3,75,1.369,1.369,0.27,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Docetaxel,Flushing,5,75,2.492,2.492,3.94,1.000,0.000,0.200,9.317,PRR=2.49 (显著关联); 严重事件率=100.0%; 罕见+严重
Docetaxel,Chest discomfort,8,75,2.927,2.927,8.80,1.000,0.125,0.250,8.847,PRR=2.93 (显著关联); 严重事件率=100.0%; 罕见+严重
Docetaxel,Skin hyperpigmentation,3,75,11.746,11.746,19.88,1.000,0.000,0.333,9.827,PRR=11.75 (显著关联); χ²=19.9 (统计显著); 罕见+严重
Docetaxel,Death,21,75,0.385,0.385,18.86,1.000,1.000,0.143,7.881,χ²=18.9 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Docetaxel,Thyroid cancer,3,75,41.115,41.115,45.24,1.000,0.000,0.000,9.827,PRR=41.12 (显著关联); χ²=45.2 (统计显著); 罕见+严重
Docetaxel,Weight decreased,3,75,0.299,0.299,4.69,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Docetaxel,Blood alkaline phosphatase increased,3,75,1.347,1.347,0.25,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Docetaxel,Hepatotoxicity,5,75,3.515,3.515,7.67,1.000,0.000,0.000,9.317,PRR=3.52 (显著关联); 严重事件率=100.0%; 罕见+严重
Docetaxel,Gastrointestinal disorder,5,75,2.175,2.175,2.83,1.000,0.200,0.400,9.317,PRR=2.18 (显著关联); 严重事件率=100.0%; 罕见+严重
Docetaxel,Porphyria non-acute,4,75,36.565,36.565,57.09,1.000,0.000,0.000,9.540,PRR=36.57 (显著关联); χ²=57.1 (统计显著); 罕见+严重
Docetaxel,Haematuria,5,75,2.175,2.175,2.83,1.000,0.000,0.200,9.317,PRR=2.18 (显著关联); 严重事件率=100.0%; 罕见+严重
Docetaxel,Hypoxia,4,75,1.231,1.231,0.16,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Docetaxel,Tenderness,3,75,11.746,11.746,19.88,1.000,0.000,0.333,9.827,PRR=11.75 (显著关联); χ²=19.9 (统计显著); 罕见+严重
Docetaxel,Recall phenomenon,4,75,36.565,36.565,57.09,1.000,0.000,0.000,9.540,PRR=36.57 (显著关联); χ²=57.1 (统计显著); 罕见+严重
Docetaxel,Cystitis haemorrhagic,4,75,9.140,9.140,20.93,1.000,0.000,0.000,9.540,PRR=9.14 (显著关联); χ²=20.9 (统计显著); 罕见+严重
Docetaxel,Hyperhidrosis,5,75,2.076,2.076,2.49,1.000,0.000,0.400,9.317,PRR=2.08 (显著关联); 严重事件率=100.0%; 罕见+严重
Docetaxel,Heart rate increased,3,75,1.080,1.080,0.02,0.667,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Docetaxel,Septic shock,4,75,1.153,1.153,0.07,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Docetaxel,Gingivitis,3,75,27.410,27.410,36.77,1.000,0.000,0.000,9.827,PRR=27.41 (显著关联); χ²=36.8 (统计显著); 罕见+严重
Docetaxel,Exposed bone in jaw,4,75,10.968,10.968,24.92,1.000,0.000,0.250,9.540,PRR=10.97 (显著关联); χ²=24.9 (统计显著); 罕见+严重
Docetaxel,Renal failure,3,75,0.396,0.396,2.62,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Docetaxel,Hyponatraemia,4,75,0.817,0.817,0.15,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Docetaxel,Pericardial effusion,5,75,2.247,2.247,3.07,1.000,0.200,0.400,9.317,PRR=2.25 (显著关联); 严重事件率=100.0%; 罕见+严重
Docetaxel,Osteoporosis,4,75,7.834,7.834,17.85,1.000,0.000,0.000,9.540,PRR=7.83 (显著关联); χ²=17.9 (统计显著); 罕见+严重
Docetaxel,Drug ineffective,4,75,0.410,0.410,3.20,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Docetaxel,Hyperthermia,3,75,11.746,11.746,19.88,1.000,0.000,0.000,9.827,PRR=11.75 (显著关联); χ²=19.9 (统计显著); 罕见+严重
Doxorubicin,Palmar-plantar erythrodysaesthesia syndrome,5,75,2.069,2.069,2.48,1.000,0.000,0.400,9.317,PRR=2.07 (显著关联); 严重事件率=100.0%; 罕见+严重
Doxorubicin,Muscular weakness,4,75,0.891,0.891,0.05,0.750,0.750,0.500,9.540,死亡率=75.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Pleural effusion,4,75,0.520,0.520,1.67,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Doxorubicin,Vertigo,3,75,1.991,1.991,1.33,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Doxorubicin,Fall,4,75,0.651,0.651,0.70,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Doxorubicin,Paraesthesia,3,75,1.111,1.111,0.03,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Doxorubicin,Platelet disorder,3,75,12.238,12.238,20.90,1.000,0.000,0.333,9.827,PRR=12.24 (显著关联); χ²=20.9 (统计显著); 罕见+严重
Doxorubicin,Neutrophil count abnormal,3,75,7.787,7.787,13.45,1.000,0.000,0.333,9.827,PRR=7.79 (显著关联); χ²=13.4 (统计显著); 罕见+严重
Doxorubicin,Renal failure acute,4,75,0.877,0.877,0.06,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Doxorubicin,Leukopenia,9,75,2.499,2.499,7.14,1.000,0.111,0.333,8.729,PRR=2.50 (显著关联); 严重事件率=100.0%; 罕见+严重
Doxorubicin,Chest pain,3,75,0.472,0.472,1.68,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Doxorubicin,Tachycardia,3,75,1.097,1.097,0.02,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Doxorubicin,Neutrophil count increased,3,75,9.518,9.518,16.54,1.000,0.000,0.333,9.827,PRR=9.52 (显著关联); χ²=16.5 (统计显著); 罕见+严重
Doxorubicin,Hypoaesthesia,3,75,0.814,0.814,0.12,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Doxorubicin,Urinary tract infection,4,75,0.581,0.581,1.14,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Haemorrhage,4,75,1.756,1.756,1.18,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Gastrointestinal haemorrhage,4,75,1.935,1.935,1.63,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Throat tightness,3,75,6.118,6.118,10.20,1.000,0.000,0.000,9.827,PRR=6.12 (显著关联); χ²=10.2 (统计显著); 罕见+严重
Doxorubicin,Paraesthesia oral,3,75,85.676,85.676,60.54,1.000,0.000,0.000,9.827,PRR=85.68 (显著关联); χ²=60.5 (统计显著); 罕见+严重
Carboplatin,Alpha 1 foetoprotein increased,3,75,73.304,73.304,51.31,1.000,0.000,0.000,9.827,PRR=73.30 (显著关联); χ²=51.3 (统计显著); 罕见+严重
Carboplatin,Proteinuria,5,75,2.143,2.143,2.68,1.000,0.000,0.200,9.317,PRR=2.14 (显著关联); 严重事件率=100.0%; 罕见+严重
Carboplatin,Neutrophil count abnormal,4,75,9.777,9.777,21.58,0.750,0.000,0.250,9.540,PRR=9.78 (显著关联); χ²=21.6 (统计显著); 罕见+严重
Carboplatin,Premature baby,3,75,12.216,12.216,19.76,1.000,0.000,0.000,9.827,PRR=12.22 (显著关联); χ²=19.8 (统计显著); 罕见+严重
Carboplatin,Exposure during pregnancy,3,75,9.162,9.162,15.22,1.000,0.000,0.000,9.827,PRR=9.16 (显著关联); χ²=15.2 (统计显著); 罕见+严重
Carboplatin,Hypoxia,4,75,1.097,1.097,0.03,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Carboplatin,Body height below normal,4,75,24.444,24.444,43.12,1.000,0.000,0.000,9.540,PRR=24.44 (显著关联); χ²=43.1 (统计显著); 罕见+严重
Carboplatin,Sarcoidosis,4,75,12.221,12.221,26.34,1.000,0.000,0.250,9.540,PRR=12.22 (显著关联); χ²=26.3 (统计显著); 罕见+严重
Carboplatin,Fall,3,75,0.415,0.415,2.32,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Carboplatin,Interstitial lung disease,4,75,0.594,0.594,1.03,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Hypophagia,3,75,1.308,1.308,0.20,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Carboplatin,Peripheral coldness,3,75,7.329,7.329,12.10,1.000,0.000,0.000,9.827,PRR=7.33 (显著关联); χ²=12.1 (统计显著); 罕见+严重
Carboplatin,Chills,3,75,0.511,0.511,1.31,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Carboplatin,Septic shock,3,75,0.762,0.762,0.21,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Carboplatin,Cerebrovascular accident,4,75,1.017,1.017,0.00,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Carboplatin,Neutropenic sepsis,4,75,1.656,1.656,0.93,1.000,0.750,0.500,9.540,死亡率=75.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Rectal haemorrhage,3,75,1.308,1.308,0.20,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Carboplatin,Hearing impaired,4,75,5.750,5.750,12.18,1.000,0.000,0.250,9.540,PRR=5.75 (显著关联); χ²=12.2 (统计显著); 罕见+严重
Carboplatin,Oedema peripheral,3,75,0.494,0.494,1.46,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Carboplatin,Lung infection,3,75,1.181,1.181,0.08,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Carboplatin,Malignant glioma,3,75,73.304,73.304,51.31,1.000,0.000,0.000,9.827,PRR=73.30 (显著关联); χ²=51.3 (统计显著); 罕见+严重
Carboplatin,Skin exfoliation,5,75,2.002,2.002,2.22,1.000,0.000,0.400,9.317,PRR=2.00 (显著关联); 严重事件率=100.0%; 罕见+严重
Carboplatin,Metastases to central nervous system,3,75,0.665,0.665,0.47,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Cisplatin,Hypoxia,4,75,1.226,1.226,0.15,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Alanine aminotransferase increased,4,75,0.609,0.609,0.95,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Body height below normal,3,75,16.385,16.385,26.08,1.000,0.000,0.000,9.827,PRR=16.38 (显著关联); χ²=26.1 (统计显著); 罕见+严重
Cisplatin,Syncope,4,75,1.136,1.136,0.06,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Blood glucose increased,3,75,1.780,1.780,0.93,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Cisplatin,Ototoxicity,3,75,27.309,27.309,36.61,1.000,0.000,0.333,9.827,PRR=27.31 (显著关联); χ²=36.6 (统计显著); 罕见+严重
Cisplatin,Metastases to skin,4,75,7.805,7.805,17.76,1.000,0.000,0.000,9.540,PRR=7.80 (显著关联); χ²=17.8 (统计显著); 罕见+严重
Cisplatin,Intestinal perforation,3,75,1.705,1.705,0.79,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Hypophagia,3,75,1.462,1.462,0.40,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Abdominal distension,3,75,0.951,0.951,0.01,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Cisplatin,Myocardial infarction,3,75,0.974,0.974,0.00,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Abdominal discomfort,4,75,0.808,0.808,0.17,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Musculoskeletal pain,3,75,1.574,1.574,0.57,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Cisplatin,Hypersensitivity,4,75,0.768,0.768,0.26,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Cisplatin,Metastases to ovary,3,75,20.481,20.481,30.59,1.000,0.000,0.000,9.827,PRR=20.48 (显著关联); χ²=30.6 (统计显著); 罕见+严重
Cisplatin,Metastases to bladder,3,75,27.309,27.309,36.61,1.000,0.000,0.000,9.827,PRR=27.31 (显著关联); χ²=36.6 (统计显著); 罕见+严重
Cisplatin,Anxiety,3,75,0.818,0.818,0.11,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Cisplatin,Retinopathy,3,75,11.703,11.703,19.80,1.000,0.000,0.000,9.827,PRR=11.70 (显著关联); χ²=19.8 (统计显著); 罕见+严重
Lenalidomide,Death,52,75,1.703,1.703,13.25,1.000,1.000,0.135,6.975,χ²=13.3 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Lenalidomide,Amnesia,3,75,5.782,5.782,10.29,1.000,0.000,0.000,9.827,PRR=5.78 (显著关联); χ²=10.3 (统计显著); 罕见+严重
Lenalidomide,Septic shock,3,75,1.444,1.444,0.39,1.000,1.000,0.667,9.827,死亡率=100.0%; 罕见+严重; 住院率=66.7%
Lenalidomide,Respiratory failure,4,75,1.232,1.232,0.17,1.000,0.750,0.500,9.540,死亡率=75.0%; 罕见+严重; 住院率=50.0%
Lenalidomide,Febrile neutropenia,4,75,0.383,0.383,3.80,1.000,1.000,1.000,9.540,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Lenalidomide,Abdominal pain,4,75,0.540,0.540,1.50,1.000,0.750,0.750,9.540,死亡率=75.0%; 罕见+严重; 住院率=75.0%
Lenalidomide,Urinary tract infection,4,75,0.942,0.942,0.01,0.750,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Lenalidomide,Rectal adenocarcinoma,3,75,19.832,19.832,36.66,1.000,0.000,0.000,9.827,PRR=19.83 (显著关联); χ²=36.7 (统计显著); 罕见+严重
Lenalidomide,Dry skin,6,75,2.120,2.120,3.30,1.000,0.000,0.000,9.134,PRR=2.12 (显著关联); 严重事件率=100.0%; 罕见+严重
Lenalidomide,Dementia,3,75,23.137,23.137,41.35,1.000,0.000,0.333,9.827,PRR=23.14 (显著关联); χ²=41.4 (统计显著); 罕见+严重
Lenalidomide,Hypersensitivity,7,75,2.333,2.333,4.92,1.000,0.143,0.143,8.980,PRR=2.33 (显著关联); 严重事件率=100.0%; 罕见+严重
Lenalidomide,Renal failure acute,3,75,1.057,1.057,0.01,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Lenalidomide,Blood creatinine increased,4,75,1.015,1.015,0.00,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Lenalidomide,Anxiety,5,75,2.361,2.361,3.63,1.000,0.000,0.400,9.317,PRR=2.36 (显著关联); 严重事件率=100.0%; 罕见+严重
Lenalidomide,Rhinorrhoea,4,75,4.629,4.629,10.08,1.000,0.000,0.250,9.540,PRR=4.63 (显著关联); χ²=10.1 (统计显著); 罕见+严重
Pomalidomide,Dysphagia,3,75,1.067,1.067,0.01,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Pomalidomide,Confusional state,6,75,2.096,2.096,3.22,0.667,0.000,0.167,9.134,PRR=2.10 (显著关联); 严重事件率=66.7%; 罕见+严重
Pomalidomide,Somnolence,6,75,3.932,3.932,11.88,0.500,0.000,0.167,9.134,PRR=3.93 (显著关联); χ²=11.9 (统计显著); 罕见+严重
Pomalidomide,Light chain analysis increased,3,75,77.551,77.551,88.70,1.000,0.000,0.333,9.827,PRR=77.55 (显著关联); χ²=88.7 (统计显著); 罕见+严重
Pomalidomide,Osteomyelitis,3,75,7.047,7.047,13.40,1.000,0.000,0.333,9.827,PRR=7.05 (显著关联); χ²=13.4 (统计显著); 罕见+严重
Pomalidomide,Urticaria,5,75,3.695,3.695,8.95,0.800,0.000,0.400,9.317,PRR=3.70 (显著关联); 严重事件率=80.0%; 罕见+严重
Pomalidomide,Back pain,10,75,2.205,2.205,6.11,0.700,0.100,0.200,8.623,PRR=2.21 (显著关联); 严重事件率=70.0%; 罕见+严重
Pomalidomide,Plasmacytoma,3,75,22.155,22.155,41.49,1.000,0.000,0.333,9.827,PRR=22.16 (显著关联); χ²=41.5 (统计显著); 罕见+严重
Bortezomib,Back pain,4,75,0.544,0.544,1.45,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Bortezomib,General physical health deterioration,4,75,0.894,0.894,0.05,1.000,0.500,1.000,9.540,死亡率=50.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Cardiomegaly,3,75,14.108,14.108,24.77,1.000,0.000,0.333,9.827,PRR=14.11 (显著关联); χ²=24.8 (统计显著); 罕见+严重
Bortezomib,Gastrooesophageal reflux disease,3,75,1.566,1.566,0.57,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Bortezomib,Bone marrow failure,8,75,2.637,2.637,7.26,1.000,0.125,0.375,8.847,PRR=2.64 (显著关联); 严重事件率=100.0%; 罕见+严重
Bortezomib,Cough,4,75,0.540,0.540,1.49,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Bortezomib,Gastrointestinal toxicity,4,75,13.175,13.175,31.11,1.000,0.000,0.000,9.540,PRR=13.18 (显著关联); χ²=31.1 (统计显著); 罕见+严重
Bortezomib,Peripheral motor neuropathy,3,75,8.977,8.977,16.18,1.000,0.000,0.000,9.827,PRR=8.98 (显著关联); χ²=16.2 (统计显著); 罕见+严重
Bortezomib,B-cell lymphoma,3,75,10.973,10.973,19.75,1.000,0.000,0.000,9.827,PRR=10.97 (显著关联); χ²=19.8 (统计显著); 罕见+严重
Carfilzomib,White blood cell count decreased,4,75,0.553,0.553,1.39,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Carfilzomib,General physical health deterioration,3,75,0.961,0.961,0.00,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Carfilzomib,Syncope,3,75,1.467,1.467,0.42,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Carfilzomib,Pain in extremity,4,75,0.920,0.920,0.03,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Insomnia,3,75,0.856,0.856,0.07,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Carfilzomib,Decreased appetite,3,75,0.253,0.253,6.37,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Carfilzomib,Dyspepsia,3,75,1.342,1.342,0.25,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Carfilzomib,Constipation,3,75,0.335,0.335,3.81,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Carfilzomib,Thrombosis,3,75,1.530,1.530,0.52,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Carfilzomib,Hypotension,4,75,0.902,0.902,0.04,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Somnolence,3,75,1.736,1.736,0.88,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Venetoclax,Cardiac failure,3,75,1.264,1.264,0.16,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Venetoclax,Myocardial infarction,3,75,1.415,1.415,0.34,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Venetoclax,Oedema,4,75,1.982,1.982,1.80,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Venetoclax,Insomnia,3,75,0.715,0.715,0.33,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Venetoclax,Headache,3,75,0.342,0.342,3.65,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Venetoclax,Urinary tract infection,4,75,0.807,0.807,0.17,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Venetoclax,General physical health deterioration,4,75,1.077,1.077,0.02,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Venetoclax,Cardiac arrest,3,75,1.918,1.918,1.22,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Venetoclax,Muscular weakness,4,75,1.238,1.238,0.17,1.000,0.750,1.000,9.540,死亡率=75.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Neutrophil count decreased,11,75,2.370,2.370,7.82,0.818,0.182,0.273,8.528,PRR=2.37 (显著关联); 严重事件率=81.8%; 罕见+严重
Ibrutinib,Myalgia,3,75,0.773,0.773,0.19,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Vitreous haemorrhage,3,75,24.989,24.989,38.25,1.000,0.000,0.333,9.827,PRR=24.99 (显著关联); χ²=38.3 (统计显著); 罕见+严重
Ibrutinib,Septic shock,3,75,1.039,1.039,0.00,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Renal impairment,3,75,0.867,0.867,0.06,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Ibrutinib,Pain in extremity,4,75,0.645,0.645,0.74,0.750,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Ibrutinib,Cerebrovascular accident,3,75,1.029,1.029,0.00,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Ibrutinib,Hypoxia,4,75,1.496,1.496,0.61,1.000,0.500,1.000,9.540,死亡率=50.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Mucosal inflammation,3,75,0.853,0.853,0.07,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Ibrutinib,Blood creatinine increased,3,75,0.544,0.544,1.09,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Creatinine renal clearance decreased,3,75,11.105,11.105,20.05,1.000,0.000,0.000,9.827,PRR=11.11 (显著关联); χ²=20.0 (统计显著); 罕见+严重
Ibrutinib,Gait disturbance,4,75,1.280,1.280,0.23,0.750,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Ibrutinib,Lung disorder,3,75,1.585,1.585,0.60,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Olaparib,Drug intolerance,8,75,3.066,3.066,9.68,0.750,0.000,0.250,8.847,PRR=3.07 (显著关联); 严重事件率=75.0%; 罕见+严重
Olaparib,Small intestinal obstruction,3,75,1.779,1.779,0.93,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Olaparib,Joint swelling,7,75,3.920,3.920,12.91,0.429,0.000,0.143,8.980,PRR=3.92 (显著关联); χ²=12.9 (统计显著); 罕见+严重
Olaparib,Carbohydrate antigen 125 increased,6,75,2.267,2.267,3.79,0.833,0.000,0.167,9.134,PRR=2.27 (显著关联); 严重事件率=83.3%; 罕见+严重
Olaparib,Myalgia,9,75,2.130,2.130,4.83,0.667,0.000,0.222,8.729,PRR=2.13 (显著关联); 严重事件率=66.7%; 罕见+严重
Olaparib,Body height decreased,4,75,29.101,29.101,52.35,0.500,0.000,0.250,9.540,PRR=29.10 (显著关联); χ²=52.3 (统计显著); 罕见+严重
Olaparib,Gastrointestinal disorder,7,75,3.341,3.341,9.91,0.571,0.000,0.143,8.980,PRR=3.34 (显著关联); 严重事件率=57.1%; 罕见+严重
Olaparib,Blood creatinine increased,14,75,2.374,2.374,9.85,0.571,0.071,0.286,8.287,PRR=2.37 (显著关联); 严重事件率=57.1%; 罕见+严重
Olaparib,Gastrooesophageal reflux disease,4,75,1.875,1.875,1.48,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Olaparib,Hypomagnesaemia,3,75,1.301,1.301,0.19,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Olaparib,Bone marrow failure,7,75,2.017,2.017,3.22,1.000,0.143,0.286,8.980,PRR=2.02 (显著关联); 严重事件率=100.0%; 罕见+严重
Olaparib,Intentional product use issue,4,75,16.628,16.628,36.06,1.000,0.000,0.250,9.540,PRR=16.63 (显著关联); χ²=36.1 (统计显著); 罕见+严重
Olaparib,Gingival pain,3,75,29.085,29.085,39.26,1.000,0.000,0.333,9.827,PRR=29.09 (显著关联); χ²=39.3 (统计显著); 罕见+严重
Olaparib,Flatulence,6,75,3.175,3.175,7.76,0.833,0.000,0.333,9.134,PRR=3.18 (显著关联); 严重事件率=83.3%; 罕见+严重
Olaparib,Abdominal discomfort,14,75,3.270,3.270,18.99,0.500,0.143,0.214,8.287,PRR=3.27 (显著关联); χ²=19.0 (统计显著); 罕见+严重
Olaparib,Metastases to liver,3,75,1.076,1.076,0.01,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Olaparib,Sepsis,4,75,0.411,0.411,3.20,1.000,0.500,1.000,9.540,死亡率=50.0%; 罕见+严重; 住院率=100.0%
Olaparib,Urinary tract infection,4,75,0.592,0.592,1.06,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Olaparib,Upper-airway cough syndrome,3,75,29.085,29.085,39.26,0.667,0.000,0.000,9.827,PRR=29.09 (显著关联); χ²=39.3 (统计显著); 罕见+严重
Olaparib,Full blood count decreased,7,75,2.717,2.717,6.68,0.571,0.143,0.000,8.980,PRR=2.72 (显著关联); 严重事件率=57.1%; 罕见+严重
Olaparib,Vasculitis,4,75,8.313,8.313,19.30,1.000,0.000,0.000,9.540,PRR=8.31 (显著关联); χ²=19.3 (统计显著); 罕见+严重
Olaparib,Adverse drug reaction,3,75,1.585,1.585,0.59,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Rucaparib,Hepatic enzyme increased,11,75,3.136,3.136,13.06,0.455,0.000,0.273,8.528,PRR=3.14 (显著关联); χ²=13.1 (统计显著); 罕见+严重
Rucaparib,Therapy cessation,8,75,5.827,5.827,23.40,0.500,0.000,0.250,8.847,PRR=5.83 (显著关联); χ²=23.4 (统计显著); 罕见+严重
Rucaparib,Feeling abnormal,13,75,3.280,3.280,16.70,0.308,0.000,0.154,8.361,PRR=3.28 (显著关联); χ²=16.7 (统计显著); 罕见+严重
Rucaparib,Hypotension,4,75,0.373,0.373,3.92,0.750,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Rucaparib,Hypophagia,3,75,1.051,1.051,0.01,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Rucaparib,Adverse event,16,75,5.533,5.533,43.84,0.500,0.000,0.312,8.153,PRR=5.53 (显著关联); χ²=43.8 (统计显著); 罕见+严重
Rucaparib,General physical health deterioration,3,75,0.397,0.397,2.55,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Rucaparib,Flatulence,12,75,4.821,4.821,27.63,0.417,0.000,0.167,8.441,PRR=4.82 (显著关联); χ²=27.6 (统计显著); 罕见+严重
Rucaparib,Alanine aminotransferase increased,17,75,2.015,2.015,7.44,0.647,0.000,0.118,8.093,PRR=2.02 (显著关联); 严重事件率=64.7%; 罕见+严重
Rucaparib,Renal function test abnormal,5,75,19.652,19.652,42.03,0.400,0.000,0.200,9.317,PRR=19.65 (显著关联); χ²=42.0 (统计显著); 罕见+严重
Rucaparib,Liver function test abnormal,3,75,1.436,1.436,0.35,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Rucaparib,Somnolence,12,75,3.235,3.235,15.05,0.417,0.000,0.167,8.441,PRR=3.23 (显著关联); χ²=15.1 (统计显著); 罕见+严重
Rucaparib,Nervousness,5,75,9.825,9.825,25.09,0.400,0.200,0.000,9.317,PRR=9.82 (显著关联); χ²=25.1 (统计显著); 罕见+严重
Rucaparib,Early satiety,3,75,29.457,29.457,31.35,0.333,0.000,0.000,9.827,PRR=29.46 (显著关联); χ²=31.4 (统计显著); 罕见+严重
Niraparib,Syncope,4,75,0.713,0.713,0.42,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Niraparib,Pericardial effusion,4,75,1.104,1.104,0.03,1.000,0.500,1.000,9.540,死亡率=50.0%; 罕见+严重; 住院率=100.0%
Niraparib,Neutropenic sepsis,3,75,0.855,0.855,0.07,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Niraparib,Amnesia,5,75,3.894,3.894,8.26,1.000,0.200,0.200,9.317,PRR=3.89 (显著关联); 严重事件率=100.0%; 罕见+严重
Niraparib,Cerebrovascular accident,3,75,0.529,0.529,1.15,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Niraparib,Tremor,8,75,2.077,2.077,3.75,0.875,0.000,0.250,8.847,PRR=2.08 (显著关联); 严重事件率=87.5%; 罕见+严重
Niraparib,Vision blurred,3,75,0.518,0.518,1.23,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Niraparib,Hypoaesthesia,4,75,0.658,0.658,0.65,0.750,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Niraparib,Hypoxia,4,75,0.769,0.769,0.25,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Niraparib,Dyspnoea exertional,6,75,2.856,2.856,5.84,1.000,0.167,0.167,9.134,PRR=2.86 (显著关联); 严重事件率=100.0%; 罕见+严重
Niraparib,Balance disorder,6,75,2.284,2.284,3.60,1.000,0.167,0.333,9.134,PRR=2.28 (显著关联); 严重事件率=100.0%; 罕见+严重
Niraparib,Platelet disorder,3,75,7.340,7.340,10.85,0.667,0.000,0.333,9.827,PRR=7.34 (显著关联); χ²=10.9 (统计显著); 罕见+严重
Niraparib,Hot flush,5,75,3.059,3.059,5.54,0.600,0.000,0.000,9.317,PRR=3.06 (显著关联); 严重事件率=60.0%; 罕见+严重
Niraparib,Product dose omission,4,75,6.229,6.229,12.15,0.500,0.000,0.000,9.540,PRR=6.23 (显著关联); χ²=12.1 (统计显著); 罕见+严重
Niraparib,Inappropriate schedule of product administration,4,75,6.229,6.229,12.15,0.750,0.000,0.250,9.540,PRR=6.23 (显著关联); χ²=12.1 (统计显著); 罕见+严重
Niraparib,Loss of personal independence in daily activities,3,75,10.276,10.276,14.82,0.667,0.000,0.000,9.827,PRR=10.28 (显著关联); χ²=14.8 (统计显著); 罕见+严重
Niraparib,Blood potassium decreased,5,75,2.089,2.089,2.38,0.800,0.000,0.200,9.317,PRR=2.09 (显著关联); 严重事件率=80.0%; 罕见+严重
Niraparib,Crying,3,75,12.846,12.846,17.67,0.333,0.000,0.000,9.827,PRR=12.85 (显著关联); χ²=17.7 (统计显著); 罕见+严重
Niraparib,Cardiac failure congestive,3,75,0.658,0.658,0.48,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Talazoparib,Epistaxis,3,75,1.187,1.187,0.08,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Talazoparib,Death,52,75,1.707,1.707,13.39,1.000,1.000,0.077,6.975,χ²=13.4 (统计显著); 死亡率=100.0%; 严重事件率=100.0%
Talazoparib,Chest pain,4,75,1.029,1.029,0.00,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Talazoparib,Alopecia,12,75,3.370,3.370,18.02,0.417,0.000,0.083,8.441,PRR=3.37 (显著关联); χ²=18.0 (统计显著); 罕见+严重
Talazoparib,Product use issue,7,75,3.784,3.784,12.88,0.429,0.000,0.000,8.980,PRR=3.78 (显著关联); χ²=12.9 (统计显著); 罕见+严重
Talazoparib,Therapy cessation,7,75,11.634,11.634,52.94,0.429,0.000,0.286,8.980,PRR=11.63 (显著关联); χ²=52.9 (统计显著); 罕见+严重
Talazoparib,Decreased immune responsiveness,3,75,34.798,34.798,54.94,1.000,0.000,0.000,9.827,PRR=34.80 (显著关联); χ²=54.9 (统计显著); 罕见+严重
Talazoparib,Acute kidney injury,3,75,1.197,1.197,0.09,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Talazoparib,Blood count abnormal,5,75,3.054,3.054,6.31,0.600,0.000,0.200,9.317,PRR=3.05 (显著关联); 严重事件率=60.0%; 罕见+严重
Talazoparib,Hypokalaemia,4,75,1.932,1.932,1.68,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Talazoparib,Back pain,3,75,0.573,0.573,0.92,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Talazoparib,Hyponatraemia,3,75,1.029,1.029,0.00,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Talazoparib,Neoplasm recurrence,3,75,6.050,6.050,10.92,0.333,0.000,0.000,9.827,PRR=6.05 (显著关联); χ²=10.9 (统计显著); 罕见+严重
Talazoparib,Musculoskeletal discomfort,3,75,11.598,11.598,22.69,1.000,0.000,0.000,9.827,PRR=11.60 (显著关联); χ²=22.7 (统计显著); 罕见+严重
Palbociclib,Mucosal inflammation,9,75,2.840,2.840,9.57,0.667,0.111,0.111,8.729,PRR=2.84 (显著关联); 严重事件率=66.7%; 罕见+严重
Palbociclib,Bone pain,5,75,2.158,2.158,2.83,0.600,0.000,0.400,9.317,PRR=2.16 (显著关联); 严重事件率=60.0%; 罕见+严重
Palbociclib,Disease progression,41,75,1.794,1.794,12.78,0.561,0.293,0.220,7.212,χ²=12.8 (统计显著); 死亡率=29.3%; 严重事件率=56.1%
Palbociclib,Neutrophil count decreased,11,75,2.487,2.487,8.79,0.909,0.000,0.273,8.528,PRR=2.49 (显著关联); 严重事件率=90.9%; 罕见+严重
Palbociclib,Ascites,3,75,1.126,1.126,0.04,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Palbociclib,Neoplasm progression,7,75,2.247,2.247,4.39,0.857,0.000,0.286,8.980,PRR=2.25 (显著关联); 严重事件率=85.7%; 罕见+严重
Palbociclib,Staphylococcal infection,3,75,6.168,6.168,10.71,1.000,0.000,0.000,9.827,PRR=6.17 (显著关联); χ²=10.7 (统计显著); 罕见+严重
Palbociclib,Metastases to bone,5,75,2.732,2.732,4.93,1.000,0.000,0.000,9.317,PRR=2.73 (显著关联); 严重事件率=100.0%; 罕见+严重
Palbociclib,Oral pain,6,75,5.528,5.528,18.60,0.500,0.000,0.167,9.134,PRR=5.53 (显著关联); χ²=18.6 (统计显著); 罕见+严重
Palbociclib,Muscle spasms,13,75,3.511,3.511,20.41,0.462,0.000,0.231,8.361,PRR=3.51 (显著关联); χ²=20.4 (统计显著); 罕见+严重
Palbociclib,Atrial fibrillation,3,75,0.611,0.611,0.70,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Palbociclib,Blood count abnormal,10,75,4.940,4.940,26.57,0.400,0.000,0.200,8.623,PRR=4.94 (显著关联); χ²=26.6 (统计显著); 罕见+严重
Palbociclib,Leukopenia,7,75,2.332,2.332,4.82,1.000,0.143,0.000,8.980,PRR=2.33 (显著关联); 严重事件率=100.0%; 罕见+严重
Palbociclib,Glossodynia,3,75,9.534,9.534,17.47,0.667,0.000,0.000,9.827,PRR=9.53 (显著关联); χ²=17.5 (统计显著); 罕见+严重
Palbociclib,Skin lesion,4,75,6.359,6.359,14.81,0.500,0.000,0.000,9.540,PRR=6.36 (显著关联); χ²=14.8 (统计显著); 罕见+严重
Palbociclib,Paraesthesia,9,75,4.444,4.444,20.57,0.444,0.000,0.000,8.729,PRR=4.44 (显著关联); χ²=20.6 (统计显著); 罕见+严重
Palbociclib,Infection,4,75,0.648,0.648,0.72,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Palbociclib,Nystagmus,3,75,52.445,52.445,58.75,1.000,0.000,0.000,9.827,PRR=52.44 (显著关联); χ²=58.8 (统计显著); 罕见+严重
Palbociclib,Dyslipidaemia,3,75,52.445,52.445,58.75,1.000,0.000,0.000,9.827,PRR=52.44 (显著关联); χ²=58.8 (统计显著); 罕见+严重
Palbociclib,Dyspepsia,3,75,0.988,0.988,0.00,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Palbociclib,Pain of skin,3,75,8.067,8.067,14.64,0.333,0.000,0.000,9.827,PRR=8.07 (显著关联); χ²=14.6 (统计显著); 罕见+严重
Ribociclib,Alanine aminotransferase increased,8,75,2.146,2.146,4.54,0.875,0.000,0.250,8.847,PRR=2.15 (显著关联); 严重事件率=87.5%; 罕见+严重
Ribociclib,Aspartate aminotransferase increased,8,75,2.290,2.290,5.38,0.750,0.000,0.250,8.847,PRR=2.29 (显著关联); 严重事件率=75.0%; 罕见+严重
Ribociclib,Febrile neutropenia,4,75,0.388,0.388,3.69,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Ribociclib,Thrombocytopenia,4,75,0.401,0.401,3.43,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Ribociclib,Tremor,5,75,3.399,3.399,7.69,0.600,0.000,0.200,9.317,PRR=3.40 (显著关联); 严重事件率=60.0%; 罕见+严重
Ribociclib,Hepatic enzyme increased,12,75,8.329,8.329,63.66,0.500,0.000,0.167,8.441,PRR=8.33 (显著关联); χ²=63.7 (统计显著); 罕见+严重
Ribociclib,Inappropriate schedule of drug administration,7,75,12.193,12.193,55.56,0.429,0.143,0.000,8.980,PRR=12.19 (显著关联); χ²=55.6 (统计显著); 罕见+严重
Ribociclib,Pulmonary embolism,4,75,0.935,0.935,0.02,1.000,0.750,1.000,9.540,死亡率=75.0%; 罕见+严重; 住院率=100.0%
Ribociclib,Liver function test increased,6,75,16.587,16.587,63.25,0.333,0.000,0.000,9.134,PRR=16.59 (显著关联); χ²=63.3 (统计显著); 罕见+严重
Ribociclib,Sinusitis,5,75,4.601,4.601,12.50,0.400,0.000,0.200,9.317,PRR=4.60 (显著关联); χ²=12.5 (统计显著); 罕见+严重
Ribociclib,Atrial fibrillation,4,75,1.101,1.101,0.04,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Ribociclib,General physical health deterioration,3,75,0.948,0.948,0.01,1.000,1.000,1.000,9.827,死亡率=100.0%; 罕见+严重; 住院率=100.0%
Abemaciclib,Pneumonia,4,75,0.320,0.320,5.52,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Abemaciclib,Blood creatinine increased,13,75,3.278,3.278,18.45,0.462,0.000,0.077,8.361,PRR=3.28 (显著关联); χ²=18.5 (统计显著); 罕见+严重
Abemaciclib,White blood cell count decreased,16,75,2.114,2.114,8.59,0.750,0.000,0.312,8.153,PRR=2.11 (显著关联); 严重事件率=75.0%; 罕见+严重
Abemaciclib,Psoriasis,3,75,14.468,14.468,27.50,1.000,0.000,0.000,9.827,PRR=14.47 (显著关联); χ²=27.5 (统计显著); 罕见+严重
Abemaciclib,Retching,6,75,8.417,8.417,31.94,0.333,0.000,0.167,9.134,PRR=8.42 (显著关联); χ²=31.9 (统计显著); 罕见+严重
Vemurafenib,General physical health deterioration,3,75,0.722,0.722,0.30,1.000,0.333,1.000,9.827,死亡率=33.3%; 罕见+严重; 住院率=100.0%
Vemurafenib,Dry skin,4,75,1.072,1.072,0.02,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Vemurafenib,Dermatitis allergic,3,75,13.395,13.395,24.29,1.000,0.000,0.333,9.827,PRR=13.39 (显著关联); χ²=24.3 (统计显著); 罕见+严重
Vemurafenib,Dehydration,4,75,0.345,0.345,4.74,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Vemurafenib,Tachycardia,4,75,1.854,1.854,1.45,1.000,0.500,0.750,9.540,死亡率=50.0%; 罕见+严重; 住院率=75.0%
Vemurafenib,Dysphagia,10,75,2.594,2.594,8.80,0.700,0.100,0.400,8.623,PRR=2.59 (显著关联); 严重事件率=70.0%; 罕见+严重
Vemurafenib,Vision blurred,6,75,2.233,2.233,3.72,0.667,0.000,0.333,9.134,PRR=2.23 (显著关联); 严重事件率=66.7%; 罕见+严重
Vemurafenib,Retinal detachment,4,75,15.885,15.885,37.47,1.000,0.000,0.250,9.540,PRR=15.89 (显著关联); χ²=37.5 (统计显著); 罕见+严重
Vemurafenib,Hypertension,4,75,0.805,0.805,0.18,1.000,0.250,1.000,9.540,死亡率=25.0%; 罕见+严重; 住院率=100.0%
Vemurafenib,Acute kidney injury,4,75,1.241,1.241,0.17,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Vemurafenib,Eosinophil count increased,3,75,13.395,13.395,24.29,0.667,0.000,0.333,9.827,PRR=13.39 (显著关联); χ²=24.3 (统计显著); 罕见+严重
Vemurafenib,Radiation skin injury,4,75,23.829,23.829,50.92,0.500,0.000,0.000,9.540,PRR=23.83 (显著关联); χ²=50.9 (统计显著); 罕见+严重
Vemurafenib,Skin cancer,3,75,15.309,15.309,27.26,1.000,0.000,0.333,9.827,PRR=15.31 (显著关联); χ²=27.3 (统计显著); 罕见+严重
Vemurafenib,Stomatitis,4,75,0.774,0.774,0.25,1.000,0.500,0.500,9.540,死亡率=50.0%; 罕见+严重; 住院率=50.0%
Vemurafenib,Panniculitis,3,75,6.302,6.302,11.04,0.667,0.000,0.333,9.827,PRR=6.30 (显著关联); χ²=11.0 (统计显著); 罕见+严重
Vemurafenib,Hair texture abnormal,3,75,6.696,6.696,11.88,0.667,0.000,0.000,9.827,PRR=6.70 (显著关联); χ²=11.9 (统计显著); 罕见+严重
Vemurafenib,Confusional state,3,75,0.708,0.708,0.34,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Vemurafenib,Hypotension,3,75,0.506,0.506,1.38,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Vemurafenib,Cardiac failure congestive,3,75,1.372,1.372,0.28,1.000,0.667,1.000,9.827,死亡率=66.7%; 罕见+严重; 住院率=100.0%
Vemurafenib,Lymphadenopathy mediastinal,4,75,35.746,35.746,65.53,1.000,0.000,0.000,9.540,PRR=35.75 (显著关联); χ²=65.5 (统计显著); 罕见+严重
Dabrafenib,Septic shock,4,75,1.470,1.470,0.56,1.000,1.000,0.750,9.540,死亡率=100.0%; 罕见+严重; 住院率=75.0%
Dabrafenib,Renal failure acute,3,75,0.798,0.798,0.14,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Dabrafenib,Adverse drug reaction,6,75,4.036,4.036,11.88,0.500,0.167,0.167,9.134,PRR=4.04 (显著关联); χ²=11.9 (统计显著); 罕见+严重
Dabrafenib,Joint swelling,6,75,3.959,3.959,11.53,0.333,0.000,0.000,9.134,PRR=3.96 (显著关联); χ²=11.5 (统计显著); 罕见+严重
Dabrafenib,Pulmonary embolism,4,75,0.697,0.697,0.50,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Dabrafenib,Thrombosis,3,75,1.125,1.125,0.04,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Dabrafenib,Vasculitis,3,75,6.986,6.986,12.44,1.000,0.000,0.000,9.827,PRR=6.99 (显著关联); χ²=12.4 (统计显著); 罕见+严重
Dabrafenib,Chorioretinopathy,3,75,52.410,52.410,58.71,1.000,0.000,0.000,9.827,PRR=52.41 (显著关联); χ²=58.7 (统计显著); 罕见+严重
Dabrafenib,Influenza like illness,5,75,3.972,3.972,9.67,1.000,0.000,0.400,9.317,PRR=3.97 (显著关联); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Chest discomfort,4,75,1.768,1.768,1.23,0.750,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Dabrafenib,Bone pain,3,75,1.261,1.261,0.15,1.000,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Dabrafenib,Metastases to central nervous system,8,75,2.666,2.666,7.47,1.000,0.125,0.375,8.847,PRR=2.67 (显著关联); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Alopecia,12,75,2.533,2.533,9.98,0.917,0.083,0.083,8.441,PRR=2.53 (显著关联); 严重事件率=91.7%; 罕见+严重
Dabrafenib,Hair texture abnormal,4,75,9.321,9.321,22.74,0.750,0.000,0.000,9.540,PRR=9.32 (显著关联); χ²=22.7 (统计显著); 罕见+严重
Dabrafenib,Viral infection,3,75,6.164,6.164,10.70,0.667,0.000,0.000,9.827,PRR=6.16 (显著关联); χ²=10.7 (统计显著); 罕见+严重
Dabrafenib,Acute kidney injury,4,75,1.214,1.214,0.14,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Dabrafenib,Blood alkaline phosphatase increased,5,75,2.962,2.962,5.80,1.000,0.000,0.400,9.317,PRR=2.96 (显著关联); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Erythema nodosum,3,75,104.822,104.822,74.83,0.667,0.000,0.000,9.827,PRR=104.82 (显著关联); χ²=74.8 (统计显著); 罕见+严重
Dabrafenib,Somnolence,3,75,1.276,1.276,0.17,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Dabrafenib,Cardiac failure,4,75,1.501,1.501,0.62,1.000,0.250,0.750,9.540,死亡率=25.0%; 罕见+严重; 住院率=75.0%
Dabrafenib,Loss of consciousness,3,75,1.689,1.689,0.78,0.667,0.333,0.667,9.827,死亡率=33.3%; 罕见+严重; 住院率=66.7%
Dabrafenib,Myocardial infarction,3,75,1.246,1.246,0.14,1.000,0.667,0.667,9.827,死亡率=66.7%; 罕见+严重; 住院率=66.7%
Dabrafenib,Muscular weakness,4,75,1.090,1.090,0.03,1.000,0.250,0.500,9.540,死亡率=25.0%; 罕见+严重; 住院率=50.0%
Pembrolizumab,Malignant neoplasm progression,24,70,1.675,1.675,5.97,1.000,0.875,0.708,7.748,死亡率=87.5%; 严重事件率=100.0%; 住院率=70.8%
Pembrolizumab,Dyspnoea,20,70,1.491,1.491,2.98,0.850,0.350,0.850,7.930,死亡率=35.0%; 严重事件率=85.0%; 住院率=85.0%
Pembrolizumab,Hyperthyroidism,3,70,4.773,4.773,7.91,0.667,0.000,0.667,9.827,PRR=4.77 (显著关联); 罕见+严重; 住院率=66.7%
Pembrolizumab,Swelling face,3,70,2.767,2.767,3.11,1.000,0.000,0.667,9.827,PRR=2.77 (显著关联); 罕见+严重; 住院率=66.7%
Nivolumab,Lung infection,3,70,2.199,2.199,1.82,1.000,0.000,1.000,9.827,PRR=2.20 (显著关联); 罕见+严重; 住院率=100.0%
Nivolumab,Vomiting,19,70,1.024,1.024,0.01,1.000,0.211,1.000,7.982,死亡率=21.1%; 严重事件率=100.0%; 住院率=100.0%
Nivolumab,Hepatitis,3,70,3.030,3.030,3.73,1.000,0.000,0.667,9.827,PRR=3.03 (显著关联); 罕见+严重; 住院率=66.7%
Nivolumab,Rash maculo-papular,3,70,2.272,2.272,1.98,1.000,0.000,1.000,9.827,PRR=2.27 (显著关联); 罕见+严重; 住院率=100.0%
Nivolumab,Seizure,3,70,2.964,2.964,3.57,1.000,0.000,1.000,9.827,PRR=2.96 (显著关联); 罕见+严重; 住院率=100.0%
Atezolizumab,Cellulitis,4,70,4.328,4.328,9.31,1.000,0.000,0.750,9.540,PRR=4.33 (显著关联); 罕见+严重; 住院率=75.0%
Atezolizumab,Diverticulitis,3,70,4.298,4.298,6.91,1.000,0.000,1.000,9.827,PRR=4.30 (显著关联); 罕见+严重; 住院率=100.0%
Atezolizumab,Gait disturbance,4,70,2.204,2.204,2.47,1.000,0.000,0.500,9.540,PRR=2.20 (显著关联); 罕见+严重; 住院率=50.0%
Atezolizumab,Rectal haemorrhage,4,70,4.171,4.171,8.79,1.000,0.000,1.000,9.540,PRR=4.17 (显著关联); 罕见+严重; 住院率=100.0%
Atezolizumab,Blood alkaline phosphatase increased,3,70,2.817,2.817,3.28,1.000,0.000,0.667,9.827,PRR=2.82 (显著关联); 罕见+严重; 住院率=66.7%
Atezolizumab,Blood bilirubin increased,4,70,3.475,3.475,6.50,1.000,0.000,1.000,9.540,PRR=3.47 (显著关联); 罕见+严重; 住院率=100.0%
Atezolizumab,Leukopenia,4,70,2.122,2.122,2.23,1.000,0.000,0.500,9.540,PRR=2.12 (显著关联); 罕见+严重; 住院率=50.0%
Atezolizumab,Adrenal insufficiency,3,70,3.015,3.015,3.76,1.000,0.000,1.000,9.827,PRR=3.01 (显著关联); 罕见+严重; 住院率=100.0%
Atezolizumab,Musculoskeletal pain,3,70,3.305,3.305,4.46,0.667,0.000,0.667,9.827,PRR=3.31 (显著关联); 罕见+严重; 住院率=66.7%
Atezolizumab,Hepatotoxicity,3,70,4.193,4.193,6.65,1.000,0.000,1.000,9.827,PRR=4.19 (显著关联); 罕见+严重; 住院率=100.0%
Durvalumab,Hypocalcaemia,3,70,3.118,3.118,3.95,1.000,0.000,1.000,9.827,PRR=3.12 (显著关联); 罕见+严重; 住院率=100.0%
Durvalumab,Off label use,32,70,3.812,3.812,58.10,0.562,0.062,0.312,7.460,PRR=3.81 (显著关联); χ²=58.1 (统计显著); 严重事件率=56.2%
Durvalumab,Photosensitivity reaction,3,70,2.647,2.647,2.84,1.000,0.000,1.000,9.827,PRR=2.65 (显著关联); 罕见+严重; 住院率=100.0%
Durvalumab,Transaminases increased,3,70,2.093,2.093,1.60,1.000,0.000,1.000,9.827,PRR=2.09 (显著关联); 罕见+严重; 住院率=100.0%
Durvalumab,Gamma-glutamyltransferase increased,3,70,4.386,4.386,7.00,1.000,0.000,0.667,9.827,PRR=4.39 (显著关联); 罕见+严重; 住院率=66.7%
Ipilimumab,Fatigue,29,70,0.910,0.910,0.24,0.759,0.241,0.621,7.559,死亡率=24.1%; 严重事件率=75.9%; 住院率=62.1%
Ipilimumab,Transaminases increased,4,70,2.478,2.478,3.23,1.000,0.000,1.000,9.540,PRR=2.48 (显著关联); 罕见+严重; 住院率=100.0%
Ipilimumab,Gastritis,3,70,3.227,3.227,4.16,1.000,0.000,1.000,9.827,PRR=3.23 (显著关联); 罕见+严重; 住院率=100.0%
Ipilimumab,Hyperglycaemia,4,70,2.044,2.044,1.97,1.000,0.000,0.750,9.540,PRR=2.04 (显著关联); 罕见+严重; 住院率=75.0%
Ipilimumab,Haemorrhage intracranial,3,70,4.542,4.542,7.26,1.000,0.000,1.000,9.827,PRR=4.54 (显著关联); 罕见+严重; 住院率=100.0%
Trastuzumab,Nervous system disorder,4,70,4.142,4.142,8.00,0.750,0.000,0.500,9.540,PRR=4.14 (显著关联); 罕见+严重; 住院率=50.0%
Trastuzumab,Toxic skin eruption,3,70,4.413,4.413,6.59,1.000,0.000,0.667,9.827,PRR=4.41 (显著关联); 罕见+严重; 住院率=66.7%
Trastuzumab,Photosensitivity reaction,4,70,2.150,2.150,2.20,0.750,0.000,0.750,9.540,PRR=2.15 (显著关联); 罕见+严重; 住院率=75.0%
Bevacizumab,Diarrhoea,44,70,1.039,1.039,0.06,1.000,0.250,0.432,7.142,死亡率=25.0%; 严重事件率=100.0%; 住院率=43.2%
Bevacizumab,Hypertension,26,70,5.209,5.209,72.04,1.000,0.192,0.154,7.668,PRR=5.21 (显著关联); χ²=72.0 (统计显著); 严重事件率=100.0%
Bevacizumab,Angina pectoris,3,70,5.761,5.761,9.61,1.000,0.000,0.667,9.827,PRR=5.76 (显著关联); 罕见+严重; 住院率=66.7%
Bevacizumab,Sinus tachycardia,3,70,4.389,4.389,6.64,1.000,0.000,1.000,9.827,PRR=4.39 (显著关联); 罕见+严重; 住院率=100.0%
Bevacizumab,Proteinuria,22,70,17.077,17.077,205.29,1.000,0.045,0.136,7.835,PRR=17.08 (显著关联); χ²=205.3 (统计显著); 严重事件率=100.0%
Bevacizumab,Cystitis,3,70,2.710,2.710,2.87,1.000,0.000,0.667,9.827,PRR=2.71 (显著关联); 罕见+严重; 住院率=66.7%
Bevacizumab,Arrhythmia,3,70,3.291,3.291,4.18,1.000,0.000,1.000,9.827,PRR=3.29 (显著关联); 罕见+严重; 住院率=100.0%
Bevacizumab,Haemoptysis,3,70,2.303,2.303,1.99,1.000,0.000,0.667,9.827,PRR=2.30 (显著关联); 罕见+严重; 住院率=66.7%
Bevacizumab,Blood potassium decreased,3,70,2.143,2.143,1.65,1.000,0.000,1.000,9.827,PRR=2.14 (显著关联); 罕见+严重; 住院率=100.0%
Bevacizumab,Aphasia,3,70,4.190,4.190,6.20,1.000,0.000,0.667,9.827,PRR=4.19 (显著关联); 罕见+严重; 住院率=66.7%
Cetuximab,Infusion related reaction,36,70,24.646,24.646,558.03,0.806,0.028,0.139,7.342,PRR=24.65 (显著关联); χ²=558.0 (统计显著); 严重事件率=80.6%
Rituximab,Cholelithiasis,3,70,4.745,4.745,7.25,1.000,0.000,1.000,9.827,PRR=4.75 (显著关联); 罕见+严重; 住院率=100.0%
Rituximab,Vasculitis,3,70,5.378,5.378,8.57,1.000,0.000,0.667,9.827,PRR=5.38 (显著关联); 罕见+严重; 住院率=66.7%
Rituximab,Abscess,3,70,5.762,5.762,9.36,1.000,0.000,0.667,9.827,PRR=5.76 (显著关联); 罕见+严重; 住院率=66.7%
Rituximab,Sleep disorder,3,70,3.507,3.507,4.58,1.000,0.000,1.000,9.827,PRR=3.51 (显著关联); 罕见+严重; 住院率=100.0%
Rituximab,Influenza like illness,4,70,2.390,2.390,2.86,1.000,0.000,0.500,9.540,PRR=2.39 (显著关联); 罕见+严重; 住院率=50.0%
Rituximab,Hepatocellular injury,3,70,3.226,3.226,3.96,1.000,0.000,1.000,9.827,PRR=3.23 (显著关联); 罕见+严重; 住院率=100.0%
Rituximab,Drug hypersensitivity,3,70,3.102,3.102,3.69,0.667,0.000,0.667,9.827,PRR=3.10 (显著关联); 罕见+严重; 住院率=66.7%
Rituximab,Inflammation,3,70,3.507,3.507,4.58,1.000,0.000,1.000,9.827,PRR=3.51 (显著关联); 罕见+严重; 住院率=100.0%
Rituximab,Basal cell carcinoma,3,70,2.688,2.688,2.78,1.000,0.000,1.000,9.827,PRR=2.69 (显著关联); 罕见+严重; 住院率=100.0%
Rituximab,Cystitis,3,70,2.372,2.372,2.10,1.000,0.000,1.000,9.827,PRR=2.37 (显著关联); 罕见+严重; 住院率=100.0%
Rituximab,Arthritis,3,70,2.444,2.444,2.26,1.000,0.000,0.667,9.827,PRR=2.44 (显著关联); 罕见+严重; 住院率=66.7%
Rituximab,Clostridium difficile infection,3,70,2.372,2.372,2.10,1.000,0.000,1.000,9.827,PRR=2.37 (显著关联); 罕见+严重; 住院率=100.0%
Rituximab,Productive cough,4,70,3.362,3.362,5.67,1.000,0.000,0.750,9.540,PRR=3.36 (显著关联); 罕见+严重; 住院率=75.0%
Rituximab,Herpes zoster,4,70,2.445,2.445,3.01,1.000,0.000,0.500,9.540,PRR=2.44 (显著关联); 罕见+严重; 住院率=50.0%
Rituximab,Pulmonary hypertension,3,70,4.246,4.246,6.19,1.000,0.000,0.667,9.827,PRR=4.25 (显著关联); 罕见+严重; 住院率=66.7%
Epcoritamab,Dysphonia,3,70,3.085,3.085,3.78,1.000,0.000,0.667,9.827,PRR=3.09 (显著关联); 罕见+严重; 住院率=66.7%
Imatinib,Second primary malignancy,34,70,34.739,34.739,457.05,1.000,0.059,0.088,7.400,PRR=34.74 (显著关联); χ²=457.1 (统计显著); 严重事件率=100.0%
Imatinib,Gastrointestinal stromal tumour,25,70,330.737,330.737,579.17,1.000,0.120,0.040,7.707,PRR=330.74 (显著关联); χ²=579.2 (统计显著); 严重事件率=100.0%
Imatinib,Muscle spasms,26,70,5.870,5.870,81.55,0.962,0.038,0.115,7.668,PRR=5.87 (显著关联); χ²=81.6 (统计显著); 严重事件率=96.2%
Imatinib,Haematochezia,3,70,2.065,2.065,1.47,1.000,0.000,1.000,9.827,PRR=2.07 (显著关联); 罕见+严重; 住院率=100.0%
Imatinib,Rash generalised,4,70,2.275,2.275,2.53,1.000,0.000,0.500,9.540,PRR=2.28 (显著关联); 罕见+严重; 住院率=50.0%
Imatinib,Arthritis,4,70,3.272,3.272,5.39,1.000,0.000,0.500,9.540,PRR=3.27 (显著关联); 罕见+严重; 住院率=50.0%
Erlotinib,Vomiting,25,70,1.005,1.005,0.00,1.000,0.240,0.640,7.707,死亡率=24.0%; 严重事件率=100.0%; 住院率=64.0%
Erlotinib,Decreased appetite,25,70,1.576,1.576,4.76,1.000,0.280,0.520,7.707,死亡率=28.0%; 严重事件率=100.0%; 住院率=52.0%
Erlotinib,Malignant neoplasm progression,31,70,1.594,1.594,6.17,1.000,0.516,0.419,7.492,死亡率=51.6%; 严重事件率=100.0%; 住院率=41.9%
Erlotinib,Asthenia,19,70,1.260,1.260,0.93,1.000,0.316,0.474,7.982,死亡率=31.6%; 严重事件率=100.0%; 住院率=47.4%
Erlotinib,Nausea,26,70,0.629,0.629,5.19,0.923,0.269,0.423,7.668,死亡率=26.9%; 严重事件率=92.3%; 住院率=42.3%
Gefitinib,Nausea,20,70,0.495,0.495,9.52,0.950,0.250,0.450,7.930,死亡率=25.0%; 严重事件率=95.0%; 住院率=45.0%
Gefitinib,Condition aggravated,3,70,2.665,2.665,2.81,1.000,0.000,0.667,9.827,PRR=2.66 (显著关联); 罕见+严重; 住院率=66.7%
Gefitinib,Dyspnoea,23,70,1.292,1.292,1.38,0.957,0.565,0.565,7.791,死亡率=56.5%; 严重事件率=95.7%; 住院率=56.5%
Gefitinib,Decreased appetite,24,70,1.555,1.555,4.31,0.958,0.500,0.583,7.748,死亡率=50.0%; 严重事件率=95.8%; 住院率=58.3%
Gefitinib,Malignant neoplasm progression,108,70,6.835,6.835,405.99,1.000,0.148,0.176,6.244,PRR=6.83 (显著关联); χ²=406.0 (统计显著); 严重事件率=100.0%
Gefitinib,Vomiting,21,70,0.863,0.863,0.42,1.000,0.476,0.571,7.881,死亡率=47.6%; 严重事件率=100.0%; 住院率=57.1%
Gefitinib,Intentional product misuse,3,70,4.158,4.158,6.23,0.667,0.000,0.667,9.827,PRR=4.16 (显著关联); 罕见+严重; 住院率=66.7%
Gefitinib,Gastric ulcer,3,70,4.950,4.950,8.02,1.000,0.000,0.667,9.827,PRR=4.95 (显著关联); 罕见+严重; 住院率=66.7%
Gefitinib,Haematemesis,3,70,3.248,3.248,4.14,1.000,0.000,1.000,9.827,PRR=3.25 (显著关联); 罕见+严重; 住院率=100.0%
Osimertinib,Diarrhoea,50,70,1.361,1.361,4.23,0.800,0.300,0.440,7.014,死亡率=30.0%; 严重事件率=80.0%; 住院率=44.0%
Osimertinib,Decreased appetite,26,70,1.710,1.710,6.92,0.923,0.423,0.423,7.668,死亡率=42.3%; 严重事件率=92.3%; 住院率=42.3%
Osimertinib,Electrocardiogram QT prolonged,4,70,3.112,3.112,5.10,1.000,0.000,1.000,9.540,PRR=3.11 (显著关联); 罕见+严重; 住院率=100.0%
Crizotinib,Ileus,3,70,4.533,4.533,7.30,1.000,0.000,1.000,9.827,PRR=4.53 (显著关联); 罕见+严重; 住院率=100.0%
Paclitaxel,Diarrhoea,25,70,0.542,0.542,8.85,0.960,0.360,0.560,7.707,死亡率=36.0%; 严重事件率=96.0%; 住院率=56.0%
Paclitaxel,Dyspnoea,28,70,1.326,1.326,2.02,1.000,0.214,0.429,7.594,死亡率=21.4%; 严重事件率=100.0%; 住院率=42.9%
Paclitaxel,Febrile neutropenia,23,70,1.452,1.452,2.92,1.000,0.522,0.522,7.791,死亡率=52.2%; 严重事件率=100.0%; 住院率=52.2%
Paclitaxel,Nausea,29,70,0.605,0.605,6.78,0.966,0.207,0.448,7.559,死亡率=20.7%; 严重事件率=96.6%; 住院率=44.8%
Paclitaxel,Hypersensitivity,19,70,4.362,4.362,40.88,1.000,0.053,0.158,7.982,PRR=4.36 (显著关联); χ²=40.9 (统计显著); 严重事件率=100.0%
Paclitaxel,Vomiting,22,70,0.756,0.756,1.59,1.000,0.364,0.500,7.835,死亡率=36.4%; 严重事件率=100.0%; 住院率=50.0%
Paclitaxel,Blister,4,70,2.897,2.897,4.35,0.750,0.000,0.750,9.540,PRR=2.90 (显著关联); 罕见+严重; 住院率=75.0%
Paclitaxel,Skin ulcer,3,70,5.431,5.431,8.81,1.000,0.000,1.000,9.827,PRR=5.43 (显著关联); 罕见+严重; 住院率=100.0%
Paclitaxel,Blood pressure decreased,4,70,3.049,3.049,4.80,1.000,0.000,0.500,9.540,PRR=3.05 (显著关联); 罕见+严重; 住院率=50.0%
Paclitaxel,C-reactive protein increased,3,70,2.286,2.286,1.94,1.000,0.000,1.000,9.827,PRR=2.29 (显著关联); 罕见+严重; 住院率=100.0%
Paclitaxel,Cystitis,3,70,2.555,2.555,2.52,1.000,0.000,1.000,9.827,PRR=2.55 (显著关联); 罕见+严重; 住院率=100.0%
Paclitaxel,Rectal haemorrhage,4,70,2.106,2.106,2.09,1.000,0.000,1.000,9.540,PRR=2.11 (显著关联); 罕见+严重; 住院率=100.0%
Docetaxel,Vomiting,31,70,1.023,1.023,0.01,0.968,0.226,0.645,7.492,死亡率=22.6%; 严重事件率=96.8%; 住院率=64.5%
Docetaxel,Ejection fraction decreased,4,70,2.491,2.491,3.15,0.750,0.000,0.500,9.540,PRR=2.49 (显著关联); 罕见+严重; 住院率=50.0%
Docetaxel,Pneumonia,19,70,0.996,0.996,0.00,0.947,0.474,0.474,7.982,死亡率=47.4%; 严重事件率=94.7%; 住院率=47.4%
Docetaxel,Fatigue,26,70,0.541,0.541,9.23,0.962,0.231,0.500,7.668,死亡率=23.1%; 严重事件率=96.2%; 住院率=50.0%
Docetaxel,Pyrexia,22,70,0.758,0.758,1.56,1.000,0.227,0.682,7.835,死亡率=22.7%; 严重事件率=100.0%; 住院率=68.2%
Docetaxel,Respiratory tract infection,3,70,2.107,2.107,1.56,1.000,0.000,0.667,9.827,PRR=2.11 (显著关联); 罕见+严重; 住院率=66.7%
Docetaxel,Blister,3,70,2.004,2.004,1.35,1.000,0.000,1.000,9.827,PRR=2.00 (显著关联); 罕见+严重; 住院率=100.0%
Docetaxel,Osteomyelitis,3,70,3.736,3.736,5.09,1.000,0.000,0.667,9.827,PRR=3.74 (显著关联); 罕见+严重; 住院率=66.7%
Docetaxel,Visual acuity reduced,4,70,4.217,4.217,8.19,1.000,0.000,0.750,9.540,PRR=4.22 (显著关联); 罕见+严重; 住院率=75.0%
Docetaxel,Metastases to lymph nodes,4,70,3.132,3.132,5.01,1.000,0.000,0.500,9.540,PRR=3.13 (显著关联); 罕见+严重; 住院率=50.0%
Docetaxel,Hypoglycaemia,3,70,5.481,5.481,8.82,1.000,0.000,1.000,9.827,PRR=5.48 (显著关联); 罕见+严重; 住院率=100.0%
Docetaxel,Atelectasis,3,70,3.914,3.914,5.48,1.000,0.000,1.000,9.827,PRR=3.91 (显著关联); 罕见+严重; 住院率=100.0%
Docetaxel,Clostridium difficile infection,4,70,3.322,3.322,5.57,1.000,0.000,1.000,9.540,PRR=3.32 (显著关联); 罕见+严重; 住院率=100.0%
Docetaxel,Cardiomyopathy,4,70,3.426,3.426,5.88,1.000,0.000,0.750,9.540,PRR=3.43 (显著关联); 罕见+严重; 住院率=75.0%
Docetaxel,Lymphocyte count decreased,3,70,3.736,3.736,5.09,1.000,0.000,1.000,9.827,PRR=3.74 (显著关联); 罕见+严重; 住院率=100.0%
Docetaxel,Lip swelling,3,70,5.481,5.481,8.82,1.000,0.000,1.000,9.827,PRR=5.48 (显著关联); 罕见+严重; 住院率=100.0%
Doxorubicin,Neutropenia,34,70,1.729,1.729,9.25,1.000,0.265,0.412,7.400,死亡率=26.5%; 严重事件率=100.0%; 住院率=41.2%
Doxorubicin,Respiratory tract infection,3,70,2.195,2.195,1.75,1.000,0.000,1.000,9.827,PRR=2.20 (显著关联); 罕见+严重; 住院率=100.0%
Doxorubicin,Liver function test abnormal,3,70,2.088,2.088,1.53,1.000,0.000,0.667,9.827,PRR=2.09 (显著关联); 罕见+严重; 住院率=66.7%
Doxorubicin,Atelectasis,3,70,4.078,4.078,5.88,1.000,0.000,1.000,9.827,PRR=4.08 (显著关联); 罕见+严重; 住院率=100.0%
Doxorubicin,Thrombocytopenia,22,70,1.411,1.411,2.38,1.000,0.318,0.409,7.835,死亡率=31.8%; 严重事件率=100.0%; 住院率=40.9%
Doxorubicin,C-reactive protein increased,3,70,2.253,2.253,1.87,1.000,0.000,0.667,9.827,PRR=2.25 (显著关联); 罕见+严重; 住院率=66.7%
Doxorubicin,Blood test abnormal,3,70,4.508,4.508,6.82,1.000,0.000,1.000,9.827,PRR=4.51 (显著关联); 罕见+严重; 住院率=100.0%
Doxorubicin,Productive cough,3,70,2.595,2.595,2.60,1.000,0.000,1.000,9.827,PRR=2.59 (显著关联); 罕见+严重; 住院率=100.0%
Doxorubicin,Pneumocystis jirovecii pneumonia,4,70,3.264,3.264,5.43,1.000,0.000,0.750,9.540,PRR=3.26 (显著关联); 罕见+严重; 住院率=75.0%
Doxorubicin,Posterior reversible encephalopathy syndrome,3,70,3.172,3.172,3.87,1.000,0.000,0.667,9.827,PRR=3.17 (显著关联); 罕见+严重; 住院率=66.7%
Doxorubicin,Hemiparesis,3,70,5.038,5.038,7.96,1.000,0.000,0.667,9.827,PRR=5.04 (显著关联); 罕见+严重; 住院率=66.7%
Doxorubicin,Leukocytosis,4,70,3.808,3.808,7.04,1.000,0.000,1.000,9.540,PRR=3.81 (显著关联); 罕见+严重; 住院率=100.0%
Carboplatin,Off label use,19,70,1.124,1.124,0.23,1.000,0.368,0.421,7.982,死亡率=36.8%; 严重事件率=100.0%; 住院率=42.1%
Carboplatin,Neoplasm,4,70,2.505,2.505,3.14,1.000,0.000,0.500,9.540,PRR=2.51 (显著关联); 罕见+严重; 住院率=50.0%
Carboplatin,Pneumocystis jirovecii pneumonia,4,70,2.792,2.792,3.96,1.000,0.000,0.500,9.540,PRR=2.79 (显著关联); 罕见+严重; 住院率=50.0%
Carboplatin,Blood creatine phosphokinase increased,4,70,4.655,4.655,9.24,1.000,0.000,0.750,9.540,PRR=4.65 (显著关联); 罕见+严重; 住院率=75.0%
Carboplatin,Hypercalcaemia,3,70,2.035,2.035,1.40,1.000,0.000,0.667,9.827,PRR=2.03 (显著关联); 罕见+严重; 住院率=66.7%
Carboplatin,Ovarian disorder,21,70,73.904,73.904,359.18,1.000,0.190,0.000,7.881,PRR=73.90 (显著关联); χ²=359.2 (统计显著); 严重事件率=100.0%
Carboplatin,Body temperature increased,3,70,3.489,3.489,4.47,1.000,0.000,0.667,9.827,PRR=3.49 (显著关联); 罕见+严重; 住院率=66.7%
Carboplatin,Blood pressure decreased,4,70,2.571,2.571,3.33,1.000,0.000,1.000,9.540,PRR=2.57 (显著关联); 罕见+严重; 住院率=100.0%
Carboplatin,Respiratory distress,3,70,2.220,2.220,1.77,1.000,0.000,0.667,9.827,PRR=2.22 (显著关联); 罕见+严重; 住院率=66.7%
Carboplatin,International normalised ratio increased,3,70,3.331,3.331,4.13,1.000,0.000,1.000,9.827,PRR=3.33 (显著关联); 罕见+严重; 住院率=100.0%
Cisplatin,Decreased appetite,28,70,1.439,1.439,3.35,1.000,0.214,0.464,7.594,死亡率=21.4%; 严重事件率=100.0%; 住院率=46.4%
Cisplatin,Anaemia,27,70,1.264,1.264,1.34,1.000,0.222,0.593,7.630,死亡率=22.2%; 严重事件率=100.0%; 住院率=59.3%
Cisplatin,Diarrhoea,37,70,0.767,0.767,2.35,0.973,0.324,0.649,7.315,死亡率=32.4%; 严重事件率=97.3%; 住院率=64.9%
Cisplatin,Dyspnoea,23,70,1.015,1.015,0.00,0.913,0.217,0.565,7.791,死亡率=21.7%; 严重事件率=91.3%; 住院率=56.5%
Cisplatin,Stomatitis,25,70,4.223,4.223,50.63,1.000,0.120,0.200,7.707,PRR=4.22 (显著关联); χ²=50.6 (统计显著); 严重事件率=100.0%
Cisplatin,Leukocytosis,3,70,2.641,2.641,2.69,1.000,0.000,0.667,9.827,PRR=2.64 (显著关联); 罕见+严重; 住院率=66.7%
Cisplatin,Thrombocytopenia,27,70,1.679,1.679,6.59,1.000,0.333,0.704,7.630,死亡率=33.3%; 严重事件率=100.0%; 住院率=70.4%
Cisplatin,Asthenia,25,70,1.363,1.363,2.17,1.000,0.240,0.640,7.707,死亡率=24.0%; 严重事件率=100.0%; 住院率=64.0%
Cisplatin,Supraventricular tachycardia,3,70,4.311,4.311,6.34,1.000,0.000,0.667,9.827,PRR=4.31 (显著关联); 罕见+严重; 住院率=66.7%
Cisplatin,Posterior reversible encephalopathy syndrome,4,70,4.202,4.202,8.14,1.000,0.000,1.000,9.540,PRR=4.20 (显著关联); 罕见+严重; 住院率=100.0%
Cisplatin,Presyncope,3,70,3.900,3.900,5.45,1.000,0.000,1.000,9.827,PRR=3.90 (显著关联); 罕见+严重; 住院率=100.0%
Cisplatin,No therapeutic response,3,70,3.150,3.150,3.80,1.000,0.000,0.667,9.827,PRR=3.15 (显著关联); 罕见+严重; 住院率=66.7%
Cisplatin,Dysuria,3,70,2.339,2.339,2.04,1.000,0.000,1.000,9.827,PRR=2.34 (显著关联); 罕见+严重; 住院率=100.0%
Lenalidomide,Loss of consciousness,4,70,3.034,3.034,4.99,1.000,0.000,0.750,9.540,PRR=3.03 (显著关联); 罕见+严重; 住院率=75.0%
Lenalidomide,Diverticulitis,3,70,3.468,3.468,4.78,1.000,0.000,1.000,9.827,PRR=3.47 (显著关联); 罕见+严重; 住院率=100.0%
Lenalidomide,Sinusitis,3,70,2.617,2.617,2.77,1.000,0.000,0.667,9.827,PRR=2.62 (显著关联); 罕见+严重; 住院率=66.7%
Lenalidomide,Convulsion,3,70,2.433,2.433,2.35,1.000,0.000,0.667,9.827,PRR=2.43 (显著关联); 罕见+严重; 住院率=66.7%
Lenalidomide,Bronchitis,3,70,2.617,2.617,2.77,1.000,0.000,0.667,9.827,PRR=2.62 (显著关联); 罕见+严重; 住院率=66.7%
Bortezomib,Toxicity to various agents,39,70,12.245,12.245,279.10,1.000,0.051,0.051,7.262,PRR=12.25 (显著关联); χ²=279.1 (统计显著); 严重事件率=100.0%
Bortezomib,Pneumonia,23,70,1.466,1.466,3.09,1.000,0.348,0.435,7.791,死亡率=34.8%; 严重事件率=100.0%; 住院率=43.5%
Bortezomib,Lymphopenia,3,70,3.656,3.656,5.04,1.000,0.000,0.667,9.827,PRR=3.66 (显著关联); 罕见+严重; 住院率=66.7%
Bortezomib,Osteomyelitis,3,70,4.488,4.488,6.93,1.000,0.000,0.667,9.827,PRR=4.49 (显著关联); 罕见+严重; 住院率=66.7%
Bortezomib,Herpes zoster,4,70,2.992,2.992,4.71,1.000,0.000,0.500,9.540,PRR=2.99 (显著关联); 罕见+严重; 住院率=50.0%
Bortezomib,Lower respiratory tract infection,3,70,3.404,3.404,4.47,1.000,0.000,1.000,9.827,PRR=3.40 (显著关联); 罕见+严重; 住院率=100.0%
Bortezomib,Unevaluable event,21,70,12.471,12.471,154.22,1.000,0.000,0.000,7.881,PRR=12.47 (显著关联); χ²=154.2 (统计显著); 严重事件率=100.0%
Bortezomib,Hospitalisation,4,70,2.926,2.926,4.50,1.000,0.000,1.000,9.540,PRR=2.93 (显著关联); 罕见+严重; 住院率=100.0%
Carfilzomib,Clostridium difficile infection,3,70,4.190,4.190,6.54,1.000,0.000,1.000,9.827,PRR=4.19 (显著关联); 罕见+严重; 住院率=100.0%
Carfilzomib,Rash maculo-papular,3,70,2.373,2.373,2.22,1.000,0.000,1.000,9.827,PRR=2.37 (显著关联); 罕见+严重; 住院率=100.0%
Carfilzomib,Pericardial effusion,4,70,3.065,3.065,5.10,1.000,0.000,0.750,9.540,PRR=3.06 (显著关联); 罕见+严重; 住院率=75.0%
Carfilzomib,Bronchitis,4,70,3.655,3.655,6.98,1.000,0.000,1.000,9.540,PRR=3.65 (显著关联); 罕见+严重; 住院率=100.0%
Carfilzomib,Pancreatitis,3,70,2.793,2.793,3.18,1.000,0.000,1.000,9.827,PRR=2.79 (显著关联); 罕见+严重; 住院率=100.0%
Carfilzomib,Laboratory test abnormal,3,70,3.096,3.096,3.90,0.667,0.000,0.667,9.827,PRR=3.10 (显著关联); 罕见+严重; 住院率=66.7%
Carfilzomib,Seizure,3,70,3.096,3.096,3.90,1.000,0.000,0.667,9.827,PRR=3.10 (显著关联); 罕见+严重; 住院率=66.7%
Venetoclax,Influenza,3,70,2.123,2.123,1.64,1.000,0.000,1.000,9.827,PRR=2.12 (显著关联); 罕见+严重; 住院率=100.0%
Venetoclax,Bronchitis,3,70,2.243,2.243,1.90,1.000,0.000,1.000,9.827,PRR=2.24 (显著关联); 罕见+严重; 住院率=100.0%
Venetoclax,Pyrexia,32,70,1.635,1.635,7.11,1.000,0.406,0.969,7.460,死亡率=40.6%; 严重事件率=100.0%; 住院率=96.9%
Venetoclax,Small intestinal obstruction,4,70,3.306,3.306,5.77,1.000,0.000,1.000,9.540,PRR=3.31 (显著关联); 罕见+严重; 住院率=100.0%
Venetoclax,Fatigue,26,70,0.787,0.787,1.37,0.846,0.231,0.500,7.668,死亡率=23.1%; 严重事件率=84.6%; 住院率=50.0%
Venetoclax,Hypercalcaemia,3,70,3.304,3.304,4.33,1.000,0.000,1.000,9.827,PRR=3.30 (显著关联); 罕见+严重; 住院率=100.0%
Venetoclax,Lymphadenopathy,19,70,13.367,13.367,156.66,0.895,0.158,0.368,7.982,PRR=13.37 (显著关联); χ²=156.7 (统计显著); 严重事件率=89.5%
Venetoclax,Hypophagia,3,70,2.123,2.123,1.64,1.000,0.000,0.667,9.827,PRR=2.12 (显著关联); 罕见+严重; 住院率=66.7%
Venetoclax,White blood cell count increased,4,70,2.833,2.833,4.30,0.750,0.000,0.500,9.540,PRR=2.83 (显著关联); 罕见+严重; 住院率=50.0%
Venetoclax,Swelling face,3,70,2.378,2.378,2.20,1.000,0.000,1.000,9.827,PRR=2.38 (显著关联); 罕见+严重; 住院率=100.0%
Venetoclax,Haematocrit decreased,4,70,3.173,3.173,5.36,1.000,0.000,0.750,9.540,PRR=3.17 (显著关联); 罕见+严重; 住院率=75.0%
Venetoclax,Myelodysplastic syndrome,4,70,2.478,2.478,3.23,1.000,0.000,0.500,9.540,PRR=2.48 (显著关联); 罕见+严重; 住院率=50.0%
Venetoclax,Herpes zoster,4,70,3.606,3.606,6.71,1.000,0.000,0.750,9.540,PRR=3.61 (显著关联); 罕见+严重; 住院率=75.0%
Ibrutinib,Transient ischaemic attack,3,70,5.259,5.259,8.66,1.000,0.000,1.000,9.827,PRR=5.26 (显著关联); 罕见+严重; 住院率=100.0%
Ibrutinib,Hypophosphataemia,3,70,2.700,2.700,2.88,1.000,0.000,0.667,9.827,PRR=2.70 (显著关联); 罕见+严重; 住院率=66.7%
Ibrutinib,Anaemia,19,70,1.068,1.068,0.08,1.000,0.368,0.895,7.982,死亡率=36.8%; 严重事件率=100.0%; 住院率=89.5%
Ibrutinib,Rash maculo-papular,4,70,2.258,2.258,2.54,0.750,0.000,0.750,9.540,PRR=2.26 (显著关联); 罕见+严重; 住院率=75.0%
Ibrutinib,Pneumonia,26,70,1.690,1.690,6.60,0.962,0.462,0.769,7.668,死亡率=46.2%; 严重事件率=96.2%; 住院率=76.9%
Ibrutinib,Diarrhoea,35,70,0.886,0.886,0.46,0.829,0.229,0.657,7.371,死亡率=22.9%; 严重事件率=82.9%; 住院率=65.7%
Ibrutinib,Asthenia,22,70,1.455,1.455,2.85,0.818,0.318,0.636,7.835,死亡率=31.8%; 严重事件率=81.8%; 住院率=63.6%
Ibrutinib,Purpura,3,70,4.996,4.996,8.08,1.000,0.000,1.000,9.827,PRR=5.00 (显著关联); 罕见+严重; 住院率=100.0%
Ibrutinib,Hypercalcaemia,3,70,2.775,2.775,3.04,1.000,0.000,1.000,9.827,PRR=2.77 (显著关联); 罕见+严重; 住院率=100.0%
Ibrutinib,Therapy cessation,4,70,4.300,4.300,8.68,0.500,0.000,0.500,9.540,PRR=4.30 (显著关联); 罕见+严重; 住院率=50.0%
Ibrutinib,Gastritis,3,70,2.629,2.629,2.72,1.000,0.000,1.000,9.827,PRR=2.63 (显著关联); 罕见+严重; 住院率=100.0%
Olaparib,Fatigue,86,70,2.062,2.062,39.60,0.581,0.093,0.174,6.472,PRR=2.06 (显著关联); χ²=39.6 (统计显著); 严重事件率=58.1%
Olaparib,Blood potassium decreased,4,70,2.770,2.770,3.98,1.000,0.000,0.500,9.540,PRR=2.77 (显著关联); 罕见+严重; 住院率=50.0%
Olaparib,Viral infection,3,70,5.131,5.131,8.18,1.000,0.000,0.667,9.827,PRR=5.13 (显著关联); 罕见+严重; 住院率=66.7%
Olaparib,Haemoglobin decreased,21,70,2.580,2.580,17.77,0.762,0.095,0.190,7.881,PRR=2.58 (显著关联); χ²=17.8 (统计显著); 严重事件率=76.2%
Olaparib,Blood glucose increased,4,70,2.585,2.585,3.44,0.500,0.000,0.500,9.540,PRR=2.58 (显著关联); 罕见+严重; 住院率=50.0%
Olaparib,Sinusitis,4,70,2.237,2.237,2.45,1.000,0.000,0.500,9.540,PRR=2.24 (显著关联); 罕见+严重; 住院率=50.0%
Olaparib,Condition aggravated,3,70,2.236,2.236,1.84,0.667,0.000,0.667,9.827,PRR=2.24 (显著关联); 罕见+严重; 住院率=66.7%
Olaparib,Dyspnoea exertional,3,70,2.236,2.236,1.84,1.000,0.000,0.667,9.827,PRR=2.24 (显著关联); 罕见+严重; 住院率=66.7%
Rucaparib,Dysgeusia,90,70,19.192,19.192,731.66,0.511,0.022,0.289,6.426,PRR=19.19 (显著关联); χ²=731.7 (统计显著); 严重事件率=51.1%
Rucaparib,Constipation,60,70,3.275,3.275,75.25,0.517,0.000,0.267,6.832,PRR=3.28 (显著关联); χ²=75.3 (统计显著); 严重事件率=51.7%
Rucaparib,Drug dose omission,44,70,9.220,9.220,205.90,0.545,0.000,0.341,7.142,PRR=9.22 (显著关联); χ²=205.9 (统计显著); 严重事件率=54.5%
Rucaparib,Decreased appetite,74,70,3.037,3.037,80.46,0.527,0.041,0.270,6.622,PRR=3.04 (显著关联); χ²=80.5 (统计显著); 严重事件率=52.7%
Rucaparib,Blood creatinine increased,23,70,2.783,2.783,21.66,0.565,0.000,0.348,7.791,PRR=2.78 (显著关联); χ²=21.7 (统计显著); 严重事件率=56.5%
Rucaparib,Red blood cell count decreased,22,70,3.984,3.984,38.53,0.636,0.045,0.364,7.835,PRR=3.98 (显著关联); χ²=38.5 (统计显著); 严重事件率=63.6%
Rucaparib,Intentional underdose,20,70,43.912,43.912,245.78,0.550,0.050,0.300,7.930,PRR=43.91 (显著关联); χ²=245.8 (统计显著); 严重事件率=55.0%
Rucaparib,Underdose,68,70,1368.432,1368.432,1248.98,0.588,0.029,0.324,6.707,PRR=1368.43 (显著关联); χ²=1249.0 (统计显著); 严重事件率=58.8%
Rucaparib,Tumour marker increased,21,70,17.292,17.292,162.23,0.762,0.000,0.333,7.881,PRR=17.29 (显著关联); χ²=162.2 (统计显著); 严重事件率=76.2%
Rucaparib,Carbohydrate antigen 125 increased,30,70,11.218,11.218,167.58,0.667,0.000,0.333,7.525,PRR=11.22 (显著关联); χ²=167.6 (统计显著); 严重事件率=66.7%
Rucaparib,Balance disorder,6,70,2.619,2.619,5.03,0.500,0.000,0.500,9.134,PRR=2.62 (显著关联); 罕见+严重; 住院率=50.0%
Rucaparib,Sleep disorder,3,70,2.560,2.560,2.40,0.667,0.000,0.667,9.827,PRR=2.56 (显著关联); 罕见+严重; 住院率=66.7%
Rucaparib,Nasal congestion,4,70,4.621,4.621,8.73,0.750,0.000,0.500,9.540,PRR=4.62 (显著关联); 罕见+严重; 住院率=50.0%
Rucaparib,Neck pain,3,70,2.677,2.677,2.63,0.667,0.000,0.667,9.827,PRR=2.68 (显著关联); 罕见+严重; 住院率=66.7%
Rucaparib,Amnesia,3,70,2.454,2.454,2.18,0.667,0.000,0.667,9.827,PRR=2.45 (显著关联); 罕见+严重; 住院率=66.7%
Niraparib,Dizziness,45,70,2.514,2.514,33.15,0.800,0.044,0.311,7.119,PRR=2.51 (显著关联); χ²=33.2 (统计显著); 严重事件率=80.0%
Niraparib,Constipation,93,70,4.912,4.912,206.06,0.688,0.043,0.312,6.393,PRR=4.91 (显著关联); χ²=206.1 (统计显著); 严重事件率=68.8%
Niraparib,Insomnia,74,70,13.634,13.634,448.20,0.527,0.000,0.216,6.622,PRR=13.63 (显著关联); χ²=448.2 (统计显著); 严重事件率=52.7%
Niraparib,Hypertension,21,70,2.255,2.255,12.12,0.857,0.048,0.333,7.881,PRR=2.25 (显著关联); χ²=12.1 (统计显著); 严重事件率=85.7%
Niraparib,Headache,48,70,2.756,2.756,42.84,0.708,0.042,0.312,7.055,PRR=2.76 (显著关联); χ²=42.8 (统计显著); 严重事件率=70.8%
Niraparib,Diplopia,3,70,2.568,2.568,2.36,1.000,0.000,0.667,9.827,PRR=2.57 (显著关联); 罕见+严重; 住院率=66.7%
Niraparib,Nausea,146,70,2.040,2.040,60.92,0.685,0.048,0.390,5.942,PRR=2.04 (显著关联); χ²=60.9 (统计显著); 严重事件率=68.5%
Niraparib,Liver function test increased,4,70,3.606,3.606,5.87,1.000,0.000,1.000,9.540,PRR=3.61 (显著关联); 罕见+严重; 住院率=100.0%
Niraparib,Carbohydrate antigen 125 increased,45,70,20.551,20.551,356.47,0.911,0.044,0.311,7.119,PRR=20.55 (显著关联); χ²=356.5 (统计显著); 严重事件率=91.1%
Niraparib,Haemoglobin decreased,47,70,3.837,3.837,74.78,0.957,0.085,0.383,7.076,PRR=3.84 (显著关联); χ²=74.8 (统计显著); 严重事件率=95.7%
Niraparib,Abdominal discomfort,20,70,2.888,2.888,19.80,0.750,0.050,0.300,7.930,PRR=2.89 (显著关联); χ²=19.8 (统计显著); 严重事件率=75.0%
Niraparib,Disease progression,31,70,0.646,0.646,5.35,0.935,0.323,0.419,7.492,死亡率=32.3%; 严重事件率=93.5%; 住院率=41.9%
Niraparib,Red blood cell count decreased,48,70,10.037,10.037,229.78,0.958,0.083,0.354,7.055,PRR=10.04 (显著关联); χ²=229.8 (统计显著); 严重事件率=95.8%
Niraparib,Blood pressure increased,39,70,12.505,12.505,223.35,0.846,0.026,0.385,7.262,PRR=12.50 (显著关联); χ²=223.4 (统计显著); 严重事件率=84.6%
Niraparib,Anxiety,24,70,5.232,5.232,58.97,0.667,0.042,0.292,7.748,PRR=5.23 (显著关联); χ²=59.0 (统计显著); 严重事件率=66.7%
Niraparib,Blood count abnormal,28,70,9.114,9.114,123.78,0.821,0.071,0.321,7.594,PRR=9.11 (显著关联); χ²=123.8 (统计显著); 严重事件率=82.1%
Niraparib,Abdominal pain upper,26,70,2.905,2.905,25.96,0.654,0.115,0.308,7.668,PRR=2.91 (显著关联); χ²=26.0 (统计显著); 严重事件率=65.4%
Niraparib,Heart rate increased,27,70,8.955,8.955,117.50,0.815,0.037,0.370,7.630,PRR=8.96 (显著关联); χ²=117.5 (统计显著); 严重事件率=81.5%
Niraparib,Blood urea increased,3,70,2.704,2.704,2.62,1.000,0.000,0.667,9.827,PRR=2.70 (显著关联); 罕见+严重; 住院率=66.7%
Niraparib,Blood potassium increased,3,70,3.425,3.425,4.05,1.000,0.000,1.000,9.827,PRR=3.42 (显著关联); 罕见+严重; 住院率=100.0%
Niraparib,Cognitive disorder,3,70,2.054,2.054,1.37,1.000,0.000,0.667,9.827,PRR=2.05 (显著关联); 罕见+严重; 住院率=66.7%
Niraparib,Sleep disorder,4,70,3.114,3.114,4.58,0.500,0.000,0.500,9.540,PRR=3.11 (显著关联); 罕见+严重; 住院率=50.0%
Niraparib,Blood urine present,3,70,4.281,4.281,5.70,1.000,0.000,0.667,9.827,PRR=4.28 (显著关联); 罕见+严重; 住院率=66.7%
Talazoparib,Neutropenia,28,70,2.300,2.300,18.55,1.000,0.107,0.250,7.594,PRR=2.30 (显著关联); χ²=18.6 (统计显著); 严重事件率=100.0%
Talazoparib,Dyspnoea,20,70,1.499,1.499,3.06,1.000,0.300,0.800,7.930,死亡率=30.0%; 严重事件率=100.0%; 住院率=80.0%
Talazoparib,Blood alkaline phosphatase increased,3,70,2.279,2.279,2.00,1.000,0.000,1.000,9.827,PRR=2.28 (显著关联); 罕见+严重; 住院率=100.0%
Talazoparib,Myocardial infarction,4,70,2.235,2.235,2.54,1.000,0.000,1.000,9.540,PRR=2.23 (显著关联); 罕见+严重; 住院率=100.0%
Talazoparib,Haematuria,3,70,2.139,2.139,1.70,1.000,0.000,1.000,9.827,PRR=2.14 (显著关联); 罕见+严重; 住院率=100.0%
Palbociclib,Lipase increased,3,70,4.559,4.559,7.15,1.000,0.000,1.000,9.827,PRR=4.56 (显著关联); 罕见+严重; 住院率=100.0%
Palbociclib,Small intestinal obstruction,3,70,2.139,2.139,1.66,1.000,0.000,1.000,9.827,PRR=2.14 (显著关联); 罕见+严重; 住院率=100.0%
Palbociclib,Pneumonia,19,70,1.274,1.274,1.02,1.000,0.263,0.684,7.982,死亡率=26.3%; 严重事件率=100.0%; 住院率=68.4%
Palbociclib,Neutropenia,83,70,5.874,5.874,263.53,0.976,0.024,0.133,6.507,PRR=5.87 (显著关联); χ²=263.5 (统计显著); 严重事件率=97.6%
Palbociclib,Product use issue,19,70,9.059,9.059,103.93,0.526,0.105,0.000,7.982,PRR=9.06 (显著关联); χ²=103.9 (统计显著); 严重事件率=52.6%
Palbociclib,Respiratory tract infection,3,70,2.688,2.688,2.86,1.000,0.000,1.000,9.827,PRR=2.69 (显著关联); 罕见+严重; 住院率=100.0%
Ribociclib,Blood alkaline phosphatase increased,4,70,3.125,3.125,5.28,1.000,0.000,0.750,9.540,PRR=3.13 (显著关联); 罕见+严重; 住院率=75.0%
Ribociclib,Neutropenia,35,70,2.961,2.961,40.23,0.971,0.029,0.200,7.371,PRR=2.96 (显著关联); χ²=40.2 (统计显著); 严重事件率=97.1%
Ribociclib,White blood cell count decreased,24,70,3.538,3.538,38.77,0.750,0.000,0.000,7.748,PRR=3.54 (显著关联); χ²=38.8 (统计显著); 严重事件率=75.0%
Ribociclib,Hypophagia,3,70,2.509,2.509,2.52,1.000,0.000,0.667,9.827,PRR=2.51 (显著关联); 罕见+严重; 住院率=66.7%
Abemaciclib,Intestinal obstruction,3,70,2.282,2.282,2.00,1.000,0.000,1.000,9.827,PRR=2.28 (显著关联); 罕见+严重; 住院率=100.0%
Abemaciclib,Mobility decreased,3,70,5.424,5.424,9.38,0.667,0.000,0.667,9.827,PRR=5.42 (显著关联); 罕见+严重; 住院率=66.7%
Abemaciclib,Oral pain,3,70,3.174,3.174,4.06,0.667,0.000,0.667,9.827,PRR=3.17 (显著关联); 罕见+严重; 住院率=66.7%
Vemurafenib,Arthralgia,41,70,6.801,6.801,161.19,0.878,0.000,0.244,7.212,PRR=6.80 (显著关联); χ²=161.2 (统计显著); 严重事件率=87.8%
Vemurafenib,Renal failure acute,20,70,6.325,6.325,73.07,1.000,0.000,0.200,7.930,PRR=6.33 (显著关联); χ²=73.1 (统计显著); 严重事件率=100.0%
Vemurafenib,Nausea,20,70,0.510,0.510,8.69,1.000,0.350,0.500,7.930,死亡率=35.0%; 严重事件率=100.0%; 住院率=50.0%
Vemurafenib,Vomiting,23,70,0.978,0.978,0.01,1.000,0.304,0.696,7.791,死亡率=30.4%; 严重事件率=100.0%; 住院率=69.6%
Vemurafenib,Haematuria,4,70,2.232,2.232,2.48,1.000,0.000,0.500,9.540,PRR=2.23 (显著关联); 罕见+严重; 住院率=50.0%
Vemurafenib,Palmar-plantar erythrodysaesthesia syndrome,4,70,2.040,2.040,1.94,1.000,0.000,0.500,9.540,PRR=2.04 (显著关联); 罕见+严重; 住院率=50.0%
Vemurafenib,Pancreatitis,4,70,2.857,2.857,4.33,1.000,0.000,0.750,9.540,PRR=2.86 (显著关联); 罕见+严重; 住院率=75.0%
Vemurafenib,Pollakiuria,4,70,3.969,3.969,7.75,1.000,0.000,0.750,9.540,PRR=3.97 (显著关联); 罕见+严重; 住院率=75.0%
Dabrafenib,Jaundice,3,70,4.990,4.990,8.12,0.667,0.000,0.667,9.827,PRR=4.99 (显著关联); 罕见+严重; 住院率=66.7%
Dabrafenib,Vomiting,28,70,1.175,1.175,0.67,0.821,0.214,0.429,7.594,死亡率=21.4%; 严重事件率=82.1%; 住院率=42.9%
Dabrafenib,Nausea,37,70,0.945,0.945,0.11,0.838,0.216,0.432,7.315,死亡率=21.6%; 严重事件率=83.8%; 住院率=43.2%
Dabrafenib,Arthralgia,19,70,2.760,2.760,18.89,0.737,0.053,0.105,7.982,PRR=2.76 (显著关联); χ²=18.9 (统计显著); 严重事件率=73.7%
Dabrafenib,Encephalopathy,3,70,4.366,4.366,6.71,1.000,0.000,1.000,9.827,PRR=4.37 (显著关联); 罕见+严重; 住院率=100.0%
Dabrafenib,Delirium,3,70,3.081,3.081,3.76,1.000,0.000,1.000,9.827,PRR=3.08 (显著关联); 罕见+严重; 住院率=100.0%
Dabrafenib,Gastric haemorrhage,3,70,5.515,5.515,9.29,1.000,0.000,1.000,9.827,PRR=5.52 (显著关联); 罕见+严重; 住院率=100.0%
Dabrafenib,Disseminated intravascular coagulation,4,70,4.235,4.235,8.54,1.000,0.000,0.750,9.540,PRR=4.24 (显著关联); 罕见+严重; 住院率=75.0%
Dabrafenib,Neoplasm,4,70,3.583,3.583,6.55,1.000,0.000,0.750,9.540,PRR=3.58 (显著关联); 罕见+严重; 住院率=75.0%
Bevacizumab,Suspected transmission of an infectious agent via product,9,65,0.000,0.000,267.43,1.000,0.000,0.000,8.729,χ²=267.4 (统计显著); 严重事件率=100.0%; 罕见+严重
Cetuximab,Adverse event,19,65,22.447,22.447,277.05,0.474,0.053,0.421,7.982,PRR=22.45 (显著关联); χ²=277.0 (统计显著); 住院率=42.1%
Rituximab,Fatigue,18,65,0.364,0.364,18.44,0.833,0.167,0.389,8.036,χ²=18.4 (统计显著); 严重事件率=83.3%; 罕见+严重
Rituximab,Rash,7,65,0.271,0.271,12.91,0.857,0.143,0.143,8.980,χ²=12.9 (统计显著); 严重事件率=85.7%; 罕见+严重
Pomalidomide,Nausea,8,65,0.291,0.291,13.06,0.625,0.000,0.375,8.847,χ²=13.1 (统计显著); 严重事件率=62.5%; 罕见+严重
Niraparib,Rash,11,65,0.273,0.273,19.53,0.636,0.000,0.091,8.528,χ²=19.5 (统计显著); 严重事件率=63.6%; 罕见+严重
Palbociclib,Malignant neoplasm progression,5,65,0.253,0.253,10.50,1.000,0.000,0.400,9.317,χ²=10.5 (统计显著); 严重事件率=100.0%; 罕见+严重
Dabrafenib,Diarrhoea,14,65,0.361,0.361,14.72,0.571,0.071,0.214,8.287,χ²=14.7 (统计显著); 严重事件率=57.1%; 罕见+严重
Pembrolizumab,Thrombocytopenia,6,60,0.596,0.596,1.57,0.667,0.000,0.500,9.134,严重事件率=66.7%; 罕见+严重; 住院率=50.0%
Pembrolizumab,Decreased appetite,13,60,1.093,1.093,0.10,0.538,0.077,0.462,8.361,严重事件率=53.8%; 罕见+严重; 住院率=46.2%
Pembrolizumab,Abdominal pain,13,60,1.812,1.812,4.38,0.615,0.154,0.615,8.361,严重事件率=61.5%; 罕见+严重; 住院率=61.5%
Pembrolizumab,Hypotension,7,60,1.560,1.560,1.32,0.714,0.000,0.714,8.980,严重事件率=71.4%; 罕见+严重; 住院率=71.4%
Pembrolizumab,Pleural effusion,8,60,1.718,1.718,2.24,1.000,0.125,1.000,8.847,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Muscular weakness,5,60,1.816,1.816,1.72,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Cough,5,60,0.951,0.951,0.01,0.600,0.000,0.600,9.317,严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Pembrolizumab,Atrial fibrillation,5,60,1.364,1.364,0.46,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pembrolizumab,Mucosal inflammation,3,60,1.181,1.181,0.08,0.333,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Pembrolizumab,Oedema peripheral,3,60,0.933,0.933,0.01,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Pembrolizumab,Metastases to central nervous system,4,60,1.692,1.692,1.06,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Pembrolizumab,Pain in extremity,5,60,1.124,1.124,0.06,0.600,0.000,0.600,9.317,严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Nivolumab,Renal failure,6,60,1.336,1.336,0.48,1.000,0.000,1.000,9.134,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Abdominal pain,11,60,1.499,1.499,1.70,1.000,0.182,1.000,8.528,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Headache,9,60,1.203,1.203,0.29,1.000,0.000,1.000,8.729,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Cough,9,60,1.721,1.721,2.53,1.000,0.111,1.000,8.729,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Infusion related reaction,5,60,1.804,1.804,1.68,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Nivolumab,Leukoderma,3,60,0.000,0.000,133.19,1.000,0.000,1.000,9.827,χ²=133.2 (统计显著); 罕见+严重; 住院率=100.0%
Nivolumab,Back pain,5,60,0.945,0.945,0.02,0.800,0.200,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Atezolizumab,Fall,5,60,1.646,1.646,1.20,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Neutropenia,7,60,0.674,0.674,1.06,1.000,0.143,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Atezolizumab,Anaemia,18,60,1.749,1.749,5.35,1.000,0.056,0.889,8.036,严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Atezolizumab,Infection,5,60,1.337,1.337,0.40,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Rash,5,60,0.411,0.411,4.04,0.800,0.000,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Atezolizumab,Systemic immune activation,3,60,0.000,0.000,168.54,1.000,0.000,0.667,9.827,χ²=168.5 (统计显著); 罕见+严重; 住院率=66.7%
Atezolizumab,Thrombocytopenia,10,60,1.251,1.251,0.47,1.000,0.100,0.800,8.623,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Atezolizumab,Nausea,10,60,0.405,0.405,8.24,0.900,0.100,0.700,8.623,严重事件率=90.0%; 罕见+严重; 住院率=70.0%
Atezolizumab,Fatigue,17,60,0.737,0.737,1.48,0.824,0.059,0.647,8.093,严重事件率=82.4%; 罕见+严重; 住院率=64.7%
Atezolizumab,Pain,4,60,0.764,0.764,0.28,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Atezolizumab,Dehydration,8,60,1.125,1.125,0.10,1.000,0.125,1.000,8.847,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Atezolizumab,Urinary tract infection,5,60,1.468,1.468,0.71,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Durvalumab,Platelet count decreased,10,60,1.118,1.118,0.12,1.000,0.200,1.000,8.623,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Dyspnoea,14,60,1.043,1.043,0.02,0.786,0.000,0.714,8.287,严重事件率=78.6%; 罕见+严重; 住院率=71.4%
Durvalumab,Nausea,13,60,0.431,0.431,9.13,0.615,0.154,0.462,8.361,严重事件率=61.5%; 罕见+严重; 住院率=46.2%
Durvalumab,Anaemia,10,60,0.775,0.775,0.62,1.000,0.100,0.700,8.623,严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Durvalumab,Pneumonia,17,60,1.522,1.522,2.82,0.941,0.118,0.882,8.093,严重事件率=94.1%; 罕见+严重; 住院率=88.2%
Durvalumab,Hypotension,8,60,1.819,1.819,2.75,1.000,0.000,1.000,8.847,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Dehydration,6,60,0.683,0.683,0.84,0.833,0.000,0.833,9.134,严重事件率=83.3%; 罕见+严重; 住院率=83.3%
Durvalumab,Urinary tract infection,5,60,1.198,1.198,0.15,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Neutropenia,5,60,0.390,0.390,4.55,0.800,0.000,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Durvalumab,Pleural effusion,7,60,1.516,1.516,1.15,0.857,0.143,0.714,8.980,严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Durvalumab,Asthenia,5,60,0.445,0.445,3.31,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Durvalumab,Somnolence,3,60,1.710,1.710,0.83,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Durvalumab,Malaise,10,60,1.234,1.234,0.42,0.500,0.300,0.300,8.623,死亡率=30.0%; 罕见+严重
Durvalumab,Rash,5,60,0.335,0.335,6.29,0.600,0.000,0.600,9.317,严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Durvalumab,Myalgia,4,60,1.461,1.461,0.55,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Durvalumab,Nasopharyngitis,3,60,1.689,1.689,0.79,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Durvalumab,Thyroxine free abnormal,3,60,0.000,0.000,137.13,1.000,0.000,1.000,9.827,χ²=137.1 (统计显著); 罕见+严重; 住院率=100.0%
Ipilimumab,Pneumonitis,8,60,1.670,1.670,2.00,1.000,0.125,1.000,8.847,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Abdominal pain upper,3,60,0.691,0.691,0.40,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Ipilimumab,Muscle spasms,3,60,0.874,0.874,0.05,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Ipilimumab,Alanine aminotransferase increased,6,60,1.385,1.385,0.60,1.000,0.167,0.667,9.134,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Ipilimumab,Aspartate aminotransferase increased,5,60,1.223,1.223,0.19,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Ipilimumab,Constipation,5,60,0.484,0.484,2.62,0.800,0.200,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Ipilimumab,Dizziness,5,60,0.583,0.583,1.42,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ipilimumab,Acute kidney injury,5,60,1.793,1.793,1.63,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ipilimumab,Abdominal pain,16,60,1.997,1.997,7.27,1.000,0.062,0.875,8.153,严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Ipilimumab,Decreased appetite,5,60,0.365,0.365,5.28,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ipilimumab,Infusion related reaction,3,60,0.956,0.956,0.01,0.333,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Ipilimumab,Gait disturbance,3,60,1.166,1.166,0.07,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Trastuzumab,Anaemia,8,60,0.368,0.368,8.16,1.000,0.125,0.500,8.847,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Trastuzumab,Malaise,8,60,0.584,0.584,2.21,0.750,0.125,0.500,8.847,严重事件率=75.0%; 罕见+严重; 住院率=50.0%
Trastuzumab,Cerebral haemorrhage,3,60,1.822,1.822,1.01,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Trastuzumab,Hypotension,9,60,1.227,1.227,0.35,1.000,0.111,0.778,8.729,严重事件率=100.0%; 罕见+严重; 住院率=77.8%
Trastuzumab,Fall,4,60,0.637,0.637,0.78,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Trastuzumab,Weight decreased,12,60,1.266,1.266,0.61,0.917,0.083,0.417,8.441,严重事件率=91.7%; 罕见+严重; 住院率=41.7%
Trastuzumab,Heart rate increased,4,60,1.490,1.490,0.59,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Trastuzumab,Influenza,3,60,1.496,1.496,0.45,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Trastuzumab,Constipation,6,60,0.398,0.398,5.15,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Trastuzumab,Dysphagia,6,60,1.180,1.180,0.15,1.000,0.000,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Trastuzumab,Respiratory failure,3,60,0.554,0.554,1.02,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Trastuzumab,Pulmonary embolism,5,60,0.701,0.701,0.60,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Trastuzumab,Infection,7,60,0.921,0.921,0.04,1.000,0.143,0.714,8.980,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Trastuzumab,Oedema peripheral,5,60,0.956,0.956,0.01,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Trastuzumab,Stomatitis,8,60,1.242,1.242,0.35,0.875,0.000,0.500,8.847,严重事件率=87.5%; 罕见+严重; 住院率=50.0%
Trastuzumab,Colitis,5,60,0.677,0.677,0.72,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Trastuzumab,White blood cell count decreased,9,60,0.744,0.744,0.74,1.000,0.000,0.556,8.729,严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Trastuzumab,Urinary tract infection,5,60,0.715,0.715,0.53,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Trastuzumab,Myocardial infarction,3,60,0.997,0.997,0.00,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Trastuzumab,Bone marrow failure,3,60,0.797,0.797,0.14,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Trastuzumab,Thrombosis,5,60,1.535,1.535,0.85,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Trastuzumab,Pyrexia,15,60,0.520,0.520,6.14,1.000,0.000,0.667,8.218,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Trastuzumab,Abdominal pain,8,60,0.661,0.661,1.30,0.875,0.125,0.500,8.847,严重事件率=87.5%; 罕见+严重; 住院率=50.0%
Trastuzumab,Abdominal pain upper,5,60,0.797,0.797,0.24,0.600,0.000,0.600,9.317,严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Bevacizumab,Influenza,3,60,1.645,1.645,0.70,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Bevacizumab,Abdominal pain,12,60,1.106,1.106,0.11,1.000,0.167,0.583,8.441,严重事件率=100.0%; 罕见+严重; 住院率=58.3%
Bevacizumab,Headache,11,60,0.999,0.999,0.00,1.000,0.091,0.545,8.528,严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Bevacizumab,Chest pain,10,60,1.768,1.768,3.03,1.000,0.100,0.700,8.623,严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Bevacizumab,Dehydration,7,60,0.525,0.525,2.84,1.000,0.000,0.857,8.980,严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Bevacizumab,Renal disorder,3,60,1.842,1.842,1.05,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Bevacizumab,Malaise,12,60,0.976,0.976,0.01,1.000,0.167,0.667,8.441,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Bevacizumab,White blood cell count decreased,11,60,1.008,1.008,0.00,1.000,0.091,0.636,8.528,严重事件率=100.0%; 罕见+严重; 住院率=63.6%
Bevacizumab,Neutrophil count decreased,9,60,1.763,1.763,2.70,1.000,0.000,0.778,8.729,严重事件率=100.0%; 罕见+严重; 住院率=77.8%
Bevacizumab,Infection,10,60,1.471,1.471,1.38,1.000,0.200,0.600,8.623,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bevacizumab,Pancytopenia,5,60,0.696,0.696,0.62,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bevacizumab,Thrombocytopenia,14,60,0.946,0.946,0.04,1.000,0.071,0.500,8.287,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Asthenia,15,60,0.898,0.898,0.16,1.000,0.200,0.533,8.218,严重事件率=100.0%; 罕见+严重; 住院率=53.3%
Bevacizumab,Breast cancer metastatic,3,60,1.616,1.616,0.65,1.000,1.000,0.000,9.827,死亡率=100.0%; 罕见+严重
Bevacizumab,Myalgia,5,60,1.209,1.209,0.17,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bevacizumab,Decreased appetite,14,60,0.784,0.784,0.78,1.000,0.143,0.429,8.287,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Bevacizumab,General physical health deterioration,8,60,1.720,1.720,2.19,1.000,0.125,0.750,8.847,严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Bevacizumab,Neoplasm progression,4,60,1.096,1.096,0.03,1.000,1.000,0.250,9.540,死亡率=100.0%; 罕见+严重
Bevacizumab,Chills,6,60,1.316,1.316,0.42,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Pruritus,3,60,0.352,0.352,3.41,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Bevacizumab,Cardiac failure congestive,3,60,1.180,1.180,0.08,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Bevacizumab,Back pain,5,60,0.638,0.638,0.97,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bevacizumab,Stomatitis,6,60,1.012,1.012,0.00,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Bevacizumab,Hepatic function abnormal,4,60,1.982,1.982,1.76,1.000,0.750,0.250,9.540,死亡率=75.0%; 罕见+严重
Bevacizumab,Platelet count decreased,7,60,0.508,0.508,3.14,1.000,0.143,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Bevacizumab,Hypophagia,3,60,1.645,1.645,0.70,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Bevacizumab,Toxicity to various agents,3,60,0.643,0.643,0.56,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Bevacizumab,Rash,8,60,0.354,0.354,8.85,1.000,0.000,0.625,8.847,严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Bevacizumab,Confusional state,5,60,1.030,1.030,0.00,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bevacizumab,Gastrointestinal haemorrhage,3,60,1.535,1.535,0.51,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Bevacizumab,Fall,3,60,0.522,0.522,1.24,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Bevacizumab,Metastases to central nervous system,3,60,0.837,0.837,0.09,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Cetuximab,Off label use,3,60,0.435,0.435,2.13,0.667,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Rituximab,Pancytopenia,6,60,0.735,0.735,0.53,1.000,0.000,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Rituximab,Hypertension,10,60,1.573,1.573,1.89,0.900,0.100,0.700,8.623,严重事件率=90.0%; 罕见+严重; 住院率=70.0%
Rituximab,Asthenia,15,60,0.785,0.785,0.81,0.933,0.067,0.800,8.218,严重事件率=93.3%; 罕见+严重; 住院率=80.0%
Rituximab,Muscular weakness,3,60,0.624,0.624,0.64,0.333,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Rituximab,Anaemia,14,60,0.627,0.627,2.87,1.000,0.000,0.786,8.287,严重事件率=100.0%; 罕见+严重; 住院率=78.6%
Rituximab,Memory impairment,3,60,1.414,1.414,0.33,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Rituximab,Cough,14,60,1.618,1.618,2.97,0.929,0.071,0.643,8.287,严重事件率=92.9%; 罕见+严重; 住院率=64.3%
Rituximab,Renal failure acute,7,60,1.482,1.482,1.00,1.000,0.000,1.000,8.980,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rituximab,Back pain,10,60,1.144,1.144,0.17,1.000,0.200,0.800,8.623,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Rituximab,Dyspnoea,11,60,0.466,0.466,6.27,1.000,0.182,0.545,8.528,严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Rituximab,Weight decreased,14,60,1.433,1.433,1.65,1.000,0.143,0.714,8.287,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Rituximab,Tendon rupture,3,60,0.000,0.000,77.68,1.000,0.000,1.000,9.827,χ²=77.7 (统计显著); 罕见+严重; 住院率=100.0%
Rituximab,Hypersensitivity,3,60,0.563,0.563,0.96,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Rituximab,Stomatitis,5,60,0.733,0.733,0.45,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Rituximab,Erythema,4,60,0.658,0.658,0.66,1.000,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Rituximab,Atrial fibrillation,5,60,0.794,0.794,0.25,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rituximab,Chest pain,9,60,1.383,1.383,0.87,1.000,0.000,0.667,8.729,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Rituximab,White blood cell count decreased,7,60,0.553,0.553,2.37,1.000,0.000,1.000,8.980,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Rituximab,Hypotension,10,60,1.318,1.318,0.70,1.000,0.200,0.500,8.623,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Rituximab,Myelodysplastic syndrome,4,60,1.680,1.680,1.00,0.750,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Rituximab,Constipation,3,60,0.190,0.190,9.85,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Rituximab,Myalgia,3,60,0.624,0.624,0.64,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Rituximab,Alanine aminotransferase increased,3,60,0.447,0.447,1.94,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Rituximab,Hyponatraemia,5,60,1.010,1.010,0.00,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Epcoritamab,Dizziness,5,60,0.513,0.513,2.19,0.800,0.200,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Epcoritamab,Primary mediastinal large B-cell lymphoma,3,60,0.000,0.000,104.92,1.000,0.000,0.667,9.827,χ²=104.9 (统计显著); 罕见+严重; 住院率=66.7%
Epcoritamab,Cough,5,60,0.742,0.742,0.42,0.800,0.200,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Epcoritamab,Back pain,7,60,1.058,1.058,0.02,0.714,0.143,0.429,8.980,严重事件率=71.4%; 罕见+严重; 住院率=42.9%
Epcoritamab,Urinary tract infection,3,60,0.546,0.546,1.08,0.667,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Epcoritamab,Oedema,4,60,1.799,1.799,1.31,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Epcoritamab,Malaise,10,60,0.948,0.948,0.03,1.000,0.200,0.500,8.623,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Epcoritamab,Arthralgia,3,60,0.417,0.417,2.34,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Epcoritamab,Pain in extremity,5,60,0.876,0.876,0.08,0.800,0.200,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Epcoritamab,Respiratory failure,3,60,0.714,0.714,0.33,1.000,1.000,0.333,9.827,死亡率=100.0%; 罕见+严重
Epcoritamab,Ascites,3,60,1.160,1.160,0.06,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Epcoritamab,Somnolence,3,60,1.316,1.316,0.21,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Epcoritamab,Blood creatinine increased,3,60,0.588,0.588,0.82,0.667,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Epcoritamab,Toxicity to various agents,7,60,1.814,1.814,2.35,1.000,0.000,0.857,8.980,严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Epcoritamab,Blood pressure increased,3,60,1.199,1.199,0.09,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Epcoritamab,Interstitial lung disease,4,60,0.876,0.876,0.07,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Epcoritamab,Hyponatraemia,3,60,0.798,0.798,0.14,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Epcoritamab,Metastases to central nervous system,4,60,1.320,1.320,0.29,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Epcoritamab,Spinal stenosis,3,60,0.000,0.000,104.92,1.000,0.000,1.000,9.827,χ²=104.9 (统计显著); 罕见+严重; 住院率=100.0%
Imatinib,Blood pressure increased,4,60,1.175,1.175,0.10,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Imatinib,Toxicity to various agents,3,60,0.548,0.548,1.05,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Imatinib,Lymphadenopathy,4,60,1.453,1.453,0.51,1.000,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Imatinib,Abdominal distension,6,60,1.892,1.892,2.26,1.000,0.000,0.667,9.134,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Imatinib,Decreased appetite,7,60,0.328,0.328,9.04,1.000,0.143,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Imatinib,Muscular weakness,7,60,1.465,1.465,0.94,1.000,0.000,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Imatinib,Asthenia,18,60,0.924,0.924,0.10,1.000,0.167,0.444,8.036,严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Imatinib,Weight decreased,16,60,1.607,1.607,3.29,1.000,0.062,0.562,8.153,严重事件率=100.0%; 罕见+严重; 住院率=56.2%
Imatinib,Chest pain,7,60,1.034,1.034,0.01,1.000,0.000,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Imatinib,Back pain,8,60,0.882,0.882,0.12,1.000,0.000,0.875,8.847,严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Imatinib,Gastrointestinal haemorrhage,3,60,1.307,1.307,0.20,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Imatinib,Lung disorder,4,60,1.688,1.688,1.01,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Imatinib,Urinary tract infection,6,60,0.808,0.808,0.25,1.000,0.000,0.667,9.134,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Imatinib,Anxiety,6,60,1.619,1.619,1.28,0.833,0.000,0.500,9.134,严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Imatinib,Pruritus,11,60,1.137,1.137,0.17,1.000,0.091,0.455,8.528,严重事件率=100.0%; 罕见+严重; 住院率=45.5%
Imatinib,Pneumonia,10,60,0.490,0.490,4.95,1.000,0.200,0.800,8.623,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Imatinib,Cardiac failure congestive,5,60,1.721,1.721,1.36,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Imatinib,Myelodysplastic syndrome,4,60,1.635,1.635,0.89,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Imatinib,Peripheral swelling,7,60,1.514,1.514,1.11,1.000,0.143,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Erlotinib,Pyrexia,10,60,0.414,0.414,7.78,1.000,0.200,0.800,8.623,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Erlotinib,Pleural effusion,5,60,0.770,0.770,0.32,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Erlotinib,Gait disturbance,5,60,1.633,1.633,1.13,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Erlotinib,Fall,10,60,1.994,1.994,4.50,1.000,0.200,0.800,8.623,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Erlotinib,Pruritus,11,60,1.464,1.464,1.49,1.000,0.091,0.545,8.528,严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Erlotinib,Blood creatinine increased,3,60,0.550,0.550,1.05,1.000,0.667,0.000,9.827,死亡率=66.7%; 罕见+严重
Erlotinib,Cardiac arrest,3,60,1.627,1.627,0.67,1.000,1.000,0.000,9.827,死亡率=100.0%; 罕见+严重
Erlotinib,Confusional state,5,60,1.128,1.128,0.07,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Erlotinib,Stomatitis,4,60,0.730,0.730,0.38,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Erlotinib,Drug dose omission,5,60,1.255,1.255,0.24,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Erlotinib,Dysgeusia,4,60,0.742,0.742,0.34,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Erlotinib,Peripheral swelling,5,60,1.367,1.367,0.46,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Gefitinib,Back pain,7,60,1.018,1.018,0.00,1.000,0.143,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Gefitinib,Neoplasm progression,3,60,0.918,0.918,0.02,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Gefitinib,Aspartate aminotransferase increased,6,60,1.251,1.251,0.28,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Alanine aminotransferase increased,6,60,1.173,1.173,0.14,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Gastrooesophageal reflux disease,3,60,1.649,1.649,0.71,0.667,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Gefitinib,Drug dose omission,4,60,1.025,1.025,0.00,1.000,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Gefitinib,Deep vein thrombosis,5,60,1.589,1.589,1.01,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Gefitinib,Mucosal inflammation,4,60,1.194,1.194,0.12,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Gefitinib,Febrile neutropenia,6,60,0.433,0.433,4.22,1.000,0.000,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Gefitinib,Asthenia,10,60,0.667,0.667,1.56,1.000,0.200,0.700,8.623,严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Gefitinib,Fall,5,60,0.994,0.994,0.00,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Gefitinib,Infection,4,60,0.643,0.643,0.75,1.000,0.750,0.250,9.540,死亡率=75.0%; 罕见+严重
Gefitinib,Product use issue,3,60,1.154,1.154,0.06,0.333,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Gefitinib,Hepatic enzyme increased,3,60,1.349,1.349,0.25,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Gefitinib,Atrial fibrillation,3,60,0.606,0.606,0.73,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Osimertinib,Lung neoplasm malignant,3,60,1.219,1.219,0.11,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Osimertinib,Hyponatraemia,5,60,1.315,1.315,0.35,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Osimertinib,Thrombocytopenia,6,60,0.452,0.452,3.79,0.833,0.167,0.500,9.134,严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Osimertinib,Adverse event,3,60,1.499,1.499,0.46,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Osimertinib,Asthenia,12,60,0.813,0.813,0.48,0.667,0.167,0.583,8.441,严重事件率=66.7%; 罕见+严重; 住院率=58.3%
Osimertinib,Vision blurred,4,60,1.427,1.427,0.48,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Osimertinib,Anaemia,5,60,0.286,0.286,8.47,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Osimertinib,Epistaxis,3,60,0.896,0.896,0.03,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Osimertinib,Lung infection,3,60,1.692,1.692,0.79,1.000,1.000,0.333,9.827,死亡率=100.0%; 罕见+严重
Osimertinib,Drug intolerance,4,60,1.749,1.749,1.18,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Osimertinib,Skin disorder,3,60,1.980,1.980,1.33,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Crizotinib,Pneumonitis,6,60,1.327,1.327,0.45,0.833,0.167,0.667,9.134,严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Crizotinib,Dehydration,11,60,1.192,1.192,0.32,0.818,0.000,0.818,8.528,严重事件率=81.8%; 罕见+严重; 住院率=81.8%
Crizotinib,Headache,4,60,0.505,0.505,1.85,0.750,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Crizotinib,Malignant neoplasm progression,3,60,0.189,0.189,9.99,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Crizotinib,Weight decreased,5,60,0.803,0.803,0.23,0.800,0.000,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Crizotinib,Interstitial lung disease,5,60,1.343,1.343,0.41,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Crizotinib,Respiratory failure,4,60,1.167,1.167,0.09,1.000,1.000,0.250,9.540,死亡率=100.0%; 罕见+严重
Paclitaxel,Myalgia,4,60,0.904,0.904,0.04,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Paclitaxel,Hypotension,7,60,0.978,0.978,0.00,1.000,0.143,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Paclitaxel,Pleural effusion,11,60,1.504,1.504,1.69,1.000,0.091,0.545,8.528,严重事件率=100.0%; 罕见+严重; 住院率=54.5%
Paclitaxel,Chest pain,4,60,0.642,0.642,0.75,1.000,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Paclitaxel,Dehydration,7,60,0.494,0.494,3.40,0.857,0.000,0.857,8.980,严重事件率=85.7%; 罕见+严重; 住院率=85.7%
Paclitaxel,Drug ineffective,3,60,0.324,0.324,4.02,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Paclitaxel,Neutrophil count decreased,9,60,1.661,1.661,2.15,1.000,0.111,0.889,8.729,严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Paclitaxel,Constipation,7,60,0.482,0.482,3.65,1.000,0.143,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Paclitaxel,Hypomagnesaemia,3,60,1.296,1.296,0.19,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Paclitaxel,Urinary tract infection,5,60,0.741,0.741,0.42,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Paclitaxel,Cardiac arrest,4,60,1.899,1.899,1.54,1.000,0.750,0.000,9.540,死亡率=75.0%; 罕见+严重
Paclitaxel,Loss of consciousness,4,60,1.899,1.899,1.54,1.000,0.500,0.000,9.540,死亡率=50.0%; 罕见+严重
Paclitaxel,Transaminases increased,4,60,1.755,1.755,1.18,1.000,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Paclitaxel,Headache,6,60,0.504,0.504,2.75,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Paclitaxel,Alanine aminotransferase increased,4,60,0.646,0.646,0.73,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Paclitaxel,White blood cell count decreased,10,60,0.860,0.860,0.21,1.000,0.100,0.800,8.623,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Paclitaxel,Intestinal perforation,3,60,1.809,1.809,0.99,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Paclitaxel,Haemorrhage,3,60,1.315,1.315,0.21,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Paclitaxel,Convulsion,3,60,1.523,1.523,0.49,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Paclitaxel,Lymphadenopathy,4,60,1.608,1.608,0.84,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Paclitaxel,Back pain,13,60,1.625,1.625,2.83,1.000,0.077,0.462,8.361,严重事件率=100.0%; 罕见+严重; 住院率=46.2%
Paclitaxel,Renal failure acute,5,60,1.122,1.122,0.06,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Paclitaxel,Gastrointestinal haemorrhage,3,60,1.447,1.447,0.38,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Paclitaxel,Blood creatinine increased,4,60,0.635,0.635,0.79,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Paclitaxel,Bone marrow failure,3,60,0.826,0.826,0.10,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Paclitaxel,Infection,5,60,0.675,0.675,0.73,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Paclitaxel,Stomatitis,5,60,0.790,0.790,0.26,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Paclitaxel,Hypoxia,6,60,1.998,1.998,2.69,1.000,0.167,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Paclitaxel,Haemoglobin decreased,6,60,0.685,0.685,0.81,1.000,0.167,0.667,9.134,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Paclitaxel,Musculoskeletal pain,3,60,1.670,1.670,0.73,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Docetaxel,Stomatitis,6,60,0.902,0.902,0.06,0.833,0.167,0.500,9.134,严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Docetaxel,Myelodysplastic syndrome,3,60,1.264,1.264,0.15,1.000,0.667,0.000,9.827,死亡率=66.7%; 罕见+严重
Docetaxel,Infection,10,60,1.311,1.311,0.67,1.000,0.200,0.700,8.623,严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Docetaxel,Dizziness,9,60,0.713,0.713,0.97,1.000,0.111,0.444,8.729,严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Docetaxel,Neutrophil count decreased,7,60,1.206,1.206,0.23,1.000,0.143,0.714,8.980,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Docetaxel,Rash,16,60,0.642,0.642,2.95,0.938,0.062,0.625,8.153,严重事件率=93.8%; 罕见+严重; 住院率=62.5%
Docetaxel,Drug intolerance,3,60,1.014,1.014,0.00,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Docetaxel,Breast cancer metastatic,3,60,1.441,1.441,0.37,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Docetaxel,Musculoskeletal pain,3,60,1.580,1.580,0.58,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Docetaxel,Platelet count decreased,6,60,0.387,0.387,5.47,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Docetaxel,White blood cell count decreased,8,60,0.646,0.646,1.44,1.000,0.000,0.500,8.847,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Docetaxel,Colitis,6,60,0.800,0.800,0.28,1.000,0.167,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Docetaxel,Cardiac arrest,3,60,1.325,1.325,0.22,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Docetaxel,Hyperglycaemia,5,60,1.734,1.734,1.40,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Docetaxel,General physical health deterioration,6,60,1.133,1.133,0.09,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Docetaxel,Urinary tract infection,7,60,0.993,0.993,0.00,1.000,0.143,1.000,8.980,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Docetaxel,Alanine aminotransferase increased,5,60,0.768,0.768,0.33,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Docetaxel,Aspartate aminotransferase increased,5,60,0.819,0.819,0.19,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Docetaxel,Oromandibular dystonia,3,60,0.000,0.000,79.21,1.000,0.000,1.000,9.827,χ²=79.2 (统计显著); 罕见+严重; 住院率=100.0%
Docetaxel,Bone marrow failure,3,60,0.782,0.782,0.17,1.000,1.000,0.333,9.827,死亡率=100.0%; 罕见+严重
Docetaxel,Rectal haemorrhage,3,60,1.467,1.467,0.41,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Doxorubicin,Arthralgia,6,60,0.670,0.670,0.91,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Asthenia,15,60,0.834,0.834,0.46,1.000,0.133,0.667,8.218,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Doxorubicin,Drug ineffective,4,60,0.428,0.428,2.90,1.000,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Doxorubicin,Cough,11,60,1.331,1.331,0.83,1.000,0.091,0.636,8.528,严重事件率=100.0%; 罕见+严重; 住院率=63.6%
Doxorubicin,Pain,6,60,0.575,0.575,1.77,1.000,0.167,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Doxorubicin,Cerebral haemorrhage,3,60,1.861,1.861,1.08,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Doxorubicin,Infusion related reaction,5,60,1.132,1.132,0.07,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Doxorubicin,Hyponatraemia,8,60,1.758,1.758,2.36,1.000,0.125,0.500,8.847,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Doxorubicin,Hypotension,12,60,1.698,1.698,3.11,1.000,0.167,0.833,8.441,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Doxorubicin,Platelet count decreased,10,60,0.680,0.680,1.40,1.000,0.200,0.900,8.623,严重事件率=100.0%; 罕见+严重; 住院率=90.0%
Doxorubicin,Weight decreased,7,60,0.738,0.738,0.61,1.000,0.143,0.714,8.980,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Doxorubicin,Heart rate increased,3,60,1.126,1.126,0.04,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Doxorubicin,Chills,4,60,0.803,0.803,0.18,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Doxorubicin,Mucosal inflammation,4,60,0.983,0.983,0.00,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Doxorubicin,Dyspnoea,15,60,0.681,0.681,2.08,0.933,0.067,0.467,8.218,严重事件率=93.3%; 罕见+严重; 住院率=46.7%
Doxorubicin,Hypersensitivity,3,60,0.598,0.598,0.77,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Doxorubicin,Product use issue,4,60,1.282,1.282,0.23,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Doxorubicin,Dehydration,8,60,0.559,0.559,2.61,1.000,0.000,0.875,8.847,严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Doxorubicin,Metastases to liver,4,60,1.427,1.427,0.47,1.000,0.750,0.000,9.540,死亡率=75.0%; 罕见+严重
Doxorubicin,Cardiac failure congestive,3,60,1.097,1.097,0.02,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Doxorubicin,White blood cell count decreased,9,60,0.760,0.760,0.63,1.000,0.000,0.889,8.729,严重事件率=100.0%; 罕见+严重; 住院率=88.9%
Doxorubicin,Cardiac arrest,4,60,1.872,1.872,1.47,1.000,1.000,0.000,9.540,死亡率=100.0%; 罕见+严重
Doxorubicin,Adverse event,3,60,1.222,1.222,0.11,1.000,0.667,0.000,9.827,死亡率=66.7%; 罕见+严重
Doxorubicin,Haemoglobin decreased,8,60,0.908,0.908,0.07,1.000,0.000,0.750,8.847,严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Doxorubicin,Hypertension,10,60,1.671,1.671,2.44,1.000,0.100,0.600,8.623,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Doxorubicin,Neutrophil count decreased,9,60,1.638,1.638,2.03,1.000,0.111,0.556,8.729,严重事件率=100.0%; 罕见+严重; 住院率=55.6%
Doxorubicin,Tumour lysis syndrome,4,60,1.935,1.935,1.63,1.000,0.750,0.000,9.540,死亡率=75.0%; 罕见+严重
Doxorubicin,Myocardial infarction,4,60,1.375,1.375,0.38,1.000,1.000,0.250,9.540,死亡率=100.0%; 罕见+严重
Doxorubicin,Renal impairment,3,60,0.743,0.743,0.25,1.000,1.000,0.000,9.827,死亡率=100.0%; 罕见+严重
Doxorubicin,Loss of consciousness,3,60,1.380,1.380,0.29,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Doxorubicin,Aspartate aminotransferase increased,5,60,0.853,0.853,0.12,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Doxorubicin,Post embolisation syndrome,3,60,0.000,0.000,82.64,1.000,0.000,0.667,9.827,χ²=82.6 (统计显著); 罕见+严重; 住院率=66.7%
Doxorubicin,Stomatitis,5,60,0.778,0.778,0.29,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Doxorubicin,Blood creatinine increased,6,60,0.950,0.950,0.01,1.000,0.000,0.667,9.134,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Doxorubicin,Strongyloidiasis,3,60,0.000,0.000,82.64,1.000,0.000,1.000,9.827,χ²=82.6 (统计显著); 罕见+严重; 住院率=100.0%
Carboplatin,Non-small cell lung cancer,3,60,1.980,1.980,1.29,1.000,0.667,0.000,9.827,死亡率=66.7%; 罕见+严重
Carboplatin,Pneumonitis,3,60,0.363,0.363,3.15,1.000,1.000,0.000,9.827,死亡率=100.0%; 罕见+严重
Carboplatin,Cough,7,60,0.711,0.711,0.76,0.857,0.143,0.429,8.980,严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Carboplatin,Second primary malignancy,4,60,1.744,1.744,1.14,1.000,0.500,0.000,9.540,死亡率=50.0%; 罕见+严重
Carboplatin,Acute myeloid leukaemia,3,60,1.878,1.878,1.10,1.000,0.667,0.000,9.827,死亡率=66.7%; 罕见+严重
Carboplatin,Pleural effusion,7,60,0.790,0.790,0.36,0.857,0.000,0.714,8.980,严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Carboplatin,Syncope,6,60,1.559,1.559,1.08,1.000,0.000,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Carboplatin,Alanine aminotransferase increased,7,60,0.970,0.970,0.01,1.000,0.143,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Carboplatin,Aspartate aminotransferase increased,8,60,1.191,1.191,0.22,1.000,0.125,0.750,8.847,严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Carboplatin,Neutrophil count decreased,11,60,1.735,1.735,3.05,1.000,0.091,0.818,8.528,严重事件率=100.0%; 罕见+严重; 住院率=81.8%
Carboplatin,Breast cancer,3,60,1.787,1.787,0.93,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Carboplatin,Constipation,14,60,0.830,0.830,0.45,1.000,0.000,0.429,8.287,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Carboplatin,Haemoglobin decreased,7,60,0.677,0.677,1.00,1.000,0.143,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Carboplatin,Lung disorder,3,60,1.162,1.162,0.06,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Carboplatin,Neuropathy peripheral,9,60,1.003,1.003,0.00,1.000,0.000,0.444,8.729,严重事件率=100.0%; 罕见+严重; 住院率=44.4%
Carboplatin,Colitis,5,60,0.591,0.591,1.32,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Carboplatin,Deep vein thrombosis,5,60,1.120,1.120,0.06,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Carboplatin,Hyponatraemia,7,60,1.305,1.305,0.45,1.000,0.000,0.714,8.980,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Carboplatin,Cardiac failure congestive,3,60,0.938,0.938,0.01,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Carboplatin,Infusion related reaction,3,60,0.571,0.571,0.90,0.667,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Carboplatin,Myalgia,7,60,1.368,1.368,0.63,1.000,0.000,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Carboplatin,Dysphagia,11,60,1.964,1.964,4.59,1.000,0.091,0.636,8.528,严重事件率=100.0%; 罕见+严重; 住院率=63.6%
Carboplatin,Abdominal discomfort,6,60,1.101,1.101,0.05,1.000,0.000,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Carboplatin,Headache,7,60,0.498,0.498,3.31,1.000,0.143,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Carboplatin,Infection,7,60,0.805,0.805,0.30,1.000,0.000,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Carboplatin,Diverticulitis,3,60,1.831,1.831,1.01,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Carboplatin,Urinary tract infection,7,60,0.885,0.885,0.10,1.000,0.143,0.714,8.980,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Carboplatin,Hepatic function abnormal,3,60,1.162,1.162,0.06,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Carboplatin,Atrial fibrillation,7,60,1.023,1.023,0.00,1.000,0.143,0.857,8.980,严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Carboplatin,Abdominal pain,16,60,1.188,1.188,0.43,1.000,0.062,0.750,8.153,严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Carboplatin,Weight decreased,5,60,0.447,0.447,3.20,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Carboplatin,Metastases to bone,4,60,1.503,1.503,0.61,1.000,0.750,0.250,9.540,死亡率=75.0%; 罕见+严重
Carboplatin,Pruritus,5,60,0.470,0.470,2.80,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Carboplatin,Hyperglycaemia,5,60,1.546,1.546,0.87,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Cisplatin,Cough,4,60,0.448,0.448,2.57,1.000,0.750,0.250,9.540,死亡率=75.0%; 罕见+严重
Cisplatin,Second primary malignancy,3,60,1.436,1.436,0.36,1.000,0.667,0.000,9.827,死亡率=66.7%; 罕见+严重
Cisplatin,Myelodysplastic syndrome,3,60,1.259,1.259,0.15,1.000,1.000,0.000,9.827,死亡率=100.0%; 罕见+严重
Cisplatin,Rash,11,60,0.435,0.435,7.51,0.909,0.000,0.545,8.528,严重事件率=90.9%; 罕见+严重; 住院率=54.5%
Cisplatin,Peripheral swelling,5,60,1.109,1.109,0.05,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Headache,5,60,0.395,0.395,4.37,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Cisplatin,Infusion related reaction,3,60,0.639,0.639,0.58,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Cisplatin,Chills,5,60,0.967,0.967,0.01,0.800,0.200,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Cisplatin,Confusional state,7,60,1.300,1.300,0.44,1.000,0.143,0.714,8.980,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Cisplatin,Neutrophil count decreased,10,60,1.752,1.752,2.90,0.900,0.000,0.600,8.623,严重事件率=90.0%; 罕见+严重; 住院率=60.0%
Cisplatin,Infection,7,60,0.900,0.900,0.07,1.000,0.000,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Cisplatin,Malaise,10,60,0.718,0.718,1.03,1.000,0.100,1.000,8.623,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Pancytopenia,10,60,1.270,1.270,0.52,1.000,0.200,0.600,8.623,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Cisplatin,Pain,16,60,1.524,1.524,2.60,1.000,0.062,0.625,8.153,严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Cisplatin,Tachycardia,3,60,1.049,1.049,0.01,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Cisplatin,Pain in extremity,6,60,0.801,0.801,0.27,1.000,0.000,1.000,9.134,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Dysgeusia,8,60,1.233,1.233,0.32,1.000,0.000,1.000,8.847,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Back pain,11,60,1.283,1.283,0.63,1.000,0.000,0.909,8.528,严重事件率=100.0%; 罕见+严重; 住院率=90.9%
Cisplatin,Dizziness,13,60,1.040,1.040,0.02,1.000,0.077,1.000,8.361,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Cisplatin,Emphysematous cholecystitis,3,60,0.000,0.000,78.91,1.000,0.000,1.000,9.827,χ²=78.9 (统计显著); 罕见+严重; 住院率=100.0%
Cisplatin,Haemoglobin decreased,6,60,0.646,0.646,1.09,0.833,0.167,0.833,9.134,严重事件率=83.3%; 罕见+严重; 住院率=83.3%
Cisplatin,Metastases to central nervous system,4,60,1.001,1.001,0.00,1.000,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Cisplatin,Blood creatinine increased,8,60,1.226,1.226,0.31,1.000,0.125,0.750,8.847,严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Cisplatin,Haemorrhage,3,60,1.240,1.240,0.13,1.000,1.000,0.333,9.827,死亡率=100.0%; 罕见+严重
Cisplatin,Convulsion,4,60,1.950,1.950,1.66,1.000,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Cisplatin,Thrombosis,3,60,0.879,0.879,0.05,1.000,0.667,0.000,9.827,死亡率=66.7%; 罕见+严重
Lenalidomide,Red blood cell count decreased,4,60,1.455,1.455,0.54,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Lenalidomide,Anaemia,6,60,0.455,0.455,3.73,0.833,0.167,0.500,9.134,严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Lenalidomide,Dyspnoea,11,60,0.804,0.804,0.49,1.000,0.182,0.636,8.528,严重事件率=100.0%; 罕见+严重; 住院率=63.6%
Lenalidomide,Dehydration,13,60,1.498,1.498,2.01,1.000,0.000,0.846,8.361,严重事件率=100.0%; 罕见+严重; 住院率=84.6%
Lenalidomide,Platelet count decreased,17,60,1.923,1.923,6.92,1.000,0.118,0.412,8.093,严重事件率=100.0%; 罕见+严重; 住院率=41.2%
Lenalidomide,Confusional state,4,60,1.232,1.232,0.17,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Lenalidomide,Pyrexia,12,60,0.688,0.688,1.60,1.000,0.000,0.833,8.441,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Lenalidomide,Muscular weakness,5,60,1.821,1.821,1.73,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Pomalidomide,Respiratory failure,3,60,1.024,1.024,0.00,1.000,1.000,0.333,9.827,死亡率=100.0%; 罕见+严重
Pomalidomide,Infection,6,60,1.455,1.455,0.81,0.833,0.167,0.500,9.134,严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Pomalidomide,Pain,7,60,1.221,1.221,0.26,1.000,0.000,0.857,8.980,严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Pomalidomide,Dyspnoea,14,60,1.153,1.153,0.27,0.929,0.071,0.500,8.287,严重事件率=92.9%; 罕见+严重; 住院率=50.0%
Pomalidomide,Stomatitis,4,60,1.121,1.121,0.05,0.500,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Pomalidomide,Vomiting,6,60,0.358,0.358,6.58,0.833,0.000,0.667,9.134,严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Pomalidomide,Renal failure,6,60,1.519,1.519,1.01,1.000,0.167,0.667,9.134,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Pomalidomide,Red blood cell count decreased,4,60,1.626,1.626,0.91,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Pomalidomide,Platelet count decreased,3,60,0.362,0.362,3.25,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Pomalidomide,Anaemia,7,60,0.595,0.595,1.84,1.000,0.143,0.714,8.980,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Pomalidomide,Urinary tract infection,6,60,1.598,1.598,1.27,1.000,0.000,1.000,9.134,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Pomalidomide,Atrial fibrillation,6,60,1.846,1.846,2.18,1.000,0.000,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Pomalidomide,Dehydration,5,60,0.627,0.627,1.06,0.800,0.000,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Bortezomib,Constipation,13,60,1.037,1.037,0.02,1.000,0.077,0.692,8.361,严重事件率=100.0%; 罕见+严重; 住院率=69.2%
Bortezomib,Platelet count decreased,8,60,0.624,0.624,1.70,0.875,0.125,0.750,8.847,严重事件率=87.5%; 罕见+严重; 住院率=75.0%
Bortezomib,Malaise,12,60,1.046,1.046,0.02,1.000,0.000,0.917,8.441,严重事件率=100.0%; 罕见+严重; 住院率=91.7%
Bortezomib,Chest pain,6,60,1.108,1.108,0.06,1.000,0.167,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Bortezomib,Oedema peripheral,6,60,1.361,1.361,0.53,1.000,0.000,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Bortezomib,Pain,10,60,1.122,1.122,0.12,0.800,0.200,0.500,8.623,严重事件率=80.0%; 罕见+严重; 住院率=50.0%
Bortezomib,Muscular weakness,5,60,1.295,1.295,0.31,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Bortezomib,Rash,10,60,0.477,0.477,5.40,1.000,0.200,0.600,8.623,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Bortezomib,Bone pain,4,60,1.605,1.605,0.84,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Bortezomib,Haemorrhage,3,60,1.495,1.495,0.45,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Bortezomib,Vomiting,15,60,0.579,0.579,4.27,1.000,0.067,0.667,8.218,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Bortezomib,Septic shock,4,60,1.385,1.385,0.40,1.000,0.750,0.250,9.540,死亡率=75.0%; 罕见+严重
Bortezomib,Leukopenia,4,60,1.218,1.218,0.15,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Bortezomib,Blood creatinine increased,5,60,0.908,0.908,0.04,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Bortezomib,Abdominal pain,10,60,0.981,0.981,0.00,1.000,0.200,0.800,8.623,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Bortezomib,Pruritus,10,60,1.296,1.296,0.62,1.000,0.000,0.900,8.623,严重事件率=100.0%; 罕见+严重; 住院率=90.0%
Bortezomib,Respiratory syncytial virus bronchiolitis,4,60,0.000,0.000,127.57,1.000,0.000,1.000,9.540,χ²=127.6 (统计显著); 罕见+严重; 住院率=100.0%
Bortezomib,Erythema,9,60,1.877,1.877,3.36,1.000,0.000,1.000,8.729,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Bortezomib,Tumour lysis syndrome,3,60,1.644,1.644,0.70,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Carfilzomib,Rash,7,60,0.479,0.479,3.77,1.000,0.000,0.714,8.980,严重事件率=100.0%; 罕见+严重; 住院率=71.4%
Carfilzomib,Pulmonary embolism,8,60,1.941,1.941,3.40,1.000,0.000,0.500,8.847,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Carfilzomib,Abdominal pain,5,60,0.696,0.696,0.64,0.800,0.200,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Carfilzomib,Vomiting,6,60,0.329,0.329,7.82,1.000,0.167,1.000,9.134,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Febrile neutropenia,12,60,1.210,1.210,0.41,1.000,0.000,0.917,8.441,严重事件率=100.0%; 罕见+严重; 住院率=91.7%
Carfilzomib,Anaemia,5,60,0.388,0.388,4.61,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Dehydration,10,60,1.172,1.172,0.24,1.000,0.100,1.000,8.623,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Dizziness,4,60,0.540,0.540,1.50,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Carfilzomib,Fall,5,60,1.363,1.363,0.46,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Malignant neoplasm progression,3,60,0.205,0.205,8.87,1.000,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Carfilzomib,Pleural effusion,6,60,1.312,1.312,0.42,1.000,0.167,1.000,9.134,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Carfilzomib,Gait disturbance,3,60,1.355,1.355,0.26,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Venetoclax,Dyspnoea,13,60,0.818,0.818,0.49,1.000,0.154,0.846,8.361,严重事件率=100.0%; 罕见+严重; 住院率=84.6%
Venetoclax,Cough,8,60,1.327,1.327,0.60,0.750,0.125,0.625,8.847,严重事件率=75.0%; 罕见+严重; 住院率=62.5%
Venetoclax,Abdominal pain,7,60,0.819,0.819,0.26,1.000,0.143,1.000,8.980,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Constipation,6,60,0.565,0.565,1.91,1.000,0.000,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Venetoclax,Infusion related reaction,5,60,1.573,1.573,0.97,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Anaemia,8,60,0.522,0.522,3.31,1.000,0.125,0.875,8.847,严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Venetoclax,Asthenia,18,60,1.405,1.405,1.94,0.944,0.167,0.722,8.036,严重事件率=94.4%; 罕见+严重; 住院率=72.2%
Venetoclax,Thrombocytopenia,15,60,1.314,1.314,1.04,0.800,0.200,0.533,8.218,严重事件率=80.0%; 罕见+严重; 住院率=53.3%
Venetoclax,Drug intolerance,3,60,1.467,1.467,0.42,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Venetoclax,White blood cell count decreased,14,60,1.676,1.676,3.52,0.857,0.071,0.429,8.287,严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Venetoclax,Fall,6,60,1.375,1.375,0.57,0.833,0.167,0.667,9.134,严重事件率=83.3%; 罕见+严重; 住院率=66.7%
Venetoclax,Vomiting,10,60,0.461,0.461,5.93,1.000,0.200,1.000,8.623,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Colitis,8,60,1.563,1.563,1.51,1.000,0.000,1.000,8.847,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Venetoclax,Pruritus,4,60,0.608,0.608,0.96,0.500,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Venetoclax,Malaise,9,60,0.937,0.937,0.04,1.000,0.111,0.778,8.729,严重事件率=100.0%; 罕见+严重; 住院率=77.8%
Venetoclax,Oedema peripheral,5,60,1.357,1.357,0.44,0.800,0.200,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Venetoclax,Renal impairment,5,60,1.754,1.754,1.51,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Venetoclax,Haemoglobin decreased,10,60,1.594,1.594,2.05,0.900,0.100,0.800,8.623,严重事件率=90.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Hypokalaemia,5,60,1.753,1.753,1.48,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Dysphagia,8,60,1.905,1.905,3.14,1.000,0.125,0.875,8.847,严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Ibrutinib,Arthralgia,13,60,1.749,1.749,3.80,0.846,0.154,0.615,8.361,严重事件率=84.6%; 罕见+严重; 住院率=61.5%
Ibrutinib,Pain,10,60,1.136,1.136,0.15,0.800,0.200,0.600,8.623,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Ibrutinib,Chest pain,10,60,1.917,1.917,3.99,0.800,0.100,0.800,8.623,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Oedema peripheral,7,60,1.619,1.619,1.52,0.857,0.143,0.571,8.980,严重事件率=85.7%; 罕见+严重; 住院率=57.1%
Ibrutinib,Fall,10,60,1.974,1.974,4.36,1.000,0.100,0.900,8.623,严重事件率=100.0%; 罕见+严重; 住院率=90.0%
Ibrutinib,Malaise,7,60,0.608,0.608,1.67,0.857,0.143,0.714,8.980,严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Ibrutinib,Confusional state,5,60,1.116,1.116,0.06,0.800,0.200,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Ibrutinib,Dyspnoea,10,60,0.524,0.524,4.05,0.700,0.200,0.500,8.623,严重事件率=70.0%; 罕见+严重; 住院率=50.0%
Ibrutinib,Constipation,11,60,0.883,0.883,0.16,0.909,0.091,0.545,8.528,严重事件率=90.9%; 罕见+严重; 住院率=54.5%
Ibrutinib,Stomatitis,8,60,1.481,1.481,1.15,0.875,0.000,0.500,8.847,严重事件率=87.5%; 罕见+严重; 住院率=50.0%
Ibrutinib,Drug dose omission,7,60,1.767,1.767,2.13,0.714,0.000,0.714,8.980,严重事件率=71.4%; 罕见+严重; 住院率=71.4%
Ibrutinib,Vomiting,15,60,0.586,0.586,4.08,0.933,0.200,0.733,8.218,严重事件率=93.3%; 罕见+严重; 住院率=73.3%
Ibrutinib,White blood cell count decreased,7,60,0.685,0.685,0.95,0.857,0.143,0.429,8.980,严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Ibrutinib,Muscle spasms,8,60,1.976,1.976,3.51,0.750,0.000,0.625,8.847,严重事件率=75.0%; 罕见+严重; 住院率=62.5%
Ibrutinib,Chills,5,60,1.180,1.180,0.13,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Ibrutinib,Hypertension,6,60,1.141,1.141,0.10,0.833,0.167,0.500,9.134,严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Ibrutinib,Memory impairment,3,60,1.752,1.752,0.89,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Ibrutinib,Infection,3,60,0.461,0.461,1.80,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Olaparib,Hypoaesthesia,6,60,1.711,1.711,1.61,1.000,0.000,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Olaparib,Malaise,13,60,1.004,1.004,0.00,0.615,0.077,0.462,8.361,严重事件率=61.5%; 罕见+严重; 住院率=46.2%
Olaparib,Somnolence,3,60,1.063,1.063,0.01,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Olaparib,Flushing,3,60,1.529,1.529,0.50,0.667,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Olaparib,Pancytopenia,8,60,1.071,1.071,0.03,1.000,0.125,0.625,8.847,严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Olaparib,Influenza like illness,3,60,1.895,1.895,1.15,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Olaparib,Gait disturbance,5,60,1.411,1.411,0.55,0.800,0.200,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Olaparib,Hypotension,4,60,0.552,0.552,1.37,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Olaparib,Chest pain,8,60,1.321,1.321,0.57,0.625,0.000,0.500,8.847,严重事件率=62.5%; 罕见+严重; 住院率=50.0%
Olaparib,Neutropenia,6,60,0.292,0.292,9.75,1.000,0.167,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Olaparib,Acute kidney injury,5,60,1.274,1.274,0.27,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Olaparib,Fall,5,60,0.834,0.834,0.15,1.000,0.200,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Olaparib,Pain in extremity,10,60,1.454,1.454,1.30,0.600,0.000,0.500,8.623,严重事件率=60.0%; 罕见+严重; 住院率=50.0%
Olaparib,Drug ineffective,3,60,0.325,0.325,3.99,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Olaparib,Oedema,5,60,1.840,1.840,1.74,0.800,0.000,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Olaparib,Hypertension,7,60,1.169,1.169,0.16,0.571,0.143,0.429,8.980,严重事件率=57.1%; 罕见+严重; 住院率=42.9%
Olaparib,Product use in unapproved indication,4,60,1.846,1.846,1.40,1.000,0.500,0.000,9.540,死亡率=50.0%; 罕见+严重
Rucaparib,Bone marrow failure,9,60,1.786,1.786,2.70,1.000,0.000,0.778,8.729,严重事件率=100.0%; 罕见+严重; 住院率=77.8%
Rucaparib,Influenza,5,60,1.818,1.818,1.60,0.600,0.000,0.600,9.317,严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Rucaparib,Stomatitis,10,60,1.102,1.102,0.09,0.800,0.200,0.500,8.623,严重事件率=80.0%; 罕见+严重; 住院率=50.0%
Rucaparib,Cough,12,60,1.002,1.002,0.00,0.583,0.000,0.500,8.441,严重事件率=58.3%; 罕见+严重; 住院率=50.0%
Rucaparib,Rash,10,60,0.284,0.284,16.68,0.500,0.100,0.500,8.623,χ²=16.7 (统计显著); 罕见+严重; 住院率=50.0%
Rucaparib,Oedema peripheral,5,60,0.671,0.671,0.74,0.800,0.000,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Rucaparib,Dysphagia,6,60,0.829,0.829,0.19,0.833,0.000,0.500,9.134,严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Rucaparib,Insomnia,8,60,0.975,0.975,0.00,0.750,0.125,0.500,8.847,严重事件率=75.0%; 罕见+严重; 住院率=50.0%
Rucaparib,Pain in extremity,10,60,0.981,0.981,0.00,0.800,0.000,0.500,8.623,严重事件率=80.0%; 罕见+严重; 住院率=50.0%
Niraparib,Urinary tract infection,16,60,1.491,1.491,2.23,1.000,0.062,0.750,8.153,严重事件率=100.0%; 罕见+严重; 住院率=75.0%
Niraparib,Epistaxis,8,60,1.223,1.223,0.29,0.875,0.000,0.625,8.847,严重事件率=87.5%; 罕见+严重; 住院率=62.5%
Niraparib,Pancytopenia,11,60,0.879,0.879,0.16,1.000,0.182,0.909,8.528,严重事件率=100.0%; 罕见+严重; 住院率=90.9%
Niraparib,Myelodysplastic syndrome,3,60,0.790,0.790,0.15,1.000,0.667,0.000,9.827,死亡率=66.7%; 罕见+严重
Niraparib,Tachycardia,6,60,1.370,1.370,0.52,0.833,0.000,0.833,9.134,严重事件率=83.3%; 罕见+严重; 住院率=83.3%
Niraparib,Chills,7,60,0.861,0.861,0.14,0.714,0.000,0.429,8.980,严重事件率=71.4%; 罕见+严重; 住院率=42.9%
Niraparib,Dysphagia,5,60,0.598,0.598,1.23,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Niraparib,Haemorrhage,6,60,1.631,1.631,1.26,1.000,0.167,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Niraparib,Neutrophil count decreased,12,60,1.335,1.335,0.88,1.000,0.167,0.417,8.441,严重事件率=100.0%; 罕见+严重; 住院率=41.7%
Niraparib,Hypotension,10,60,0.838,0.838,0.28,1.000,0.100,0.700,8.623,严重事件率=100.0%; 罕见+严重; 住院率=70.0%
Niraparib,Renal failure,7,60,0.589,0.589,1.82,1.000,0.143,1.000,8.980,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Niraparib,Drug dose omission,13,60,1.769,1.769,3.70,0.769,0.077,0.462,8.361,严重事件率=76.9%; 罕见+严重; 住院率=46.2%
Niraparib,Myalgia,12,60,1.714,1.714,3.05,0.917,0.083,0.500,8.441,严重事件率=91.7%; 罕见+严重; 住院率=50.0%
Niraparib,Stomatitis,16,60,1.595,1.595,3.04,0.875,0.000,0.500,8.153,严重事件率=87.5%; 罕见+严重; 住院率=50.0%
Niraparib,Gait disturbance,7,60,1.186,1.186,0.18,0.857,0.143,0.429,8.980,严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Niraparib,Muscular weakness,7,60,0.958,0.958,0.01,1.000,0.143,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Niraparib,Cough,11,60,0.797,0.797,0.51,0.727,0.000,0.545,8.528,严重事件率=72.7%; 罕见+严重; 住院率=54.5%
Niraparib,Hypersensitivity,5,60,0.606,0.606,1.16,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Niraparib,Renal disorder,5,60,1.784,1.784,1.47,1.000,0.000,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Niraparib,Pleural effusion,5,60,0.391,0.391,4.34,1.000,0.200,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Niraparib,Rectal haemorrhage,6,60,1.939,1.939,2.31,1.000,0.167,0.833,9.134,严重事件率=100.0%; 罕见+严重; 住院率=83.3%
Niraparib,Infection,4,60,0.317,0.317,5.41,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Niraparib,Drug intolerance,3,60,0.633,0.633,0.58,0.667,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Talazoparib,Colitis,5,60,1.124,1.124,0.06,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Talazoparib,Pneumonia,14,60,1.232,1.232,0.57,1.000,0.143,0.571,8.287,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Talazoparib,General physical health deterioration,3,60,0.938,0.938,0.01,0.667,0.667,0.333,9.827,死亡率=66.7%; 罕见+严重
Talazoparib,Vomiting,13,60,0.706,0.706,1.49,0.692,0.077,0.615,8.361,严重事件率=69.2%; 罕见+严重; 住院率=61.5%
Talazoparib,Pyrexia,17,60,0.987,0.987,0.00,1.000,0.176,0.706,8.093,严重事件率=100.0%; 罕见+严重; 住院率=70.6%
Talazoparib,Aspartate aminotransferase increased,7,60,1.969,1.969,3.11,1.000,0.143,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Talazoparib,Asthenia,11,60,0.987,0.987,0.00,0.909,0.182,0.727,8.528,严重事件率=90.9%; 罕见+严重; 住院率=72.7%
Talazoparib,Urinary tract infection,7,60,1.683,1.683,1.81,0.714,0.143,0.571,8.980,严重事件率=71.4%; 罕见+严重; 住院率=57.1%
Talazoparib,Hypotension,5,60,1.108,1.108,0.05,1.000,0.000,1.000,9.317,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Talazoparib,Fall,5,60,1.331,1.331,0.39,0.800,0.000,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Talazoparib,Dizziness,8,60,1.071,1.071,0.04,0.625,0.000,0.500,8.847,严重事件率=62.5%; 罕见+严重; 住院率=50.0%
Talazoparib,Dyspepsia,3,60,1.311,1.311,0.21,0.333,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Palbociclib,Oedema peripheral,5,60,1.196,1.196,0.15,0.800,0.200,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Palbociclib,Abdominal distension,4,60,1.644,1.644,0.93,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Palbociclib,Metastases to liver,4,60,1.747,1.747,1.18,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Palbociclib,Hypertension,3,60,0.587,0.587,0.83,1.000,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Palbociclib,Urinary tract infection,5,60,0.894,0.894,0.06,0.600,0.200,0.600,9.317,严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Palbociclib,Anaemia,16,60,0.938,0.938,0.06,0.938,0.125,0.438,8.153,严重事件率=93.8%; 罕见+严重; 住院率=43.8%
Palbociclib,Pain in extremity,11,60,1.936,1.936,4.53,0.818,0.000,0.455,8.528,严重事件率=81.8%; 罕见+严重; 住院率=45.5%
Palbociclib,Renal failure,3,60,0.505,0.505,1.39,1.000,1.000,0.333,9.827,死亡率=100.0%; 罕见+严重
Palbociclib,Febrile neutropenia,4,60,0.290,0.290,6.64,0.750,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Ribociclib,Anaemia,9,60,0.697,0.697,1.12,0.889,0.000,0.556,8.729,严重事件率=88.9%; 罕见+严重; 住院率=55.6%
Ribociclib,Pleural effusion,5,60,1.073,1.073,0.02,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Ribociclib,Back pain,8,60,1.583,1.583,1.61,0.625,0.125,0.500,8.847,严重事件率=62.5%; 罕见+严重; 住院率=50.0%
Ribociclib,Pneumonitis,7,60,1.666,1.666,1.74,1.000,0.143,0.857,8.980,严重事件率=100.0%; 罕见+严重; 住院率=85.7%
Ribociclib,Drug ineffective,9,60,1.618,1.618,1.98,0.333,0.222,0.000,8.729,死亡率=22.2%; 罕见+严重
Ribociclib,Myocardial infarction,3,60,1.672,1.672,0.76,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Ribociclib,Chest pain,6,60,1.579,1.579,1.20,0.667,0.000,0.500,9.134,严重事件率=66.7%; 罕见+严重; 住院率=50.0%
Abemaciclib,Pyrexia,5,60,0.265,0.265,9.73,0.800,0.200,0.800,9.317,严重事件率=80.0%; 罕见+严重; 住院率=80.0%
Abemaciclib,Hypotension,7,60,1.467,1.467,0.97,0.857,0.000,0.429,8.980,严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Abemaciclib,Asthenia,18,60,1.539,1.539,3.13,0.556,0.000,0.444,8.036,严重事件率=55.6%; 罕见+严重; 住院率=44.4%
Abemaciclib,Anaemia,7,60,0.499,0.499,3.34,1.000,0.000,0.571,8.980,严重事件率=100.0%; 罕见+严重; 住院率=57.1%
Abemaciclib,Pulmonary embolism,7,60,1.542,1.542,1.25,1.000,0.143,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Vemurafenib,Thrombocytopenia,4,60,0.306,0.306,6.02,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Vemurafenib,Weight decreased,12,60,1.619,1.619,2.61,1.000,0.167,0.417,8.441,严重事件率=100.0%; 罕见+严重; 住院率=41.7%
Vemurafenib,Decreased appetite,11,60,0.711,0.711,1.21,1.000,0.000,0.455,8.528,严重事件率=100.0%; 罕见+严重; 住院率=45.5%
Vemurafenib,Asthenia,12,60,0.829,0.829,0.39,1.000,0.167,0.583,8.441,严重事件率=100.0%; 罕见+严重; 住院率=58.3%
Vemurafenib,Abdominal pain,5,60,0.523,0.523,2.07,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Vemurafenib,Neutropenia,7,60,0.419,0.419,5.34,1.000,0.143,0.429,8.980,严重事件率=100.0%; 罕见+严重; 住院率=42.9%
Vemurafenib,Oropharyngeal pain,3,60,1.551,1.551,0.55,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Vemurafenib,Chest pain,5,60,0.996,0.996,0.00,0.800,0.000,0.600,9.317,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Vemurafenib,Blood creatinine increased,8,60,1.606,1.606,1.69,1.000,0.000,0.500,8.847,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Vemurafenib,Dyspnoea,9,60,0.505,0.505,4.12,1.000,0.111,0.667,8.729,严重事件率=100.0%; 罕见+严重; 住院率=66.7%
Vemurafenib,Dysgeusia,7,60,1.404,1.404,0.76,0.857,0.143,0.429,8.980,严重事件率=85.7%; 罕见+严重; 住院率=42.9%
Vemurafenib,Anaemia,5,60,0.292,0.292,8.17,0.600,0.000,0.600,9.317,严重事件率=60.0%; 罕见+严重; 住院率=60.0%
Vemurafenib,Neoplasm malignant,3,60,1.947,1.947,1.27,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Vemurafenib,Abdominal pain upper,4,60,0.810,0.810,0.17,1.000,0.250,0.250,9.540,死亡率=25.0%; 罕见+严重
Dabrafenib,Chest pain,7,60,1.381,1.381,0.68,0.857,0.143,0.571,8.980,严重事件率=85.7%; 罕见+严重; 住院率=57.1%
Dabrafenib,Thrombocytopenia,8,60,0.604,0.604,1.95,1.000,0.000,0.625,8.847,严重事件率=100.0%; 罕见+严重; 住院率=62.5%
Dabrafenib,Cerebrovascular accident,3,60,1.079,1.079,0.02,1.000,0.333,0.333,9.827,死亡率=33.3%; 罕见+严重
Dabrafenib,Oedema peripheral,6,60,1.445,1.445,0.76,1.000,0.167,0.500,9.134,严重事件率=100.0%; 罕见+严重; 住院率=50.0%
Dabrafenib,Peripheral swelling,4,60,1.125,1.125,0.05,0.500,0.500,0.250,9.540,死亡率=50.0%; 罕见+严重
Dabrafenib,Infection,8,60,1.324,1.324,0.59,1.000,0.125,1.000,8.847,严重事件率=100.0%; 罕见+严重; 住院率=100.0%
Dabrafenib,Confusional state,8,60,1.916,1.916,3.20,0.875,0.125,0.875,8.847,严重事件率=87.5%; 罕见+严重; 住院率=87.5%
Dabrafenib,Hypotension,10,60,1.714,1.714,2.73,1.000,0.100,0.800,8.623,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Dabrafenib,Dizziness,10,60,1.014,1.014,0.00,0.800,0.200,0.600,8.623,严重事件率=80.0%; 罕见+严重; 住院率=60.0%
Dabrafenib,Weight decreased,3,60,0.381,0.381,2.89,0.667,0.333,0.000,9.827,死亡率=33.3%; 罕见+严重
Dabrafenib,Anaemia,8,60,0.460,0.460,4.79,0.875,0.000,0.875,8.847,严重事件率=87.5%; 罕见+严重; 住院率=87.5%
Dabrafenib,Dysphagia,8,60,1.998,1.998,3.64,0.750,0.125,0.625,8.847,严重事件率=75.0%; 罕见+严重; 住院率=62.5%
Dabrafenib,Aspartate aminotransferase increased,9,60,1.931,1.931,3.69,0.778,0.000,0.444,8.729,严重事件率=77.8%; 罕见+严重; 住院率=44.4%
Dabrafenib,Abdominal pain,6,60,0.616,0.616,1.36,0.833,0.000,0.833,9.134,严重事件率=83.3%; 罕见+严重; 住院率=83.3%
Dabrafenib,Atrial fibrillation,5,60,1.032,1.032,0.00,1.000,0.000,0.800,9.317,严重事件率=100.0%; 罕见+严重; 住院率=80.0%
Dabrafenib,Myalgia,7,60,1.957,1.957,3.00,0.571,0.143,0.429,8.980,严重事件率=57.1%; 罕见+严重; 住院率=42.9%
Dabrafenib,General physical health deterioration,8,60,1.956,1.956,3.41,1.000,0.125,0.875,8.847,严重事件率=100.0%; 罕见+严重; 住院率=87.5%
Dabrafenib,Blood creatinine increased,6,60,1.163,1.163,0.13,0.833,0.000,0.500,9.134,严重事件率=83.3%; 罕见+严重; 住院率=50.0%
Dabrafenib,Urinary tract infection,7,60,1.266,1.266,0.36,0.857,0.000,0.714,8.980,严重事件率=85.7%; 罕见+严重; 住院率=71.4%
Dabrafenib,Erythema,4,60,0.855,0.855,0.09,1.000,0.250,0.000,9.540,死亡率=25.0%; 罕见+严重
Dabrafenib,Pneumonia,5,60,0.323,0.323,6.74,1.000,0.200,0.600,9.317,严重事件率=100.0%; 罕见+严重; 住院率=60.0%
Pembrolizumab,Death,28,55,0.880,0.880,0.42,1.000,1.000,0.393,7.594,死亡率=100.0%; 严重事件率=100.0%
Pembrolizumab,Blood lactate dehydrogenase increased,3,55,3.642,3.642,5.20,0.333,0.000,0.000,9.827,PRR=3.64 (显著关联); 罕见+严重
Nivolumab,Diarrhoea,54,55,1.940,1.940,21.55,1.000,0.074,0.981,6.937,χ²=21.5 (统计显著); 严重事件率=100.0%; 住院率=98.1%
Atezolizumab,Tremor,4,55,3.276,3.276,5.85,0.500,0.000,0.250,9.540,PRR=3.28 (显著关联); 罕见+严重
Durvalumab,Malignant neoplasm progression,19,55,1.329,1.329,1.43,1.000,0.211,0.368,7.982,死亡率=21.1%; 严重事件率=100.0%
Durvalumab,Embolism,3,55,4.128,4.128,6.38,1.000,0.000,0.333,9.827,PRR=4.13 (显著关联); 罕见+严重
Durvalumab,Lung disorder,3,55,2.226,2.226,1.89,0.667,0.000,0.333,9.827,PRR=2.23 (显著关联); 罕见+严重
Durvalumab,Death,19,55,0.597,0.597,4.77,1.000,1.000,0.211,7.982,死亡率=100.0%; 严重事件率=100.0%
Durvalumab,Vision blurred,5,55,2.413,2.413,3.83,0.400,0.000,0.200,9.317,PRR=2.41 (显著关联); 罕见+严重
Durvalumab,Pancreatitis,3,55,2.751,2.751,3.08,1.000,0.000,0.333,9.827,PRR=2.75 (显著关联); 罕见+严重
Durvalumab,Ileus,3,55,4.840,4.840,8.08,1.000,0.000,0.333,9.827,PRR=4.84 (显著关联); 罕见+严重
Durvalumab,Autoimmune hepatitis,3,55,4.128,4.128,6.38,1.000,0.000,0.333,9.827,PRR=4.13 (显著关联); 罕见+严重
Durvalumab,Hyperhidrosis,3,55,2.062,2.062,1.53,0.667,0.000,0.333,9.827,PRR=2.06 (显著关联); 罕见+严重
Ipilimumab,Rash pruritic,3,55,2.270,2.270,1.96,0.667,0.000,0.333,9.827,PRR=2.27 (显著关联); 罕见+严重
Trastuzumab,Cognitive disorder,3,55,3.354,3.353,4.26,1.000,0.000,0.333,9.827,PRR=3.35 (显著关联); 罕见+严重
Trastuzumab,Disease progression,46,55,1.616,1.616,9.48,0.978,0.217,0.065,7.097,死亡率=21.7%; 严重事件率=97.8%
Trastuzumab,Neoplasm,3,55,2.095,2.095,1.54,1.000,0.000,0.000,9.827,PRR=2.10 (显著关联); 罕见+严重
Trastuzumab,Cardiomyopathy,4,55,3.495,3.495,6.10,1.000,0.000,0.250,9.540,PRR=3.49 (显著关联); 罕见+严重
Trastuzumab,Swelling,4,55,2.541,2.541,3.30,1.000,0.000,0.000,9.540,PRR=2.54 (显著关联); 罕见+严重
Trastuzumab,Metastases to lymph nodes,3,55,2.328,2.328,2.02,1.000,0.000,0.333,9.827,PRR=2.33 (显著关联); 罕见+严重
Trastuzumab,Osteonecrosis of jaw,3,55,2.328,2.328,2.02,1.000,0.000,0.000,9.827,PRR=2.33 (显著关联); 罕见+严重
Trastuzumab,Hepatotoxicity,3,55,2.044,2.044,1.44,1.000,0.000,0.000,9.827,PRR=2.04 (显著关联); 罕见+严重
Trastuzumab,Metastases to lung,4,55,2.942,2.942,4.47,1.000,0.000,0.250,9.540,PRR=2.94 (显著关联); 罕见+严重
Trastuzumab,Jaundice,3,55,3.993,3.993,5.67,1.000,0.000,0.000,9.827,PRR=3.99 (显著关联); 罕见+严重
Trastuzumab,Supraventricular tachycardia,3,55,4.413,4.413,6.59,1.000,0.000,0.000,9.827,PRR=4.41 (显著关联); 罕见+严重
Trastuzumab,Dyspnoea exertional,4,55,2.942,2.942,4.47,0.750,0.000,0.000,9.540,PRR=2.94 (显著关联); 罕见+严重
Trastuzumab,Rash generalised,4,55,2.430,2.430,2.98,0.500,0.000,0.000,9.540,PRR=2.43 (显著关联); 罕见+严重
Trastuzumab,Respiratory tract infection,3,55,2.149,2.149,1.65,1.000,0.000,0.333,9.827,PRR=2.15 (显著关联); 罕见+严重
Bevacizumab,Death,48,55,1.023,1.023,0.02,1.000,1.000,0.062,7.055,死亡率=100.0%; 严重事件率=100.0%
Bevacizumab,Transient ischaemic attack,3,55,4.851,4.851,7.66,1.000,0.000,0.333,9.827,PRR=4.85 (显著关联); 罕见+严重
Bevacizumab,Osteomyelitis,3,55,4.190,4.190,6.20,1.000,0.000,0.000,9.827,PRR=4.19 (显著关联); 罕见+严重
Cetuximab,Burning sensation,3,55,4.085,4.085,6.43,0.333,0.000,0.333,9.827,PRR=4.09 (显著关联); 罕见+严重
Cetuximab,Nasopharyngitis,3,55,2.262,2.262,2.00,0.333,0.000,0.333,9.827,PRR=2.26 (显著关联); 罕见+严重
Cetuximab,Tachycardia,3,55,2.408,2.408,2.33,0.667,0.000,0.333,9.827,PRR=2.41 (显著关联); 罕见+严重
Cetuximab,Urticaria,4,55,3.531,3.531,6.72,0.500,0.000,0.000,9.540,PRR=3.53 (显著关联); 罕见+严重
Cetuximab,Weight increased,3,55,2.982,2.982,3.70,0.333,0.000,0.000,9.827,PRR=2.98 (显著关联); 罕见+严重
Rituximab,Death,38,55,0.698,0.698,4.45,1.000,1.000,0.211,7.288,死亡率=100.0%; 严重事件率=100.0%
Rituximab,Diarrhoea,21,55,0.420,0.420,15.42,0.952,0.190,0.429,7.881,χ²=15.4 (统计显著); 严重事件率=95.2%; 住院率=42.9%
Rituximab,Nausea,25,55,0.481,0.481,12.72,0.920,0.200,0.520,7.707,χ²=12.7 (统计显著); 严重事件率=92.0%; 住院率=52.0%
Rituximab,Prostate cancer,3,55,3.507,3.507,4.58,1.000,0.000,0.000,9.827,PRR=3.51 (显著关联); 罕见+严重
Rituximab,Anaphylactic reaction,3,55,2.602,2.602,2.59,1.000,0.000,0.000,9.827,PRR=2.60 (显著关联); 罕见+严重
Rituximab,Bacteraemia,3,55,4.246,4.246,6.19,1.000,0.000,0.000,9.827,PRR=4.25 (显著关联); 罕见+严重
Rituximab,Haematochezia,3,55,2.122,2.122,1.59,1.000,0.000,0.000,9.827,PRR=2.12 (显著关联); 罕见+严重
Rituximab,Squamous cell carcinoma,3,55,3.102,3.102,3.69,1.000,0.000,0.000,9.827,PRR=3.10 (显著关联); 罕见+严重
Rituximab,Therapeutic response decreased,3,55,4.745,4.745,7.25,1.000,0.000,0.000,9.827,PRR=4.75 (显著关联); 罕见+严重
Epcoritamab,Platelet count decreased,20,55,1.772,1.772,6.11,0.950,0.300,0.350,7.930,死亡率=30.0%; 严重事件率=95.0%
Epcoritamab,Blood glucose increased,3,55,2.347,2.347,2.11,0.333,0.000,0.333,9.827,PRR=2.35 (显著关联); 罕见+严重
Imatinib,Malignant neoplasm progression,30,55,1.193,1.193,0.84,1.000,0.300,0.100,7.525,死亡率=30.0%; 严重事件率=100.0%
Imatinib,Stress,3,55,4.361,4.361,6.40,1.000,0.000,0.333,9.827,PRR=4.36 (显著关联); 罕见+严重
Imatinib,Migraine,3,55,2.907,2.907,3.25,1.000,0.000,0.333,9.827,PRR=2.91 (显著关联); 罕见+严重
Imatinib,Cataract,3,55,3.019,3.019,3.49,1.000,0.000,0.333,9.827,PRR=3.02 (显著关联); 罕见+严重
Imatinib,Mobility decreased,4,55,4.553,4.553,9.08,1.000,0.000,0.250,9.540,PRR=4.55 (显著关联); 罕见+严重
Imatinib,Therapeutic response decreased,3,55,4.618,4.618,6.95,0.667,0.000,0.000,9.827,PRR=4.62 (显著关联); 罕见+严重
Imatinib,Rash erythematous,3,55,2.907,2.907,3.25,0.667,0.000,0.333,9.827,PRR=2.91 (显著关联); 罕见+严重
Imatinib,Ocular hyperaemia,3,55,3.019,3.019,3.49,1.000,0.000,0.000,9.827,PRR=3.02 (显著关联); 罕见+严重
Imatinib,Lacrimation increased,4,55,3.377,3.377,5.70,1.000,0.000,0.000,9.540,PRR=3.38 (显著关联); 罕见+严重
Erlotinib,Fatigue,26,55,0.666,0.666,3.98,0.962,0.269,0.346,7.668,死亡率=26.9%; 严重事件率=96.2%
Erlotinib,Lacrimation increased,3,55,3.154,3.154,3.91,1.000,0.000,0.000,9.827,PRR=3.15 (显著关联); 罕见+严重
Erlotinib,Blister,4,55,3.366,3.366,5.85,1.000,0.000,0.250,9.540,PRR=3.37 (显著关联); 罕见+严重
Erlotinib,Skin discolouration,3,55,3.154,3.154,3.91,1.000,0.000,0.000,9.827,PRR=3.15 (显著关联); 罕见+严重
Erlotinib,Dermatitis,3,55,2.968,2.968,3.49,1.000,0.000,0.000,9.827,PRR=2.97 (显著关联); 罕见+严重
Erlotinib,Blindness,3,55,3.882,3.882,5.58,1.000,0.000,0.000,9.827,PRR=3.88 (显著关联); 罕见+严重
Erlotinib,Hyperhidrosis,4,55,2.009,2.009,1.85,1.000,0.000,0.250,9.540,PRR=2.01 (显著关联); 罕见+严重
Erlotinib,Embolism,4,55,4.081,4.081,8.03,1.000,0.000,0.000,9.540,PRR=4.08 (显著关联); 罕见+严重
Gefitinib,Osteonecrosis of jaw,4,55,3.962,3.962,7.70,1.000,0.000,0.250,9.540,PRR=3.96 (显著关联); 罕见+严重
Gefitinib,Haematotoxicity,3,55,2.120,2.120,1.62,1.000,0.000,0.000,9.827,PRR=2.12 (显著关联); 罕见+严重
Osimertinib,Flatulence,4,55,2.456,2.456,3.12,0.500,0.000,0.250,9.540,PRR=2.46 (显著关联); 罕见+严重
Osimertinib,Nasopharyngitis,5,55,2.161,2.161,2.84,0.400,0.200,0.000,9.317,PRR=2.16 (显著关联); 罕见+严重
Osimertinib,Rash,26,55,1.364,1.364,2.30,0.654,0.269,0.308,7.668,死亡率=26.9%; 严重事件率=65.4%
Osimertinib,Nausea,29,55,0.734,0.734,2.55,0.793,0.414,0.379,7.559,死亡率=41.4%; 严重事件率=79.3%
Osimertinib,Fatigue,31,55,0.832,0.832,0.95,0.613,0.419,0.258,7.492,死亡率=41.9%; 严重事件率=61.3%
Osimertinib,Therapy cessation,3,55,3.280,3.280,4.22,0.667,0.000,0.000,9.827,PRR=3.28 (显著关联); 罕见+严重
Crizotinib,Abdominal discomfort,7,55,2.327,2.327,4.88,0.429,0.000,0.286,8.980,PRR=2.33 (显著关联); 罕见+严重
Crizotinib,Paraesthesia,5,55,2.923,2.923,5.77,0.400,0.000,0.000,9.317,PRR=2.92 (显著关联); 罕见+严重
Crizotinib,Memory impairment,3,55,2.305,2.305,2.05,0.333,0.000,0.333,9.827,PRR=2.30 (显著关联); 罕见+严重
Crizotinib,Deep vein thrombosis,6,55,2.437,2.437,4.67,0.333,0.167,0.333,9.134,PRR=2.44 (显著关联); 罕见+严重
Crizotinib,Hepatotoxicity,4,55,4.384,4.384,9.25,0.750,0.000,0.250,9.540,PRR=4.38 (显著关联); 罕见+严重
Crizotinib,Renal disorder,3,55,2.628,2.628,2.78,1.000,0.000,0.333,9.827,PRR=2.63 (显著关联); 罕见+严重
Paclitaxel,Anaemia,25,55,1.237,1.237,1.03,1.000,0.280,0.280,7.707,死亡率=28.0%; 严重事件率=100.0%
Paclitaxel,Disease progression,32,55,1.137,1.137,0.47,0.969,0.344,0.188,7.460,死亡率=34.4%; 严重事件率=96.9%
Paclitaxel,Nervous system disorder,3,55,3.103,3.103,3.72,1.000,0.000,0.000,9.827,PRR=3.10 (显著关联); 罕见+严重
Paclitaxel,Death,36,55,0.712,0.712,3.79,1.000,1.000,0.111,7.342,死亡率=100.0%; 严重事件率=100.0%
Paclitaxel,Neutropenia,33,55,1.699,1.699,8.42,0.939,0.273,0.212,7.430,死亡率=27.3%; 严重事件率=93.9%
Paclitaxel,Rhinorrhoea,3,55,2.118,2.118,1.59,1.000,0.000,0.000,9.827,PRR=2.12 (显著关联); 罕见+严重
Paclitaxel,Vasculitis,3,55,5.793,5.793,9.56,1.000,0.000,0.333,9.827,PRR=5.79 (显著关联); 罕见+严重
Paclitaxel,Rash erythematous,3,55,3.218,3.218,3.98,1.000,0.000,0.333,9.827,PRR=3.22 (显著关联); 罕见+严重
Paclitaxel,Neurotoxicity,3,55,3.778,3.778,5.23,1.000,0.000,0.333,9.827,PRR=3.78 (显著关联); 罕见+严重
Paclitaxel,Oxygen saturation decreased,3,55,3.103,3.103,3.72,1.000,0.000,0.333,9.827,PRR=3.10 (显著关联); 罕见+严重
Paclitaxel,Left ventricular dysfunction,3,55,3.620,3.620,4.88,1.000,0.000,0.333,9.827,PRR=3.62 (显著关联); 罕见+严重
Paclitaxel,Embolism,3,55,2.555,2.555,2.52,1.000,0.000,0.333,9.827,PRR=2.55 (显著关联); 罕见+严重
Paclitaxel,Peripheral sensory neuropathy,4,55,3.863,3.863,7.22,1.000,0.000,0.250,9.540,PRR=3.86 (显著关联); 罕见+严重
Paclitaxel,Toxic epidermal necrolysis,3,55,4.573,4.573,6.98,1.000,0.000,0.333,9.827,PRR=4.57 (显著关联); 罕见+严重
Docetaxel,Disease progression,27,55,0.899,0.899,0.28,1.000,0.556,0.074,7.630,死亡率=55.6%; 严重事件率=100.0%
Docetaxel,Dyspnoea,35,55,1.591,1.591,6.81,0.943,0.229,0.400,7.371,死亡率=22.9%; 严重事件率=94.3%
Docetaxel,Anaemia,24,55,1.120,1.120,0.28,1.000,0.375,0.375,7.748,死亡率=37.5%; 严重事件率=100.0%
Docetaxel,Malignant neoplasm progression,19,55,0.774,0.774,1.15,1.000,0.421,0.316,7.982,死亡率=42.1%; 严重事件率=100.0%
Docetaxel,Coma,3,55,3.574,3.574,4.74,1.000,0.000,0.333,9.827,PRR=3.57 (显著关联); 罕见+严重
Docetaxel,Thrombocytopenia,19,55,1.160,1.160,0.38,1.000,0.368,0.316,7.982,死亡率=36.8%; 严重事件率=100.0%
Docetaxel,Throat tightness,3,55,5.872,5.872,9.62,1.000,0.000,0.000,9.827,PRR=5.87 (显著关联); 罕见+严重
Docetaxel,Swelling,4,55,2.491,2.491,3.15,1.000,0.000,0.250,9.540,PRR=2.49 (显著关联); 罕见+严重
Docetaxel,Vertigo,4,55,2.610,2.610,3.49,1.000,0.000,0.250,9.540,PRR=2.61 (显著关联); 罕见+严重
Docetaxel,Neurotoxicity,3,55,3.574,3.574,4.74,1.000,0.000,0.333,9.827,PRR=3.57 (显著关联); 罕见+严重
Doxorubicin,Skin toxicity,3,55,3.724,3.724,5.10,1.000,0.000,0.000,9.827,PRR=3.72 (显著关联); 罕见+严重
Doxorubicin,Off label use,25,55,1.762,1.762,7.34,1.000,0.320,0.200,7.707,死亡率=32.0%; 严重事件率=100.0%
Doxorubicin,Death,30,55,0.580,0.580,8.27,1.000,1.000,0.067,7.525,死亡率=100.0%; 严重事件率=100.0%
Doxorubicin,Lethargy,4,55,2.719,2.719,3.82,1.000,0.000,0.250,9.540,PRR=2.72 (显著关联); 罕见+严重
Doxorubicin,Fatigue,21,55,0.452,0.452,12.77,1.000,0.143,0.476,7.881,χ²=12.8 (统计显著); 严重事件率=100.0%; 住院率=47.6%
Doxorubicin,Lymphopenia,3,55,3.172,3.172,3.87,1.000,0.000,0.000,9.827,PRR=3.17 (显著关联); 罕见+严重
Doxorubicin,Hepatotoxicity,3,55,2.088,2.088,1.53,1.000,0.000,0.000,9.827,PRR=2.09 (显著关联); 罕见+严重
Carboplatin,Disease progression,25,55,0.738,0.738,2.11,1.000,0.520,0.200,7.707,死亡率=52.0%; 严重事件率=100.0%
Carboplatin,Malignant neoplasm progression,22,55,0.803,0.803,0.97,1.000,0.364,0.318,7.835,死亡率=36.4%; 严重事件率=100.0%
Carboplatin,Throat tightness,3,55,5.235,5.235,8.12,1.000,0.000,0.000,9.827,PRR=5.23 (显著关联); 罕见+严重
Carboplatin,Oral candidiasis,3,55,2.617,2.617,2.60,1.000,0.000,0.000,9.827,PRR=2.62 (显著关联); 罕见+严重
Carboplatin,Ageusia,3,55,3.857,3.857,5.26,1.000,0.000,0.000,9.827,PRR=3.86 (显著关联); 罕见+严重
Carboplatin,Osteoporosis,3,55,4.886,4.886,7.41,1.000,0.000,0.000,9.827,PRR=4.89 (显著关联); 罕见+严重
Carboplatin,Cystitis haemorrhagic,3,55,5.637,5.637,8.92,1.000,0.000,0.333,9.827,PRR=5.64 (显著关联); 罕见+严重
Carboplatin,Angina pectoris,3,55,4.580,4.580,6.78,1.000,0.000,0.000,9.827,PRR=4.58 (显著关联); 罕见+严重
Carboplatin,Hemiparesis,3,55,4.311,4.311,6.22,1.000,0.000,0.000,9.827,PRR=4.31 (显著关联); 罕见+严重
Carboplatin,Nervous system disorder,3,55,2.617,2.617,2.60,1.000,0.000,0.333,9.827,PRR=2.62 (显著关联); 罕见+严重
Cisplatin,Neutropenia,32,55,1.548,1.548,5.52,1.000,0.344,0.375,7.460,死亡率=34.4%; 严重事件率=100.0%
Cisplatin,Vomiting,48,55,1.625,1.625,10.10,0.958,0.125,0.604,7.055,χ²=10.1 (统计显著); 严重事件率=95.8%; 住院率=60.4%
Cisplatin,Aphasia,3,55,3.723,3.723,5.06,1.000,0.000,0.333,9.827,PRR=3.72 (显著关联); 罕见+严重
Cisplatin,Diverticulitis,3,55,2.047,2.047,1.44,1.000,0.000,0.333,9.827,PRR=2.05 (显著关联); 罕见+严重
Cisplatin,Metastases to lymph nodes,4,55,3.121,3.121,4.98,1.000,0.000,0.000,9.540,PRR=3.12 (显著关联); 罕见+严重
Lenalidomide,Blood count abnormal,4,55,2.403,2.403,3.03,0.750,0.000,0.000,9.540,PRR=2.40 (显著关联); 罕见+严重
Lenalidomide,Weight increased,3,55,2.201,2.201,1.83,0.667,0.000,0.000,9.827,PRR=2.20 (显著关联); 罕见+严重
Lenalidomide,Arthritis,3,55,4.205,4.205,6.55,0.667,0.000,0.333,9.827,PRR=4.20 (显著关联); 罕见+严重
Pomalidomide,Adverse drug reaction,3,55,2.817,2.817,3.26,0.667,0.000,0.333,9.827,PRR=2.82 (显著关联); 罕见+严重
Pomalidomide,Paraesthesia,3,55,2.012,2.012,1.43,0.667,0.000,0.333,9.827,PRR=2.01 (显著关联); 罕见+严重
Pomalidomide,Rash pruritic,4,55,3.902,3.902,7.84,0.500,0.000,0.000,9.540,PRR=3.90 (显著关联); 罕见+严重
Pomalidomide,Sinusitis,3,55,2.924,2.924,3.51,1.000,0.000,0.000,9.827,PRR=2.92 (显著关联); 罕见+严重
Pomalidomide,Pollakiuria,3,55,4.189,4.189,6.59,0.667,0.000,0.000,9.827,PRR=4.19 (显著关联); 罕见+严重
Bortezomib,Neutropenia,20,55,1.137,1.137,0.30,1.000,0.250,0.300,7.930,死亡率=25.0%; 严重事件率=100.0%
Bortezomib,Death,49,55,1.123,1.123,0.58,1.000,1.000,0.122,7.034,死亡率=100.0%; 严重事件率=100.0%
Bortezomib,Nausea,21,55,0.494,0.494,10.03,1.000,0.095,0.571,7.881,χ²=10.0 (统计显著); 严重事件率=100.0%; 住院率=57.1%
Bortezomib,Disease recurrence,3,55,3.949,3.949,5.71,1.000,0.000,0.333,9.827,PRR=3.95 (显著关联); 罕见+严重
Bortezomib,Osteonecrosis of jaw,3,55,2.742,2.742,2.97,1.000,0.000,0.333,9.827,PRR=2.74 (显著关联); 罕见+严重
Bortezomib,Dysuria,3,55,2.820,2.820,3.14,1.000,0.000,0.333,9.827,PRR=2.82 (显著关联); 罕见+严重
Bortezomib,Treatment failure,3,55,4.114,4.114,6.09,1.000,0.000,0.333,9.827,PRR=4.11 (显著关联); 罕见+严重
Bortezomib,Cytomegalovirus infection,4,55,4.116,4.116,8.11,1.000,0.000,0.000,9.540,PRR=4.12 (显著关联); 罕见+严重
Bortezomib,Lethargy,4,55,3.135,3.135,5.14,1.000,0.000,0.000,9.540,PRR=3.14 (显著关联); 罕见+严重
Bortezomib,Burning sensation,4,55,2.926,2.926,4.50,0.750,0.000,0.250,9.540,PRR=2.93 (显著关联); 罕见+严重
Carfilzomib,Death,35,55,1.146,1.146,0.59,1.000,1.000,0.200,7.371,死亡率=100.0%; 严重事件率=100.0%
Venetoclax,Cardiac disorder,3,55,2.477,2.477,2.42,1.000,0.000,0.333,9.827,PRR=2.48 (显著关联); 罕见+严重
Venetoclax,Death,24,55,0.643,0.643,4.37,1.000,1.000,0.250,7.748,死亡率=100.0%; 严重事件率=100.0%
Venetoclax,Squamous cell carcinoma,3,55,4.576,4.576,7.31,1.000,0.000,0.333,9.827,PRR=4.58 (显著关联); 罕见+严重
Ibrutinib,Death,41,55,0.941,0.941,0.14,1.000,1.000,0.122,7.212,死亡率=100.0%; 严重事件率=100.0%
Ibrutinib,Arthritis,3,55,3.027,3.027,3.62,0.667,0.000,0.333,9.827,PRR=3.03 (显著关联); 罕见+严重
Olaparib,Disease progression,19,55,0.662,0.662,3.02,0.947,0.316,0.316,7.982,死亡率=31.6%; 严重事件率=94.7%
Olaparib,Death,44,55,0.882,0.882,0.62,1.000,1.000,0.182,7.142,死亡率=100.0%; 严重事件率=100.0%
Olaparib,Tumour marker increased,4,55,2.837,2.837,4.18,1.000,0.000,0.250,9.540,PRR=2.84 (显著关联); 罕见+严重
Olaparib,Oral pain,4,55,2.908,2.908,4.39,0.500,0.000,0.250,9.540,PRR=2.91 (显著关联); 罕见+严重
Olaparib,Memory impairment,4,55,2.077,2.077,2.01,0.750,0.000,0.000,9.540,PRR=2.08 (显著关联); 罕见+严重
Olaparib,Local swelling,3,55,2.813,2.813,3.08,0.333,0.000,0.333,9.827,PRR=2.81 (显著关联); 罕见+严重
Olaparib,Abdominal distension,6,55,2.103,2.103,3.11,0.500,0.000,0.167,9.134,PRR=2.10 (显著关联); 罕见+严重
Olaparib,Neoplasm,3,55,2.180,2.180,1.72,1.000,0.000,0.333,9.827,PRR=2.18 (显著关联); 罕见+严重
Rucaparib,Dyspepsia,12,55,2.433,2.433,8.52,0.417,0.000,0.250,8.441,PRR=2.43 (显著关联); 罕见+严重
Rucaparib,Memory impairment,6,55,2.182,2.182,3.28,0.500,0.000,0.167,9.134,PRR=2.18 (显著关联); 罕见+严重
Rucaparib,International normalised ratio increased,4,55,3.741,3.741,6.41,0.750,0.000,0.000,9.540,PRR=3.74 (显著关联); 罕见+严重
Rucaparib,Photosensitivity reaction,6,55,2.357,2.357,3.97,0.333,0.000,0.000,9.134,PRR=2.36 (显著关联); 罕见+严重
Rucaparib,Blood urea increased,3,55,3.100,3.100,3.50,0.667,0.000,0.000,9.827,PRR=3.10 (显著关联); 罕见+严重
Rucaparib,Sunburn,3,55,4.531,4.531,6.37,0.333,0.000,0.333,9.827,PRR=4.53 (显著关联); 罕见+严重
Rucaparib,Candida infection,3,55,2.181,2.181,1.64,0.333,0.000,0.000,9.827,PRR=2.18 (显著关联); 罕见+严重
Rucaparib,Fungal infection,3,55,3.100,3.100,3.50,0.667,0.000,0.333,9.827,PRR=3.10 (显著关联); 罕见+严重
Niraparib,Diarrhoea,27,55,0.345,0.345,30.08,0.815,0.000,0.481,7.630,χ²=30.1 (统计显著); 严重事件率=81.5%; 住院率=48.1%
Niraparib,Vomiting,72,55,1.575,1.575,12.59,0.764,0.042,0.514,6.649,χ²=12.6 (统计显著); 严重事件率=76.4%; 住院率=51.4%
Niraparib,Asthenia,50,55,1.807,1.807,15.02,0.880,0.120,0.560,7.014,χ²=15.0 (统计显著); 严重事件率=88.0%; 住院率=56.0%
Niraparib,Dehydration,41,55,1.888,1.888,14.28,0.927,0.000,0.634,7.212,χ²=14.3 (统计显著); 严重事件率=92.7%; 住院率=63.4%
Niraparib,Glomerular filtration rate decreased,3,55,6.422,6.422,9.43,1.000,0.000,0.333,9.827,PRR=6.42 (显著关联); 罕见+严重
Niraparib,Blood test abnormal,3,55,2.704,2.704,2.62,0.667,0.000,0.333,9.827,PRR=2.70 (显著关联); 罕见+严重
Niraparib,Blood pressure fluctuation,3,55,6.422,6.422,9.43,1.000,0.000,0.333,9.827,PRR=6.42 (显著关联); 罕见+严重
Niraparib,Dysphonia,4,55,2.015,2.015,1.72,0.750,0.000,0.000,9.540,PRR=2.01 (显著关联); 罕见+严重
Niraparib,Abdominal pain lower,3,55,3.952,3.952,5.07,1.000,0.000,0.333,9.827,PRR=3.95 (显著关联); 罕见+严重
Niraparib,Incorrect dose administered,4,55,2.740,2.740,3.59,0.750,0.000,0.250,9.540,PRR=2.74 (显著关联); 罕见+严重
Niraparib,Nervousness,3,55,4.281,4.281,5.70,0.667,0.000,0.333,9.827,PRR=4.28 (显著关联); 罕见+严重
Talazoparib,Lymphadenopathy,4,55,2.577,2.577,3.56,1.000,0.000,0.000,9.540,PRR=2.58 (显著关联); 罕见+严重
Talazoparib,Full blood count decreased,4,55,2.378,2.378,2.96,0.500,0.000,0.000,9.540,PRR=2.38 (显著关联); 罕见+严重
Talazoparib,Cognitive disorder,3,55,5.566,5.566,9.79,0.667,0.000,0.333,9.827,PRR=5.57 (显著关联); 罕见+严重
Palbociclib,Blood glucose increased,3,55,2.278,2.278,1.96,0.333,0.000,0.333,9.827,PRR=2.28 (显著关联); 罕见+严重
Palbociclib,Sinusitis,4,55,2.689,2.689,3.82,0.500,0.000,0.000,9.540,PRR=2.69 (显著关联); 罕见+严重
Palbociclib,Candida infection,3,55,3.883,3.883,5.60,1.000,0.000,0.000,9.827,PRR=3.88 (显著关联); 罕见+严重
Palbociclib,Arthritis,3,55,3.177,3.177,3.98,0.333,0.000,0.000,9.827,PRR=3.18 (显著关联); 罕见+严重
Palbociclib,Upper respiratory tract infection,3,55,2.833,2.833,3.19,0.667,0.000,0.000,9.827,PRR=2.83 (显著关联); 罕见+严重
Palbociclib,Contusion,6,55,2.875,2.875,6.56,0.333,0.000,0.333,9.134,PRR=2.88 (显著关联); 罕见+严重
Palbociclib,Arthralgia,15,55,2.139,2.139,8.22,0.400,0.000,0.200,8.218,PRR=2.14 (显著关联); 罕见+严重
Palbociclib,Cataract,3,55,4.032,4.032,5.95,0.667,0.000,0.000,9.827,PRR=4.03 (显著关联); 罕见+严重
Palbociclib,Lacrimation increased,4,55,4.512,4.512,9.38,0.500,0.000,0.000,9.540,PRR=4.51 (显著关联); 罕见+严重
Palbociclib,Feeling abnormal,5,55,2.032,2.032,2.40,0.400,0.200,0.400,9.317,PRR=2.03 (显著关联); 罕见+严重
Palbociclib,Anxiety,6,55,2.163,2.163,3.42,0.500,0.000,0.167,9.134,PRR=2.16 (显著关联); 罕见+严重
Palbociclib,Weight increased,4,55,2.255,2.255,2.54,0.500,0.000,0.250,9.540,PRR=2.25 (显著关联); 罕见+严重
Palbociclib,Osteonecrosis of jaw,3,55,2.912,2.912,3.37,1.000,0.000,0.000,9.827,PRR=2.91 (显著关联); 罕见+严重
Palbociclib,Joint swelling,4,55,2.542,2.542,3.38,0.500,0.000,0.000,9.540,PRR=2.54 (显著关联); 罕见+严重
Ribociclib,Lethargy,3,55,3.269,3.269,4.31,0.333,0.000,0.000,9.827,PRR=3.27 (显著关联); 罕见+严重
Ribociclib,Mouth ulceration,3,55,5.624,5.624,9.94,0.333,0.000,0.000,9.827,PRR=5.62 (显著关联); 罕见+严重
Ribociclib,Seizure,3,55,3.055,3.055,3.80,1.000,0.000,0.000,9.827,PRR=3.06 (显著关联); 罕见+严重
Ribociclib,Laboratory test abnormal,3,55,3.055,3.055,3.80,0.667,0.000,0.000,9.827,PRR=3.06 (显著关联); 罕见+严重
Ribociclib,Blister,3,55,3.428,3.428,4.69,0.333,0.000,0.000,9.827,PRR=3.43 (显著关联); 罕见+严重
Ribociclib,Metastases to bone,4,55,2.885,2.885,4.52,1.000,0.000,0.000,9.540,PRR=2.88 (显著关联); 罕见+严重
Ribociclib,Drug interaction,3,55,2.555,2.555,2.63,0.333,0.000,0.333,9.827,PRR=2.56 (显著关联); 罕见+严重
Ribociclib,Abdominal discomfort,8,55,2.869,2.869,8.90,0.500,0.000,0.250,8.847,PRR=2.87 (显著关联); 罕见+严重
Ribociclib,Gastrooesophageal reflux disease,5,55,3.846,3.846,9.48,0.400,0.000,0.000,9.317,PRR=3.85 (显著关联); 罕见+严重
Ribociclib,Full blood count decreased,4,55,2.403,2.403,3.04,0.500,0.000,0.000,9.540,PRR=2.40 (显著关联); 罕见+严重
Ribociclib,Neoplasm malignant,3,55,2.555,2.555,2.63,1.000,0.000,0.333,9.827,PRR=2.56 (显著关联); 罕见+严重
Abemaciclib,Liver disorder,3,55,2.365,2.365,2.18,0.667,0.000,0.000,9.827,PRR=2.37 (显著关联); 罕见+严重
Abemaciclib,Vision blurred,6,55,2.715,2.715,5.94,0.333,0.000,0.000,9.134,PRR=2.71 (显著关联); 罕见+严重
Abemaciclib,Flatulence,3,55,2.243,2.243,1.91,0.333,0.000,0.333,9.827,PRR=2.24 (显著关联); 罕见+严重
Abemaciclib,Death,21,55,0.613,0.613,4.72,0.952,0.952,0.048,7.881,死亡率=95.2%; 严重事件率=95.2%
Abemaciclib,Peripheral swelling,8,55,2.899,2.899,9.04,0.375,0.000,0.250,8.847,PRR=2.90 (显著关联); 罕见+严重
Vemurafenib,Death,37,55,0.907,0.907,0.32,1.000,1.000,0.135,7.315,死亡率=100.0%; 严重事件率=100.0%
Vemurafenib,Drug-induced liver injury,3,55,3.570,3.570,4.90,1.000,0.000,0.333,9.827,PRR=3.57 (显著关联); 罕见+严重
Vemurafenib,Urticaria,4,55,2.011,2.011,1.87,0.750,0.000,0.250,9.540,PRR=2.01 (显著关联); 罕见+严重
Vemurafenib,Neoplasm,4,55,3.664,3.664,6.81,1.000,0.000,0.000,9.540,PRR=3.66 (显著关联); 罕见+严重
Vemurafenib,Swelling face,4,55,2.916,2.916,4.51,0.500,0.000,0.000,9.540,PRR=2.92 (显著关联); 罕见+严重
Vemurafenib,Ageusia,3,55,5.639,5.639,9.59,1.000,0.000,0.333,9.827,PRR=5.64 (显著关联); 罕见+严重
Dabrafenib,Death,57,55,1.404,1.404,5.81,1.000,1.000,0.211,6.883,死亡率=100.0%; 严重事件率=100.0%
Dabrafenib,Disease progression,23,55,0.972,0.972,0.02,0.957,0.565,0.261,7.791,死亡率=56.5%; 严重事件率=95.7%
Dabrafenib,Skin exfoliation,6,55,3.497,3.497,9.41,0.500,0.000,0.000,9.134,PRR=3.50 (显著关联); 罕见+严重
Dabrafenib,Vision blurred,6,55,2.184,2.184,3.50,0.500,0.000,0.000,9.134,PRR=2.18 (显著关联); 罕见+严重
Dabrafenib,Feeling hot,3,55,3.742,3.742,5.28,0.333,0.000,0.000,9.827,PRR=3.74 (显著关联); 罕见+严重
Dabrafenib,Electrocardiogram QT prolonged,4,55,3.105,3.105,5.08,1.000,0.000,0.250,9.540,PRR=3.11 (显著关联); 罕见+严重
Dabrafenib,Dermatitis,4,55,4.235,4.235,8.54,1.000,0.000,0.250,9.540,PRR=4.24 (显著关联); 罕见+严重
Dabrafenib,Blood creatine phosphokinase increased,3,55,4.763,4.763,7.61,0.333,0.000,0.333,9.827,PRR=4.76 (显著关联); 罕见+严重
Pembrolizumab,Fatigue,57,50,2.120,2.120,29.39,0.281,0.035,0.228,6.883,PRR=2.12 (显著关联); χ²=29.4 (统计显著)
Pembrolizumab,Pruritus,28,50,5.571,5.571,89.31,0.036,0.036,0.036,7.594,PRR=5.57 (显著关联); χ²=89.3 (统计显著)
Pembrolizumab,Arthralgia,16,50,3.034,3.034,19.69,0.188,0.000,0.125,8.153,PRR=3.03 (显著关联); χ²=19.7 (统计显著)
Pembrolizumab,Rash maculo-papular,16,50,15.875,15.875,160.50,0.125,0.062,0.125,8.153,PRR=15.88 (显著关联); χ²=160.5 (统计显著)
Pembrolizumab,Vitiligo,5,50,115.590,115.590,158.16,0.000,0.000,0.000,9.317,PRR=115.59 (显著关联); χ²=158.2 (统计显著)
Pembrolizumab,Lymphocyte count decreased,6,50,14.609,14.609,56.27,0.000,0.000,0.000,9.134,PRR=14.61 (显著关联); χ²=56.3 (统计显著)
Pembrolizumab,Hyperglycaemia,10,50,6.266,6.266,37.79,0.200,0.000,0.200,8.623,PRR=6.27 (显著关联); χ²=37.8 (统计显著)
Atezolizumab,No adverse event,8,50,23.050,23.050,117.43,0.000,0.000,0.000,8.847,PRR=23.05 (显著关联); χ²=117.4 (统计显著)
Atezolizumab,Circumstance or information capable of leading to medication error,4,50,28.697,28.697,69.76,0.000,0.000,0.000,9.540,PRR=28.70 (显著关联); χ²=69.8 (统计显著)
Durvalumab,Lipase increased,4,50,8.514,8.514,21.89,0.250,0.000,0.000,9.540,PRR=8.51 (显著关联); χ²=21.9 (统计显著)
Durvalumab,Product use in unapproved indication,28,50,34.320,34.320,503.42,0.429,0.071,0.214,7.594,PRR=34.32 (显著关联); χ²=503.4 (统计显著)
Durvalumab,Circumstance or information capable of leading to medication error,3,50,15.600,15.600,30.02,0.000,0.000,0.000,9.827,PRR=15.60 (显著关联); χ²=30.0 (统计显著)
Cetuximab,Hypomagnesaemia,16,50,18.837,18.837,201.24,0.188,0.062,0.062,8.153,PRR=18.84 (显著关联); χ²=201.2 (统计显著)
Cetuximab,Speech disorder,31,50,48.933,48.933,786.35,0.000,0.000,0.000,7.492,PRR=48.93 (显著关联); χ²=786.3 (统计显著)
Cetuximab,Skin disorder,17,50,27.752,27.752,294.46,0.059,0.000,0.000,8.093,PRR=27.75 (显著关联); χ²=294.5 (统计显著)
Cetuximab,Rash,95,50,10.973,10.973,645.21,0.137,0.000,0.011,6.372,PRR=10.97 (显著关联); χ²=645.2 (统计显著)
Cetuximab,Pruritus,21,50,5.507,5.507,68.19,0.238,0.000,0.048,7.881,PRR=5.51 (显著关联); χ²=68.2 (统计显著)
Cetuximab,Malaise,36,50,6.602,6.602,145.60,0.028,0.000,0.028,7.342,PRR=6.60 (显著关联); χ²=145.6 (统计显著)
Cetuximab,Rash pruritic,7,50,8.809,8.809,41.46,0.000,0.000,0.000,8.980,PRR=8.81 (显著关联); χ²=41.5 (统计显著)
Cetuximab,Dry skin,28,50,16.545,16.545,309.40,0.071,0.000,0.000,7.594,PRR=16.55 (显著关联); χ²=309.4 (统计显著)
Cetuximab,Erythema,10,50,4.014,4.014,20.64,0.300,0.000,0.100,8.623,PRR=4.01 (显著关联); χ²=20.6 (统计显著)
Cetuximab,Drug dose omission,8,50,3.841,3.841,15.42,0.000,0.000,0.000,8.847,PRR=3.84 (显著关联); χ²=15.4 (统计显著)
Cetuximab,Skin exfoliation,7,50,7.464,7.464,34.17,0.143,0.000,0.000,8.980,PRR=7.46 (显著关联); χ²=34.2 (统计显著)
Cetuximab,Weight decreased,13,50,3.108,3.108,17.09,0.000,0.000,0.000,8.361,PRR=3.11 (显著关联); χ²=17.1 (统计显著)
Cetuximab,Nail disorder,8,50,24.010,24.010,124.54,0.125,0.125,0.125,8.847,PRR=24.01 (显著关联); χ²=124.5 (统计显著)
Cetuximab,Hypoacusis,6,50,29.027,29.027,108.57,0.000,0.000,0.000,9.134,PRR=29.03 (显著关联); χ²=108.6 (统计显著)
Cetuximab,Skin fissures,7,50,25.924,25.924,115.97,0.000,0.000,0.000,8.980,PRR=25.92 (显著关联); χ²=116.0 (统计显著)
Cetuximab,Onychoclasis,4,50,8.652,8.652,23.30,0.000,0.000,0.000,9.540,PRR=8.65 (显著关联); χ²=23.3 (统计显著)
Cetuximab,Acne,15,50,20.710,20.710,205.09,0.133,0.067,0.067,8.218,PRR=20.71 (显著关联); χ²=205.1 (统计显著)
Cetuximab,Rash pustular,8,50,45.846,45.846,198.11,0.125,0.000,0.125,8.847,PRR=45.85 (显著关联); χ²=198.1 (统计显著)
Cetuximab,Hearing impaired,5,50,19.630,19.630,65.90,0.000,0.000,0.000,9.317,PRR=19.63 (显著关联); χ²=65.9 (统计显著)
Cetuximab,Drug administration error,5,50,52.356,52.356,134.43,0.000,0.000,0.000,9.317,PRR=52.36 (显著关联); χ²=134.4 (统计显著)
Cetuximab,Blood magnesium decreased,5,50,12.078,12.078,41.68,0.200,0.000,0.000,9.317,PRR=12.08 (显著关联); χ²=41.7 (统计显著)
Cetuximab,Conjunctivitis,4,50,17.927,17.927,48.71,0.000,0.000,0.000,9.540,PRR=17.93 (显著关联); χ²=48.7 (统计显著)
Cetuximab,Dysphonia,5,50,9.514,9.514,32.36,0.000,0.000,0.000,9.317,PRR=9.51 (显著关联); χ²=32.4 (统计显著)
Osimertinib,Dermatitis acneiform,5,50,6.041,6.041,17.37,0.200,0.000,0.200,9.317,PRR=6.04 (显著关联); χ²=17.4 (统计显著)
Crizotinib,Dysphagia,12,50,3.887,3.887,22.83,0.250,0.083,0.083,8.441,PRR=3.89 (显著关联); χ²=22.8 (统计显著)
Crizotinib,Local swelling,4,50,5.847,5.847,13.81,0.000,0.000,0.000,9.540,PRR=5.85 (显著关联); χ²=13.8 (统计显著)
Crizotinib,Off label use,20,50,2.141,2.141,11.08,0.450,0.200,0.100,7.930,PRR=2.14 (显著关联); χ²=11.1 (统计显著)
Crizotinib,Peripheral swelling,15,50,5.864,5.864,51.49,0.133,0.000,0.000,8.218,PRR=5.86 (显著关联); χ²=51.5 (统计显著)
Crizotinib,Throat irritation,3,50,7.734,7.734,14.58,0.000,0.000,0.000,9.827,PRR=7.73 (显著关联); χ²=14.6 (统计显著)
Crizotinib,Visual impairment,11,50,5.507,5.507,34.89,0.091,0.091,0.000,8.528,PRR=5.51 (显著关联); χ²=34.9 (统计显著)
Crizotinib,Dysgeusia,14,50,3.610,3.610,23.53,0.286,0.071,0.071,8.287,PRR=3.61 (显著关联); χ²=23.5 (统计显著)
Crizotinib,Vision blurred,11,50,5.325,5.325,33.35,0.091,0.000,0.000,8.528,PRR=5.32 (显著关联); χ²=33.3 (统计显著)
Crizotinib,Vitreous floaters,8,50,88.028,88.028,222.85,0.125,0.000,0.000,8.847,PRR=88.03 (显著关联); χ²=222.8 (统计显著)
Crizotinib,Neoplasm malignant,15,50,15.430,15.430,144.83,0.133,0.133,0.000,8.218,PRR=15.43 (显著关联); χ²=144.8 (统计显著)
Crizotinib,Swelling,5,50,5.102,5.102,14.37,0.200,0.000,0.200,9.317,PRR=5.10 (显著关联); χ²=14.4 (统计显著)
Pomalidomide,Drug intolerance,7,50,4.711,4.711,18.26,0.143,0.000,0.143,8.980,PRR=4.71 (显著关联); χ²=18.3 (统计显著)
Pomalidomide,No adverse event,4,50,8.621,8.621,22.56,0.250,0.000,0.000,9.540,PRR=8.62 (显著关联); χ²=22.6 (统计显著)
Olaparib,Nausea,112,50,2.621,2.621,91.60,0.464,0.062,0.179,6.208,PRR=2.62 (显著关联); χ²=91.6 (统计显著)
Rucaparib,Fatigue,210,50,3.915,3.915,329.53,0.390,0.019,0.219,5.579,PRR=3.92 (显著关联); χ²=329.5 (统计显著)
Rucaparib,Vomiting,81,50,2.069,2.069,36.87,0.494,0.037,0.309,6.532,PRR=2.07 (显著关联); χ²=36.9 (统计显著)
Rucaparib,Nausea,210,50,3.667,3.667,296.93,0.424,0.014,0.210,5.579,PRR=3.67 (显著关联); χ²=296.9 (统计显著)
Rucaparib,Abdominal pain upper,32,50,4.280,4.280,62.02,0.500,0.031,0.312,7.460,PRR=4.28 (显著关联); χ²=62.0 (统计显著)
Rucaparib,Prescribed underdose,54,50,360.300,360.300,949.49,0.481,0.019,0.130,6.937,PRR=360.30 (显著关联); χ²=949.5 (统计显著)
Rucaparib,Off label use,51,50,2.657,2.657,43.09,0.412,0.059,0.216,6.994,PRR=2.66 (显著关联); χ²=43.1 (统计显著)
Rucaparib,Abdominal discomfort,24,50,4.122,4.122,44.18,0.292,0.000,0.125,7.748,PRR=4.12 (显著关联); χ²=44.2 (统计显著)
Rucaparib,Dry mouth,10,50,3.278,3.278,12.85,0.100,0.000,0.100,8.623,PRR=3.28 (显著关联); χ²=12.8 (统计显著)
Rucaparib,Increased appetite,3,50,8.416,8.416,13.04,0.000,0.000,0.000,9.827,PRR=8.42 (显著关联); χ²=13.0 (统计显著)
Rucaparib,Drug ineffective,29,50,2.375,2.375,19.31,0.483,0.034,0.103,7.559,PRR=2.38 (显著关联); χ²=19.3 (统计显著)
Rucaparib,Viral upper respiratory tract infection,4,50,39.291,39.291,47.27,0.250,0.000,0.250,9.540,PRR=39.29 (显著关联); χ²=47.3 (统计显著)
Niraparib,Sunburn,4,50,5.710,5.710,11.00,0.250,0.000,0.000,9.540,PRR=5.71 (显著关联); χ²=11.0 (统计显著)
Talazoparib,Drug interaction,7,50,6.385,6.385,27.17,0.143,0.000,0.000,8.980,PRR=6.38 (显著关联); χ²=27.2 (统计显著)
Palbociclib,Fatigue,102,50,3.040,3.040,114.41,0.343,0.049,0.108,6.301,PRR=3.04 (显著关联); χ²=114.4 (统计显著)
Palbociclib,Alopecia,25,50,5.779,5.779,81.00,0.360,0.000,0.120,7.707,PRR=5.78 (显著关联); χ²=81.0 (统计显著)
Palbociclib,Stomatitis,19,50,3.960,3.960,36.17,0.368,0.000,0.105,7.982,PRR=3.96 (显著关联); χ²=36.2 (统计显著)
Palbociclib,White blood cell count decreased,65,50,8.382,8.382,317.97,0.462,0.000,0.123,6.752,PRR=8.38 (显著关联); χ²=318.0 (统计显著)
Palbociclib,Neoplasm malignant,10,50,7.311,7.311,43.51,0.000,0.000,0.000,8.623,PRR=7.31 (显著关联); χ²=43.5 (统计显著)
Palbociclib,Musculoskeletal chest pain,3,50,6.168,6.168,10.71,0.000,0.000,0.000,9.827,PRR=6.17 (显著关联); χ²=10.7 (统计显著)
Ribociclib,Dizziness,20,50,2.832,2.832,21.39,0.500,0.150,0.300,7.930,PRR=2.83 (显著关联); χ²=21.4 (统计显著)
Ribociclib,Nausea,71,50,2.594,2.594,59.21,0.324,0.028,0.169,6.663,PRR=2.59 (显著关联); χ²=59.2 (统计显著)
Ribociclib,Malaise,19,50,2.425,2.425,14.47,0.421,0.000,0.158,7.982,PRR=2.42 (显著关联); χ²=14.5 (统计显著)
Ribociclib,Feeling hot,4,50,6.949,6.949,17.30,0.250,0.000,0.000,9.540,PRR=6.95 (显著关联); χ²=17.3 (统计显著)
Ribociclib,Hot flush,7,50,12.662,12.662,57.62,0.286,0.000,0.000,8.980,PRR=12.66 (显著关联); χ²=57.6 (统计显著)
Ribociclib,Pruritus generalised,3,50,7.031,7.031,13.17,0.000,0.000,0.000,9.827,PRR=7.03 (显著关联); χ²=13.2 (统计显著)
Ribociclib,Hypoaesthesia oral,3,50,17.581,17.581,33.31,0.000,0.000,0.000,9.827,PRR=17.58 (显著关联); χ²=33.3 (统计显著)
Abemaciclib,Diarrhoea,194,50,8.451,8.451,882.13,0.232,0.010,0.124,5.658,PRR=8.45 (显著关联); χ²=882.1 (统计显著)
Abemaciclib,Fatigue,63,50,2.220,2.220,36.47,0.270,0.000,0.095,6.783,PRR=2.22 (显著关联); χ²=36.5 (统计显著)
Abemaciclib,Nausea,69,50,2.316,2.316,44.19,0.362,0.000,0.203,6.692,PRR=2.32 (显著关联); χ²=44.2 (统计显著)
Abemaciclib,Vomiting,48,50,2.619,2.619,41.99,0.354,0.000,0.292,7.055,PRR=2.62 (显著关联); χ²=42.0 (统计显著)
Abemaciclib,Constipation,25,50,2.741,2.741,24.75,0.280,0.000,0.160,7.707,PRR=2.74 (显著关联); χ²=24.7 (统计显著)
Abemaciclib,Decreased appetite,38,50,3.214,3.214,50.70,0.421,0.000,0.184,7.288,PRR=3.21 (显著关联); χ²=50.7 (统计显著)
Abemaciclib,Abdominal pain upper,18,50,4.867,4.867,47.81,0.167,0.000,0.111,8.036,PRR=4.87 (显著关联); χ²=47.8 (统计显著)
Abemaciclib,Dry eye,5,50,9.054,9.054,28.85,0.000,0.000,0.000,9.317,PRR=9.05 (显著关联); χ²=28.8 (统计显著)
Abemaciclib,Lacrimation increased,7,50,10.882,10.882,48.82,0.000,0.000,0.000,8.980,PRR=10.88 (显著关联); χ²=48.8 (统计显著)
Abemaciclib,Joint swelling,5,50,4.022,4.022,10.11,0.200,0.000,0.000,9.317,PRR=4.02 (显著关联); χ²=10.1 (统计显著)
Pembrolizumab,Type 1 diabetes mellitus,2,45,46.119,46.119,43.13,1.000,0.000,0.000,10.233,χ²=43.1 (统计显著); 罕见+严重
Pembrolizumab,Guillain-Barre syndrome,2,45,13.176,13.176,17.10,1.000,0.000,1.000,10.233,χ²=17.1 (统计显著); 罕见+严重
Pembrolizumab,Iritis,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Lichenoid keratosis,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Pneumonitis chemical,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Muscle necrosis,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Small intestinal perforation,2,45,18.446,18.446,23.03,1.000,0.000,1.000,10.233,χ²=23.0 (统计显著); 罕见+严重
Pembrolizumab,Occult blood positive,1,45,46.080,46.080,21.56,1.000,1.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Abscess neck,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Diarrhoea haemorrhagic,2,45,18.446,18.446,23.03,1.000,0.000,1.000,10.233,χ²=23.0 (统计显著); 罕见+严重
Pembrolizumab,Lymphangitis,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Central nervous system neoplasm,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Autoimmune pancreatitis,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Hepatitis cholestatic,1,45,23.040,23.040,13.74,1.000,1.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Drug withdrawal maintenance therapy,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Iridocyclitis,2,45,92.239,92.239,58.79,1.000,0.000,0.500,10.233,χ²=58.8 (统计显著); 罕见+严重
Pembrolizumab,Blood corticotrophin decreased,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Psoriatic arthropathy,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Abscess limb,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Enteritis,2,45,8.384,8.384,10.75,0.500,0.000,0.500,10.233,χ²=10.8 (统计显著); 罕见+严重
Pembrolizumab,Streptococcal sepsis,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Liver abscess,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Micturition disorder,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Blood fibrinogen decreased,1,45,46.080,46.080,21.56,1.000,1.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Tri-iodothyronine free decreased,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Blood corticotrophin increased,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Pemphigoid,2,45,23.058,23.058,27.49,1.000,0.000,0.500,10.233,χ²=27.5 (统计显著); 罕见+严重
Pembrolizumab,Bone neoplasm,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Joint effusion,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Gastroenteritis radiation,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Helicobacter infection,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Lichen planus,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Hyperlipasaemia,1,45,46.080,46.080,21.56,1.000,1.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Ketoacidosis,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Dialysis,1,45,23.040,23.040,13.74,1.000,1.000,0.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Intraocular pressure decreased,1,45,0.000,0.000,45.06,1.000,0.000,0.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Metastatic ocular melanoma,1,45,0.000,0.000,45.06,1.000,1.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Central nervous system haemorrhage,1,45,46.080,46.080,21.56,1.000,1.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Axillary pain,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Empyema,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Hyperprolactinaemia,1,45,23.040,23.040,13.74,1.000,0.000,0.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Tracheomalacia,1,45,0.000,0.000,45.06,1.000,1.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Tongue oedema,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Meningitis noninfective,1,45,0.000,0.000,45.06,1.000,0.000,0.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Hypertriglyceridaemia,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Pembrolizumab,Hepatitis acute,2,45,92.239,92.239,58.79,1.000,0.500,1.000,10.233,χ²=58.8 (统计显著); 罕见+严重
Pembrolizumab,Pulmonary endarterectomy,1,45,0.000,0.000,45.06,1.000,1.000,0.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Colitis microscopic,1,45,46.080,46.080,21.56,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Therapeutic response delayed,1,45,0.000,0.000,45.06,1.000,1.000,0.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Hypoglycaemic coma,1,45,0.000,0.000,45.06,1.000,0.000,1.000,10.926,χ²=45.1 (统计显著); 罕见+严重
Pembrolizumab,Status epilepticus,1,45,46.080,46.080,21.56,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Pembrolizumab,Adrenocortical insufficiency acute,1,45,23.040,23.040,13.74,1.000,0.000,1.000,10.926,χ²=13.7 (统计显著); 罕见+严重
Nivolumab,Ileus paralytic,2,45,8.262,8.262,10.55,1.000,0.000,1.000,10.233,χ²=10.5 (统计显著); 罕见+严重
Nivolumab,Paraparesis,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Enterocolitis infectious,2,45,18.179,18.179,22.65,1.000,0.000,1.000,10.233,χ²=22.7 (统计显著); 罕见+严重
Nivolumab,Duodenal ulcer haemorrhage,1,45,22.706,22.706,13.52,1.000,1.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Epididymitis,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Myasthenic syndrome,1,45,45.412,45.412,21.23,1.000,1.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Facial nerve disorder,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Adrenocortical insufficiency acute,1,45,22.706,22.706,13.52,1.000,1.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Secondary adrenocortical insufficiency,2,45,12.984,12.984,16.81,1.000,0.500,0.500,10.233,χ²=16.8 (统计显著); 罕见+严重
Nivolumab,Polydipsia,1,45,45.412,45.412,21.23,1.000,0.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Polymyositis,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Hypogonadism male,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Medical device discomfort,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Varicocele,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Testicular pain,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Bandaemia,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Fulminant type 1 diabetes mellitus,2,45,90.901,90.901,57.90,1.000,0.000,1.000,10.233,χ²=57.9 (统计显著); 罕见+严重
Nivolumab,Chronic respiratory failure,1,45,0.000,0.000,44.40,1.000,1.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Troponin I increased,1,45,45.412,45.412,21.23,1.000,0.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Ischaemic neuropathy,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Autoimmune pancreatitis,2,45,90.901,90.901,57.90,1.000,0.000,1.000,10.233,χ²=57.9 (统计显著); 罕见+严重
Nivolumab,Pericardial effusion malignant,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Metastases to kidney,1,45,0.000,0.000,44.40,1.000,1.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Carcinoid tumour,1,45,0.000,0.000,44.40,1.000,1.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Inguinal hernia,1,45,45.412,45.412,21.23,1.000,1.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Product delivery mechanism issue,1,45,0.000,0.000,44.40,1.000,1.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Liver carcinoma ruptured,1,45,0.000,0.000,44.40,1.000,1.000,0.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Thyroxine free decreased,2,45,45.449,45.449,42.46,1.000,1.000,1.000,10.233,χ²=42.5 (统计显著); 罕见+严重
Nivolumab,Lymphangiosis carcinomatosa,2,45,9.089,9.089,11.72,1.000,1.000,1.000,10.233,χ²=11.7 (统计显著); 罕见+严重
Nivolumab,Tri-iodothyronine free decreased,2,45,90.901,90.901,57.90,1.000,1.000,1.000,10.233,χ²=57.9 (统计显著); 罕见+严重
Nivolumab,Torticollis,1,45,0.000,0.000,44.40,1.000,1.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Coagulopathy,2,45,8.262,8.262,10.55,1.000,1.000,0.000,10.233,χ²=10.5 (统计显著); 罕见+严重
Nivolumab,Meningitis aseptic,2,45,12.984,12.984,16.81,1.000,0.000,1.000,10.233,χ²=16.8 (统计显著); 罕见+严重
Nivolumab,Ejaculation failure,1,45,45.412,45.412,21.23,1.000,0.000,0.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Gastritis haemorrhagic,1,45,45.412,45.412,21.23,1.000,0.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Vestibular disorder,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Incoherent,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Radiation necrosis,2,45,22.724,22.724,27.05,1.000,0.000,0.500,10.233,χ²=27.0 (统计显著); 罕见+严重
Nivolumab,Pseudarthrosis,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Autoimmune arthritis,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Oesophageal ulcer,2,45,12.984,12.984,16.81,0.500,0.000,0.000,10.233,χ²=16.8 (统计显著); 罕见+严重
Nivolumab,Polymyalgia rheumatica,1,45,45.412,45.412,21.23,1.000,0.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Hepatic rupture,1,45,0.000,0.000,44.40,1.000,1.000,0.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Asteatosis,1,45,0.000,0.000,44.40,1.000,0.000,0.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Adrenocorticotropic hormone deficiency,1,45,22.706,22.706,13.52,1.000,1.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Bile duct stenosis,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Cholangitis,2,45,8.262,8.262,10.55,1.000,0.500,1.000,10.233,χ²=10.5 (统计显著); 罕见+严重
Nivolumab,Biliary stent placement,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Cardiac hypertrophy,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Glomerulonephritis minimal lesion,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Allergic granulomatous angiitis,1,45,45.412,45.412,21.23,1.000,0.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Cauda equina syndrome,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Hypovolaemic shock,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Vogt-Koyanagi-Harada syndrome,1,45,45.412,45.412,21.23,1.000,0.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Iridocyclitis,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Alopecia areata,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Interleukin level increased,1,45,45.412,45.412,21.23,1.000,1.000,0.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,CSF granulocyte count abnormal,1,45,0.000,0.000,44.40,1.000,1.000,0.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Encephalitis toxic,1,45,0.000,0.000,44.40,1.000,1.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Oesophageal stenosis,1,45,0.000,0.000,44.40,1.000,1.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Inferior vena caval occlusion,1,45,0.000,0.000,44.40,1.000,0.000,1.000,10.926,χ²=44.4 (统计显著); 罕见+严重
Nivolumab,Hepatitis acute,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Nivolumab,Volvulus,1,45,45.412,45.412,21.23,1.000,0.000,1.000,10.926,χ²=21.2 (统计显著); 罕见+严重
Nivolumab,Endocrine disorder,1,45,22.706,22.706,13.52,1.000,0.000,1.000,10.926,χ²=13.5 (统计显著); 罕见+严重
Atezolizumab,Pneumoperitoneum,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Pneumonia mycoplasmal,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Neuropathic arthropathy,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Immune-mediated hepatitis,2,45,12.727,12.727,17.34,1.000,0.000,0.500,10.233,χ²=17.3 (统计显著); 罕见+严重
Atezolizumab,Pneumonia pneumococcal,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Ejection fraction abnormal,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Pyopneumothorax,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Large intestinal obstruction,2,45,16.364,16.364,22.01,1.000,0.000,1.000,10.233,χ²=22.0 (统计显著); 罕见+严重
Atezolizumab,Post procedural complication,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Encephalitis,2,45,16.364,16.364,22.01,1.000,0.000,0.500,10.233,χ²=22.0 (统计显著); 罕见+严重
Atezolizumab,Cholangitis,2,45,10.413,10.413,14.12,1.000,0.000,1.000,10.233,χ²=14.1 (统计显著); 罕见+严重
Atezolizumab,Type 1 diabetes mellitus,1,45,19.073,19.073,12.61,1.000,0.000,0.000,10.926,χ²=12.6 (统计显著); 罕见+严重
Atezolizumab,Ileal perforation,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Small intestine ulcer,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Bilirubin conjugated increased,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Infective exacerbation of chronic obstructive airways disease,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Enterocolitis infectious,2,45,22.911,22.911,29.36,1.000,0.000,1.000,10.233,χ²=29.4 (统计显著); 罕见+严重
Atezolizumab,Superior vena cava syndrome,2,45,28.639,28.639,34.88,1.000,0.500,1.000,10.233,χ²=34.9 (统计显著); 罕见+严重
Atezolizumab,Autoimmune colitis,2,45,19.092,19.092,25.22,1.000,0.000,1.000,10.233,χ²=25.2 (统计显著); 罕见+严重
Atezolizumab,Escherichia pyelonephritis,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Tracheobronchitis,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Duodenal obstruction,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Colonic fistula,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Pleural fistula,1,45,57.222,57.222,27.12,1.000,1.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Impaired gastric emptying,2,45,19.092,19.092,25.22,1.000,0.500,1.000,10.233,χ²=25.2 (统计显著); 罕见+严重
Atezolizumab,Lung consolidation,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Dermatitis bullous,2,45,22.911,22.911,29.36,1.000,0.000,1.000,10.233,χ²=29.4 (统计显著); 罕见+严重
Atezolizumab,Guillain-Barre syndrome,2,45,16.364,16.364,22.01,1.000,0.500,1.000,10.233,χ²=22.0 (统计显著); 罕见+严重
Atezolizumab,Parotitis,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Upper respiratory tract infection bacterial,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Cardiac tamponade,2,45,11.455,11.455,15.59,1.000,0.000,1.000,10.233,χ²=15.6 (统计显著); 罕见+严重
Atezolizumab,Localised oedema,1,45,19.073,19.073,12.61,1.000,0.000,1.000,10.926,χ²=12.6 (统计显著); 罕见+严重
Atezolizumab,Emphysema,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Intestinal haemorrhage,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Factor VIII inhibition,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Disease progression,2,45,0.133,0.133,10.85,1.000,1.000,0.500,10.233,χ²=10.9 (统计显著); 罕见+严重
Atezolizumab,Postrenal failure,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Urinary tract infection pseudomonal,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Fear,1,45,19.073,19.073,12.61,1.000,1.000,1.000,10.926,χ²=12.6 (统计显著); 罕见+严重
Atezolizumab,Fear of death,1,45,19.073,19.073,12.61,1.000,1.000,1.000,10.926,χ²=12.6 (统计显著); 罕见+严重
Atezolizumab,Nephritis,2,45,38.187,38.187,42.62,1.000,0.500,0.500,10.233,χ²=42.6 (统计显著); 罕见+严重
Atezolizumab,Henoch-Schonlein purpura nephritis,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Retinal vasculitis,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Sepsis syndrome,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Mastication disorder,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Optic neuritis,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Eyelid ptosis,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Immobile,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Crepitations,1,45,19.073,19.073,12.61,1.000,0.000,1.000,10.926,χ²=12.6 (统计显著); 罕见+严重
Atezolizumab,Organ failure,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Optic neuropathy,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Choroidal detachment,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Peripheral arthritis,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Loss of control of legs,1,45,0.000,0.000,56.18,1.000,0.000,0.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Radiation oesophagitis,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Ocular toxicity,1,45,0.000,0.000,56.18,1.000,0.000,0.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Hepatic haematoma,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Atezolizumab,Sinus bradycardia,1,45,57.222,57.222,27.12,1.000,0.000,1.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Skin irritation,1,45,19.073,19.073,12.61,1.000,0.000,1.000,10.926,χ²=12.6 (统计显著); 罕见+严重
Atezolizumab,Electrocardiogram T wave inversion,1,45,0.000,0.000,56.18,1.000,0.000,0.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Blood triglycerides increased,1,45,57.222,57.222,27.12,1.000,0.000,0.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Neuroborreliosis,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Herpes zoster disseminated,1,45,19.073,19.073,12.61,1.000,0.000,1.000,10.926,χ²=12.6 (统计显著); 罕见+严重
Atezolizumab,Tubulointerstitial nephritis,2,45,9.545,9.545,12.86,1.000,0.000,1.000,10.233,χ²=12.9 (统计显著); 罕见+严重
Atezolizumab,Empyema,1,45,57.222,57.222,27.12,1.000,0.000,0.000,10.926,χ²=27.1 (统计显著); 罕见+严重
Atezolizumab,Oesophagopleural fistula,1,45,0.000,0.000,56.18,1.000,0.000,0.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Compartment syndrome,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Stomatococcal infection,1,45,0.000,0.000,56.18,1.000,0.000,1.000,10.926,χ²=56.2 (统计显著); 罕见+严重
Atezolizumab,Enterocolitis bacterial,1,45,28.610,28.610,17.44,1.000,0.000,1.000,10.926,χ²=17.4 (统计显著); 罕见+严重
Durvalumab,Fatigue,13,45,0.456,0.456,7.90,0.692,0.154,0.385,8.361,严重事件率=69.2%; 罕见+严重
Durvalumab,Metastatic neoplasm,2,45,8.502,8.502,10.95,1.000,1.000,0.500,10.233,χ²=10.9 (统计显著); 罕见+严重
Durvalumab,Occult blood positive,1,45,46.727,46.727,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Cellulitis streptococcal,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Metastases to pelvis,1,45,0.000,0.000,45.71,1.000,1.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Metastases to abdominal cavity,1,45,15.575,15.575,10.01,1.000,1.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Lower gastrointestinal haemorrhage,2,45,15.588,15.588,20.01,1.000,0.000,0.500,10.233,χ²=20.0 (统计显著); 罕见+严重
Durvalumab,Nephritis,2,45,31.177,31.177,34.26,1.000,0.000,1.000,10.233,χ²=34.3 (统计显著); 罕见+严重
Durvalumab,Chronic inflammatory demyelinating polyradiculoneuropathy,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Hepatic infection,2,45,0.000,0.000,91.42,1.000,0.000,1.000,10.233,χ²=91.4 (统计显著); 罕见+严重
Durvalumab,Post-traumatic stress disorder,1,45,0.000,0.000,45.71,1.000,0.000,0.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Cough,7,45,1.364,1.364,0.64,0.571,0.143,0.143,8.980,严重事件率=57.1%; 罕见+严重
Durvalumab,Systemic scleroderma,1,45,0.000,0.000,45.71,1.000,1.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Large intestinal haemorrhage,1,45,23.363,23.363,13.96,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Hypoparathyroidism,2,45,0.000,0.000,91.42,1.000,0.000,1.000,10.233,χ²=91.4 (统计显著); 罕见+严重
Durvalumab,Cholangitis infective,2,45,0.000,0.000,91.42,1.000,0.000,1.000,10.233,χ²=91.4 (统计显著); 罕见+严重
Durvalumab,Bacillus infection,2,45,0.000,0.000,91.42,1.000,0.000,1.000,10.233,χ²=91.4 (统计显著); 罕见+严重
Durvalumab,Myasthenic syndrome,1,45,46.727,46.727,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Pharyngeal haemorrhage,1,45,0.000,0.000,45.71,1.000,1.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Back pain,8,45,1.580,1.580,1.59,0.625,0.125,0.125,8.847,严重事件率=62.5%; 罕见+严重
Durvalumab,Encephalomyelitis,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Guttate psoriasis,2,45,0.000,0.000,91.42,1.000,0.000,0.000,10.233,χ²=91.4 (统计显著); 罕见+严重
Durvalumab,Post procedural fistula,1,45,46.727,46.727,21.89,1.000,1.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Bronchopleural fistula,1,45,0.000,0.000,45.71,1.000,1.000,0.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Infusion site swelling,1,45,46.727,46.727,21.89,1.000,0.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Non-small cell lung cancer stage III,1,45,0.000,0.000,45.71,1.000,0.000,0.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Tracheal stenosis,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Encephalitis autoimmune,1,45,0.000,0.000,45.71,1.000,1.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Weight decreased,5,45,0.858,0.858,0.11,0.600,0.000,0.200,9.317,严重事件率=60.0%; 罕见+严重
Durvalumab,Influenza A virus test positive,1,45,46.727,46.727,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Autoimmune colitis,2,45,15.588,15.588,20.01,1.000,0.000,1.000,10.233,χ²=20.0 (统计显著); 罕见+严重
Durvalumab,Chorea,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Amyloidosis,1,45,15.575,15.575,10.01,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Immune-mediated adverse reaction,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Aortic aneurysm,1,45,46.727,46.727,21.89,1.000,1.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Type 1 diabetes mellitus,1,45,15.575,15.575,10.01,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Oesophageal fistula,1,45,15.575,15.575,10.01,1.000,1.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Mediastinitis,1,45,46.727,46.727,21.89,1.000,1.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Perforated ulcer,1,45,23.363,23.363,13.96,1.000,1.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Soft tissue necrosis,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Duodenal obstruction,1,45,23.363,23.363,13.96,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Non-small cell lung cancer recurrent,1,45,15.575,15.575,10.01,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Device related thrombosis,1,45,46.727,46.727,21.89,1.000,0.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Respiratory tract irritation,1,45,23.363,23.363,13.96,1.000,0.000,0.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Autoimmune thyroid disorder,1,45,0.000,0.000,45.71,1.000,0.000,0.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Intervertebral disc injury,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Fibula fracture,1,45,15.575,15.575,10.01,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Overweight,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Head discomfort,1,45,15.575,15.575,10.01,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Scleral disorder,1,45,0.000,0.000,45.71,1.000,0.000,0.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Necrotising myositis,1,45,0.000,0.000,45.71,1.000,0.000,0.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Embolism arterial,1,45,23.363,23.363,13.96,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Autoimmune disorder,1,45,23.363,23.363,13.96,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Mixed liver injury,2,45,93.534,93.534,59.65,1.000,0.000,1.000,10.233,χ²=59.6 (统计显著); 罕见+严重
Durvalumab,Post procedural sepsis,1,45,23.363,23.363,13.96,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Arteritis,1,45,46.727,46.727,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Liver abscess,1,45,23.363,23.363,13.96,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Inflammatory marker increased,1,45,46.727,46.727,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Bile duct stenosis,1,45,23.363,23.363,13.96,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Steroid diabetes,1,45,46.727,46.727,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Thyroiditis,2,45,13.361,13.361,17.38,1.000,0.000,0.500,10.233,χ²=17.4 (统计显著); 罕见+严重
Durvalumab,Adrenal disorder,1,45,46.727,46.727,21.89,1.000,0.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Limb injury,2,45,10.391,10.391,13.57,0.500,0.500,0.000,10.233,χ²=13.6 (统计显著); 罕见+严重
Durvalumab,Respiratory rate increased,1,45,15.575,15.575,10.01,1.000,1.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Blood thyroid stimulating hormone decreased,2,45,11.690,11.690,15.28,0.500,0.000,0.500,10.233,χ²=15.3 (统计显著); 罕见+严重
Durvalumab,Vertebral column mass,1,45,46.727,46.727,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Tumour hyperprogression,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Mediastinum neoplasm,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Critical illness,1,45,46.727,46.727,21.89,1.000,1.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Jejunal ulcer,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Facial nerve disorder,1,45,23.363,23.363,13.96,1.000,0.000,0.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Endocrine ophthalmopathy,1,45,0.000,0.000,45.71,1.000,0.000,0.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Pneumonia necrotising,1,45,23.363,23.363,13.96,1.000,1.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Arterial haemorrhage,1,45,15.575,15.575,10.01,1.000,1.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Colon cancer stage IV,1,45,0.000,0.000,45.71,1.000,0.000,0.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Apnoea,1,45,15.575,15.575,10.01,1.000,1.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Durvalumab,Nasal polyps,1,45,0.000,0.000,45.71,1.000,0.000,1.000,10.926,χ²=45.7 (统计显著); 罕见+严重
Durvalumab,Peritonitis bacterial,1,45,23.363,23.363,13.96,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Durvalumab,Diabetic metabolic decompensation,1,45,46.727,46.727,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Durvalumab,Back injury,1,45,46.727,46.727,21.89,1.000,1.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Ipilimumab,Hypertension,5,45,1.160,1.160,0.10,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Ipilimumab,Respiratory tract inflammation,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Paraparesis,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Hepatic haematoma,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Meningitis aseptic,2,45,11.675,11.675,14.80,1.000,0.000,1.000,10.233,χ²=14.8 (统计显著); 罕见+严重
Ipilimumab,Hypothalamo-pituitary disorder,2,45,27.244,27.244,29.57,1.000,0.000,1.000,10.233,χ²=29.6 (统计显著); 罕见+严重
Ipilimumab,Feeling of despair,1,45,40.837,40.837,18.95,1.000,1.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Venous thrombosis,2,45,16.346,16.346,20.06,1.000,1.000,1.000,10.233,χ²=20.1 (统计显著); 罕见+严重
Ipilimumab,Immune system disorder,2,45,8.172,8.172,10.22,1.000,1.000,0.500,10.233,χ²=10.2 (统计显著); 罕见+严重
Ipilimumab,Delusion,1,45,20.418,20.418,12.01,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Fungal skin infection,2,45,27.244,27.244,29.57,1.000,1.000,1.000,10.233,χ²=29.6 (统计显著); 罕见+严重
Ipilimumab,Oxygen supplementation,1,45,40.837,40.837,18.95,1.000,1.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Torsade de pointes,1,45,0.000,0.000,39.83,1.000,1.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Schizophrenia,1,45,40.837,40.837,18.95,1.000,1.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Gastrointestinal infection,2,45,9.080,9.080,11.47,1.000,0.500,1.000,10.233,χ²=11.5 (统计显著); 罕见+严重
Ipilimumab,Exfoliative rash,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Peritoneal haemorrhage,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Marrow hyperplasia,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Unresponsive to stimuli,2,45,9.080,9.080,11.47,1.000,0.000,1.000,10.233,χ²=11.5 (统计显著); 罕见+严重
Ipilimumab,Autoimmune disorder,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Thyroiditis,2,45,11.675,11.675,14.80,1.000,0.000,0.500,10.233,χ²=14.8 (统计显著); 罕见+严重
Ipilimumab,Affective disorder,1,45,0.000,0.000,39.83,1.000,1.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Peritoneal dialysis,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Listless,1,45,40.837,40.837,18.95,1.000,0.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Blood thyroid stimulating hormone decreased,2,45,10.216,10.216,12.96,1.000,0.000,1.000,10.233,χ²=13.0 (统计显著); 罕见+严重
Ipilimumab,Demyelinating polyneuropathy,1,45,40.837,40.837,18.95,1.000,0.000,0.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Myelitis transverse,1,45,40.837,40.837,18.95,1.000,0.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Urogenital disorder,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Illusion,1,45,20.418,20.418,12.01,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Adrenocortical insufficiency acute,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Fungal test positive,1,45,40.837,40.837,18.95,1.000,0.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Blood culture positive,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Blood cortisol decreased,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Adrenocorticotropic hormone deficiency,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Blood luteinising hormone decreased,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Blood follicle stimulating hormone decreased,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Hormone level abnormal,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Large intestinal ulcer,1,45,40.837,40.837,18.95,1.000,0.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Adrenal disorder,1,45,40.837,40.837,18.95,1.000,0.000,0.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Stillbirth,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Endocrine disorder,2,45,81.736,81.736,51.82,1.000,0.000,1.000,10.233,χ²=51.8 (统计显著); 罕见+严重
Ipilimumab,Adrenal suppression,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Brain operation,1,45,40.837,40.837,18.95,1.000,0.000,0.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Petit mal epilepsy,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Hypothermia,2,45,27.244,27.244,29.57,1.000,0.000,0.500,10.233,χ²=29.6 (统计显著); 罕见+严重
Ipilimumab,Lower gastrointestinal haemorrhage,2,45,13.621,13.621,17.10,1.000,0.000,1.000,10.233,χ²=17.1 (统计显著); 罕见+严重
Ipilimumab,Oesophageal perforation,1,45,40.837,40.837,18.95,1.000,1.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Pituitary tumour,2,45,20.433,20.433,24.02,1.000,0.000,0.500,10.233,χ²=24.0 (统计显著); 罕见+严重
Ipilimumab,Peritoneal necrosis,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Axillary mass,1,45,40.837,40.837,18.95,1.000,0.000,0.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Concomitant disease progression,1,45,20.418,20.418,12.01,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Retinitis,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Portal hypertension,1,45,40.837,40.837,18.95,1.000,0.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Strangulated hernia,1,45,0.000,0.000,39.83,1.000,1.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Neurological examination abnormal,2,45,40.867,40.867,37.90,1.000,1.000,1.000,10.233,χ²=37.9 (统计显著); 罕见+严重
Ipilimumab,Mesenteric panniculitis,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Vogt-Koyanagi-Harada syndrome,1,45,40.837,40.837,18.95,1.000,0.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Abdominal sepsis,1,45,0.000,0.000,39.83,1.000,1.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Urine output decreased,2,45,10.216,10.216,12.96,1.000,0.500,0.500,10.233,χ²=13.0 (统计显著); 罕见+严重
Ipilimumab,Ectopic pregnancy,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Adrenalitis,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Neutropenia,1,45,0.068,0.068,12.40,1.000,0.000,1.000,10.926,χ²=12.4 (统计显著); 罕见+严重
Ipilimumab,Colectomy,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Acute psychosis,1,45,40.837,40.837,18.95,1.000,0.000,0.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Fuchs^ syndrome,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Myoglobin blood increased,1,45,0.000,0.000,39.83,1.000,1.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Epstein-Barr virus test,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Herpes simplex,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Perirectal abscess,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Calculus ureteric,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Hyperuricaemia,2,45,13.621,13.621,17.10,1.000,0.500,1.000,10.233,χ²=17.1 (统计显著); 罕见+严重
Ipilimumab,Alcoholism,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Eosinophilic pneumonia,1,45,40.837,40.837,18.95,1.000,0.000,0.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Cytomegalovirus colitis,1,45,20.418,20.418,12.01,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Tooth abscess,1,45,20.418,20.418,12.01,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Sialoadenitis,1,45,0.000,0.000,39.83,1.000,0.000,0.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Anal fistula,1,45,20.418,20.418,12.01,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Ipilimumab,Retroperitoneal haemorrhage,1,45,40.837,40.837,18.95,1.000,0.000,1.000,10.926,χ²=19.0 (统计显著); 罕见+严重
Ipilimumab,Infected neoplasm,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Ipilimumab,Autoimmune pancytopenia,1,45,0.000,0.000,39.83,1.000,0.000,1.000,10.926,χ²=39.8 (统计显著); 罕见+严重
Trastuzumab,Decreased appetite,17,45,0.871,0.871,0.30,0.882,0.059,0.353,8.093,严重事件率=88.2%; 罕见+严重
Trastuzumab,Pleural effusion,9,45,1.175,1.175,0.22,0.889,0.111,0.333,8.729,严重事件率=88.9%; 罕见+严重
Trastuzumab,Pain,15,45,1.457,1.457,1.95,0.933,0.133,0.200,8.218,严重事件率=93.3%; 罕见+严重
Trastuzumab,Arteriovenous malformation,1,45,27.929,27.929,12.53,1.000,1.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Cough,10,45,1.179,1.179,0.25,0.900,0.100,0.300,8.623,严重事件率=90.0%; 罕见+严重
Trastuzumab,Central nervous system infection,1,45,27.929,27.929,12.53,1.000,1.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Dilatation ventricular,2,45,11.177,11.177,12.77,1.000,0.500,0.500,10.233,χ²=12.8 (统计显著); 罕见+严重
Trastuzumab,Anorectal disorder,1,45,27.929,27.929,12.53,1.000,1.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Carpal tunnel decompression,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Neutropenia,13,45,0.617,0.617,2.87,1.000,0.154,0.385,8.361,严重事件率=100.0%; 罕见+严重
Trastuzumab,Skin induration,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Vascular calcification,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Cholecystitis chronic,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Muscle spasticity,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Polycythaemia,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Haemoglobin increased,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Chest pain,8,45,1.270,1.270,0.42,0.875,0.000,0.375,8.847,严重事件率=87.5%; 罕见+严重
Trastuzumab,Dry skin,9,45,1.967,1.967,3.83,0.667,0.111,0.111,8.729,严重事件率=66.7%; 罕见+严重
Trastuzumab,Arthralgia,11,45,1.230,1.230,0.43,0.818,0.000,0.364,8.528,严重事件率=81.8%; 罕见+严重
Trastuzumab,Deafness unilateral,2,45,9.314,9.314,10.73,1.000,1.000,1.000,10.233,χ²=10.7 (统计显著); 罕见+严重
Trastuzumab,Myelitis,1,45,0.000,0.000,26.95,1.000,0.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Mastectomy,2,45,0.000,0.000,53.90,1.000,0.000,0.500,10.233,χ²=53.9 (统计显著); 罕见+严重
Trastuzumab,Breast reconstruction,1,45,0.000,0.000,26.95,1.000,0.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Abdominal discomfort,6,45,1.260,1.260,0.30,1.000,0.000,0.333,9.134,严重事件率=100.0%; 罕见+严重
Trastuzumab,Off label use,5,45,0.325,0.325,6.61,0.800,0.000,0.200,9.317,严重事件率=80.0%; 罕见+严重
Trastuzumab,Application site discomfort,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Back pain,10,45,1.189,1.189,0.28,0.900,0.000,0.400,8.623,严重事件率=90.0%; 罕见+严重
Trastuzumab,Pruritus,13,45,1.449,1.449,1.64,0.769,0.000,0.231,8.361,严重事件率=76.9%; 罕见+严重
Trastuzumab,Increased tendency to bruise,2,45,9.314,9.314,10.73,1.000,0.000,0.000,10.233,χ²=10.7 (统计显著); 罕见+严重
Trastuzumab,Breast ulceration,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Neuropathy peripheral,9,45,1.148,1.148,0.16,0.889,0.111,0.222,8.729,严重事件率=88.9%; 罕见+严重
Trastuzumab,Aortic valve sclerosis,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Tricuspid valve incompetence,2,45,13.971,13.971,15.48,1.000,0.500,0.500,10.233,χ²=15.5 (统计显著); 罕见+严重
Trastuzumab,Myocardial strain,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Dermo-hypodermitis,2,45,55.888,55.888,34.66,1.000,0.000,1.000,10.233,χ²=34.7 (统计显著); 罕见+严重
Trastuzumab,Corneal exfoliation,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Lacrimation decreased,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Ventricular dyskinesia,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Gastrointestinal inflammation,2,45,18.628,18.628,19.31,1.000,0.000,1.000,10.233,χ²=19.3 (统计显著); 罕见+严重
Trastuzumab,Asthenopia,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Thrombocytopenia,3,45,0.179,0.179,10.74,1.000,0.000,0.333,9.827,χ²=10.7 (统计显著); 罕见+严重
Trastuzumab,Interstitial lung disease,6,45,1.034,1.034,0.01,1.000,0.167,0.167,9.134,严重事件率=100.0%; 罕见+严重
Trastuzumab,Breast neoplasm,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Hysterectomy,2,45,55.888,55.888,34.66,1.000,0.000,0.000,10.233,χ²=34.7 (统计显著); 罕见+严重
Trastuzumab,Blood bilirubin decreased,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Major depression,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Alanine aminotransferase increased,5,45,0.784,0.784,0.28,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Trastuzumab,Suspected counterfeit product,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Cardiovascular insufficiency,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Heart valve incompetence,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Inflammatory carcinoma of breast stage IV,1,45,27.929,27.929,12.53,1.000,1.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Metastases to pancreas,1,45,0.000,0.000,26.95,1.000,1.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Arachnoiditis,1,45,0.000,0.000,26.95,1.000,0.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Atrioventricular block second degree,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Corneal disorder,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Systemic lupus erythematosus,2,45,0.000,0.000,53.90,1.000,0.000,1.000,10.233,χ²=53.9 (统计显著); 罕见+严重
Trastuzumab,Gait disturbance,7,45,1.938,1.938,2.85,1.000,0.000,0.143,8.980,严重事件率=100.0%; 罕见+严重
Trastuzumab,Coordination abnormal,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Laryngitis,2,45,9.314,9.314,10.73,1.000,0.000,0.500,10.233,χ²=10.7 (统计显著); 罕见+严重
Trastuzumab,Thoracic operation,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Hypermetropia,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Contrast media allergy,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Muscle spasms,6,45,1.223,1.223,0.22,1.000,0.000,0.000,9.134,严重事件率=100.0%; 罕见+严重
Trastuzumab,Oesophageal infection,1,45,0.000,0.000,26.95,1.000,0.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Intracranial tumour haemorrhage,2,45,18.628,18.628,19.31,1.000,0.000,0.000,10.233,χ²=19.3 (统计显著); 罕见+严重
Trastuzumab,Implant site extravasation,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Body temperature fluctuation,2,45,27.943,27.943,25.05,1.000,0.000,0.000,10.233,χ²=25.1 (统计显著); 罕见+严重
Trastuzumab,Breast pain,2,45,27.943,27.943,25.05,1.000,0.000,0.000,10.233,χ²=25.1 (统计显著); 罕见+严重
Trastuzumab,Bladder prolapse,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Uterine prolapse,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Muscle fatigue,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Extrasystoles,2,45,18.628,18.628,19.31,0.500,0.000,0.000,10.233,χ²=19.3 (统计显著); 罕见+严重
Trastuzumab,Insomnia,7,45,1.207,1.207,0.23,0.714,0.000,0.000,8.980,严重事件率=71.4%; 罕见+严重
Trastuzumab,Pituitary tumour,2,45,13.971,13.971,15.48,1.000,0.000,0.000,10.233,χ²=15.5 (统计显著); 罕见+严重
Trastuzumab,Pemphigus,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Epidermal growth factor receptor decreased,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Carbon dioxide increased,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Eczema,2,45,9.314,9.314,10.73,0.500,0.500,0.500,10.233,χ²=10.7 (统计显著); 罕见+严重
Trastuzumab,Cor pulmonale,1,45,0.000,0.000,26.95,1.000,1.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Subcutaneous abscess,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Anuria,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Temperature intolerance,2,45,18.628,18.628,19.31,1.000,0.000,0.500,10.233,χ²=19.3 (统计显著); 罕见+严重
Trastuzumab,Tumour embolism,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Foetal death,2,45,18.628,18.628,19.31,1.000,0.500,0.000,10.233,χ²=19.3 (统计显著); 罕见+严重
Trastuzumab,Foetal malformation,1,45,0.000,0.000,26.95,1.000,1.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Blepharospasm,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Mucosal dryness,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Rectal fissure,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Echocardiogram abnormal,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Nipple exudate bloody,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Acute psychosis,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Paranoia,1,45,0.000,0.000,26.95,1.000,0.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Tension,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Device failure,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Nasal ulcer,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Hyperventilation,2,45,18.628,18.628,19.31,0.500,0.000,0.000,10.233,χ²=19.3 (统计显著); 罕见+严重
Trastuzumab,Burning feet syndrome,1,45,27.929,27.929,12.53,1.000,0.000,0.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Vitreous adhesions,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Metastases to thorax,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Periarthritis,1,45,0.000,0.000,26.95,1.000,1.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Local reaction,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Cardiac discomfort,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Bone decalcification,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Anhidrosis,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Hair colour changes,1,45,27.929,27.929,12.53,1.000,0.000,1.000,10.926,χ²=12.5 (统计显著); 罕见+严重
Trastuzumab,Chemical injury,1,45,0.000,0.000,26.95,1.000,0.000,0.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Abnormal dreams,1,45,0.000,0.000,26.95,1.000,0.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Trastuzumab,Infusion site bruising,1,45,0.000,0.000,26.95,1.000,0.000,1.000,10.926,χ²=26.9 (统计显著); 罕见+严重
Bevacizumab,Pain,9,45,0.939,0.939,0.03,1.000,0.111,0.333,8.729,严重事件率=100.0%; 罕见+严重
Bevacizumab,Anaemia,11,45,0.560,0.560,3.56,1.000,0.091,0.091,8.528,严重事件率=100.0%; 罕见+严重
Bevacizumab,Nephritic syndrome,2,45,61.435,61.435,38.34,1.000,0.000,1.000,10.233,χ²=38.3 (统计显著); 罕见+严重
Bevacizumab,Nephrotic syndrome,2,45,20.478,20.478,21.50,1.000,0.000,0.500,10.233,χ²=21.5 (统计显著); 罕见+严重
Bevacizumab,Dyspnoea,16,45,0.784,0.784,0.89,1.000,0.125,0.375,8.153,严重事件率=100.0%; 罕见+严重
Bevacizumab,Hepatic artery aneurysm,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Cystitis noninfective,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Neutropenia,15,45,0.786,0.786,0.81,1.000,0.133,0.200,8.218,严重事件率=100.0%; 罕见+严重
Bevacizumab,Intestinal resection,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Colonic abscess,2,45,12.286,12.286,14.33,1.000,0.000,1.000,10.233,χ²=14.3 (统计显著); 罕见+严重
Bevacizumab,Rectal obstruction,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Nasal septum deviation,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Haemostasis,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Weight fluctuation,2,45,8.775,8.775,10.37,1.000,0.000,0.000,10.233,χ²=10.4 (统计显著); 罕见+严重
Bevacizumab,Renal failure,6,45,0.902,0.902,0.06,1.000,0.000,0.000,9.134,严重事件率=100.0%; 罕见+严重
Bevacizumab,Haptoglobin decreased,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Small intestinal perforation,2,45,12.286,12.286,14.33,1.000,0.500,0.500,10.233,χ²=14.3 (统计显著); 罕见+严重
Bevacizumab,Computerised tomogram abnormal,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Tumour necrosis,1,45,30.700,30.700,13.90,1.000,1.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Tendon pain,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Tendon disorder,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Electrocardiogram ST segment abnormal,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Urinary tract obstruction,2,45,15.358,15.358,17.31,1.000,0.000,0.500,10.233,χ²=17.3 (统计显著); 罕见+严重
Bevacizumab,Visual field defect,2,45,30.717,30.717,27.81,1.000,0.000,0.000,10.233,χ²=27.8 (统计显著); 罕见+严重
Bevacizumab,Small intestine ulcer,1,45,30.700,30.700,13.90,1.000,1.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Catheterisation cardiac,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Rectal discharge,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Adenocarcinoma,2,45,20.478,20.478,21.50,1.000,0.000,0.500,10.233,χ²=21.5 (统计显著); 罕见+严重
Bevacizumab,Dysplasia,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Varices oesophageal,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Cough,5,45,0.633,0.633,1.00,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Bevacizumab,Cerebrospinal fluid leakage,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Extradural abscess,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Skin necrosis,2,45,15.358,15.358,17.31,1.000,0.500,0.000,10.233,χ²=17.3 (统计显著); 罕见+严重
Bevacizumab,Cataract nuclear,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Retinal oedema,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Abdominal wall neoplasm,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Retinal pigment epithelial tear,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Dermatomyositis,2,45,12.286,12.286,14.33,1.000,0.000,1.000,10.233,χ²=14.3 (统计显著); 罕见+严重
Bevacizumab,Bone marrow failure,6,45,1.808,1.808,1.97,1.000,0.000,0.000,9.134,严重事件率=100.0%; 罕见+严重
Bevacizumab,Cell marker increased,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Pulmonary cavitation,2,45,30.717,30.717,27.81,1.000,0.500,0.000,10.233,χ²=27.8 (统计显著); 罕见+严重
Bevacizumab,Blood chromogranin A increased,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Acute tonsillitis,2,45,0.000,0.000,59.43,1.000,0.000,1.000,10.233,χ²=59.4 (统计显著); 罕见+严重
Bevacizumab,Anastomotic complication,2,45,30.717,30.717,27.81,1.000,0.000,0.500,10.233,χ²=27.8 (统计显著); 罕见+严重
Bevacizumab,Deep vein thrombosis,5,45,1.409,1.409,0.55,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Bevacizumab,Hemiplegia,2,45,20.478,20.478,21.50,1.000,0.000,1.000,10.233,χ²=21.5 (统计显著); 罕见+严重
Bevacizumab,Supraventricular extrasystoles,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Exercise tolerance decreased,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Pneumatosis,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Spinal cord compression,2,45,20.478,20.478,21.50,1.000,0.500,1.000,10.233,χ²=21.5 (统计显著); 罕见+严重
Bevacizumab,Antinuclear antibody increased,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Metastases to heart,2,45,20.478,20.478,21.50,1.000,0.000,0.000,10.233,χ²=21.5 (统计显著); 罕见+严重
Bevacizumab,Vocal cord paresis,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Cranial nerve disorder,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Punctate keratitis,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Wound abscess,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Nasal oedema,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Erythema,8,45,1.546,1.546,1.41,1.000,0.125,0.375,8.847,严重事件率=100.0%; 罕见+严重
Bevacizumab,Pelvic fluid collection,1,45,30.700,30.700,13.90,1.000,1.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Ventricular fibrillation,2,45,20.478,20.478,21.50,1.000,0.000,0.000,10.233,χ²=21.5 (统计显著); 罕见+严重
Bevacizumab,Coagulation factor decreased,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Coombs test positive,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Prerenal failure,2,45,10.238,10.238,12.09,1.000,0.000,1.000,10.233,χ²=12.1 (统计显著); 罕见+严重
Bevacizumab,Age-related macular degeneration,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Retinal degeneration,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Lacrimal structure injury,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Acute abdomen,2,45,0.000,0.000,59.43,1.000,0.000,0.500,10.233,χ²=59.4 (统计显著); 罕见+严重
Bevacizumab,Spinal epidural haemorrhage,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Gastrointestinal wall thickening,1,45,30.700,30.700,13.90,1.000,1.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Peripheral nerve sheath tumour malignant,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Wound decomposition,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Spinal cord oedema,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Myocardial infarction,5,45,1.873,1.873,1.85,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Bevacizumab,Jejunal perforation,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Metamorphopsia,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Colour blindness,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Ultrasound scan abnormal,1,45,30.700,30.700,13.90,1.000,1.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Lip disorder,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Finger amputation,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Gastrointestinal anastomotic leak,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Ureteral disorder,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Pelvic abscess,2,45,61.435,61.435,38.34,1.000,0.000,0.500,10.233,χ²=38.3 (统计显著); 罕见+严重
Bevacizumab,Aspartate aminotransferase,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Gingival inflammation,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Superinfection bacterial,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Meningioma surgery,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Exploratory operation,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Small intestine polyp,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Collateral circulation,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Product substitution issue,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Head and neck cancer metastatic,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Acquired diaphragmatic eventration,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Therapy responder,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Diarrhoea infectious,1,45,30.700,30.700,13.90,1.000,1.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Intracranial aneurysm,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Stoma site abscess,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Eye infection staphylococcal,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Oesophagobronchial fistula,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Necrotising colitis,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Colorectal cancer,1,45,30.700,30.700,13.90,1.000,1.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Retinal haemorrhage,2,45,12.286,12.286,14.33,1.000,0.000,0.000,10.233,χ²=14.3 (统计显著); 罕见+严重
Bevacizumab,Costochondritis,1,45,30.700,30.700,13.90,1.000,0.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Retroperitoneal neoplasm,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Hernia,2,45,10.238,10.238,12.09,1.000,0.500,0.500,10.233,χ²=12.1 (统计显著); 罕见+严重
Bevacizumab,Foreign body sensation in eyes,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Rash papulosquamous,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Catheter site discharge,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Abscess intestinal,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Duodenal perforation,1,45,30.700,30.700,13.90,1.000,1.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Duodenal fistula,1,45,0.000,0.000,29.71,1.000,1.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Wernicke-Korsakoff syndrome,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Retinal neovascularisation,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Retinal exudates,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Hypoperfusion,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Micturition frequency decreased,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Fingerprint loss,1,45,0.000,0.000,29.71,1.000,1.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Cartilage injury,1,45,0.000,0.000,29.71,1.000,0.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Keratorhexis,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Essential tremor,1,45,30.700,30.700,13.90,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Protein urine absent,1,45,0.000,0.000,29.71,1.000,1.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Bronchial haemorrhage,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Varicose vein,1,45,30.700,30.700,13.90,1.000,1.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Bevacizumab,Coma scale abnormal,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Gastrectomy,1,45,0.000,0.000,29.71,1.000,0.000,1.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Rectal perforation,1,45,0.000,0.000,29.71,1.000,1.000,0.000,10.926,χ²=29.7 (统计显著); 罕见+严重
Bevacizumab,Ischaemia,2,45,15.358,15.358,17.31,1.000,0.000,0.000,10.233,χ²=17.3 (统计显著); 罕见+严重
Bevacizumab,Peripheral T-cell lymphoma unspecified,1,45,30.700,30.700,13.90,1.000,1.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Cetuximab,Dyspnoea,13,45,1.298,1.298,0.83,0.923,0.077,0.231,8.361,严重事件率=92.3%; 罕见+严重
Cetuximab,Suture related complication,1,45,62.545,62.545,29.77,1.000,1.000,1.000,10.926,χ²=29.8 (统计显著); 罕见+严重
Cetuximab,Megacolon,1,45,20.848,20.848,13.93,1.000,1.000,1.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Cetuximab,Urinary tract disorder,1,45,15.635,15.635,10.77,1.000,1.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Cetuximab,Blood pressure immeasurable,1,45,62.545,62.545,29.77,1.000,0.000,0.000,10.926,χ²=29.8 (统计显著); 罕见+严重
Cetuximab,Pulse absent,1,45,15.635,15.635,10.77,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Cetuximab,Anaphylactoid reaction,2,45,125.233,125.233,80.68,1.000,0.000,0.500,10.233,χ²=80.7 (统计显著); 罕见+严重
Cetuximab,Penile erythema,1,45,0.000,0.000,61.49,1.000,0.000,0.000,10.926,χ²=61.5 (统计显著); 罕见+严重
Cetuximab,Hair growth abnormal,2,45,15.652,15.652,21.55,0.500,0.000,0.000,10.233,χ²=21.5 (统计显著); 罕见+严重
Cetuximab,Apparent death,1,45,31.272,31.272,19.21,1.000,0.000,0.000,10.926,χ²=19.2 (统计显著); 罕见+严重
Cetuximab,Pallor,2,45,8.943,8.943,12.12,1.000,0.000,0.500,10.233,χ²=12.1 (统计显著); 罕见+严重
Cetuximab,Chest pain,5,45,1.749,1.749,1.52,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Cetuximab,Dandruff,1,45,62.545,62.545,29.77,1.000,0.000,0.000,10.926,χ²=29.8 (统计显著); 罕见+严重
Cetuximab,Staphylococcal skin infection,1,45,0.000,0.000,61.49,1.000,0.000,1.000,10.926,χ²=61.5 (统计显著); 罕见+严重
Cetuximab,Obstructive airways disorder,1,45,15.635,15.635,10.77,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Cetuximab,Consciousness fluctuating,1,45,0.000,0.000,61.49,1.000,1.000,0.000,10.926,χ²=61.5 (统计显著); 罕见+严重
Cetuximab,Heart rate decreased,2,45,8.943,8.943,12.12,1.000,0.500,0.500,10.233,χ²=12.1 (统计显著); 罕见+严重
Cetuximab,Eye movement disorder,1,45,20.848,20.848,13.93,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Cetuximab,Blood pressure abnormal,1,45,20.848,20.848,13.93,1.000,0.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Cetuximab,Vital functions abnormal,1,45,0.000,0.000,61.49,1.000,0.000,0.000,10.926,χ²=61.5 (统计显著); 罕见+严重
Cetuximab,Stridor,1,45,62.545,62.545,29.77,1.000,0.000,0.000,10.926,χ²=29.8 (统计显著); 罕见+严重
Cetuximab,Aphonia,1,45,15.635,15.635,10.77,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Rituximab,Malignant neoplasm progression,2,45,0.077,0.077,20.89,1.000,0.500,0.000,10.233,χ²=20.9 (统计显著); 罕见+严重
Rituximab,Pterygium,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Femoral neck fracture,2,45,8.961,8.961,10.22,1.000,0.500,0.500,10.233,χ²=10.2 (统计显著); 罕见+严重
Rituximab,Sensory loss,2,45,10.753,10.753,12.17,1.000,0.500,0.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Rituximab,Grand mal convulsion,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Vaginal ulceration,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Headache,15,45,1.208,1.208,0.49,0.867,0.133,0.333,8.218,严重事件率=86.7%; 罕见+严重
Rituximab,Renal colic,2,45,53.768,53.768,33.25,1.000,0.000,1.000,10.233,χ²=33.3 (统计显著); 罕见+严重
Rituximab,Drug dependence,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Fasciitis,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Castleman^s disease,2,45,13.441,13.441,14.79,1.000,1.000,0.000,10.233,χ²=14.8 (统计显著); 罕见+严重
Rituximab,Hepatic necrosis,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Cushingoid,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Microangiopathic haemolytic anaemia,1,45,26.871,26.871,12.00,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,"Bladder cancer stage I, with cancer in situ",1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Joint arthroplasty,2,45,0.000,0.000,51.79,1.000,0.000,1.000,10.233,χ²=51.8 (统计显著); 罕见+严重
Rituximab,Trapezectomy,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Ligament operation,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Synovial rupture,2,45,0.000,0.000,51.79,1.000,0.000,1.000,10.233,χ²=51.8 (统计显著); 罕见+严重
Rituximab,Mantle cell lymphoma recurrent,2,45,53.768,53.768,33.25,1.000,0.500,0.000,10.233,χ²=33.3 (统计显著); 罕见+严重
Rituximab,Colitis microscopic,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Injection site pustule,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Chills,8,45,1.559,1.559,1.45,0.750,0.125,0.375,8.847,严重事件率=75.0%; 罕见+严重
Rituximab,Meniscus injury,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Injection site infection,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Injection site haemorrhage,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Fractured coccyx,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Vein discolouration,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Vascular pain,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Poor peripheral circulation,2,45,26.884,26.884,24.00,0.500,0.500,0.500,10.233,χ²=24.0 (统计显著); 罕见+严重
Rituximab,Post-traumatic pain,1,45,26.871,26.871,12.00,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Larynx irritation,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Bronchial obstruction,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Osteochondrosis,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Gastric polyps,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Iron deficiency anaemia,2,45,10.753,10.753,12.17,1.000,0.500,1.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Rituximab,Prinzmetal angina,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Cryptococcosis,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Abscess limb,2,45,53.768,53.768,33.25,1.000,0.000,1.000,10.233,χ²=33.3 (统计显著); 罕见+严重
Rituximab,Venous insufficiency,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Occipital neuralgia,2,45,0.000,0.000,51.79,1.000,0.000,0.500,10.233,χ²=51.8 (统计显著); 罕见+严重
Rituximab,Granuloma,2,45,17.922,17.922,18.47,1.000,0.000,0.500,10.233,χ²=18.5 (统计显著); 罕见+严重
Rituximab,Cystitis escherichia,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Ear disorder,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Humerus fracture,2,45,26.884,26.884,24.00,1.000,0.500,1.000,10.233,χ²=24.0 (统计显著); 罕见+严重
Rituximab,Cervicitis,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Subcutaneous abscess,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Blood pressure immeasurable,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Pulse abnormal,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Acute graft versus host disease in intestine,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Acute graft versus host disease in skin,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Hiatus hernia,2,45,17.922,17.922,18.47,1.000,0.000,0.500,10.233,χ²=18.5 (统计显著); 罕见+严重
Rituximab,Colon cancer stage II,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Drug ineffective,16,45,1.697,1.697,4.11,0.938,0.000,0.188,8.153,严重事件率=93.8%; 罕见+严重
Rituximab,Acquired gene mutation,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Lymphadenitis,2,45,13.441,13.441,14.79,1.000,0.000,1.000,10.233,χ²=14.8 (统计显著); 罕见+严重
Rituximab,Lymph node pain,2,45,13.441,13.441,14.79,1.000,0.000,1.000,10.233,χ²=14.8 (统计显著); 罕见+严重
Rituximab,Bone marrow transplant,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Necrosis,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Transplant rejection,3,45,0.000,0.000,77.68,1.000,0.000,0.000,9.827,χ²=77.7 (统计显著); 罕见+严重
Rituximab,Serratia infection,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Helicobacter infection,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Blood calcium decreased,2,45,8.961,8.961,10.22,1.000,0.500,0.500,10.233,χ²=10.2 (统计显著); 罕见+严重
Rituximab,Anion gap increased,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Red cell distribution width increased,2,45,10.753,10.753,12.17,1.000,0.000,0.500,10.233,χ²=12.2 (统计显著); 罕见+严重
Rituximab,Blood bicarbonate increased,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Ophthalmic herpes simplex,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Coronary artery bypass,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Hepatocellular carcinoma,2,45,13.441,13.441,14.79,1.000,1.000,0.500,10.233,χ²=14.8 (统计显著); 罕见+严重
Rituximab,Portal vein occlusion,1,45,0.000,0.000,25.89,1.000,1.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Intestinal haemorrhage,2,45,53.768,53.768,33.25,1.000,0.500,0.000,10.233,χ²=33.3 (统计显著); 罕见+严重
Rituximab,Enterococcal infection,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Haemangioma of skin,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Pseudomonal bacteraemia,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Parkinson^s disease,2,45,26.884,26.884,24.00,1.000,0.500,0.500,10.233,χ²=24.0 (统计显著); 罕见+严重
Rituximab,Muscle injury,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Muscle enzyme increased,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Bronchiolitis,2,45,53.768,53.768,33.25,1.000,0.000,0.500,10.233,χ²=33.3 (统计显著); 罕见+严重
Rituximab,Eastern Cooperative Oncology Group performance status,1,45,26.871,26.871,12.00,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Mantle cell lymphoma,2,45,13.441,13.441,14.79,1.000,0.500,0.000,10.233,χ²=14.8 (统计显著); 罕见+严重
Rituximab,Ligament rupture,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Bladder prolapse,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Depression suicidal,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Arthritis bacterial,2,45,53.768,53.768,33.25,1.000,0.000,1.000,10.233,χ²=33.3 (统计显著); 罕见+严重
Rituximab,Septic arthritis staphylococcal,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Monocytosis,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Pleuropericarditis,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Lupus nephritis,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Pneumonectomy,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Salivary gland enlargement,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Central venous catheterisation,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Diabetic retinopathy,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,End stage renal disease,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Genitourinary tract infection,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Portal hypertensive gastropathy,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Wound necrosis,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Basedow^s disease,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,C-reactive protein abnormal,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Meningitis bacterial,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Joint dislocation,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Open angle glaucoma,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Atrophy,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Basophil count decreased,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Vasodilatation,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Neuromyelitis optica,2,45,0.000,0.000,51.79,1.000,0.000,0.000,10.233,χ²=51.8 (统计显著); 罕见+严重
Rituximab,"Follicle centre lymphoma, follicular grade I, II, III refractory",1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Nephrogenic systemic fibrosis,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Kidney transplant rejection,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Adenoiditis,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Pyoderma streptococcal,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Polyomavirus-associated nephropathy,2,45,0.000,0.000,51.79,1.000,0.000,0.000,10.233,χ²=51.8 (统计显著); 罕见+严重
Rituximab,Transplant failure,2,45,0.000,0.000,51.79,1.000,0.500,0.000,10.233,χ²=51.8 (统计显著); 罕见+严重
Rituximab,Blood fibrinogen increased,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Procalcitonin increased,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Haptoglobin increased,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Brain natriuretic peptide increased,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Allergic granulomatous angiitis,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Lung abscess,2,45,0.000,0.000,51.79,1.000,1.000,1.000,10.233,χ²=51.8 (统计显著); 罕见+严重
Rituximab,Arterial thrombosis,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Posture abnormal,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Polyarthritis,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Aplasia pure red cell,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Emphysema,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,ADAMTS13 activity decreased,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Bone marrow failure,5,45,1.305,1.305,0.33,1.000,0.000,0.000,9.317,严重事件率=100.0%; 罕见+严重
Rituximab,Infection in an immunocompromised host,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Granulomatosis with polyangiitis,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Ankle arthroplasty,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Melanoderma,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Suicide attempt,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Blood pressure systolic abnormal,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Device dislocation,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Cholecystectomy,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Drug level above therapeutic,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Brain stem syndrome,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Immunoglobulins abnormal,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Malignant neoplasm of ampulla of Vater,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Rales,2,45,13.441,13.441,14.79,1.000,0.000,1.000,10.233,χ²=14.8 (统计显著); 罕见+严重
Rituximab,Balanoposthitis,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Gastric dilatation,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Temporal arteritis,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Negative thoughts,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Transaminases abnormal,1,45,0.000,0.000,25.89,1.000,1.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Multiple sclerosis,2,45,13.441,13.441,14.79,0.500,0.000,0.000,10.233,χ²=14.8 (统计显著); 罕见+严重
Rituximab,Labyrinthitis,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Bone fissure,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Dysglobulinaemia,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Connective tissue disorder,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Autoimmune neutropenia,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Focal segmental glomerulosclerosis,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Blood pressure diastolic abnormal,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Pelvic fracture,2,45,10.753,10.753,12.17,1.000,1.000,1.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Rituximab,Vitreous degeneration,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Optic nerve injury,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Refraction disorder,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Uterine leiomyoma,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Chorioretinitis,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Septic embolus,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Haptoglobin decreased,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Blood beta-D-glucan increased,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Hypertensive encephalopathy,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Lymphocyte count abnormal,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Chronic hepatitis C,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Lymphocytic infiltration,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Lower respiratory tract infection bacterial,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Chronic hepatitis B,1,45,0.000,0.000,25.89,1.000,0.000,0.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Burkitt^s leukaemia,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Lupus-like syndrome,2,45,26.884,26.884,24.00,1.000,0.000,0.000,10.233,χ²=24.0 (统计显著); 罕见+严重
Rituximab,Hepatosplenic candidiasis,2,45,13.441,13.441,14.79,1.000,0.000,1.000,10.233,χ²=14.8 (统计显著); 罕见+严重
Rituximab,Shift to the left,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Staphylococcal osteomyelitis,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Pupillary reflex impaired,1,45,0.000,0.000,25.89,1.000,1.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Hepatic cancer recurrent,1,45,0.000,0.000,25.89,1.000,1.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Conjunctivitis bacterial,1,45,26.871,26.871,12.00,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Lymphoproliferative disorder,1,45,26.871,26.871,12.00,1.000,1.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Multiple sclerosis relapse,2,45,26.884,26.884,24.00,0.500,0.000,0.500,10.233,χ²=24.0 (统计显著); 罕见+严重
Rituximab,Epstein-Barr virus associated lymphoma,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Pneumonia cryptococcal,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Zygomycosis,1,45,26.871,26.871,12.00,1.000,1.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Injection site discomfort,1,45,0.000,0.000,25.89,1.000,0.000,1.000,10.926,χ²=25.9 (统计显著); 罕见+严重
Rituximab,Abortion spontaneous,1,45,26.871,26.871,12.00,1.000,0.000,0.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Herpes ophthalmic,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Glossopharyngeal nerve paralysis,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Vagus nerve paralysis,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Rituximab,Otitis media acute,1,45,26.871,26.871,12.00,1.000,0.000,1.000,10.926,χ²=12.0 (统计显著); 罕见+严重
Epcoritamab,Glucose-6-phosphate dehydrogenase deficiency,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Diarrhoea,1,45,0.026,0.026,34.43,1.000,0.000,1.000,10.926,χ²=34.4 (统计显著); 罕见+严重
Epcoritamab,Adverse reaction,1,45,17.984,17.984,10.40,1.000,0.000,1.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Product dose omission in error,2,45,71.987,71.987,45.34,0.500,0.500,0.500,10.233,χ²=45.3 (统计显著); 罕见+严重
Epcoritamab,Treatment delayed,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Oral infection,1,45,17.984,17.984,10.40,1.000,1.000,1.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Neurological symptom,2,45,8.997,8.997,11.05,0.500,0.500,0.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Epcoritamab,Myopathy,2,45,11.997,11.997,14.69,1.000,0.000,0.000,10.233,χ²=14.7 (统计显著); 罕见+严重
Epcoritamab,Tumour flare,2,45,17.996,17.996,20.79,1.000,0.000,0.500,10.233,χ²=20.8 (统计显著); 罕见+严重
Epcoritamab,Injection site rash,3,45,0.000,0.000,104.92,0.667,0.000,0.333,9.827,χ²=104.9 (统计显著); 罕见+严重
Epcoritamab,Rash,9,45,0.468,0.468,5.12,0.556,0.111,0.111,8.729,严重事件率=55.6%; 罕见+严重
Epcoritamab,Hyperferritinaemia,1,45,0.000,0.000,34.97,1.000,1.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Hypertransaminasaemia,2,45,35.993,35.993,33.05,0.500,0.500,0.500,10.233,χ²=33.1 (统计显著); 罕见+严重
Epcoritamab,Lactic acidosis,2,45,11.997,11.997,14.69,1.000,1.000,0.500,10.233,χ²=14.7 (统计显著); 罕见+严重
Epcoritamab,Fungal myositis,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Injection site pruritus,1,45,17.984,17.984,10.40,1.000,1.000,0.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Headache,5,45,0.521,0.521,2.09,0.800,0.200,0.200,9.317,严重事件率=80.0%; 罕见+严重
Epcoritamab,Positron emission tomogram abnormal,1,45,17.984,17.984,10.40,1.000,0.000,0.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Follicular lymphoma stage III,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Blood immunoglobulin G decreased,3,45,0.000,0.000,104.92,1.000,0.000,0.333,9.827,χ²=104.9 (统计显著); 罕见+严重
Epcoritamab,Rhinovirus infection,2,45,17.996,17.996,20.79,1.000,0.500,1.000,10.233,χ²=20.8 (统计显著); 罕见+严重
Epcoritamab,Enterovirus infection,1,45,35.969,35.969,16.53,1.000,1.000,1.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Defaecation urgency,1,45,35.969,35.969,16.53,1.000,1.000,1.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Vein rupture,1,45,0.000,0.000,34.97,1.000,1.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Metastases to bone marrow,1,45,0.000,0.000,34.97,1.000,1.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Small intestinal perforation,2,45,14.396,14.396,17.30,1.000,0.000,0.500,10.233,χ²=17.3 (统计显著); 罕见+严重
Epcoritamab,Interleukin level increased,1,45,35.969,35.969,16.53,1.000,0.000,1.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Abdominal wall haematoma,1,45,0.000,0.000,34.97,1.000,1.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Peritoneal haematoma,1,45,0.000,0.000,34.97,1.000,1.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Peripheral venous disease,1,45,35.969,35.969,16.53,1.000,1.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Inflammatory marker increased,1,45,35.969,35.969,16.53,1.000,0.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Bone marrow necrosis,1,45,35.969,35.969,16.53,1.000,1.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Respiratory rate decreased,1,45,35.969,35.969,16.53,1.000,1.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Opportunistic infection,1,45,35.969,35.969,16.53,1.000,0.000,1.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Laryngeal oedema,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Follicular lymphoma refractory,1,45,0.000,0.000,34.97,1.000,1.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Gastric ulcer haemorrhage,1,45,17.984,17.984,10.40,1.000,1.000,1.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Diffuse large B-cell lymphoma recurrent,2,45,0.000,0.000,69.95,1.000,0.000,0.000,10.233,χ²=69.9 (统计显著); 罕见+严重
Epcoritamab,Decreased immune responsiveness,2,45,14.396,14.396,17.30,1.000,0.000,0.000,10.233,χ²=17.3 (统计显著); 罕见+严重
Epcoritamab,Citrobacter sepsis,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,High grade B-cell lymphoma refractory,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Enteritis infectious,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Fungal test positive,1,45,35.969,35.969,16.53,1.000,1.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Type I hypersensitivity,1,45,17.984,17.984,10.40,1.000,0.000,0.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Cholangitis acute,1,45,35.969,35.969,16.53,1.000,0.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Computerised tomogram head abnormal,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Hypercapnia,2,45,35.993,35.993,33.05,1.000,1.000,0.500,10.233,χ²=33.1 (统计显著); 罕见+严重
Epcoritamab,Eastern Cooperative Oncology Group performance status worsened,2,45,17.996,17.996,20.79,1.000,0.500,0.500,10.233,χ²=20.8 (统计显著); 罕见+严重
Epcoritamab,Enterobacter bacteraemia,1,45,0.000,0.000,34.97,1.000,1.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Adrenomegaly,1,45,0.000,0.000,34.97,1.000,1.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Cytomegalovirus chorioretinitis,1,45,17.984,17.984,10.40,1.000,0.000,0.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Stenotrophomonas bacteraemia,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Tonsillar neoplasm,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Aortic aneurysm rupture,1,45,0.000,0.000,34.97,1.000,1.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Epstein-Barr virus infection,1,45,35.969,35.969,16.53,1.000,1.000,1.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Lung opacity,1,45,35.969,35.969,16.53,1.000,1.000,1.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Psychotic disorder,1,45,17.984,17.984,10.40,1.000,0.000,1.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Pulmonary infarction,1,45,0.000,0.000,34.97,1.000,1.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Orbital swelling,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Erythema of eyelid,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Catheter site thrombosis,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Follicular lymphoma,2,45,0.000,0.000,69.95,1.000,0.500,0.500,10.233,χ²=69.9 (统计显著); 罕见+严重
Epcoritamab,Adrenal haemorrhage,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Enterocolitis viral,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Fungating wound,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Enterocolitis bacterial,1,45,17.984,17.984,10.40,1.000,0.000,1.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Sudden hearing loss,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,T-cell lymphoma,2,45,35.993,35.993,33.05,1.000,1.000,0.500,10.233,χ²=33.1 (统计显著); 罕见+严重
Epcoritamab,Laziness,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Gaze palsy,1,45,35.969,35.969,16.53,1.000,0.000,1.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Conjunctival disorder,1,45,17.984,17.984,10.40,1.000,0.000,1.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Bronchostenosis,1,45,0.000,0.000,34.97,1.000,1.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Viral pharyngitis,1,45,35.969,35.969,16.53,1.000,0.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Metapneumovirus infection,1,45,17.984,17.984,10.40,1.000,0.000,0.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Coronavirus infection,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Secondary immunodeficiency,2,45,35.993,35.993,33.05,1.000,0.500,0.500,10.233,χ²=33.1 (统计显著); 罕见+严重
Epcoritamab,Pulmonary artery stenosis,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Blood fibrinogen decreased,1,45,35.969,35.969,16.53,1.000,1.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Cytomegalovirus enterocolitis,2,45,71.987,71.987,45.34,1.000,1.000,1.000,10.233,χ²=45.3 (统计显著); 罕见+严重
Epcoritamab,Palliative care,2,45,35.993,35.993,33.05,1.000,0.000,0.000,10.233,χ²=33.1 (统计显著); 罕见+严重
Epcoritamab,Dementia Alzheimer^s type,1,45,17.984,17.984,10.40,1.000,0.000,0.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Steroid diabetes,1,45,35.969,35.969,16.53,1.000,0.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Serum ferritin decreased,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Haemorrhagic gastroenteritis,1,45,0.000,0.000,34.97,1.000,1.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Psoas abscess,1,45,0.000,0.000,34.97,1.000,1.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Systemic candida,1,45,17.984,17.984,10.40,1.000,1.000,1.000,10.926,χ²=10.4 (统计显著); 罕见+严重
Epcoritamab,Spondylitis,1,45,0.000,0.000,34.97,1.000,0.000,1.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Vessel puncture site erythema,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Sarcoma,1,45,35.969,35.969,16.53,1.000,0.000,0.000,10.926,χ²=16.5 (统计显著); 罕见+严重
Epcoritamab,Adenoviral haemorrhagic cystitis,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Epcoritamab,Cytomegalovirus enteritis,1,45,0.000,0.000,34.97,1.000,0.000,0.000,10.926,χ²=35.0 (统计显著); 罕见+严重
Imatinib,Constipation,2,45,0.123,0.123,11.92,1.000,0.500,0.000,10.233,χ²=11.9 (统计显著); 罕见+严重
Imatinib,Fear of death,2,45,26.162,26.162,23.28,1.000,0.000,0.000,10.233,χ²=23.3 (统计显著); 罕见+严重
Imatinib,Disease progression,2,45,0.061,0.061,27.38,1.000,0.000,0.500,10.233,χ²=27.4 (统计显著); 罕见+严重
Imatinib,Ocular icterus,2,45,17.441,17.441,17.89,0.500,0.000,0.000,10.233,χ²=17.9 (统计显著); 罕见+严重
Imatinib,Periorbital contusion,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,CSF test abnormal,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Bone pain,6,45,1.963,1.963,2.53,1.000,0.000,0.167,9.134,严重事件率=100.0%; 罕见+严重
Imatinib,Bladder neoplasm,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Cough,7,45,0.762,0.762,0.49,0.857,0.000,0.143,8.980,严重事件率=85.7%; 罕见+严重
Imatinib,Concomitant disease progression,2,45,52.324,52.324,32.29,1.000,0.000,0.500,10.233,χ²=32.3 (统计显著); 罕见+严重
Imatinib,Scleroderma,2,45,10.464,10.464,11.76,1.000,0.000,0.000,10.233,χ²=11.8 (统计显著); 罕见+严重
Imatinib,Restrictive pulmonary disease,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Dyspnoea,18,45,0.753,0.753,1.34,0.944,0.167,0.333,8.036,严重事件率=94.4%; 罕见+严重
Imatinib,Spinal column stenosis,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Abdominal discomfort,8,45,1.598,1.598,1.62,0.875,0.000,0.125,8.847,严重事件率=87.5%; 罕见+严重
Imatinib,Polyp,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Headache,18,45,1.425,1.425,2.05,0.944,0.056,0.389,8.036,严重事件率=94.4%; 罕见+严重
Imatinib,Food allergy,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Dysgeusia,8,45,1.182,1.182,0.21,1.000,0.000,0.125,8.847,严重事件率=100.0%; 罕见+严重
Imatinib,Right ventricular failure,1,45,0.000,0.000,25.17,1.000,1.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Brain natriuretic peptide increased,1,45,26.149,26.149,11.64,1.000,1.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Alopecia,6,45,0.912,0.912,0.05,0.833,0.000,0.000,9.134,严重事件率=83.3%; 罕见+严重
Imatinib,Arthralgia,14,45,1.485,1.485,2.00,0.929,0.000,0.214,8.287,严重事件率=92.9%; 罕见+严重
Imatinib,Internal haemorrhage,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Gait disturbance,6,45,1.539,1.539,1.03,1.000,0.167,0.167,9.134,严重事件率=100.0%; 罕见+严重
Imatinib,Pain in extremity,8,45,1.035,1.035,0.01,1.000,0.000,0.375,8.847,严重事件率=100.0%; 罕见+严重
Imatinib,Gastric antral vascular ectasia,2,45,52.324,52.324,32.29,1.000,0.000,0.500,10.233,χ²=32.3 (统计显著); 罕见+严重
Imatinib,Paralysis,2,45,17.441,17.441,17.89,1.000,0.000,0.500,10.233,χ²=17.9 (统计显著); 罕见+严重
Imatinib,Hypereosinophilic syndrome,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Vitamin K deficiency,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Exercise tolerance decreased,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Eosinophilic myocarditis,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Neuropathy peripheral,5,45,0.585,0.585,1.38,1.000,0.200,0.200,9.317,严重事件率=100.0%; 罕见+严重
Imatinib,Red blood cell count decreased,5,45,1.037,1.037,0.01,0.800,0.000,0.400,9.317,严重事件率=80.0%; 罕见+严重
Imatinib,Abdominal pain upper,10,45,1.540,1.540,1.71,0.800,0.000,0.300,8.623,严重事件率=80.0%; 罕见+严重
Imatinib,Skin tightness,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Intra-abdominal pressure increased,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Insomnia,8,45,1.300,1.300,0.50,1.000,0.000,0.250,8.847,严重事件率=100.0%; 罕见+严重
Imatinib,Central nervous system leukaemia,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Lung neoplasm malignant,5,45,1.557,1.557,0.90,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Imatinib,Crohn^s disease,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Vision blurred,6,45,1.635,1.635,1.34,1.000,0.000,0.000,9.134,严重事件率=100.0%; 罕见+严重
Imatinib,Tuberculosis,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Brain injury,1,45,26.149,26.149,11.64,1.000,1.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Decreased immune responsiveness,2,45,10.464,10.464,11.76,1.000,0.500,1.000,10.233,χ²=11.8 (统计显著); 罕见+严重
Imatinib,White blood cell count decreased,11,45,0.857,0.857,0.24,0.909,0.182,0.364,8.528,严重事件率=90.9%; 罕见+严重
Imatinib,Intussusception,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Pterygium,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Hypertension,9,45,1.369,1.369,0.81,0.889,0.000,0.222,8.729,严重事件率=88.9%; 罕见+严重
Imatinib,Oedema peripheral,8,45,1.464,1.464,1.07,1.000,0.125,0.250,8.847,严重事件率=100.0%; 罕见+严重
Imatinib,Platelet count decreased,7,45,0.433,0.433,4.88,1.000,0.143,0.000,8.980,严重事件率=100.0%; 罕见+严重
Imatinib,Inguinal hernia,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Non-alcoholic steatohepatitis,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Portal hypertensive gastropathy,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Testicular hypertrophy,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Bronchitis chronic,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,H1N1 influenza,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Spinal cord haemorrhage,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Arteriospasm coronary,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Tunnel vision,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Low birth weight baby,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Drug level increased,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Post procedural complication,2,45,52.324,52.324,32.29,1.000,1.000,0.000,10.233,χ²=32.3 (统计显著); 罕见+严重
Imatinib,Nasal obstruction,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Small cell lung cancer recurrent,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Dehydration,5,45,0.317,0.317,6.93,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Imatinib,Recurrent cancer,2,45,10.464,10.464,11.76,1.000,0.000,0.000,10.233,χ²=11.8 (统计显著); 罕见+严重
Imatinib,Gastric fistula,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Diabetic gangrene,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Oesophageal neoplasm,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Dystrophic calcification,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Hyperlipidaemia,2,45,10.464,10.464,11.76,0.500,0.000,0.500,10.233,χ²=11.8 (统计显著); 罕见+严重
Imatinib,Blood glucose abnormal,2,45,52.324,52.324,32.29,0.500,0.000,0.500,10.233,χ²=32.3 (统计显著); 罕见+严重
Imatinib,Hepatic cancer metastatic,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Bronchial carcinoma,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Pulse pressure decreased,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Pulmonary hypertensive crisis,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Bipolar disorder,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Painful defaecation,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Paranasal sinus hypersecretion,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Injection site haematoma,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Foreign body in eye,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Dizziness,10,45,0.759,0.759,0.71,1.000,0.000,0.200,8.623,严重事件率=100.0%; 罕见+严重
Imatinib,Abdominal mass,2,45,13.080,13.080,14.31,1.000,1.000,0.500,10.233,χ²=14.3 (统计显著); 罕见+严重
Imatinib,Pseudoporphyria,2,45,0.000,0.000,50.35,1.000,0.000,0.000,10.233,χ²=50.3 (统计显著); 罕见+严重
Imatinib,Skin erosion,2,45,52.324,52.324,32.29,1.000,0.000,0.000,10.233,χ²=32.3 (统计显著); 罕见+严重
Imatinib,Skin fragility,2,45,52.324,52.324,32.29,1.000,0.000,0.000,10.233,χ²=32.3 (统计显著); 罕见+严重
Imatinib,Tumour rupture,2,45,52.324,52.324,32.29,1.000,0.000,0.500,10.233,χ²=32.3 (统计显著); 罕见+严重
Imatinib,Myeloid leukaemia,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Meralgia paraesthetica,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Metastases to spleen,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Cardiac discomfort,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Venous occlusion,2,45,17.441,17.441,17.89,1.000,0.000,1.000,10.233,χ²=17.9 (统计显著); 罕见+严重
Imatinib,Product physical issue,2,45,17.441,17.441,17.89,1.000,0.000,0.500,10.233,χ²=17.9 (统计显著); 罕见+严重
Imatinib,Bone formation increased,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Basedow^s disease,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Anal fissure,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Myeloblast count increased,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Right atrial dilatation,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Chronic myeloid leukaemia recurrent,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Hand fracture,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Chromosome analysis abnormal,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Gene mutation identification test positive,2,45,26.162,26.162,23.28,1.000,0.000,0.000,10.233,χ²=23.3 (统计显著); 罕见+严重
Imatinib,Catheter site infection,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Gangrene,2,45,52.324,52.324,32.29,1.000,0.500,1.000,10.233,χ²=32.3 (统计显著); 罕见+严重
Imatinib,Peripheral arterial occlusive disease,2,45,13.080,13.080,14.31,1.000,0.500,0.500,10.233,χ²=14.3 (统计显著); 罕见+严重
Imatinib,Cystitis radiation,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Abortion spontaneous,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Tooth erosion,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Urticaria,5,45,1.869,1.869,1.81,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Imatinib,Ewing^s sarcoma,1,45,0.000,0.000,25.17,1.000,1.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Drug dependence,1,45,26.149,26.149,11.64,1.000,1.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Colon neoplasm,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Metastases to muscle,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Arthropod infestation,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Adenoid cystic carcinoma,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Hepatic mass,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Stress fracture,2,45,0.000,0.000,50.35,1.000,0.000,0.000,10.233,χ²=50.3 (统计显著); 罕见+严重
Imatinib,Back injury,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Malabsorption,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Appendix cancer,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Oncologic complication,2,45,26.162,26.162,23.28,1.000,1.000,0.500,10.233,χ²=23.3 (统计显著); 罕见+严重
Imatinib,Pulmonary vein stenosis,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Pulmonary function test decreased,1,45,26.149,26.149,11.64,1.000,1.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Venous stenosis,1,45,0.000,0.000,25.17,1.000,1.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Ventricular septal defect,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Chloroma,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Megakaryocytes abnormal,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Red blood cell abnormality,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Lymph gland infection,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Cytogenetic analysis abnormal,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Congenital diaphragmatic hernia,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Engraft failure,1,45,0.000,0.000,25.17,1.000,1.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Nasal inflammation,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,VIth nerve paralysis,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Red blood cell sedimentation rate increased,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Cushingoid,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Parophthalmia,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Ocular surface disease,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Vulvovaginal pain,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Graft versus host disease in skin,2,45,10.464,10.464,11.76,1.000,0.000,0.000,10.233,χ²=11.8 (统计显著); 罕见+严重
Imatinib,Impaired driving ability,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Bleeding time prolonged,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Ear swelling,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Exposure via father,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Bone neoplasm,1,45,26.149,26.149,11.64,1.000,1.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Intentional overdose,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Bone marrow myelogram abnormal,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Frustration,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Normal newborn,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Gestational diabetes,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Umbilical hernia,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Febrile convulsion,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Breast cancer stage I,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Uterine neoplasm,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Sarcoma,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Iodine allergy,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Skin sensitisation,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Lichen planus,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Infarction,1,45,0.000,0.000,25.17,1.000,1.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Expired product administered,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Gastric dilatation,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Hypotonia,1,45,26.149,26.149,11.64,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Oxygen saturation increased,1,45,0.000,0.000,25.17,1.000,1.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Accident,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Breast disorder,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Volvulus,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Haemoglobin increased,1,45,26.149,26.149,11.64,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Tongue haemorrhage,1,45,0.000,0.000,25.17,1.000,0.000,1.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Brain compression,1,45,26.149,26.149,11.64,1.000,1.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Imatinib,Metastases to eye,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Imatinib,Bone density decreased,1,45,0.000,0.000,25.17,1.000,0.000,0.000,10.926,χ²=25.2 (统计显著); 罕见+严重
Erlotinib,Abdominal symptom,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Computerised tomogram abnormal,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Abdominal discomfort,5,45,1.255,1.255,0.24,0.800,0.000,0.400,9.317,严重事件率=80.0%; 罕见+严重
Erlotinib,Weight fluctuation,2,45,9.611,9.611,11.64,1.000,0.000,0.000,10.233,χ²=11.6 (统计显著); 罕见+严重
Erlotinib,Surgical failure,2,45,22.427,22.427,23.83,1.000,0.000,0.000,10.233,χ²=23.8 (统计显著); 罕见+严重
Erlotinib,Schizophrenia,1,45,33.621,33.621,15.36,1.000,1.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Folliculitis,2,45,22.427,22.427,23.83,1.000,0.000,0.500,10.233,χ²=23.8 (统计显著); 罕见+严重
Erlotinib,Alopecia,9,45,1.794,1.794,2.89,1.000,0.111,0.222,8.729,严重事件率=100.0%; 罕见+严重
Erlotinib,Tongue eruption,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Taeniasis,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Dyspepsia,5,45,1.617,1.617,1.09,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Erlotinib,Neutrophilia,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Forearm fracture,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Angle closure glaucoma,2,45,0.000,0.000,65.26,1.000,0.000,0.500,10.233,χ²=65.3 (统计显著); 罕见+严重
Erlotinib,Ocular hypertension,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Keratitis,2,45,11.213,11.213,13.53,1.000,0.000,1.000,10.233,χ²=13.5 (统计显著); 罕见+严重
Erlotinib,Pancreatic enzymes increased,2,45,11.213,11.213,13.53,1.000,1.000,1.000,10.233,χ²=13.5 (统计显著); 罕见+严重
Erlotinib,Muscle spasms,5,45,1.218,1.218,0.18,0.800,0.000,0.400,9.317,严重事件率=80.0%; 罕见+严重
Erlotinib,Mechanical ileus,1,45,0.000,0.000,32.63,1.000,1.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Colonic fistula,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Pneumatosis,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Ulcer,2,45,13.456,13.456,15.97,1.000,0.000,0.500,10.233,χ²=16.0 (统计显著); 罕见+严重
Erlotinib,Thyroid mass,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Scab,2,45,16.820,16.820,19.24,1.000,0.000,0.500,10.233,χ²=19.2 (统计显著); 罕见+严重
Erlotinib,Lung operation,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Neuroendocrine tumour,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Hernial eventration,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Incision site haematoma,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Drug ineffective,5,45,0.633,0.633,1.01,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Erlotinib,Onychomycosis,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Catheter placement,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Amylase increased,2,45,9.611,9.611,11.64,1.000,0.000,0.500,10.233,χ²=11.6 (统计显著); 罕见+严重
Erlotinib,Prostate cancer stage I,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Neutropenia,8,45,0.452,0.452,5.01,1.000,0.125,0.000,8.847,严重事件率=100.0%; 罕见+严重
Erlotinib,Corneal thinning,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Corneal disorder,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Corneal irritation,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Hemianopia homonymous,2,45,0.000,0.000,65.26,1.000,0.500,0.500,10.233,χ²=65.3 (统计显著); 罕见+严重
Erlotinib,Neuropsychiatric syndrome,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Hyperaesthesia,2,45,16.820,16.820,19.24,1.000,0.000,0.500,10.233,χ²=19.2 (统计显著); 罕见+严重
Erlotinib,Micturition disorder,1,45,33.621,33.621,15.36,1.000,1.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Conjunctival ulcer,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Tonsil cancer,2,45,0.000,0.000,65.26,1.000,0.000,0.000,10.233,χ²=65.3 (统计显著); 罕见+严重
Erlotinib,Nail bed bleeding,2,45,0.000,0.000,65.26,1.000,0.000,0.500,10.233,χ²=65.3 (统计显著); 罕见+严重
Erlotinib,Acetabulum fracture,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Cholangitis acute,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Swelling of eyelid,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Brain mass,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Nasal mucosal disorder,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Onychomadesis,2,45,16.820,16.820,19.24,1.000,0.000,0.500,10.233,χ²=19.2 (统计显著); 罕见+严重
Erlotinib,Investigation abnormal,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Eyelids pruritus,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Nail ridging,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Accidental overdose,2,45,8.410,8.410,10.13,1.000,0.000,0.000,10.233,χ²=10.1 (统计显著); 罕见+严重
Erlotinib,Keratorhexis,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Corneal operation,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Arterial thrombosis,1,45,33.621,33.621,15.36,1.000,1.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Hip surgery,1,45,0.000,0.000,32.63,1.000,1.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Sputum discoloured,1,45,33.621,33.621,15.36,1.000,1.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Aorto-oesophageal fistula,1,45,0.000,0.000,32.63,1.000,1.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Chronic hepatitis,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Respiration abnormal,1,45,33.621,33.621,15.36,1.000,0.000,1.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Cardiac fibrillation,2,45,33.642,33.642,30.72,1.000,0.000,0.000,10.233,χ²=30.7 (统计显著); 罕见+严重
Erlotinib,Paresis,1,45,0.000,0.000,32.63,1.000,1.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Anaemia macrocytic,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Hyperchromic anaemia,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Hepatobiliary disease,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Concussion,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Reading disorder,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Bone development abnormal,1,45,33.621,33.621,15.36,1.000,0.000,0.000,10.926,χ²=15.4 (统计显著); 罕见+严重
Erlotinib,Aptyalism,1,45,0.000,0.000,32.63,1.000,0.000,1.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Brain stem infarction,1,45,0.000,0.000,32.63,1.000,1.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Central nervous system necrosis,1,45,0.000,0.000,32.63,1.000,1.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Cerebellar infarction,1,45,0.000,0.000,32.63,1.000,1.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Erlotinib,Eyelid irritation,1,45,0.000,0.000,32.63,1.000,0.000,0.000,10.926,χ²=32.6 (统计显著); 罕见+严重
Gefitinib,Blood creatinine increased,8,45,1.558,1.558,1.47,1.000,0.125,0.125,8.847,严重事件率=100.0%; 罕见+严重
Gefitinib,Neuropsychiatric syndrome,1,45,34.619,34.619,15.86,1.000,0.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Abnormal behaviour,2,45,9.897,9.897,12.07,1.000,0.000,0.500,10.233,χ²=12.1 (统计显著); 罕见+严重
Gefitinib,Skin hypertrophy,2,45,23.094,23.094,24.62,1.000,0.000,0.000,10.233,χ²=24.6 (统计显著); 罕见+严重
Gefitinib,Cerebellar ataxia,2,45,0.000,0.000,67.25,1.000,0.000,1.000,10.233,χ²=67.3 (统计显著); 罕见+严重
Gefitinib,Blood pressure,1,45,0.000,0.000,33.63,1.000,1.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Vascular insufficiency,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Spinal cord compression,2,45,23.094,23.094,24.62,1.000,0.500,1.000,10.233,χ²=24.6 (统计显著); 罕见+严重
Gefitinib,Chest pain,10,45,1.995,1.995,4.52,1.000,0.100,0.200,8.623,严重事件率=100.0%; 罕见+严重
Gefitinib,Peripheral circulatory failure,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Acute prerenal failure,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Ileal ulcer,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Large intestinal ulcer,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Seborrhoeic dermatitis,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Gastrointestinal erosion,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Lung carcinoma cell type unspecified recurrent,1,45,0.000,0.000,33.63,1.000,1.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Growth of eyelashes,2,45,8.659,8.659,10.52,1.000,0.500,0.000,10.233,χ²=10.5 (统计显著); 罕见+严重
Gefitinib,Nodule,2,45,8.659,8.659,10.52,1.000,0.500,0.000,10.233,χ²=10.5 (统计显著); 罕见+严重
Gefitinib,Metastases to the mediastinum,2,45,34.641,34.641,31.71,1.000,0.500,0.000,10.233,χ²=31.7 (统计显著); 罕见+严重
Gefitinib,Thrombocytopenia,8,45,0.600,0.600,2.01,1.000,0.125,0.000,8.847,严重事件率=100.0%; 罕见+严重
Gefitinib,Neutropenia,5,45,0.289,0.289,8.31,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Gefitinib,Pneumococcal infection,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Tenosynovitis,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Diabetic metabolic decompensation,1,45,34.619,34.619,15.86,1.000,1.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Genital pain,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Ulcer,2,45,13.856,13.856,16.54,1.000,0.500,0.500,10.233,χ²=16.5 (统计显著); 罕见+严重
Gefitinib,Apathy,1,45,34.619,34.619,15.86,1.000,0.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Chronic gastritis,2,45,0.000,0.000,67.25,1.000,0.500,1.000,10.233,χ²=67.3 (统计显著); 罕见+严重
Gefitinib,Iron deficiency anaemia,2,45,13.856,13.856,16.54,1.000,1.000,1.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Gefitinib,Thyroid disorder,2,45,8.659,8.659,10.52,1.000,0.000,1.000,10.233,χ²=10.5 (统计显著); 罕见+严重
Gefitinib,Cholecystitis infective,2,45,34.641,34.641,31.71,1.000,0.500,1.000,10.233,χ²=31.7 (统计显著); 罕见+严重
Gefitinib,Pneumonitis,6,45,1.049,1.049,0.01,1.000,0.000,0.167,9.134,严重事件率=100.0%; 罕见+严重
Gefitinib,Pyogenic granuloma,2,45,69.283,69.283,43.55,1.000,0.000,0.500,10.233,χ²=43.5 (统计显著); 罕见+严重
Gefitinib,Alopecia,8,45,1.631,1.631,1.80,0.750,0.000,0.125,8.847,严重事件率=75.0%; 罕见+严重
Gefitinib,Corneal erosion,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Radiation interaction,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Anal erosion,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Neurogenic bladder,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Hilar lymphadenopathy,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Metastases to adrenals,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Atrial thrombosis,1,45,34.619,34.619,15.86,1.000,1.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Nasal ulcer,1,45,34.619,34.619,15.86,1.000,1.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Pneumatosis intestinalis,2,45,13.856,13.856,16.54,1.000,0.500,1.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Gefitinib,Forced vital capacity decreased,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Lung cyst,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Forced expiratory volume decreased,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Secondary hypothyroidism,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Hypothalamic pituitary adrenal axis suppression,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Cranial nerve disorder,1,45,34.619,34.619,15.86,1.000,0.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Staring,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Coagulation test abnormal,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Paraneoplastic pleural effusion,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Acute left ventricular failure,1,45,34.619,34.619,15.86,1.000,1.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,"Sleep disorder due to general medical condition, insomnia type",1,45,34.619,34.619,15.86,1.000,0.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Eyelid rash,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Pulmonary air leakage,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Vitamin K deficiency,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Paraneoplastic syndrome,2,45,34.641,34.641,31.71,1.000,0.500,0.500,10.233,χ²=31.7 (统计显著); 罕见+严重
Gefitinib,Hypoventilation,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Vena cava embolism,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Bicytopenia,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Cerebellar syndrome,1,45,34.619,34.619,15.86,1.000,0.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Polymyalgia rheumatica,1,45,34.619,34.619,15.86,1.000,0.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Pleural fistula,1,45,34.619,34.619,15.86,1.000,0.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Xeroderma,1,45,34.619,34.619,15.86,1.000,1.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Hyperammonaemia,1,45,34.619,34.619,15.86,1.000,0.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Mucinous breast carcinoma,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Hypertrichosis,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Pyoderma,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Vulvovaginal discomfort,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Electrocardiogram QT shortened,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Drug level decreased,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Subacute cutaneous lupus erythematosus,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Respiratory depression,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Rectal ulcer,1,45,34.619,34.619,15.86,1.000,1.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Pulmonary artery thrombosis,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Endometrial cancer,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Hydrometra,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Uterine inflammation,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Fibrin D dimer increased,2,45,34.641,34.641,31.71,1.000,0.500,1.000,10.233,χ²=31.7 (统计显著); 罕见+严重
Gefitinib,Cystitis pseudomonal,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Lung adenocarcinoma stage IV,1,45,34.619,34.619,15.86,1.000,0.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Acute haemorrhagic conjunctivitis,1,45,34.619,34.619,15.86,1.000,0.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Acute monocytic leukaemia,1,45,0.000,0.000,33.63,1.000,0.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Arteriosclerosis coronary artery,1,45,34.619,34.619,15.86,1.000,0.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Premature delivery,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Normal newborn,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Cerebral venous thrombosis,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Gastrointestinal ulcer,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Nosocomial infection,1,45,0.000,0.000,33.63,1.000,1.000,0.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Drug tolerance,1,45,34.619,34.619,15.86,1.000,0.000,0.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Laryngeal cancer,1,45,0.000,0.000,33.63,1.000,1.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Gefitinib,Device related thrombosis,1,45,34.619,34.619,15.86,1.000,1.000,1.000,10.926,χ²=15.9 (统计显著); 罕见+严重
Gefitinib,Abdominal neoplasm,1,45,0.000,0.000,33.63,1.000,0.000,1.000,10.926,χ²=33.6 (统计显著); 罕见+严重
Osimertinib,Nail discolouration,2,45,11.661,11.661,14.19,1.000,0.000,0.500,10.233,χ²=14.2 (统计显著); 罕见+严重
Osimertinib,Bowel movement irregularity,1,45,17.482,17.482,10.06,1.000,0.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Body height decreased,2,45,11.661,11.661,14.19,1.000,0.000,0.500,10.233,χ²=14.2 (统计显著); 罕见+严重
Osimertinib,Multiple fractures,1,45,17.482,17.482,10.06,1.000,0.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Tendonitis,2,45,23.324,23.324,24.89,0.500,0.000,0.000,10.233,χ²=24.9 (统计显著); 罕见+严重
Osimertinib,Road traffic accident,2,45,11.661,11.661,14.19,1.000,0.000,1.000,10.233,χ²=14.2 (统计显著); 罕见+严重
Osimertinib,Hydrothorax,1,45,17.482,17.482,10.06,1.000,1.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Diffuse alveolar damage,1,45,17.482,17.482,10.06,1.000,1.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Therapeutic response unexpected,2,45,11.661,11.661,14.19,0.500,0.000,0.500,10.233,χ²=14.2 (统计显著); 罕见+严重
Osimertinib,Anti-platelet antibody,1,45,0.000,0.000,33.97,1.000,1.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Pleural neoplasm,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Conjunctivitis bacterial,1,45,34.965,34.965,16.03,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Pain,6,45,0.705,0.705,0.70,0.833,0.000,0.000,9.134,严重事件率=83.3%; 罕见+严重
Osimertinib,Headache,5,45,0.506,0.506,2.28,0.800,0.200,0.400,9.317,严重事件率=80.0%; 罕见+严重
Osimertinib,Food aversion,1,45,17.482,17.482,10.06,1.000,0.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Radiation interaction,1,45,34.965,34.965,16.03,1.000,1.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Ligament sprain,1,45,17.482,17.482,10.06,1.000,1.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Hyporesponsive to stimuli,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Retinal vascular occlusion,1,45,0.000,0.000,33.97,1.000,0.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Renal impairment,5,45,1.548,1.548,0.90,0.800,0.200,0.400,9.317,严重事件率=80.0%; 罕见+严重
Osimertinib,Temperature difference of extremities,1,45,0.000,0.000,33.97,1.000,1.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Acute haemorrhagic conjunctivitis,1,45,34.965,34.965,16.03,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Acute interstitial pneumonitis,1,45,17.482,17.482,10.06,1.000,1.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Protein-losing gastroenteropathy,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Gastroduodenal ulcer,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Gastrointestinal oedema,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Dry throat,2,45,23.324,23.324,24.89,0.500,0.000,0.500,10.233,χ²=24.9 (统计显著); 罕见+严重
Osimertinib,Genital herpes,1,45,17.482,17.482,10.06,1.000,0.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Sneezing,2,45,11.661,11.661,14.19,1.000,0.000,0.500,10.233,χ²=14.2 (统计显著); 罕见+严重
Osimertinib,Craniocerebral injury,1,45,0.000,0.000,33.97,1.000,1.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Hyperplasia,2,45,9.995,9.995,12.23,0.500,0.000,0.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Osimertinib,Non-small cell lung cancer stage IV,1,45,0.000,0.000,33.97,1.000,1.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Respiratory acidosis,1,45,0.000,0.000,33.97,1.000,1.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Medical device site infection,1,45,0.000,0.000,33.97,1.000,1.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Hunger,1,45,17.482,17.482,10.06,1.000,0.000,0.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Abdominal pain upper,5,45,0.998,0.998,0.00,0.800,0.000,0.400,9.317,严重事件率=80.0%; 罕见+严重
Osimertinib,Bladder pain,1,45,17.482,17.482,10.06,1.000,0.000,0.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Nightmare,2,45,17.493,17.493,20.13,1.000,0.000,0.500,10.233,χ²=20.1 (统计显著); 罕见+严重
Osimertinib,Large intestinal haemorrhage,1,45,17.482,17.482,10.06,1.000,1.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Counterfeit drug administered,1,45,0.000,0.000,33.97,1.000,1.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Rubella,1,45,0.000,0.000,33.97,1.000,1.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Tracheobronchitis,1,45,34.965,34.965,16.03,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Xeroderma,1,45,34.965,34.965,16.03,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Extremity necrosis,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Ingrowing nail,1,45,17.482,17.482,10.06,1.000,0.000,0.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Klebsiella test positive,1,45,17.482,17.482,10.06,1.000,1.000,0.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Aspartate aminotransferase abnormal,1,45,34.965,34.965,16.03,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Mean cell haemoglobin concentration increased,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Thoracic cavity lavage,1,45,0.000,0.000,33.97,1.000,1.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Infectious pleural effusion,2,45,13.994,13.994,16.73,1.000,0.500,1.000,10.233,χ²=16.7 (统计显著); 罕见+严重
Osimertinib,Thoracic cavity drainage,1,45,0.000,0.000,33.97,1.000,1.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Periorbital cellulitis,1,45,34.965,34.965,16.03,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Hair disorder,2,45,34.987,34.987,32.05,0.500,0.000,0.000,10.233,χ²=32.1 (统计显著); 罕见+严重
Osimertinib,Autoimmune retinopathy,1,45,0.000,0.000,33.97,1.000,0.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Allergic eosinophilia,1,45,0.000,0.000,33.97,1.000,1.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Choking,1,45,17.482,17.482,10.06,1.000,0.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Eosinophilic pneumonia,1,45,34.965,34.965,16.03,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Nail infection,2,45,69.975,69.975,44.01,1.000,1.000,0.500,10.233,χ²=44.0 (统计显著); 罕见+严重
Osimertinib,Dacryostenosis acquired,1,45,0.000,0.000,33.97,1.000,1.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Skin atrophy,2,45,34.987,34.987,32.05,1.000,0.500,0.500,10.233,χ²=32.1 (统计显著); 罕见+严重
Osimertinib,Genital haemorrhage,1,45,0.000,0.000,33.97,1.000,0.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Dyspareunia,1,45,0.000,0.000,33.97,1.000,0.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Genital injury,1,45,0.000,0.000,33.97,1.000,0.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Sinus pain,1,45,34.965,34.965,16.03,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Cyst,1,45,34.965,34.965,16.03,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Depressive symptom,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Lip disorder,1,45,34.965,34.965,16.03,1.000,1.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Vocal cord paralysis,2,45,9.995,9.995,12.23,1.000,1.000,0.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Osimertinib,Tumour compression,1,45,17.482,17.482,10.06,1.000,1.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Positron emission tomogram abnormal,1,45,17.482,17.482,10.06,1.000,1.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Delusion,1,45,17.482,17.482,10.06,1.000,1.000,0.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Small cell lung cancer,2,45,11.661,11.661,14.19,1.000,1.000,0.000,10.233,χ²=14.2 (统计显著); 罕见+严重
Osimertinib,Cardiac valve disease,1,45,17.482,17.482,10.06,1.000,1.000,0.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Hepatitis cholestatic,1,45,17.482,17.482,10.06,1.000,0.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Tibia fracture,1,45,34.965,34.965,16.03,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Product blister packaging issue,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Poor quality drug administered,1,45,34.965,34.965,16.03,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Microangiopathic haemolytic anaemia,1,45,34.965,34.965,16.03,1.000,1.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Osimertinib,Fulminant type 1 diabetes mellitus,1,45,17.482,17.482,10.06,1.000,0.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Psychomotor retardation,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Thrombotic cerebral infarction,1,45,0.000,0.000,33.97,1.000,0.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Nasal discharge discolouration,1,45,0.000,0.000,33.97,1.000,0.000,0.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Ocular discomfort,1,45,17.482,17.482,10.06,1.000,1.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Pneumobilia,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Osimertinib,Hypertensive heart disease,1,45,17.482,17.482,10.06,1.000,0.000,1.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Osimertinib,Urinary tract inflammation,1,45,0.000,0.000,33.97,1.000,0.000,1.000,10.926,χ²=34.0 (统计显著); 罕见+严重
Crizotinib,Renal abscess,2,45,0.000,0.000,85.51,1.000,0.000,1.000,10.233,χ²=85.5 (统计显著); 罕见+严重
Crizotinib,Oesophageal ulcer,2,45,12.514,12.514,16.08,0.500,0.000,0.500,10.233,χ²=16.1 (统计显著); 罕见+严重
Crizotinib,Endotracheal intubation,1,45,43.768,43.768,20.41,1.000,1.000,1.000,10.926,χ²=20.4 (统计显著); 罕见+严重
Crizotinib,Optic neuropathy,2,45,87.607,87.607,55.71,1.000,0.000,0.000,10.233,χ²=55.7 (统计显著); 罕见+严重
Crizotinib,Pyopneumothorax,1,45,43.768,43.768,20.41,1.000,1.000,1.000,10.926,χ²=20.4 (统计显著); 罕见+严重
Crizotinib,Faeces pale,1,45,21.884,21.884,12.98,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Crizotinib,Prostatitis,1,45,43.768,43.768,20.41,1.000,0.000,0.000,10.926,χ²=20.4 (统计显著); 罕见+严重
Crizotinib,Chylothorax,1,45,0.000,0.000,42.76,1.000,0.000,1.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Neurosis,1,45,0.000,0.000,42.76,1.000,1.000,1.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Lung adenocarcinoma metastatic,2,45,43.803,43.803,40.82,1.000,1.000,0.000,10.233,χ²=40.8 (统计显著); 罕见+严重
Crizotinib,Neutropenia,5,45,0.366,0.366,5.26,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Crizotinib,Muscle abscess,1,45,0.000,0.000,42.76,1.000,0.000,1.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Oesophageal pain,2,45,43.803,43.803,40.82,0.500,0.000,0.000,10.233,χ²=40.8 (统计显著); 罕见+严重
Crizotinib,Renal impairment,5,45,1.939,1.939,2.12,0.800,0.000,0.400,9.317,严重事件率=80.0%; 罕见+严重
Crizotinib,Generalised tonic-clonic seizure,2,45,17.520,17.520,21.72,1.000,0.000,1.000,10.233,χ²=21.7 (统计显著); 罕见+严重
Crizotinib,Faecal incontinence,2,45,10.949,10.949,14.12,1.000,0.000,1.000,10.233,χ²=14.1 (统计显著); 罕见+严重
Crizotinib,Neuroblastoma,2,45,0.000,0.000,85.51,1.000,1.000,0.000,10.233,χ²=85.5 (统计显著); 罕见+严重
Crizotinib,Brain stem haemorrhage,1,45,0.000,0.000,42.76,1.000,0.000,1.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Subarachnoid haemorrhage,2,45,12.514,12.514,16.08,1.000,0.000,1.000,10.233,χ²=16.1 (统计显著); 罕见+严重
Crizotinib,Spleen disorder,1,45,21.884,21.884,12.98,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Crizotinib,Blindness transient,1,45,21.884,21.884,12.98,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Crizotinib,Ruptured cerebral aneurysm,1,45,43.768,43.768,20.41,1.000,0.000,1.000,10.926,χ²=20.4 (统计显著); 罕见+严重
Crizotinib,Barrett^s oesophagus,1,45,0.000,0.000,42.76,1.000,0.000,0.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Increased bronchial secretion,1,45,0.000,0.000,42.76,1.000,0.000,1.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Vasogenic cerebral oedema,1,45,21.884,21.884,12.98,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Crizotinib,Enuresis,1,45,43.768,43.768,20.41,1.000,0.000,1.000,10.926,χ²=20.4 (统计显著); 罕见+严重
Crizotinib,Eye movement disorder,2,45,43.803,43.803,40.82,0.500,0.000,0.500,10.233,χ²=40.8 (统计显著); 罕见+严重
Crizotinib,Oesophageal candidiasis,1,45,21.884,21.884,12.98,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Crizotinib,Renal haematoma,1,45,0.000,0.000,42.76,1.000,0.000,0.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Perinephritis,1,45,0.000,0.000,42.76,1.000,0.000,0.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Clear cell sarcoma of soft tissue,1,45,0.000,0.000,42.76,1.000,1.000,1.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Crizotinib,Mediastinitis,1,45,43.768,43.768,20.41,1.000,0.000,1.000,10.926,χ²=20.4 (统计显著); 罕见+严重
Crizotinib,Vertebral column mass,1,45,43.768,43.768,20.41,1.000,0.000,1.000,10.926,χ²=20.4 (统计显著); 罕见+严重
Crizotinib,Coma hepatic,1,45,21.884,21.884,12.98,1.000,1.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Crizotinib,Dementia,2,45,12.514,12.514,16.08,1.000,0.000,0.000,10.233,χ²=16.1 (统计显著); 罕见+严重
Crizotinib,Oesophageal food impaction,1,45,0.000,0.000,42.76,1.000,0.000,0.000,10.926,χ²=42.8 (统计显著); 罕见+严重
Paclitaxel,Type IV hypersensitivity reaction,2,45,11.582,11.582,13.33,1.000,0.000,0.500,10.233,χ²=13.3 (统计显著); 罕见+严重
Paclitaxel,Arthralgia,7,45,0.796,0.796,0.34,0.857,0.000,0.000,8.980,严重事件率=85.7%; 罕见+严重
Paclitaxel,Rash,15,45,0.635,0.635,2.91,1.000,0.067,0.400,8.218,严重事件率=100.0%; 罕见+严重
Paclitaxel,Off label use,8,45,0.544,0.544,2.87,1.000,0.000,0.250,8.847,严重事件率=100.0%; 罕见+严重
Paclitaxel,Colonic abscess,2,45,11.582,11.582,13.33,1.000,0.000,1.000,10.233,χ²=13.3 (统计显著); 罕见+严重
Paclitaxel,Thrombocytopenia,16,45,1.024,1.024,0.01,1.000,0.188,0.312,8.153,严重事件率=100.0%; 罕见+严重
Paclitaxel,Pain,10,45,0.987,0.987,0.00,0.900,0.200,0.100,8.623,严重事件率=90.0%; 罕见+严重
Paclitaxel,Tumour necrosis,1,45,28.942,28.942,13.03,1.000,1.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Pruritus,12,45,1.380,1.380,1.15,1.000,0.083,0.250,8.441,严重事件率=100.0%; 罕见+严重
Paclitaxel,Deafness unilateral,2,45,9.652,9.652,11.23,1.000,1.000,1.000,10.233,χ²=11.2 (统计显著); 罕见+严重
Paclitaxel,Blepharospasm,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Hypokalaemia,6,45,1.849,1.849,2.12,1.000,0.000,0.333,9.134,严重事件率=100.0%; 罕见+严重
Paclitaxel,Optic disc disorder,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Traumatic lung injury,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Prothrombin time ratio decreased,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Thymoma,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Oliguria,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Blood pH decreased,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Haemodialysis,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Hyperuricaemia,2,45,9.652,9.652,11.23,1.000,0.500,0.500,10.233,χ²=11.2 (统计显著); 罕见+严重
Paclitaxel,Macule,2,45,11.582,11.582,13.33,1.000,0.000,1.000,10.233,χ²=13.3 (统计显著); 罕见+严重
Paclitaxel,Epidermal necrosis,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Actinic elastosis,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Hyperaemia,2,45,0.000,0.000,55.92,1.000,0.000,0.500,10.233,χ²=55.9 (统计显著); 罕见+严重
Paclitaxel,Skin mass,2,45,14.478,14.478,16.15,1.000,0.000,0.000,10.233,χ²=16.2 (统计显著); 罕见+严重
Paclitaxel,Vasculitic rash,1,45,0.000,0.000,27.96,1.000,0.000,0.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Ultrasound scan abnormal,1,45,28.942,28.942,13.03,1.000,1.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Oesophageal discomfort,1,45,0.000,0.000,27.96,1.000,1.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Ureteral disorder,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Infusion related reaction,5,45,1.148,1.148,0.09,0.800,0.200,0.000,9.317,严重事件率=80.0%; 罕见+严重
Paclitaxel,Porphyria non-acute,2,45,11.582,11.582,13.33,1.000,0.000,0.000,10.233,χ²=13.3 (统计显著); 罕见+严重
Paclitaxel,Gingival inflammation,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Choking sensation,2,45,14.478,14.478,16.15,1.000,0.000,0.000,10.233,χ²=16.2 (统计显著); 罕见+严重
Paclitaxel,Peripheral nerve palsy,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Inflammatory carcinoma of breast stage IV,1,45,28.942,28.942,13.03,1.000,1.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Diarrhoea infectious,1,45,28.942,28.942,13.03,1.000,1.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Vaginal discharge,2,45,9.652,9.652,11.23,1.000,0.000,0.500,10.233,χ²=11.2 (统计显著); 罕见+严重
Paclitaxel,Lip infection,2,45,0.000,0.000,55.92,1.000,0.000,1.000,10.233,χ²=55.9 (统计显著); 罕见+严重
Paclitaxel,Pelvic inflammatory disease,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Rash papulosquamous,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Mucosal infection,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Rhinitis allergic,2,45,19.304,19.304,20.11,1.000,0.000,0.000,10.233,χ²=20.1 (统计显著); 罕见+严重
Paclitaxel,Pulmonary hilar enlargement,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Economic problem,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Intraspinal abscess,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Adams-Stokes syndrome,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Ischaemia,2,45,14.478,14.478,16.15,1.000,0.000,0.000,10.233,χ²=16.2 (统计显著); 罕见+严重
Paclitaxel,Hypersthenuria,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Blood hyposmosis,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Pemphigus,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Vaginal abscess,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Dermatologic examination abnormal,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Febrile infection,1,45,28.942,28.942,13.03,1.000,1.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Menopausal symptoms,1,45,0.000,0.000,27.96,1.000,0.000,0.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Oesophageal squamous cell carcinoma metastatic,1,45,28.942,28.942,13.03,1.000,1.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Gastritis haemorrhagic,1,45,28.942,28.942,13.03,1.000,1.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Abdominal wall abscess,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Mucosal haemorrhage,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Hangover,1,45,28.942,28.942,13.03,1.000,1.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Mucosal dryness,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Rectal fissure,1,45,28.942,28.942,13.03,1.000,0.000,0.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Vasospasm,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Tricuspid valve incompetence,2,45,14.478,14.478,16.15,1.000,0.500,1.000,10.233,χ²=16.2 (统计显著); 罕见+严重
Paclitaxel,Oral mucosa erosion,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Tongue coated,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Abdominal abscess,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Pulmonary tuberculosis,1,45,0.000,0.000,27.96,1.000,0.000,0.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Hypouricaemia,1,45,0.000,0.000,27.96,1.000,0.000,0.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Gravitational oedema,1,45,0.000,0.000,27.96,1.000,0.000,0.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Hyperchlorhydria,1,45,0.000,0.000,27.96,1.000,0.000,0.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Muscle injury,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Infective myositis,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Anaemia of malignant disease,1,45,0.000,0.000,27.96,1.000,0.000,1.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Small intestinal haemorrhage,1,45,28.942,28.942,13.03,1.000,0.000,1.000,10.926,χ²=13.0 (统计显著); 罕见+严重
Paclitaxel,Immune reconstitution inflammatory syndrome,1,45,0.000,0.000,27.96,1.000,0.000,0.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Paclitaxel,Brain death,1,45,0.000,0.000,27.96,1.000,1.000,0.000,10.926,χ²=28.0 (统计显著); 罕见+严重
Docetaxel,Arthralgia,5,45,0.533,0.533,1.92,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Docetaxel,Myalgia,7,45,1.535,1.535,1.18,1.000,0.143,0.286,8.980,严重事件率=100.0%; 罕见+严重
Docetaxel,Asthenia,16,45,0.856,0.856,0.36,0.938,0.188,0.312,8.153,严重事件率=93.8%; 罕见+严重
Docetaxel,Alopecia,6,45,0.955,0.955,0.01,0.833,0.000,0.167,9.134,严重事件率=83.3%; 罕见+严重
Docetaxel,Hypersensitivity,9,45,1.802,1.802,2.89,0.778,0.000,0.222,8.729,严重事件率=77.8%; 罕见+严重
Docetaxel,Decreased appetite,18,45,0.906,0.906,0.16,0.889,0.167,0.333,8.036,严重事件率=88.9%; 罕见+严重
Docetaxel,Hyperparathyroidism,2,45,18.264,18.264,18.87,1.000,0.000,1.000,10.233,χ²=18.9 (统计显著); 罕见+严重
Docetaxel,Vitamin D deficiency,2,45,54.794,54.794,33.93,1.000,0.000,1.000,10.233,χ²=33.9 (统计显著); 罕见+严重
Docetaxel,Pain,7,45,0.646,0.646,1.27,1.000,0.000,0.286,8.980,严重事件率=100.0%; 罕见+严重
Docetaxel,Headache,5,45,0.396,0.396,4.33,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Docetaxel,Infusion site pruritus,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Dry skin,5,45,1.037,1.037,0.01,1.000,0.000,0.000,9.317,严重事件率=100.0%; 罕见+严重
Docetaxel,Vaginal inflammation,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Pruritus,6,45,0.635,0.635,1.17,0.833,0.000,0.333,9.134,严重事件率=83.3%; 罕见+严重
Docetaxel,Prostate cancer metastatic,2,45,13.698,13.698,15.12,1.000,0.500,0.000,10.233,χ²=15.1 (统计显著); 罕见+严重
Docetaxel,Prostatic specific antigen increased,2,45,27.396,27.396,24.51,1.000,0.500,0.500,10.233,χ²=24.5 (统计显著); 罕见+严重
Docetaxel,Bone pain,5,45,1.691,1.691,1.28,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Docetaxel,Back pain,10,45,1.165,1.165,0.22,0.900,0.000,0.100,8.623,严重事件率=90.0%; 罕见+严重
Docetaxel,Oedema peripheral,5,45,0.937,0.937,0.02,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Docetaxel,Cytomegalovirus colitis,2,45,54.794,54.794,33.93,1.000,0.500,0.000,10.233,χ²=33.9 (统计显著); 罕见+严重
Docetaxel,Apoptosis,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Off label use,10,45,0.647,0.647,1.79,1.000,0.200,0.000,8.623,严重事件率=100.0%; 罕见+严重
Docetaxel,Tracheo-oesophageal fistula,1,45,0.000,0.000,26.40,1.000,1.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Catheter site extravasation,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Sensory disturbance,2,45,18.264,18.264,18.87,1.000,0.000,0.500,10.233,χ²=18.9 (统计显著); 罕见+严重
Docetaxel,Duodenitis,1,45,27.383,27.383,12.26,1.000,0.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Viral sepsis,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Skin injury,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Infusion site swelling,1,45,27.383,27.383,12.26,1.000,0.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Osteolysis,2,45,13.698,13.698,15.12,1.000,0.500,0.000,10.233,χ²=15.1 (统计显著); 罕见+严重
Docetaxel,Metastatic lymphoma,1,45,27.383,27.383,12.26,1.000,1.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Erythroleukaemia,1,45,27.383,27.383,12.26,1.000,1.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Clonus,2,45,54.794,54.794,33.93,1.000,0.000,0.500,10.233,χ²=33.9 (统计显著); 罕见+严重
Docetaxel,Periodontitis,2,45,13.698,13.698,15.12,1.000,0.000,0.000,10.233,χ²=15.1 (统计显著); 罕见+严重
Docetaxel,Drug effect delayed,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Simple partial seizures,1,45,27.383,27.383,12.26,1.000,1.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Abdominal rigidity,1,45,27.383,27.383,12.26,1.000,0.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Snoring,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Infectious colitis,2,45,54.794,54.794,33.93,1.000,0.500,1.000,10.233,χ²=33.9 (统计显著); 罕见+严重
Docetaxel,Accelerated idioventricular rhythm,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Tumour ulceration,1,45,0.000,0.000,26.40,1.000,1.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Oesophageal obstruction,1,45,0.000,0.000,26.40,1.000,1.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Bronchial carcinoma,1,45,27.383,27.383,12.26,1.000,0.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Formication,2,45,54.794,54.794,33.93,1.000,0.000,0.000,10.233,χ²=33.9 (统计显著); 罕见+严重
Docetaxel,Sense of oppression,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Tumour embolism,1,45,27.383,27.383,12.26,1.000,0.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Metastases to ovary,2,45,10.958,10.958,12.46,1.000,0.000,0.000,10.233,χ²=12.5 (统计显著); 罕见+严重
Docetaxel,Metastases to bladder,2,45,13.698,13.698,15.12,1.000,0.000,0.000,10.233,χ²=15.1 (统计显著); 罕见+严重
Docetaxel,Pneumonia escherichia,1,45,0.000,0.000,26.40,1.000,1.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Enterococcal sepsis,1,45,27.383,27.383,12.26,1.000,1.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Skin candida,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Sputum discoloured,1,45,27.383,27.383,12.26,1.000,1.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Haemorrhagic anaemia,2,45,54.794,54.794,33.93,1.000,1.000,0.500,10.233,χ²=33.9 (统计显著); 罕见+严重
Docetaxel,Barotrauma,1,45,0.000,0.000,26.40,1.000,1.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Ischaemic enteritis,1,45,0.000,0.000,26.40,1.000,1.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Gas gangrene,1,45,0.000,0.000,26.40,1.000,1.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Phaeochromocytoma,1,45,27.383,27.383,12.26,1.000,0.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Skin fibrosis,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Scrotal oedema,1,45,27.383,27.383,12.26,1.000,0.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Hyaluronic acid decreased,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,"Hallucination, visual",2,45,18.264,18.264,18.87,1.000,0.000,0.000,10.233,χ²=18.9 (统计显著); 罕见+严重
Docetaxel,Head titubation,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Gastrostomy,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Infusion site erythema,2,45,54.794,54.794,33.93,1.000,0.000,0.000,10.233,χ²=33.9 (统计显著); 罕见+严重
Docetaxel,Infusion site discolouration,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Infusion site oedema,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Abdominal wall haemorrhage,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Partial seizures with secondary generalisation,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Hepatitis C,2,45,18.264,18.264,18.87,1.000,0.000,0.000,10.233,χ²=18.9 (统计显著); 罕见+严重
Docetaxel,Systolic dysfunction,1,45,27.383,27.383,12.26,1.000,0.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Renal atrophy,1,45,27.383,27.383,12.26,1.000,1.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Eosinophil count decreased,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Gastric varices,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,"Hallucination, auditory",1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Enterovesical fistula,2,45,0.000,0.000,52.81,1.000,0.000,0.000,10.233,χ²=52.8 (统计显著); 罕见+严重
Docetaxel,Dental necrosis,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Wound infection,2,45,13.698,13.698,15.12,1.000,0.000,0.000,10.233,χ²=15.1 (统计显著); 罕见+严重
Docetaxel,PO2 decreased,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Breath sounds abnormal,2,45,10.958,10.958,12.46,1.000,1.000,0.500,10.233,χ²=12.5 (统计显著); 罕见+严重
Docetaxel,Injection site thrombosis,3,45,0.000,0.000,79.21,1.000,0.000,0.000,9.827,χ²=79.2 (统计显著); 罕见+严重
Docetaxel,Fluid imbalance,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Chronic hepatitis C,1,45,27.383,27.383,12.26,1.000,0.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Salivary gland calculus,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Invasive lobular breast carcinoma,1,45,27.383,27.383,12.26,1.000,0.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Post procedural infection,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Oesophageal spasm,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Blood bicarbonate decreased,1,45,0.000,0.000,26.40,1.000,1.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Venous oxygen partial pressure decreased,1,45,0.000,0.000,26.40,1.000,1.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Amaurosis,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Faecaluria,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,HER-2 positive breast cancer,1,45,0.000,0.000,26.40,1.000,1.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Drug tolerance,1,45,27.383,27.383,12.26,1.000,0.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Screaming,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Affect lability,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Thought blocking,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Inappropriate affect,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Abscess neck,1,45,27.383,27.383,12.26,1.000,0.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Pharyngeal fistula,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Thermal burn,2,45,10.958,10.958,12.46,1.000,0.000,0.000,10.233,χ²=12.5 (统计显著); 罕见+严重
Docetaxel,Brain stem syndrome,1,45,27.383,27.383,12.26,1.000,0.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Premature delivery,1,45,27.383,27.383,12.26,1.000,0.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Dyspraxia,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Metastases to placenta,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Caesarean section,2,45,54.794,54.794,33.93,1.000,0.000,1.000,10.233,χ²=33.9 (统计显著); 罕见+严重
Docetaxel,Nail hypertrophy,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Neonatal respiratory distress syndrome,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Feeding disorder neonatal,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Anaemia neonatal,1,45,0.000,0.000,26.40,1.000,0.000,1.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Low birth weight baby,1,45,27.383,27.383,12.26,1.000,0.000,1.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Acute hepatitis B,1,45,0.000,0.000,26.40,1.000,1.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Hepatitis fulminant,1,45,0.000,0.000,26.40,1.000,1.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Osteomyelitis acute,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Primary sequestrum,1,45,0.000,0.000,26.40,1.000,0.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Docetaxel,Granulocyte count decreased,1,45,27.383,27.383,12.26,1.000,0.000,0.000,10.926,χ²=12.3 (统计显著); 罕见+严重
Docetaxel,Stupor,1,45,0.000,0.000,26.40,1.000,1.000,0.000,10.926,χ²=26.4 (统计显著); 罕见+严重
Doxorubicin,Pancytopenia,10,45,1.328,1.328,0.74,1.000,0.100,0.300,8.623,严重事件率=100.0%; 罕见+严重
Doxorubicin,Grand mal convulsion,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Wound secretion,2,45,9.514,9.514,11.03,1.000,0.000,1.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Doxorubicin,Castleman^s disease,2,45,14.271,14.271,15.88,1.000,1.000,0.000,10.233,χ²=15.9 (统计显著); 罕见+严重
Doxorubicin,Arteriovenous malformation,1,45,28.528,28.528,12.82,1.000,1.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Brain abscess,2,45,19.028,19.028,19.78,1.000,1.000,0.500,10.233,χ²=19.8 (统计显著); 罕见+严重
Doxorubicin,Central nervous system infection,1,45,28.528,28.528,12.82,1.000,1.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Decreased appetite,18,45,0.945,0.945,0.05,1.000,0.056,0.333,8.036,严重事件率=100.0%; 罕见+严重
Doxorubicin,Anorectal disorder,1,45,28.528,28.528,12.82,1.000,1.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Pneumomediastinum,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Hodgkin^s disease nodular sclerosis,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,White blood cell disorder,2,45,11.417,11.417,13.10,1.000,0.000,0.000,10.233,χ²=13.1 (统计显著); 罕见+严重
Doxorubicin,Electrocardiogram QT interval abnormal,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Interstitial lung disease,5,45,0.874,0.874,0.08,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Doxorubicin,Acquired gene mutation,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Lymphadenitis,2,45,14.271,14.271,15.88,1.000,0.000,1.000,10.233,χ²=15.9 (统计显著); 罕见+严重
Doxorubicin,Lymph node pain,2,45,14.271,14.271,15.88,1.000,0.000,1.000,10.233,χ²=15.9 (统计显著); 罕见+严重
Doxorubicin,Bone marrow transplant,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Necrosis,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Rectal ulcer,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Cerebral artery embolism,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Renal failure,5,45,0.695,0.695,0.63,1.000,0.200,0.200,9.317,严重事件率=100.0%; 罕见+严重
Doxorubicin,Appendiceal abscess,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Protein urine,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,"Follicle centre lymphoma, follicular grade I, II, III refractory",1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Myocardial strain,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Refractory anaemia with an excess of blasts,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Monoclonal immunoglobulin present,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Thyroid cancer metastatic,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Renal cancer metastatic,1,45,0.000,0.000,27.55,1.000,1.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Intestinal fistula,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Colon injury,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Infection in an immunocompromised host,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Electrocardiogram T wave amplitude decreased,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Oedema mouth,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Blood phosphorus abnormal,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Leiomyosarcoma recurrent,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Angina unstable,2,45,9.514,9.514,11.03,1.000,1.000,0.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Doxorubicin,Urinary tract infection bacterial,1,45,28.528,28.528,12.82,1.000,1.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Central nervous system haemorrhage,1,45,28.528,28.528,12.82,1.000,1.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Haemodynamic instability,1,45,28.528,28.528,12.82,1.000,1.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Malignant neoplasm of ampulla of Vater,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Generalised tonic-clonic seizure,2,45,11.417,11.417,13.10,1.000,0.500,1.000,10.233,χ²=13.1 (统计显著); 罕见+严重
Doxorubicin,Hepatosplenomegaly,2,45,9.514,9.514,11.03,1.000,0.500,0.500,10.233,χ²=11.0 (统计显著); 罕见+严重
Doxorubicin,Hyperammonaemia,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Loss of proprioception,2,45,0.000,0.000,55.10,1.000,0.500,1.000,10.233,χ²=55.1 (统计显著); 罕见+严重
Doxorubicin,Vitreous degeneration,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Optic nerve injury,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Refraction disorder,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Brain herniation,1,45,0.000,0.000,27.55,1.000,1.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Decerebrate posture,1,45,0.000,0.000,27.55,1.000,1.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Oesophageal varices haemorrhage,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Burkitt^s leukaemia,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Fibrin D dimer increased,2,45,28.543,28.543,25.65,1.000,0.000,0.000,10.233,χ²=25.6 (统计显著); 罕见+严重
Doxorubicin,Kidney fibrosis,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Hyperparathyroidism secondary,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Granulocytes abnormal,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Iatrogenic injury,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Epstein-Barr virus associated lymphoma,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Device failure,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Renal transplant,2,45,0.000,0.000,55.10,1.000,0.000,0.500,10.233,χ²=55.1 (统计显著); 罕见+严重
Doxorubicin,Drug clearance decreased,2,45,11.417,11.417,13.10,1.000,0.000,0.000,10.233,χ²=13.1 (统计显著); 罕见+严重
Doxorubicin,Foetal exposure during pregnancy,2,45,9.514,9.514,11.03,1.000,0.000,0.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Doxorubicin,Fanconi syndrome acquired,2,45,57.087,57.087,35.45,1.000,1.000,0.000,10.233,χ²=35.5 (统计显著); 罕见+严重
Doxorubicin,Bronchopneumopathy,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Diphyllobothriasis,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Herpes ophthalmic,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Glossopharyngeal nerve paralysis,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Vagus nerve paralysis,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Viraemia,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Monoclonal gammopathy,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Rhodococcus infection,2,45,0.000,0.000,55.10,1.000,0.000,1.000,10.233,χ²=55.1 (统计显著); 罕见+严重
Doxorubicin,Nephrogenic diabetes insipidus,1,45,0.000,0.000,27.55,1.000,1.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Non-Hodgkin^s lymphoma recurrent,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Metastatic lymphoma,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Erythroleukaemia,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Gingival ulceration,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Sarcoma metastatic,1,45,0.000,0.000,27.55,1.000,1.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Pituitary tumour,2,45,14.271,14.271,15.88,1.000,0.000,0.000,10.233,χ²=15.9 (统计显著); 罕见+严重
Doxorubicin,Pancreatitis necrotising,2,45,0.000,0.000,55.10,1.000,0.000,1.000,10.233,χ²=55.1 (统计显著); 罕见+严重
Doxorubicin,Pancreatic abscess,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Oedematous pancreatitis,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Pancreas infection,2,45,0.000,0.000,55.10,1.000,0.000,1.000,10.233,χ²=55.1 (统计显著); 罕见+严重
Doxorubicin,Citrobacter infection,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Spinal cord injury,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Extensor plantar response,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Hypotonia,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Hyperreflexia,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Spinal cord ischaemia,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Dyschezia,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Enterobacter infection,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Peripheral T-cell lymphoma unspecified,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Metastases to breast,2,45,9.514,9.514,11.03,1.000,1.000,0.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Doxorubicin,Hypercoagulation,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Epidermal growth factor receptor decreased,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Carbon dioxide increased,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Chemotherapy,1,45,0.000,0.000,27.55,1.000,1.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Blood lactate dehydrogenase,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Blast cells present,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Bronchial disorder,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Chondrosarcoma metastatic,2,45,28.543,28.543,25.65,1.000,1.000,0.000,10.233,χ²=25.6 (统计显著); 罕见+严重
Doxorubicin,Diaphragm muscle weakness,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Wound complication,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Breast conserving surgery,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Medical device implantation,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Clonic convulsion,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Peripheral artery thrombosis,2,45,28.543,28.543,25.65,1.000,0.000,0.000,10.233,χ²=25.6 (统计显著); 罕见+严重
Doxorubicin,Breast lump removal,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Catheter placement,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Pregnancy,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Systolic dysfunction,1,45,28.528,28.528,12.82,1.000,0.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Infection reactivation,2,45,57.087,57.087,35.45,1.000,0.000,1.000,10.233,χ²=35.5 (统计显著); 罕见+严重
Doxorubicin,Vocal cord polyp,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Biopsy site unspecified abnormal,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Pulmonary toxicity,2,45,9.514,9.514,11.03,1.000,0.500,0.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Doxorubicin,Embolism venous,2,45,11.417,11.417,13.10,1.000,0.500,0.500,10.233,χ²=13.1 (统计显著); 罕见+严重
Doxorubicin,Small cell lung cancer metastatic,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Vein disorder,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Parvovirus infection,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Acute hepatitis C,2,45,11.417,11.417,13.10,1.000,0.000,1.000,10.233,χ²=13.1 (统计显著); 罕见+严重
Doxorubicin,Venoocclusive disease,1,45,0.000,0.000,27.55,1.000,0.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Monocyte count increased,2,45,28.543,28.543,25.65,1.000,0.000,1.000,10.233,χ²=25.6 (统计显著); 罕见+严重
Doxorubicin,Culture positive,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Citrobacter test positive,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Pneumonia streptococcal,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,T-cell type acute leukaemia,2,45,0.000,0.000,55.10,1.000,1.000,0.000,10.233,χ²=55.1 (统计显著); 罕见+严重
Doxorubicin,Hodgkin^s disease recurrent,1,45,0.000,0.000,27.55,1.000,1.000,0.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Rhabdomyosarcoma,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Metastases to pituitary gland,1,45,28.528,28.528,12.82,1.000,1.000,0.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Dumping syndrome,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Doxorubicin,Irritable bowel syndrome,1,45,28.528,28.528,12.82,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Doxorubicin,Biliary cirrhosis primary,1,45,0.000,0.000,27.55,1.000,0.000,1.000,10.926,χ²=27.5 (统计显著); 罕见+严重
Carboplatin,Rectal tenesmus,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Pain in extremity,10,45,1.221,1.221,0.36,1.000,0.100,0.300,8.623,严重事件率=100.0%; 罕见+严重
Carboplatin,Hypoaesthesia,8,45,1.956,1.956,3.30,1.000,0.125,0.250,8.847,严重事件率=100.0%; 罕见+严重
Carboplatin,Carpal tunnel decompression,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Hypertension,12,45,1.737,1.737,3.33,1.000,0.000,0.083,8.441,严重事件率=100.0%; 罕见+严重
Carboplatin,Colonic abscess,2,45,9.769,9.769,10.79,1.000,0.000,1.000,10.233,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Toxicity to various agents,7,45,1.230,1.230,0.27,0.857,0.143,0.286,8.980,严重事件率=85.7%; 罕见+严重
Carboplatin,Duodenal perforation,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Jejunal perforation,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Arthralgia,5,45,0.475,0.475,2.71,1.000,0.000,0.000,9.317,严重事件率=100.0%; 罕见+严重
Carboplatin,Surgical failure,2,45,16.282,16.282,16.52,1.000,0.000,0.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Carboplatin,Rash,18,45,0.646,0.646,3.20,1.000,0.167,0.333,8.036,严重事件率=100.0%; 罕见+严重
Carboplatin,Hypersensitivity vasculitis,2,45,12.211,12.211,13.17,1.000,0.000,1.000,10.233,χ²=13.2 (统计显著); 罕见+严重
Carboplatin,Ascites,5,45,1.342,1.342,0.39,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Carboplatin,Dilatation ventricular,2,45,9.769,9.769,10.79,1.000,0.000,1.000,10.233,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Back pain,12,45,1.258,1.258,0.57,0.917,0.000,0.167,8.441,严重事件率=91.7%; 罕见+严重
Carboplatin,Heat stroke,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Stomatitis,5,45,0.666,0.666,0.78,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Carboplatin,Dizziness,14,45,1.005,1.005,0.00,0.929,0.071,0.357,8.287,严重事件率=92.9%; 罕见+严重
Carboplatin,Taeniasis,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Optic disc disorder,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Primary hypothyroidism,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Growth hormone deficiency,2,45,16.282,16.282,16.52,1.000,0.000,0.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Carboplatin,Deafness neurosensory,2,45,24.423,24.423,21.56,1.000,0.000,0.500,10.233,χ²=21.6 (统计显著); 罕见+严重
Carboplatin,Diet refusal,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Prothrombin time ratio decreased,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Rhabdoid tumour,1,45,0.000,0.000,23.44,1.000,1.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Primitive neuroectodermal tumour,1,45,24.412,24.412,10.78,1.000,1.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Blood luteinising hormone increased,2,45,48.847,48.847,29.99,1.000,1.000,0.000,10.233,χ²=30.0 (统计显著); 罕见+严重
Carboplatin,Blood follicle stimulating hormone increased,2,45,48.847,48.847,29.99,1.000,1.000,0.000,10.233,χ²=30.0 (统计显著); 罕见+严重
Carboplatin,Calculus ureteric,2,45,48.847,48.847,29.99,1.000,0.000,0.500,10.233,χ²=30.0 (统计显著); 罕见+严重
Carboplatin,Ovarian epithelial cancer,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Malaise,8,45,0.511,0.511,3.49,1.000,0.125,0.250,8.847,严重事件率=100.0%; 罕见+严重
Carboplatin,Nephroblastoma,1,45,0.000,0.000,23.44,1.000,1.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Limb asymmetry,2,45,24.423,24.423,21.56,1.000,0.000,0.000,10.233,χ²=21.6 (统计显著); 罕见+严重
Carboplatin,Rhabdomyosarcoma,1,45,24.412,24.412,10.78,1.000,1.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Papule,2,45,12.211,12.211,13.17,1.000,0.000,0.500,10.233,χ²=13.2 (统计显著); 罕见+严重
Carboplatin,Macule,2,45,9.769,9.769,10.79,1.000,0.000,1.000,10.233,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Epidermal necrosis,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Actinic elastosis,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Tracheal fistula,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Folate deficiency,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Urinary tract infection fungal,1,45,24.412,24.412,10.78,1.000,1.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Anxiety,6,45,1.511,1.511,0.93,1.000,0.000,0.333,9.134,严重事件率=100.0%; 罕见+严重
Carboplatin,Pain,7,45,0.576,0.576,2.04,1.000,0.143,0.000,8.980,严重事件率=100.0%; 罕见+严重
Carboplatin,Pulmonary artery wall hypertrophy,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Muscular weakness,7,45,1.368,1.368,0.63,1.000,0.000,0.286,8.980,严重事件率=100.0%; 罕见+严重
Carboplatin,Gait disturbance,5,45,1.185,1.185,0.13,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Carboplatin,Alopecia,7,45,0.999,0.999,0.00,1.000,0.000,0.143,8.980,严重事件率=100.0%; 罕见+严重
Carboplatin,Communication disorder,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Polydipsia,1,45,24.412,24.412,10.78,1.000,1.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Gastrointestinal candidiasis,1,45,0.000,0.000,23.44,1.000,1.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Culture positive,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Blood pressure systolic decreased,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Growth retardation,3,45,0.000,0.000,70.32,1.000,0.000,0.000,9.827,χ²=70.3 (统计显著); 罕见+严重
Carboplatin,Thoracic operation,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Suffocation feeling,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Ileal perforation,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,ACTH-producing pituitary tumour,1,45,24.412,24.412,10.78,1.000,1.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Malignant pituitary tumour,1,45,24.412,24.412,10.78,1.000,1.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Duodenitis,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Pelvic inflammatory disease,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Azotaemia,1,45,24.412,24.412,10.78,1.000,1.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Erosive oesophagitis,2,45,12.211,12.211,13.17,1.000,0.000,0.500,10.233,χ²=13.2 (统计显著); 罕见+严重
Carboplatin,Hypernatraemia,2,45,24.423,24.423,21.56,1.000,0.000,0.500,10.233,χ²=21.6 (统计显著); 罕见+严重
Carboplatin,Metabolic syndrome,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Ototoxicity,2,45,12.211,12.211,13.17,1.000,0.000,0.000,10.233,χ²=13.2 (统计显著); 罕见+严重
Carboplatin,Oesophageal perforation,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Osteomyelitis fungal,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Enterococcal infection,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Extradural neoplasm,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Leukopenia,6,45,1.382,1.382,0.57,0.833,0.000,0.167,9.134,严重事件率=83.3%; 罕见+严重
Carboplatin,Salpingo-oophorectomy unilateral,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Rhinitis allergic,2,45,16.282,16.282,16.52,1.000,0.000,0.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Carboplatin,Pulmonary hilar enlargement,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Blood immunoglobulin A increased,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,"Astrocytoma, low grade",1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Defaecation urgency,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Bronchial obstruction,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Astrocytoma malignant,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Renal tubular disorder,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Haemorrhage subcutaneous,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Vaginal abscess,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Wound complication,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Dermatologic examination abnormal,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Anuria,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Injury,2,45,24.423,24.423,21.56,1.000,0.000,0.000,10.233,χ²=21.6 (统计显著); 罕见+严重
Carboplatin,Klebsiella bacteraemia,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Abdominal wall abscess,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Documented hypersensitivity to administered drug,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Inhibitory drug interaction,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Anal fissure,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Anal haemorrhage,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Asphyxia,2,45,24.423,24.423,21.56,1.000,1.000,0.000,10.233,χ²=21.6 (统计显著); 罕见+严重
Carboplatin,Hangover,1,45,24.412,24.412,10.78,1.000,1.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Vasospasm,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Arterial occlusive disease,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Metastases to neck,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Pulmonary valve incompetence,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Exostosis,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Induration,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Electrocardiogram PR prolongation,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Incisional hernia,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Pelvic cyst,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Left ventricular hypertrophy,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Hypertrophy,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Aortic valve disease,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Tricuspid valve disease,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Aortic arteriosclerosis,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Blepharitis,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Carotid artery stenosis,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Pyuria,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Vasodilatation,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Proteus test positive,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Soft tissue inflammation,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Diverticulum intestinal,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Intervertebral disc space narrowing,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Thyroid cyst,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Major depression,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Deformity,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Pancreatic atrophy,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Carotid arteriosclerosis,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Vertebral foraminal stenosis,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Mitral valve disease,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Physical disability,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Insulin resistance,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Kyphosis,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Testicular atrophy,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Sebaceous hyperplasia,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Stress urinary incontinence,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Libido decreased,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Atrioventricular block first degree,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Embolism venous,2,45,9.769,9.769,10.79,1.000,0.000,0.500,10.233,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Hypermetropia,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Eczema nummular,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Ureteric dilatation,1,45,0.000,0.000,23.44,1.000,0.000,0.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Clonic convulsion,1,45,24.412,24.412,10.78,1.000,0.000,0.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Perseveration,1,45,0.000,0.000,23.44,1.000,0.000,1.000,10.926,χ²=23.4 (统计显著); 罕见+严重
Carboplatin,Ruptured cerebral aneurysm,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Oral mucosa erosion,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Carboplatin,Tongue coated,1,45,24.412,24.412,10.78,1.000,0.000,1.000,10.926,χ²=10.8 (统计显著); 罕见+严重
Cisplatin,Leukopenia,7,45,1.821,1.821,2.33,1.000,0.143,0.143,8.980,严重事件率=100.0%; 罕见+严重
Cisplatin,Radiation oesophagitis,2,45,54.591,54.591,33.80,1.000,0.000,0.000,10.233,χ²=33.8 (统计显著); 罕见+严重
Cisplatin,Castleman^s disease,2,45,13.647,13.647,15.06,1.000,1.000,0.000,10.233,χ²=15.1 (统计显著); 罕见+严重
Cisplatin,Nasal septum deviation,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Haemostasis,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Tumour perforation,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Suture related complication,1,45,27.282,27.282,12.20,1.000,1.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Mixed hepatocellular cholangiocarcinoma,1,45,0.000,0.000,26.30,1.000,1.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Carotid artery dissection,2,45,0.000,0.000,52.61,1.000,0.000,1.000,10.233,χ²=52.6 (统计显著); 罕见+严重
Cisplatin,Peripheral artery dissection,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Poisoning,1,45,27.282,27.282,12.20,1.000,1.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Pharyngeal inflammation,1,45,0.000,0.000,26.30,1.000,1.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Small cell lung cancer,2,45,9.098,9.098,10.42,1.000,0.500,0.000,10.233,χ²=10.4 (统计显著); 罕见+严重
Cisplatin,Infusion site reaction,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Growth hormone deficiency,2,45,18.196,18.196,18.79,1.000,0.500,0.000,10.233,χ²=18.8 (统计显著); 罕见+严重
Cisplatin,Primitive neuroectodermal tumour,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Germ cell cancer metastatic,1,45,0.000,0.000,26.30,1.000,1.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Type II hypersensitivity,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Pancreatic enzymes increased,2,45,9.098,9.098,10.42,1.000,1.000,1.000,10.233,χ²=10.4 (统计显著); 罕见+严重
Cisplatin,Blood sodium abnormal,2,45,54.591,54.591,33.80,1.000,0.000,1.000,10.233,χ²=33.8 (统计显著); 罕见+严重
Cisplatin,Incorrect drug administration duration,2,45,27.295,27.295,24.41,1.000,0.000,1.000,10.233,χ²=24.4 (统计显著); 罕见+严重
Cisplatin,Pneumonia adenoviral,2,45,18.196,18.196,18.79,1.000,1.000,0.000,10.233,χ²=18.8 (统计显著); 罕见+严重
Cisplatin,Intestinal fistula,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Abdominal pain upper,6,45,0.940,0.940,0.02,1.000,0.000,0.333,9.134,严重事件率=100.0%; 罕见+严重
Cisplatin,Colon injury,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Echolalia,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Epstein-Barr virus infection,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Herpes simplex otitis externa,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Bone marrow toxicity,2,45,9.098,9.098,10.42,1.000,1.000,1.000,10.233,χ²=10.4 (统计显著); 罕见+严重
Cisplatin,Electrocardiogram T wave amplitude decreased,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Oedema mouth,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Blood phosphorus abnormal,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Culture urine positive,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Streptococcus test positive,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Enteritis necroticans,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Breath odour,2,45,13.647,13.647,15.06,1.000,0.000,0.500,10.233,χ²=15.1 (统计显著); 罕见+严重
Cisplatin,Tetany,1,45,0.000,0.000,26.30,1.000,1.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Erythropenia,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Superinfection bacterial,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Mesenteric vein thrombosis,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Lung adenocarcinoma stage IV,1,45,27.282,27.282,12.20,1.000,1.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Panic reaction,2,45,0.000,0.000,52.61,1.000,0.000,0.500,10.233,χ²=52.6 (统计显著); 罕见+严重
Cisplatin,ACTH-producing pituitary tumour,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Malignant pituitary tumour,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Implant site pain,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Blood glucose,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Gastrointestinal tube insertion,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Enterobacter test positive,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Hyponatraemic seizure,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Azotaemia,1,45,27.282,27.282,12.20,1.000,1.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Metastatic gastric cancer,1,45,0.000,0.000,26.30,1.000,1.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Hyposideraemia,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Scrotal abscess,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Appendicitis perforated,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Retroperitoneal abscess,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Gingival ulceration,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Bronchial fistula,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Traumatic lung injury,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Medical device complication,1,45,0.000,0.000,26.30,1.000,1.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Splenic infarction,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Renal infarct,2,45,0.000,0.000,52.61,1.000,1.000,0.000,10.233,χ²=52.6 (统计显著); 罕见+严重
Cisplatin,Simple partial seizures,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Enterococcus test positive,1,45,0.000,0.000,26.30,1.000,1.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Candida test positive,1,45,27.282,27.282,12.20,1.000,1.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Pancreatic mass,1,45,27.282,27.282,12.20,1.000,1.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Chondrosarcoma metastatic,2,45,27.295,27.295,24.41,1.000,1.000,0.000,10.233,χ²=24.4 (统计显著); 罕见+严重
Cisplatin,Multi-organ disorder,2,45,18.196,18.196,18.79,1.000,1.000,1.000,10.233,χ²=18.8 (统计显著); 罕见+严重
Cisplatin,Hyperpyrexia,2,45,10.917,10.917,12.40,1.000,1.000,1.000,10.233,χ²=12.4 (统计显著); 罕见+严重
Cisplatin,Thermal burn,2,45,10.917,10.917,12.40,1.000,1.000,1.000,10.233,χ²=12.4 (统计显著); 罕见+严重
Cisplatin,Pyuria,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Breakthrough pain,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Lip and/or oral cavity cancer,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Human chorionic gonadotropin decreased,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Vulvovaginal erythema,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Vulvovaginal swelling,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Oesophageal squamous cell carcinoma metastatic,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Bladder spasm,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Anaemia of chronic disease,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Iron deficiency,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Blood chloride abnormal,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Urine leukocyte esterase positive,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Coronary artery restenosis,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Coronary artery thrombosis,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Intermittent claudication,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Aortic arteriosclerosis,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Iliac artery occlusion,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Opportunistic infection,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Vertigo positional,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Parvovirus infection,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Osteoradionecrosis,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Parotitis,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Ear pain,2,45,13.647,13.647,15.06,1.000,0.500,0.500,10.233,χ²=15.1 (统计显著); 罕见+严重
Cisplatin,Tongue injury,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Oropharyngeal swelling,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Tuberculous pleurisy,1,45,0.000,0.000,26.30,1.000,1.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Granulomatous pneumonitis,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Phaeochromocytoma,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Deafness bilateral,2,45,18.196,18.196,18.79,1.000,0.500,0.000,10.233,χ²=18.8 (统计显著); 罕见+严重
Cisplatin,Medication error,2,45,10.917,10.917,12.40,1.000,0.000,1.000,10.233,χ²=12.4 (统计显著); 罕见+严重
Cisplatin,Pubis fracture,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Benign lung neoplasm,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Chyluria,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Drug level increased,1,45,27.282,27.282,12.20,1.000,0.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Zygomycosis,1,45,27.282,27.282,12.20,1.000,1.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Retinal ischaemia,2,45,54.591,54.591,33.80,1.000,0.000,0.000,10.233,χ²=33.8 (统计显著); 罕见+严重
Cisplatin,Chest X-ray abnormal,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Plasma cell myeloma,5,45,0.655,0.655,0.85,1.000,0.000,0.000,9.317,严重事件率=100.0%; 罕见+严重
Cisplatin,Haematocrit abnormal,1,45,27.282,27.282,12.20,1.000,1.000,1.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Retinal exudates,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Haemodialysis,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Retinal vasculitis,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Muscle fibrosis,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Bone development abnormal,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Temporomandibular joint syndrome,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Tooth malformation,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Tooth hypoplasia,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Oral cavity fistula,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Fistula discharge,1,45,27.282,27.282,12.20,1.000,0.000,0.000,10.926,χ²=12.2 (统计显著); 罕见+严重
Cisplatin,Burning mouth syndrome,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Mucosal necrosis,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Mucosal ulceration,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Malocclusion,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Dysbacteriosis,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Salivary gland atrophy,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Salivary gland disorder,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Auricular swelling,1,45,0.000,0.000,26.30,1.000,0.000,0.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Cisplatin,Eccrine squamous syringometaplasia,2,45,18.196,18.196,18.79,1.000,0.500,0.000,10.233,χ²=18.8 (统计显著); 罕见+严重
Cisplatin,Retroperitoneal lymphadenopathy,1,45,0.000,0.000,26.30,1.000,0.000,1.000,10.926,χ²=26.3 (统计显著); 罕见+严重
Lenalidomide,Pruritus,7,45,1.259,1.259,0.35,0.857,0.000,0.286,8.980,严重事件率=85.7%; 罕见+严重
Lenalidomide,White blood cell count decreased,11,45,1.521,1.521,1.83,0.909,0.091,0.364,8.528,严重事件率=90.9%; 罕见+严重
Lenalidomide,Intestinal ischaemia,2,45,18.494,18.494,23.10,1.000,0.500,0.000,10.233,χ²=23.1 (统计显著); 罕见+严重
Lenalidomide,Enterocolitis bacterial,1,45,23.100,23.100,13.78,1.000,0.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Protein total increased,2,45,23.119,23.119,27.57,1.000,0.000,0.000,10.233,χ²=27.6 (统计显著); 罕见+严重
Lenalidomide,Gallbladder disorder,2,45,9.246,9.246,11.98,1.000,0.000,1.000,10.233,χ²=12.0 (统计显著); 罕见+严重
Lenalidomide,Amaurosis fugax,1,45,46.200,46.200,21.62,1.000,1.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Rash,14,45,0.948,0.948,0.04,1.000,0.143,0.286,8.287,严重事件率=100.0%; 罕见+严重
Lenalidomide,Pain,5,45,0.774,0.774,0.32,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Lenalidomide,Cough,5,45,0.954,0.954,0.01,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Lenalidomide,Decreased appetite,6,45,0.496,0.496,2.92,1.000,0.167,0.333,9.134,严重事件率=100.0%; 罕见+严重
Lenalidomide,Drug ineffective,6,45,1.049,1.049,0.01,1.000,0.167,0.167,9.134,严重事件率=100.0%; 罕见+严重
Lenalidomide,Atrial thrombosis,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Road traffic accident,2,45,15.412,15.412,19.75,1.000,0.500,0.500,10.233,χ²=19.8 (统计显著); 罕见+严重
Lenalidomide,Sternal fracture,1,45,23.100,23.100,13.78,1.000,0.000,1.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Upper respiratory tract inflammation,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Blood electrolytes abnormal,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Adrenal gland injury,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Pathological fracture,2,45,8.406,8.406,10.79,1.000,0.500,1.000,10.233,χ²=10.8 (统计显著); 罕见+严重
Lenalidomide,Spinal disorder,1,45,23.100,23.100,13.78,1.000,0.000,1.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Refractory cytopenia with multilineage dysplasia,1,45,23.100,23.100,13.78,1.000,1.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Mucoepidermoid carcinoma of salivary gland,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Hodgkin^s disease,1,45,23.100,23.100,13.78,1.000,1.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Open angle glaucoma,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Cyst rupture,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Superficial spreading melanoma stage unspecified,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Haemarthrosis,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Bone marrow leukaemic cell infiltration,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Tongue injury,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Pneumonia legionella,1,45,23.100,23.100,13.78,1.000,1.000,1.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Cerebral atrophy,1,45,23.100,23.100,13.78,1.000,0.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Cervical vertebral fracture,1,45,0.000,0.000,45.18,1.000,1.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Graft versus host disease in gastrointestinal tract,1,45,23.100,23.100,13.78,1.000,0.000,1.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Open fracture,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Soliloquy,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Faecal volume decreased,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Metastatic squamous cell carcinoma,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Paget^s disease of nipple,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Performance status decreased,2,45,8.406,8.406,10.79,1.000,0.000,1.000,10.233,χ²=10.8 (统计显著); 罕见+严重
Lenalidomide,Oesophageal achalasia,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Tongue neoplasm malignant stage unspecified,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Goodpasture^s syndrome,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Haemangioma of skin,1,45,46.200,46.200,21.62,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Pseudomonal bacteraemia,1,45,46.200,46.200,21.62,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Arterial disorder,1,45,0.000,0.000,45.18,1.000,1.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Campylobacter gastroenteritis,1,45,46.200,46.200,21.62,1.000,1.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Pneumonia influenzal,1,45,23.100,23.100,13.78,1.000,1.000,1.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Haemophilus infection,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Treatment noncompliance,2,45,92.479,92.479,58.95,1.000,0.000,0.500,10.233,χ²=58.9 (统计显著); 罕见+严重
Lenalidomide,Plasmacytoma,2,45,11.558,11.558,15.08,1.000,0.000,0.000,10.233,χ²=15.1 (统计显著); 罕见+严重
Lenalidomide,Miliaria,1,45,46.200,46.200,21.62,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Sensation of heaviness,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Renal haemorrhage,1,45,23.100,23.100,13.78,1.000,1.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Weight decreased,6,45,1.022,1.022,0.00,1.000,0.167,0.167,9.134,严重事件率=100.0%; 罕见+严重
Lenalidomide,Polycythaemia vera,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Malignant neoplasm of unknown primary site,1,45,46.200,46.200,21.62,1.000,1.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Pertussis,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Varicella,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Dermatitis allergic,2,45,10.274,10.274,13.38,1.000,0.000,0.500,10.233,χ²=13.4 (统计显著); 罕见+严重
Lenalidomide,Pneumonia pneumococcal,1,45,23.100,23.100,13.78,1.000,0.000,1.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Breakthrough pain,1,45,46.200,46.200,21.62,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Myelodysplastic syndrome transformation,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Corynebacterium sepsis,1,45,46.200,46.200,21.62,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Lobar pneumonia,2,45,46.239,46.239,43.25,1.000,0.000,0.000,10.233,χ²=43.2 (统计显著); 罕见+严重
Lenalidomide,Sluggishness,1,45,23.100,23.100,13.78,1.000,0.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Lhermitte^s sign,1,45,23.100,23.100,13.78,1.000,0.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Erectile dysfunction,2,45,23.119,23.119,27.57,1.000,0.000,0.500,10.233,χ²=27.6 (统计显著); 罕见+严重
Lenalidomide,Nerve root injury,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Abscess oral,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Drug clearance increased,1,45,46.200,46.200,21.62,1.000,0.000,1.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Drug level changed,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Sinus headache,1,45,23.100,23.100,13.78,1.000,0.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Lenalidomide,Depression suicidal,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Skin wrinkling,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Loss of libido,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Angioimmunoblastic T-cell lymphoma,1,45,46.200,46.200,21.62,1.000,1.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Pharyngeal oedema,2,45,8.406,8.406,10.79,1.000,0.000,0.000,10.233,χ²=10.8 (统计显著); 罕见+严重
Lenalidomide,Tongue dry,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Drooling,1,45,0.000,0.000,45.18,1.000,0.000,0.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Lenalidomide,Hyporeflexia,1,45,46.200,46.200,21.62,1.000,0.000,0.000,10.926,χ²=21.6 (统计显著); 罕见+严重
Lenalidomide,Eosinophilic cellulitis,1,45,0.000,0.000,45.18,1.000,0.000,1.000,10.926,χ²=45.2 (统计显著); 罕见+严重
Pomalidomide,Decreased appetite,5,45,0.461,0.461,3.02,0.800,0.000,0.200,9.317,严重事件率=80.0%; 罕见+严重
Pomalidomide,Asthenia,13,45,1.308,1.308,0.88,0.846,0.154,0.385,8.361,严重事件率=84.6%; 罕见+严重
Pomalidomide,Neutropenia,13,45,1.146,1.146,0.23,1.000,0.077,0.231,8.361,严重事件率=100.0%; 罕见+严重
Pomalidomide,Rash,9,45,0.674,0.674,1.35,0.778,0.000,0.111,8.729,严重事件率=77.8%; 罕见+严重
Pomalidomide,Lumbar vertebral fracture,1,45,17.201,17.201,11.22,1.000,0.000,1.000,10.926,χ²=11.2 (统计显著); 罕见+严重
Pomalidomide,Dizziness,10,45,1.503,1.503,1.58,0.700,0.100,0.200,8.623,严重事件率=70.0%; 罕见+严重
Pomalidomide,Hepatic necrosis,1,45,51.604,51.604,24.32,1.000,0.000,1.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Haemoglobin decreased,6,45,1.224,1.224,0.23,1.000,0.000,0.333,9.134,严重事件率=100.0%; 罕见+严重
Pomalidomide,Orchitis,2,45,0.000,0.000,101.15,1.000,0.000,0.000,10.233,χ²=101.1 (统计显著); 罕见+严重
Pomalidomide,Drug ineffective,10,45,1.992,1.992,4.60,1.000,0.200,0.300,8.623,严重事件率=100.0%; 罕见+严重
Pomalidomide,Urethral stenosis,1,45,0.000,0.000,50.57,1.000,0.000,0.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Thrombocytopenia,10,45,1.127,1.127,0.13,1.000,0.100,0.300,8.623,严重事件率=100.0%; 罕见+严重
Pomalidomide,Neck injury,1,45,0.000,0.000,50.57,1.000,0.000,0.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Sternal fracture,1,45,25.801,25.801,15.58,1.000,0.000,0.000,10.926,χ²=15.6 (统计显著); 罕见+严重
Pomalidomide,Cough,6,45,1.285,1.285,0.36,1.000,0.000,0.333,9.134,严重事件率=100.0%; 罕见+严重
Pomalidomide,Diarrhoea,11,45,0.419,0.419,8.32,0.909,0.000,0.273,8.528,严重事件率=90.9%; 罕见+严重
Pomalidomide,Tongue discolouration,1,45,25.801,25.801,15.58,1.000,0.000,0.000,10.926,χ²=15.6 (统计显著); 罕见+严重
Pomalidomide,Sickle cell anaemia with crisis,1,45,0.000,0.000,50.57,1.000,0.000,1.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Refusal of treatment by patient,1,45,25.801,25.801,15.58,1.000,0.000,1.000,10.926,χ²=15.6 (统计显著); 罕见+严重
Pomalidomide,Pruritus,7,45,1.407,1.407,0.78,0.714,0.000,0.286,8.980,严重事件率=71.4%; 罕见+严重
Pomalidomide,Constipation,12,45,1.504,1.504,1.89,0.583,0.000,0.083,8.441,严重事件率=58.3%; 罕见+严重
Pomalidomide,Hepatitis B reactivation,1,45,51.604,51.604,24.32,1.000,1.000,1.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Back disorder,1,45,25.801,25.801,15.58,1.000,0.000,0.000,10.926,χ²=15.6 (统计显著); 罕见+严重
Pomalidomide,Clavicle fracture,1,45,17.201,17.201,11.22,1.000,0.000,0.000,10.926,χ²=11.2 (统计显著); 罕见+严重
Pomalidomide,Bone disorder,2,45,34.434,34.434,38.14,1.000,0.000,0.500,10.233,χ²=38.1 (统计显著); 罕见+严重
Pomalidomide,Multiple fractures,1,45,25.801,25.801,15.58,1.000,0.000,1.000,10.926,χ²=15.6 (统计显著); 罕见+严重
Pomalidomide,Sinusitis bacterial,1,45,17.201,17.201,11.22,1.000,1.000,1.000,10.926,χ²=11.2 (统计显著); 罕见+严重
Pomalidomide,Wound infection staphylococcal,2,45,103.305,103.305,66.13,1.000,0.000,1.000,10.233,χ²=66.1 (统计显著); 罕见+严重
Pomalidomide,Incorrect drug administration duration,1,45,17.201,17.201,11.22,1.000,0.000,1.000,10.926,χ²=11.2 (统计显著); 罕见+严重
Pomalidomide,Cardiac myxoma,1,45,0.000,0.000,50.57,1.000,1.000,1.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Hypermagnesaemia,1,45,0.000,0.000,50.57,1.000,1.000,1.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Endocarditis staphylococcal,1,45,0.000,0.000,50.57,1.000,0.000,1.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Tooth disorder,2,45,20.659,20.659,26.17,0.500,0.000,0.000,10.233,χ²=26.2 (统计显著); 罕见+严重
Pomalidomide,Rib fracture,2,45,12.911,12.911,17.21,1.000,0.000,0.500,10.233,χ²=17.2 (统计显著); 罕见+严重
Pomalidomide,Colorectal cancer,1,45,51.604,51.604,24.32,1.000,0.000,0.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Diabetic retinopathy,1,45,51.604,51.604,24.32,1.000,0.000,0.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Axillary mass,1,45,51.604,51.604,24.32,1.000,0.000,0.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Pharyngitis,2,45,11.477,11.477,15.32,0.500,0.000,0.000,10.233,χ²=15.3 (统计显著); 罕见+严重
Pomalidomide,Prostatic specific antigen increased,2,45,51.652,51.652,48.63,1.000,0.000,0.500,10.233,χ²=48.6 (统计显著); 罕见+严重
Pomalidomide,Wound abscess,1,45,51.604,51.604,24.32,1.000,0.000,1.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Coagulation time prolonged,1,45,0.000,0.000,50.57,1.000,0.000,0.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Light chain analysis decreased,1,45,0.000,0.000,50.57,1.000,0.000,0.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Compression fracture,2,45,25.825,25.825,31.15,1.000,0.500,0.500,10.233,χ²=31.2 (统计显著); 罕见+严重
Pomalidomide,Gastroenteritis norovirus,1,45,51.604,51.604,24.32,1.000,0.000,1.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Procedural pain,1,45,17.201,17.201,11.22,1.000,0.000,1.000,10.926,χ²=11.2 (统计显著); 罕见+严重
Pomalidomide,Arthritis infective,2,45,0.000,0.000,101.15,1.000,0.000,1.000,10.233,χ²=101.1 (统计显著); 罕见+严重
Pomalidomide,Bleeding varicose vein,1,45,0.000,0.000,50.57,1.000,1.000,0.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Osteomyelitis chronic,1,45,0.000,0.000,50.57,1.000,0.000,1.000,10.926,χ²=50.6 (统计显著); 罕见+严重
Pomalidomide,Glucose tolerance impaired,1,45,25.801,25.801,15.58,1.000,0.000,0.000,10.926,χ²=15.6 (统计显著); 罕见+严重
Pomalidomide,Pneumonia fungal,2,45,8.607,8.607,11.28,1.000,0.500,0.500,10.233,χ²=11.3 (统计显著); 罕见+严重
Pomalidomide,Hip fracture,2,45,7.945,7.945,10.30,1.000,0.500,0.500,10.233,χ²=10.3 (统计显著); 罕见+严重
Pomalidomide,Urinary tract infection fungal,1,45,51.604,51.604,24.32,1.000,0.000,1.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Laceration,2,45,10.329,10.329,13.75,1.000,0.000,0.500,10.233,χ²=13.7 (统计显著); 罕见+严重
Pomalidomide,Ear infection,2,45,20.659,20.659,26.17,1.000,0.000,0.000,10.233,χ²=26.2 (统计显著); 罕见+严重
Pomalidomide,Pain in extremity,6,45,1.519,1.519,1.01,0.833,0.000,0.333,9.134,严重事件率=83.3%; 罕见+严重
Pomalidomide,Postoperative wound infection,1,45,25.801,25.801,15.58,1.000,0.000,1.000,10.926,χ²=15.6 (统计显著); 罕见+严重
Pomalidomide,Peripheral artery bypass,1,45,51.604,51.604,24.32,1.000,0.000,1.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Respiratory rate decreased,1,45,51.604,51.604,24.32,1.000,0.000,0.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Soft tissue mass,1,45,51.604,51.604,24.32,1.000,0.000,1.000,10.926,χ²=24.3 (统计显著); 罕见+严重
Pomalidomide,Klebsiella sepsis,1,45,17.201,17.201,11.22,1.000,1.000,1.000,10.926,χ²=11.2 (统计显著); 罕见+严重
Bortezomib,Amaurosis fugax,1,45,32.883,32.883,14.99,1.000,1.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Wound secretion,2,45,10.967,10.967,13.17,1.000,0.000,1.000,10.233,χ²=13.2 (统计显著); 罕见+严重
Bortezomib,Injection site nodule,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Injection site discolouration,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Injection site dryness,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Rheumatic disorder,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Hypertension,7,45,1.323,1.323,0.51,1.000,0.000,0.286,8.980,严重事件率=100.0%; 罕见+严重
Bortezomib,Peripheral sensorimotor neuropathy,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Graft versus host disease in gastrointestinal tract,2,45,65.806,65.806,41.24,1.000,0.000,1.000,10.233,χ²=41.2 (统计显著); 罕见+严重
Bortezomib,Shoulder deformity,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Intervertebral disc protrusion,2,45,16.451,16.451,18.75,1.000,0.000,1.000,10.233,χ²=18.8 (统计显著); 罕见+严重
Bortezomib,Renal atrophy,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Vertebral osteophyte,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Kyphosis,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Osteopenia,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Tooth impacted,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Dizziness,5,45,0.469,0.469,2.85,1.000,0.200,0.200,9.317,严重事件率=100.0%; 罕见+严重
Bortezomib,Pulmonary valve incompetence,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Lung consolidation,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Trigger finger,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Myopathy,2,45,10.967,10.967,13.17,1.000,0.000,0.500,10.233,χ²=13.2 (统计显著); 罕见+严重
Bortezomib,Electrocardiogram QRS complex prolonged,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Osteonecrosis,2,45,16.451,16.451,18.75,1.000,0.000,0.500,10.233,χ²=18.8 (统计显著); 罕见+严重
Bortezomib,Ligament disorder,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Costochondritis,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Upper airway resistance syndrome,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Physical disability,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Lumbosacral plexus lesion,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Radiation neuropathy,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Body fat disorder,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Deformity thorax,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Hypertrophy,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Tendon disorder,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Arteriosclerosis,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Arteriosclerosis coronary artery,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Injury,2,45,32.902,32.902,29.98,1.000,0.000,1.000,10.233,χ²=30.0 (统计显著); 罕见+严重
Bortezomib,Intercostal neuralgia,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Myofascial pain syndrome,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Left ventricular hypertrophy,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Intervertebral disc space narrowing,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Arrhythmia supraventricular,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Enthesopathy,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Gingival abscess,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Ventricular hypertrophy,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Left atrial dilatation,2,45,32.902,32.902,29.98,1.000,0.000,1.000,10.233,χ²=30.0 (统计显著); 罕见+严重
Bortezomib,Right atrial dilatation,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Aortic disorder,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Scrotal disorder,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Loose tooth,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Cor pulmonale chronic,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Peripheral venous disease,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Retinal artery occlusion,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Intervertebral disc compression,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Congenital cystic kidney disease,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Nephrosclerosis,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Faecal volume decreased,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Tongue neoplasm malignant stage unspecified,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Mucosal inflammation,6,45,1.732,1.732,1.70,1.000,0.000,0.333,9.134,严重事件率=100.0%; 罕见+严重
Bortezomib,Epstein-Barr virus test positive,2,45,0.000,0.000,63.79,1.000,0.000,0.000,10.233,χ²=63.8 (统计显著); 罕见+严重
Bortezomib,Viral haemorrhagic cystitis,2,45,0.000,0.000,63.79,1.000,0.000,0.000,10.233,χ²=63.8 (统计显著); 罕见+严重
Bortezomib,Graft versus host disease in skin,2,45,13.160,13.160,15.56,1.000,0.000,0.000,10.233,χ²=15.6 (统计显著); 罕见+严重
Bortezomib,Respiratory syncytial virus infection,2,45,32.902,32.902,29.98,1.000,0.000,0.000,10.233,χ²=30.0 (统计显著); 罕见+严重
Bortezomib,BK virus infection,2,45,0.000,0.000,63.79,1.000,0.000,0.000,10.233,χ²=63.8 (统计显著); 罕见+严重
Bortezomib,Drug clearance increased,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Erythema infectiosum,1,45,0.000,0.000,31.89,1.000,1.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Angioimmunoblastic T-cell lymphoma,1,45,32.883,32.883,14.99,1.000,1.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Kidney transplant rejection,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Anal ulcer,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Monoclonal immunoglobulin present,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Thyroid cancer metastatic,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Coccidioidomycosis,1,45,0.000,0.000,31.89,1.000,1.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Acute myeloid leukaemia recurrent,1,45,0.000,0.000,31.89,1.000,1.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Dyssomnia,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Decreased appetite,10,45,0.594,0.594,2.60,1.000,0.200,0.300,8.623,严重事件率=100.0%; 罕见+严重
Bortezomib,Neuroendocrine tumour,1,45,32.883,32.883,14.99,1.000,1.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Vascular dementia,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Urine output increased,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Intraductal proliferative breast lesion,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Multimorbidity,1,45,0.000,0.000,31.89,1.000,1.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Tuberculosis,1,45,32.883,32.883,14.99,1.000,1.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Malignant neoplasm progression,2,45,0.095,0.095,16.54,1.000,1.000,1.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Bortezomib,Hydrocele,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Amoebic colitis,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Balanoposthitis,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Tongue blistering,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Pneumonia streptococcal,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Pancreatic mass,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Blood stem cell harvest failure,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Refractory cytopenia with unilineage dysplasia,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Cerebellar syndrome,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Gastrointestinal obstruction,2,45,32.902,32.902,29.98,1.000,1.000,0.500,10.233,χ²=30.0 (统计显著); 罕见+严重
Bortezomib,Mitral valve stenosis,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Limb amputation,1,45,0.000,0.000,31.89,1.000,1.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Neurogenic bladder,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Hypertonia,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Hypercoagulation,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Periorbital cellulitis,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Blast cells present,1,45,32.883,32.883,14.99,1.000,1.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Tooth injury,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Blood lactate dehydrogenase abnormal,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Aspartate aminotransferase abnormal,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Polyp,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Respiratory syncytial virus test positive,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Hyperviscosity syndrome,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,B-cell type acute leukaemia,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Transplant,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Mononeuropathy multiplex,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Anaesthesia,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Disorder of orbit,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Acute polyneuropathy,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Enterobacter infection,1,45,32.883,32.883,14.99,1.000,1.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Inflammatory bowel disease,1,45,0.000,0.000,31.89,1.000,1.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Emergency care,2,45,0.000,0.000,63.79,1.000,0.000,0.000,10.233,χ²=63.8 (统计显著); 罕见+严重
Bortezomib,Dysentery,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Echocardiogram abnormal,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Sudden onset of sleep,1,45,0.000,0.000,31.89,1.000,0.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Sinus node dysfunction,1,45,0.000,0.000,31.89,1.000,1.000,1.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Myelitis transverse,1,45,32.883,32.883,14.99,1.000,0.000,0.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Aortic valve disease,1,45,32.883,32.883,14.99,1.000,0.000,1.000,10.926,χ²=15.0 (统计显著); 罕见+严重
Bortezomib,Mesothelioma,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Light chain analysis abnormal,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Bortezomib,Papillary thyroid cancer,2,45,65.806,65.806,41.24,1.000,0.000,1.000,10.233,χ²=41.2 (统计显著); 罕见+严重
Bortezomib,Cytomegalovirus chorioretinitis,2,45,65.806,65.806,41.24,1.000,0.000,0.000,10.233,χ²=41.2 (统计显著); 罕见+严重
Bortezomib,Autonomic neuropathy,1,45,0.000,0.000,31.89,1.000,0.000,0.000,10.926,χ²=31.9 (统计显著); 罕见+严重
Carfilzomib,Drug reaction with eosinophilia and systemic symptoms,2,45,15.824,15.824,20.36,1.000,0.000,1.000,10.233,χ²=20.4 (统计显著); 罕见+严重
Carfilzomib,Corona virus infection,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Stevens-Johnson syndrome,2,45,7.911,7.911,10.12,1.000,0.000,1.000,10.233,χ²=10.1 (统计显著); 罕见+严重
Carfilzomib,Hypersensitivity,5,45,1.684,1.684,1.30,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Carfilzomib,Hepatitis B reactivation,1,45,47.434,47.434,22.24,1.000,1.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Erysipelas,2,45,10.548,10.548,13.82,1.000,0.000,1.000,10.233,χ²=13.8 (统计显著); 罕见+严重
Carfilzomib,Phlebitis infective,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Lower respiratory tract inflammation,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Salmonellosis,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Restrictive cardiomyopathy,2,45,31.649,31.649,34.82,1.000,0.000,0.500,10.233,χ²=34.8 (统计显著); 罕见+严重
Carfilzomib,Arthritis reactive,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Pneumonia fungal,2,45,7.911,7.911,10.12,1.000,1.000,0.500,10.233,χ²=10.1 (统计显著); 罕见+严重
Carfilzomib,Hepatitis toxic,1,45,47.434,47.434,22.24,1.000,0.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Neutrophil count decreased,5,45,1.474,1.474,0.72,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Carfilzomib,Pancreatic disorder,1,45,47.434,47.434,22.24,1.000,0.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Pulmonary congestion,2,45,18.989,18.989,23.80,1.000,0.000,1.000,10.233,χ²=23.8 (统计显著); 罕见+严重
Carfilzomib,Febrile infection,1,45,47.434,47.434,22.24,1.000,0.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Sputum increased,1,45,0.000,0.000,46.41,1.000,1.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Rectal adenocarcinoma,2,45,11.867,11.867,15.56,1.000,0.000,1.000,10.233,χ²=15.6 (统计显著); 罕见+严重
Carfilzomib,Pyelonephritis chronic,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Congestive cardiomyopathy,2,45,18.989,18.989,23.80,1.000,0.000,0.000,10.233,χ²=23.8 (统计显著); 罕见+严重
Carfilzomib,Faecal incontinence,2,45,11.867,11.867,15.56,1.000,0.500,0.500,10.233,χ²=15.6 (统计显著); 罕见+严重
Carfilzomib,Apnoea,1,45,15.811,15.811,10.18,1.000,0.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Nephropathy,1,45,15.811,15.811,10.18,1.000,1.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Therapeutic product ineffective for unapproved indication,1,45,0.000,0.000,46.41,1.000,0.000,0.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Parainfluenzae virus infection,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Infusion site pain,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Atrioventricular block complete,1,45,15.811,15.811,10.18,1.000,0.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Metapneumovirus infection,1,45,23.716,23.716,14.19,1.000,1.000,1.000,10.926,χ²=14.2 (统计显著); 罕见+严重
Carfilzomib,Listeriosis,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Fibrosis,1,45,0.000,0.000,46.41,1.000,1.000,0.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Nocardiosis,2,45,0.000,0.000,92.83,1.000,1.000,0.000,10.233,χ²=92.8 (统计显著); 罕见+严重
Carfilzomib,Adenocarcinoma gastric,1,45,47.434,47.434,22.24,1.000,0.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Venous thrombosis limb,1,45,15.811,15.811,10.18,1.000,0.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Carotid artery aneurysm,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Ophthalmoplegia,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Hypoxic-ischaemic encephalopathy,2,45,94.950,94.950,60.59,1.000,0.500,1.000,10.233,χ²=60.6 (统计显著); 罕见+严重
Carfilzomib,Dialysis related complication,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Localised oedema,1,45,15.811,15.811,10.18,1.000,0.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Jugular vein thrombosis,2,45,23.736,23.736,28.39,1.000,0.000,1.000,10.233,χ²=28.4 (统计显著); 罕见+严重
Carfilzomib,Acute interstitial pneumonitis,1,45,23.716,23.716,14.19,1.000,0.000,1.000,10.926,χ²=14.2 (统计显著); 罕见+严重
Carfilzomib,Invasive lobular breast carcinoma,1,45,47.434,47.434,22.24,1.000,0.000,0.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Vena cava thrombosis,1,45,15.811,15.811,10.18,1.000,0.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Subclavian vein thrombosis,1,45,15.811,15.811,10.18,1.000,0.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Device malfunction,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Rectal cancer stage II,2,45,0.000,0.000,92.83,1.000,0.000,0.000,10.233,χ²=92.8 (统计显著); 罕见+严重
Carfilzomib,Naevus haemorrhage,1,45,0.000,0.000,46.41,1.000,0.000,0.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Cardiac amyloidosis,2,45,0.000,0.000,92.83,1.000,0.000,1.000,10.233,χ²=92.8 (统计显著); 罕见+严重
Carfilzomib,Tachyarrhythmia,1,45,23.716,23.716,14.19,1.000,0.000,1.000,10.926,χ²=14.2 (统计显著); 罕见+严重
Carfilzomib,Porokeratosis,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Incision site cellulitis,1,45,23.716,23.716,14.19,1.000,0.000,1.000,10.926,χ²=14.2 (统计显著); 罕见+严重
Carfilzomib,Human metapneumovirus test positive,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Fluid overload,2,45,13.563,13.563,17.69,1.000,0.000,1.000,10.233,χ²=17.7 (统计显著); 罕见+严重
Carfilzomib,Bundle branch block right,1,45,23.716,23.716,14.19,1.000,0.000,1.000,10.926,χ²=14.2 (统计显著); 罕见+严重
Carfilzomib,Bile duct stone,2,45,94.950,94.950,60.59,1.000,0.000,1.000,10.233,χ²=60.6 (统计显著); 罕见+严重
Carfilzomib,Diastolic dysfunction,1,45,15.811,15.811,10.18,1.000,1.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Respiratory arrest,2,45,13.563,13.563,17.69,1.000,1.000,1.000,10.233,χ²=17.7 (统计显著); 罕见+严重
Carfilzomib,Meningoencephalitis herpetic,1,45,0.000,0.000,46.41,1.000,1.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Parkinson^s disease,1,45,15.811,15.811,10.18,1.000,0.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Ear discomfort,1,45,47.434,47.434,22.24,1.000,0.000,0.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Kidney fibrosis,1,45,47.434,47.434,22.24,1.000,1.000,0.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Renal artery thrombosis,1,45,0.000,0.000,46.41,1.000,1.000,0.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Glomerulosclerosis,1,45,0.000,0.000,46.41,1.000,1.000,0.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Renal tubular atrophy,1,45,0.000,0.000,46.41,1.000,1.000,0.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Thrombophlebitis superficial,2,45,0.000,0.000,92.83,1.000,0.500,0.500,10.233,χ²=92.8 (统计显著); 罕见+严重
Carfilzomib,Blood immunoglobulin G increased,1,45,23.716,23.716,14.19,1.000,0.000,0.000,10.926,χ²=14.2 (统计显著); 罕见+严重
Carfilzomib,Retinal vein occlusion,2,45,47.474,47.474,44.48,1.000,0.000,0.000,10.233,χ²=44.5 (统计显著); 罕见+严重
Carfilzomib,Multiple fractures,1,45,23.716,23.716,14.19,1.000,1.000,1.000,10.926,χ²=14.2 (统计显著); 罕见+严重
Carfilzomib,Neuritis,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Radiculitis lumbosacral,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Oedema genital,1,45,47.434,47.434,22.24,1.000,0.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Cellulitis of male external genital organ,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Acute pulmonary oedema,2,45,8.630,8.630,11.16,1.000,0.500,1.000,10.233,χ²=11.2 (统计显著); 罕见+严重
Carfilzomib,Haemodynamic instability,1,45,47.434,47.434,22.24,1.000,1.000,0.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Refractory anaemia with an excess of blasts,1,45,47.434,47.434,22.24,1.000,0.000,0.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Atrial tachycardia,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,B precursor type acute leukaemia,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Intracardiac thrombus,3,45,0.000,0.000,139.24,1.000,0.000,0.000,9.827,χ²=139.2 (统计显著); 罕见+严重
Carfilzomib,Respiratory syncytial virus infection,1,45,15.811,15.811,10.18,1.000,0.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Hyperviscosity syndrome,1,45,47.434,47.434,22.24,1.000,0.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Pulseless electrical activity,2,45,31.649,31.649,34.82,1.000,0.500,1.000,10.233,χ²=34.8 (统计显著); 罕见+严重
Carfilzomib,Glomerulonephropathy,1,45,0.000,0.000,46.41,1.000,1.000,0.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Carfilzomib,Shock haemorrhagic,1,45,15.811,15.811,10.18,1.000,1.000,1.000,10.926,χ²=10.2 (统计显著); 罕见+严重
Carfilzomib,Splenic rupture,1,45,47.434,47.434,22.24,1.000,1.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Mucosal infection,1,45,47.434,47.434,22.24,1.000,0.000,1.000,10.926,χ²=22.2 (统计显著); 罕见+严重
Carfilzomib,Diverticulitis intestinal haemorrhagic,1,45,0.000,0.000,46.41,1.000,0.000,1.000,10.926,χ²=46.4 (统计显著); 罕见+严重
Venetoclax,Abdominal adhesions,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Neutropenic infection,1,45,19.807,19.807,11.60,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Hepatic steatosis,2,45,8.808,8.808,11.03,1.000,0.000,1.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Venetoclax,Herpes simplex pneumonia,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Enterovirus infection,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Rhinovirus infection,2,45,19.821,19.821,23.21,1.000,0.000,1.000,10.233,χ²=23.2 (统计显著); 罕见+严重
Venetoclax,Pneumonia respiratory syncytial viral,2,45,79.288,79.288,50.19,1.000,0.000,1.000,10.233,χ²=50.2 (统计显著); 罕见+严重
Venetoclax,Candida pneumonia,1,45,0.000,0.000,38.61,1.000,1.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Cytomegalovirus oesophagitis,2,45,0.000,0.000,77.22,1.000,1.000,1.000,10.233,χ²=77.2 (统计显著); 罕见+严重
Venetoclax,Febrile bone marrow aplasia,2,45,13.213,13.213,16.49,1.000,0.000,1.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Venetoclax,Catheterisation cardiac,1,45,39.615,39.615,18.34,1.000,0.000,0.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Biliary adenoma,1,45,0.000,0.000,38.61,1.000,0.000,0.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Kidney angiomyolipoma,1,45,0.000,0.000,38.61,1.000,0.000,0.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Stasis dermatitis,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Guillain-Barre syndrome,2,45,11.326,11.326,14.26,1.000,1.000,1.000,10.233,χ²=14.3 (统计显著); 罕见+严重
Venetoclax,Appendicitis,2,45,13.213,13.213,16.49,1.000,0.000,1.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Venetoclax,Peritoneal tuberculosis,2,45,0.000,0.000,77.22,1.000,0.000,1.000,10.233,χ²=77.2 (统计显著); 罕见+严重
Venetoclax,Colitis ulcerative,2,45,13.213,13.213,16.49,1.000,0.000,1.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Venetoclax,Acute sinusitis,2,45,39.643,39.643,36.69,1.000,0.000,1.000,10.233,χ²=36.7 (统计显著); 罕见+严重
Venetoclax,Prothrombin time prolonged,1,45,19.807,19.807,11.60,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Sinus bradycardia,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Oral infection,1,45,19.807,19.807,11.60,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Infective exacerbation of bronchiectasis,1,45,0.000,0.000,38.61,1.000,1.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Enterococcal bacteraemia,1,45,39.615,39.615,18.34,1.000,1.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Pneumonia pseudomonal,2,45,39.643,39.643,36.69,1.000,1.000,1.000,10.233,χ²=36.7 (统计显著); 罕见+严重
Venetoclax,Coeliac artery stenosis,1,45,19.807,19.807,11.60,1.000,1.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Splenic infarction,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Candida test positive,1,45,39.615,39.615,18.34,1.000,1.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Blood lactic acid increased,1,45,39.615,39.615,18.34,1.000,1.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Bone marrow necrosis,1,45,39.615,39.615,18.34,1.000,1.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Transfusion reaction,2,45,39.643,39.643,36.69,1.000,0.500,0.500,10.233,χ²=36.7 (统计显著); 罕见+严重
Venetoclax,Septic arthritis staphylococcal,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Enzyme level abnormal,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Lumbar spinal stenosis,2,45,79.288,79.288,50.19,1.000,0.000,1.000,10.233,χ²=50.2 (统计显著); 罕见+严重
Venetoclax,Acute left ventricular failure,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Hyperphosphataemia,2,45,39.643,39.643,36.69,1.000,0.000,0.500,10.233,χ²=36.7 (统计显著); 罕见+严重
Venetoclax,Jugular vein distension,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Bundle branch block left,1,45,19.807,19.807,11.60,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Conduction disorder,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Bacterial sepsis,2,45,13.213,13.213,16.49,1.000,1.000,1.000,10.233,χ²=16.5 (统计显著); 罕见+严重
Venetoclax,Urinary tract infection pseudomonal,1,45,19.807,19.807,11.60,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Red blood cell count decreased,6,45,1.904,1.904,2.38,0.833,0.000,0.333,9.134,严重事件率=83.3%; 罕见+严重
Venetoclax,Abdominal lymphadenopathy,2,45,79.288,79.288,50.19,1.000,0.000,0.500,10.233,χ²=50.2 (统计显著); 罕见+严重
Venetoclax,Aspergillus infection,2,45,15.856,15.856,19.36,1.000,0.500,0.500,10.233,χ²=19.4 (统计显著); 罕见+严重
Venetoclax,Respiratory tract infection fungal,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Weight decreased,5,45,0.727,0.727,0.49,0.600,0.000,0.200,9.317,严重事件率=60.0%; 罕见+严重
Venetoclax,Pulmonary mycosis,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Campylobacter gastroenteritis,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Stridor,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Pneumonia necrotising,1,45,19.807,19.807,11.60,1.000,1.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Renal vein compression,1,45,0.000,0.000,38.61,1.000,1.000,0.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Obliterative bronchiolitis,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Gilbert^s syndrome,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Prostatic disorder,1,45,19.807,19.807,11.60,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Urine flow decreased,1,45,0.000,0.000,38.61,1.000,0.000,0.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Richter^s syndrome,2,45,79.288,79.288,50.19,1.000,0.500,1.000,10.233,χ²=50.2 (统计显著); 罕见+严重
Venetoclax,Cryptococcosis,1,45,39.615,39.615,18.34,1.000,1.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Subretinal fluid,2,45,0.000,0.000,77.22,1.000,0.500,1.000,10.233,χ²=77.2 (统计显著); 罕见+严重
Venetoclax,Retinal disorder,1,45,0.000,0.000,38.61,1.000,1.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Retinopathy,2,45,9.910,9.910,12.48,1.000,0.500,1.000,10.233,χ²=12.5 (统计显著); 罕见+严重
Venetoclax,Small cell carcinoma,1,45,0.000,0.000,38.61,1.000,1.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Corynebacterium sepsis,1,45,39.615,39.615,18.34,1.000,1.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,H1N1 influenza,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Ear discomfort,1,45,39.615,39.615,18.34,1.000,0.000,0.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Viral myocarditis,1,45,0.000,0.000,38.61,1.000,0.000,0.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Cytokine storm,2,45,79.288,79.288,50.19,1.000,0.000,1.000,10.233,χ²=50.2 (统计显著); 罕见+严重
Venetoclax,Chronic lymphocytic leukaemia transformation,1,45,19.807,19.807,11.60,1.000,1.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Metabolic encephalopathy,1,45,19.807,19.807,11.60,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Fluid replacement,2,45,39.643,39.643,36.69,1.000,0.000,0.000,10.233,χ²=36.7 (统计显著); 罕见+严重
Venetoclax,Catheter site cellulitis,1,45,39.615,39.615,18.34,1.000,1.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Klebsiella sepsis,2,45,39.643,39.643,36.69,1.000,0.500,1.000,10.233,χ²=36.7 (统计显著); 罕见+严重
Venetoclax,Lymphocytic leukaemia,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Diabetes mellitus inadequate control,2,45,11.326,11.326,14.26,1.000,0.000,1.000,10.233,χ²=14.3 (统计显著); 罕见+严重
Venetoclax,Escherichia pyelonephritis,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Myocardial necrosis marker increased,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Red blood cell count increased,1,45,19.807,19.807,11.60,1.000,0.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Pulmonary granuloma,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Obstruction,1,45,19.807,19.807,11.60,1.000,1.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Rehabilitation therapy,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Large intestine polyp,2,45,26.428,26.428,28.59,1.000,0.000,1.000,10.233,χ²=28.6 (统计显著); 罕见+严重
Venetoclax,Oesophageal polyp,1,45,0.000,0.000,38.61,1.000,1.000,0.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Oesophageal carcinoma,1,45,19.807,19.807,11.60,1.000,1.000,0.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Bladder obstruction,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Escherichia sepsis,2,45,39.643,39.643,36.69,1.000,0.000,1.000,10.233,χ²=36.7 (统计显著); 罕见+严重
Venetoclax,Tibia fracture,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Spleen disorder,1,45,19.807,19.807,11.60,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Blood bilirubin decreased,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Coronary artery disease,2,45,8.808,8.808,11.03,1.000,0.000,1.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Venetoclax,Blood lactate dehydrogenase decreased,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Haemolysis,2,45,19.821,19.821,23.21,1.000,0.000,1.000,10.233,χ²=23.2 (统计显著); 罕见+严重
Venetoclax,Atrophy,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Wheelchair user,1,45,0.000,0.000,38.61,1.000,0.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Cholecystectomy,1,45,39.615,39.615,18.34,1.000,0.000,1.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,T-cell lymphoma,2,45,39.643,39.643,36.69,1.000,1.000,1.000,10.233,χ²=36.7 (统计显著); 罕见+严重
Venetoclax,Wound evisceration,2,45,0.000,0.000,77.22,1.000,1.000,1.000,10.233,χ²=77.2 (统计显著); 罕见+严重
Venetoclax,Spinal operation,1,45,0.000,0.000,38.61,1.000,1.000,1.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Haemorrhage urinary tract,1,45,19.807,19.807,11.60,1.000,0.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Bone marrow tumour cell infiltration,1,45,0.000,0.000,38.61,1.000,0.000,0.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Venetoclax,Liver abscess,1,45,19.807,19.807,11.60,1.000,1.000,1.000,10.926,χ²=11.6 (统计显著); 罕见+严重
Venetoclax,Haematocrit abnormal,1,45,39.615,39.615,18.34,1.000,0.000,0.000,10.926,χ²=18.3 (统计显著); 罕见+严重
Venetoclax,Immunoglobulin therapy,1,45,0.000,0.000,38.61,1.000,0.000,0.000,10.926,χ²=38.6 (统计显著); 罕见+严重
Ibrutinib,Traumatic haematoma,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Polyomavirus test positive,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Renal haemorrhage,2,45,66.601,66.601,41.77,1.000,0.000,1.000,10.233,χ²=41.8 (统计显著); 罕见+严重
Ibrutinib,Tongue ulceration,2,45,33.300,33.300,30.38,1.000,0.000,1.000,10.233,χ²=30.4 (统计显著); 罕见+严重
Ibrutinib,Metabolic encephalopathy,2,45,66.601,66.601,41.77,1.000,0.500,1.000,10.233,χ²=41.8 (统计显著); 罕见+严重
Ibrutinib,Haemothorax,3,45,0.000,0.000,96.87,1.000,0.000,0.333,9.827,χ²=96.9 (统计显著); 罕见+严重
Ibrutinib,Vascular injury,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Epigastric discomfort,2,45,22.199,22.199,23.55,1.000,0.000,1.000,10.233,χ²=23.6 (统计显著); 罕见+严重
Ibrutinib,Diverticulum,2,45,9.513,9.513,11.49,1.000,0.500,1.000,10.233,χ²=11.5 (统计显著); 罕见+严重
Ibrutinib,Renal cyst,2,45,9.513,9.513,11.49,1.000,0.000,1.000,10.233,χ²=11.5 (统计显著); 罕见+严重
Ibrutinib,Embolic cerebral infarction,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Cardiac valve vegetation,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Aortic intramural haematoma,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Cardiac death,1,45,0.000,0.000,32.29,1.000,1.000,0.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Post procedural haematuria,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Supportive care,1,45,0.000,0.000,32.29,1.000,1.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Aspergillus infection,2,45,13.319,13.319,15.78,1.000,1.000,1.000,10.233,χ²=15.8 (统计显著); 罕见+严重
Ibrutinib,Splenic rupture,1,45,33.280,33.280,15.19,1.000,1.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Meningioma,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Hyphaema,1,45,33.280,33.280,15.19,1.000,0.000,0.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Nasopharyngeal cancer,1,45,0.000,0.000,32.29,1.000,1.000,0.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Drug reaction with eosinophilia and systemic symptoms,2,45,11.099,11.099,13.36,1.000,0.000,1.000,10.233,χ²=13.4 (统计显著); 罕见+严重
Ibrutinib,Device dislocation,1,45,33.280,33.280,15.19,1.000,0.000,0.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Arterial occlusive disease,1,45,33.280,33.280,15.19,1.000,1.000,0.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Synovial cyst,1,45,0.000,0.000,32.29,1.000,0.000,0.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Ischaemic cardiomyopathy,2,45,16.649,16.649,19.02,1.000,0.500,0.000,10.233,χ²=19.0 (统计显著); 罕见+严重
Ibrutinib,Hypersensitivity pneumonitis,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,B-cell small lymphocytic lymphoma,1,45,0.000,0.000,32.29,1.000,1.000,0.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Malignant neoplasm progression,1,45,0.048,0.048,18.16,1.000,1.000,0.000,10.926,χ²=18.2 (统计显著); 罕见+严重
Ibrutinib,Monarthritis,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Traumatic intracranial haemorrhage,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Mallory-Weiss syndrome,2,45,22.199,22.199,23.55,1.000,0.000,1.000,10.233,χ²=23.6 (统计显著); 罕见+严重
Ibrutinib,Hepatitis toxic,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Atypical mycobacterial infection,1,45,0.000,0.000,32.29,1.000,0.000,0.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Muscle haemorrhage,2,45,66.601,66.601,41.77,1.000,0.000,1.000,10.233,χ²=41.8 (统计显著); 罕见+严重
Ibrutinib,Serum sickness,2,45,0.000,0.000,64.58,1.000,0.000,1.000,10.233,χ²=64.6 (统计显著); 罕见+严重
Ibrutinib,Retinal haemorrhage,2,45,13.319,13.319,15.78,1.000,0.000,0.000,10.233,χ²=15.8 (统计显著); 罕见+严重
Ibrutinib,Lymphoma transformation,1,45,0.000,0.000,32.29,1.000,1.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Ophthalmic herpes zoster,1,45,0.000,0.000,32.29,1.000,1.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Iron overload,2,45,0.000,0.000,64.58,1.000,0.500,1.000,10.233,χ²=64.6 (统计显著); 罕见+严重
Ibrutinib,Mucosal haemorrhage,1,45,33.280,33.280,15.19,1.000,1.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Haemorrhage subcutaneous,1,45,33.280,33.280,15.19,1.000,1.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Skin warm,1,45,33.280,33.280,15.19,1.000,0.000,0.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Coronary artery occlusion,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Meningism,2,45,0.000,0.000,64.58,1.000,0.000,1.000,10.233,χ²=64.6 (统计显著); 罕见+严重
Ibrutinib,Pneumonia pseudomonal,2,45,33.300,33.300,30.38,1.000,0.000,1.000,10.233,χ²=30.4 (统计显著); 罕见+严重
Ibrutinib,Bladder mass,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Lymphoma,2,45,11.099,11.099,13.36,0.500,0.000,0.000,10.233,χ²=13.4 (统计显著); 罕见+严重
Ibrutinib,Skin laceration,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Bronchitis viral,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Catheter site cellulitis,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Viral pharyngitis,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Post-traumatic pain,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Otitis externa,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Post procedural pulmonary embolism,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Chronic myelomonocytic leukaemia,2,45,0.000,0.000,64.58,1.000,1.000,1.000,10.233,χ²=64.6 (统计显著); 罕见+严重
Ibrutinib,Raynaud^s phenomenon,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Meningitis cryptococcal,1,45,0.000,0.000,32.29,1.000,1.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Mantle cell lymphoma,2,45,16.649,16.649,19.02,1.000,1.000,1.000,10.233,χ²=19.0 (统计显著); 罕见+严重
Ibrutinib,Macular degeneration,2,45,33.300,33.300,30.38,1.000,0.000,0.000,10.233,χ²=30.4 (统计显著); 罕见+严重
Ibrutinib,Temporal arteritis,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Peripheral artery bypass,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Off label use,1,45,0.077,0.077,10.69,1.000,0.000,1.000,10.926,χ²=10.7 (统计显著); 罕见+严重
Ibrutinib,Device loosening,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Extradural haematoma,1,45,0.000,0.000,32.29,1.000,0.000,0.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Prostatitis,1,45,33.280,33.280,15.19,1.000,0.000,0.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Neurosensory hypoacusis,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Muscular dystrophy,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Granulocytopenia,1,45,0.000,0.000,32.29,1.000,0.000,1.000,10.926,χ²=32.3 (统计显著); 罕见+严重
Ibrutinib,Abdominal abscess,1,45,33.280,33.280,15.19,1.000,0.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Chronic lymphocytic leukaemia transformation,2,45,66.601,66.601,41.77,1.000,1.000,1.000,10.233,χ²=41.8 (统计显著); 罕见+严重
Ibrutinib,Aortic aneurysm,1,45,33.280,33.280,15.19,1.000,1.000,1.000,10.926,χ²=15.2 (统计显著); 罕见+严重
Ibrutinib,Beta 2 microglobulin increased,2,45,0.000,0.000,64.58,1.000,0.000,0.000,10.233,χ²=64.6 (统计显著); 罕见+严重
Olaparib,Headache,16,45,1.399,1.399,1.65,0.625,0.062,0.125,8.153,严重事件率=62.5%; 罕见+严重
Olaparib,Dizziness,15,45,1.287,1.287,0.88,0.733,0.200,0.267,8.218,严重事件率=73.3%; 罕见+严重
Olaparib,Arthralgia,16,45,1.904,1.904,6.15,0.750,0.062,0.188,8.153,严重事件率=75.0%; 罕见+严重
Olaparib,Intestinal metastasis,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Dyspnoea,11,45,0.504,0.504,5.01,0.909,0.182,0.364,8.528,严重事件率=90.9%; 罕见+严重
Olaparib,Genital pain,1,45,29.055,29.055,13.09,1.000,1.000,1.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Constipation,15,45,1.063,1.063,0.05,0.533,0.133,0.400,8.218,严重事件率=53.3%; 罕见+严重
Olaparib,Post procedural fistula,1,45,29.055,29.055,13.09,1.000,0.000,1.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Malignant peritoneal neoplasm,1,45,0.000,0.000,28.07,1.000,1.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Dysgeusia,8,45,1.314,1.314,0.55,0.625,0.125,0.125,8.847,严重事件率=62.5%; 罕见+严重
Olaparib,Weight decreased,11,45,1.202,1.202,0.34,0.636,0.091,0.091,8.528,严重事件率=63.6%; 罕见+严重
Olaparib,Breast cancer stage IV,1,45,29.055,29.055,13.09,1.000,0.000,1.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Fallopian tube cancer,1,45,0.000,0.000,28.07,1.000,0.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Regurgitation,2,45,0.000,0.000,56.15,0.500,0.000,0.000,10.233,χ²=56.1 (统计显著); 罕见+严重
Olaparib,Painful respiration,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Drug dose omission,8,45,1.777,1.777,2.46,0.750,0.125,0.000,8.847,严重事件率=75.0%; 罕见+严重
Olaparib,Red blood cell count decreased,7,45,1.642,1.642,1.60,1.000,0.000,0.286,8.980,严重事件率=100.0%; 罕见+严重
Olaparib,Ovarian cancer stage IV,1,45,0.000,0.000,28.07,1.000,0.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,White blood cell count decreased,6,45,0.511,0.511,2.64,0.833,0.167,0.333,9.134,严重事件率=83.3%; 罕见+严重
Olaparib,Cough,11,45,1.356,1.356,0.94,0.545,0.091,0.364,8.528,严重事件率=54.5%; 罕见+严重
Olaparib,Thrombocytopenia,13,45,0.829,0.829,0.43,0.846,0.077,0.385,8.361,严重事件率=84.6%; 罕见+严重
Olaparib,Platelet count decreased,11,45,0.765,0.765,0.74,0.818,0.091,0.364,8.528,严重事件率=81.8%; 罕见+严重
Olaparib,Back pain,13,45,1.632,1.632,2.88,0.692,0.077,0.231,8.361,严重事件率=69.2%; 罕见+严重
Olaparib,Peritonitis bacterial,2,45,58.142,58.142,36.15,1.000,1.000,0.000,10.233,χ²=36.2 (统计显著); 罕见+严重
Olaparib,Metastases to central nervous system,7,45,1.921,1.921,2.79,1.000,0.143,0.143,8.980,严重事件率=100.0%; 罕见+严重
Olaparib,Drug ineffective for unapproved indication,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Frustration,1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Blood electrolytes decreased,1,45,0.000,0.000,28.07,1.000,0.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Neuropathy peripheral,12,45,1.617,1.617,2.56,0.667,0.083,0.333,8.441,严重事件率=66.7%; 罕见+严重
Olaparib,Paraesthesia,5,45,1.939,1.939,2.05,0.600,0.000,0.400,9.317,严重事件率=60.0%; 罕见+严重
Olaparib,Bone pain,5,45,1.795,1.795,1.60,0.800,0.200,0.200,9.317,严重事件率=80.0%; 罕见+严重
Olaparib,Vulvitis,1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Biliary dilatation,1,45,0.000,0.000,28.07,1.000,1.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Blood lactic acid increased,1,45,29.055,29.055,13.09,1.000,1.000,1.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Vascular calcification,1,45,29.055,29.055,13.09,1.000,1.000,1.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Confusional state,5,45,0.974,0.974,0.00,0.800,0.200,0.200,9.317,严重事件率=80.0%; 罕见+严重
Olaparib,Varicose vein,1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Abdominal infection,2,45,19.380,19.380,20.20,1.000,0.000,0.500,10.233,χ²=20.2 (统计显著); 罕见+严重
Olaparib,Subileus,2,45,11.627,11.627,13.40,1.000,0.500,0.500,10.233,χ²=13.4 (统计显著); 罕见+严重
Olaparib,Pelvic cyst,1,45,29.055,29.055,13.09,1.000,0.000,1.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Coombs positive haemolytic anaemia,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Bile duct obstruction,2,45,11.627,11.627,13.40,1.000,0.500,0.000,10.233,χ²=13.4 (统计显著); 罕见+严重
Olaparib,Hepatic cancer,1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Drug specific antibody present,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Large intestinal stenosis,1,45,0.000,0.000,28.07,1.000,0.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Histiocytosis haematophagic,2,45,9.689,9.689,11.29,1.000,0.000,0.500,10.233,χ²=11.3 (统计显著); 罕见+严重
Olaparib,Terminal insomnia,1,45,0.000,0.000,28.07,1.000,0.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Bipolar disorder,1,45,29.055,29.055,13.09,1.000,0.000,1.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Erythroblastosis,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Myelocytosis,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Malignant bowel obstruction,1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Prostate cancer metastatic,2,45,14.535,14.535,16.23,1.000,0.500,1.000,10.233,χ²=16.2 (统计显著); 罕见+严重
Olaparib,Diastasis recti abdominis,1,45,0.000,0.000,28.07,1.000,1.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Bacillus bacteraemia,1,45,0.000,0.000,28.07,1.000,0.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Tearfulness,1,45,0.000,0.000,28.07,1.000,1.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Peritoneal carcinoma metastatic,1,45,0.000,0.000,28.07,1.000,1.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Anxiety disorder,1,45,0.000,0.000,28.07,1.000,1.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Breast oedema,1,45,0.000,0.000,28.07,1.000,0.000,1.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,"Sleep disorder due to general medical condition, insomnia type",1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Aplasia pure red cell,1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Suprapubic pain,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Eyelid ptosis,1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Olaparib,Strabismus,1,45,0.000,0.000,28.07,1.000,0.000,0.000,10.926,χ²=28.1 (统计显著); 罕见+严重
Olaparib,Spinal column stenosis,1,45,29.055,29.055,13.09,1.000,0.000,0.000,10.926,χ²=13.1 (统计显著); 罕见+严重
Rucaparib,Pelvic mass,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Febrile neutropenia,2,45,0.081,0.081,19.60,1.000,0.000,1.000,10.233,χ²=19.6 (统计显著); 罕见+严重
Rucaparib,Colostomy closure,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Nasopharyngitis,6,45,1.472,1.472,0.80,0.833,0.000,0.167,9.134,严重事件率=83.3%; 罕见+严重
Rucaparib,Pain,16,45,1.094,1.094,0.12,0.625,0.000,0.375,8.153,严重事件率=62.5%; 罕见+严重
Rucaparib,Neuropathy peripheral,17,45,1.584,1.584,3.19,0.529,0.000,0.235,8.093,严重事件率=52.9%; 罕见+严重
Rucaparib,Catheter management,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Thrombocytopenia,14,45,0.603,0.603,3.33,0.929,0.000,0.357,8.287,严重事件率=92.9%; 罕见+严重
Rucaparib,Aspartate aminotransferase increased,12,45,1.473,1.473,1.60,0.667,0.000,0.250,8.441,严重事件率=66.7%; 罕见+严重
Rucaparib,Peripheral swelling,7,45,1.135,1.135,0.10,0.714,0.143,0.286,8.980,严重事件率=71.4%; 罕见+严重
Rucaparib,Electrolyte substitution therapy,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Alopecia,10,45,1.168,1.168,0.22,0.700,0.000,0.400,8.623,严重事件率=70.0%; 罕见+严重
Rucaparib,Parosmia,2,45,39.262,39.262,23.63,0.500,0.000,0.500,10.233,χ²=23.6 (统计显著); 罕见+严重
Rucaparib,Prescribed overdose,2,45,39.262,39.262,23.63,0.500,0.500,0.500,10.233,χ²=23.6 (统计显著); 罕见+严重
Rucaparib,Wound haemorrhage,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Feeling of body temperature change,2,45,0.000,0.000,37.33,1.000,0.000,1.000,10.233,χ²=37.3 (统计显著); 罕见+严重
Rucaparib,Medication residue present,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Arthralgia,15,45,1.197,1.197,0.43,0.667,0.000,0.333,8.218,严重事件率=66.7%; 罕见+严重
Rucaparib,Paracentesis,2,45,0.000,0.000,37.33,0.500,0.000,0.000,10.233,χ²=37.3 (统计显著); 罕见+严重
Rucaparib,Neutrophil percentage decreased,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,High density lipoprotein decreased,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Monocyte percentage increased,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Tremor,5,45,1.422,1.422,0.55,0.600,0.000,0.200,9.317,严重事件率=60.0%; 罕见+严重
Rucaparib,Pyrexia,6,45,0.144,0.144,28.39,0.333,0.000,0.333,9.134,χ²=28.4 (统计显著); 罕见+严重
Rucaparib,Urinary tract infection,15,45,1.594,1.594,2.89,0.600,0.000,0.267,8.218,严重事件率=60.0%; 罕见+严重
Rucaparib,Drug intolerance,6,45,1.510,1.510,0.91,0.667,0.000,0.167,9.134,严重事件率=66.7%; 罕见+严重
Rucaparib,Influenza virus test positive,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Disease progression,2,45,0.046,0.046,37.23,0.500,0.000,0.500,10.233,χ²=37.2 (统计显著); 罕见+严重
Rucaparib,Thyroid hormones decreased,2,45,0.000,0.000,37.33,1.000,0.000,0.000,10.233,χ²=37.3 (统计显著); 罕见+严重
Rucaparib,Oropharyngeal discomfort,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Lymph node abscess,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Renal mass,1,45,0.000,0.000,18.67,1.000,1.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Colostomy,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Stoma site haemorrhage,2,45,19.631,19.631,16.81,1.000,0.000,1.000,10.233,χ²=16.8 (统计显著); 罕见+严重
Rucaparib,Biliary tract operation,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Pharyngeal abscess,2,45,0.000,0.000,37.33,1.000,0.000,0.500,10.233,χ²=37.3 (统计显著); 罕见+严重
Rucaparib,Oral mucosal exfoliation,2,45,39.262,39.262,23.63,0.500,0.000,0.500,10.233,χ²=23.6 (统计显著); 罕见+严重
Rucaparib,Pelvic discomfort,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Colon operation,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Vaginal neoplasm,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Rash vesicular,2,45,13.087,13.087,12.74,0.500,0.500,0.500,10.233,χ²=12.7 (统计显著); 罕见+严重
Rucaparib,Ureteral stent insertion,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Solar dermatitis,2,45,19.631,19.631,16.81,0.500,0.000,0.000,10.233,χ²=16.8 (统计显著); 罕见+严重
Rucaparib,Radiation associated pain,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Therapy partial responder,1,45,0.000,0.000,18.67,1.000,0.000,1.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Rucaparib,Endoscopy gastrointestinal,1,45,0.000,0.000,18.67,1.000,0.000,0.000,10.926,χ²=18.7 (统计显著); 罕见+严重
Niraparib,Renal impairment,12,45,1.941,1.941,4.62,1.000,0.000,0.333,8.441,严重事件率=100.0%; 罕见+严重
Niraparib,Faeces hard,2,45,17.123,17.123,14.33,0.500,0.000,0.000,10.233,χ²=14.3 (统计显著); 罕见+严重
Niraparib,Pain in extremity,16,45,1.413,1.413,1.67,0.938,0.000,0.312,8.153,严重事件率=93.8%; 罕见+严重
Niraparib,Malignant neoplasm progression,2,45,0.049,0.049,34.15,1.000,0.000,0.000,10.233,χ²=34.1 (统计显著); 罕见+严重
Niraparib,Confusional state,16,45,1.989,1.989,6.61,1.000,0.062,0.375,8.153,严重事件率=100.0%; 罕见+严重
Niraparib,"Hallucination, visual",2,45,11.415,11.415,10.77,1.000,0.000,1.000,10.233,χ²=10.8 (统计显著); 罕见+严重
Niraparib,Back pain,15,45,1.117,1.117,0.16,0.733,0.000,0.400,8.218,严重事件率=73.3%; 罕见+严重
Niraparib,Dysgeusia,11,45,1.082,1.082,0.06,0.727,0.091,0.364,8.528,严重事件率=72.7%; 罕见+严重
Niraparib,Deposit eye,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Chest discomfort,7,45,1.577,1.577,1.28,0.857,0.000,0.286,8.980,严重事件率=85.7%; 罕见+严重
Niraparib,Oral pruritus,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Hyperhidrosis,7,45,1.874,1.874,2.42,0.857,0.000,0.143,8.980,严重事件率=85.7%; 罕见+严重
Niraparib,Neuropathy peripheral,14,45,1.120,1.120,0.16,0.714,0.143,0.286,8.287,严重事件率=71.4%; 罕见+严重
Niraparib,Drug ineffective,15,45,1.007,1.007,0.00,0.800,0.000,0.400,8.218,严重事件率=80.0%; 罕见+严重
Niraparib,Catheter site haemorrhage,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Blood urea abnormal,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Peripheral swelling,8,45,1.141,1.141,0.12,1.000,0.000,0.250,8.847,严重事件率=100.0%; 罕见+严重
Niraparib,Genito-pelvic pain/penetration disorder,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Alopecia,8,45,0.805,0.805,0.34,0.750,0.000,0.375,8.847,严重事件率=75.0%; 罕见+严重
Niraparib,Gastrointestinal stoma output abnormal,1,45,0.000,0.000,16.17,1.000,1.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Throat lesion,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Postoperative hernia,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Mean cell haemoglobin increased,2,45,34.246,34.246,20.32,1.000,0.000,0.500,10.233,χ²=20.3 (统计显著); 罕见+严重
Niraparib,Eating disorder symptom,2,45,0.000,0.000,32.33,1.000,0.000,1.000,10.233,χ²=32.3 (统计显著); 罕见+严重
Niraparib,Carotid artery insufficiency,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Back disorder,2,45,34.246,34.246,20.32,0.500,0.000,0.000,10.233,χ²=20.3 (统计显著); 罕见+严重
Niraparib,Refractoriness to platelet transfusion,1,45,0.000,0.000,16.17,1.000,1.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Rotator cuff syndrome,2,45,17.123,17.123,14.33,0.500,0.000,0.500,10.233,χ²=14.3 (统计显著); 罕见+严重
Niraparib,Muscle disorder,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Dissociation,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Pruritus,11,45,0.743,0.743,0.88,0.818,0.000,0.364,8.528,严重事件率=81.8%; 罕见+严重
Niraparib,Lymphocyte percentage increased,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Intensive care,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Pain,16,45,0.954,0.954,0.03,0.750,0.062,0.312,8.153,严重事件率=75.0%; 罕见+严重
Niraparib,Erythema,5,45,0.527,0.527,1.93,1.000,0.000,0.000,9.317,严重事件率=100.0%; 罕见+严重
Niraparib,Haematocrit,1,45,0.000,0.000,16.17,1.000,1.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Bone pain,5,45,1.056,1.056,0.01,0.800,0.200,0.200,9.317,严重事件率=80.0%; 罕见+严重
Niraparib,Intraocular pressure increased,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Muscle spasms,5,45,0.619,0.619,1.06,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Niraparib,Arthralgia,13,45,0.897,0.897,0.14,0.846,0.000,0.308,8.361,严重事件率=84.6%; 罕见+严重
Niraparib,Hip arthroplasty,2,45,34.246,34.246,20.32,1.000,0.000,0.500,10.233,χ²=20.3 (统计显著); 罕见+严重
Niraparib,Weight abnormal,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Aphthous ulcer,2,45,11.415,11.415,10.77,0.500,0.000,0.500,10.233,χ²=10.8 (统计显著); 罕见+严重
Niraparib,Glomerular filtration rate abnormal,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Renal neoplasm,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Judgement impaired,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Patella fracture,2,45,34.246,34.246,20.32,1.000,0.000,1.000,10.233,χ²=20.3 (统计显著); 罕见+严重
Niraparib,Sepsis,1,45,0.060,0.060,13.85,1.000,1.000,0.000,10.926,χ²=13.9 (统计显著); 罕见+严重
Niraparib,Frustration tolerance decreased,2,45,0.000,0.000,32.33,0.500,0.000,0.000,10.233,χ²=32.3 (统计显著); 罕见+严重
Niraparib,Tachyphrenia,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Impaired quality of life,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Gastrointestinal surgery,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Cardiac pacemaker insertion,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Knee operation,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Aspiration pleural cavity,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Mineral supplementation,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Off label use,1,45,0.039,0.039,21.89,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Niraparib,Mean cell volume decreased,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Mean cell haemoglobin decreased,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Red blood cell nucleated morphology present,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Oral contusion,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Stoma obstruction,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Fluid replacement,2,45,17.123,17.123,14.33,1.000,0.000,0.500,10.233,χ²=14.3 (统计显著); 罕见+严重
Niraparib,Gastric bypass,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Brain scan abnormal,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Nasal odour,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Polycystic ovaries,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Nasal abscess,1,45,0.000,0.000,16.17,1.000,0.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Gastrointestinal stoma complication,1,45,0.000,0.000,16.17,1.000,0.000,0.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Niraparib,Benign tumour excision,1,45,0.000,0.000,16.17,1.000,1.000,1.000,10.926,χ²=16.2 (统计显著); 罕见+严重
Talazoparib,Bronchial hyperreactivity,1,45,0.000,0.000,45.30,1.000,1.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Retroperitoneal haemorrhage,1,45,46.321,46.321,21.68,1.000,0.000,1.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Disease progression,14,45,0.774,0.774,0.86,0.714,0.071,0.143,8.287,严重事件率=71.4%; 罕见+严重
Talazoparib,Nausea,18,45,0.596,0.596,4.57,0.556,0.111,0.389,8.036,严重事件率=55.6%; 罕见+严重
Talazoparib,Constipation,5,45,0.549,0.549,1.77,0.600,0.000,0.400,9.317,严重事件率=60.0%; 罕见+严重
Talazoparib,Lymphangitis,1,45,46.321,46.321,21.68,1.000,0.000,0.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Hyphaema,1,45,46.321,46.321,21.68,1.000,0.000,0.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Product dispensing error,1,45,0.000,0.000,45.30,1.000,0.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Liver function test decreased,1,45,0.000,0.000,45.30,1.000,0.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Extra dose administered,1,45,46.321,46.321,21.68,1.000,1.000,0.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Leukaemia,2,45,10.301,10.301,13.43,1.000,0.500,0.500,10.233,χ²=13.4 (统计显著); 罕见+严重
Talazoparib,Decreased appetite,6,45,0.498,0.498,2.90,0.667,0.167,0.333,9.134,严重事件率=66.7%; 罕见+严重
Talazoparib,Bacterial vaginosis,1,45,0.000,0.000,45.30,1.000,0.000,0.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Madarosis,2,45,18.543,18.543,23.17,0.500,0.000,0.000,10.233,χ²=23.2 (统计显著); 罕见+严重
Talazoparib,Illness,1,45,46.321,46.321,21.68,1.000,0.000,0.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Product dose omission in error,1,45,23.160,23.160,13.82,1.000,0.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Talazoparib,Atypical pneumonia,2,45,13.244,13.244,17.20,1.000,0.500,0.500,10.233,χ²=17.2 (统计显著); 罕见+严重
Talazoparib,Hypercalcaemia of malignancy,1,45,0.000,0.000,45.30,1.000,1.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Anaemia macrocytic,1,45,46.321,46.321,21.68,1.000,0.000,0.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Lyme disease,1,45,0.000,0.000,45.30,1.000,0.000,0.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Autoimmune neutropenia,1,45,46.321,46.321,21.68,1.000,0.000,1.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Extrapyramidal disorder,1,45,0.000,0.000,45.30,1.000,1.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Psychomotor skills impaired,1,45,23.160,23.160,13.82,1.000,1.000,1.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Talazoparib,Weight fluctuation,2,45,13.244,13.244,17.20,0.500,0.000,0.000,10.233,χ²=17.2 (统计显著); 罕见+严重
Talazoparib,Stoma site abscess,1,45,46.321,46.321,21.68,1.000,0.000,1.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Glucocorticoid deficiency,1,45,0.000,0.000,45.30,1.000,0.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Product prescribing error,1,45,0.000,0.000,45.30,1.000,0.000,0.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Intentional product use issue,2,45,10.301,10.301,13.43,0.500,0.000,0.500,10.233,χ²=13.4 (统计显著); 罕见+严重
Talazoparib,Lactate dehydrogenase urine increased,1,45,0.000,0.000,45.30,1.000,0.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Urine uric acid decreased,1,45,0.000,0.000,45.30,1.000,0.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Vascular rupture,1,45,0.000,0.000,45.30,1.000,0.000,0.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,BRCA1 gene mutation,1,45,0.000,0.000,45.30,1.000,1.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Herpes simplex reactivation,1,45,0.000,0.000,45.30,1.000,1.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Lung opacity,1,45,46.321,46.321,21.68,1.000,1.000,1.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Bone fissure,1,45,46.321,46.321,21.68,1.000,0.000,0.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Product use complaint,1,45,23.160,23.160,13.82,1.000,0.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Talazoparib,Pneumonia necrotising,1,45,23.160,23.160,13.82,1.000,1.000,0.000,10.926,χ²=13.8 (统计显著); 罕见+严重
Talazoparib,Therapy interrupted,2,45,15.452,15.452,19.81,0.500,0.000,0.500,10.233,χ²=19.8 (统计显著); 罕见+严重
Talazoparib,Blood folate decreased,2,45,0.000,0.000,90.61,1.000,0.000,1.000,10.233,χ²=90.6 (统计显著); 罕见+严重
Talazoparib,Acute coronary syndrome,2,45,8.428,8.428,10.82,1.000,0.000,1.000,10.233,χ²=10.8 (统计显著); 罕见+严重
Talazoparib,Bone marrow infiltration,1,45,0.000,0.000,45.30,1.000,0.000,0.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Product prescribing issue,1,45,0.000,0.000,45.30,1.000,0.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Blood pressure systolic decreased,1,45,46.321,46.321,21.68,1.000,0.000,1.000,10.926,χ²=21.7 (统计显著); 罕见+严重
Talazoparib,Intermenstrual bleeding,1,45,0.000,0.000,45.30,1.000,0.000,1.000,10.926,χ²=45.3 (统计显著); 罕见+严重
Talazoparib,Therapeutic product effect decreased,2,45,0.000,0.000,90.61,1.000,0.000,0.000,10.233,χ²=90.6 (统计显著); 罕见+严重
Talazoparib,Carbohydrate antigen 15-3 increased,2,45,46.359,46.359,43.37,1.000,0.000,0.000,10.233,χ²=43.4 (统计显著); 罕见+严重
Palbociclib,Thrombocytopenia,16,45,1.238,1.238,0.67,1.000,0.062,0.125,8.153,严重事件率=100.0%; 罕见+严重
Palbociclib,Pruritus,5,45,0.673,0.673,0.75,0.600,0.000,0.000,9.317,严重事件率=60.0%; 罕见+严重
Palbociclib,Blood culture positive,1,45,17.459,17.459,10.05,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Palbociclib,Blood creatine phosphokinase MB increased,2,45,69.882,69.882,43.95,1.000,0.000,1.000,10.233,χ²=43.9 (统计显著); 罕见+严重
Palbociclib,Amylase increased,2,45,9.982,9.982,12.20,1.000,0.000,1.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Palbociclib,Troponin I increased,1,45,34.919,34.919,16.00,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Palbociclib,Asthenia,18,45,1.237,1.237,0.75,0.611,0.111,0.278,8.036,严重事件率=61.1%; 罕见+严重
Palbociclib,Insomnia,6,45,1.286,1.286,0.35,1.000,0.167,0.167,9.134,严重事件率=100.0%; 罕见+严重
Palbociclib,Sedation,1,45,17.459,17.459,10.05,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Palbociclib,Tumour pain,2,45,9.982,9.982,12.20,1.000,0.500,1.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Palbociclib,Low density lipoprotein increased,1,45,34.919,34.919,16.00,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Palbociclib,Otitis media acute,1,45,34.919,34.919,16.00,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Palbociclib,Abdominal pain,10,45,1.042,1.042,0.02,0.800,0.100,0.400,8.623,严重事件率=80.0%; 罕见+严重
Palbociclib,Scrotal oedema,1,45,34.919,34.919,16.00,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Palbociclib,Pleural effusion,9,45,1.470,1.470,1.25,0.889,0.111,0.333,8.729,严重事件率=88.9%; 罕见+严重
Palbociclib,Platelet count decreased,18,45,1.538,1.538,3.10,0.833,0.111,0.333,8.036,严重事件率=83.3%; 罕见+严重
Palbociclib,Squamous cell carcinoma of lung,2,45,34.941,34.941,32.01,1.000,1.000,1.000,10.233,χ²=32.0 (统计显著); 罕见+严重
Palbociclib,Retinal haemorrhage,2,45,13.975,13.975,16.71,1.000,0.000,1.000,10.233,χ²=16.7 (统计显著); 罕见+严重
Palbociclib,Herpes zoster disseminated,2,45,34.941,34.941,32.01,1.000,0.000,1.000,10.233,χ²=32.0 (统计显著); 罕见+严重
Palbociclib,Haemoglobin decreased,6,45,0.827,0.827,0.20,0.833,0.000,0.333,9.134,严重事件率=83.3%; 罕见+严重
Palbociclib,Pain,13,45,1.569,1.569,2.46,0.692,0.154,0.231,8.361,严重事件率=69.2%; 罕见+严重
Palbociclib,Embolic stroke,1,45,0.000,0.000,33.92,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Cardiac valve disease,1,45,17.459,17.459,10.05,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Palbociclib,Metastases to pituitary gland,1,45,34.919,34.919,16.00,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Palbociclib,Diabetes insipidus,1,45,17.459,17.459,10.05,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Palbociclib,Hypoaesthesia,5,45,1.696,1.696,1.32,0.600,0.000,0.200,9.317,严重事件率=60.0%; 罕见+严重
Palbociclib,Nasal discomfort,2,45,23.293,23.293,24.86,0.500,0.000,0.000,10.233,χ²=24.9 (统计显著); 罕见+严重
Palbociclib,Pharyngeal disorder,1,45,17.459,17.459,10.05,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Palbociclib,Neuropathy peripheral,7,45,1.106,1.106,0.07,0.571,0.000,0.143,8.980,严重事件率=57.1%; 罕见+严重
Palbociclib,Dental discomfort,1,45,0.000,0.000,33.92,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Malignant ascites,2,45,17.470,17.470,20.10,1.000,0.000,0.000,10.233,χ²=20.1 (统计显著); 罕见+严重
Palbociclib,Gait disturbance,5,45,1.696,1.696,1.32,1.000,0.200,0.200,9.317,严重事件率=100.0%; 罕见+严重
Palbociclib,Hyperlipidaemia,2,45,13.975,13.975,16.71,1.000,0.000,0.000,10.233,χ²=16.7 (统计显著); 罕见+严重
Palbociclib,Peripheral swelling,6,45,1.719,1.719,1.66,0.667,0.000,0.167,9.134,严重事件率=66.7%; 罕见+严重
Palbociclib,Hernia repair,1,45,0.000,0.000,33.92,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Parathyroid disorder,1,45,0.000,0.000,33.92,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Soft tissue mass,1,45,34.919,34.919,16.00,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Palbociclib,Pupils unequal,1,45,0.000,0.000,33.92,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Jaw disorder,2,45,0.000,0.000,67.85,1.000,0.000,0.500,10.233,χ²=67.8 (统计显著); 罕见+严重
Palbociclib,Lumbar spinal stenosis,1,45,17.459,17.459,10.05,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Palbociclib,Muscle mass,1,45,0.000,0.000,33.92,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Osteopenia,1,45,34.919,34.919,16.00,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Palbociclib,Pancreatic carcinoma metastatic,2,45,17.470,17.470,20.10,0.500,0.500,0.000,10.233,χ²=20.1 (统计显著); 罕见+严重
Palbociclib,Lower limb fracture,1,45,17.459,17.459,10.05,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Palbociclib,Streptococcal bacteraemia,1,45,0.000,0.000,33.92,1.000,1.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Laryngeal disorder,1,45,0.000,0.000,33.92,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Alanine aminotransferase abnormal,1,45,0.000,0.000,33.92,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Panic attack,2,45,9.982,9.982,12.20,0.500,0.000,0.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Palbociclib,Tongue exfoliation,1,45,0.000,0.000,33.92,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Neck deformity,1,45,0.000,0.000,33.92,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Palbociclib,Cervical cord compression,1,45,0.000,0.000,33.92,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Ribociclib,Constipation,16,45,1.841,1.841,5.67,0.562,0.125,0.312,8.153,严重事件率=56.2%; 罕见+严重
Ribociclib,Gastric antral vascular ectasia,1,45,23.404,23.404,13.99,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Ribociclib,Benign renal neoplasm,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Vertebral lesion,1,45,46.809,46.809,21.93,1.000,0.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Ribociclib,Influenza A virus test positive,1,45,46.809,46.809,21.93,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Ribociclib,Pain,10,45,1.601,1.601,2.11,0.700,0.000,0.200,8.623,严重事件率=70.0%; 罕见+严重
Ribociclib,Poisoning,1,45,46.809,46.809,21.93,1.000,0.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Ribociclib,Headache,14,45,1.966,1.966,6.13,0.571,0.000,0.143,8.287,严重事件率=57.1%; 罕见+严重
Ribociclib,Oedema peripheral,5,45,1.604,1.604,1.07,0.600,0.000,0.200,9.317,严重事件率=60.0%; 罕见+严重
Ribociclib,Carcinoembryonic antigen increased,1,45,15.602,15.602,10.03,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Ribociclib,Eructation,2,45,11.711,11.711,15.32,0.500,0.000,0.500,10.233,χ²=15.3 (统计显著); 罕见+严重
Ribociclib,Hepatic cyst,1,45,15.602,15.602,10.03,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Ribociclib,Steatorrhoea,1,45,0.000,0.000,45.79,1.000,0.000,1.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Thrombocytosis,2,45,8.517,8.517,10.97,1.000,0.000,0.500,10.233,χ²=11.0 (统计显著); 罕见+严重
Ribociclib,Ureteric obstruction,1,45,15.602,15.602,10.03,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Ribociclib,Hepatic cancer,1,45,46.809,46.809,21.93,1.000,0.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Ribociclib,Weight gain poor,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Electrocardiogram abnormal,1,45,23.404,23.404,13.99,1.000,0.000,0.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Ribociclib,Lung neoplasm,1,45,15.602,15.602,10.03,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Ribociclib,Blood glucose decreased,2,45,8.517,8.517,10.97,0.500,0.000,0.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Ribociclib,Eye infection,1,45,23.404,23.404,13.99,1.000,0.000,0.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Ribociclib,Clavicle fracture,1,45,15.602,15.602,10.03,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Ribociclib,Bone cancer,2,45,31.232,31.232,34.32,1.000,0.000,0.000,10.233,χ²=34.3 (统计显著); 罕见+严重
Ribociclib,Groin abscess,1,45,23.404,23.404,13.99,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Ribociclib,Blood creatine increased,2,45,8.517,8.517,10.97,0.500,0.000,0.000,10.233,χ²=11.0 (统计显著); 罕见+严重
Ribociclib,Critical illness,1,45,46.809,46.809,21.93,1.000,0.000,1.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Ribociclib,Diarrhoea haemorrhagic,2,45,18.738,18.738,23.44,1.000,0.000,0.000,10.233,χ²=23.4 (统计显著); 罕见+严重
Ribociclib,Nonspecific reaction,2,45,0.000,0.000,91.58,0.500,0.000,0.500,10.233,χ²=91.6 (统计显著); 罕见+严重
Ribociclib,Rash papular,2,45,10.409,10.409,13.60,0.500,0.000,0.000,10.233,χ²=13.6 (统计显著); 罕见+严重
Ribociclib,Lupus-like syndrome,1,45,15.602,15.602,10.03,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Ribociclib,Respiratory symptom,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Food poisoning,1,45,15.602,15.602,10.03,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Ribociclib,Intervertebral disc disorder,1,45,0.000,0.000,45.79,1.000,0.000,1.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Biliary sepsis,1,45,0.000,0.000,45.79,1.000,0.000,1.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Pharyngitis streptococcal,1,45,23.404,23.404,13.99,1.000,0.000,0.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Ribociclib,Urethral disorder,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Escherichia infection,1,45,15.602,15.602,10.03,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Ribociclib,Concomitant disease aggravated,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Wrong dose,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Hypovitaminosis,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Vitreous floaters,2,45,9.368,9.368,12.17,0.500,0.000,0.000,10.233,χ²=12.2 (统计显著); 罕见+严重
Ribociclib,Astigmatism,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Pulmonary venous thrombosis,1,45,0.000,0.000,45.79,1.000,0.000,0.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Occult blood,1,45,0.000,0.000,45.79,1.000,0.000,1.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Procedural pain,2,45,46.849,46.849,43.85,1.000,1.000,1.000,10.233,χ²=43.9 (统计显著); 罕见+严重
Ribociclib,Respiration abnormal,1,45,46.809,46.809,21.93,1.000,0.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Ribociclib,Stenosis,1,45,0.000,0.000,45.79,1.000,0.000,1.000,10.926,χ²=45.8 (统计显著); 罕见+严重
Ribociclib,Onychomycosis,1,45,46.809,46.809,21.93,1.000,0.000,0.000,10.926,χ²=21.9 (统计显著); 罕见+严重
Ribociclib,Procedural complication,1,45,23.404,23.404,13.99,1.000,0.000,1.000,10.926,χ²=14.0 (统计显著); 罕见+严重
Ribociclib,Cerebral ischaemia,1,45,15.602,15.602,10.03,1.000,1.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Abemaciclib,Scrotal infection,1,45,0.000,0.000,42.33,1.000,0.000,1.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Cardiogenic shock,1,45,43.340,43.340,20.20,1.000,0.000,1.000,10.926,χ²=20.2 (统计显著); 罕见+严重
Abemaciclib,Gingival blister,1,45,0.000,0.000,42.33,1.000,0.000,0.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Stomatitis,7,45,1.679,1.679,1.79,0.714,0.000,0.143,8.980,严重事件率=71.4%; 罕见+严重
Abemaciclib,Infected bite,1,45,0.000,0.000,42.33,1.000,0.000,0.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Haemoglobin decreased,5,45,0.852,0.852,0.12,0.800,0.000,0.400,9.317,严重事件率=80.0%; 罕见+严重
Abemaciclib,Urine odour abnormal,1,45,0.000,0.000,42.33,1.000,0.000,0.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Cytotoxic oedema,1,45,0.000,0.000,42.33,1.000,0.000,1.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Platelet count decreased,8,45,0.824,0.824,0.29,0.625,0.000,0.250,8.847,严重事件率=62.5%; 罕见+严重
Abemaciclib,Pancytopenia,5,45,0.984,0.984,0.00,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Abemaciclib,Fibula fracture,2,45,43.374,43.374,40.40,1.000,0.000,0.000,10.233,χ²=40.4 (统计显著); 罕见+严重
Abemaciclib,Vertebral lesion,1,45,43.340,43.340,20.20,1.000,0.000,0.000,10.926,χ²=20.2 (统计显著); 罕见+严重
Abemaciclib,Spinal cord infection,1,45,0.000,0.000,42.33,1.000,0.000,1.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Oedema peripheral,5,45,1.485,1.485,0.74,0.600,0.000,0.200,9.317,严重事件率=60.0%; 罕见+严重
Abemaciclib,Breast cancer female,1,45,21.669,21.669,12.84,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Abemaciclib,Caesarean section,1,45,21.669,21.669,12.84,1.000,0.000,1.000,10.926,χ²=12.8 (统计显著); 罕见+严重
Abemaciclib,Fine motor skill dysfunction,1,45,43.340,43.340,20.20,1.000,0.000,1.000,10.926,χ²=20.2 (统计显著); 罕见+严重
Abemaciclib,Anaphylactoid shock,1,45,0.000,0.000,42.33,1.000,0.000,0.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Renal impairment,5,45,1.920,1.920,2.05,0.600,0.000,0.200,9.317,严重事件率=60.0%; 罕见+严重
Abemaciclib,Pain,5,45,0.726,0.726,0.49,0.600,0.000,0.000,9.317,严重事件率=60.0%; 罕见+严重
Abemaciclib,Disease progression,6,45,0.305,0.305,9.02,0.667,0.167,0.000,9.134,严重事件率=66.7%; 罕见+严重
Abemaciclib,Haemorrhoidal haemorrhage,2,45,86.749,86.749,55.14,1.000,0.000,1.000,10.233,χ²=55.1 (统计显著); 罕见+严重
Abemaciclib,Anal incontinence,1,45,0.000,0.000,42.33,1.000,0.000,0.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Hypogeusia,2,45,28.915,28.915,31.56,1.000,0.000,0.000,10.233,χ²=31.6 (统计显著); 罕见+严重
Abemaciclib,Pain in extremity,8,45,1.720,1.720,2.24,0.625,0.000,0.000,8.847,严重事件率=62.5%; 罕见+严重
Abemaciclib,Intertrigo,2,45,0.000,0.000,84.66,1.000,0.000,0.000,10.233,χ²=84.7 (统计显著); 罕见+严重
Abemaciclib,Road traffic accident,2,45,14.457,14.457,18.33,1.000,0.000,0.000,10.233,χ²=18.3 (统计显著); 罕见+严重
Abemaciclib,Breast cellulitis,1,45,0.000,0.000,42.33,1.000,0.000,0.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Metastases to chest wall,1,45,0.000,0.000,42.33,1.000,0.000,0.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Gait inability,3,45,0.000,0.000,126.99,0.333,0.000,0.333,9.827,χ²=127.0 (统计显著); 罕见+严重
Abemaciclib,Pulmonary function test decreased,1,45,43.340,43.340,20.20,1.000,1.000,1.000,10.926,χ²=20.2 (统计显著); 罕见+严重
Abemaciclib,Decreased activity,1,45,0.000,0.000,42.33,1.000,0.000,0.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Onychomadesis,2,45,21.686,21.686,25.67,0.500,0.000,0.000,10.233,χ²=25.7 (统计显著); 罕见+严重
Abemaciclib,Impaired driving ability,1,45,43.340,43.340,20.20,1.000,0.000,1.000,10.926,χ²=20.2 (统计显著); 罕见+严重
Abemaciclib,Tumour marker abnormal,1,45,0.000,0.000,42.33,1.000,0.000,1.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Renal injury,1,45,0.000,0.000,42.33,1.000,0.000,1.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Abemaciclib,Gastrointestinal bacterial infection,1,45,0.000,0.000,42.33,1.000,0.000,1.000,10.926,χ²=42.3 (统计显著); 罕见+严重
Vemurafenib,Neuroendocrine carcinoma of the skin,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Malignant neoplasm of pleura,1,45,0.000,0.000,34.68,1.000,1.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Proctoparalysis,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Vaginal prolapse,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Lower extremity mass,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Laryngeal leukoplakia,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Leukoplakia,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Pain in extremity,10,45,1.788,1.788,3.18,0.800,0.100,0.300,8.623,严重事件率=80.0%; 罕见+严重
Vemurafenib,Dysaesthesia,2,45,35.700,35.700,32.76,1.000,0.000,0.500,10.233,χ²=32.8 (统计显著); 罕见+严重
Vemurafenib,Keratosis pilaris,2,45,0.000,0.000,69.36,0.500,0.500,0.000,10.233,χ²=69.4 (统计显著); 罕见+严重
Vemurafenib,Xerosis,2,45,0.000,0.000,69.36,1.000,0.000,1.000,10.233,χ²=69.4 (统计显著); 罕见+严重
Vemurafenib,Dermoid cyst,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Cough,5,45,0.736,0.736,0.45,1.000,0.200,0.400,9.317,严重事件率=100.0%; 罕见+严重
Vemurafenib,Hyperpyrexia,2,45,14.279,14.279,17.14,1.000,0.000,0.500,10.233,χ²=17.1 (统计显著); 罕见+严重
Vemurafenib,Dry gangrene,1,45,0.000,0.000,34.68,1.000,1.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Renal tubular acidosis,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Vascular compression,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Vulvovaginal pruritus,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Chorioretinopathy,2,45,23.799,23.799,25.46,1.000,0.000,0.000,10.233,χ²=25.5 (统计显著); 罕见+严重
Vemurafenib,Kaposi^s sarcoma,2,45,14.279,14.279,17.14,1.000,0.000,0.000,10.233,χ²=17.1 (统计显著); 罕见+严重
Vemurafenib,Periodontal disease,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Pruritus,10,45,1.406,1.406,1.09,1.000,0.200,0.200,8.623,严重事件率=100.0%; 罕见+严重
Vemurafenib,Fanconi syndrome,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Mental impairment,2,45,10.199,10.199,12.54,1.000,0.000,0.000,10.233,χ²=12.5 (统计显著); 罕见+严重
Vemurafenib,Renal impairment,5,45,1.580,1.580,0.98,1.000,0.000,0.400,9.317,严重事件率=100.0%; 罕见+严重
Vemurafenib,Burns second degree,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Psychomotor hyperactivity,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Ocular discomfort,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Adenocarcinoma of colon,2,45,23.799,23.799,25.46,1.000,0.000,1.000,10.233,χ²=25.5 (统计显著); 罕见+严重
Vemurafenib,Dysgraphia,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Adenoma benign,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Exposure to contaminated air,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Vulvitis,1,45,35.677,35.677,16.38,1.000,0.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Ejaculation failure,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Bone loss,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Acrochordon,2,45,14.279,14.279,17.14,0.500,0.000,0.500,10.233,χ²=17.1 (统计显著); 罕见+严重
Vemurafenib,Muscle enzyme increased,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Blood cholesterol increased,2,45,10.199,10.199,12.54,1.000,0.000,0.000,10.233,χ²=12.5 (统计显著); 罕见+严重
Vemurafenib,Abnormal behaviour,2,45,10.199,10.199,12.54,1.000,0.000,0.500,10.233,χ²=12.5 (统计显著); 罕见+严重
Vemurafenib,Peyronie^s disease,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Dupuytren^s contracture,2,45,0.000,0.000,69.36,1.000,0.000,0.000,10.233,χ²=69.4 (统计显著); 罕见+严重
Vemurafenib,Metastases to peritoneum,2,45,14.279,14.279,17.14,0.500,0.000,0.000,10.233,χ²=17.1 (统计显著); 罕见+严重
Vemurafenib,Solar dermatitis,2,45,35.700,35.700,32.76,1.000,1.000,0.000,10.233,χ²=32.8 (统计显著); 罕见+严重
Vemurafenib,Lymphoproliferative disorder,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Formication,1,45,17.838,17.838,10.30,1.000,0.000,1.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Melanocytic naevus,2,45,35.700,35.700,32.76,0.500,0.000,0.000,10.233,χ²=32.8 (统计显著); 罕见+严重
Vemurafenib,Chalazion,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Panniculitis lobular,4,45,0.000,0.000,138.72,1.000,0.000,0.000,9.540,χ²=138.7 (统计显著); 罕见+严重
Vemurafenib,Septal panniculitis,3,45,0.000,0.000,104.04,1.000,0.000,0.000,9.827,χ²=104.0 (统计显著); 罕见+严重
Vemurafenib,Brain operation,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Hyperthermia malignant,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Relapsing fever,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Acute generalised exanthematous pustulosis,2,45,71.401,71.401,44.95,1.000,0.000,1.000,10.233,χ²=45.0 (统计显著); 罕见+严重
Vemurafenib,Cerebrovascular disorder,1,45,17.838,17.838,10.30,1.000,0.000,1.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Dysplastic naevus,1,45,0.000,0.000,34.68,1.000,1.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Dermatitis bullous,2,45,14.279,14.279,17.14,1.000,0.500,0.000,10.233,χ²=17.1 (统计显著); 罕见+严重
Vemurafenib,Brain compression,1,45,35.677,35.677,16.38,1.000,0.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Adenocarcinoma pancreas,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Benign neoplasm,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Benign neoplasm of skin,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Anal abscess,1,45,0.000,0.000,34.68,1.000,1.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Brain injury,1,45,35.677,35.677,16.38,1.000,1.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Genital discomfort,1,45,0.000,0.000,34.68,1.000,1.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Posture abnormal,1,45,35.677,35.677,16.38,1.000,1.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Gaze palsy,1,45,35.677,35.677,16.38,1.000,1.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Facial paresis,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Haematological malignancy,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Food aversion,1,45,17.838,17.838,10.30,1.000,0.000,1.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Rash morbilliform,2,45,35.700,35.700,32.76,1.000,0.000,0.500,10.233,χ²=32.8 (统计显著); 罕见+严重
Vemurafenib,Milia,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Malignant melanoma stage IV,1,45,0.000,0.000,34.68,1.000,1.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Adenocarcinoma gastric,1,45,35.677,35.677,16.38,1.000,1.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Groin abscess,1,45,17.838,17.838,10.30,1.000,0.000,1.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Therapy responder,1,45,35.677,35.677,16.38,1.000,1.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Incarcerated inguinal hernia,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Gastric polyps,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Breast neoplasm,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Neoplasm skin,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Papilloma,1,45,0.000,0.000,34.68,1.000,1.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Lymphocyte morphology abnormal,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Iatrogenic injury,1,45,35.677,35.677,16.38,1.000,0.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Generalised erythema,2,45,11.899,11.899,14.55,1.000,0.500,0.000,10.233,χ²=14.5 (统计显著); 罕见+严重
Vemurafenib,Vitritis,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Pharyngeal hypoaesthesia,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Pharyngeal disorder,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Iritis,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Blindness transient,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Dyshidrotic eczema,2,45,0.000,0.000,69.36,1.000,0.500,0.000,10.233,χ²=69.4 (统计显著); 罕见+严重
Vemurafenib,Mineral metabolism disorder,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Pancreatic disorder,1,45,35.677,35.677,16.38,1.000,0.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Ischaemic hepatitis,1,45,0.000,0.000,34.68,1.000,1.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Pneumonia legionella,1,45,17.838,17.838,10.30,1.000,0.000,1.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Monocytosis,1,45,35.677,35.677,16.38,1.000,0.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Eczema nummular,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Infected cyst,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Acne cystic,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Blood alkaline phosphatase abnormal,1,45,17.838,17.838,10.30,1.000,0.000,1.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Arteritis,1,45,35.677,35.677,16.38,1.000,0.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Neutrophilic panniculitis,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Hyperlipasaemia,1,45,35.677,35.677,16.38,1.000,0.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Skin depigmentation,1,45,0.000,0.000,34.68,1.000,1.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Melanosis,1,45,0.000,0.000,34.68,1.000,1.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Hair colour changes,1,45,35.677,35.677,16.38,1.000,1.000,0.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Hypertriglyceridaemia,1,45,17.838,17.838,10.30,1.000,1.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Pyogenic granuloma,1,45,17.838,17.838,10.30,1.000,0.000,0.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Skin erosion,1,45,17.838,17.838,10.30,1.000,1.000,1.000,10.926,χ²=10.3 (统计显著); 罕见+严重
Vemurafenib,Conjunctival disorder,2,45,71.401,71.401,44.95,1.000,1.000,1.000,10.233,χ²=45.0 (统计显著); 罕见+严重
Vemurafenib,Vulvovaginal erythema,1,45,35.677,35.677,16.38,1.000,1.000,1.000,10.926,χ²=16.4 (统计显著); 罕见+严重
Vemurafenib,Vulvar erosion,1,45,0.000,0.000,34.68,1.000,1.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Blood albumin increased,1,45,0.000,0.000,34.68,1.000,0.000,1.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Acanthosis,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Vemurafenib,Dermatitis infected,1,45,0.000,0.000,34.68,1.000,0.000,0.000,10.926,χ²=34.7 (统计显著); 罕见+严重
Dabrafenib,Fibrinolysis,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Pruritus,7,45,0.950,0.950,0.02,0.857,0.000,0.143,8.980,严重事件率=85.7%; 罕见+严重
Dabrafenib,Feeling of despair,1,45,34.895,34.895,15.99,1.000,1.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Venous thrombosis,2,45,13.966,13.966,16.69,1.000,1.000,1.000,10.233,χ²=16.7 (统计显著); 罕见+严重
Dabrafenib,Delusion,1,45,17.447,17.447,10.04,1.000,1.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Fungal skin infection,2,45,23.278,23.278,24.84,1.000,1.000,1.000,10.233,χ²=24.8 (统计显著); 罕见+严重
Dabrafenib,Oxygen supplementation,1,45,34.895,34.895,15.99,1.000,1.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Pain in extremity,8,45,1.383,1.383,0.79,0.875,0.000,0.250,8.847,严重事件率=87.5%; 罕见+严重
Dabrafenib,Dry skin,7,45,1.882,1.882,2.65,0.714,0.000,0.143,8.980,严重事件率=71.4%; 罕见+严重
Dabrafenib,Skin hypertrophy,2,45,23.278,23.278,24.84,0.500,0.000,0.000,10.233,χ²=24.8 (统计显著); 罕见+严重
Dabrafenib,Vascular neoplasm,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Superior vena cava occlusion,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Tongue blistering,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Lichenoid keratosis,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Eye inflammation,1,45,17.447,17.447,10.04,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Decreased appetite,16,45,1.024,1.024,0.01,0.812,0.188,0.312,8.153,严重事件率=81.2%; 罕见+严重
Dabrafenib,Illusion,2,45,69.836,69.836,43.92,1.000,0.500,1.000,10.233,χ²=43.9 (统计显著); 罕见+严重
Dabrafenib,Large intestinal haemorrhage,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Small intestinal haemorrhage,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Leukopenia,5,45,1.632,1.632,1.13,1.000,0.000,0.200,9.317,严重事件率=100.0%; 罕见+严重
Dabrafenib,Adenocarcinoma pancreas,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Alanine aminotransferase increased,7,45,1.389,1.389,0.71,0.857,0.000,0.286,8.980,严重事件率=85.7%; 罕见+严重
Dabrafenib,Diarrhoea haemorrhagic,2,45,13.966,13.966,16.69,1.000,0.000,1.000,10.233,χ²=16.7 (统计显著); 罕见+严重
Dabrafenib,Haemorrhagic diathesis,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Prothrombin time prolonged,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Atypical fibroxanthoma,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Enuresis,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Polycythaemia vera,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Neutropenia,16,45,0.957,0.957,0.03,1.000,0.000,0.312,8.153,严重事件率=100.0%; 罕见+严重
Dabrafenib,Drug ineffective,12,45,1.627,1.627,2.66,0.750,0.167,0.333,8.441,严重事件率=75.0%; 罕见+严重
Dabrafenib,Therapeutic response changed,2,45,23.278,23.278,24.84,1.000,0.500,0.000,10.233,χ²=24.8 (统计显著); 罕见+严重
Dabrafenib,Back pain,5,45,0.726,0.726,0.49,0.800,0.000,0.400,9.317,严重事件率=80.0%; 罕见+严重
Dabrafenib,Meningoradiculitis,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Demyelinating polyneuropathy,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Colon cancer recurrent,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Joint dislocation,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Tumour rupture,1,45,17.447,17.447,10.04,1.000,1.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Neurological symptom,2,45,8.728,8.728,10.63,1.000,0.000,1.000,10.233,χ²=10.6 (统计显著); 罕见+严重
Dabrafenib,Metrorrhagia,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Palmoplantar keratoderma,2,45,0.000,0.000,67.80,1.000,0.000,0.000,10.233,χ²=67.8 (统计显著); 罕见+严重
Dabrafenib,Breast cancer stage II,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Atrioventricular block second degree,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Cyst,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Rosacea,1,45,17.447,17.447,10.04,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Hyporeflexia,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Radiculopathy,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Superficial spreading melanoma stage unspecified,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Emergency care examination,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Tumour excision,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Lymphadenectomy,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Parotidectomy,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Chorioretinal disorder,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Off label use,1,45,0.080,0.080,10.13,1.000,0.000,0.000,10.926,χ²=10.1 (统计显著); 罕见+严重
Dabrafenib,Carpal tunnel syndrome,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Motor dysfunction,2,45,17.458,17.458,20.08,1.000,0.500,0.500,10.233,χ²=20.1 (统计显著); 罕见+严重
Dabrafenib,Ocular vasculitis,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Mastitis,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Exophthalmos,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Ocular hypertension,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Ejection fraction,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Neoplasm skin,1,45,34.895,34.895,15.99,1.000,1.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Thyroid neoplasm,1,45,17.447,17.447,10.04,1.000,1.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Listless,1,45,34.895,34.895,15.99,1.000,1.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Thyroidectomy,1,45,0.000,0.000,33.90,1.000,1.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Cough,6,45,0.868,0.868,0.11,0.833,0.000,0.167,9.134,严重事件率=83.3%; 罕见+严重
Dabrafenib,Vitritis,1,45,17.447,17.447,10.04,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Sedation,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Febrile neutropenia,1,45,0.072,0.072,11.54,1.000,0.000,0.000,10.926,χ²=11.5 (统计显著); 罕见+严重
Dabrafenib,Vasogenic cerebral oedema,2,45,69.836,69.836,43.92,1.000,0.500,0.500,10.233,χ²=43.9 (统计显著); 罕见+严重
Dabrafenib,Coronary arterial stent insertion,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Sweating fever,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Glioblastoma multiforme,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Pharyngeal hypoaesthesia,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Pharyngeal disorder,1,45,17.447,17.447,10.04,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Choking,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Blood calcium abnormal,1,45,0.000,0.000,33.90,1.000,1.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Status epilepticus,1,45,34.895,34.895,15.99,1.000,1.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Pneumonia legionella,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,International normalised ratio decreased,2,45,0.000,0.000,67.80,1.000,0.000,0.000,10.233,χ²=67.8 (统计显著); 罕见+严重
Dabrafenib,Ocular vascular disorder,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Infected cyst,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Acne cystic,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Electrocardiogram repolarisation abnormality,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Postoperative wound infection,1,45,17.447,17.447,10.04,1.000,0.000,1.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Cutaneous sarcoidosis,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Cancer surgery,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Malignant neoplasm of unknown primary site,1,45,34.895,34.895,15.99,1.000,0.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Portal hypertension,1,45,34.895,34.895,15.99,1.000,1.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Cow^s milk intolerance,1,45,0.000,0.000,33.90,1.000,1.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Rhinitis,1,45,17.447,17.447,10.04,1.000,0.000,0.000,10.926,χ²=10.0 (统计显著); 罕见+严重
Dabrafenib,Dysphemia,1,45,0.000,0.000,33.90,1.000,0.000,0.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Trigeminal neuralgia,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Coordination abnormal,1,45,34.895,34.895,15.99,1.000,1.000,0.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Blast cells absent,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Dabrafenib,Red blood cell schistocytes present,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Shift to the left,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Neutrophilia,1,45,34.895,34.895,15.99,1.000,0.000,1.000,10.926,χ²=16.0 (统计显著); 罕见+严重
Dabrafenib,Endodontic procedure,1,45,0.000,0.000,33.90,1.000,0.000,1.000,10.926,χ²=33.9 (统计显著); 罕见+严重
Pembrolizumab,Headache,13,40,1.790,1.790,4.20,0.462,0.000,0.462,8.361,罕见+严重; 住院率=46.2%
Pembrolizumab,Syncope,3,40,1.425,1.425,0.36,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Pembrolizumab,Hypokalaemia,4,40,1.922,1.922,1.65,0.500,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Pembrolizumab,Malaise,3,40,0.356,0.356,3.36,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Nivolumab,Chills,4,40,1.279,1.279,0.23,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Nivolumab,Syncope,3,40,1.404,1.404,0.33,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Atezolizumab,Vomiting,4,40,0.264,0.264,7.88,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Atezolizumab,Infusion related reaction,4,40,1.804,1.804,1.36,0.750,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Atezolizumab,Deep vein thrombosis,3,40,1.547,1.547,0.55,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Atezolizumab,Blood creatinine increased,4,40,1.257,1.257,0.20,0.750,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Atezolizumab,Constipation,4,40,0.541,0.541,1.50,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Atezolizumab,Platelet count decreased,3,40,0.402,0.402,2.58,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Atezolizumab,Dysphagia,3,40,1.183,1.183,0.08,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Durvalumab,Blood creatinine increased,3,40,0.765,0.765,0.21,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Durvalumab,Oedema peripheral,4,40,1.271,1.271,0.22,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Durvalumab,Cardiac failure,3,40,1.491,1.491,0.46,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Durvalumab,Pulmonary embolism,3,40,0.696,0.696,0.38,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Durvalumab,Dizziness,3,40,0.397,0.397,2.64,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Durvalumab,Infusion related reaction,4,40,1.472,1.472,0.57,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Durvalumab,Insomnia,3,40,0.843,0.843,0.08,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Durvalumab,Chills,3,40,0.979,0.979,0.00,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Ipilimumab,Febrile neutropenia,4,40,0.339,0.339,4.94,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Ipilimumab,Loss of consciousness,3,40,1.977,1.977,1.34,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Ipilimumab,Visual impairment,3,40,1.276,1.276,0.17,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Ipilimumab,Urinary tract infection,3,40,0.621,0.621,0.67,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Ipilimumab,Abdominal distension,3,40,1.424,1.424,0.36,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Ipilimumab,Depression,3,40,1.726,1.726,0.85,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Ipilimumab,Fall,4,40,0.933,0.933,0.02,0.750,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Ipilimumab,Blood creatinine increased,3,40,0.668,0.668,0.47,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Ipilimumab,Lung infection,3,40,1.977,1.977,1.34,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Ipilimumab,Cerebrovascular accident,3,40,1.263,1.263,0.15,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Trastuzumab,Chills,4,40,0.786,0.786,0.22,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Trastuzumab,Tachycardia,3,40,1.074,1.074,0.01,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Trastuzumab,Hyperglycaemia,3,40,1.034,1.034,0.00,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Trastuzumab,Alopecia,3,40,0.478,0.478,1.62,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Trastuzumab,Hypertension,3,40,0.470,0.470,1.70,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Trastuzumab,Confusional state,3,40,0.554,0.554,1.02,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Trastuzumab,Convulsion,4,40,1.996,1.996,1.79,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Trastuzumab,Syncope,3,40,0.863,0.863,0.06,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Trastuzumab,Neutropenic sepsis,4,40,1.894,1.894,1.52,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Trastuzumab,Full blood count decreased,3,40,1.060,1.060,0.01,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Trastuzumab,Dysgeusia,3,40,0.459,0.459,1.80,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Trastuzumab,Leukopenia,3,40,0.768,0.768,0.20,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Trastuzumab,Aspartate aminotransferase increased,4,40,0.664,0.664,0.64,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Trastuzumab,Neutrophil count decreased,3,40,0.513,0.513,1.31,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Bevacizumab,Haematuria,3,40,1.417,1.417,0.34,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Bevacizumab,Atrial fibrillation,4,40,0.721,0.721,0.41,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Bevacizumab,Pneumonitis,3,40,0.457,0.457,1.84,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Bevacizumab,Dysphagia,4,40,0.852,0.852,0.10,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Bevacizumab,Aspartate aminotransferase increased,4,40,0.730,0.730,0.38,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Bevacizumab,Lymphadenopathy,3,40,1.261,1.261,0.15,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Bevacizumab,Abdominal pain upper,4,40,0.697,0.697,0.50,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Bevacizumab,Haemoglobin decreased,4,40,0.480,0.480,2.13,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Bevacizumab,Peripheral swelling,3,40,0.736,0.736,0.27,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Rituximab,Joint swelling,4,40,1.955,1.955,1.67,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Rituximab,Peripheral swelling,4,40,0.866,0.866,0.08,0.750,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Rituximab,Swelling,3,40,1.792,1.792,0.95,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Rituximab,Hyperhidrosis,3,40,1.185,1.185,0.08,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Rituximab,Oedema peripheral,4,40,0.730,0.730,0.37,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Rituximab,Abdominal pain upper,3,40,0.454,0.454,1.85,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Rituximab,Lymphadenopathy,3,40,1.104,1.104,0.03,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Rituximab,Depression,4,40,1.536,1.536,0.68,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Epcoritamab,Feeling abnormal,3,40,1.226,1.226,0.12,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Epcoritamab,Myalgia,4,40,1.124,1.124,0.05,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Imatinib,Stomatitis,4,40,0.567,0.567,1.24,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Imatinib,Hypoaesthesia,4,40,1.005,1.005,0.00,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Imatinib,Blood glucose increased,3,40,1.706,1.706,0.79,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Imatinib,Paraesthesia,4,40,1.376,1.376,0.38,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Imatinib,Hypersensitivity,4,40,0.736,0.736,0.35,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Imatinib,Renal impairment,4,40,0.917,0.917,0.03,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Imatinib,Renal failure,4,40,0.507,0.507,1.81,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Imatinib,Nasopharyngitis,4,40,1.276,1.276,0.22,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Imatinib,Dyspepsia,4,40,0.996,0.996,0.00,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Imatinib,Neoplasm,3,40,1.962,1.962,1.26,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Imatinib,Pancreatitis,3,40,1.538,1.538,0.51,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Imatinib,Gastrooesophageal reflux disease,3,40,1.245,1.245,0.13,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Imatinib,Thrombosis,4,40,1.137,1.137,0.06,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Imatinib,Pericardial effusion,4,40,1.688,1.688,1.01,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Imatinib,White blood cell count increased,4,40,1.869,1.869,1.45,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Erlotinib,White blood cell count decreased,3,40,0.293,0.293,4.90,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Erlotinib,Visual impairment,3,40,1.050,1.050,0.01,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Erlotinib,Paraesthesia,3,40,1.310,1.310,0.20,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Erlotinib,Platelet count decreased,3,40,0.236,0.236,7.10,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Erlotinib,Thrombosis,3,40,1.084,1.084,0.02,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Erlotinib,Tachycardia,4,40,1.747,1.747,1.18,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Erlotinib,Bone marrow failure,3,40,0.960,0.960,0.00,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Erlotinib,Heart rate increased,3,40,1.327,1.327,0.23,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Gefitinib,Oedema peripheral,4,40,0.941,0.941,0.01,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Gefitinib,Disease progression,44,40,1.919,1.919,17.09,1.000,0.159,0.068,7.142,χ²=17.1 (统计显著); 严重事件率=100.0%
Gefitinib,Dizziness,4,40,0.394,0.394,3.55,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Gefitinib,Headache,3,40,0.299,0.299,4.72,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Osimertinib,Alanine aminotransferase increased,3,40,0.582,0.582,0.86,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Osimertinib,General physical health deterioration,3,40,0.708,0.708,0.34,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Osimertinib,Haemoglobin decreased,4,40,0.547,0.547,1.43,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Crizotinib,White blood cell count decreased,4,40,0.510,0.510,1.80,0.500,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Paclitaxel,Pericardial effusion,4,40,1.868,1.868,1.46,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Paclitaxel,Bone pain,4,40,1.412,1.412,0.44,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Paclitaxel,Oedema,3,40,1.071,1.071,0.01,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Paclitaxel,Photosensitivity reaction,3,40,1.638,1.638,0.68,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Paclitaxel,Fall,3,40,0.492,0.492,1.49,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Paclitaxel,Cerebrovascular accident,3,40,0.894,0.894,0.03,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Paclitaxel,Hyponatraemia,4,40,0.863,0.863,0.08,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Paclitaxel,Gastrointestinal disorder,3,40,1.336,1.336,0.23,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Paclitaxel,Skin exfoliation,3,40,1.378,1.378,0.29,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Docetaxel,Pain in extremity,3,40,0.396,0.396,2.62,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Docetaxel,Pulmonary embolism,4,40,0.546,0.546,1.42,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Docetaxel,Syncope,3,40,0.846,0.846,0.08,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Docetaxel,Abdominal discomfort,3,40,0.603,0.603,0.74,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Docetaxel,Fluid retention,3,40,1.956,1.956,1.26,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Docetaxel,Hypoaesthesia,4,40,1.053,1.053,0.01,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Docetaxel,Toxicity to various agents,4,40,0.771,0.771,0.26,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Docetaxel,Red blood cell count decreased,4,40,0.862,0.862,0.08,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Docetaxel,Hypotension,4,40,0.520,0.520,1.66,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Docetaxel,Atrial fibrillation,4,40,0.643,0.643,0.74,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Docetaxel,Deep vein thrombosis,3,40,0.739,0.739,0.26,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Docetaxel,Loss of consciousness,3,40,1.325,1.325,0.22,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Doxorubicin,Diarrhoea,20,40,0.424,0.424,14.35,1.000,0.000,0.400,7.930,χ²=14.3 (统计显著); 严重事件率=100.0%
Doxorubicin,Back pain,3,40,0.352,0.352,3.39,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Doxorubicin,Deep vein thrombosis,3,40,0.770,0.770,0.19,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Doxorubicin,Cellulitis,3,40,1.585,1.585,0.59,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Doxorubicin,Oropharyngeal pain,3,40,1.240,1.240,0.13,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Doxorubicin,Lymphadenopathy,3,40,1.172,1.172,0.07,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Doxorubicin,Dysphagia,3,40,0.589,0.589,0.81,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Doxorubicin,Speech disorder,4,40,1.679,1.679,1.00,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Doxorubicin,Convulsion,3,40,1.502,1.502,0.46,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Carboplatin,Neutropenia,40,40,1.760,1.760,11.43,0.950,0.150,0.275,7.237,χ²=11.4 (统计显著); 严重事件率=95.0%
Carboplatin,Abdominal pain upper,3,40,0.413,0.413,2.36,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Carboplatin,Hypomagnesaemia,4,40,1.480,1.480,0.56,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Carboplatin,Somnolence,3,40,0.893,0.893,0.04,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Carboplatin,Epistaxis,3,40,0.625,0.625,0.63,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Carboplatin,Thrombosis,3,40,0.787,0.787,0.16,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Carboplatin,Peripheral swelling,3,40,0.585,0.585,0.83,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Carboplatin,Gastrointestinal disorder,3,40,1.126,1.126,0.04,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Carboplatin,Oedema,4,40,1.220,1.220,0.15,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Carboplatin,Blood potassium decreased,3,40,1.703,1.703,0.78,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Carboplatin,Lymphadenopathy,4,40,1.356,1.356,0.34,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Carboplatin,Burning sensation,3,40,1.592,1.592,0.59,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Cisplatin,Atrial fibrillation,3,40,0.478,0.478,1.62,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Cisplatin,Aspartate aminotransferase increased,3,40,0.483,0.483,1.56,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Cisplatin,Vertigo,3,40,1.904,1.904,1.16,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Cisplatin,Hypokalaemia,4,40,1.136,1.136,0.06,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Cisplatin,Blood pressure increased,4,40,1.226,1.226,0.15,0.750,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Cisplatin,Hyperglycaemia,4,40,1.364,1.364,0.36,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Cisplatin,Dyspepsia,4,40,1.039,1.039,0.01,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Cisplatin,Balance disorder,3,40,1.705,1.705,0.79,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Cisplatin,Haematuria,4,40,1.706,1.706,1.06,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Cisplatin,Fall,3,40,0.464,0.464,1.75,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Lenalidomide,Hypotension,4,40,0.879,0.879,0.06,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Lenalidomide,Nasopharyngitis,3,40,1.670,1.670,0.76,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Lenalidomide,Chest pain,4,40,1.026,1.026,0.00,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Lenalidomide,Epistaxis,4,40,1.594,1.594,0.83,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Pomalidomide,Hypersensitivity,4,40,1.454,1.454,0.54,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Pomalidomide,Interstitial lung disease,3,40,0.937,0.937,0.01,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Pomalidomide,Cardiac failure,3,40,1.647,1.647,0.72,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Pomalidomide,Blood creatinine increased,3,40,0.845,0.845,0.08,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Pomalidomide,Blood pressure increased,3,40,1.721,1.721,0.86,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Bortezomib,Drug intolerance,3,40,1.218,1.218,0.11,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Bortezomib,Paraesthesia,3,40,1.281,1.281,0.17,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Bortezomib,Urticaria,4,40,1.854,1.854,1.44,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Bortezomib,Headache,4,40,0.380,0.380,3.86,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Bortezomib,Pneumonitis,3,40,0.490,0.490,1.52,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Bortezomib,Dehydration,3,40,0.238,0.238,6.99,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Bortezomib,Urinary tract infection,3,40,0.500,0.500,1.43,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Bortezomib,Tremor,3,40,1.389,1.389,0.30,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Bortezomib,Chills,3,40,0.689,0.689,0.40,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Bortezomib,Confusional state,3,40,0.652,0.652,0.53,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Carfilzomib,Interstitial lung disease,4,40,1.156,1.156,0.08,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Carfilzomib,Renal impairment,3,40,1.237,1.237,0.13,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Carfilzomib,Malaise,4,40,0.491,0.491,2.03,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Carfilzomib,Cough,3,40,0.582,0.582,0.87,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Venetoclax,Hyponatraemia,3,40,0.879,0.879,0.05,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Venetoclax,Stomatitis,3,40,0.641,0.641,0.58,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Venetoclax,Back pain,4,40,0.656,0.656,0.69,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Venetoclax,Alanine aminotransferase increased,3,40,0.659,0.659,0.50,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Venetoclax,Aspartate aminotransferase increased,4,40,0.942,0.942,0.01,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Venetoclax,Blood bilirubin increased,3,40,1.774,1.774,0.94,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Venetoclax,Chest pain,3,40,0.655,0.655,0.52,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Venetoclax,Tremor,3,40,1.674,1.674,0.76,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Venetoclax,Feeling abnormal,4,40,1.822,1.822,1.38,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Ibrutinib,Tremor,3,40,1.406,1.406,0.33,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Ibrutinib,Abdominal pain upper,4,40,0.755,0.755,0.30,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Ibrutinib,Gastrooesophageal reflux disease,3,40,1.585,1.585,0.60,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Ibrutinib,Pericardial effusion,3,40,1.585,1.585,0.60,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Ibrutinib,Heart rate increased,4,40,1.776,1.776,1.24,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Ibrutinib,Rectal haemorrhage,3,40,1.783,1.783,0.95,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Ibrutinib,Hyperhidrosis,4,40,1.988,1.988,1.79,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Ibrutinib,Oropharyngeal pain,3,40,1.447,1.447,0.38,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Ibrutinib,Somnolence,3,40,1.217,1.217,0.11,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Ibrutinib,Blood bilirubin increased,3,40,1.490,1.490,0.45,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Olaparib,Vomiting,54,40,1.972,1.972,22.40,0.537,0.093,0.296,6.937,χ²=22.4 (统计显著); 严重事件率=53.7%
Olaparib,Malignant neoplasm progression,43,40,1.955,1.955,17.55,1.000,0.186,0.233,7.165,χ²=17.6 (统计显著); 严重事件率=100.0%
Olaparib,Hypersensitivity,3,40,0.609,0.609,0.71,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Olaparib,Influenza,3,40,1.557,1.557,0.55,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Olaparib,Oedema peripheral,3,40,0.588,0.588,0.82,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Olaparib,Urticaria,3,40,1.210,1.210,0.10,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Olaparib,Thrombosis,3,40,0.937,0.937,0.01,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Olaparib,Deep vein thrombosis,3,40,0.785,0.785,0.17,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Olaparib,Muscular weakness,3,40,0.675,0.675,0.44,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Olaparib,Renal impairment,4,40,1.019,1.019,0.00,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Rucaparib,Pleural effusion,4,40,0.357,0.357,4.30,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Rucaparib,Malignant neoplasm progression,62,40,1.962,1.962,24.44,0.726,0.161,0.387,6.799,χ²=24.4 (统计显著); 严重事件率=72.6%
Rucaparib,Abdominal pain,31,40,1.948,1.948,12.16,0.613,0.065,0.323,7.492,χ²=12.2 (统计显著); 严重事件率=61.3%
Rucaparib,Fall,4,40,0.448,0.448,2.53,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Rucaparib,Blood potassium decreased,4,40,1.870,1.870,1.40,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Rucaparib,Colitis,4,40,0.378,0.378,3.80,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Rucaparib,Pulmonary oedema,3,40,1.226,1.226,0.11,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Rucaparib,Mental status changes,3,40,1.402,1.402,0.31,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Rucaparib,Contusion,3,40,0.774,0.774,0.18,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Rucaparib,Hypersensitivity,3,40,0.411,0.411,2.35,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Rucaparib,Chills,4,40,0.552,0.552,1.34,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Rucaparib,Visual impairment,3,40,0.613,0.613,0.68,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Rucaparib,Rectal haemorrhage,3,40,1.051,1.051,0.01,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Rucaparib,Oral pain,4,40,1.963,1.963,1.63,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Niraparib,Fatigue,106,40,1.503,1.503,14.62,0.745,0.047,0.377,6.263,χ²=14.6 (统计显著); 严重事件率=74.5%
Niraparib,Decreased appetite,58,40,1.992,1.992,23.58,0.741,0.034,0.328,6.866,χ²=23.6 (统计显著); 严重事件率=74.1%
Niraparib,Hypophagia,4,40,1.245,1.245,0.17,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Niraparib,Haematemesis,3,40,1.605,1.605,0.59,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Niraparib,Rash pruritic,4,40,1.292,1.292,0.23,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Niraparib,Leukopenia,3,40,0.470,0.470,1.64,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Niraparib,Pneumonitis,3,40,0.255,0.255,6.06,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Niraparib,Oropharyngeal pain,4,40,1.007,1.007,0.00,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Niraparib,Mucosal inflammation,3,40,0.438,0.438,1.98,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Niraparib,Gastrooesophageal reflux disease,4,40,1.104,1.104,0.03,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Niraparib,Adverse event,3,40,0.733,0.733,0.26,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Niraparib,Memory impairment,4,40,1.223,1.223,0.14,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Niraparib,Rhinorrhoea,3,40,1.252,1.252,0.13,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Niraparib,Skin disorder,3,40,0.969,0.969,0.00,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Niraparib,Sinusitis,3,40,0.969,0.969,0.00,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Talazoparib,Somnolence,3,40,1.695,1.695,0.80,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Talazoparib,Gait disturbance,3,40,1.323,1.323,0.22,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Palbociclib,Aspartate aminotransferase increased,3,40,0.619,0.619,0.67,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Palbociclib,Chest pain,4,40,0.775,0.775,0.25,0.500,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Palbociclib,Constipation,12,40,1.014,1.014,0.00,0.500,0.167,0.417,8.441,罕见+严重; 住院率=41.7%
Palbociclib,Pulmonary embolism,3,40,0.520,0.520,1.27,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Palbociclib,Bone marrow failure,3,40,0.997,0.997,0.00,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Palbociclib,Deep vein thrombosis,4,40,1.270,1.270,0.21,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Palbociclib,Dehydration,4,40,0.338,0.338,4.94,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Ribociclib,Hypotension,4,40,0.890,0.890,0.05,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Ribociclib,Neutrophil count decreased,3,40,0.860,0.860,0.06,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Ribociclib,Pyrexia,9,40,0.519,0.519,3.79,0.444,0.000,0.444,8.729,罕见+严重; 住院率=44.4%
Ribociclib,Hyponatraemia,4,40,1.397,1.397,0.43,0.750,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Ribociclib,Dehydration,4,40,0.453,0.453,2.53,0.750,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Ribociclib,Chills,4,40,1.319,1.319,0.29,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Ribociclib,Dyspepsia,4,40,1.784,1.784,1.29,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Ribociclib,Renal failure,4,40,0.908,0.908,0.04,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Ribociclib,Heart rate increased,3,40,1.848,1.848,1.10,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Abemaciclib,Hypokalaemia,4,40,1.807,1.807,1.35,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Abemaciclib,Fall,4,40,0.990,0.990,0.00,1.000,0.000,0.750,9.540,罕见+严重; 住院率=75.0%
Abemaciclib,Gait disturbance,3,40,1.238,1.238,0.13,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Abemaciclib,Acute kidney injury,3,40,1.120,1.120,0.04,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Vemurafenib,Malaise,4,40,0.369,0.369,4.12,0.750,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Vemurafenib,Cardiac failure,4,40,1.535,1.535,0.69,1.000,0.000,1.000,9.540,罕见+严重; 住院率=100.0%
Vemurafenib,Back pain,3,40,0.441,0.441,2.03,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Vemurafenib,Pleural effusion,3,40,0.485,0.485,1.56,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Vemurafenib,Cellulitis,3,40,1.983,1.983,1.34,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Vemurafenib,Adrenal insufficiency,3,40,1.878,1.878,1.14,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Vemurafenib,Oedema,3,40,1.321,1.321,0.22,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Dabrafenib,Urticaria,4,40,1.967,1.967,1.74,1.000,0.000,0.500,9.540,罕见+严重; 住院率=50.0%
Dabrafenib,Colitis,3,40,0.502,0.502,1.41,1.000,0.000,1.000,9.827,罕见+严重; 住院率=100.0%
Dabrafenib,Neuropathy peripheral,3,40,0.464,0.464,1.77,1.000,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
Dabrafenib,White blood cell count decreased,3,40,0.304,0.304,4.58,0.667,0.000,0.667,9.827,罕见+严重; 住院率=66.7%
